Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" ABAT GABAT ENSG00000183044 "4-aminobutyrate aminotransferase" P80404 16 8674565-8784575 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Neurotransmitter degradation" "Aminotransferase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 53.3;liver: 136.5;pancreas: 54.2" "Cell line enhanced" "Detected in many" "Hep G2: 44.3;MCF7: 28.5;RH-30: 25.1;T-47d: 15.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041528, HPA041690" Enhanced Supported Supported Mitochondria 1500000 Mitochondria "HPA041528: AB_10795690, HPA041690: AB_10794674" "unprognostic (1.77e-2)" "unprognostic (3.27e-1)" "unprognostic (1.00e-1)" "unprognostic (2.71e-1)" "unprognostic (2.90e-1)" "unprognostic (2.05e-1)" "prognostic favourable (5.36e-5)" "prognostic favourable (5.93e-4)" "unprognostic (1.71e-1)" "unprognostic (1.30e-1)" "unprognostic (1.56e-2)" "unprognostic (1.04e-1)" "prognostic favourable (5.44e-8)" "unprognostic (2.10e-1)" "unprognostic (2.48e-2)" "unprognostic (3.80e-1)" "unprognostic (1.50e-2)" 2.1 12.6 26.1 2.7 39.3 1.7 3.2 19.9 43.3 2.2 5.2 10.9 0.1 17.5 2.1 5.0 3.0 2.8 2.7 6.2 20.4 30.9 53.3 136.5 2.8 2.8 24.5 26.1 5.3 54.2 4.0 22.1 2.3 14.3 9.9 4.2 2.6 2.6 2.5 1.4 2.1 8.4 2.1 14.1 2.5 3.9 6.3 11.8 1.0 12.7 0.4 3.3 6.4 1.1 2.2 1.9 8.8 5.8 1.6 2.5 1.8 0.2 0.0 11.8 6.7 1.9 0.6 0.5 1.4 0.8 0.7 0.2 4.4 0.3 1.4 0.5 0.8 3.0 0.7 2.8 0.9 0.8 0.6 1.9 0.0 44.3 3.1 0.4 3.0 2.5 1.2 1.2 0.5 0.2 0.3 1.0 0.2 28.5 0.7 0.2 1.0 0.1 3.4 25.1 0.6 0.4 7.0 1.9 5.7 0.6 0.4 0.0 15.6 1.2 0.2 0.2 2.0 0.9 0.0 1.1 0.1 0.3 0.3 2.0 1.4 1.1 3.1 4.1 2.5 3.6 1.1 0.8 1.7 1.7 1.9 2.2 1.1 1.8 8.8 1.6 5.8 0.3 1.6 1.8 26.1 39.3 19.9 35.1 20.4 30.9 24.5 26.1 14.3 11.8 ABCA1 "ABC1, HDLDT1, TGD" ENSG00000165029 "ATP binding cassette subfamily A member 1" O95477 9 104781002-104928237 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism, Transport" "Atherosclerosis, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HSkMC: 16.9;U-87 MG: 38.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "eosinophil: 11.6;neutrophil: 10.6" "Lineage enriched" "Detected in many" 6 "granulocytes: 11.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA057283, CAB069889" Approved Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB069889: AB_10002789, HPA057283: " "unprognostic (1.58e-2)" "unprognostic (2.54e-1)" "unprognostic (1.46e-1)" "unprognostic (2.80e-1)" "unprognostic (7.47e-3)" "unprognostic (1.85e-1)" "unprognostic (9.22e-2)" "unprognostic (9.80e-2)" "unprognostic (2.04e-1)" "unprognostic (7.28e-3)" "unprognostic (2.14e-1)" "unprognostic (4.78e-2)" "unprognostic (1.04e-2)" "unprognostic (2.00e-3)" "unprognostic (2.51e-2)" "unprognostic (6.71e-2)" "unprognostic (2.57e-1)" 25.7 38.1 6.3 9.8 13.1 15.8 23.0 2.3 8.5 8.2 14.8 8.0 6.5 4.4 7.8 9.6 7.0 7.9 13.6 10.7 7.5 3.7 7.1 33.3 12.7 29.4 18.9 2.3 8.7 5.4 1.8 3.3 20.1 10.2 9.4 9.4 7.7 6.3 8.7 21.3 12.1 8.1 25.2 16.1 12.8 7.3 8.8 8.0 16.9 5.8 2.2 5.0 16.4 20.0 1.8 0.2 11.6 1.5 0.1 0.6 0.1 0.0 2.6 2.2 0.0 6.5 2.4 2.0 2.8 10.8 0.9 1.0 0.4 0.3 3.8 3.1 2.8 0.0 1.2 0.1 0.8 0.0 0.0 0.4 0.9 9.4 11.7 0.0 6.7 16.9 0.7 11.0 0.2 1.0 0.0 9.7 0.2 0.3 2.3 5.1 3.1 0.8 0.0 0.0 0.2 1.8 1.8 0.3 0.1 2.9 0.5 0.6 0.0 1.9 0.9 2.9 0.2 3.8 3.1 3.8 1.8 2.3 38.7 0.0 0.0 2.2 0.8 11.6 0.2 1.0 0.2 1.2 0.3 0.0 0.2 1.8 0.6 0.0 10.6 0.1 1.5 0.1 0.1 0.1 6.3 13.1 2.3 4.0 7.5 3.7 18.9 2.3 10.2 8.0 ABCC1 "GS-X, MRP, MRP1" ENSG00000103222 "ATP binding cassette subfamily C member 1" P33527 16 15949577-16143074 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" Transport Hydrolase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "EFO-21: 38.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 7.5;eosinophil: 3.1;T-reg: 2.1" "Group enriched" "Detected in many" 7 "granulocytes: 7.5;T-cells: 2.1" "Low region specificity" "Detected in all" HPA002380 Uncertain Supported "Plasma membrane" "Plasma membrane" "HPA002380: AB_1844432" "unprognostic (9.97e-2)" "unprognostic (2.06e-1)" "unprognostic (2.05e-2)" "unprognostic (2.94e-1)" "unprognostic (4.89e-2)" "unprognostic (1.15e-1)" "prognostic unfavourable (5.42e-5)" "unprognostic (3.42e-1)" "unprognostic (3.31e-1)" "unprognostic (4.07e-2)" "unprognostic (9.78e-3)" "unprognostic (7.19e-2)" "prognostic unfavourable (1.55e-6)" "unprognostic (1.84e-1)" "unprognostic (1.15e-1)" "unprognostic (1.43e-2)" "unprognostic (1.80e-2)" 8.9 8.2 2.4 8.3 3.1 8.4 9.6 4.4 5.0 8.3 10.7 2.6 15.5 3.5 10.5 12.7 14.7 5.6 9.6 8.0 2.1 2.4 4.5 1.6 10.9 12.2 3.0 2.1 6.8 5.8 18.4 4.2 5.2 4.1 9.6 4.1 12.0 16.9 10.9 20.8 6.6 8.2 16.4 4.0 9.2 10.9 15.1 2.3 26.8 15.7 12.6 15.6 15.3 11.8 0.7 0.5 7.5 0.5 0.4 2.1 0.2 2.2 24.2 0.1 6.3 5.6 3.5 1.3 7.1 8.7 6.2 6.4 3.8 17.5 6.6 38.2 13.7 6.5 2.0 7.0 4.7 11.5 2.2 8.1 14.2 14.0 16.7 2.9 21.1 7.3 4.7 1.8 1.0 6.8 8.2 3.4 1.9 4.5 5.2 2.7 3.8 3.6 18.5 3.6 3.2 2.3 8.2 3.5 5.8 9.0 9.8 2.4 3.4 1.5 0.6 0.4 1.4 5.1 5.7 6.3 3.2 2.2 3.2 3.0 0.7 7.5 0.1 3.1 0.6 0.4 0.6 0.7 0.5 0.6 0.5 0.3 0.6 0.6 0.0 0.4 0.5 0.3 2.1 0.2 2.4 3.1 4.4 5.0 2.1 2.4 3.0 2.1 4.1 2.3 ABCC2 "CMOAT, cMRP, DJS, MRP2" ENSG00000023839 "ATP binding cassette subfamily C member 2" Q92887 10 99782732-99852192 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" Transport "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 28.4;kidney: 25.6;liver: 74.3" "Group enriched" "Detected in some" 5 "A549: 59.0;Hep G2: 58.8" "Cancer enhanced" "Detected in many" "liver cancer: 24.0" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 4.1" "Lineage enriched" "Detected in single" 6 "granulocytes: 4.1" "Not detected" "Not detected" "Not detected" "Not detected" "HPA004860, CAB037271" Enhanced "CAB037271: AB_2221326, HPA004860: AB_1844433" "unprognostic (1.49e-3)" "unprognostic (5.92e-2)" "unprognostic (1.59e-1)" "unprognostic (3.67e-1)" "unprognostic (1.93e-2)" "unprognostic (2.33e-1)" "unprognostic (2.51e-1)" "unprognostic (7.15e-3)" "unprognostic (5.68e-2)" "unprognostic (2.01e-1)" "unprognostic (4.30e-1)" "unprognostic (1.40e-3)" "prognostic unfavourable (1.93e-5)" "unprognostic (1.31e-1)" "unprognostic (3.22e-2)" "unprognostic (2.95e-1)" "unprognostic (1.26e-2)" 0.8 0.3 0.1 0.1 0.1 0.1 1.1 0.3 0.1 0.2 13.4 0.1 0.1 16.1 0.3 0.5 0.2 0.4 13.7 0.2 0.1 0.1 25.6 74.3 0.3 0.1 0.1 0.1 0.2 0.6 0.0 0.1 1.2 0.1 0.3 0.0 0.1 0.3 0.1 0.6 0.6 28.4 0.1 0.2 0.8 0.4 0.4 0.1 0.1 0.3 0.4 0.1 0.7 0.3 0.3 0.7 4.1 0.2 0.1 0.5 0.0 0.0 59.0 0.9 2.9 4.5 3.5 1.0 0.1 0.3 0.1 0.2 12.6 0.1 0.1 0.1 0.2 0.3 0.1 0.1 0.2 0.1 0.1 0.0 0.2 58.8 0.1 0.0 0.2 0.5 4.1 0.4 0.4 0.1 0.0 0.1 0.0 0.2 0.0 0.4 0.1 0.0 0.1 0.0 0.1 0.4 0.0 0.0 0.0 0.1 0.9 7.3 0.0 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.0 0.0 4.8 0.9 0.3 4.1 0.2 0.3 0.3 0.0 0.4 0.2 0.3 0.1 0.3 0.3 0.3 0.1 1.3 0.1 0.1 0.7 0.5 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 ABCC8 "ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2" ENSG00000006071 "ATP binding cassette subfamily C member 8" Q09428 11 17392498-17476879 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" Transport Receptor "Diabetes mellitus, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 28.0;pancreas: 25.5;pituitary gland: 26.6" "Group enriched" "Detected in some" 5 "A549: 4.6;AN3-CA: 3.7;SCLC-21H: 6.5" "Cancer enriched" "Detected in some" 9 "pancreatic cancer: 16.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB011451, HPA042318" Approved Approved "Nucleoli,Golgi apparatus,Cytosol" Nucleoli "Golgi apparatus, Cytosol" "CAB011451: , HPA042318: " "unprognostic (4.30e-2)" "unprognostic (1.02e-1)" "unprognostic (5.09e-2)" "unprognostic (4.73e-2)" "unprognostic (9.48e-3)" "unprognostic (2.23e-1)" "unprognostic (4.46e-3)" "unprognostic (2.53e-3)" "unprognostic (6.04e-2)" "unprognostic (2.34e-2)" "unprognostic (8.72e-3)" "unprognostic (1.13e-1)" "unprognostic (2.22e-2)" "unprognostic (1.96e-2)" "unprognostic (6.88e-5)" "unprognostic (2.72e-2)" "unprognostic (1.85e-1)" 1.3 6.7 4.4 0.8 6.1 0.9 4.0 28.0 12.3 3.0 1.3 2.6 7.7 1.9 3.1 3.7 0.8 1.2 0.9 2.9 5.1 4.8 1.0 0.8 2.9 0.8 3.6 7.2 0.9 25.5 1.0 26.6 1.6 8.5 2.8 1.3 0.7 0.9 8.5 2.3 1.1 1.5 1.3 4.0 0.9 3.5 1.1 2.3 0.0 6.2 0.0 0.8 0.7 0.8 0.1 0.0 0.5 0.0 0.1 0.2 0.0 0.0 4.6 0.1 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 6.5 0.9 0.0 0.1 0.1 0.1 0.0 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.5 0.1 0.0 0.0 0.0 0.0 4.4 6.1 28.0 12.3 5.1 4.8 3.6 7.2 8.5 2.3 ABCC9 "CMD1O, SUR2" ENSG00000069431 "ATP binding cassette subfamily C member 9" O60706 12 21797401-21942529 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" Transport Receptor "Atrial fibrillation, Cardiomyopathy, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "ASC diff: 17.2;BJ hTERT+: 9.9;CACO-2: 15.7;HSkMC: 20.5;U-138 MG: 17.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007279 Uncertain Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA007279: AB_1844435" "unprognostic (4.82e-2)" "unprognostic (3.62e-2)" "unprognostic (5.51e-4)" "unprognostic (1.09e-1)" "unprognostic (1.09e-1)" "unprognostic (8.30e-2)" "unprognostic (3.17e-2)" "unprognostic (1.50e-2)" "unprognostic (2.47e-2)" "unprognostic (8.72e-2)" "unprognostic (2.51e-2)" "unprognostic (3.57e-1)" "prognostic unfavourable (1.85e-5)" "unprognostic (2.66e-2)" "unprognostic (1.21e-2)" "unprognostic (3.10e-3)" "unprognostic (8.22e-5)" 21.6 4.7 5.5 2.6 5.4 1.2 25.8 1.5 8.6 12.4 6.8 4.8 5.1 3.0 15.3 6.3 9.1 9.5 9.6 26.2 5.7 2.6 5.6 31.1 6.2 2.7 2.9 4.2 11.8 5.8 1.7 2.7 2.8 5.5 7.0 1.6 10.8 4.8 8.4 33.2 3.3 4.1 17.1 4.9 3.5 9.1 3.4 4.2 0.1 6.3 14.5 1.2 9.5 8.4 1.6 0.9 1.8 0.8 0.5 0.9 0.0 0.6 0.1 7.3 0.2 17.2 7.8 0.2 4.0 9.9 4.4 2.2 15.7 0.6 0.3 0.8 0.4 0.2 0.0 0.0 4.6 0.2 0.1 0.3 0.5 0.2 0.0 0.3 0.4 20.5 0.0 4.4 1.6 0.0 0.2 0.9 0.2 0.9 0.1 0.2 1.0 0.4 0.3 0.2 0.2 0.0 0.8 0.3 1.2 0.2 0.3 0.1 0.8 0.2 0.2 17.1 1.2 1.4 5.2 0.7 0.8 0.3 4.2 0.2 0.3 0.9 0.5 0.4 0.9 0.4 0.6 0.7 0.7 0.7 0.2 1.6 0.6 0.8 1.8 0.5 0.8 0.9 0.4 0.0 5.5 5.4 1.5 8.6 5.7 2.6 2.9 4.2 5.5 4.2 ABL1 "ABL, c-ABL, JTK7, p150" ENSG00000097007 "ABL proto-oncogene 1, non-receptor tyrosine kinase" P00519 9 130713946-130887675 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Autophagy, Cell adhesion, DNA damage, DNA repair, Endocytosis" "DNA-binding, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002686, HPA027251, HPA027280, HPA028409" Supported Enhanced "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "CAB002686: , HPA027251: AB_1844453, HPA027280: AB_1844454, HPA028409: AB_10601011" "unprognostic (4.82e-2)" "unprognostic (3.99e-2)" "unprognostic (5.55e-2)" "unprognostic (4.72e-2)" "unprognostic (1.16e-1)" "unprognostic (1.46e-1)" "unprognostic (3.75e-3)" "unprognostic (1.89e-3)" "unprognostic (2.34e-1)" "unprognostic (2.54e-2)" "unprognostic (1.09e-2)" "unprognostic (1.48e-1)" "unprognostic (3.96e-3)" "unprognostic (1.10e-2)" "unprognostic (1.47e-1)" "unprognostic (1.22e-1)" "unprognostic (1.06e-1)" 20.1 11.6 12.4 15.0 18.1 10.7 22.0 6.7 16.0 28.9 34.3 29.1 12.1 11.9 26.6 16.9 21.4 20.8 30.9 14.2 10.3 8.4 9.9 6.7 13.8 8.7 24.1 9.4 24.2 12.2 27.7 14.5 13.6 17.1 27.3 15.8 19.4 14.6 18.0 10.8 14.2 17.0 66.6 14.3 10.8 21.9 9.8 21.2 5.8 19.5 11.4 9.1 35.8 31.9 3.1 3.1 1.1 5.0 2.4 2.6 1.6 7.0 15.7 16.9 20.4 24.8 30.3 6.2 12.4 19.5 14.6 12.4 12.3 9.2 11.6 7.2 16.5 13.7 8.5 11.5 10.8 7.3 5.3 7.6 26.9 10.5 16.9 11.7 10.7 22.1 12.7 26.1 16.2 20.2 42.6 9.3 17.8 13.4 14.8 9.6 18.7 11.6 17.2 21.9 12.6 14.7 8.3 15.8 19.7 20.8 8.1 10.0 15.9 10.8 23.1 56.0 14.5 21.4 19.5 2.8 6.6 15.6 23.1 9.7 17.7 0.2 2.1 1.1 2.0 1.2 2.6 3.1 2.0 1.9 2.0 1.4 1.9 1.7 0.2 2.4 5.0 3.1 0.9 1.6 12.4 18.1 6.7 16.0 10.3 8.4 24.1 9.4 17.1 21.2 AC008397.2 ENSG00000285188 "CAMP-specific 3',5'-cyclic phosphodiesterase 4C " Q08493 19 18207961-18255419 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 22.4;intestine: 15.6;pancreas: 14.2" "Cell line enhanced" "Detected in some" "BEWO: 3.6;U-2197: 1.6;U-87 MG: 4.7" "Not detected" "Not detected" "Not detected" "Not detected" HPA048975 Uncertain "HPA048975: " 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 1.2 1.9 15.6 0.0 0.0 1.3 1.1 3.6 4.0 1.0 22.4 0.6 0.0 0.6 0.0 2.0 0.0 0.0 0.0 0.0 14.2 0.0 0.0 0.8 0.0 0.0 1.7 0.0 2.1 1.1 3.7 0.0 8.0 0.6 0.0 0.4 7.1 0.2 0.0 0.0 0.4 0.8 4.1 0.7 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 3.6 0.1 0.0 0.0 0.2 0.0 0.3 0.3 0.3 0.0 0.5 0.0 0.0 0.2 0.1 0.0 0.1 0.2 0.9 0.0 0.0 0.2 0.4 0.0 0.8 0.0 0.0 0.3 0.7 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.4 0.1 0.0 0.1 0.2 0.1 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.2 1.6 0.0 0.3 0.2 0.1 4.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ACAA1 ENSG00000060971 "Acetyl-CoA acyltransferase 1" P09110 3 38103129-38137242 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism" "Acyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 152.1" "Cell line enhanced" "Detected in all" "SK-BR-3: 85.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006764, HPA007244" Enhanced Enhanced Peroxisomes 4300000 Peroxisomes "HPA006764: AB_1078085, HPA007244: AB_1078084" "prognostic favourable (3.00e-4)" "unprognostic (5.57e-2)" "unprognostic (4.54e-2)" "prognostic favourable (7.53e-4)" "unprognostic (2.63e-1)" "prognostic favourable (1.23e-4)" "unprognostic (9.35e-3)" "unprognostic (2.91e-2)" "unprognostic (8.11e-2)" "unprognostic (2.22e-1)" "unprognostic (2.24e-1)" "unprognostic (4.90e-1)" "prognostic favourable (6.99e-9)" "unprognostic (1.72e-1)" "unprognostic (1.99e-1)" "unprognostic (2.50e-2)" "unprognostic (1.65e-2)" 9.5 12.7 11.0 5.6 11.9 9.6 10.2 8.1 14.3 6.7 16.1 12.5 10.6 23.4 4.9 13.3 12.1 4.6 16.0 17.7 10.2 8.9 48.7 152.1 8.2 5.9 14.0 9.4 5.0 19.2 7.4 5.9 6.8 11.0 13.4 12.4 7.3 11.5 9.4 9.8 6.2 23.8 4.8 12.7 10.0 8.5 4.4 10.9 5.7 9.3 10.1 10.2 9.4 7.0 9.2 47.0 32.8 45.2 17.8 19.3 18.8 8.4 9.2 3.1 9.9 13.6 7.9 10.9 7.8 11.3 8.9 8.5 12.3 9.5 5.0 5.6 12.4 5.6 8.5 13.1 4.9 7.3 8.8 6.5 8.1 34.8 8.8 14.8 14.5 14.7 9.4 7.6 5.5 12.0 6.0 5.9 9.9 11.0 14.3 10.6 3.3 11.2 3.3 6.0 8.4 25.1 25.1 2.7 4.2 7.6 85.3 5.4 8.8 11.9 8.7 5.4 5.2 10.7 10.6 7.8 5.0 3.9 8.8 12.9 8.5 15.3 29.9 32.8 13.6 40.7 11.4 9.2 13.1 13.3 47.0 8.7 13.0 12.1 20.4 17.8 45.2 27.7 19.3 18.8 11.0 11.9 8.1 14.3 10.2 8.9 14.0 9.4 11.0 10.9 ACE "ACE1, CD143, DCP1" ENSG00000159640 "Angiotensin I converting enzyme" P12821 17 63477061-63498380 "Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Carboxypeptidase, Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "intestine: 205.6" "Group enriched" "Detected in some" 4 "ASC TERT1: 35.9;HUVEC TERT2: 18.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "memory B-cell: 3.7" "Group enriched" "Detected in many" 23 "B-cells: 3.7;monocytes: 2.0;T-cells: 1.9" "CAB002426, CAB002921, HPA029298, HPA069790" Enhanced Approved Vesicles "Secreted to blood" 121920000 92000000 Vesicles "CAB002426: AB_442052, CAB002921: , HPA029298: AB_10960255, HPA069790: " "unprognostic (4.72e-2)" "unprognostic (4.16e-1)" "unprognostic (1.93e-3)" "unprognostic (6.06e-2)" "unprognostic (2.78e-1)" "unprognostic (1.35e-2)" "unprognostic (4.37e-1)" "unprognostic (1.54e-1)" "unprognostic (1.56e-1)" "unprognostic (1.25e-2)" "unprognostic (3.13e-2)" "unprognostic (2.38e-1)" "unprognostic (7.66e-2)" "unprognostic (9.07e-2)" "unprognostic (1.66e-1)" "unprognostic (1.08e-1)" "unprognostic (2.76e-2)" 6.8 2.0 0.5 2.4 4.2 0.0 2.9 0.5 1.1 5.3 83.2 0.7 37.7 46.4 4.5 5.1 1.7 1.5 4.4 4.7 0.6 0.7 2.6 1.4 16.3 2.2 0.4 0.7 1.4 3.0 3.6 3.6 3.6 0.8 3.4 1.4 1.7 2.5 20.1 3.6 1.3 205.6 2.4 0.6 1.4 1.9 32.6 1.3 0.5 6.9 3.1 2.2 1.7 1.6 3.7 0.1 0.0 2.0 0.0 1.9 0.4 0.0 0.0 0.0 0.0 1.5 35.9 0.4 1.3 2.6 0.0 0.0 0.5 3.1 0.7 1.0 6.1 0.0 1.7 0.0 0.0 0.0 0.7 3.4 0.0 0.0 0.8 0.0 0.0 2.4 0.0 0.0 0.0 18.3 3.0 0.0 0.0 0.6 0.0 0.7 0.2 0.3 0.1 0.2 0.5 0.0 0.0 4.5 3.2 0.0 0.0 0.0 1.6 0.2 0.0 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.4 0.6 0.9 3.7 1.9 1.4 0.1 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.4 0.5 4.2 0.5 1.1 0.6 0.7 0.4 0.7 0.8 1.3 ACE2 ENSG00000130234 "Angiotensin I converting enzyme 2" Q9BYF1 X 15561033-15602148 "Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins" "Host-virus interaction" "Carboxypeptidase, Host cell receptor for virus entry, Hydrolase, Metalloprotease, Protease, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "intestine: 122.0" "Cell line enhanced" "Detected in some" "BEWO: 2.4;HaCaT: 4.1;Hep G2: 2.4;NB-4: 2.2;RPMI-8226: 2.0;RT4: 2.4;SH-SY5Y: 2.8" "Cancer enhanced" "Detected in many" "renal cancer: 26.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Not detected" "Not detected" "HPA000288, CAB026174" Enhanced "Secreted to blood" 85000 "CAB026174: , HPA000288: AB_1078160" "unprognostic (1.40e-1)" "unprognostic (7.26e-2)" "unprognostic (2.76e-2)" "unprognostic (5.71e-2)" "unprognostic (2.51e-1)" "unprognostic (5.26e-2)" "prognostic favourable (4.21e-4)" "unprognostic (2.34e-2)" "unprognostic (6.74e-3)" "unprognostic (2.54e-3)" "unprognostic (1.00e-1)" "unprognostic (1.74e-1)" "prognostic favourable (2.12e-5)" "unprognostic (1.94e-1)" "unprognostic (9.62e-2)" "unprognostic (2.11e-1)" "unprognostic (7.10e-2)" 4.5 0.4 0.2 0.8 0.2 0.0 2.3 0.2 0.2 0.4 49.1 0.2 2.3 46.0 0.4 2.7 1.2 0.6 16.4 10.5 0.2 0.1 23.2 1.2 0.8 0.6 0.2 0.2 1.3 1.6 0.0 0.2 1.0 0.2 0.5 1.3 0.2 1.1 1.2 0.7 0.2 122.0 0.3 0.2 0.2 0.5 17.9 0.2 0.2 4.5 0.5 0.2 0.4 0.9 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.2 0.0 0.4 0.0 0.7 0.0 2.4 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.6 0.0 4.1 0.2 0.1 0.0 0.1 0.1 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 2.2 0.1 0.2 0.0 0.0 2.0 0.4 2.4 0.6 2.8 0.1 0.3 0.2 0.2 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 ACHE YT ENSG00000087085 "Acetylcholinesterase (Cartwright blood group)" P22303 7 100889994-100896974 "Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Neurotransmitter degradation" "Blood group antigen, Hydrolase, Serine esterase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 43.8;skeletal muscle: 98.2" "Cell line enhanced" "Detected in some" "BEWO: 8.0;CACO-2: 12.6;K-562: 14.8;Karpas-707: 24.7;U-2 OS: 5.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA027098 Approved "Golgi apparatus,Vesicles" "Intracellular and membrane" 650000 "Golgi apparatus" Vesicles "HPA027098: " "unprognostic (2.23e-1)" "unprognostic (9.44e-2)" "unprognostic (2.71e-2)" "unprognostic (5.80e-3)" "prognostic unfavourable (5.27e-4)" "unprognostic (2.49e-1)" "unprognostic (2.54e-1)" "unprognostic (1.36e-2)" "unprognostic (2.48e-2)" "unprognostic (8.92e-2)" "unprognostic (2.65e-2)" "unprognostic (1.78e-1)" "prognostic unfavourable (3.88e-5)" "unprognostic (2.95e-1)" "unprognostic (2.59e-2)" "unprognostic (9.28e-2)" "unprognostic (8.38e-2)" 1.4 4.8 5.8 3.5 16.1 10.3 1.4 22.8 11.8 1.4 4.2 2.7 1.4 5.7 1.9 2.6 2.8 1.8 3.1 4.5 5.5 43.8 1.4 1.8 1.8 5.9 22.2 4.8 1.7 1.6 7.0 3.2 2.0 37.9 3.3 3.4 4.6 6.5 3.3 98.2 1.4 7.9 1.9 8.7 2.3 2.1 1.9 2.6 3.5 1.6 15.9 3.2 2.1 1.2 0.0 0.3 0.0 0.0 0.0 0.7 0.0 0.0 0.2 0.3 0.2 0.5 0.0 8.0 0.3 0.0 0.1 0.2 12.6 0.3 0.0 0.4 0.0 0.4 2.1 0.1 0.0 4.3 0.5 0.2 0.0 0.1 0.0 0.0 0.4 0.4 0.0 0.1 0.0 0.0 14.8 24.7 0.1 3.5 0.0 0.1 1.2 0.2 0.0 0.0 0.0 0.0 0.0 0.7 1.4 0.0 1.0 0.0 0.0 0.0 0.1 0.7 5.9 0.1 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.8 16.1 22.8 11.8 5.5 43.8 22.2 4.8 37.9 2.6 ADA ENSG00000196839 "Adenosine deaminase" P00813 20 44619522-44652233 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Nucleotide metabolism" Hydrolase "Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 64.0;intestine: 142.2;lymphoid tissue: 99.0" "Cell line enriched" "Detected in many" 8 "MOLT-4: 197.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "non-classical monocyte: 64.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001399, CAB004307, HPA023884" Enhanced Supported "Plasma membrane,Cytosol" 650000 "Plasma membrane" Cytosol "CAB004307: AB_626634, HPA001399: AB_1078099, HPA023884: AB_1844573" "unprognostic (4.30e-2)" "unprognostic (6.89e-2)" "unprognostic (3.96e-2)" "prognostic unfavourable (1.23e-7)" "unprognostic (9.33e-2)" "unprognostic (9.07e-3)" "prognostic unfavourable (6.77e-5)" "prognostic unfavourable (2.20e-4)" "unprognostic (1.59e-1)" "unprognostic (2.16e-1)" "unprognostic (3.66e-2)" "unprognostic (3.48e-1)" "prognostic unfavourable (2.94e-14)" "unprognostic (2.29e-1)" "unprognostic (1.04e-2)" "unprognostic (1.53e-1)" "unprognostic (1.82e-1)" 8.1 3.2 2.5 5.4 6.5 5.3 5.1 0.9 5.0 2.8 7.4 5.0 1.8 142.2 1.7 3.4 4.6 2.4 3.0 9.2 2.7 0.8 1.3 2.1 2.8 8.9 3.6 2.3 1.2 2.4 0.8 0.3 1.8 3.9 1.8 1.5 0.7 2.6 1.3 2.0 2.8 5.0 2.1 1.3 9.5 19.7 1.6 6.1 99.0 2.8 2.1 7.6 3.6 2.6 1.3 41.6 0.5 64.0 16.9 10.3 9.6 1.4 3.9 2.0 1.3 3.9 5.4 3.3 1.4 0.8 1.4 1.0 1.8 1.5 4.0 1.7 1.8 0.2 1.4 5.8 0.8 0.3 1.8 0.8 0.7 1.4 1.6 0.6 2.1 26.1 2.5 0.5 0.9 5.4 2.0 3.3 0.6 3.4 197.1 2.9 0.5 1.4 10.6 2.8 9.8 0.2 0.0 0.0 0.9 2.1 0.4 2.5 0.4 1.9 1.7 1.0 2.0 2.2 0.2 4.3 2.7 8.3 0.3 3.3 0.9 0.0 1.8 0.2 8.7 30.7 5.7 1.3 7.3 10.3 6.8 1.0 5.7 8.1 0.5 16.9 64.0 41.6 5.3 9.6 2.5 6.5 0.9 5.0 2.7 0.8 3.6 2.3 3.9 6.1 ADH1A ADH1 ENSG00000187758 "Alcohol dehydrogenase 1A (class I), alpha polypeptide" P07327 4 99276367-99291028 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 322 "liver: 250.3" "Cell line enriched" "Detected in some" 5 "ASC diff: 10.9" "Cancer enriched" "Detected in some" 251 "liver cancer: 165.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB009562, HPA047814, HPA060902" Enhanced Approved "Plasma membrane,Cytosol" 12000000 "Plasma membrane, Cytosol" "CAB009562: AB_2257984, HPA047814: , HPA060902: " "unprognostic (5.89e-2)" "unprognostic (6.16e-2)" "unprognostic (1.20e-1)" "unprognostic (2.07e-1)" "unprognostic (4.40e-1)" "prognostic favourable (2.38e-4)" "unprognostic (2.78e-3)" "unprognostic (4.25e-1)" "unprognostic (4.79e-3)" "unprognostic (6.21e-2)" "unprognostic (9.36e-2)" "unprognostic (3.25e-2)" "unprognostic (1.40e-1)" "unprognostic (2.86e-2)" 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 250.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 10.9 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.7 0.0 0.0 0.0 0.1 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.9 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 ADH1B ADH2 ENSG00000196616 "Alcohol dehydrogenase 1B (class I), beta polypeptide" P00325 4 99304964-99352760 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adipose tissue: 253.5;liver: 466.3" "Cell line enriched" "Detected in some" 7 "ASC diff: 385.0" "Cancer enriched" "Detected in many" 31 "liver cancer: 223.1" "Group enriched" "Detected in some" 5 "midbrain: 2.3;pons and medulla: 1.6" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "HPA047814, HPA060902" Supported Approved "Plasma membrane,Cytosol" 16000000 "Plasma membrane, Cytosol" "HPA047814: , HPA060902: " "unprognostic (5.13e-2)" "unprognostic (9.80e-3)" "unprognostic (6.59e-2)" "unprognostic (5.56e-2)" "unprognostic (9.49e-2)" "unprognostic (5.53e-2)" "unprognostic (1.54e-3)" "unprognostic (1.04e-2)" "unprognostic (6.51e-2)" "unprognostic (2.73e-2)" "unprognostic (7.47e-3)" "unprognostic (7.79e-2)" "prognostic unfavourable (7.87e-4)" "unprognostic (4.60e-3)" "unprognostic (2.33e-1)" "unprognostic (2.58e-1)" "unprognostic (1.60e-2)" 253.5 12.3 0.2 21.8 0.0 0.4 78.7 0.2 0.4 18.3 60.0 0.4 5.7 3.5 12.8 14.4 33.5 22.3 31.9 24.2 0.3 0.0 9.2 466.3 43.8 17.5 2.3 0.1 18.0 8.7 0.8 5.3 0.9 1.6 30.7 10.1 2.3 11.2 3.9 20.5 11.9 25.4 30.8 2.4 5.9 10.9 18.0 0.2 0.2 16.1 9.7 2.0 42.3 76.0 0.6 0.2 1.2 0.3 0.8 0.4 0.0 0.0 0.0 0.0 0.0 385.0 56.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 12.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.3 0.3 0.2 0.1 0.1 0.2 0.4 0.1 0.0 0.6 0.3 0.4 1.2 0.8 0.1 0.2 0.1 0.0 0.2 0.0 0.2 0.0 0.3 0.0 2.3 0.1 1.6 0.2 ADH1C ADH3 ENSG00000248144 "Alcohol dehydrogenase 1C (class I), gamma polypeptide" P00326 4 99336492-99353027 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "intestine: 47.1;liver: 149.4;stomach 1: 43.1" "Group enriched" "Detected in some" 4 "ASC TERT1: 5.1;HSkMC: 15.1" "Cancer enriched" "Detected in many" 7 "liver cancer: 238.2" "Not detected" "Not detected" "Not detected" "Not detected" "HPA047814, HPA060902" Supported Supported "Plasma membrane,Cytosol" 9700000 "Plasma membrane, Cytosol" "HPA047814: , HPA060902: " "unprognostic (3.98e-2)" "unprognostic (9.88e-3)" "unprognostic (7.04e-2)" "unprognostic (1.90e-1)" "unprognostic (5.14e-1)" "unprognostic (1.57e-1)" "prognostic favourable (4.55e-4)" "prognostic favourable (2.99e-4)" "unprognostic (8.25e-2)" "unprognostic (8.89e-3)" "unprognostic (7.95e-2)" "unprognostic (2.04e-1)" "unprognostic (1.12e-1)" "unprognostic (1.21e-1)" "unprognostic (1.53e-1)" "unprognostic (1.70e-1)" "unprognostic (9.37e-2)" 4.7 0.0 0.0 18.5 0.0 0.0 1.1 0.0 0.0 1.1 37.9 0.0 1.1 43.4 0.3 1.2 1.7 0.0 12.0 2.0 0.0 8.3 149.4 1.1 0.0 0.2 0.0 1.1 11.4 0.0 0.0 0.0 0.0 2.5 13.6 0.0 1.1 0.8 6.0 0.0 47.1 0.9 0.5 0.0 43.1 1.6 0.0 0.0 0.5 2.0 0.2 1.3 0.7 0.2 0.2 0.3 0.1 0.1 0.3 0.1 0.0 2.2 0.0 0.1 1.7 5.1 1.1 0.0 0.6 0.1 0.0 0.0 0.0 0.2 0.2 0.2 0.1 0.0 0.0 0.0 0.1 0.0 0.5 0.3 0.1 0.5 1.4 0.3 15.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.4 0.9 0.4 0.1 0.1 0.9 2.1 0.9 0.0 0.4 1.6 0.7 0.8 0.0 0.2 0.0 0.1 0.0 0.6 0.3 0.2 0.1 0.0 0.3 0.0 0.8 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.2 0.0 0.1 0.3 0.1 0.0 0.2 0.0 0.1 ADK AK ENSG00000156110 "Adenosine kinase" P55263 10 74151185-74709303 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Purine salvage" "Kinase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 71.9" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB032876, HPA038391, HPA038409" Approved Supported Nucleoplasm,Cytosol 320000 "Nucleoplasm, Cytosol" "CAB032876: AB_2242229, HPA038391: , HPA038409: AB_10675798" "unprognostic (1.55e-3)" "unprognostic (1.09e-1)" "unprognostic (1.88e-1)" "unprognostic (2.62e-2)" "unprognostic (2.52e-2)" "prognostic unfavourable (1.93e-4)" "prognostic favourable (9.91e-4)" "unprognostic (2.64e-1)" "unprognostic (2.88e-1)" "unprognostic (1.55e-1)" "unprognostic (8.15e-3)" "unprognostic (2.51e-1)" "unprognostic (1.89e-3)" "unprognostic (2.03e-1)" "unprognostic (2.88e-2)" "unprognostic (4.97e-3)" "unprognostic (2.95e-2)" 13.8 10.7 11.8 13.6 25.4 12.1 14.5 11.2 11.8 9.5 9.3 9.0 9.6 8.8 6.6 10.6 29.4 8.9 6.3 15.7 9.8 11.1 19.0 71.9 15.1 17.9 12.3 9.3 5.2 12.6 15.1 23.5 43.2 11.6 8.7 10.8 8.5 13.1 11.4 18.1 20.8 6.4 8.3 13.2 11.3 7.4 11.9 10.3 13.4 20.8 24.1 21.9 12.6 14.7 49.3 23.0 5.4 21.6 6.5 15.7 9.8 37.5 8.5 9.0 12.0 9.0 13.9 20.7 32.6 25.9 25.3 28.4 23.7 39.2 19.7 8.2 13.1 34.4 10.5 34.7 40.6 13.2 12.1 12.5 13.9 25.5 10.3 20.0 5.1 12.8 23.0 18.4 45.9 22.0 9.9 6.4 19.0 21.0 23.5 27.1 2.5 60.0 22.7 15.6 16.9 27.7 20.7 7.1 8.4 14.3 55.8 10.8 37.1 15.1 18.8 8.4 15.5 22.4 26.9 9.2 10.4 22.2 15.9 28.8 5.1 1.3 10.1 1.4 4.5 18.0 10.0 29.7 9.5 8.2 23.0 49.3 7.9 6.5 5.4 6.5 21.6 16.7 15.7 9.8 11.8 25.4 11.2 11.8 9.8 11.1 12.3 9.3 11.6 10.3 ADORA1 RDC7 ENSG00000163485 "Adenosine A1 receptor" P30542 1 203090654-203167405 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 38.7" "Cell line enhanced" "Detected in some" "CACO-2: 19.3;MCF7: 11.6;RH-30: 31.9;RPTEC TERT1: 15.5;SK-BR-3: 17.3;U-138 MG: 10.4" "Cancer enhanced" "Detected in many" "glioma: 24.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044383 Supported "Plasma membrane" "Plasma membrane" "HPA044383: " "unprognostic (3.93e-3)" "unprognostic (8.16e-2)" "unprognostic (6.16e-2)" "unprognostic (2.38e-3)" "unprognostic (2.25e-2)" "unprognostic (2.34e-1)" "unprognostic (4.64e-2)" "unprognostic (4.17e-2)" "unprognostic (3.04e-1)" "unprognostic (4.80e-3)" "unprognostic (1.42e-1)" "unprognostic (2.98e-1)" "unprognostic (2.96e-3)" "unprognostic (1.54e-1)" "unprognostic (1.27e-1)" "unprognostic (4.13e-2)" "unprognostic (5.76e-4)" 4.5 1.0 19.7 2.6 21.7 0.8 6.1 9.7 38.7 1.1 1.6 27.4 0.0 2.0 2.0 1.6 1.6 2.0 1.8 13.8 19.8 12.1 4.2 1.0 2.8 1.4 22.8 13.4 0.8 15.5 15.5 0.9 8.9 25.0 1.2 1.6 1.8 8.9 1.3 2.0 1.9 1.8 1.3 20.7 7.4 1.6 16.3 15.9 0.0 3.2 0.0 1.4 3.4 0.3 0.0 0.6 0.0 0.1 0.0 0.0 0.1 0.1 1.4 0.3 0.1 0.1 0.8 0.1 0.9 1.4 0.3 0.2 19.3 0.3 0.0 4.4 3.5 0.0 0.3 0.0 0.1 0.0 0.5 0.0 0.2 0.0 0.3 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.0 0.0 3.0 11.6 0.0 0.0 5.0 0.0 0.0 31.9 1.0 15.5 0.0 0.3 0.3 2.1 17.3 0.2 1.0 0.4 0.0 10.4 5.3 0.0 5.6 0.0 0.0 0.0 5.2 0.0 0.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 19.7 21.7 9.7 25.7 19.8 12.1 22.8 13.4 25.0 15.9 ADORA2A "ADORA2, RDC8" ENSG00000128271 "Adenosine A2a receptor" P29274 22 24417879-24442360 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 22.8;bone marrow: 28.1;brain: 43.9;lymphoid tissue: 59.0" "Cell line enhanced" "Detected in many" "Daudi: 15.0;Karpas-707: 20.7;RPMI-8226: 14.6;SK-BR-3: 29.7;U-266/70: 20.8;U-266/84: 27.1;U-698: 21.2" "Not detected" "Not detected" "Region enriched" "Detected in all" 8 "basal ganglia: 43.9" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Region enriched" "Detected in some" 10 "basal ganglia: 357.5" "Region enriched" "Detected in single" 95 "basal ganglia: 166.0" "CAB001943, HPA065566, HPA075997" Enhanced Supported "CAB001943: , HPA065566: , HPA075997: " "unprognostic (7.30e-2)" "unprognostic (2.42e-2)" "unprognostic (3.30e-2)" "unprognostic (2.04e-1)" "unprognostic (7.44e-2)" "unprognostic (1.88e-3)" "unprognostic (9.85e-2)" "unprognostic (3.63e-1)" "unprognostic (2.88e-2)" "unprognostic (4.57e-3)" "unprognostic (2.15e-3)" "unprognostic (1.87e-3)" "unprognostic (6.81e-4)" "unprognostic (1.50e-1)" "unprognostic (9.78e-3)" "unprognostic (1.30e-1)" "unprognostic (7.10e-3)" 1.0 2.4 1.9 10.4 43.9 28.1 1.5 3.4 3.8 0.8 2.0 1.7 0.3 5.4 1.4 1.4 1.0 0.9 2.4 3.5 2.4 1.8 3.5 4.3 5.1 14.8 2.6 1.6 1.2 0.8 0.0 2.1 1.4 2.3 1.6 0.8 3.3 2.7 1.5 1.2 0.9 2.6 0.7 1.3 7.5 2.8 2.0 5.7 59.0 1.3 0.9 8.6 3.8 1.3 17.7 1.1 13.7 9.0 2.2 22.8 11.2 0.2 0.3 0.4 0.1 0.2 0.1 0.4 0.2 9.3 0.5 0.9 1.7 0.1 15.0 1.0 0.2 0.3 0.9 0.0 0.0 1.8 2.6 0.2 0.0 2.1 0.1 0.3 7.5 0.1 0.0 2.8 0.0 3.3 0.1 20.7 0.0 0.2 5.2 1.6 0.6 0.0 0.1 0.7 14.6 0.0 0.1 1.5 8.7 0.4 29.7 0.1 0.3 1.4 0.2 0.9 1.4 0.2 0.1 20.8 27.1 21.2 4.7 5.1 0.1 3.0 0.8 4.8 8.6 2.6 20.1 9.6 16.1 16.9 1.1 17.7 22.8 18.3 13.7 2.2 9.0 1.1 21.4 11.2 1.9 43.9 3.4 3.8 2.4 1.8 2.6 1.6 2.3 5.7 ADORA2B ENSG00000170425 "Adenosine A2b receptor" P29275 17 15944917-15975746 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HMC-1: 56.7;hTERT-HME1: 21.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 12.8;myeloid DC: 8.4" "Group enriched" "Detected in many" 86 "dendritic cells: 8.4;granulocytes: 12.8;monocytes: 4.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA073747 Uncertain Cytosol Cytosol "HPA073747: " "unprognostic (6.04e-3)" "unprognostic (1.22e-1)" "unprognostic (8.14e-2)" "unprognostic (1.32e-2)" "unprognostic (4.68e-1)" "unprognostic (7.88e-3)" "unprognostic (2.64e-4)" "unprognostic (1.44e-1)" "unprognostic (1.84e-1)" "unprognostic (1.50e-2)" "unprognostic (2.18e-3)" "unprognostic (1.38e-1)" "unprognostic (1.66e-9)" "unprognostic (2.07e-1)" "unprognostic (3.49e-1)" "unprognostic (1.50e-2)" "unprognostic (2.84e-1)" 1.5 1.5 7.6 4.5 9.1 1.6 1.8 7.3 8.7 2.9 15.3 2.4 0.0 0.8 1.7 1.5 11.1 2.2 3.8 1.2 6.6 3.0 0.6 0.7 4.1 1.0 1.9 5.4 0.6 2.8 0.4 1.9 9.0 5.2 1.7 12.8 10.5 1.9 0.7 0.7 10.4 1.6 2.8 3.9 0.7 2.6 0.7 2.6 0.1 0.6 4.4 4.5 6.8 5.6 0.0 8.4 12.8 4.5 0.0 0.0 1.5 11.2 6.2 0.2 0.2 2.0 3.9 0.2 2.1 9.7 6.3 7.9 2.9 11.8 1.5 2.7 1.9 17.7 2.7 16.2 8.5 3.2 6.2 10.9 2.0 4.3 7.9 0.0 56.7 2.3 6.9 9.0 21.2 3.2 0.5 0.0 6.2 2.9 0.7 2.2 0.6 8.8 0.0 0.1 0.0 6.5 3.0 0.3 0.4 4.8 1.2 2.9 0.0 1.7 2.6 2.3 6.0 6.3 10.1 0.9 0.0 0.0 9.0 0.0 3.1 12.8 4.0 2.6 0.0 4.5 0.0 0.0 0.0 0.0 8.4 0.0 0.0 0.0 0.4 0.0 2.3 0.1 0.0 1.5 7.6 9.1 7.3 8.7 6.6 3.0 1.9 5.4 5.2 2.6 ADRA1A "ADRA1C, ADRA1L1" ENSG00000120907 "Adrenoceptor alpha 1A" P35348 8 26748150-26867273 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 45.1" "Group enriched" "Detected in some" 5 "ASC diff: 1.3;HAP1: 1.8;NTERA-2: 2.4;U-2 OS: 1.5" "Cancer enhanced" "Detected in some" "liver cancer: 0.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029678, HPA029679" Approved Supported "HPA029678: AB_10602108, HPA029679: " "unprognostic (1.27e-1)" "unprognostic (1.68e-2)" "unprognostic (1.99e-1)" "unprognostic (3.57e-1)" "unprognostic (5.04e-4)" "unprognostic (1.97e-1)" "unprognostic (9.55e-2)" "unprognostic (3.08e-1)" "unprognostic (1.58e-2)" "unprognostic (7.47e-2)" "unprognostic (1.71e-2)" "unprognostic (6.06e-3)" "unprognostic (7.41e-2)" "unprognostic (1.52e-2)" "unprognostic (1.30e-1)" 14.5 0.7 7.1 1.1 3.9 0.3 3.4 6.2 4.9 0.9 1.5 5.9 4.9 1.0 1.8 2.0 0.9 0.6 0.5 10.1 11.6 2.0 0.8 45.1 3.9 1.4 4.7 4.7 1.0 0.5 0.3 0.6 0.3 3.8 10.2 0.7 0.6 4.6 11.2 0.6 0.9 1.3 2.4 1.9 7.0 1.2 0.5 4.2 0.0 0.6 0.1 0.6 0.6 0.7 0.3 0.0 0.3 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.1 1.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.4 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.3 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.3 0.0 0.2 0.3 0.2 0.0 0.0 0.0 0.0 7.1 3.9 6.2 4.9 11.6 2.0 4.7 4.7 3.8 4.2 ADRA1B ENSG00000170214 "Adrenoceptor alpha 1B" P35368 5 159865080-159972544 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 21.6;liver: 20.3;lymphoid tissue: 17.4" "Cell line enhanced" "Detected in some" "EFO-21: 13.0;HaCaT: 6.6;TIME: 11.0;U-2 OS: 9.2;U-251 MG: 7.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA074416 Supported "Plasma membrane" "Plasma membrane" "HPA074416: " "unprognostic (4.93e-3)" "unprognostic (2.94e-2)" "unprognostic (1.79e-1)" "prognostic unfavourable (6.00e-5)" "prognostic unfavourable (6.98e-4)" "unprognostic (4.08e-3)" "unprognostic (1.67e-3)" "unprognostic (1.68e-1)" "unprognostic (6.12e-2)" "prognostic favourable (2.67e-4)" "unprognostic (2.28e-1)" "unprognostic (1.37e-1)" "prognostic unfavourable (1.40e-6)" "unprognostic (5.24e-4)" "unprognostic (2.54e-1)" "prognostic favourable (3.19e-5)" "unprognostic (1.59e-2)" 5.3 2.9 5.3 0.9 9.0 0.4 2.3 1.3 21.6 0.9 1.2 0.7 0.8 1.2 1.5 3.6 1.1 3.6 1.3 3.3 6.2 5.8 7.4 20.3 4.7 2.3 1.2 13.9 6.2 0.8 1.0 0.8 1.1 5.2 1.6 1.1 0.9 1.0 1.9 1.6 1.3 1.7 1.2 0.9 17.4 0.9 0.8 0.5 0.0 2.0 0.0 1.1 0.8 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 4.7 0.3 0.0 2.4 0.9 0.1 0.5 0.2 0.6 0.3 0.0 4.2 0.0 13.0 3.8 6.6 0.0 0.5 0.3 0.0 0.3 0.0 1.6 0.0 5.0 0.0 0.0 2.8 0.0 0.0 0.2 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.1 0.6 0.0 0.7 0.0 4.5 0.0 0.4 0.0 0.0 0.3 0.4 0.1 0.0 11.0 0.1 9.2 0.0 7.0 0.0 0.0 0.0 3.3 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.3 9.0 1.3 21.6 6.2 5.8 1.2 13.9 5.2 0.5 ADRA1D "ADRA1, ADRA1A, ADRA1R" ENSG00000171873 "Adrenoceptor alpha 1D" P25100 20 4220631-4249074 "FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 17.7" "Cell line enhanced" "Detected in some" "A549: 2.7;BJ: 11.7;CAPAN-2: 5.3;fHDF/TERT166: 6.9" "Low cancer specificity" "Detected in some" "Group enriched" "Detected in many" 4 "cerebral cortex: 7.4;hippocampal formation: 17.7" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "cerebral cortex: 23.5;hippocampal formation: 31.8;olfactory region: 11.0" "Low region specificity" "Detected in many" HPA038789 Uncertain "HPA038789: AB_10673475" "unprognostic (5.37e-2)" "unprognostic (4.65e-1)" "unprognostic (8.73e-2)" "unprognostic (7.75e-11)" "unprognostic (7.83e-3)" "unprognostic (1.54e-2)" "unprognostic (7.62e-2)" "unprognostic (7.82e-4)" "unprognostic (4.41e-3)" "unprognostic (8.37e-2)" "unprognostic (6.09e-2)" "unprognostic (7.24e-3)" "unprognostic (7.71e-7)" "unprognostic (5.21e-3)" "unprognostic (2.76e-1)" "unprognostic (6.01e-3)" "unprognostic (3.32e-5)" 2.5 1.1 1.9 0.5 2.8 0.3 1.0 0.1 7.4 9.1 2.4 1.4 1.1 0.6 4.7 1.8 0.9 3.5 1.2 0.4 17.7 1.7 0.5 0.4 2.9 1.5 0.5 1.1 1.0 1.2 0.4 0.0 0.7 2.9 8.8 1.0 0.0 0.8 6.0 1.2 0.4 0.8 1.6 0.5 3.6 2.5 1.5 0.0 0.0 0.9 0.0 0.4 3.3 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.2 0.0 0.0 0.0 0.0 11.7 2.1 0.8 0.2 0.5 5.3 0.0 0.0 6.9 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.7 0.3 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.4 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 2.8 0.1 7.4 17.7 1.7 0.5 1.1 2.9 0.0 ADRA2B "ADRA2L1, ADRA2RL1, ADRARL1" ENSG00000274286 "Adrenoceptor alpha 2B" P18089 2 96112875-96116245 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "BEWO: 5.2;EFO-21: 3.3;HAP1: 1.8;NTERA-2: 1.8;SCLC-21H: 1.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" HPA066029 Approved "HPA066029: " "unprognostic (6.16e-2)" "unprognostic (1.31e-2)" "unprognostic (1.76e-2)" "unprognostic (4.93e-4)" "unprognostic (1.84e-2)" "unprognostic (5.24e-2)" "unprognostic (6.80e-5)" "unprognostic (4.85e-2)" "unprognostic (1.69e-1)" "unprognostic (3.16e-2)" "unprognostic (8.34e-2)" "unprognostic (2.54e-1)" "unprognostic (2.21e-1)" "unprognostic (4.43e-2)" "unprognostic (3.39e-1)" "unprognostic (1.36e-1)" "unprognostic (6.55e-2)" 4.9 2.2 0.3 0.4 2.2 1.2 8.1 0.1 0.7 4.5 4.0 1.9 0.2 0.5 1.3 7.5 4.3 0.8 3.2 6.1 0.5 2.9 7.5 0.3 0.2 4.4 0.0 5.0 2.3 1.0 0.0 1.3 3.3 3.3 0.4 0.9 1.8 2.9 8.0 0.3 1.2 2.1 0.6 4.8 0.7 2.6 1.9 0.0 2.1 1.8 0.0 3.8 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.1 0.2 0.0 3.3 0.0 0.3 1.8 0.0 0.0 0.0 0.8 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.7 0.0 0.1 1.8 0.3 0.0 0.0 0.4 0.0 0.3 1.4 0.0 0.0 1.2 0.0 0.3 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ADRA2C "ADRA2L2, ADRA2RL2, ADRARL2" ENSG00000184160 "Adrenoceptor alpha 2C" P18825 4 3766348-3768526 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "cervix, uterine: 35.1" "Cell line enhanced" "Detected in some" "Hep G2: 11.0;MCF7: 18.2;NTERA-2: 6.4;SCLC-21H: 7.0;SH-SY5Y: 8.5;T-47d: 6.0" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 5 "basal ganglia: 9.8" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Region enriched" "Detected in many" 6 "basal ganglia: 41.4" HPA057688 Uncertain "HPA057688: " "unprognostic (1.44e-2)" "unprognostic (2.21e-3)" "unprognostic (1.23e-1)" "unprognostic (2.02e-2)" "unprognostic (4.70e-2)" "unprognostic (1.11e-1)" "unprognostic (7.12e-2)" "unprognostic (6.69e-2)" "unprognostic (1.88e-1)" "unprognostic (3.71e-1)" "unprognostic (3.24e-2)" "unprognostic (9.08e-3)" "unprognostic (1.01e-2)" "unprognostic (6.00e-2)" "unprognostic (2.63e-1)" "unprognostic (1.72e-1)" "unprognostic (6.48e-2)" 6.5 2.4 2.1 1.0 9.8 0.4 9.2 0.5 2.6 35.1 1.5 0.6 12.8 1.0 20.3 18.0 2.1 6.4 5.5 3.0 1.2 1.0 9.2 1.3 2.0 1.2 0.7 1.6 7.6 4.1 0.5 4.2 27.6 1.1 7.3 0.6 3.6 0.8 24.6 2.6 2.1 0.9 3.0 0.7 7.5 0.7 6.2 2.0 0.2 0.8 1.9 0.5 2.1 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.1 0.1 0.5 0.0 0.2 0.4 0.0 0.0 0.0 2.0 1.2 0.0 2.1 0.3 0.0 0.2 0.0 0.0 0.0 5.6 0.0 0.0 11.0 0.6 0.0 0.8 0.9 0.4 0.0 0.0 0.0 0.4 0.0 2.7 18.2 0.0 0.0 6.4 0.0 0.0 5.9 0.0 0.0 0.3 7.0 8.5 2.5 0.0 0.1 6.0 0.1 0.0 0.0 4.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 9.8 0.5 1.4 1.2 1.0 0.7 1.6 1.1 2.0 ADRB1 ADRB1R ENSG00000043591 "Adrenoceptor beta 1" P08588 10 114044056-114046908 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 48.0;placenta: 41.7" "Cell line enhanced" "Detected in some" "HDLM-2: 10.0;THP-1: 6.8;TIME: 8.7;U-937: 5.1" "Cancer enriched" "Detected in many" 10 "prostate cancer: 12.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "myeloid DC: 1.9" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in many" 4 "amygdala: 10.0;basal ganglia: 7.3;cerebral cortex: 17.1;hippocampal formation: 11.3;thalamus: 6.9" "Low region specificity" "Detected in many" HPA067972 Enhanced "HPA067972: " "unprognostic (1.45e-3)" "unprognostic (1.18e-3)" "unprognostic (1.44e-1)" "unprognostic (4.92e-2)" "unprognostic (3.22e-1)" "unprognostic (8.88e-2)" "unprognostic (9.28e-2)" "unprognostic (3.52e-2)" "unprognostic (1.51e-1)" "unprognostic (1.96e-2)" "unprognostic (2.77e-4)" "unprognostic (1.33e-1)" "unprognostic (7.80e-3)" "unprognostic (1.53e-1)" "unprognostic (1.85e-1)" "unprognostic (1.59e-2)" "unprognostic (1.44e-1)" 4.3 1.0 6.9 1.1 14.0 1.3 5.9 1.0 10.7 0.8 3.1 0.8 0.0 1.8 0.9 0.9 1.9 0.8 0.9 48.0 5.6 2.4 1.7 2.5 18.3 0.9 3.5 4.4 0.8 2.4 0.9 1.2 41.7 2.6 6.5 1.6 4.5 10.7 0.8 3.1 0.9 2.3 0.9 1.3 1.7 1.4 1.0 2.5 0.0 1.0 0.0 1.1 1.1 0.4 1.4 1.9 0.1 1.3 0.0 0.5 0.1 2.0 1.2 0.2 1.3 0.0 0.0 0.3 0.1 0.1 0.2 0.2 0.5 1.6 0.3 0.4 0.0 0.4 0.1 0.1 0.3 10.0 0.6 0.4 0.2 0.2 0.0 0.4 0.7 0.0 1.1 0.0 2.0 0.2 0.1 0.1 0.2 1.2 1.6 1.4 0.4 3.9 0.3 0.4 0.1 0.0 1.7 0.2 0.3 0.0 0.8 0.1 0.3 6.8 8.7 0.3 0.1 0.2 0.2 0.0 0.1 0.5 0.0 5.1 0.2 0.0 1.3 0.0 0.5 0.9 0.0 0.6 0.1 0.3 1.9 1.4 0.0 0.4 0.1 0.0 0.1 0.2 0.0 0.1 6.9 14.0 1.0 10.7 5.6 2.4 3.5 4.4 2.6 2.5 ADRB2 "ADRB2R, ADRBR, B2AR, BAR" ENSG00000169252 "Adrenoceptor beta 2" P07550 5 148825245-148828687 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 34.6" "Cell line enhanced" "Detected in many" "hTCEpi: 24.0;hTERT-HME1: 25.0;PC-3: 10.3" "Low cancer specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003431, HPA075322" Uncertain Uncertain Cytosol Cytosol "HPA003431: AB_1845333, HPA075322: " "unprognostic (2.28e-2)" "unprognostic (1.50e-1)" "unprognostic (1.21e-1)" "unprognostic (1.17e-2)" "unprognostic (1.69e-1)" "unprognostic (1.17e-1)" "unprognostic (9.35e-3)" "unprognostic (5.54e-2)" "unprognostic (2.34e-1)" "unprognostic (9.85e-2)" "unprognostic (3.17e-2)" "unprognostic (2.23e-1)" "prognostic favourable (3.15e-9)" "unprognostic (1.55e-2)" "unprognostic (1.46e-1)" "unprognostic (1.49e-1)" "unprognostic (7.65e-2)" 11.7 0.2 0.7 0.9 0.4 4.6 13.8 0.0 0.3 6.1 0.9 0.3 0.9 0.2 6.4 1.4 1.1 2.8 0.7 0.3 0.2 6.0 8.5 1.1 0.9 0.0 0.0 0.5 0.0 4.0 3.8 0.7 3.3 0.1 4.4 15.9 1.3 1.2 1.0 3.7 2.9 0.0 0.5 2.0 2.3 5.4 4.8 6.1 14.0 10.8 7.3 34.6 9.6 7.5 0.0 0.0 0.0 0.3 0.0 0.0 1.4 4.3 2.0 2.2 0.0 3.2 0.0 2.1 0.4 6.7 0.0 9.1 2.3 0.0 0.2 0.0 1.6 0.0 0.2 0.0 3.8 0.0 24.0 0.6 25.0 0.9 0.0 2.8 5.2 0.0 0.0 4.1 0.1 10.3 2.2 1.4 4.2 1.0 1.9 0.0 0.0 1.8 0.1 0.6 0.0 2.3 4.0 0.0 1.7 2.4 1.1 0.7 0.0 0.1 0.0 4.9 0.8 3.5 4.7 14.0 34.6 7.8 25.7 4.8 8.2 20.9 5.3 3.0 1.4 12.9 7.6 7.3 10.8 6.1 0.4 9.6 ADRB3 ENSG00000188778 "Adrenoceptor beta 3" P13945 8 37962991-37966965 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Diabetes mellitus, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 23.9;ovary: 15.7;smooth muscle: 10.8" "Cell line enhanced" "Detected in some" "HeLa: 2.3;Karpas-707: 1.0;U-2 OS: 1.3" "Not detected" "Not detected" "Region enhanced" "Detected in single" "amygdala: 1.3" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in some" "Not detected" "Not detected" HPA061969 Uncertain "HPA061969: " "unprognostic (1.70e-1)" "unprognostic (2.24e-1)" "unprognostic (6.64e-3)" "unprognostic (5.41e-1)" "unprognostic (1.07e-2)" "unprognostic (1.07e-1)" "unprognostic (1.14e-1)" "unprognostic (9.49e-2)" "unprognostic (2.33e-1)" "unprognostic (1.06e-3)" "unprognostic (3.77e-2)" "unprognostic (2.29e-8)" "unprognostic (1.10e-3)" "unprognostic (2.81e-2)" "unprognostic (5.37e-2)" "unprognostic (6.06e-3)" 0.4 0.1 1.3 1.9 0.3 0.3 0.3 0.0 0.8 1.6 2.3 0.0 0.0 0.4 0.9 1.9 1.7 5.3 23.9 0.1 0.2 0.1 0.1 0.0 0.2 1.2 0.0 0.0 15.7 0.0 0.0 0.0 4.7 0.0 4.1 0.4 0.0 0.0 0.1 0.0 0.1 0.9 10.8 0.0 0.0 3.0 0.2 0.0 0.0 0.0 0.0 0.1 9.9 1.5 0.9 0.2 1.2 0.4 0.8 0.5 0.0 0.2 0.2 0.1 0.1 0.2 0.6 0.0 0.1 0.0 0.1 0.0 0.0 0.6 0.3 0.0 0.3 0.0 0.3 0.0 0.1 0.1 0.0 0.0 2.3 0.4 0.8 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.2 1.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.3 0.0 0.0 0.1 0.4 0.3 0.4 1.3 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.0 1.0 0.3 0.3 0.1 0.1 0.4 0.7 0.2 0.1 0.0 0.9 0.2 0.2 1.2 0.8 0.4 0.2 0.5 0.0 1.3 0.3 0.0 0.8 0.2 0.1 0.0 0.0 0.0 0.0 AGTR1 "AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R" ENSG00000144891 "Angiotensin II receptor type 1" P30556 3 148697784-148743008 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 29.6;placenta: 44.9" "Cell line enhanced" "Detected in some" "ASC diff: 62.9;ASC TERT1: 8.8;BJ hTERT+ SV40 Large T+: 12.0;HBF TERT88: 18.9;HSkMC: 11.4" "Group enriched" "Detected in many" 8 "breast cancer: 9.6;liver cancer: 9.8;prostate cancer: 6.8;renal cancer: 2.8" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA003596 Enhanced Uncertain Vesicles Vesicles "HPA003596: AB_1845163" "unprognostic (2.19e-1)" "unprognostic (1.17e-1)" "unprognostic (8.78e-2)" "unprognostic (2.48e-4)" "unprognostic (5.28e-3)" "unprognostic (1.55e-1)" "unprognostic (3.46e-1)" "unprognostic (1.28e-2)" "unprognostic (3.26e-2)" "unprognostic (3.08e-2)" "unprognostic (9.25e-3)" "unprognostic (4.11e-2)" "unprognostic (4.79e-2)" "unprognostic (3.21e-3)" "unprognostic (1.46e-1)" "unprognostic (2.54e-1)" "unprognostic (5.41e-3)" 18.8 11.6 0.0 0.1 0.0 0.0 10.8 0.0 0.0 0.8 5.5 0.0 0.6 0.5 0.5 2.2 1.6 3.1 0.0 0.1 5.7 29.6 2.6 0.0 0.9 0.8 0.6 0.6 0.8 44.9 1.3 1.0 1.0 1.0 2.9 4.4 0.7 1.1 0.0 2.3 1.7 0.2 4.1 0.0 4.2 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 62.9 8.8 0.0 0.0 1.3 12.0 6.9 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 18.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.4 0.0 1.1 0.6 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 AKR1C2 "BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD" ENSG00000151632 "Aldo-keto reductase family 1 member C2" P52895 10 4987400-5018031 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Lipid metabolism, Steroid metabolism" Oxidoreductase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 71.9;liver: 122.7;tongue: 111.8" "Group enriched" "Detected in some" 4 "A549: 134.6;ASC diff: 167.1;Hep G2: 251.2;RT4: 76.9" "Group enriched" "Detected in many" 6 "cervical cancer: 21.7;head and neck cancer: 31.5;liver cancer: 50.2;lung cancer: 69.0;urothelial cancer: 35.7" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 5 "plasmacytoid DC: 1.4" "Lineage enriched" "Detected in single" 5 "dendritic cells: 1.4" "CAB047304, HPA068265" Enhanced Approved "Nucleoplasm,Nucleoli fibrillar center,Endoplasmic reticulum,Cytosol" "Nucleoplasm, Cytosol" "Nucleoli fibrillar center, Endoplasmic reticulum" "CAB047304: , HPA068265: " "unprognostic (6.77e-2)" "unprognostic (8.88e-3)" "unprognostic (3.02e-2)" "unprognostic (2.24e-1)" "unprognostic (1.31e-1)" "unprognostic (1.72e-2)" "unprognostic (2.86e-2)" "unprognostic (8.65e-2)" "unprognostic (5.03e-2)" "unprognostic (2.58e-1)" "unprognostic (1.02e-1)" "unprognostic (6.25e-3)" "unprognostic (8.58e-2)" "unprognostic (1.09e-2)" "unprognostic (8.60e-3)" "unprognostic (1.46e-2)" "unprognostic (8.30e-2)" 60.4 4.0 1.8 2.0 3.3 0.0 71.9 2.5 2.1 1.3 2.9 1.0 1.2 5.5 1.0 3.0 17.4 1.5 19.4 9.3 1.7 2.3 4.8 122.7 5.9 1.1 4.7 0.9 1.9 2.4 0.0 1.8 0.1 4.2 8.1 2.4 2.0 12.0 2.4 19.8 4.2 2.4 4.4 3.9 0.6 26.2 2.3 2.6 0.1 4.2 111.8 5.5 25.3 11.9 0.0 1.4 0.3 0.0 0.0 0.0 0.0 0.0 134.6 0.1 14.2 167.1 5.7 0.0 0.0 0.5 0.0 0.1 0.5 0.0 0.0 0.7 0.9 3.8 0.0 0.7 0.0 0.0 0.0 0.0 38.0 251.2 0.3 0.0 0.0 14.9 8.4 0.7 0.7 0.0 5.1 0.0 1.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 2.2 1.2 76.9 0.0 0.0 1.3 0.0 0.0 0.0 0.2 0.5 0.3 0.1 4.9 0.0 0.0 0.0 0.0 1.7 2.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 1.8 3.3 2.5 2.1 1.7 2.3 4.7 0.9 4.2 2.6 AKR1D1 SRD5B1 ENSG00000122787 "Aldo-keto reductase family 1 member D1" P51857 7 138002324-138117986 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Bile acid catabolism, Lipid degradation, Lipid metabolism, Steroid metabolism" Oxidoreductase "Disease mutation, FDA approved drug targets, Intrahepatic cholestasis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 38 "liver: 103.2" "Cell line enriched" "Detected in single" 20 "Hep G2: 16.5" "Cancer enriched" "Detected in single" 77 "liver cancer: 20.1" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA057002 Enhanced Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA057002: " "unprognostic (2.38e-1)" "unprognostic (1.65e-2)" "unprognostic (1.02e-2)" "unprognostic (1.52e-2)" "prognostic favourable (9.91e-5)" "unprognostic (6.11e-2)" "unprognostic (2.31e-1)" "unprognostic (1.30e-1)" "unprognostic (6.87e-2)" "unprognostic (2.94e-1)" "unprognostic (9.68e-3)" "unprognostic (2.90e-1)" "unprognostic (5.80e-2)" "unprognostic (3.11e-1)" "unprognostic (1.67e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 103.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.5 2.7 0.5 0.7 0.7 0.2 0.2 0.0 0.2 0.2 0.0 0.0 0.5 0.1 0.0 0.1 0.0 0.8 0.2 0.2 0.1 0.0 0.3 0.0 0.0 0.2 0.3 0.1 0.4 0.3 16.5 0.0 0.5 0.6 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.0 0.0 0.3 0.2 0.1 0.2 0.1 0.4 0.0 0.3 0.0 0.1 0.2 0.2 0.1 0.1 0.2 0.4 0.2 0.2 0.1 0.3 0.2 0.3 0.3 0.2 0.2 0.2 0.3 2.7 0.5 0.6 0.4 0.4 0.3 0.6 0.4 0.4 0.3 1.1 0.5 0.7 1.8 0.7 0.5 0.5 0.5 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 ALAD "ALADH, PBGS" ENSG00000148218 "Aminolevulinate dehydratase" P13716 9 113386317-113401333 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Heme biosynthesis, Porphyrin biosynthesis" "Allosteric enzyme, Lyase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 84.2" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA021023, HPA022124" Enhanced 44000000 "HPA021023: AB_1844716, HPA022124: AB_1844717" "unprognostic (2.75e-1)" "unprognostic (6.26e-2)" "prognostic unfavourable (7.33e-5)" "prognostic favourable (5.64e-4)" "unprognostic (4.16e-2)" "unprognostic (9.49e-2)" "prognostic favourable (8.80e-5)" "unprognostic (2.87e-3)" "unprognostic (3.49e-1)" "unprognostic (2.95e-1)" "unprognostic (1.62e-1)" "unprognostic (3.31e-2)" "prognostic favourable (1.65e-4)" "unprognostic (1.75e-1)" "unprognostic (1.22e-1)" "unprognostic (3.40e-1)" "unprognostic (1.31e-2)" 19.9 70.3 24.1 6.4 26.3 27.3 13.7 14.0 24.8 8.3 10.5 28.3 8.8 11.6 7.5 11.5 14.6 6.8 13.0 23.3 24.6 20.8 29.9 84.2 8.4 5.9 37.5 20.6 12.3 18.8 24.1 7.2 10.2 27.9 14.5 10.2 9.8 37.2 15.1 10.6 15.6 10.7 8.9 40.1 5.9 18.1 5.4 28.6 4.7 10.9 6.6 7.5 9.0 8.0 7.6 12.1 19.1 13.1 5.5 9.7 7.6 3.4 6.0 4.7 6.6 32.9 22.7 30.0 9.3 15.7 6.2 7.8 8.3 7.2 4.8 5.7 13.2 12.7 3.4 6.4 3.6 12.0 4.3 9.6 7.5 10.9 7.5 8.7 8.2 19.1 4.8 5.6 2.5 12.1 3.6 7.2 10.1 25.1 10.0 8.7 2.4 11.9 7.9 8.2 8.3 9.6 7.2 4.3 4.1 11.8 14.4 8.5 15.2 10.0 13.1 5.5 4.2 10.8 5.2 10.7 10.0 3.8 15.5 8.1 5.9 7.2 11.5 19.1 9.7 13.1 5.4 5.9 8.4 5.4 12.1 7.6 8.1 8.9 5.6 5.5 12.7 4.9 8.5 7.6 24.1 26.3 14.0 24.8 24.6 20.8 37.5 20.6 27.9 28.6 ALDH2 ENSG00000111275 "Aldehyde dehydrogenase 2 family (mitochondrial)" P05091 12 111766887-111817529 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 279.7" "Cell line enhanced" "Detected in many" "ASC diff: 26.2;HHSteC: 29.4;SK-BR-3: 59.1;THP-1: 26.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 45.8;myeloid DC: 46.6" "Group enriched" "Detected in many" 4 "dendritic cells: 46.6;monocytes: 45.8" HPA051065 Approved 1400000 "HPA051065: " "unprognostic (9.22e-3)" "unprognostic (1.20e-2)" "unprognostic (4.14e-3)" "prognostic favourable (2.63e-4)" "unprognostic (1.16e-1)" "unprognostic (1.32e-3)" "prognostic favourable (3.95e-7)" "unprognostic (5.62e-3)" "unprognostic (3.00e-1)" "unprognostic (1.16e-1)" "unprognostic (8.22e-2)" "unprognostic (1.51e-1)" "prognostic favourable (5.24e-6)" "unprognostic (9.70e-2)" "unprognostic (3.40e-1)" "unprognostic (1.50e-2)" "prognostic unfavourable (7.71e-4)" 88.9 34.0 42.1 17.0 44.6 9.9 39.6 14.3 30.9 10.4 25.3 17.5 16.8 25.6 9.0 11.6 26.4 10.3 28.5 45.0 30.9 24.2 59.0 279.7 38.1 13.3 34.1 32.6 16.1 14.0 2.2 7.6 4.0 30.6 13.5 26.2 13.1 17.9 30.7 40.1 43.5 25.5 29.4 26.6 8.0 34.9 9.5 23.8 3.3 12.0 28.1 18.2 17.0 22.9 1.4 46.6 10.8 45.8 0.7 0.2 21.7 2.4 3.8 5.5 9.4 26.2 3.9 18.0 2.6 4.9 1.2 0.9 6.7 3.5 0.1 13.5 5.9 4.7 0.0 1.3 0.8 0.1 1.8 0.2 2.4 18.2 29.4 0.2 0.2 7.2 6.7 4.4 0.1 7.8 4.9 0.8 1.2 0.1 0.2 6.6 7.3 0.6 0.1 0.1 0.5 9.1 0.1 2.2 6.8 6.6 59.1 0.0 5.9 26.3 0.3 0.1 5.0 0.1 0.1 1.6 0.8 7.1 6.5 0.2 0.1 0.9 45.8 10.8 0.1 20.1 0.2 1.4 0.0 0.1 46.6 1.2 0.1 0.1 2.3 0.7 5.0 15.5 0.1 21.7 42.1 44.6 14.3 30.9 30.9 24.2 34.1 32.6 30.6 23.8 ALDH3B2 ALDH8 ENSG00000132746 "Aldehyde dehydrogenase 3 family member B2" P48448 11 67662162-67681200 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Oxidoreductase "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "breast: 28.1;esophagus: 48.2;lymphoid tissue: 34.2;skin 1: 38.7" "Group enriched" "Detected in some" 5 "MCF7: 30.9;SK-BR-3: 32.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "naive B-cell: 1.0" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" HPA045132 Approved "HPA045132: AB_10795993" "unprognostic (2.25e-1)" "unprognostic (2.41e-1)" "unprognostic (1.65e-1)" "unprognostic (8.65e-2)" "unprognostic (2.13e-1)" "unprognostic (6.09e-2)" "unprognostic (3.12e-2)" "unprognostic (6.32e-2)" "unprognostic (1.48e-1)" "unprognostic (5.56e-2)" "unprognostic (1.24e-2)" "unprognostic (1.40e-2)" "unprognostic (2.59e-2)" "unprognostic (1.61e-1)" "unprognostic (1.15e-2)" "unprognostic (5.92e-2)" 0.1 0.0 0.1 0.1 0.1 0.0 28.1 0.1 0.1 6.7 0.1 0.1 5.0 0.0 1.5 2.4 48.2 1.5 0.1 0.1 0.1 0.0 0.6 0.1 0.6 0.1 0.1 0.1 0.4 0.1 0.6 0.3 11.2 0.1 1.8 0.0 0.1 17.1 4.6 0.1 38.7 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.8 0.1 25.7 34.2 4.6 11.6 1.0 0.1 0.6 0.2 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.5 1.8 1.6 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 30.9 2.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 4.6 0.0 0.0 0.0 32.0 0.0 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.2 0.6 0.0 0.2 0.0 0.0 0.0 0.0 0.1 1.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 ALK CD246 ENSG00000171094 "ALK receptor tyrosine kinase" Q9UM73 2 29192774-29921566 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 8.1;pituitary gland: 17.9" "Cell line enriched" "Detected in some" 6 "SH-SY5Y: 26.4" "Group enriched" "Detected in some" 5 "glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010694 Approved Supported "Plasma membrane" "Plasma membrane" "HPA010694: AB_1078133" "unprognostic (4.96e-2)" "unprognostic (1.11e-2)" "unprognostic (1.45e-1)" "unprognostic (4.56e-7)" "unprognostic (7.17e-2)" "unprognostic (1.71e-1)" "unprognostic (9.07e-3)" "unprognostic (6.29e-3)" "unprognostic (1.18e-1)" "unprognostic (1.01e-1)" "unprognostic (2.67e-4)" "unprognostic (3.70e-2)" "unprognostic (2.06e-2)" "unprognostic (7.15e-2)" "unprognostic (1.98e-1)" "unprognostic (1.38e-1)" "unprognostic (3.61e-2)" 1.8 3.1 3.6 1.2 4.4 0.3 1.1 0.5 8.1 0.7 2.1 2.0 0.0 0.7 0.5 0.5 0.6 0.5 1.2 0.4 3.4 4.9 0.4 0.5 1.1 0.5 2.7 4.2 0.6 0.4 0.4 17.9 0.5 5.5 0.5 1.2 2.4 0.9 0.8 0.3 0.9 1.5 0.9 2.1 0.5 0.8 4.9 0.9 0.0 1.6 0.0 0.3 0.6 1.2 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 3.5 0.0 0.0 0.1 0.3 26.4 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 3.1 0.0 4.0 0.0 0.1 0.0 0.7 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 3.6 4.4 0.5 5.9 3.4 4.9 2.7 4.2 5.5 0.9 ALOX5 5-LOX ENSG00000012779 "Arachidonate 5-lipoxygenase" P09917 10 45374176-45446119 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Leukotriene biosynthesis" "Dioxygenase, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 45.2;bone marrow: 39.9;lymphoid tissue: 41.8" "Cell line enhanced" "Detected in some" "BEWO: 7.8;Daudi: 21.8;HMC-1: 15.6;Karpas-707: 6.9;RT4: 10.2;U-266/70: 10.3;U-698: 7.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA071285 Enhanced Supported Nucleoplasm Nucleoplasm "HPA071285: " "unprognostic (2.57e-2)" "unprognostic (2.81e-1)" "unprognostic (4.82e-2)" "unprognostic (1.75e-2)" "unprognostic (7.98e-3)" "unprognostic (1.26e-1)" "unprognostic (5.32e-2)" "unprognostic (8.69e-2)" "unprognostic (1.86e-2)" "unprognostic (6.91e-2)" "unprognostic (5.04e-2)" "unprognostic (3.42e-1)" "prognostic unfavourable (1.80e-5)" "unprognostic (5.59e-3)" "unprognostic (4.22e-2)" "unprognostic (1.53e-1)" "prognostic favourable (7.18e-4)" 7.4 3.9 2.9 18.3 7.4 39.9 5.8 13.2 3.2 3.4 6.5 6.4 1.0 4.5 3.2 4.7 4.9 5.4 8.0 6.1 3.9 2.6 4.8 2.6 34.7 36.9 9.0 1.7 2.6 10.0 1.3 1.7 11.2 6.1 7.8 3.4 3.2 6.6 3.4 1.1 2.9 14.4 7.8 8.4 41.8 4.5 2.0 6.2 2.4 3.0 1.4 16.7 27.2 10.5 14.8 11.1 45.2 21.3 0.0 0.5 9.5 0.0 0.0 0.0 0.0 0.0 0.0 7.8 0.0 0.0 0.0 0.0 0.0 6.0 21.8 0.7 0.0 0.3 0.2 0.0 0.0 0.4 0.2 4.2 0.0 0.0 0.0 0.0 15.6 0.0 0.0 0.0 0.0 0.0 0.1 6.9 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.8 0.2 10.2 0.5 0.0 0.0 0.2 0.0 0.1 0.5 0.0 0.0 1.2 0.0 0.0 10.3 1.9 7.2 0.0 0.1 0.0 36.7 21.3 27.0 0.0 20.0 0.1 14.8 0.5 0.2 11.1 10.4 0.0 0.0 45.2 0.0 19.6 0.3 0.1 9.5 2.9 7.4 13.2 3.2 3.9 2.6 9.0 1.7 6.1 6.2 ALPPL2 ENSG00000163286 "Alkaline phosphatase, placental like 2" P10696 2 232406843-232410714 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "fallopian tube: 4.2;lung: 9.4" "Group enriched" "Detected in some" 4 "CAPAN-2: 24.5;HaCaT: 18.0" "Cancer enhanced" "Detected in many" "endometrial cancer: 49.1;testis cancer: 64.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB020698, HPA038764, HPA038765, HPA051699" Supported Approved "Plasma membrane" "Intracellular and membrane" "Plasma membrane" "CAB020698: , HPA038764: , HPA038765: , HPA051699: " "unprognostic (1.39e-1)" "unprognostic (6.63e-3)" "unprognostic (1.27e-2)" "unprognostic (2.89e-1)" "unprognostic (1.46e-1)" "unprognostic (1.26e-1)" "unprognostic (1.69e-3)" "unprognostic (1.65e-1)" "unprognostic (2.67e-1)" "unprognostic (6.72e-3)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 1.0 0.0 0.0 0.2 1.5 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 9.4 0.0 0.0 0.0 1.5 0.0 0.0 0.0 1.9 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.6 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.5 24.5 0.0 0.0 0.0 18.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 AMY2A AMY2 ENSG00000243480 "Amylase, alpha 2A (pancreatic)" P04746 1 103616811-103625780 "Enzymes, FDA approved drug targets, Predicted secreted proteins" "Carbohydrate metabolism" "Glycosidase, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 31 "pancreas: 1849.4" "Cell line enhanced" "Detected in some" "THP-1: 1.0;U-2 OS: 1.2" "Cancer enriched" "Detected in single" 2010 "pancreatic cancer: 200.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA045394, HPA045399, CAB045960, HPA046980" Enhanced "Secreted to digestive system" 77000000 "CAB045960: AB_2226891, HPA045394: , HPA045399: , HPA046980: " "unprognostic (3.27e-1)" "unprognostic (1.78e-3)" "unprognostic (3.24e-2)" "unprognostic (1.29e-1)" "unprognostic (2.13e-2)" 0.2 0.0 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.9 1849.4 0.0 0.2 0.2 0.2 0.2 0.0 0.2 59.9 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.3 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 ANO1 "DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A" ENSG00000131620 "Anoctamin 1" Q5XXA6 11 70078302-70189528 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Developmental protein, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "ductus deferens: 142.4;epididymis: 38.5;salivary gland: 122.9;seminal vesicle: 93.6" "Group enriched" "Detected in some" 5 "A-431: 33.8;CAPAN-2: 52.0;HaCaT: 63.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA032148, HPA057356" Enhanced Supported "Nucleoplasm,Plasma membrane" "Plasma membrane" Nucleoplasm "HPA032148: , HPA057356: " "unprognostic (2.73e-1)" "unprognostic (7.91e-2)" "unprognostic (3.66e-2)" "prognostic favourable (4.58e-6)" "unprognostic (1.90e-1)" "prognostic unfavourable (7.28e-5)" "unprognostic (1.16e-3)" "prognostic unfavourable (2.40e-4)" "unprognostic (2.13e-2)" "unprognostic (3.51e-1)" "prognostic unfavourable (1.70e-4)" "unprognostic (1.21e-1)" "prognostic unfavourable (4.09e-6)" "unprognostic (1.56e-1)" "unprognostic (1.06e-1)" "unprognostic (8.85e-3)" "unprognostic (1.81e-1)" 6.9 0.4 1.1 2.1 1.1 0.0 17.2 1.6 1.4 9.7 5.3 1.1 142.4 0.2 14.2 38.5 3.6 11.7 10.6 6.9 1.1 0.2 2.6 24.4 4.4 1.5 1.0 1.0 3.9 4.5 0.5 2.0 6.2 1.5 7.2 1.7 1.7 122.9 93.6 3.4 19.1 1.8 5.7 1.0 1.1 9.5 7.6 0.9 1.1 8.9 8.1 3.8 4.5 5.9 0.0 0.0 0.0 0.0 0.0 0.3 0.0 33.8 1.3 0.0 1.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 52.0 0.0 0.6 0.0 63.4 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.2 4.9 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.0 10.8 0.2 4.1 0.1 0.1 0.0 0.3 0.0 0.8 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 1.1 1.6 1.4 1.1 0.2 1.0 1.0 1.5 0.9 ANXA1 "ANX1, LPC1" ENSG00000135046 "Annexin A1" P04083 9 73151757-73170393 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters" "Adaptive immunity, Immunity, Inflammatory response, Innate immunity" "Phospholipase A2 inhibitor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 432.6;tongue: 235.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA011271, HPA011272, CAB013023, CAB035987, CAB058693" Enhanced Enhanced "Nucleoplasm,Plasma membrane,Cytosol" "Secreted to blood" 77000000 "Plasma membrane, Cytosol" Nucleoplasm "CAB013023: AB_2533983, CAB035987: , CAB058693: , HPA011271: AB_1844883, HPA011272: AB_1844884" "unprognostic (2.53e-2)" "unprognostic (1.31e-1)" "unprognostic (9.08e-2)" "prognostic favourable (5.71e-5)" "unprognostic (1.53e-2)" "unprognostic (4.28e-2)" "unprognostic (1.82e-2)" "unprognostic (1.30e-2)" "unprognostic (1.30e-1)" "unprognostic (1.14e-1)" "unprognostic (2.54e-3)" "unprognostic (1.47e-1)" "unprognostic (9.82e-3)" "unprognostic (1.13e-1)" "unprognostic (8.55e-2)" "prognostic favourable (4.57e-5)" "prognostic unfavourable (6.19e-6)" 52.7 3.5 2.7 11.5 3.3 81.4 45.9 0.9 2.5 61.5 8.5 3.6 5.5 2.4 6.9 11.2 432.6 11.9 14.9 8.9 3.2 2.5 9.1 2.1 37.3 7.6 4.3 1.9 11.7 2.4 0.5 6.3 149.5 13.5 12.9 4.4 6.4 93.0 7.2 7.9 11.6 6.4 12.3 6.5 5.9 5.9 5.6 3.1 3.9 21.7 235.4 153.3 18.0 83.1 0.7 98.9 146.2 79.1 27.3 52.5 102.8 65.9 104.2 4.7 4.9 66.5 63.3 0.3 114.3 71.4 47.3 32.1 3.0 59.7 0.1 37.8 99.7 81.2 10.1 69.2 37.5 37.3 0.7 5.0 31.0 0.1 53.1 11.0 2.5 36.4 57.4 47.8 94.0 67.0 20.9 2.8 58.3 0.2 19.4 6.0 5.9 42.4 0.0 26.6 0.2 106.4 14.0 0.0 0.0 39.3 1.0 26.4 0.2 1.7 82.7 55.5 34.9 76.2 58.6 0.4 0.1 0.2 128.1 10.2 83.4 146.2 79.1 141.1 52.2 21.5 52.5 0.7 47.0 45.9 98.9 0.2 13.7 25.4 8.6 27.3 19.3 3.5 8.3 102.8 2.7 3.3 0.9 2.5 3.2 2.5 4.3 1.9 13.5 3.1 ANXA3 ANX3 ENSG00000138772 "Annexin A3" P12429 4 78551519-78610451 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Phospholipase A2 inhibitor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 83.0" "Cell line enhanced" "Detected in many" "A-431: 52.0;CACO-2: 53.3;CAPAN-2: 72.2;EFO-21: 44.2;hTERT-HME1: 73.6;RPTEC TERT1: 62.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 319 "neutrophil: 51.3" "Lineage enriched" "Detected in single" 319 "granulocytes: 51.3" "Low region specificity" "Detected in all" "HPA013398, HPA013431" Enhanced Enhanced Cytosol 7400000 Cytosol "HPA013398: AB_1844861, HPA013431: AB_1844862" "unprognostic (2.66e-1)" "unprognostic (5.65e-3)" "unprognostic (4.92e-3)" "unprognostic (8.67e-2)" "unprognostic (2.41e-1)" "unprognostic (5.02e-3)" "unprognostic (4.17e-2)" "unprognostic (1.87e-1)" "unprognostic (5.09e-2)" "unprognostic (2.10e-3)" "prognostic unfavourable (1.28e-4)" "unprognostic (4.82e-2)" "prognostic favourable (8.48e-6)" "unprognostic (2.23e-1)" "unprognostic (2.02e-2)" "unprognostic (7.20e-2)" "unprognostic (3.30e-2)" 20.3 1.1 4.0 7.1 7.4 83.0 16.2 2.4 6.8 7.0 8.5 2.3 0.9 4.2 3.4 4.2 25.0 4.6 11.7 20.5 5.2 5.2 19.8 1.6 46.0 5.7 6.6 5.6 2.8 14.7 6.5 5.8 33.7 10.4 18.8 7.4 2.6 50.8 3.6 14.2 4.1 9.3 5.3 4.0 11.0 23.4 1.8 5.0 2.0 45.3 13.6 7.4 2.8 5.9 0.1 0.0 51.3 0.1 0.0 0.0 0.5 52.0 9.9 0.1 0.1 0.1 0.2 0.0 0.6 0.0 1.5 1.4 53.3 72.2 0.0 44.2 1.8 20.6 0.0 38.1 2.3 0.2 0.4 4.6 21.3 3.2 6.1 0.6 0.0 0.3 33.8 0.5 73.6 15.1 0.1 0.0 0.2 2.0 0.2 0.0 1.6 7.3 0.0 0.1 0.0 62.0 6.0 0.0 0.0 30.7 7.6 2.2 1.3 0.6 19.1 0.1 6.9 0.0 11.7 0.4 0.6 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 51.3 0.0 0.1 0.0 0.0 0.5 4.0 7.4 2.4 6.8 5.2 5.2 6.6 5.6 10.4 5.0 AOC3 "HPAO, VAP-1, VAP1" ENSG00000131471 "Amine oxidase, copper containing 3" Q16853 17 42851184-42858130 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enriched" "Detected in some" 18 "ASC diff: 83.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 13 "neutrophil: 1.2" "Lineage enriched" "Detected in single" 13 "granulocytes: 1.2" "Low region specificity" "Detected in many" "HPA000980, CAB025797" Enhanced Approved "Golgi apparatus,Cytosol" "Secreted - unknown location" 240000000 Cytosol "Golgi apparatus" "CAB025797: , HPA000980: AB_1078170" "unprognostic (2.20e-1)" "unprognostic (4.49e-2)" "prognostic unfavourable (3.68e-4)" "unprognostic (2.97e-2)" "unprognostic (1.17e-1)" "unprognostic (2.64e-1)" "unprognostic (2.22e-1)" "unprognostic (2.15e-2)" "unprognostic (1.48e-1)" "unprognostic (4.00e-2)" "unprognostic (2.95e-1)" "unprognostic (9.02e-2)" "prognostic unfavourable (1.79e-5)" "unprognostic (5.61e-2)" "unprognostic (1.67e-1)" "unprognostic (8.39e-2)" "prognostic unfavourable (6.98e-4)" 97.0 11.5 0.4 18.7 1.0 0.0 67.7 0.5 1.3 26.9 44.3 1.0 16.3 3.6 44.7 34.8 36.1 18.5 50.9 12.1 0.4 0.4 5.8 8.3 48.0 7.9 0.5 1.2 23.8 2.4 2.2 1.3 10.8 2.0 36.5 9.4 32.1 8.0 24.7 7.7 5.5 15.0 79.2 0.6 7.5 17.7 16.2 0.3 1.0 6.6 11.6 2.6 75.9 20.9 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 83.5 0.1 1.3 0.0 0.0 0.0 0.2 0.2 0.0 0.1 0.2 0.0 0.1 0.2 0.0 0.2 0.3 1.4 0.1 0.1 4.6 0.2 0.0 0.2 0.9 0.2 0.1 0.2 0.0 0.0 0.4 0.1 0.0 0.0 0.3 0.1 0.1 0.2 0.2 0.7 0.0 0.5 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.7 0.3 0.1 1.2 1.3 0.1 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.4 1.0 0.5 1.3 0.4 0.4 0.5 1.2 2.0 0.3 APEX1 "APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1" ENSG00000100823 "Apurinic/apyrimidinic endodeoxyribonuclease 1" P27695 14 20455191-20457772 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair, Transcription, Transcription regulation" "Activator, DNA-binding, Endonuclease, Exonuclease, Hydrolase, Lyase, Nuclease, Repressor, RNA-binding" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000956, HPA002564, CAB004294, CAB047307" Supported Supported Nucleoplasm 98000 Nucleoplasm "CAB004294: AB_626685, CAB047307: , HPA000956: , HPA002564: AB_1078174" "unprognostic (2.80e-3)" "unprognostic (1.39e-1)" "unprognostic (1.55e-2)" "unprognostic (4.74e-3)" "unprognostic (1.97e-2)" "unprognostic (5.88e-2)" "prognostic unfavourable (7.82e-5)" "unprognostic (4.21e-2)" "unprognostic (3.14e-2)" "unprognostic (2.46e-2)" "unprognostic (2.42e-2)" "unprognostic (1.68e-1)" "unprognostic (1.38e-1)" "unprognostic (1.22e-1)" "unprognostic (1.83e-2)" "unprognostic (2.54e-1)" "unprognostic (7.08e-2)" 43.9 52.8 30.6 33.2 32.5 55.6 43.6 24.1 44.9 38.5 41.9 37.3 28.4 44.1 53.2 30.1 40.7 42.9 46.4 34.4 28.0 27.4 44.4 61.3 31.8 44.5 30.2 31.1 64.7 48.4 31.8 21.7 29.4 34.4 36.1 39.8 36.0 35.5 38.9 53.2 41.2 37.6 40.9 30.1 51.0 41.7 20.9 28.3 73.2 51.2 38.5 48.4 41.8 32.7 35.0 53.0 1.5 23.7 20.6 32.5 38.4 43.9 54.1 48.5 44.7 34.1 49.3 41.8 41.3 44.5 61.6 53.5 39.4 43.7 84.9 36.9 31.5 47.2 57.7 43.7 57.2 37.9 24.6 34.4 32.0 65.6 35.9 109.2 35.8 50.9 48.3 40.1 39.8 51.4 39.9 28.0 49.3 42.8 69.9 46.0 47.8 48.9 77.8 54.5 35.6 51.7 59.3 58.5 37.3 44.8 55.9 44.4 34.0 49.4 33.1 32.5 54.5 32.7 38.5 37.6 65.1 57.3 14.5 69.4 41.0 0.1 23.7 1.5 19.0 20.5 25.9 35.0 23.8 22.6 46.8 31.4 32.5 28.3 1.5 20.6 12.4 53.0 14.1 38.4 30.6 32.5 24.1 44.9 28.0 27.4 30.2 31.1 34.4 28.3 APP AD1 ENSG00000142192 "Amyloid beta precursor protein" P05067 21 25880550-26171128 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Cell adhesion, Endocytosis, Notch signaling pathway" "Heparin-binding, Protease inhibitor, Serine protease inhibitor" "Alzheimer disease, Amyloidosis, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "plasmacytoid DC: 24.0" "Lineage enriched" "Detected in many" 6 "dendritic cells: 24.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000157, HPA001462" Enhanced Approved "Golgi apparatus,Vesicles" 15000000 "Golgi apparatus" Vesicles "CAB000157: AB_323833, HPA001462: AB_1078185" "unprognostic (3.30e-1)" "unprognostic (1.02e-2)" "unprognostic (1.90e-1)" "unprognostic (1.24e-1)" "unprognostic (1.92e-1)" "unprognostic (3.69e-3)" "unprognostic (2.54e-1)" "unprognostic (8.22e-2)" "unprognostic (1.28e-1)" "unprognostic (9.45e-2)" "unprognostic (4.28e-2)" "unprognostic (5.35e-2)" "prognostic favourable (2.79e-6)" "unprognostic (3.77e-2)" "unprognostic (2.46e-1)" "unprognostic (5.23e-2)" "unprognostic (2.08e-3)" 44.8 92.5 89.9 26.3 109.3 21.2 79.9 64.5 139.1 51.7 63.4 86.9 72.0 39.7 52.2 57.2 33.0 57.6 63.4 69.1 104.6 97.7 102.2 54.5 50.2 12.9 97.4 95.8 58.9 57.1 36.4 34.1 79.7 83.2 49.2 59.6 48.9 47.2 66.6 17.2 38.2 34.9 69.3 109.0 26.3 37.9 32.2 67.5 13.9 85.0 21.5 16.7 52.5 58.4 1.5 24.0 0.9 3.9 0.3 1.5 1.8 31.5 40.8 44.8 37.3 61.1 75.8 48.4 64.1 85.6 32.5 38.3 23.4 77.6 0.0 74.7 50.1 21.6 27.3 75.3 27.5 1.2 22.0 0.0 24.6 16.4 59.6 29.9 1.6 68.3 83.3 38.1 70.0 145.5 0.0 3.3 51.0 35.4 0.5 0.3 35.2 36.5 19.6 43.2 26.3 110.1 22.2 22.8 33.3 68.8 45.3 32.2 40.1 32.6 155.5 72.4 30.7 26.3 30.3 19.9 0.2 0.3 58.9 0.1 69.5 0.4 3.9 0.0 0.1 1.2 0.2 0.5 1.4 0.5 3.4 1.5 1.5 0.4 0.9 0.3 0.9 24.0 0.3 1.8 89.9 109.3 64.5 124.6 104.6 97.7 97.4 95.8 83.2 67.5 AR "AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1" ENSG00000169083 "Androgen receptor" P10275 X 67544032-67730619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 49.0" "Cell line enhanced" "Detected in some" "AF22: 11.0;BJ hTERT+: 9.6;HAP1: 14.1;LHCN-M2: 12.4;RH-30: 20.5;T-47d: 8.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 16 "plasmacytoid DC: 5.4" "Lineage enriched" "Detected in single" 16 "dendritic cells: 5.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000001, HPA065701, CAB065764" Enhanced Approved Mitochondria Mitochondria "CAB000001: AB_2060174, CAB065764: AB_10620739, HPA065701: " "unprognostic (1.34e-1)" "unprognostic (8.10e-3)" "unprognostic (2.49e-2)" "unprognostic (5.95e-2)" "unprognostic (1.04e-2)" "unprognostic (3.35e-2)" "prognostic favourable (8.77e-4)" "unprognostic (4.99e-2)" "unprognostic (1.72e-1)" "unprognostic (7.79e-2)" "unprognostic (2.30e-1)" "unprognostic (2.29e-1)" "prognostic favourable (1.03e-8)" "unprognostic (8.23e-3)" "unprognostic (8.90e-2)" "unprognostic (4.23e-2)" "unprognostic (7.97e-2)" 10.1 1.2 0.9 1.6 0.9 0.1 10.7 0.4 1.6 34.4 1.9 2.4 25.4 0.2 20.5 20.5 2.2 17.5 4.3 5.7 0.9 1.5 6.3 49.0 1.5 0.2 1.2 0.7 14.4 1.0 0.1 2.3 0.3 1.9 28.0 0.5 3.8 1.6 36.1 8.1 3.9 1.1 7.6 1.9 0.9 1.6 9.3 1.2 5.4 3.1 2.0 1.2 6.3 13.1 0.0 5.4 0.3 0.0 0.1 0.0 0.1 0.0 4.6 11.0 0.0 0.0 0.1 0.0 5.8 9.6 0.4 0.1 0.2 0.0 0.0 0.0 0.7 0.0 14.1 0.0 0.1 0.0 1.8 0.0 1.1 0.0 0.6 0.0 0.0 4.5 0.0 1.6 0.0 3.4 4.0 1.8 12.4 1.2 0.0 0.0 4.4 0.0 0.0 20.5 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 8.6 5.2 0.2 0.2 2.0 0.1 2.9 0.0 0.0 0.0 4.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 5.4 0.0 0.1 0.9 0.9 0.4 1.6 0.9 1.5 1.2 0.7 1.9 1.2 ASIC1 "ACCN2, BNaC2, hBNaC2" ENSG00000110881 "Acid sensing ion channel subunit 1" P78348 12 50057548-50083611 "FDA approved drug targets, Predicted membrane proteins" "Calcium transport, Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 43.7" "Cell line enhanced" "Detected in many" "HEK 293: 16.8;SH-SY5Y: 19.4" "Cancer enhanced" "Detected in many" "glioma: 12.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA058870 Supported "Golgi apparatus,Plasma membrane" "Golgi apparatus, Plasma membrane" "HPA058870: " "unprognostic (5.32e-3)" "unprognostic (1.70e-1)" "unprognostic (4.00e-2)" "unprognostic (3.56e-2)" "unprognostic (2.41e-1)" "unprognostic (3.48e-3)" "unprognostic (2.92e-3)" "unprognostic (3.00e-2)" "unprognostic (1.72e-1)" "unprognostic (9.37e-2)" "unprognostic (2.34e-2)" "unprognostic (2.86e-3)" "unprognostic (6.97e-7)" "unprognostic (7.19e-2)" "unprognostic (3.73e-1)" "unprognostic (2.78e-3)" "unprognostic (8.27e-5)" 2.5 1.7 13.9 1.8 20.3 0.8 2.9 20.1 43.7 5.3 3.1 12.8 0.3 2.3 2.5 1.2 3.4 3.6 4.0 2.2 12.3 14.3 1.6 0.9 1.3 1.3 12.9 8.5 1.4 1.4 5.2 0.5 1.5 10.2 4.5 2.5 1.8 5.6 3.4 1.3 1.5 2.5 3.6 5.4 1.1 4.3 1.4 11.0 0.4 1.1 0.0 1.0 2.6 1.0 0.0 0.0 0.0 0.0 0.0 0.6 0.3 2.1 4.7 6.2 14.0 1.9 2.9 3.5 1.5 4.1 2.7 2.7 3.3 1.7 1.3 3.2 0.9 2.2 6.1 5.2 1.6 1.3 16.8 4.2 6.6 2.0 2.7 6.3 15.8 7.4 2.5 0.4 0.6 0.5 2.8 0.1 2.2 2.6 6.0 12.3 2.6 8.3 6.1 5.9 2.8 1.3 0.2 9.2 19.4 3.5 1.2 2.1 7.7 4.1 0.4 2.7 9.1 1.8 0.8 0.0 0.0 0.0 3.5 5.6 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.3 13.9 20.3 20.1 18.3 12.3 14.3 12.9 8.5 10.2 11.0 ATIC "AICARFT, IMPCHASE, PURH" ENSG00000138363 "5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase" P31939 2 215311817-215349773 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Purine biosynthesis" "Hydrolase, Multifunctional enzyme, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013462, HPA021012" Supported Enhanced "Plasma membrane,Cytosol" 3400000 "Plasma membrane, Cytosol" "CAB013462: , HPA021012: AB_1845169" "unprognostic (1.41e-2)" "unprognostic (2.18e-1)" "unprognostic (1.13e-2)" "unprognostic (8.46e-2)" "unprognostic (2.90e-1)" "unprognostic (3.81e-2)" "prognostic unfavourable (1.99e-7)" "unprognostic (1.86e-2)" "unprognostic (5.07e-2)" "unprognostic (1.83e-1)" "unprognostic (6.31e-3)" "unprognostic (9.21e-2)" "prognostic unfavourable (8.77e-4)" "unprognostic (1.00e-1)" "unprognostic (1.30e-1)" "unprognostic (4.18e-2)" "unprognostic (4.39e-3)" 19.4 27.4 21.1 23.0 28.4 16.9 24.8 12.1 32.3 20.6 26.7 29.1 18.1 23.4 27.9 15.6 19.1 21.9 19.1 18.2 20.3 21.1 23.1 35.6 17.3 36.1 29.7 19.9 23.4 32.9 25.1 21.1 31.1 24.4 21.9 35.9 19.5 14.4 29.4 35.5 17.0 20.6 26.7 21.7 29.0 20.4 15.0 28.0 46.3 16.1 13.5 35.3 27.6 18.0 21.7 13.4 2.9 8.9 19.6 22.8 10.0 20.2 30.7 17.1 29.1 23.0 23.3 8.6 20.7 18.0 23.7 27.2 59.1 31.8 29.5 25.7 21.6 21.3 37.6 31.2 34.0 21.9 36.4 35.9 26.3 53.0 29.8 44.9 18.4 19.7 24.0 31.6 38.2 15.8 46.3 24.6 32.5 29.9 39.1 21.8 65.9 17.2 36.4 24.7 26.4 25.1 32.7 26.9 18.6 16.6 20.5 23.4 33.6 16.0 13.9 20.1 20.8 25.9 13.0 31.1 40.6 61.2 17.5 25.1 29.0 2.9 6.0 0.1 13.2 8.9 22.8 21.7 18.6 20.0 13.4 13.2 18.9 17.5 0.7 19.6 7.4 11.7 17.7 10.0 21.1 28.4 12.1 32.3 20.3 21.1 29.7 19.9 24.4 28.0 ATP1A1 ENSG00000163399 "ATPase Na+/K+ transporting subunit alpha 1" P05023 1 116372668-116410261 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" "Cancer-related genes, Charcot-Marie-Tooth disease, Epilepsy, FDA approved drug targets, Mental retardation, Neurodegeneration, Neuropathy, Primary hypomagnesemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 195.4;parathyroid gland: 194.4" "Cell line enhanced" "Detected in all" "SK-MEL-30: 248.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018702, CAB069993" Enhanced 380000 "CAB018702: AB_626713, CAB069993: AB_2060979" "unprognostic (6.18e-2)" "unprognostic (2.18e-1)" "unprognostic (6.91e-2)" "unprognostic (1.42e-2)" "unprognostic (6.80e-2)" "unprognostic (2.15e-1)" "prognostic unfavourable (1.42e-4)" "unprognostic (1.80e-1)" "unprognostic (1.21e-2)" "unprognostic (6.32e-2)" "unprognostic (1.61e-2)" "unprognostic (1.65e-1)" "prognostic favourable (8.98e-8)" "unprognostic (4.75e-2)" "unprognostic (1.17e-1)" "unprognostic (3.11e-2)" "prognostic unfavourable (4.01e-4)" 17.4 25.6 22.4 16.2 40.3 10.5 26.9 74.2 67.4 17.8 121.9 14.2 56.1 92.3 13.1 38.3 34.9 17.7 65.8 41.1 26.1 18.7 162.7 34.6 35.1 9.6 19.2 27.6 17.4 78.6 194.4 25.0 19.2 34.1 22.1 65.7 24.1 84.4 53.7 19.0 40.5 195.4 17.7 20.7 13.7 25.0 17.0 13.9 9.1 101.2 13.7 16.2 14.2 23.1 10.3 22.0 6.4 29.7 10.4 30.2 17.2 32.9 12.2 12.7 6.3 25.5 24.7 65.2 19.8 39.4 24.4 34.7 48.7 23.7 26.1 28.0 23.4 43.1 25.0 41.7 35.5 9.6 27.7 15.2 23.0 41.1 19.5 38.1 21.4 27.5 69.9 28.4 37.5 29.9 25.0 25.3 21.6 65.6 15.4 13.8 29.8 24.5 14.9 29.6 23.1 88.1 34.0 12.5 11.0 30.7 58.4 248.8 15.3 22.1 26.3 13.9 19.5 35.9 40.0 12.2 9.5 20.1 42.7 22.0 81.6 6.4 13.3 6.1 23.2 20.9 24.8 10.3 26.4 24.9 22.0 5.3 30.2 22.0 1.6 10.4 29.7 11.1 20.3 17.2 22.4 40.3 74.2 67.4 26.1 18.7 19.2 27.6 34.1 13.9 ATP2C1 "ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1" ENSG00000017260 "ATPase secretory pathway Ca2+ transporting 1" P98194 3 130850595-131016712 "Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010207, HPA035116, HPA069684" Supported Supported "Golgi apparatus" 28000 "Golgi apparatus" "CAB010207: AB_2061744, HPA035116: AB_10673106, HPA069684: " "unprognostic (1.52e-1)" "unprognostic (1.37e-1)" "unprognostic (2.74e-2)" "unprognostic (1.08e-1)" "unprognostic (2.99e-1)" "unprognostic (1.32e-2)" "prognostic unfavourable (5.06e-6)" "unprognostic (7.66e-2)" "unprognostic (6.52e-2)" "unprognostic (2.45e-1)" "prognostic unfavourable (1.52e-4)" "unprognostic (8.44e-2)" "prognostic favourable (1.55e-4)" "unprognostic (2.19e-1)" "unprognostic (1.95e-1)" "unprognostic (3.73e-2)" "unprognostic (3.06e-1)" 18.6 22.9 29.6 14.5 29.4 20.4 36.8 24.5 34.6 22.2 21.6 23.0 14.3 14.4 19.3 18.0 16.9 23.4 16.8 19.2 31.6 32.3 28.0 17.1 30.7 16.0 31.8 25.4 18.5 14.6 47.6 31.0 19.6 26.7 54.0 22.4 18.1 20.3 16.6 16.1 21.3 16.0 19.2 44.6 11.1 18.7 16.0 25.6 20.5 21.7 15.5 15.4 19.3 29.6 4.7 7.6 21.6 7.0 8.7 7.2 4.9 36.2 14.2 14.3 13.8 40.0 32.5 15.4 39.6 52.8 19.9 25.2 23.1 29.9 13.1 27.5 37.4 43.2 26.8 21.8 29.2 28.4 9.6 35.0 15.1 10.7 25.6 13.9 42.7 25.4 22.0 20.9 23.8 21.1 10.0 23.9 24.5 16.1 13.6 11.1 16.2 15.5 9.9 14.3 20.7 36.7 24.4 22.1 13.2 34.0 10.6 19.9 15.8 11.5 28.7 21.2 11.9 27.3 18.2 15.5 18.8 19.5 21.9 10.5 17.7 21.6 7.0 12.1 6.3 6.0 5.9 4.7 6.2 5.6 7.6 2.9 4.3 4.3 3.5 8.7 7.0 6.6 7.2 4.9 29.6 29.4 24.5 34.6 31.6 32.3 31.8 25.4 26.7 25.6 ATP4A ATP6A ENSG00000105675 "ATPase H+/K+ transporting alpha subunit" P20648 19 35550043-35563658 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Hydrogen ion transport, Ion transport, Potassium transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 24 "stomach 1: 120.1" "Cell line enhanced" "Detected in some" "THP-1: 1.1;U-138 MG: 1.5" "Cancer enriched" "Detected in single" 21 "stomach cancer: 5.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" HPA039154 Enhanced 790000 "HPA039154: AB_10672772" "unprognostic (3.54e-2)" "unprognostic (6.98e-3)" "unprognostic (2.77e-2)" "unprognostic (1.43e-1)" "unprognostic (5.84e-3)" "unprognostic (4.96e-2)" "unprognostic (1.02e-1)" "unprognostic (1.50e-1)" "unprognostic (9.68e-2)" "unprognostic (1.47e-3)" "unprognostic (3.90e-3)" "unprognostic (3.92e-2)" "unprognostic (4.86e-2)" "unprognostic (1.23e-1)" "unprognostic (2.18e-1)" 0.1 0.2 0.1 0.1 0.6 0.0 0.1 0.1 0.6 0.1 0.1 3.4 0.1 0.0 0.1 0.1 4.9 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 2.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 2.1 0.1 0.1 120.1 0.1 0.1 0.7 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 1.1 0.0 1.5 0.3 0.0 0.0 0.3 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.1 0.6 0.1 0.0 0.1 0.1 0.1 0.1 ATP4B ATP6B ENSG00000186009 "ATPase H+/K+ transporting beta subunit" P51164 13 113648804-113658186 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Cell adhesion, Hydrogen ion transport, Ion transport, Potassium transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 24 "stomach 1: 156.3" "Cell line enhanced" "Detected in some" "REH: 3.8;RPMI-8226: 1.6;SCLC-21H: 2.6" "Cancer enriched" "Detected in some" 12 "stomach cancer: 8.9" "Region enriched" "Detected in single" 9 "cerebral cortex: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA045400, HPA052649" Enhanced "HPA045400: AB_2679314, HPA052649: AB_2681900" "unprognostic (9.92e-2)" "unprognostic (2.19e-1)" "unprognostic (2.66e-1)" "unprognostic (4.86e-1)" "unprognostic (6.43e-3)" "unprognostic (7.81e-3)" "unprognostic (1.95e-1)" "unprognostic (3.22e-1)" "unprognostic (6.50e-2)" "unprognostic (6.65e-4)" "unprognostic (2.25e-1)" "unprognostic (2.78e-1)" "unprognostic (3.78e-2)" 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 1.0 0.1 0.1 2.0 0.1 0.0 0.1 0.1 1.5 1.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 6.5 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 156.3 0.1 0.1 0.6 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 3.8 0.0 1.6 0.0 0.0 2.6 0.9 0.2 0.7 0.0 0.1 0.8 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 1.0 0.1 0.1 0.1 0.1 0.1 0.1 ATP6V1B2 "ATP6B2, HO57, VATB, Vma2, VPP3" ENSG00000147416 "ATPase H+ transporting V1 subunit B2" P21281 8 20197367-20226819 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters" "Hydrogen ion transport, Ion transport, Transport" Hydrolase "Deafness, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 116.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "classical monocyte: 69.7;eosinophil: 47.6;intermediate monocyte: 62.5;myeloid DC: 34.5;neutrophil: 116.0;non-classical monocyte: 54.1" "Group enriched" "Detected in all" 10 "dendritic cells: 34.5;granulocytes: 116.0;monocytes: 69.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008147 Enhanced Supported Vesicles 240000 Vesicles "HPA008147: AB_1845195" "unprognostic (1.90e-1)" "unprognostic (7.24e-3)" "unprognostic (3.62e-2)" "unprognostic (2.57e-1)" "unprognostic (2.84e-2)" "unprognostic (5.59e-3)" "unprognostic (1.76e-2)" "unprognostic (3.78e-2)" "unprognostic (4.68e-2)" "unprognostic (4.23e-3)" "unprognostic (1.29e-2)" "unprognostic (1.34e-1)" "prognostic favourable (8.41e-4)" "unprognostic (2.41e-1)" "unprognostic (2.09e-2)" "unprognostic (2.47e-2)" "unprognostic (5.25e-2)" 17.1 29.9 31.7 25.8 45.0 14.4 13.2 39.2 72.9 12.2 13.9 15.9 5.5 16.2 10.6 12.2 15.3 10.3 14.8 13.9 33.8 47.8 53.9 18.0 22.8 17.5 46.9 47.1 10.9 12.2 18.8 23.6 18.5 64.2 11.0 16.5 17.3 12.8 10.9 18.2 18.2 21.1 15.0 19.2 20.9 10.7 24.0 12.7 10.3 12.7 9.3 17.5 14.3 12.4 4.9 34.5 116.0 69.7 4.8 7.1 51.1 10.7 18.0 22.4 7.3 30.7 19.0 20.2 24.2 15.6 31.3 32.4 20.3 6.3 19.1 9.8 23.1 9.2 17.7 16.1 33.3 8.0 11.9 13.2 8.2 15.5 36.0 9.4 27.7 16.9 14.8 19.4 17.9 19.5 19.7 18.5 33.4 6.1 27.5 11.2 16.6 7.9 11.4 28.9 9.9 28.9 17.0 17.4 25.1 11.7 15.9 77.1 20.6 17.4 20.6 15.7 12.0 25.9 19.3 7.5 10.1 22.5 21.8 22.5 39.8 15.9 69.7 47.6 5.7 62.5 6.2 4.9 5.9 6.1 34.5 4.3 6.1 6.0 116.0 4.8 54.1 8.4 7.1 51.1 31.7 45.0 39.2 69.0 33.8 47.8 46.9 47.1 64.2 12.7 ATP6V1C1 "ATP6C, ATP6D, VATC, Vma5" ENSG00000155097 "ATPase H+ transporting V1 subunit C1" P21283 8 103021063-103073051 "FDA approved drug targets, Predicted intracellular proteins, Transporters" "Hydrogen ion transport, Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023943, HPA057297" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA023943: AB_1845197, HPA057297: " "unprognostic (5.73e-3)" "unprognostic (3.30e-1)" "unprognostic (1.09e-2)" "unprognostic (1.93e-2)" "unprognostic (1.52e-2)" "unprognostic (3.35e-2)" "prognostic unfavourable (8.82e-4)" "unprognostic (3.29e-2)" "unprognostic (3.87e-1)" "unprognostic (5.62e-2)" "unprognostic (1.19e-1)" "unprognostic (5.59e-2)" "unprognostic (3.98e-2)" "unprognostic (1.23e-1)" "unprognostic (3.85e-1)" "unprognostic (3.88e-1)" "unprognostic (2.83e-1)" 17.1 23.1 25.1 16.8 36.7 6.5 15.7 26.2 58.8 13.6 11.1 11.4 7.6 12.1 14.1 10.9 10.6 12.2 13.7 19.0 28.5 28.0 35.0 18.1 12.9 15.9 23.2 33.3 14.4 12.9 21.3 29.2 20.2 45.1 13.2 13.7 11.5 10.4 12.2 11.7 8.5 12.8 14.5 15.0 14.3 12.1 13.0 12.5 10.7 26.9 8.4 15.6 15.5 10.7 10.6 16.3 27.9 24.3 10.0 12.5 10.8 29.5 17.8 9.4 7.0 24.7 16.0 11.6 22.2 22.2 24.9 29.5 13.1 30.0 19.0 25.5 17.6 11.9 18.6 17.3 35.7 12.5 14.3 18.6 13.5 15.6 26.4 9.9 22.4 15.3 22.5 33.5 16.1 18.7 23.6 15.7 27.7 13.4 18.6 7.3 8.3 17.2 10.8 16.7 14.4 27.9 21.3 12.1 10.4 12.5 11.9 38.9 24.8 11.8 22.3 14.5 14.7 32.2 15.5 20.5 7.4 18.1 28.1 20.6 14.0 8.4 17.4 20.6 9.1 24.3 10.2 10.6 7.7 8.9 16.3 10.2 9.0 9.7 27.9 10.0 22.1 8.8 12.5 10.8 25.1 36.7 26.2 58.8 28.5 28.0 23.2 33.3 45.1 12.5 AVPR1B AVPR3 ENSG00000198049 "Arginine vasopressin receptor 1B" P47901 1 206109692-206117699 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 23 "pituitary gland: 52.8" "Cell line enhanced" "Detected in single" "PC-3: 3.5" "Cancer enhanced" "Detected in some" "renal cancer: 1.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA075404 Enhanced "HPA075404: " "unprognostic (4.87e-2)" "unprognostic (1.44e-1)" "unprognostic (4.82e-1)" "unprognostic (2.82e-1)" "unprognostic (2.87e-1)" "unprognostic (1.08e-2)" "unprognostic (3.33e-1)" "unprognostic (2.96e-2)" "unprognostic (6.23e-2)" "unprognostic (7.65e-2)" "unprognostic (1.86e-1)" "unprognostic (6.66e-3)" 0.0 0.0 0.2 0.2 0.2 0.0 0.0 0.6 0.5 0.1 1.3 0.0 0.0 1.0 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.6 0.0 0.0 0.1 0.0 0.0 0.0 2.1 0.0 52.8 0.1 0.1 0.2 0.8 0.0 0.0 0.4 0.0 0.0 1.0 0.1 0.0 0.0 2.2 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.5 0.9 3.5 0.0 0.0 0.2 0.0 0.3 0.3 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.6 0.1 0.0 0.1 0.0 0.0 0.1 0.0 BCHE "CHE1, CHE2, E1" ENSG00000114200 Butyrylcholinesterase P06276 3 165772904-165837472 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Serine esterase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "liver: 145.4" "Cell line enriched" "Detected in some" 9 "Karpas-707: 128.6" "Group enriched" "Detected in many" 6 "glioma: 24.0;liver cancer: 13.7;melanoma: 18.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA001560 Approved "Secreted to blood" 13000000000 "HPA001560: AB_1078271" "unprognostic (4.74e-2)" "unprognostic (2.00e-1)" "unprognostic (9.21e-4)" "unprognostic (8.19e-8)" "unprognostic (2.66e-2)" "prognostic unfavourable (1.06e-4)" "unprognostic (1.44e-1)" "unprognostic (5.04e-2)" "unprognostic (6.15e-2)" "unprognostic (9.59e-2)" "unprognostic (5.15e-2)" "unprognostic (3.65e-2)" "unprognostic (3.18e-3)" "unprognostic (4.46e-5)" "unprognostic (2.17e-2)" "unprognostic (5.92e-2)" "unprognostic (4.26e-4)" 14.0 3.9 6.7 6.2 4.3 0.4 1.9 3.6 9.1 24.4 15.5 4.7 8.3 1.8 20.2 13.4 20.0 18.0 2.2 7.8 6.1 4.4 2.8 145.4 3.7 0.7 5.5 2.7 10.3 1.1 0.4 1.2 0.5 4.7 4.7 5.3 0.7 1.0 10.5 1.1 2.8 6.4 13.9 3.4 3.7 1.9 1.8 6.1 1.0 0.8 0.4 0.5 9.7 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 14.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 1.2 0.0 0.0 0.0 5.3 0.0 0.0 0.9 0.0 0.9 0.0 0.1 0.0 0.0 0.0 1.0 0.0 0.0 4.1 0.2 0.0 1.3 0.6 0.0 128.6 0.0 0.0 0.0 0.0 0.3 0.1 0.0 4.7 10.7 0.1 0.0 0.0 0.1 0.0 0.0 7.4 5.7 0.0 0.0 3.2 0.0 0.0 1.3 0.5 0.0 0.2 1.3 0.0 14.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.7 4.3 3.6 4.3 6.1 4.4 5.5 2.7 4.7 6.1 BCL2 "Bcl-2, PPP1R50" ENSG00000171791 "BCL2, apoptosis regulator" P10415 18 63123346-63320128 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Apoptosis "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 22.3;U-266/70: 77.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "gdT-cell: 2.3;MAIT T-cell: 7.6;memory B-cell: 5.2;memory CD4 T-cell: 6.3;memory CD8 T-cell: 3.8;naive B-cell: 4.1;naive CD4 T-cell: 5.1;naive CD8 T-cell: 4.5;T-reg: 6.7" "Group enriched" "Detected in many" 8 "B-cells: 5.2;T-cells: 7.6" "Low region specificity" "Detected in all" "CAB000003, HPA055295" Enhanced Supported "Nucleoplasm,Nuclear membrane" "Nuclear membrane" Nucleoplasm "CAB000003: AB_2064429, HPA055295: " "unprognostic (1.11e-3)" "prognostic favourable (5.13e-5)" "unprognostic (5.49e-2)" "unprognostic (1.19e-1)" "unprognostic (1.89e-1)" "unprognostic (3.05e-3)" "unprognostic (2.88e-1)" "unprognostic (1.93e-3)" "unprognostic (4.78e-2)" "unprognostic (2.08e-1)" "unprognostic (2.23e-2)" "unprognostic (8.51e-2)" "prognostic favourable (1.29e-8)" "unprognostic (6.67e-2)" "unprognostic (1.19e-1)" "prognostic unfavourable (2.47e-4)" "unprognostic (2.63e-1)" 12.9 3.0 10.1 15.7 9.4 5.3 24.6 4.7 8.4 14.8 7.8 7.4 9.1 5.0 17.1 9.3 4.7 12.2 9.2 6.5 10.0 8.1 8.5 2.3 5.0 14.6 10.8 5.6 18.2 2.9 19.6 7.0 22.4 9.2 8.4 5.9 10.8 5.4 15.7 20.0 6.3 10.5 8.6 9.3 17.8 5.4 3.5 10.5 21.0 35.6 2.9 13.4 7.9 16.4 5.2 0.3 0.7 0.2 0.7 7.6 1.9 0.4 0.1 2.3 1.8 2.7 0.4 0.8 0.2 0.2 0.7 0.5 1.1 0.1 0.0 0.4 0.2 0.1 2.0 0.3 0.4 13.3 0.4 0.0 0.6 0.2 0.5 12.1 1.8 0.5 0.2 0.9 1.9 0.2 0.2 22.3 0.4 0.4 2.5 5.2 0.5 0.4 11.4 0.5 8.6 3.8 1.8 1.9 1.8 0.0 0.0 2.7 0.1 10.2 0.1 3.0 1.0 0.3 1.5 77.6 10.2 0.8 0.5 8.6 1.7 0.7 0.0 0.0 2.3 0.0 7.6 5.2 6.3 3.8 0.1 4.1 5.1 4.5 0.1 0.7 0.2 0.3 6.7 1.9 10.1 9.4 4.7 8.4 10.0 8.1 10.8 5.6 9.2 10.5 BCR "ALL, BCR1, CML, D22S11, D22S662, PHL" ENSG00000186716 "BCR, RhoGEF and GTPase activating protein" P11274 22 23179704-23318037 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "GTPase activation, Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "K-562: 43.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010421, CAB018545, HPA038337" Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB010421: AB_2274682, CAB018545: AB_2063918, HPA038337: AB_10675795" "unprognostic (7.46e-3)" "unprognostic (2.43e-2)" "unprognostic (2.15e-3)" "unprognostic (1.16e-1)" "unprognostic (5.35e-2)" "unprognostic (1.45e-1)" "unprognostic (5.08e-2)" "unprognostic (1.44e-1)" "unprognostic (7.55e-2)" "unprognostic (1.81e-1)" "unprognostic (9.46e-2)" "unprognostic (2.39e-2)" "prognostic favourable (9.15e-10)" "unprognostic (1.47e-1)" "unprognostic (7.10e-2)" "unprognostic (4.10e-2)" "unprognostic (7.43e-2)" 14.5 8.4 24.0 9.1 41.2 26.7 10.5 14.2 26.5 13.6 9.7 10.3 10.6 8.7 9.2 13.9 19.3 10.8 8.3 7.8 20.9 13.0 16.3 8.3 11.3 10.9 16.0 15.6 8.8 12.9 14.5 14.9 15.7 14.2 7.0 6.8 8.3 15.5 9.7 3.4 12.8 8.7 9.0 9.5 9.1 14.0 9.6 15.4 11.8 16.6 5.5 9.2 9.2 8.8 1.5 0.8 1.2 1.0 2.8 6.6 2.5 18.6 8.1 12.4 12.7 7.4 5.1 18.8 6.8 6.3 6.3 5.1 14.1 7.5 13.0 12.6 5.7 19.2 1.3 18.8 1.8 24.9 12.9 11.4 11.1 11.2 9.7 10.5 6.0 4.3 12.7 9.4 8.2 21.8 43.5 6.1 2.8 12.3 9.8 8.2 10.5 7.9 12.9 5.0 8.6 9.7 11.8 11.4 10.8 12.4 10.7 5.1 6.7 8.6 24.6 3.8 0.4 6.1 5.5 1.4 5.6 4.6 9.7 8.0 5.8 0.0 1.0 0.0 6.6 0.4 2.3 1.4 3.3 3.3 0.8 1.5 2.6 3.6 1.2 2.8 1.0 0.8 1.6 2.5 24.0 41.2 14.2 24.9 20.9 13.0 16.0 15.6 14.2 15.4 BDKRB2 BK-2 ENSG00000168398 "Bradykinin receptor B2" P30411 14 96204679-96244166 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC TERT1: 22.3;BJ hTERT+: 41.1;U-87 MG: 17.7" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 6 "cerebellum: 13.5;pons and medulla: 5.7" "Cell type enhanced" "Detected in single" "memory CD8 T-cell: 1.2" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA003551, HPA050841" Approved Supported "Plasma membrane" "Plasma membrane" "HPA003551: , HPA050841: " "unprognostic (1.03e-1)" "unprognostic (7.90e-2)" "unprognostic (1.12e-1)" "unprognostic (1.83e-1)" "unprognostic (8.79e-3)" "unprognostic (2.68e-2)" "unprognostic (1.93e-1)" "unprognostic (4.66e-2)" "unprognostic (1.94e-1)" "unprognostic (2.84e-2)" "unprognostic (3.19e-1)" "unprognostic (1.72e-1)" "unprognostic (3.32e-3)" "unprognostic (3.11e-2)" "unprognostic (9.40e-2)" "unprognostic (9.90e-2)" "unprognostic (1.49e-2)" 9.0 1.2 1.5 3.7 1.0 0.0 4.7 13.5 1.1 12.2 9.0 1.3 4.4 5.6 8.5 12.7 14.9 5.1 21.1 4.3 0.8 0.7 12.1 0.7 2.2 0.4 0.9 0.3 4.7 6.8 0.9 1.1 2.9 5.7 6.9 9.2 0.9 3.1 11.3 2.7 4.0 10.3 11.3 1.3 0.4 4.2 3.2 0.0 0.6 3.6 13.9 4.4 16.7 13.5 0.0 0.9 0.0 0.0 0.0 1.2 0.0 0.7 2.6 0.0 4.8 7.3 22.3 0.0 2.4 41.1 1.4 1.6 0.1 4.5 0.0 0.1 3.7 6.4 0.0 1.0 1.2 0.5 0.0 0.0 0.5 0.0 3.5 0.0 0.0 6.8 3.3 4.1 2.1 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 1.0 0.0 1.4 0.0 1.5 0.5 0.7 6.8 0.0 0.4 0.0 0.0 0.1 0.1 1.4 0.0 0.1 0.0 0.0 17.7 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 1.5 1.0 13.5 1.1 0.8 0.7 0.9 0.3 5.7 0.0 BLVRB "FLR, SDR43U1" ENSG00000090013 "Biliverdin reductase B" P30043 19 40447765-40465840 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 137.6" "Cell line enhanced" "Detected in many" "A549: 82.6;K-562: 75.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "classical monocyte: 73.4" "Group enriched" "Detected in all" 7 "dendritic cells: 54.8;monocytes: 73.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041698, HPA041937" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" 440000000 Cytosol "Nucleoplasm, Plasma membrane" "HPA041698: AB_10796781, HPA041937: AB_10794308" "unprognostic (1.86e-1)" "unprognostic (1.14e-2)" "unprognostic (4.23e-1)" "unprognostic (1.50e-1)" "unprognostic (2.08e-1)" "unprognostic (2.46e-1)" "unprognostic (9.92e-2)" "unprognostic (1.20e-2)" "unprognostic (8.56e-2)" "unprognostic (1.35e-1)" "prognostic unfavourable (3.90e-4)" "unprognostic (2.30e-1)" "unprognostic (2.70e-1)" "unprognostic (2.02e-1)" "unprognostic (5.11e-2)" "unprognostic (1.25e-1)" "unprognostic (3.92e-2)" 36.9 17.9 10.9 12.8 12.2 137.6 28.9 3.5 10.9 17.0 26.7 7.7 18.5 20.9 14.1 19.6 45.3 14.6 19.0 31.0 8.2 8.6 31.8 72.4 37.3 30.0 11.7 9.6 21.3 19.4 5.7 5.6 32.2 13.8 22.9 7.7 17.5 27.1 22.1 43.4 16.7 26.4 22.1 9.7 47.1 31.1 7.6 7.9 6.6 24.3 42.9 24.4 29.9 22.1 8.6 54.8 9.1 73.4 4.0 5.3 34.4 34.8 82.6 1.1 12.3 11.5 11.1 9.8 4.4 12.9 6.0 11.7 16.2 31.7 11.7 34.0 7.9 11.1 4.2 9.6 1.2 19.8 3.6 17.8 12.5 9.8 26.5 0.2 5.2 10.8 18.2 8.0 4.4 6.3 75.0 21.3 7.0 54.2 0.9 1.0 0.3 23.1 8.2 3.9 18.9 7.5 23.5 0.0 1.8 13.4 35.2 13.5 34.3 2.7 6.8 16.0 17.2 24.6 2.3 11.6 13.6 4.4 41.8 7.0 6.2 5.0 73.4 2.6 4.6 33.7 4.4 8.6 4.0 4.0 54.8 5.4 4.2 3.3 9.1 4.0 16.9 11.5 5.3 34.4 10.9 12.2 3.5 10.9 8.2 8.6 11.7 9.6 13.8 7.9 BRAF BRAF1 ENSG00000157764 "B-Raf proto-oncogene, serine/threonine kinase" P15056 7 140719327-140924928 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001328, CAB004552, HPA071048" Approved Approved Vesicles,Cytosol Vesicles Cytosol "CAB004552: AB_626760, HPA001328: AB_1078296, HPA071048: " "unprognostic (2.98e-3)" "unprognostic (5.66e-2)" "unprognostic (2.20e-2)" "unprognostic (2.66e-3)" "unprognostic (2.44e-1)" "unprognostic (1.48e-2)" "unprognostic (2.07e-2)" "unprognostic (4.23e-2)" "unprognostic (4.07e-2)" "unprognostic (1.58e-2)" "unprognostic (6.53e-2)" "unprognostic (1.91e-2)" "unprognostic (3.79e-3)" "unprognostic (2.08e-1)" "unprognostic (1.76e-1)" "unprognostic (8.01e-2)" "unprognostic (5.46e-2)" 13.1 12.1 20.1 16.5 20.4 27.8 14.2 29.9 21.5 12.4 12.3 9.5 12.5 9.3 15.3 17.0 11.8 11.5 12.0 13.6 13.2 12.2 13.7 12.8 15.9 13.3 9.9 17.8 16.8 13.2 28.9 24.8 13.7 15.3 14.5 11.0 10.7 11.6 16.6 12.9 15.6 10.5 13.0 10.9 12.3 12.0 24.9 12.2 13.5 16.6 7.5 12.1 18.6 18.1 2.6 1.9 7.5 2.4 7.0 5.6 1.1 5.4 4.6 6.8 8.1 8.3 10.7 10.9 6.1 6.5 4.9 7.1 5.0 5.9 9.3 4.7 6.2 3.0 6.0 4.8 9.0 8.6 4.9 6.0 4.5 4.6 7.0 9.8 6.1 7.1 5.4 5.2 10.8 5.7 9.5 16.7 8.7 2.9 13.0 10.3 6.3 2.9 8.5 5.8 7.6 4.8 10.4 7.9 6.6 7.0 4.3 6.3 4.0 6.7 8.4 5.3 4.1 11.5 4.9 19.4 11.0 14.8 8.7 9.9 5.7 3.3 2.0 7.5 3.1 1.7 2.1 2.6 3.0 2.4 1.6 2.6 5.6 2.8 4.1 7.0 2.4 1.9 2.7 1.1 20.1 20.4 29.9 21.5 13.2 12.2 9.9 17.8 15.3 12.2 BTK "AGMX1, ATK, IMD1, PSCTK1, XLA" ENSG00000010671 "Bruton tyrosine kinase" Q06187 X 101349447-101390796 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Apoptosis, Immunity, Innate immunity, Transcription, Transcription regulation" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 77.5;lymphoid tissue: 37.0" "Cell line enhanced" "Detected in some" "Daudi: 28.8;HEL: 40.0;HMC-1: 144.1;U-937: 20.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 77.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001198, HPA002028, CAB016689" Enhanced Supported "Plasma membrane,Cytosol" 610000 "Plasma membrane, Cytosol" "CAB016689: AB_1611894, HPA001198: AB_1078305, HPA002028: AB_1078306" "unprognostic (3.19e-2)" "unprognostic (2.51e-3)" "unprognostic (1.06e-2)" "unprognostic (3.66e-2)" "unprognostic (5.69e-2)" "unprognostic (3.76e-3)" "unprognostic (6.55e-2)" "unprognostic (3.58e-3)" "unprognostic (6.02e-2)" "unprognostic (3.12e-1)" "unprognostic (1.02e-1)" "unprognostic (1.41e-1)" "unprognostic (2.08e-3)" "unprognostic (7.80e-2)" "unprognostic (1.29e-2)" "unprognostic (1.56e-2)" "unprognostic (8.14e-2)" 7.3 2.4 3.3 23.5 5.6 14.0 2.6 0.8 3.6 2.3 3.0 4.7 0.3 2.2 1.9 2.6 2.4 2.0 3.7 3.3 3.3 2.5 2.2 2.5 10.7 25.1 5.4 1.2 1.2 1.5 0.2 1.4 3.2 4.1 2.5 4.5 1.5 3.2 1.0 1.0 2.5 12.9 3.3 10.8 37.0 3.1 1.3 6.3 4.0 1.7 1.8 36.7 5.8 2.0 13.7 13.2 77.5 20.7 0.0 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 40.0 0.0 0.0 0.0 16.0 144.1 0.0 0.0 0.0 0.0 0.0 8.4 0.3 0.0 0.0 0.0 11.2 0.2 0.0 12.1 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.5 0.0 0.0 0.0 0.0 0.0 0.3 0.1 13.7 0.0 20.9 0.0 77.5 11.3 19.3 0.0 18.1 0.0 13.7 0.0 0.0 13.2 13.7 0.0 0.0 4.5 0.0 20.7 6.0 0.0 6.1 3.3 5.6 0.8 3.6 3.3 2.5 5.4 1.2 4.1 6.3 CA1 Car1 ENSG00000133742 "Carbonic anhydrase 1" P00915 8 85327608-85379014 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "bone marrow: 156.0;intestine: 203.6" "Cell line enriched" "Detected in single" 1206 "HEL: 165.2" "Group enriched" "Detected in some" 10 "colorectal cancer: 3.4;stomach cancer: 0.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA006558, CAB025790" Enhanced 7800000000 "CAB025790: , HPA006558: AB_1845989" "unprognostic (1.44e-1)" "unprognostic (7.56e-2)" "unprognostic (1.70e-1)" "unprognostic (3.57e-3)" "unprognostic (2.08e-2)" "unprognostic (1.66e-1)" "unprognostic (2.84e-2)" "unprognostic (2.03e-2)" "unprognostic (1.73e-2)" "unprognostic (6.12e-2)" "unprognostic (1.63e-1)" "unprognostic (1.04e-1)" "unprognostic (5.61e-2)" "unprognostic (3.01e-2)" "unprognostic (2.38e-1)" "unprognostic (3.95e-2)" 1.8 0.4 0.5 11.5 0.5 156.0 0.4 0.3 0.4 0.3 95.4 1.5 0.0 0.0 0.3 0.0 0.6 0.7 0.0 17.6 0.5 0.4 0.8 2.9 32.2 0.2 0.9 0.0 0.8 0.5 0.0 1.0 24.0 0.6 1.1 203.6 2.6 0.3 0.1 3.1 0.2 0.4 3.2 0.5 14.3 0.3 0.3 0.0 0.2 7.5 0.0 0.2 4.5 16.0 0.7 0.7 0.0 0.3 0.0 0.1 7.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 165.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 7.5 0.5 0.5 0.3 0.4 0.5 0.4 0.9 0.0 0.6 0.0 CA12 HsT18816 ENSG00000074410 "Carbonic anhydrase 12" O43570 15 63321378-63382161 "Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins" Lyase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 103.5" "Cell line enhanced" "Detected in many" "A549: 38.2;ASC TERT1: 40.3;RT4: 40.5;SK-BR-3: 32.5;T-47d: 52.3;U-138 MG: 55.8;U-87 MG: 67.0" "Cancer enhanced" "Detected in all" "renal cancer: 109.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA008773, CAB025181, CAB062549, CAB068179, HPA073203" Enhanced Approved Nucleoplasm,Vesicles 29000 Nucleoplasm Vesicles "CAB025181: , CAB062549: , CAB068179: , HPA008773: AB_1078394, HPA073203: " "unprognostic (2.01e-1)" "unprognostic (8.38e-3)" "unprognostic (3.47e-1)" "unprognostic (3.25e-3)" "unprognostic (2.73e-2)" "unprognostic (2.47e-2)" "unprognostic (7.48e-2)" "unprognostic (3.43e-3)" "unprognostic (2.29e-1)" "unprognostic (4.67e-2)" "prognostic unfavourable (3.80e-6)" "unprognostic (2.59e-1)" "unprognostic (1.51e-1)" "unprognostic (2.38e-1)" "unprognostic (6.56e-2)" "unprognostic (7.26e-2)" "unprognostic (1.21e-1)" 3.7 0.3 4.7 15.0 27.4 0.3 14.5 3.7 2.3 15.7 32.0 2.6 5.0 0.4 9.8 12.3 42.8 8.5 2.6 1.6 4.9 1.4 103.5 0.3 1.2 0.3 1.8 0.2 2.1 43.8 0.3 3.9 5.9 16.9 3.8 30.3 8.5 8.2 17.9 0.5 44.1 2.4 18.1 0.1 0.4 2.2 1.3 6.7 0.0 1.7 18.4 25.9 10.6 14.5 0.3 0.2 0.6 0.7 0.3 0.2 0.0 0.0 38.2 0.6 0.0 5.1 40.3 2.0 2.7 2.5 0.4 0.7 0.2 0.0 0.0 9.4 2.2 0.2 0.0 1.8 1.1 0.0 1.3 0.0 2.6 0.0 0.1 0.0 0.0 15.2 2.1 11.6 3.7 0.4 0.0 0.0 0.5 22.0 0.0 0.0 0.6 6.0 0.0 0.0 0.0 0.0 40.5 0.3 0.0 0.1 32.5 0.0 52.3 0.0 0.0 55.8 3.0 1.8 0.0 0.0 0.0 0.0 67.0 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.1 0.2 0.6 0.3 0.7 0.2 0.1 0.0 4.7 27.4 3.7 1.3 4.9 1.4 1.8 0.2 16.9 6.7 CA14 ENSG00000118298 "Carbonic anhydrase 14" Q9ULX7 1 150257159-150265078 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 20.9;retina: 29.4;seminal vesicle: 16.5;skeletal muscle: 24.1" "Group enriched" "Detected in some" 18 "AF22: 28.0;AN3-CA: 16.6;NTERA-2: 21.8;SK-MEL-30: 55.8" "Group enriched" "Detected in many" 7 "glioma: 4.9;melanoma: 23.2" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008482 Approved Approved "Plasma membrane" "Plasma membrane" "HPA008482: AB_1078395" "unprognostic (3.06e-2)" "unprognostic (1.67e-1)" "unprognostic (2.10e-2)" "unprognostic (3.25e-2)" "prognostic favourable (8.47e-4)" "unprognostic (7.28e-2)" "unprognostic (4.48e-2)" "unprognostic (1.49e-1)" "unprognostic (2.10e-1)" "unprognostic (2.47e-1)" "unprognostic (5.46e-2)" "unprognostic (1.73e-1)" "unprognostic (5.89e-3)" "unprognostic (1.91e-1)" "unprognostic (1.49e-1)" "unprognostic (1.22e-1)" "unprognostic (5.80e-2)" 0.1 0.3 4.6 0.2 5.2 0.9 0.3 1.4 6.8 0.1 1.7 10.8 0.1 0.3 0.1 0.5 1.6 1.3 0.7 4.4 6.4 4.1 0.3 6.3 0.2 0.2 11.3 3.2 1.4 0.3 0.8 0.1 0.3 4.4 3.2 0.7 29.4 0.6 16.5 24.1 3.7 0.6 0.5 20.9 0.3 0.8 0.5 2.7 0.1 0.9 0.1 0.1 0.2 0.1 2.8 2.2 2.1 2.0 0.2 1.6 0.2 0.2 0.0 28.0 16.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.1 0.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 21.8 0.2 0.0 0.0 0.0 0.0 0.0 0.7 0.4 0.0 0.1 55.8 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.2 1.2 0.1 0.1 0.1 0.0 0.0 0.9 1.3 1.6 2.0 0.6 2.0 1.0 1.2 0.2 2.8 1.2 1.3 2.1 0.2 0.5 2.2 0.0 0.2 4.6 5.2 1.4 4.7 6.4 4.1 11.3 3.2 4.4 2.7 CA2 "CA-II, CAII, Car2" ENSG00000104267 "Carbonic anhydrase 2" P00918 8 85463852-85481493 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Lyase "Disease mutation, FDA approved drug targets, Osteopetrosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 108.1;stomach 1: 171.5" "Cell line enhanced" "Detected in some" "HaCaT: 33.1;HEK 293: 139.1;THP-1: 58.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 20.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA001550, CAB010102" Enhanced 790000000 "CAB010102: AB_626796, HPA001550: AB_1078393" "unprognostic (6.78e-2)" "unprognostic (3.06e-2)" "unprognostic (1.05e-2)" "unprognostic (1.63e-1)" "unprognostic (2.59e-1)" "unprognostic (9.24e-2)" "unprognostic (1.74e-1)" "unprognostic (1.72e-2)" "unprognostic (1.07e-1)" "unprognostic (5.23e-2)" "unprognostic (1.57e-1)" "unprognostic (9.89e-2)" "prognostic favourable (5.57e-6)" "unprognostic (2.45e-1)" "unprognostic (2.03e-1)" "unprognostic (1.32e-1)" "unprognostic (6.49e-3)" 1.6 2.2 24.4 21.5 32.6 32.4 6.9 4.3 23.2 1.3 108.1 28.9 42.0 46.9 0.9 2.2 5.6 0.9 33.0 4.3 29.1 14.5 53.5 43.0 10.2 1.3 49.0 14.2 0.5 9.1 3.1 2.0 3.5 65.0 0.8 105.6 7.0 14.0 54.2 9.2 13.3 7.6 6.0 27.5 2.5 171.5 5.1 58.3 0.0 3.8 2.4 1.1 1.0 1.4 1.9 8.0 20.3 8.2 0.0 4.4 17.5 0.5 0.3 1.5 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 1.9 0.1 0.0 1.2 0.0 33.1 4.8 1.6 0.0 0.0 139.1 4.3 2.4 0.0 0.0 3.0 0.6 0.0 8.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 5.3 0.4 0.0 2.7 0.1 0.0 0.4 1.1 0.0 0.0 0.7 0.0 0.0 0.0 58.3 0.0 0.0 0.9 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 20.3 3.1 4.4 0.1 8.2 4.4 0.6 0.0 0.4 8.0 1.9 0.0 0.0 6.8 0.0 7.1 0.8 0.0 17.5 24.4 32.6 4.3 23.2 29.1 14.5 49.0 14.2 65.0 58.3 CA3 "CAIII, Car3" ENSG00000164879 "Carbonic anhydrase 3" P07451 8 85373436-85449040 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "skeletal muscle: 347.5" "Group enriched" "Detected in some" 32 "HEL: 23.3;RH-30: 39.2" "Group enriched" "Detected in many" 7 "glioma: 23.1;prostate cancer: 9.4" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.8" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "CAB004967, HPA021775, HPA026700" Enhanced 31000000 "CAB004967: AB_437014, HPA021775: AB_1845990, HPA026700: AB_1845991" "prognostic favourable (4.24e-6)" "unprognostic (1.40e-1)" "unprognostic (1.50e-2)" "unprognostic (2.22e-3)" "unprognostic (4.71e-2)" "unprognostic (8.43e-3)" "unprognostic (3.56e-2)" "unprognostic (4.04e-2)" "unprognostic (1.11e-1)" "unprognostic (3.68e-1)" "unprognostic (4.71e-2)" "unprognostic (3.54e-1)" "unprognostic (3.19e-2)" "unprognostic (1.18e-1)" "unprognostic (9.96e-2)" "unprognostic (1.39e-1)" "unprognostic (2.19e-1)" 18.0 0.4 0.2 0.1 0.2 0.5 0.6 0.2 0.1 0.5 0.3 0.0 0.1 0.1 0.6 29.0 9.5 1.0 0.2 1.3 0.2 0.1 0.2 0.2 4.1 0.0 0.1 0.0 0.1 0.1 0.0 0.3 0.0 0.0 6.6 0.0 0.0 5.5 0.2 347.5 0.3 0.4 1.4 0.1 0.1 0.3 0.5 0.0 0.0 0.3 14.1 3.4 0.7 0.5 0.5 1.8 0.0 0.0 0.0 0.8 0.2 0.9 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.5 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.2 0.1 23.3 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.3 0.0 0.8 0.0 0.0 0.0 1.8 0.0 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.0 0.0 0.0 CA4 "CAIV, Car4, RP17" ENSG00000167434 "Carbonic anhydrase 4" P22748 17 60149936-60170899 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Lyase "Disease mutation, FDA approved drug targets, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 81.7" "Cell line enhanced" "Detected in some" "HEK 293: 1.4;HUVEC TERT2: 1.7;NTERA-2: 3.9;RPMI-8226: 1.5;RPTEC TERT1: 2.2" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 4 "cerebellum: 50.1" "Cell type enriched" "Detected in some" 7 "neutrophil: 37.0" "Lineage enriched" "Detected in single" 370 "granulocytes: 37.0" "Region enriched" "Detected in all" 5 "cerebellum: 336.9" "Low region specificity" "Detected in many" "HPA011089, HPA017258" Enhanced Supported Vesicles 190000 Vesicles "HPA011089: AB_1845996, HPA017258: AB_1845997" "unprognostic (2.07e-2)" "unprognostic (7.85e-2)" "unprognostic (1.55e-2)" "unprognostic (7.78e-3)" "unprognostic (8.42e-2)" "unprognostic (1.19e-1)" "unprognostic (3.19e-2)" "unprognostic (5.84e-2)" "unprognostic (7.76e-2)" "unprognostic (9.74e-2)" "unprognostic (1.54e-1)" "unprognostic (1.71e-2)" "unprognostic (2.68e-3)" "unprognostic (8.59e-2)" "unprognostic (1.43e-1)" "unprognostic (2.45e-1)" "unprognostic (4.57e-2)" 32.2 0.9 3.4 9.8 4.4 5.7 46.4 50.1 11.8 2.3 81.7 2.0 31.5 1.4 2.3 17.4 0.9 1.7 12.2 8.8 4.7 2.6 12.0 0.3 33.3 2.4 3.5 5.2 1.9 9.5 3.3 5.1 3.2 3.0 2.4 54.9 20.3 4.8 24.0 10.0 1.0 3.2 1.1 2.1 4.9 2.5 1.2 0.3 0.2 23.1 5.0 0.2 1.7 7.9 0.0 0.0 37.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.7 0.1 0.3 0.0 0.0 0.0 0.5 0.9 0.0 0.3 0.0 0.0 0.4 1.4 0.0 0.0 0.8 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.3 3.9 0.0 0.0 0.2 1.5 2.2 0.0 0.8 0.4 0.2 0.0 0.0 0.0 0.6 0.0 0.2 0.9 0.5 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 37.0 0.0 0.0 0.0 0.0 0.0 3.4 4.4 50.1 11.8 4.7 2.6 3.5 5.2 3.0 0.3 CA7 ENSG00000168748 "Carbonic anhydrase 7" P43166 16 66844379-66854153 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "intestine: 37.2" "Cell line enhanced" "Detected in some" "CACO-2: 1.2;HAP1: 1.8;NTERA-2: 1.5;REH: 3.3;SCLC-21H: 2.7;THP-1: 5.5" "Cancer enhanced" "Detected in some" "colorectal cancer: 0.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA047237 Uncertain "HPA047237: " "unprognostic (8.77e-4)" "unprognostic (5.23e-4)" "unprognostic (1.57e-1)" "unprognostic (1.96e-2)" "unprognostic (2.19e-1)" "unprognostic (2.16e-2)" "unprognostic (7.90e-2)" "unprognostic (1.59e-1)" "unprognostic (1.84e-2)" "unprognostic (9.62e-2)" "unprognostic (1.69e-2)" "unprognostic (7.12e-3)" "unprognostic (8.47e-2)" "unprognostic (5.20e-1)" "unprognostic (1.90e-2)" "unprognostic (6.46e-2)" 0.2 0.2 3.2 0.4 7.5 0.2 0.2 3.9 7.7 0.2 37.2 0.3 0.0 4.8 0.3 0.9 0.3 0.2 0.2 0.2 6.3 0.5 0.2 0.2 0.2 0.2 0.7 2.9 0.2 0.2 0.2 0.0 0.2 1.8 0.2 32.0 0.0 1.1 0.4 0.2 0.2 22.8 1.0 0.1 0.2 0.2 0.5 1.3 0.1 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.2 0.0 0.4 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.9 3.3 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 7.5 3.9 7.7 6.3 0.5 0.7 2.9 1.8 1.3 CACNA1A "APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6" ENSG00000141837 "Calcium voltage-gated channel subunit alpha1 A" O00555 19 13206442-13633025 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "brain: 77.9" "Group enriched" "Detected in some" 5 "SCLC-21H: 30.5;U-87 MG: 17.2" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in all" 4 "cerebellum: 77.9" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA064258, HPA071902" Enhanced Supported Uncertain "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA064258: , HPA071902: " "unprognostic (1.09e-1)" "unprognostic (3.73e-3)" "unprognostic (2.27e-1)" "unprognostic (2.78e-4)" "unprognostic (4.00e-2)" "unprognostic (2.29e-3)" "unprognostic (5.47e-2)" "unprognostic (3.13e-1)" "unprognostic (2.86e-1)" "unprognostic (1.14e-2)" "prognostic favourable (4.32e-4)" "unprognostic (5.31e-3)" "unprognostic (5.03e-6)" "unprognostic (6.29e-2)" "unprognostic (1.59e-1)" "unprognostic (2.61e-2)" "unprognostic (6.25e-2)" 2.2 5.3 7.6 1.0 12.2 0.7 0.9 77.9 19.7 0.8 1.5 1.8 0.0 3.9 1.2 2.8 0.7 2.2 0.8 1.1 5.7 5.1 0.7 0.5 0.7 1.3 3.9 7.3 1.1 3.0 0.7 1.5 0.6 7.2 0.8 1.7 1.2 0.9 0.8 1.3 0.7 2.8 0.9 3.3 1.3 7.7 1.9 2.8 0.0 0.7 0.0 1.0 0.8 0.3 2.8 0.8 1.9 1.1 0.8 0.8 0.4 0.0 0.1 0.0 3.8 0.1 0.3 0.0 1.6 1.5 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 2.0 0.0 1.2 0.0 0.0 0.0 4.5 0.1 0.0 0.0 0.1 0.9 0.2 0.4 0.0 0.1 0.0 0.1 30.5 0.0 0.0 0.0 0.2 0.0 1.2 0.1 0.1 0.6 0.1 0.0 0.0 0.0 0.0 17.2 0.0 0.4 1.9 0.4 0.7 0.5 0.5 0.8 2.8 0.5 0.3 0.4 1.7 0.6 0.7 1.6 0.8 1.1 0.8 0.6 0.4 7.6 12.2 77.9 17.4 5.7 5.1 3.9 7.3 7.2 2.8 CACNA1B "CACNL1A5, CACNN, Cav2.2" ENSG00000148408 "Calcium voltage-gated channel subunit alpha1 B" Q00975 9 137877789-138124624 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 6.2;brain: 18.9;fallopian tube: 6.6;pituitary gland: 4.8;testis: 8.1" "Cell line enriched" "Detected in some" 5 "SCLC-21H: 20.7" "Cancer enhanced" "Detected in some" "testis cancer: 2.2" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA044347 Uncertain "HPA044347: AB_10960837" "unprognostic (1.34e-3)" "unprognostic (2.70e-2)" "unprognostic (8.08e-2)" "unprognostic (2.51e-7)" "unprognostic (8.10e-2)" "unprognostic (1.51e-2)" "unprognostic (1.33e-1)" "unprognostic (3.10e-1)" "unprognostic (2.50e-1)" "unprognostic (2.36e-2)" "unprognostic (9.73e-4)" "unprognostic (5.98e-2)" "unprognostic (6.63e-6)" "unprognostic (4.25e-2)" "unprognostic (4.72e-1)" "unprognostic (7.77e-3)" "unprognostic (8.69e-2)" 0.5 6.2 5.7 0.7 8.7 0.5 0.5 18.7 18.9 1.2 0.8 0.2 0.0 0.6 0.6 1.7 0.4 6.6 1.4 1.0 4.5 7.3 0.4 1.2 0.5 0.5 2.9 9.1 0.5 1.2 0.4 4.8 0.4 3.6 1.6 0.8 0.4 0.4 1.3 0.4 0.9 0.7 0.8 4.5 0.6 0.6 8.1 1.4 0.0 0.9 0.0 0.4 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 20.7 3.9 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.7 8.7 18.7 10.9 4.5 7.3 2.9 9.1 3.6 1.4 CACNA1C "CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS" ENSG00000151067 "Calcium voltage-gated channel subunit alpha1 C" Q13936 12 1970786-2697950 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Host-virus interaction, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Brugada syndrome, Disease mutation, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 32.5" "Cell line enriched" "Detected in some" 17 "HDLM-2: 46.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 4.2" "Group enriched" "Detected in many" 19 "NK-cells: 4.2;T-cells: 1.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039796, CAB079031" Enhanced Approved "CAB079031: , HPA039796: AB_10673019" "unprognostic (1.76e-1)" "unprognostic (1.19e-1)" "unprognostic (6.29e-2)" "unprognostic (9.35e-2)" "unprognostic (3.71e-2)" "unprognostic (1.60e-2)" "unprognostic (4.68e-2)" "unprognostic (7.99e-2)" "unprognostic (3.07e-2)" "unprognostic (1.03e-5)" "unprognostic (1.93e-2)" "unprognostic (1.01e-1)" "unprognostic (4.02e-7)" "unprognostic (8.85e-2)" "unprognostic (3.60e-2)" "unprognostic (6.90e-2)" "unprognostic (3.39e-2)" 3.8 2.5 8.6 6.0 7.7 1.4 2.4 7.1 11.7 11.2 26.5 1.3 7.4 2.4 29.7 4.5 5.2 4.3 7.1 32.5 5.5 4.0 2.7 1.4 4.7 2.0 2.4 6.6 2.7 3.2 1.5 8.1 5.1 3.9 7.9 3.8 6.5 2.4 8.1 2.3 1.7 5.2 28.8 1.9 3.5 7.2 11.3 1.7 0.0 2.0 1.1 1.7 12.6 5.4 0.0 0.1 0.0 0.1 4.2 1.2 0.2 0.0 0.0 0.0 0.0 1.6 1.0 0.1 1.7 2.0 1.1 0.7 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.4 46.5 0.4 0.6 0.0 0.0 1.1 0.0 0.0 2.6 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.3 2.5 0.0 0.0 0.0 0.0 2.1 0.1 0.6 0.0 0.0 0.0 0.6 0.0 1.2 0.0 0.5 0.7 0.0 0.0 0.9 0.7 0.0 4.2 0.1 0.1 0.4 0.2 8.6 7.7 7.1 11.7 5.5 4.0 2.4 6.6 3.9 1.7 CACNA1D "CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2" ENSG00000157388 "Calcium voltage-gated channel subunit alpha1 D" Q01668 3 53328963-53813733 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Cancer-related genes, Deafness, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HMC-1: 14.1;RPMI-8226: 32.8;SK-BR-3: 6.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 9 "basophil: 7.2" "Lineage enriched" "Detected in single" 20 "granulocytes: 7.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA020215 Uncertain Approved "Nuclear membrane" "Nuclear membrane" "HPA020215: AB_1845860" "unprognostic (5.85e-2)" "unprognostic (4.90e-3)" "unprognostic (5.09e-2)" "unprognostic (2.24e-2)" "unprognostic (7.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.92e-1)" "unprognostic (2.32e-2)" "unprognostic (2.95e-1)" "unprognostic (4.42e-2)" "unprognostic (3.90e-3)" "unprognostic (1.53e-1)" "prognostic favourable (8.34e-8)" "unprognostic (1.14e-1)" "unprognostic (3.05e-2)" "unprognostic (8.09e-3)" "unprognostic (6.70e-3)" 0.6 13.4 10.0 0.8 12.6 1.4 3.6 12.2 16.5 11.2 2.8 3.7 0.1 3.3 6.8 13.2 1.2 14.9 6.2 1.8 5.3 3.5 4.2 3.0 9.0 0.5 2.5 9.6 1.2 5.3 3.0 13.6 1.4 8.7 5.7 3.1 10.1 1.1 3.5 0.6 1.5 4.2 1.7 2.2 4.4 1.8 3.0 1.6 0.0 5.2 0.0 0.6 2.3 0.6 0.1 0.3 7.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 0.0 1.5 1.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 14.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.2 0.0 0.0 0.1 32.8 0.3 2.2 3.0 1.3 0.2 6.2 0.7 1.8 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 7.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 10.0 12.6 12.2 16.5 5.3 3.5 2.5 9.6 8.7 1.6 CACNA1E "BII, CACH6, CACNL1A6, Cav2.3" ENSG00000198216 "Calcium voltage-gated channel subunit alpha1 E" Q15878 1 181317690-181808084 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "brain: 30.8" "Cell line enhanced" "Detected in some" "CACO-2: 4.0;NB-4: 2.5;NTERA-2: 2.9;SCLC-21H: 2.3;U-266/70: 7.0" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 8 "neutrophil: 1.8" "Lineage enriched" "Detected in single" 8 "granulocytes: 1.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042515, CAB079032" Approved Approved "Plasma membrane,Actin filaments,Cytosol" "Plasma membrane" "Actin filaments, Cytosol" "CAB079032: , HPA042515: " "unprognostic (3.96e-3)" "unprognostic (1.89e-1)" "unprognostic (1.05e-2)" "unprognostic (1.54e-5)" "unprognostic (6.56e-2)" "unprognostic (3.16e-2)" "unprognostic (4.30e-3)" "unprognostic (1.18e-1)" "unprognostic (2.40e-1)" "unprognostic (9.48e-3)" "unprognostic (1.04e-1)" "unprognostic (2.06e-1)" "unprognostic (9.85e-7)" "unprognostic (1.74e-2)" "unprognostic (2.07e-2)" "unprognostic (1.16e-1)" "unprognostic (3.75e-2)" 0.6 3.0 17.9 2.1 19.7 3.1 0.5 3.9 22.5 0.6 0.8 1.3 0.0 0.6 0.6 4.4 1.1 2.3 0.6 0.6 30.8 5.8 3.8 0.6 0.6 1.4 2.4 10.6 0.5 0.6 0.5 0.2 0.8 4.2 0.5 0.8 0.5 0.5 0.5 0.6 0.5 1.1 1.0 5.2 0.9 0.8 2.8 2.4 0.0 0.6 0.0 1.0 0.6 0.1 0.2 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 1.4 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 2.9 0.0 0.0 0.0 1.0 1.3 0.0 2.3 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.1 0.0 0.0 7.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 17.9 19.7 3.9 22.5 30.8 5.8 2.4 10.6 4.2 2.4 CACNA1F "AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2" ENSG00000102001 "Calcium voltage-gated channel subunit alpha1 F" O60840 X 49205063-49233371 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Sensory transduction, Transport, Vision" "Calcium channel, Ion channel, Voltage-gated channel" "Cone-rod dystrophy, Congenital stationary night blindness, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "retina: 55.8" "Cell line enhanced" "Detected in some" "A549: 2.5;BEWO: 2.5;MCF7: 2.8;U-266/70: 4.6" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 4.6" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" HPA068379 Enhanced "HPA068379: " "unprognostic (1.20e-3)" "unprognostic (8.62e-2)" "unprognostic (4.25e-3)" "unprognostic (1.56e-2)" "unprognostic (8.46e-2)" "unprognostic (1.84e-1)" "unprognostic (1.23e-2)" "unprognostic (1.76e-1)" "unprognostic (1.23e-1)" "unprognostic (9.04e-2)" "unprognostic (7.36e-2)" "unprognostic (1.59e-1)" "unprognostic (6.08e-7)" "unprognostic (8.03e-2)" "unprognostic (1.09e-1)" "unprognostic (4.65e-2)" "unprognostic (3.77e-3)" 0.7 0.8 1.8 0.7 1.5 4.0 1.8 5.3 2.0 0.7 1.0 0.7 0.7 1.9 0.7 2.7 0.7 1.0 0.7 0.7 0.8 0.6 0.7 0.7 1.4 2.7 0.7 0.7 0.7 1.4 0.0 0.7 0.7 0.7 0.7 1.5 55.8 1.2 0.9 0.7 2.4 3.7 0.7 0.7 1.8 1.0 0.7 0.7 0.7 1.2 0.7 0.9 0.7 0.7 1.4 4.6 2.0 0.9 0.5 1.0 0.2 0.2 2.5 0.2 0.0 0.6 0.0 2.5 0.4 0.2 0.0 0.0 0.1 0.9 1.4 0.5 0.5 0.1 0.4 0.0 0.0 0.1 0.0 0.7 0.0 0.5 0.5 0.1 0.8 0.6 0.0 0.4 0.0 0.7 1.0 0.3 0.0 2.8 1.3 1.5 1.1 0.0 0.1 0.0 0.5 0.4 1.5 0.6 0.0 0.0 0.1 0.0 0.9 1.5 1.0 0.2 0.3 0.2 0.1 4.6 1.6 0.0 0.8 0.4 0.0 0.9 0.7 0.6 0.6 0.5 0.5 0.7 0.8 0.4 0.8 1.4 0.5 1.0 2.0 0.5 0.9 4.6 0.7 0.2 1.8 1.5 5.3 2.0 0.8 0.6 0.7 0.7 0.7 0.7 CACNA1G "Cav3.1, NBR13" ENSG00000006283 "Calcium voltage-gated channel subunit alpha1 G" O43497 17 50561068-50627474 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 22.8;cervix, uterine: 13.6" "Cell line enhanced" "Detected in some" "A549: 13.3;HeLa: 4.6;SCLC-21H: 4.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004714 Uncertain "HPA004714: AB_1078368" "unprognostic (1.90e-2)" "unprognostic (5.83e-2)" "unprognostic (2.85e-2)" "unprognostic (1.08e-1)" "unprognostic (4.00e-1)" "unprognostic (9.89e-2)" "unprognostic (1.47e-2)" "unprognostic (2.73e-1)" "unprognostic (1.02e-4)" "unprognostic (1.47e-2)" "unprognostic (2.16e-2)" "unprognostic (9.76e-2)" "unprognostic (4.87e-12)" "unprognostic (3.34e-2)" "unprognostic (1.62e-1)" "unprognostic (1.56e-3)" "unprognostic (6.63e-2)" 1.7 1.0 3.5 0.9 5.2 1.3 2.1 22.8 17.1 13.6 1.0 2.7 0.0 0.9 7.4 1.0 1.6 5.7 1.2 3.8 2.4 8.8 0.7 1.1 0.9 1.2 5.3 7.9 7.1 0.6 0.6 0.4 1.4 6.1 2.5 0.8 4.3 1.1 1.6 0.8 3.9 0.8 2.1 5.9 0.9 0.9 1.7 2.3 0.0 1.2 0.0 1.0 1.0 3.9 1.3 1.3 2.7 0.8 0.7 1.4 0.0 0.0 13.3 3.1 3.5 0.9 0.1 0.2 0.1 0.0 0.1 0.1 2.8 0.5 0.0 1.0 0.1 0.5 1.6 0.0 0.3 1.8 0.6 0.9 4.6 0.7 0.1 0.2 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.7 0.0 0.0 1.2 0.8 1.4 1.1 0.0 0.0 0.2 4.1 1.8 2.8 0.1 0.0 0.2 0.1 0.3 1.4 3.9 0.5 0.1 1.0 0.1 0.0 0.5 0.1 0.5 0.5 0.8 0.6 1.4 0.4 0.7 0.8 0.7 0.8 0.2 1.3 0.9 1.0 2.7 0.7 0.4 1.3 0.5 0.0 3.5 5.2 22.8 17.1 2.4 8.8 5.3 7.9 6.1 2.3 CACNA1H Cav3.2 ENSG00000196557 "Calcium voltage-gated channel subunit alpha1 H" O95180 16 1153121-1221772 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 49.5" "Cell line enhanced" "Detected in some" "A549: 10.8;AN3-CA: 15.6;MCF7: 28.6;T-47d: 8.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA039125 Approved Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "HPA039125: AB_10795578" "unprognostic (1.66e-3)" "unprognostic (2.10e-1)" "unprognostic (4.07e-2)" "unprognostic (1.21e-3)" "unprognostic (1.37e-2)" "unprognostic (2.15e-1)" "unprognostic (4.39e-2)" "unprognostic (2.38e-2)" "unprognostic (1.06e-1)" "unprognostic (3.30e-2)" "prognostic favourable (3.12e-5)" "unprognostic (1.66e-2)" "prognostic unfavourable (1.78e-5)" "unprognostic (1.93e-2)" "unprognostic (4.65e-2)" "unprognostic (1.70e-2)" "unprognostic (5.55e-2)" 5.0 6.8 5.1 4.2 12.0 0.3 3.3 0.3 4.3 17.5 28.1 1.6 10.2 5.4 25.7 5.9 16.3 11.7 26.0 2.2 2.5 2.1 4.7 5.5 3.5 0.7 1.0 2.8 31.8 2.1 6.6 14.8 1.9 2.0 21.0 2.2 4.2 1.7 24.9 2.9 4.8 8.5 49.5 1.1 0.5 9.7 11.7 2.1 0.0 5.2 1.4 0.5 34.6 20.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 10.8 1.8 15.6 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.4 0.0 0.0 0.0 6.4 0.0 0.0 6.5 1.9 0.0 2.8 0.2 0.0 0.0 0.0 0.0 2.8 0.0 0.0 28.6 0.0 0.0 5.8 2.2 0.0 0.0 0.1 2.9 0.0 0.0 0.0 0.0 0.0 0.5 8.5 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 12.0 0.3 4.3 2.5 2.1 1.0 2.8 2.0 2.1 CACNA1S "CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5" ENSG00000081248 "Calcium voltage-gated channel subunit alpha1 S" Q13698 1 201039512-201112566 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "skeletal muscle: 83.1" "Group enriched" "Detected in some" 32 "BEWO: 5.4;HSkMC: 6.9" "Cancer enhanced" "Detected in single" "head and neck cancer: 0.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Region enriched" "Detected in single" 20 "olfactory region: 5.3" "CAB009507, HPA048892, HPA056815" Enhanced "CAB009507: AB_2069576, HPA048892: , HPA056815: " "unprognostic (2.14e-2)" "unprognostic (1.38e-1)" "unprognostic (1.12e-2)" "unprognostic (1.09e-1)" "unprognostic (3.52e-3)" "unprognostic (4.53e-2)" "unprognostic (2.84e-1)" "unprognostic (2.23e-1)" "unprognostic (2.53e-2)" "unprognostic (1.51e-1)" "unprognostic (4.72e-3)" "unprognostic (1.12e-1)" "unprognostic (5.28e-2)" "unprognostic (7.36e-2)" "unprognostic (1.57e-1)" 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.9 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.4 0.6 0.0 83.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 10.6 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.4 0.1 0.1 0.1 0.1 0.0 CACNA2D1 "CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3" ENSG00000153956 "Calcium voltage-gated channel auxiliary subunit alpha2delta 1" P54289 7 81946444-82443798 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 59.0" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 18.1;HUVEC TERT2: 24.7;SH-SY5Y: 28.7;TIME: 17.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008213, HPA008621" Enhanced "Intracellular and membrane" 310000000 "HPA008213: AB_1845862, HPA008621: AB_1845863" "unprognostic (5.07e-3)" "unprognostic (2.21e-1)" "unprognostic (4.27e-3)" "unprognostic (2.92e-2)" "unprognostic (2.27e-1)" "unprognostic (1.39e-1)" "unprognostic (1.70e-1)" "unprognostic (3.22e-1)" "unprognostic (3.76e-1)" "unprognostic (2.05e-1)" "unprognostic (6.24e-3)" "unprognostic (2.23e-2)" "prognostic unfavourable (1.16e-4)" "unprognostic (4.28e-3)" "unprognostic (2.13e-1)" "unprognostic (9.18e-2)" "unprognostic (1.03e-4)" 9.9 13.4 15.7 4.2 18.1 0.7 4.3 8.8 20.8 5.7 11.3 7.3 1.0 5.0 7.1 2.9 5.4 4.1 6.3 25.8 12.7 14.9 8.0 1.8 3.6 2.2 6.3 15.6 7.8 2.0 1.9 8.3 4.2 8.6 12.8 5.3 1.9 3.3 6.6 59.0 4.7 3.5 13.0 5.6 4.3 5.5 3.7 8.0 0.0 16.9 14.6 3.3 6.8 7.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 4.8 0.0 8.5 10.8 0.0 10.5 6.8 5.2 5.1 0.0 1.5 0.0 0.0 9.1 0.0 5.0 0.0 6.9 0.0 6.8 0.3 6.8 0.0 5.6 2.3 0.0 6.3 0.0 18.1 0.0 24.7 0.0 0.1 11.6 0.0 0.0 0.0 5.7 2.2 1.0 0.9 0.0 0.4 0.4 9.7 28.7 2.0 0.0 0.0 0.0 0.0 17.7 9.3 7.0 9.2 0.0 0.0 0.0 0.0 7.8 0.0 5.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.7 18.1 8.8 20.8 12.7 14.9 6.3 15.6 8.6 8.0 CACNA2D2 KIAA0558 ENSG00000007402 "Calcium voltage-gated channel auxiliary subunit alpha2delta 2" Q9NY47 3 50362799-50504244 "FDA approved drug targets, Predicted intracellular proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "lung: 86.1" "Cell line enriched" "Detected in some" 8 "SH-SY5Y: 64.9" "Cancer enhanced" "Detected in many" "testis cancer: 20.4" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA034771, HPA071829" Enhanced Approved Vesicles 1000000 Vesicles "HPA034771: AB_10603555, HPA071829: " "unprognostic (2.06e-1)" "unprognostic (2.37e-1)" "unprognostic (1.72e-2)" "prognostic unfavourable (7.62e-5)" "unprognostic (6.59e-2)" "unprognostic (6.37e-2)" "unprognostic (6.91e-2)" "unprognostic (6.57e-3)" "unprognostic (4.39e-2)" "unprognostic (1.17e-1)" "prognostic favourable (1.21e-4)" "unprognostic (2.71e-2)" "unprognostic (1.57e-4)" "unprognostic (3.03e-1)" "unprognostic (4.14e-2)" "unprognostic (3.55e-1)" "unprognostic (4.22e-2)" 1.0 0.9 1.6 1.3 11.1 1.1 1.4 14.9 6.5 1.1 1.7 0.9 0.6 1.4 1.7 1.2 0.9 1.1 0.9 7.6 1.7 9.1 1.6 0.5 86.1 1.3 3.9 3.2 2.2 4.0 3.8 6.0 1.9 6.1 3.0 2.0 6.1 1.5 1.4 1.7 2.6 1.7 1.4 1.4 1.5 4.1 5.8 2.5 0.2 2.3 0.1 0.7 0.7 0.7 1.8 0.3 0.7 0.1 2.3 3.6 1.1 0.0 0.0 1.0 2.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 8.3 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 2.6 0.1 0.0 0.0 0.2 0.0 0.0 6.2 64.9 0.2 0.1 0.0 0.5 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.4 2.2 0.0 2.7 1.8 2.6 2.0 0.0 1.3 3.6 2.2 0.0 2.3 0.1 0.3 3.2 1.1 1.6 11.1 14.9 6.5 1.7 9.1 3.9 3.2 6.1 2.5 CACNB1 CACNLB1 ENSG00000067191 "Calcium voltage-gated channel auxiliary subunit beta 1" Q02641 17 39173456-39197703 "FDA approved drug targets, Predicted intracellular proteins" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "skeletal muscle: 130.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023343 Approved "HPA023343: AB_1845866" "unprognostic (3.44e-2)" "unprognostic (1.89e-2)" "unprognostic (1.69e-3)" "prognostic unfavourable (3.80e-4)" "unprognostic (3.99e-2)" "unprognostic (1.52e-2)" "unprognostic (1.37e-2)" "unprognostic (2.80e-3)" "unprognostic (4.43e-1)" "unprognostic (1.04e-3)" "unprognostic (5.98e-2)" "unprognostic (3.38e-1)" "unprognostic (1.94e-11)" "unprognostic (7.62e-2)" "unprognostic (2.30e-1)" "unprognostic (1.34e-2)" "unprognostic (7.44e-3)" 2.0 2.4 7.8 2.2 14.9 1.6 2.0 5.4 22.0 3.3 2.3 2.0 6.0 1.7 2.3 3.7 4.2 2.3 2.0 2.8 8.6 6.4 1.3 1.1 3.0 2.1 3.3 11.0 2.6 1.4 1.6 2.0 1.8 7.6 3.6 2.2 0.8 3.4 5.7 130.9 5.8 1.7 2.4 1.9 2.0 1.8 2.3 2.1 1.7 2.0 7.3 1.8 1.8 1.6 0.1 3.1 0.1 1.2 1.8 3.2 0.8 6.0 2.7 3.4 7.8 3.8 4.7 0.1 3.6 4.5 3.4 4.3 2.0 6.1 10.4 3.8 5.4 5.6 3.3 6.0 2.6 4.9 3.7 1.4 6.4 0.8 7.8 0.3 0.9 5.1 1.9 7.1 8.1 2.4 0.9 9.1 3.5 1.6 7.4 2.7 2.4 2.0 5.1 11.3 4.5 1.4 1.9 8.5 5.2 2.1 11.5 3.4 8.1 4.1 3.4 6.1 7.1 4.5 3.6 4.3 1.4 1.7 5.1 0.0 2.5 0.0 1.2 0.0 2.0 0.6 3.2 0.1 1.9 2.6 0.5 0.1 0.6 1.2 0.1 1.8 0.3 3.1 0.5 0.8 7.8 14.9 5.4 22.0 8.6 6.4 3.3 11.0 7.6 2.1 CACNB2 "CACNLB2, MYSB" ENSG00000165995 "Calcium voltage-gated channel auxiliary subunit beta 2" Q08289 10 18140677-18543557 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Brugada syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HAP1: 10.5;HSkMC: 13.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035326 Enhanced Approved "Microtubules,Cytokinetic bridge,Mitotic spindle" "Microtubules, Cytokinetic bridge, Mitotic spindle" "HPA035326: AB_10669903" "unprognostic (3.03e-3)" "unprognostic (3.04e-1)" "unprognostic (1.49e-2)" "unprognostic (1.16e-1)" "unprognostic (4.58e-3)" "unprognostic (4.67e-4)" "unprognostic (8.03e-2)" "unprognostic (3.76e-2)" "unprognostic (8.10e-2)" "unprognostic (1.70e-1)" "unprognostic (7.78e-4)" "unprognostic (1.40e-1)" "prognostic favourable (3.56e-5)" "unprognostic (3.48e-2)" "unprognostic (5.72e-2)" "unprognostic (1.03e-1)" "unprognostic (8.16e-2)" 2.7 15.6 10.5 4.2 16.4 2.1 2.8 27.0 25.8 7.0 11.6 1.9 7.4 3.4 9.6 5.8 9.7 7.8 4.6 15.8 8.8 9.7 4.6 4.0 2.7 1.8 4.3 11.8 18.1 8.6 2.7 16.9 1.3 9.2 9.7 8.7 10.0 7.1 18.0 2.1 5.6 9.4 31.1 2.4 1.7 6.5 2.0 3.2 0.1 2.5 0.0 1.0 13.4 12.8 1.9 0.8 4.0 0.7 1.0 3.7 0.2 0.2 1.4 0.9 0.7 0.7 0.4 0.6 0.4 0.0 0.1 0.4 0.6 0.6 1.1 0.2 0.3 0.9 10.5 0.0 0.0 0.4 3.2 1.0 1.8 1.9 2.7 0.8 1.9 13.2 0.0 0.0 0.0 0.0 1.1 2.2 0.0 0.8 1.1 1.2 3.8 0.1 0.9 1.0 1.0 0.0 1.1 5.3 1.5 0.1 0.1 0.4 0.2 1.1 0.2 0.7 2.4 0.4 0.7 2.4 2.3 2.2 0.3 1.5 0.5 4.0 0.5 0.6 1.0 0.7 1.4 1.3 1.1 0.5 0.1 1.9 1.8 2.6 0.7 1.0 0.7 0.8 3.7 0.2 10.5 16.4 27.0 18.3 8.8 9.7 4.3 11.8 9.2 3.2 CACNB3 CACNLB3 ENSG00000167535 "Calcium voltage-gated channel auxiliary subunit beta 3" P54284 12 48813794-48828941 "FDA approved drug targets, Predicted intracellular proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 42.9" "Cell line enhanced" "Detected in many" "U-937: 45.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 4.7" "Lineage enriched" "Detected in single" 9 "T-cells: 4.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA059515 Approved "Golgi apparatus,Vesicles" "Golgi apparatus, Vesicles" "HPA059515: " "unprognostic (1.77e-2)" "unprognostic (4.84e-2)" "unprognostic (2.16e-3)" "unprognostic (2.12e-2)" "unprognostic (8.76e-2)" "unprognostic (2.68e-1)" "unprognostic (2.06e-1)" "unprognostic (3.60e-2)" "unprognostic (3.27e-2)" "unprognostic (2.24e-1)" "unprognostic (5.67e-3)" "unprognostic (1.04e-1)" "unprognostic (5.44e-3)" "unprognostic (6.31e-3)" "unprognostic (6.58e-2)" "unprognostic (1.98e-1)" "unprognostic (2.78e-3)" 3.8 3.7 27.4 2.9 22.4 1.2 4.2 18.5 42.9 11.9 9.1 1.5 3.0 3.8 22.6 8.1 11.6 16.1 6.7 2.6 16.4 12.2 3.9 1.3 6.1 1.7 10.0 14.5 24.1 2.1 2.8 4.2 5.3 4.4 5.7 7.8 3.4 4.5 9.1 2.1 7.8 5.8 20.4 2.4 2.2 4.7 4.7 2.3 4.6 6.1 3.4 3.6 7.5 6.9 0.2 0.5 0.0 0.3 0.0 4.7 0.5 6.8 5.4 9.1 18.5 11.1 7.9 5.5 7.0 14.8 10.4 6.2 1.7 5.6 0.8 9.2 11.7 7.3 8.2 7.6 3.9 7.9 2.5 3.6 4.4 0.2 4.4 0.6 3.9 5.0 4.6 4.3 2.1 11.8 0.5 2.9 6.7 17.0 8.4 0.9 5.6 4.6 9.7 2.0 2.7 7.5 12.9 12.9 12.8 2.1 15.5 5.1 10.6 3.0 11.3 6.6 9.4 3.2 3.8 3.3 1.3 0.2 5.5 45.1 2.0 0.0 0.3 0.0 0.9 0.1 0.4 0.2 1.8 1.8 0.5 0.0 0.4 0.2 0.0 0.0 0.0 0.4 4.7 0.5 27.4 22.4 18.5 42.9 16.4 12.2 10.0 14.5 4.4 2.3 CACNB4 EJM4 ENSG00000182389 "Calcium voltage-gated channel auxiliary subunit beta 4" O00305 2 151832768-152099475 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 35.7" "Cell line enriched" "Detected in some" 4 "HMC-1: 20.7" "Low cancer specificity" "Detected in single" "Group enriched" "Detected in all" 4 "basal ganglia: 28.0;cerebellum: 35.7;cerebral cortex: 21.7;olfactory region: 10.9;pons and medulla: 9.8" "Cell type enriched" "Detected in some" 5 "neutrophil: 7.0" "Lineage enriched" "Detected in many" 5 "granulocytes: 7.0" HPA015601 Approved "HPA015601: AB_1845873" "unprognostic (2.92e-1)" "unprognostic (1.98e-1)" "unprognostic (1.80e-1)" "unprognostic (1.29e-1)" "unprognostic (1.14e-1)" "unprognostic (1.49e-2)" "unprognostic (3.70e-1)" "unprognostic (9.42e-4)" "unprognostic (1.23e-1)" "unprognostic (1.98e-1)" "unprognostic (1.05e-3)" "unprognostic (2.02e-1)" "unprognostic (1.55e-2)" "unprognostic (7.26e-3)" "unprognostic (3.93e-2)" "unprognostic (9.55e-3)" "unprognostic (2.45e-1)" 1.6 1.7 5.2 1.3 28.0 1.7 3.2 35.7 28.0 1.4 1.2 2.6 0.0 1.2 1.4 1.7 3.1 1.1 2.1 1.1 4.5 4.4 2.8 0.9 3.9 1.1 4.3 10.9 1.3 1.2 1.0 3.8 2.1 9.8 3.9 1.4 0.9 2.1 3.9 0.8 11.7 1.1 4.2 3.0 1.2 1.6 4.1 3.4 0.0 3.1 0.0 2.2 3.5 0.8 0.4 1.3 7.0 0.6 0.2 0.1 0.1 0.0 0.0 0.7 0.7 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 1.9 0.0 0.1 0.3 3.2 0.0 0.1 4.0 0.0 0.2 20.7 0.2 0.1 0.4 0.0 0.0 0.0 0.5 0.1 0.0 0.2 0.3 0.5 0.6 1.8 0.2 0.6 1.2 0.6 1.4 0.7 0.0 0.0 0.0 3.3 0.8 0.0 1.9 2.1 0.6 0.4 0.4 0.0 0.0 0.5 4.8 0.1 1.2 0.6 0.0 0.1 0.0 0.1 0.1 0.0 0.0 1.3 0.4 0.1 0.1 7.0 0.2 0.0 1.3 0.0 0.1 5.2 28.0 35.7 21.7 4.5 4.4 4.3 10.9 9.8 3.4 CALY "CALCYON, DRD1IP, NSG3" ENSG00000130643 "Calcyon neuron specific vesicular protein" Q9NYX4 10 133324072-133336935 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "adrenal gland: 26.5;brain: 98.9;pituitary gland: 47.7" "Cell line enhanced" "Detected in some" "SH-SY5Y: 2.7;U-266/70: 2.6" "Group enriched" "Detected in some" 14 "glioma: 1.7;pancreatic cancer: 7.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 1.3;naive CD4 T-cell: 1.0" "Lineage enriched" "Detected in single" 14 "T-cells: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042283 Enhanced "HPA042283: AB_10794417" "unprognostic (1.43e-2)" "unprognostic (7.84e-2)" "unprognostic (3.77e-3)" "unprognostic (1.41e-2)" "unprognostic (7.32e-2)" "unprognostic (9.81e-3)" "unprognostic (2.56e-1)" "unprognostic (7.48e-2)" "unprognostic (1.36e-1)" "unprognostic (1.18e-1)" "prognostic favourable (3.54e-4)" "unprognostic (1.23e-2)" "unprognostic (4.19e-10)" "unprognostic (8.04e-3)" "unprognostic (1.29e-1)" "unprognostic (3.60e-1)" "unprognostic (1.63e-1)" 1.8 26.5 27.1 2.7 57.4 1.8 1.8 12.7 67.1 1.7 2.6 3.6 0.0 5.0 1.7 1.9 1.8 2.0 1.8 1.7 31.8 98.9 1.7 1.7 1.9 2.0 25.1 39.8 1.7 6.3 1.7 47.7 1.7 33.9 1.8 2.4 0.7 2.1 2.0 1.7 1.9 3.8 2.1 14.3 1.9 4.1 4.3 4.8 0.0 1.9 0.0 1.9 1.7 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.6 0.1 0.8 0.3 0.0 0.0 0.0 0.3 0.6 0.6 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.1 0.3 0.0 0.0 0.3 0.0 0.1 0.0 0.8 1.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.0 1.1 0.0 0.0 0.3 0.0 0.0 0.4 0.1 0.0 0.0 0.0 2.7 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.3 0.0 0.1 2.6 0.0 0.0 0.3 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.3 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 27.1 57.4 12.7 45.9 31.8 98.9 25.1 39.8 33.9 4.8 CAMLG "CAML, GET2" ENSG00000164615 "Calcium modulating ligand" P49069 5 134738501-134752160 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Host-virus interaction" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA052636, HPA056472" Approved Approved Nucleoplasm,Nucleoli,Vesicles Vesicles "Nucleoplasm, Nucleoli" "HPA052636: , HPA056472: " "unprognostic (9.23e-2)" "unprognostic (8.54e-2)" "unprognostic (2.95e-1)" "unprognostic (2.21e-1)" "unprognostic (1.07e-1)" "unprognostic (1.07e-2)" "unprognostic (3.68e-2)" "unprognostic (5.41e-3)" "unprognostic (3.07e-1)" "unprognostic (8.54e-2)" "unprognostic (5.34e-3)" "unprognostic (4.58e-2)" "prognostic unfavourable (1.09e-5)" "unprognostic (3.26e-2)" "unprognostic (1.43e-2)" "unprognostic (2.19e-1)" "unprognostic (3.16e-1)" 24.2 29.0 37.6 14.3 32.4 22.7 29.3 28.2 39.3 33.3 32.7 15.5 20.2 26.1 31.7 45.2 21.4 23.0 21.8 22.3 32.4 38.3 20.1 19.7 18.9 18.4 36.2 22.7 53.0 25.7 14.8 21.9 14.0 22.4 27.5 14.3 21.7 15.9 26.2 32.5 19.7 22.2 30.4 26.0 15.1 17.7 36.6 14.0 21.1 21.6 18.5 19.3 40.3 20.0 25.0 16.1 32.1 23.3 16.6 28.6 17.4 9.5 7.4 12.8 23.7 28.4 44.0 5.7 13.6 19.8 10.2 19.3 13.6 14.6 39.1 20.0 9.5 12.4 10.5 16.6 14.5 18.2 19.4 10.4 13.6 11.1 20.9 5.5 32.9 35.6 18.1 12.5 21.6 19.2 6.5 18.2 15.1 10.7 14.5 23.2 6.5 7.5 16.3 16.9 15.1 17.5 9.4 18.9 13.3 9.8 6.2 32.6 17.2 11.5 18.4 9.9 6.1 15.1 12.3 17.2 18.5 15.0 16.7 17.3 5.4 32.1 15.2 32.1 18.3 17.3 24.6 25.0 26.4 22.9 16.1 22.4 27.8 26.8 27.6 16.6 23.3 14.7 28.6 17.4 37.6 32.4 28.2 39.3 32.4 38.3 36.2 22.7 22.4 14.0 CARTPT CART ENSG00000164326 "CART prepropeptide" Q16568 5 71719163-71721048 "FDA approved drug targets, Predicted secreted proteins" "Neuropeptide, Neurotransmitter" "FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "adrenal gland: 67.5;brain: 101.4" "Group enriched" "Detected in some" 7 "NB-4: 1.0;SH-SY5Y: 3.4" "Cancer enriched" "Detected in many" 9 "breast cancer: 117.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "hippocampal formation: 179.9" "CAB025515, HPA046278, CAB079776" Enhanced Supported "Secreted to blood" "CAB025515: , CAB079776: , HPA046278: AB_10961570" "unprognostic (1.37e-1)" "unprognostic (1.43e-1)" "unprognostic (2.27e-1)" "unprognostic (3.45e-2)" "unprognostic (6.67e-2)" "prognostic unfavourable (4.36e-4)" "unprognostic (1.14e-1)" 1.6 67.5 8.0 2.8 22.3 0.5 5.8 0.1 29.0 0.5 3.4 2.1 0.0 3.5 0.6 0.9 3.5 0.7 0.6 0.5 31.1 101.4 0.5 0.5 0.5 0.5 1.0 4.5 0.5 5.3 0.5 1.7 0.5 54.1 3.3 3.1 1.6 0.5 0.5 0.5 0.5 1.4 8.1 8.6 0.5 3.4 1.9 9.7 0.0 3.4 0.0 0.5 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 22.3 0.1 29.0 31.1 101.4 1.0 4.5 54.1 9.7 CASR "FHH, GPRC2A, HHC, HHC1, NSHPT" ENSG00000036828 "Calcium sensing receptor" P41180 3 122183683-122291629 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "parathyroid gland: 155.3" "Cell line enhanced" "Detected in some" "RPTEC TERT1: 4.0" "Cancer enriched" "Detected in some" 7 "pancreatic cancer: 5.5" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA039686, HPA050335" Enhanced "HPA039686: AB_10673536, HPA050335: AB_2681092" "unprognostic (1.97e-2)" "unprognostic (7.40e-2)" "unprognostic (8.20e-4)" "unprognostic (3.15e-1)" "unprognostic (8.55e-4)" "unprognostic (1.58e-1)" "unprognostic (7.32e-2)" "unprognostic (7.67e-2)" "unprognostic (1.62e-1)" "unprognostic (1.48e-1)" "unprognostic (1.91e-5)" "unprognostic (2.72e-1)" "unprognostic (2.26e-1)" "unprognostic (1.24e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.8 0.4 0.0 0.1 0.0 0.0 0.0 0.0 21.0 0.0 0.1 0.2 18.1 0.5 0.0 0.0 0.1 0.0 0.6 12.1 155.3 0.6 0.0 0.2 0.0 0.0 0.6 0.5 0.0 0.0 0.0 0.6 0.3 0.2 0.2 0.5 0.3 0.0 0.1 1.6 0.0 0.1 0.7 0.0 1.4 0.5 1.1 0.3 0.8 1.1 0.2 0.6 1.3 0.7 1.1 0.3 0.3 0.7 0.7 0.0 0.0 0.1 0.6 0.8 1.1 0.9 0.4 0.5 0.2 0.2 0.3 0.8 0.1 1.4 1.1 1.1 0.0 0.7 0.8 0.4 0.4 0.4 0.2 0.2 0.6 2.0 0.3 0.7 0.5 0.9 1.4 0.6 0.6 0.5 0.6 4.0 1.5 0.6 0.8 0.9 0.5 0.3 0.9 0.3 1.3 1.0 1.8 1.0 0.3 1.6 1.1 0.5 0.7 0.6 1.0 1.0 0.3 0.1 0.9 0.2 0.9 0.7 0.9 0.9 0.1 1.4 0.7 0.6 1.1 0.8 0.2 0.5 1.1 0.2 0.0 0.0 0.0 0.6 0.1 0.2 0.1 0.0 0.2 0.0 CAT ENSG00000121691 Catalase P04040 11 34438925-34472062 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Hydrogen peroxide" "Mitogen, Oxidoreductase, Peroxidase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 258.3;liver: 184.8" "Cell line enhanced" "Detected in many" "HL-60: 75.2;THP-1: 62.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in all" 13 "eosinophil: 258.3" "Lineage enriched" "Detected in all" 13 "granulocytes: 258.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001515, HPA051282, HPA055838" Enhanced Enhanced Vesicles 960000000 Vesicles "CAB001515: AB_384710, HPA051282: AB_2681419, HPA055838: AB_2682937" "unprognostic (3.62e-2)" "unprognostic (2.72e-1)" "unprognostic (3.59e-3)" "unprognostic (5.43e-2)" "unprognostic (4.44e-2)" "unprognostic (5.80e-3)" "prognostic favourable (9.67e-4)" "unprognostic (9.95e-3)" "unprognostic (3.22e-1)" "unprognostic (7.23e-2)" "unprognostic (3.34e-2)" "unprognostic (9.77e-2)" "prognostic favourable (1.96e-8)" "unprognostic (1.01e-1)" "unprognostic (7.31e-2)" "unprognostic (4.77e-2)" "unprognostic (6.59e-3)" 70.0 33.0 9.4 10.1 9.6 54.2 36.1 3.1 7.7 15.3 26.6 18.6 15.7 22.2 13.5 9.5 14.8 14.2 19.0 22.4 10.7 5.2 50.4 184.8 26.1 21.3 14.5 6.0 11.0 24.7 7.1 5.0 16.4 10.2 23.2 11.3 11.4 14.5 13.2 27.8 19.7 29.2 11.6 11.3 17.9 15.9 6.2 11.6 23.4 41.7 14.9 11.5 20.4 24.9 7.6 19.9 258.3 17.5 5.5 5.0 17.8 6.1 6.8 5.0 7.8 48.4 21.1 10.6 7.8 9.9 8.8 9.7 3.8 6.2 15.2 7.6 15.5 14.7 8.4 8.5 9.8 13.2 7.7 12.8 7.3 21.9 5.7 75.2 6.4 11.3 5.9 2.6 1.0 10.6 26.5 6.3 11.1 5.8 15.4 13.4 0.0 16.6 10.9 23.8 12.4 24.1 23.3 2.6 4.0 8.8 14.2 11.6 20.3 62.8 7.5 5.3 5.2 13.2 4.6 5.1 2.9 3.2 10.4 51.8 3.8 12.5 17.5 258.3 3.2 14.7 3.8 7.6 3.8 3.6 19.9 6.8 3.8 4.0 17.1 5.5 15.5 13.4 5.0 17.8 9.4 9.6 3.1 7.7 10.7 5.2 14.5 6.0 10.2 11.6 CCL2 "GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF" ENSG00000108691 "C-C motif chemokine ligand 2" P13500 17 34255218-34257203 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Chemotaxis, Inflammatory response" Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 4 "BJ hTERT+: 159.2;HMC-1: 207.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "classical monocyte: 10.3;eosinophil: 3.9" "Group enriched" "Detected in many" 6 "granulocytes: 3.9;monocytes: 10.3" "Low region specificity" "Detected in many" "CAB013676, HPA019163" Approved Approved "Golgi apparatus,Vesicles" "Secreted to blood" 342420 "Golgi apparatus" Vesicles "CAB013676: , HPA019163: AB_1846179" "unprognostic (6.43e-2)" "unprognostic (4.14e-2)" "unprognostic (4.78e-2)" "unprognostic (5.57e-2)" "unprognostic (2.37e-3)" "unprognostic (8.64e-2)" "unprognostic (2.78e-2)" "unprognostic (7.53e-2)" "unprognostic (2.90e-1)" "unprognostic (1.19e-1)" "unprognostic (9.33e-2)" "unprognostic (2.65e-1)" "prognostic unfavourable (4.51e-4)" "unprognostic (1.33e-1)" "unprognostic (2.50e-2)" "unprognostic (1.81e-1)" "unprognostic (4.92e-2)" 78.1 31.2 10.3 52.3 50.6 19.1 19.0 1.5 23.3 9.7 41.9 28.6 3.0 9.4 7.2 7.6 14.4 25.8 62.0 76.9 45.1 6.7 32.5 38.4 105.2 16.9 16.0 2.0 28.6 32.8 15.2 17.3 22.8 63.6 42.0 25.3 22.3 13.5 13.4 17.8 10.5 16.7 34.6 85.4 16.1 30.2 4.6 8.6 4.8 20.8 21.6 19.1 27.2 9.0 0.0 1.1 3.9 10.3 0.0 0.1 2.3 0.0 1.2 3.4 0.0 9.6 8.2 0.0 9.7 159.2 20.7 44.4 0.5 0.0 0.0 7.7 2.2 5.3 0.3 0.0 10.5 0.0 0.0 0.0 1.1 0.0 0.3 0.0 207.5 9.1 0.0 4.3 0.2 9.4 0.5 1.7 0.0 0.0 0.0 1.5 0.4 0.0 0.0 0.2 1.7 29.6 0.0 0.0 0.6 0.0 0.5 0.2 0.3 0.2 0.5 11.1 0.4 0.3 0.0 0.1 0.0 0.0 6.5 3.0 7.0 0.0 10.3 3.9 0.0 0.3 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.1 0.7 0.0 0.0 0.3 0.0 2.3 10.3 50.6 1.5 23.3 45.1 6.7 16.0 2.0 63.6 8.6 CCND1 "BCL1, D11S287E, PRAD1, U21B31" ENSG00000110092 "Cyclin D1" P24385 11 69641087-69654474 "Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, Transcription, Transcription regulation" "Cyclin, Repressor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-266/70: 94.3;WM-115: 131.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 3.0;myeloid DC: 3.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000024, HPA027802" Uncertain Supported Nucleoplasm Nucleoplasm "CAB000024: AB_563678, HPA027802: " "unprognostic (4.90e-2)" "unprognostic (1.54e-1)" "unprognostic (7.62e-2)" "unprognostic (1.39e-2)" "unprognostic (2.18e-1)" "prognostic unfavourable (5.51e-4)" "unprognostic (1.38e-1)" "unprognostic (2.53e-2)" "unprognostic (9.46e-2)" "unprognostic (4.84e-3)" "prognostic unfavourable (1.96e-4)" "unprognostic (4.39e-2)" "unprognostic (2.61e-3)" "unprognostic (4.38e-3)" "unprognostic (1.16e-1)" "unprognostic (6.40e-3)" "unprognostic (2.57e-1)" 52.0 11.6 9.7 6.0 9.7 0.7 22.8 3.4 7.7 15.4 8.9 15.4 19.9 8.4 18.8 23.1 37.7 11.8 31.0 23.9 10.8 8.8 14.5 68.1 22.2 3.7 12.4 5.6 6.5 31.5 83.2 16.6 38.1 10.0 30.7 6.8 24.8 25.6 21.7 2.0 43.6 10.4 16.5 12.6 12.9 19.2 4.0 7.5 9.0 17.1 23.1 23.6 21.4 22.1 3.0 3.4 0.8 0.0 0.0 0.9 0.3 47.6 19.1 6.3 0.1 19.6 20.7 13.7 75.6 28.1 8.8 5.2 21.4 37.0 0.0 34.3 39.3 34.9 0.6 20.5 15.9 0.1 3.8 0.0 4.7 21.7 4.7 0.3 0.7 11.7 4.0 12.4 4.8 15.1 0.0 0.1 69.5 20.2 0.0 2.7 11.6 21.1 0.1 20.2 1.1 41.0 29.5 1.0 25.0 0.9 17.9 47.0 10.9 0.9 63.0 43.4 12.1 18.8 51.3 94.3 56.3 0.1 37.1 0.6 131.3 0.8 0.0 0.0 0.9 0.0 0.1 3.0 0.4 0.2 3.4 2.5 0.8 0.2 0.2 0.0 0.0 0.0 0.0 0.3 9.7 9.7 3.4 7.7 10.8 8.8 12.4 5.6 10.0 7.5 CD44 "CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1" ENSG00000026508 "CD44 molecule (Indian blood group)" P16070 11 35138870-35232402 "Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion" "Blood group antigen, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000112, CAB000316, HPA005785" Enhanced Enhanced "Golgi apparatus,Plasma membrane" "Secreted - unknown location" 2400000000 "Plasma membrane" "Golgi apparatus" "CAB000112: , CAB000316: AB_2076596, HPA005785: AB_1078467" "unprognostic (5.33e-2)" "unprognostic (1.85e-1)" "unprognostic (4.97e-2)" "unprognostic (9.90e-3)" "unprognostic (3.50e-3)" "unprognostic (1.46e-2)" "unprognostic (1.56e-2)" "unprognostic (8.12e-2)" "unprognostic (1.57e-1)" "unprognostic (4.18e-2)" "unprognostic (1.51e-3)" "unprognostic (4.63e-2)" "prognostic unfavourable (1.78e-8)" "unprognostic (6.41e-2)" "unprognostic (4.14e-2)" "unprognostic (3.93e-2)" "unprognostic (7.98e-2)" 45.5 9.0 10.5 42.5 21.7 53.0 35.6 4.7 13.4 43.2 19.5 26.3 8.3 10.6 80.5 20.3 66.5 18.6 48.0 11.7 14.9 9.3 12.4 9.1 43.4 48.4 31.5 6.1 12.8 83.9 0.8 3.8 19.4 40.7 30.1 24.5 30.2 148.2 22.4 15.9 107.7 18.9 44.5 100.5 30.9 19.9 7.2 20.3 17.9 20.6 53.9 53.7 55.0 54.2 22.7 41.0 19.1 65.2 54.6 53.1 59.9 41.5 37.6 0.3 0.1 22.7 62.8 0.1 81.5 63.8 45.4 25.3 2.5 13.1 0.0 10.9 115.5 71.7 0.8 88.6 62.4 8.9 0.4 1.5 18.5 0.0 22.4 21.1 97.8 28.3 70.0 61.1 49.6 15.9 0.3 13.6 43.5 0.2 1.9 13.9 0.8 11.1 0.1 7.7 0.6 66.5 12.0 0.1 0.1 15.4 0.4 36.9 2.2 1.2 45.6 56.6 10.2 69.4 83.7 23.6 25.4 0.2 85.9 11.9 82.2 19.1 65.2 6.0 26.2 45.7 37.0 22.7 39.8 34.9 41.0 16.2 34.5 28.7 16.4 54.6 59.3 14.2 53.1 59.9 10.5 21.7 4.7 13.4 14.9 9.3 31.5 6.1 40.7 20.3 CDK4 PSK-J3 ENSG00000135446 "Cyclin dependent kinase 4" P11802 12 57747727-57756013 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in all" 10 "HBEC3-KT: 125.1;LHCN-M2: 138.1;RH-30: 434.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006024, CAB013116, CAB069405" Supported Supported "Nucleoplasm,Nuclear membrane,Nucleoli,Cytosol" Cytosol "Nucleoplasm, Nuclear membrane, Nucleoli" "CAB013116: AB_2536376, CAB069405: AB_1613464, HPA006024: " "unprognostic (8.88e-2)" "unprognostic (2.53e-1)" "unprognostic (5.27e-2)" "unprognostic (9.01e-2)" "unprognostic (2.21e-1)" "unprognostic (1.10e-1)" "prognostic unfavourable (2.09e-7)" "unprognostic (7.39e-2)" "unprognostic (3.23e-3)" "unprognostic (2.93e-2)" "unprognostic (3.19e-2)" "unprognostic (9.10e-2)" "prognostic unfavourable (3.15e-5)" "unprognostic (3.32e-1)" "unprognostic (1.67e-1)" "unprognostic (3.64e-1)" "unprognostic (1.57e-2)" 32.2 43.1 13.8 22.2 15.7 24.0 45.0 13.1 17.9 36.3 28.2 20.1 22.8 15.2 51.4 28.1 29.9 31.0 32.3 27.4 14.5 12.1 24.0 36.9 26.8 26.4 18.3 13.7 61.4 54.4 18.9 34.2 25.0 16.0 37.2 26.9 26.2 29.3 24.1 27.8 25.6 20.7 34.1 13.5 27.2 23.9 24.6 17.5 29.2 54.3 32.1 27.5 33.6 30.9 29.6 25.5 2.6 19.9 15.8 32.1 22.2 9.3 10.8 14.3 12.7 13.1 11.5 9.5 5.4 17.6 23.8 19.8 15.4 8.9 13.6 9.7 8.4 7.2 19.7 125.1 18.1 6.7 9.1 12.7 7.3 10.8 15.4 14.4 8.8 11.3 9.2 14.6 16.8 15.3 13.5 11.7 138.1 13.5 13.7 11.7 16.8 11.0 12.4 434.6 12.6 7.4 14.7 12.9 12.1 9.5 7.2 14.4 9.6 17.5 6.9 11.2 10.5 12.6 10.9 5.8 9.5 20.9 10.3 13.3 13.4 1.7 14.3 2.6 26.2 19.9 27.0 29.6 23.1 23.7 21.0 28.1 32.1 28.5 1.2 15.8 12.0 25.5 16.6 22.2 13.8 15.7 13.1 17.9 14.5 12.1 18.3 13.7 16.0 17.5 CDK6 PLSTIRE ENSG00000105810 "Cyclin dependent kinase 6" Q00534 7 92604921-92836594 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Primary microcephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 74.6" "Cell line enhanced" "Detected in many" "MOLT-4: 91.7;REH: 44.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002637, CAB004363" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB004363: AB_627242, HPA002637: AB_1846432" "unprognostic (1.29e-1)" "unprognostic (5.98e-3)" "unprognostic (9.07e-2)" "unprognostic (2.78e-3)" "unprognostic (2.56e-2)" "unprognostic (3.24e-2)" "unprognostic (3.39e-1)" "unprognostic (2.42e-3)" "unprognostic (7.19e-2)" "unprognostic (7.78e-3)" "prognostic unfavourable (3.86e-6)" "unprognostic (4.06e-2)" "unprognostic (4.09e-3)" "unprognostic (1.09e-1)" "unprognostic (7.88e-2)" "unprognostic (1.93e-1)" "prognostic unfavourable (2.33e-5)" 6.6 11.3 6.0 9.1 7.5 22.5 5.9 2.4 6.0 7.8 10.0 9.6 5.7 7.5 6.0 5.9 8.5 4.6 7.8 6.6 6.9 4.2 6.5 7.5 7.3 7.4 7.0 5.2 5.0 10.0 25.7 4.2 20.5 7.5 6.1 9.2 4.4 10.9 6.1 2.0 11.6 9.4 9.8 7.5 6.3 10.8 5.4 8.0 74.6 4.3 9.2 10.3 6.7 9.0 3.6 5.6 6.5 4.8 3.9 7.1 2.3 6.0 2.8 7.8 5.0 2.3 2.6 1.6 6.3 3.9 3.1 3.0 7.7 4.7 4.7 3.6 4.2 3.8 4.3 9.0 7.4 10.3 3.0 11.8 5.4 7.4 1.4 7.3 0.5 2.5 4.9 4.2 20.0 1.2 11.2 13.0 5.6 1.2 91.7 0.7 2.4 2.6 44.8 27.6 7.9 4.3 0.1 4.1 26.8 0.7 2.1 3.7 0.1 12.0 4.6 10.3 16.1 4.0 12.6 7.0 0.1 6.3 1.5 25.0 13.6 4.9 1.9 6.5 5.2 3.9 5.9 2.0 5.5 5.6 4.0 3.6 7.1 4.0 1.1 3.9 4.8 5.6 2.8 2.3 6.0 7.5 2.4 6.0 6.9 4.2 7.0 5.2 7.5 8.0 CES1 "CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1" ENSG00000198848 "Carboxylesterase 1" P23141 16 55802851-55833337 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Hydrolase, Serine esterase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "liver: 355.0" "Group enriched" "Detected in some" 5 "Hep G2: 93.9;THP-1: 101.2" "Cancer enriched" "Detected in all" 6 "liver cancer: 711.4" "Not detected" "Not detected" "Group enriched" "Detected in many" 18 "classical monocyte: 32.6;myeloid DC: 32.9" "Group enriched" "Detected in many" 20 "dendritic cells: 32.9;monocytes: 32.6" "Not detected" "Not detected" "HPA012023, HPA046717" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" 40000000 "Endoplasmic reticulum" "HPA012023: AB_1846554, HPA046717: AB_2679770" "unprognostic (1.04e-2)" "unprognostic (9.85e-2)" "unprognostic (2.94e-1)" "unprognostic (1.28e-1)" "unprognostic (1.55e-3)" "unprognostic (7.46e-3)" "unprognostic (1.51e-1)" "unprognostic (1.42e-1)" "unprognostic (3.51e-1)" "unprognostic (5.74e-2)" "unprognostic (4.62e-2)" "unprognostic (3.29e-2)" "unprognostic (1.91e-2)" "unprognostic (5.32e-2)" "unprognostic (1.92e-1)" "unprognostic (2.87e-1)" "prognostic unfavourable (9.92e-4)" 27.1 1.7 0.3 0.5 0.4 2.1 24.7 0.4 0.6 3.1 8.9 0.5 1.5 2.4 7.3 2.1 4.5 6.7 57.7 8.1 0.3 0.0 0.7 355.0 19.8 2.3 0.3 0.6 3.9 1.3 0.0 0.8 1.1 0.6 11.2 1.0 3.8 3.9 4.0 1.6 1.4 3.5 10.2 0.7 4.4 7.0 1.0 0.3 0.4 1.7 2.3 1.5 8.2 16.1 0.2 32.9 0.2 32.6 0.1 1.6 12.1 0.0 0.6 0.0 0.0 14.1 0.0 0.4 0.0 0.0 0.0 0.0 6.5 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 93.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 101.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 20.3 0.0 0.0 32.6 0.1 1.3 1.8 0.5 0.2 0.2 1.6 32.9 0.2 0.2 0.4 0.2 0.1 0.4 1.7 0.1 12.1 0.3 0.4 0.4 0.6 0.3 0.0 0.3 0.6 0.6 0.3 CFTR "ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR" ENSG00000001626 "Cystic fibrosis transmembrane conductance regulator" P13569 7 117465784-117715971 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Isomerase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "pancreas: 103.0" "Group enriched" "Detected in some" 22 "CACO-2: 12.5;MOLT-4: 47.0;U-266/70: 25.7" "Cancer enhanced" "Detected in many" "colorectal cancer: 23.9;pancreatic cancer: 28.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Region enriched" "Detected in many" 5 "olfactory region: 6.3" "CAB001951, HPA021939" Enhanced "CAB001951: , HPA021939: AB_1846578" "unprognostic (6.38e-3)" "unprognostic (9.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.44e-2)" "unprognostic (8.74e-2)" "unprognostic (8.57e-2)" "prognostic unfavourable (9.44e-4)" "unprognostic (3.20e-3)" "unprognostic (1.13e-1)" "unprognostic (8.89e-2)" "unprognostic (1.55e-2)" "unprognostic (2.14e-2)" "unprognostic (4.78e-3)" "unprognostic (1.24e-1)" "unprognostic (2.58e-1)" "unprognostic (9.08e-2)" "unprognostic (6.64e-2)" 0.4 0.2 0.4 10.5 0.4 0.0 0.3 0.3 0.3 2.5 19.8 0.1 0.8 10.5 0.6 2.1 0.4 0.4 15.8 0.3 0.4 0.3 1.1 1.4 5.7 0.1 0.5 0.1 0.3 103.0 0.0 0.3 0.1 0.1 1.5 12.5 0.1 22.4 0.1 0.3 1.1 24.2 0.3 0.7 0.3 0.6 0.9 0.1 0.1 0.3 0.2 0.3 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.5 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.0 0.0 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 25.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.3 0.3 0.4 0.3 0.5 0.1 0.1 0.1 CHD1 ENSG00000153922 "Chromodomain helicase DNA binding protein 1" O14646 5 98853985-98928957 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Helicase, Hydrolase" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 70.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA022236 Approved Approved "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "HPA022236: " "unprognostic (2.63e-1)" "unprognostic (2.31e-1)" "unprognostic (1.09e-2)" "unprognostic (4.11e-2)" "unprognostic (7.79e-2)" "unprognostic (7.15e-2)" "unprognostic (6.50e-2)" "unprognostic (1.00e-2)" "unprognostic (1.79e-1)" "unprognostic (2.88e-1)" "unprognostic (4.94e-2)" "unprognostic (3.15e-1)" "prognostic unfavourable (7.25e-6)" "unprognostic (2.69e-1)" "unprognostic (3.33e-1)" "unprognostic (1.52e-1)" "unprognostic (1.17e-1)" 13.0 7.4 5.5 15.8 7.5 41.7 10.2 14.9 5.5 9.4 9.3 4.7 7.9 6.6 11.3 7.5 7.6 10.8 10.6 6.8 4.9 3.1 7.3 10.1 12.1 8.8 8.8 3.2 18.1 8.3 9.3 12.0 11.1 6.4 7.7 7.4 5.6 8.1 11.5 13.2 8.2 12.3 8.3 7.2 17.2 8.6 12.0 7.4 70.1 8.1 5.5 9.3 10.4 11.3 10.1 7.1 16.7 8.2 8.1 8.4 2.2 11.4 10.5 24.8 16.8 8.4 8.7 21.7 11.9 7.8 9.7 12.6 13.1 8.9 9.7 11.6 6.9 9.6 19.4 13.1 20.3 15.2 14.6 17.2 12.6 9.9 9.3 16.5 13.4 7.5 5.4 16.8 17.0 11.7 20.7 15.0 9.7 9.2 32.8 7.2 16.7 12.8 27.9 17.4 14.6 8.5 11.0 11.6 9.9 15.3 8.0 19.3 7.7 11.4 13.1 20.8 11.2 13.0 21.0 10.5 11.0 20.7 11.4 16.6 12.5 11.4 8.2 10.7 6.5 7.5 8.2 10.1 6.1 6.1 7.1 9.4 8.4 6.6 16.7 8.1 7.1 5.2 6.3 2.2 5.5 7.5 14.9 5.5 4.9 3.1 8.8 3.2 6.4 7.4 CHRM1 ENSG00000168539 "Cholinergic receptor muscarinic 1" P11229 11 62908679-62921807 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "brain: 34.7;prostate: 28.2;salivary gland: 25.3" "Cell line enhanced" "Detected in some" "MCF7: 8.0;SK-BR-3: 4.0;T-47d: 2.6;WM-115: 1.4" "Cancer enriched" "Detected in some" 16 "prostate cancer: 27.9" "Group enriched" "Detected in many" 10 "amygdala: 13.2;basal ganglia: 22.0;cerebral cortex: 34.7;hippocampal formation: 14.2;olfactory region: 14.0" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 9 "amygdala: 74.1;basal ganglia: 65.6;cerebral cortex: 83.5;hippocampal formation: 100.4;olfactory region: 36.8" "HPA014101, CAB022366" Enhanced Supported Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB022366: , HPA014101: AB_1854210" "unprognostic (3.19e-2)" "unprognostic (2.14e-1)" "unprognostic (2.25e-1)" "unprognostic (1.31e-2)" "unprognostic (7.94e-2)" "unprognostic (2.29e-1)" "unprognostic (1.16e-2)" "unprognostic (2.89e-2)" "unprognostic (1.91e-1)" "unprognostic (2.76e-1)" "unprognostic (2.08e-1)" "unprognostic (8.57e-4)" "unprognostic (4.88e-1)" "unprognostic (6.43e-2)" "unprognostic (1.75e-1)" 0.5 3.7 13.2 0.8 22.0 0.5 3.2 0.2 34.7 0.6 1.3 0.5 0.0 1.0 0.7 0.6 0.8 0.8 0.7 0.6 14.2 1.7 0.7 0.6 2.9 0.6 1.4 14.0 0.5 1.2 1.0 0.1 0.8 0.1 28.2 1.3 1.3 25.3 0.6 0.6 2.6 1.3 0.6 0.3 0.6 1.9 0.6 1.8 0.0 0.8 0.0 0.7 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 8.0 0.0 0.2 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 4.0 0.7 2.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.2 22.0 0.2 34.7 14.2 1.7 1.4 14.0 0.1 1.8 CHRM2 ENSG00000181072 "Cholinergic receptor muscarinic 2" P08172 7 136868669-137020255 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 25.5;heart muscle: 35.0;smooth muscle: 32.8" "Cell line enriched" "Detected in some" 5 "fHDF/TERT166: 43.7" "Cancer enhanced" "Detected in single" "stomach cancer: 0.8" "Region enhanced" "Detected in many" "pons and medulla: 15.7" "Cell type enhanced" "Detected in single" "neutrophil: 1.3" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB022338, HPA029795" Approved "CAB022338: , HPA029795: AB_10601357" "unprognostic (3.51e-2)" "unprognostic (3.73e-4)" "unprognostic (5.77e-2)" "unprognostic (1.78e-2)" "unprognostic (1.97e-1)" "unprognostic (4.00e-1)" "unprognostic (2.69e-1)" "unprognostic (1.43e-2)" "unprognostic (1.80e-1)" "unprognostic (1.35e-3)" 0.8 0.9 3.6 7.2 1.9 0.3 0.8 0.8 6.0 0.9 8.9 0.0 0.0 0.9 0.8 0.3 0.8 0.8 25.5 35.0 0.9 0.9 0.8 1.2 1.0 0.2 0.9 2.2 0.8 0.8 0.2 0.9 1.7 15.7 5.4 3.9 0.0 0.8 0.2 0.8 0.8 3.7 32.8 5.0 0.8 2.7 2.3 1.5 0.0 0.8 0.0 0.2 14.0 1.8 0.0 0.2 1.3 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 9.0 0.1 0.0 0.0 0.0 0.0 0.0 43.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.7 0.2 0.0 0.0 3.6 1.9 0.8 6.0 0.9 0.9 0.9 2.2 15.7 1.5 CHRM3 ENSG00000133019 "Cholinergic receptor muscarinic 3" P20309 1 239386565-239915452 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "retina: 39.8" "Cell line enhanced" "Detected in some" "RPMI-8226: 9.9;SH-SY5Y: 31.8;U-266/70: 13.2;U-266/84: 9.4" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "cerebral cortex: 8.7" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.3" "Group enriched" "Detected in many" 18 "monocytes: 1.2;T-cells: 2.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA024106, HPA048036" Approved Supported "Plasma membrane" "Plasma membrane" "HPA024106: AB_1854211, HPA048036: " "unprognostic (1.63e-1)" "unprognostic (4.82e-2)" "unprognostic (1.05e-1)" "unprognostic (4.11e-3)" "unprognostic (3.48e-3)" "unprognostic (5.81e-2)" "unprognostic (2.30e-3)" "unprognostic (5.18e-2)" "unprognostic (1.71e-1)" "unprognostic (1.27e-1)" "unprognostic (6.29e-2)" "unprognostic (6.44e-2)" "unprognostic (5.34e-4)" "unprognostic (3.04e-2)" "unprognostic (2.67e-1)" "unprognostic (1.02e-1)" "unprognostic (4.88e-2)" 0.8 0.0 2.1 1.4 1.8 0.0 0.8 0.8 8.7 0.8 5.9 0.8 0.8 0.8 1.4 0.8 6.6 0.3 0.8 0.8 2.5 1.8 0.8 0.8 1.5 0.8 0.8 1.1 4.3 8.7 0.2 0.8 0.8 0.8 3.8 2.2 39.8 13.7 2.5 0.8 0.7 1.2 3.3 0.8 1.0 4.8 1.7 0.8 1.3 1.3 0.8 1.6 7.1 0.8 0.0 0.0 0.0 1.2 0.0 2.3 0.2 0.0 0.0 0.2 0.2 0.0 0.0 0.5 0.3 0.0 0.2 0.0 0.0 0.0 0.0 1.3 0.0 3.4 0.3 2.3 1.6 0.0 2.2 0.3 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.6 5.5 0.5 0.8 0.0 0.0 2.8 5.0 0.0 0.7 9.9 0.4 0.5 0.0 31.8 0.0 0.1 0.1 1.1 0.0 0.0 1.3 0.5 0.1 0.3 13.2 9.4 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.3 1.2 0.7 0.0 0.5 0.4 0.0 0.0 2.3 0.7 0.0 0.0 0.7 0.0 0.5 0.2 2.1 1.8 0.8 8.7 2.5 1.8 0.8 1.1 0.8 0.8 CHRM4 ENSG00000180720 "Cholinergic receptor muscarinic 4" P08173 11 46385098-46386608 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 11.7;intestine: 8.0;lymphoid tissue: 17.2" "Cell line enhanced" "Detected in some" "RH-30: 4.9;SCLC-21H: 14.2;U-2 OS: 4.1" "Low cancer specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 6 "amygdala: 26.8;basal ganglia: 65.9;cerebral cortex: 30.5;hippocampal formation: 26.4;olfactory region: 36.4" "Group enriched" "Detected in many" 7 "amygdala: 5.5;basal ganglia: 15.3;cerebral cortex: 8.6;hippocampal formation: 7.6;olfactory region: 20.1" "CAB022444, HPA072083" Enhanced Uncertain "Nucleoplasm,Golgi apparatus" "Golgi apparatus" Nucleoplasm "CAB022444: , HPA072083: " "unprognostic (7.11e-2)" "unprognostic (3.79e-1)" "unprognostic (5.31e-2)" "unprognostic (7.38e-2)" "unprognostic (8.63e-3)" "unprognostic (1.38e-1)" "unprognostic (6.02e-2)" "unprognostic (1.03e-1)" "unprognostic (1.48e-1)" "unprognostic (2.96e-3)" "unprognostic (4.08e-3)" "unprognostic (5.02e-2)" "unprognostic (3.83e-2)" "unprognostic (3.64e-1)" "unprognostic (1.71e-1)" "unprognostic (3.56e-1)" "unprognostic (5.08e-2)" 0.0 0.5 1.1 0.2 11.7 1.6 0.0 0.0 6.0 0.0 0.6 3.7 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.6 0.0 0.0 0.2 0.0 0.2 0.0 0.2 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 1.2 8.0 0.1 0.0 17.2 0.8 4.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.7 0.3 0.1 0.2 0.0 3.0 0.0 0.1 0.2 0.1 1.4 0.2 0.3 0.3 0.0 0.1 1.8 0.1 0.0 2.1 0.3 0.5 0.2 0.0 0.2 0.5 0.6 0.0 0.0 0.1 0.1 0.1 0.6 0.2 0.0 1.0 0.2 0.2 0.6 0.2 0.0 4.9 0.0 0.0 0.1 14.2 0.3 0.4 0.1 0.1 0.1 2.4 0.0 0.4 4.1 0.0 0.1 0.7 0.5 0.2 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 CHRM5 ENSG00000184984 "Cholinergic receptor muscarinic 5" P08912 15 33968720-34067457 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 4 "brain: 22.8" "Group enriched" "Detected in some" 5 "BEWO: 5.4;HMC-1: 18.8" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "neutrophil: 4.8" "Lineage enriched" "Detected in single" 5 "granulocytes: 4.8" "Region enhanced" "Detected in many" "hypothalamus: 15.4" "Low region specificity" "Detected in many" HPA013172 Uncertain "HPA013172: AB_1854212" "unprognostic (8.19e-2)" "unprognostic (2.13e-1)" "unprognostic (7.67e-2)" "unprognostic (4.32e-1)" "unprognostic (3.05e-3)" "unprognostic (2.77e-1)" "unprognostic (2.49e-2)" "unprognostic (2.79e-1)" "unprognostic (3.02e-1)" "unprognostic (1.27e-2)" "unprognostic (4.61e-4)" "unprognostic (7.95e-2)" "unprognostic (1.33e-6)" "unprognostic (1.42e-1)" "unprognostic (4.53e-2)" "unprognostic (1.38e-1)" "unprognostic (9.07e-2)" 0.3 0.5 1.2 0.9 15.7 1.3 2.1 0.8 6.9 0.3 0.4 5.1 0.0 1.1 0.5 0.8 0.5 0.3 0.6 0.3 6.8 4.4 0.6 0.9 0.4 1.0 5.8 4.5 0.5 1.0 0.1 0.5 4.8 17.8 0.6 0.3 0.0 0.5 0.1 0.7 1.8 1.8 0.2 22.8 0.7 0.6 5.2 0.0 0.0 2.3 0.0 0.3 0.4 0.3 0.3 0.9 4.8 0.3 0.2 0.3 0.0 0.1 0.2 0.8 0.3 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.5 0.1 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.2 0.7 0.3 0.2 0.0 0.5 18.8 0.4 0.0 0.2 0.1 0.0 0.6 1.2 0.1 0.2 0.2 2.2 0.2 0.3 0.1 0.3 0.2 0.0 0.4 0.3 0.3 0.3 0.7 0.2 0.2 1.1 0.2 0.2 0.2 0.2 0.1 0.9 0.3 0.4 0.1 0.2 0.3 1.5 0.3 0.2 0.3 0.1 0.3 0.2 0.2 0.2 0.1 0.3 0.1 0.2 4.8 0.2 0.1 0.9 0.2 0.0 1.2 15.7 0.8 6.9 6.8 4.4 5.8 4.5 17.8 0.0 CHRNA3 ENSG00000080644 "Cholinergic receptor nicotinic alpha 3 subunit" P32297 15 78593052-78621295 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "adrenal gland: 33.6;lymphoid tissue: 57.2;retina: 74.1" "Cell line enriched" "Detected in some" 5 "SH-SY5Y: 84.4" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in some" "cerebellum: 6.0" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA029430 Approved "HPA029430: AB_10603785" "unprognostic (2.28e-1)" "unprognostic (3.45e-1)" "unprognostic (2.58e-2)" "unprognostic (2.36e-1)" "unprognostic (1.32e-1)" "unprognostic (1.12e-1)" "unprognostic (9.16e-3)" "unprognostic (1.97e-1)" "unprognostic (4.28e-2)" "unprognostic (7.20e-2)" "unprognostic (3.12e-1)" "unprognostic (1.01e-1)" "unprognostic (1.86e-4)" "unprognostic (2.65e-3)" "unprognostic (2.76e-1)" "unprognostic (1.53e-1)" "unprognostic (4.48e-1)" 0.4 33.6 0.8 4.0 2.4 0.1 0.3 6.0 0.4 0.5 8.2 0.7 0.2 1.2 0.5 0.1 0.5 0.1 0.8 0.4 0.2 0.8 0.1 0.1 0.3 2.8 0.4 0.0 0.1 0.2 0.1 1.5 0.2 1.2 0.6 3.4 74.1 0.2 0.6 0.1 0.6 2.9 2.8 0.2 0.2 3.6 0.9 0.5 57.2 0.2 0.2 0.7 0.8 0.6 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.1 16.0 84.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 2.4 6.0 0.4 0.2 0.8 0.4 0.0 1.2 0.5 CHRNA4 "BFNC, EBN, EBN1" ENSG00000101204 "Cholinergic receptor nicotinic alpha 4 subunit" P43681 20 63343223-63378401 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 16.4;liver: 38.8;parathyroid gland: 21.6" "Cell line enriched" "Detected in some" 5 "U-2 OS: 7.5" "Cancer enhanced" "Detected in some" "liver cancer: 1.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "midbrain: 22.6;pons and medulla: 19.3;thalamus: 29.6" CAB034064 Uncertain "CAB034064: AB_2080535" "unprognostic (3.40e-1)" "unprognostic (1.71e-1)" "unprognostic (2.87e-2)" "unprognostic (3.98e-1)" "unprognostic (8.03e-2)" "unprognostic (1.75e-1)" "unprognostic (1.22e-1)" "unprognostic (1.74e-1)" "unprognostic (2.10e-3)" "unprognostic (5.72e-4)" "unprognostic (9.02e-3)" "unprognostic (9.79e-4)" "unprognostic (6.77e-2)" "unprognostic (1.08e-1)" "unprognostic (3.81e-2)" 0.6 0.8 5.2 0.6 8.7 0.6 0.6 3.1 14.5 0.6 0.6 11.0 0.0 0.6 0.6 0.6 0.6 2.0 0.6 0.6 5.1 6.8 2.1 38.8 0.7 0.6 11.3 8.2 0.7 0.6 21.6 1.0 0.6 16.4 1.3 0.6 5.7 0.6 0.6 0.6 0.6 0.6 0.6 3.9 4.8 0.6 1.9 3.9 0.0 1.2 0.0 0.6 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 8.7 3.1 14.5 5.1 6.8 11.3 8.2 16.4 3.9 CHRNA7 ENSG00000175344 "Cholinergic receptor nicotinic alpha 7 subunit" P36544 15 31923438-32173018 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 27.2" "Cell line enhanced" "Detected in some" "AN3-CA: 6.2;RT4: 12.0;SH-SY5Y: 6.7;SK-BR-3: 13.2;U-2 OS: 10.9" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA029422, CAB033624" Enhanced "CAB033624: AB_784835, HPA029422: AB_10600863" "unprognostic (3.43e-2)" "unprognostic (8.44e-2)" "unprognostic (2.02e-1)" "unprognostic (4.61e-4)" "unprognostic (6.19e-2)" "unprognostic (1.31e-1)" "unprognostic (2.14e-2)" "unprognostic (5.08e-2)" "unprognostic (1.63e-1)" "unprognostic (4.31e-2)" "unprognostic (3.22e-1)" "unprognostic (1.05e-1)" "unprognostic (2.40e-2)" "unprognostic (4.36e-3)" "unprognostic (5.44e-2)" "unprognostic (7.41e-3)" "unprognostic (2.43e-1)" 0.8 12.9 4.4 1.5 3.4 2.3 2.0 0.9 8.4 1.1 12.2 1.0 1.1 7.9 1.4 0.8 0.8 0.7 4.6 1.2 2.5 5.6 0.9 0.4 1.2 2.0 3.8 2.7 2.9 4.9 1.8 2.0 0.4 11.8 2.2 4.0 11.7 2.1 1.2 0.8 0.7 27.2 0.9 3.1 5.2 11.2 5.1 0.6 0.1 4.3 0.9 1.4 3.1 2.0 0.3 1.2 3.1 1.1 1.8 0.7 0.4 0.0 1.4 2.3 6.2 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 2.9 0.0 0.0 0.0 1.8 0.4 0.0 1.8 0.0 0.2 0.6 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.2 0.0 0.2 1.1 0.0 0.0 3.7 0.2 0.2 12.0 0.5 6.7 0.2 13.2 0.0 0.0 0.0 0.7 0.0 10.9 0.2 0.0 0.0 0.0 0.3 0.0 0.3 0.0 1.5 1.1 3.1 0.7 0.4 0.2 0.3 0.4 0.1 1.2 0.2 0.2 0.3 0.7 1.8 0.6 0.7 0.5 0.4 4.4 3.4 0.9 8.4 2.5 5.6 3.8 2.7 11.8 0.6 CHRNB4 ENSG00000117971 "Cholinergic receptor nicotinic beta 4 subunit" P30926 15 78624119-78727754 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "adrenal gland: 6.6;lymphoid tissue: 18.5;retina: 10.6;testis: 10.7" "Group enriched" "Detected in some" 16 "SCLC-21H: 20.2;SH-SY5Y: 26.2" "Cancer enhanced" "Detected in some" "testis cancer: 2.0" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 5 "olfactory region: 6.5;pons and medulla: 1.4;thalamus: 4.6" "Not detected" "Not detected" HPA059484 Approved "Endoplasmic reticulum,Cell Junctions" "Endoplasmic reticulum" "Cell Junctions" "HPA059484: " "unprognostic (4.74e-2)" "unprognostic (4.54e-1)" "unprognostic (1.26e-2)" "unprognostic (8.77e-5)" "unprognostic (8.15e-2)" "unprognostic (6.43e-3)" "unprognostic (1.10e-1)" "unprognostic (2.30e-2)" "unprognostic (1.09e-1)" "unprognostic (3.19e-1)" "unprognostic (1.40e-1)" "unprognostic (1.49e-1)" "unprognostic (1.45e-4)" "unprognostic (7.00e-3)" "unprognostic (2.58e-1)" "unprognostic (8.50e-2)" "unprognostic (7.76e-2)" 0.2 6.6 2.7 3.9 0.8 0.7 0.2 0.5 0.4 0.6 2.3 0.2 0.0 0.2 0.8 0.7 1.4 0.1 0.1 0.8 1.0 0.3 0.5 0.1 0.1 2.9 0.2 0.0 0.3 0.2 0.0 1.6 0.0 1.3 0.2 1.1 10.6 2.2 2.4 0.6 0.3 1.0 0.9 1.0 1.0 0.8 10.7 0.1 18.5 0.4 0.3 1.1 0.5 0.5 1.5 0.4 1.4 0.8 1.0 0.8 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 20.2 26.2 0.1 0.3 0.1 0.0 0.0 0.0 0.1 0.3 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 1.4 0.8 0.3 0.5 0.2 0.6 0.9 0.5 0.6 0.2 1.5 0.8 0.8 1.4 1.0 0.4 0.4 0.3 0.0 2.7 0.8 0.5 0.4 1.0 0.3 0.2 0.0 1.3 0.1 CKB CKBB ENSG00000166165 "Creatine kinase B" P12277 14 103519659-103523111 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 158.5" "Cell line enhanced" "Detected in many" "CACO-2: 53.1;HEK 293: 135.1;SCLC-21H: 76.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 10 "non-classical monocyte: 50.0" "Lineage enriched" "Detected in many" 17 "monocytes: 50.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001254, CAB047313" Enhanced Supported Cytosol 50000000 Cytosol "CAB047313: , HPA001254: AB_1078528" "unprognostic (9.97e-2)" "unprognostic (1.33e-3)" "unprognostic (4.25e-3)" "unprognostic (1.10e-1)" "unprognostic (7.63e-2)" "unprognostic (3.62e-2)" "unprognostic (1.64e-1)" "unprognostic (1.30e-1)" "unprognostic (4.24e-1)" "unprognostic (4.60e-2)" "unprognostic (2.68e-3)" "unprognostic (9.89e-3)" "prognostic favourable (4.02e-8)" "unprognostic (2.62e-1)" "unprognostic (1.10e-1)" "unprognostic (1.67e-2)" "unprognostic (2.13e-1)" 32.4 27.3 75.4 10.4 114.6 3.1 5.3 94.3 158.5 29.1 121.5 51.4 23.8 17.6 37.3 8.9 28.6 35.7 17.8 36.4 60.7 43.2 26.7 3.4 12.8 3.6 63.4 93.3 15.8 10.2 20.3 9.7 3.7 63.3 107.5 55.0 43.9 18.3 92.1 19.1 14.4 17.5 53.2 31.9 3.6 66.7 22.1 50.9 0.0 19.8 7.8 3.9 43.0 13.0 0.0 2.9 1.4 50.0 0.0 0.1 0.9 0.3 6.7 26.9 1.4 0.2 0.2 0.5 2.9 0.0 0.3 0.1 53.1 0.8 0.0 3.2 2.0 5.9 7.8 0.1 0.0 1.2 135.1 10.0 29.7 18.2 1.1 0.0 8.2 1.0 0.0 0.2 0.1 0.0 17.4 0.4 0.4 2.2 0.2 0.3 10.5 21.0 1.7 0.5 27.6 4.9 0.2 76.9 31.6 5.7 0.9 2.1 2.5 4.1 0.1 0.1 5.2 0.5 12.6 1.3 0.3 0.9 0.7 0.2 0.9 0.3 0.1 1.4 0.0 5.1 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.1 0.1 0.0 50.0 0.0 0.1 0.9 75.4 114.6 94.3 152.7 60.7 43.2 63.4 93.3 63.3 50.9 CKM CKMM ENSG00000104879 "Creatine kinase, M-type" P06732 19 45306414-45322977 "Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "skeletal muscle: 1374.7;tongue: 354.9" "Cell line enriched" "Detected in some" 4 "SCLC-21H: 36.8" "Group enriched" "Detected in many" 33 "head and neck cancer: 64.4;prostate cancer: 14.3" "Not detected" "Not detected" "Group enriched" "Detected in some" 9 "classical monocyte: 2.8;intermediate monocyte: 1.1;myeloid DC: 2.1" "Group enriched" "Detected in many" 25 "dendritic cells: 2.1;monocytes: 2.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA047859 Enhanced 190000000 "HPA047859: " "unprognostic (3.51e-1)" "unprognostic (7.63e-2)" "unprognostic (2.61e-2)" "unprognostic (4.14e-1)" "unprognostic (7.68e-3)" "unprognostic (4.04e-3)" "unprognostic (1.85e-2)" "unprognostic (4.23e-2)" "unprognostic (5.19e-2)" "unprognostic (1.81e-1)" "unprognostic (5.00e-1)" "unprognostic (9.46e-3)" "unprognostic (9.67e-8)" "unprognostic (3.23e-1)" "unprognostic (1.73e-1)" "unprognostic (2.33e-1)" "unprognostic (1.95e-1)" 13.9 0.1 0.2 0.1 0.2 0.1 0.4 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.1 23.5 21.1 0.1 0.1 187.9 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.0 0.1 0.2 0.1 0.1 0.1 0.0 2.8 0.1 0.8 17.6 0.2 1374.7 0.2 0.2 0.2 0.3 0.1 0.5 0.3 0.0 0.0 11.1 354.9 24.8 0.2 0.1 0.0 2.1 0.0 2.8 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 2.9 0.0 0.1 8.7 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 3.3 0.1 0.1 0.0 0.0 36.8 0.0 0.0 0.0 0.0 0.0 8.4 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 1.1 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.0 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.0 0.0 0.0 CKMT1A CKMT1 ENSG00000223572 "Creatine kinase, mitochondrial 1A" P12532 15 43692886-43699222 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 17.2;esophagus: 19.9;intestine: 25.5" "Cell line enhanced" "Detected in many" "HaCaT: 42.6;hTCEpi: 19.3;SCLC-21H: 15.1;SK-BR-3: 33.5;T-47d: 29.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" HPA043491 Uncertain "Intracellular and membrane" 2100000 "HPA043491: " "unprognostic (2.04e-2)" "unprognostic (2.53e-2)" "unprognostic (1.17e-1)" "unprognostic (4.02e-3)" "unprognostic (3.80e-1)" "unprognostic (7.44e-2)" "unprognostic (2.21e-1)" "unprognostic (3.10e-1)" "unprognostic (1.75e-1)" "unprognostic (1.31e-1)" "unprognostic (1.72e-1)" "unprognostic (2.51e-2)" "unprognostic (3.78e-9)" "unprognostic (3.52e-2)" "unprognostic (1.03e-1)" "unprognostic (7.37e-2)" "unprognostic (1.73e-3)" 0.0 0.7 4.8 1.9 6.3 0.0 2.1 17.2 12.6 1.8 25.5 24.7 0.0 0.0 19.9 0.4 3.0 0.0 5.6 7.9 0.9 0.0 0.0 0.0 5.0 0.0 0.1 2.1 1.4 2.5 0.5 24.1 7.2 0.0 0.0 13.0 21.7 0.9 1.1 0.0 7.8 0.0 0.6 4.4 1.4 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.2 0.0 0.3 0.0 10.6 0.0 0.0 0.0 0.0 2.2 7.3 0.0 0.4 0.0 42.6 6.1 12.5 0.0 0.0 4.7 0.0 0.7 0.2 0.0 0.0 2.0 0.0 19.3 0.0 3.3 0.0 1.9 0.0 0.0 9.9 0.0 0.0 3.0 2.3 0.0 0.0 1.9 2.0 1.5 15.1 5.9 0.0 33.5 2.2 29.9 0.2 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CKMT1B "CKMT, CKMT1, UMTCK" ENSG00000237289 "Creatine kinase, mitochondrial 1B" P12532 15 43593054-43604901 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 52.7;intestine: 28.1" "Cell line enhanced" "Detected in many" "HaCaT: 40.4;HBEC3-KT: 15.5;hTCEpi: 20.8;SCLC-21H: 15.6;SK-BR-3: 49.7;T-47d: 28.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" HPA043491 Uncertain "Intracellular and membrane" 2100000 "HPA043491: " "unprognostic (3.47e-2)" "unprognostic (9.73e-3)" "unprognostic (3.10e-1)" "prognostic unfavourable (2.55e-5)" "unprognostic (1.29e-1)" "unprognostic (1.96e-1)" "unprognostic (5.19e-2)" "unprognostic (2.84e-1)" "unprognostic (3.64e-1)" "unprognostic (5.75e-2)" "unprognostic (2.39e-1)" "unprognostic (1.15e-2)" "unprognostic (2.26e-8)" "unprognostic (1.71e-2)" "unprognostic (1.69e-1)" "unprognostic (4.43e-2)" "unprognostic (4.36e-2)" 0.0 0.3 5.4 1.6 8.8 0.0 1.6 52.7 13.6 0.7 28.1 22.4 0.0 0.0 13.8 0.2 2.8 0.0 6.8 7.4 0.9 0.0 0.0 0.0 5.4 0.0 0.2 1.4 1.3 3.7 0.6 23.1 4.8 0.0 0.0 7.6 16.2 1.2 1.8 0.0 10.0 0.0 1.7 4.1 1.7 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.1 0.0 9.8 0.0 0.0 0.0 0.0 2.3 6.9 0.0 0.3 0.0 40.4 8.1 15.5 0.0 0.1 4.7 0.0 1.0 1.0 0.0 0.0 2.3 0.0 20.8 0.0 1.8 0.0 2.6 0.0 0.0 9.8 0.0 0.0 3.2 4.3 0.0 0.0 0.2 0.7 1.0 15.6 5.5 0.2 49.7 2.9 28.9 0.0 0.0 0.0 0.5 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CKMT2 SMTCK ENSG00000131730 "Creatine kinase, mitochondrial 2" P17540 5 81233285-81266397 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 13 "heart muscle: 153.2;skeletal muscle: 182.4;tongue: 103.6" "Cell line enhanced" "Detected in some" "ASC diff: 3.6;BEWO: 5.9;Hep G2: 5.1;HHSteC: 3.9;T-47d: 9.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 9 "NK-cell: 3.8" "Lineage enriched" "Detected in single" 9 "NK-cells: 3.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA051880 Enhanced 3200000 "HPA051880: " "unprognostic (3.64e-3)" "unprognostic (1.15e-1)" "unprognostic (2.82e-3)" "unprognostic (1.88e-2)" "unprognostic (1.21e-2)" "unprognostic (2.41e-2)" "unprognostic (1.73e-2)" "unprognostic (3.57e-2)" "unprognostic (2.12e-1)" "unprognostic (1.03e-1)" "unprognostic (2.82e-1)" "unprognostic (1.84e-1)" "unprognostic (1.60e-2)" "unprognostic (5.34e-2)" "unprognostic (2.28e-1)" "unprognostic (1.76e-1)" "unprognostic (2.75e-3)" 2.5 5.0 1.3 0.3 1.9 0.2 0.8 0.4 1.2 1.2 0.5 1.2 2.5 0.3 1.3 11.5 3.0 1.2 1.5 153.2 1.5 0.9 2.7 0.3 0.4 0.3 2.3 1.4 1.6 1.3 1.1 0.7 0.3 4.1 2.0 0.3 2.5 9.1 2.1 182.4 0.5 0.6 1.4 2.8 0.4 2.1 0.9 1.5 0.0 3.3 103.6 2.9 1.0 0.6 0.4 0.1 0.0 0.4 3.8 0.3 0.0 0.1 0.9 0.0 0.9 3.6 0.7 5.9 0.1 0.0 0.0 0.0 0.3 0.3 0.6 0.4 0.0 0.1 0.0 0.0 0.0 0.5 3.1 0.0 0.7 5.1 3.9 0.4 0.2 1.4 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.7 0.2 0.1 0.7 0.4 0.8 0.9 0.0 0.0 0.1 0.7 0.7 0.5 0.4 0.8 9.5 0.4 0.8 0.5 0.9 0.5 0.3 0.1 0.1 0.8 0.4 0.5 0.9 0.0 0.2 0.0 0.1 0.4 0.0 0.1 0.3 0.0 0.0 0.4 0.1 0.2 0.0 3.8 0.0 0.1 0.2 0.0 1.3 1.9 0.4 1.2 1.5 0.9 2.3 1.4 4.1 1.5 CLCN2 "ClC-2, CLC2, EJM6" ENSG00000114859 "Chloride voltage-gated channel 2" P51788 3 184346185-184361651 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 21.0;intestine: 20.2" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009397, HPA014545, HPA024108" Approved Approved Cytosol Cytosol "CAB009397: AB_2079256, HPA014545: AB_1846881, HPA024108: AB_1846883" "unprognostic (1.13e-1)" "unprognostic (4.01e-2)" "unprognostic (6.48e-2)" "unprognostic (5.11e-3)" "unprognostic (1.15e-1)" "unprognostic (2.53e-2)" "prognostic unfavourable (4.67e-8)" "unprognostic (1.72e-2)" "unprognostic (2.26e-1)" "unprognostic (1.23e-1)" "unprognostic (2.10e-1)" "unprognostic (2.50e-3)" "unprognostic (1.19e-1)" "unprognostic (4.40e-2)" "unprognostic (5.88e-2)" "unprognostic (4.60e-2)" "unprognostic (1.35e-1)" 1.6 5.4 4.9 2.6 8.3 1.3 1.6 8.8 6.3 2.8 20.2 16.9 5.1 11.6 4.5 5.0 1.7 2.8 21.0 1.5 6.3 3.1 3.7 1.8 1.3 1.0 15.3 4.1 6.1 5.9 4.4 4.0 1.5 8.9 2.6 14.0 15.6 3.7 9.0 1.2 2.2 11.8 2.4 10.8 1.6 2.7 11.9 9.8 0.1 3.2 1.3 1.3 2.2 2.2 0.0 0.0 0.0 0.4 0.0 0.1 0.0 7.9 2.8 2.3 6.1 2.1 1.8 5.3 2.8 1.6 2.8 1.8 14.9 2.7 2.8 7.9 1.4 13.8 3.3 3.1 0.8 2.5 4.0 2.5 5.8 6.3 1.3 1.0 2.5 3.4 2.5 2.4 2.8 2.7 0.9 1.4 0.9 4.4 0.8 1.3 3.4 4.3 4.9 2.2 9.5 3.5 6.0 3.8 2.3 2.9 10.4 4.7 8.4 1.1 1.3 1.4 4.3 7.0 6.9 3.7 4.8 1.7 2.5 4.8 6.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 8.3 8.8 6.3 6.3 3.1 15.3 4.1 8.9 9.8 CNR1 "CANN6, CB-R, CB1, CB1A, CB1K5, CNR" ENSG00000118432 "Cannabinoid receptor 1" P21554 6 88139864-88166359 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 30.5" "Group enriched" "Detected in some" 7 "ASC diff: 39.4;HSkMC: 26.0" "Cancer enriched" "Detected in many" 13 "glioma: 12.5" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "memory B-cell: 2.9;naive B-cell: 2.1" "Lineage enriched" "Detected in single" 6 "B-cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042256, HPA069945" Enhanced Supported "Plasma membrane,Actin filaments" "Plasma membrane" "Actin filaments" "HPA042256: , HPA069945: " "unprognostic (1.28e-1)" "unprognostic (7.04e-2)" "unprognostic (4.61e-2)" "unprognostic (4.08e-3)" "unprognostic (1.21e-1)" "unprognostic (1.07e-3)" "unprognostic (1.37e-1)" "unprognostic (2.07e-2)" "unprognostic (2.49e-1)" "unprognostic (1.16e-2)" "unprognostic (2.74e-2)" "unprognostic (2.68e-1)" "unprognostic (1.70e-1)" "unprognostic (5.59e-3)" "unprognostic (2.68e-3)" "unprognostic (5.88e-2)" "unprognostic (7.00e-2)" 19.4 6.4 18.0 5.2 15.8 1.5 14.9 13.8 30.5 3.9 5.5 0.8 0.8 2.3 3.1 4.7 3.7 5.5 3.6 1.4 17.6 7.7 0.9 0.7 6.4 6.5 2.3 14.7 4.1 1.8 1.3 18.3 5.2 4.2 1.5 5.1 0.0 4.3 4.0 1.7 2.4 4.2 5.8 3.2 2.3 2.3 2.7 2.8 0.0 2.6 0.0 9.9 2.7 3.1 2.9 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 39.4 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.1 0.8 1.3 0.0 2.6 0.0 0.0 26.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.2 0.0 3.2 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.6 2.2 0.0 0.0 0.0 0.0 0.0 0.7 3.2 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 2.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 18.0 15.8 13.8 21.4 17.6 7.7 2.3 14.7 4.2 2.8 CNR2 CB2 ENSG00000188822 "Cannabinoid receptor 2" P34972 1 23870526-23913362 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Inflammatory response" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "blood: 19.2;lymphoid tissue: 31.1" "Cell line enhanced" "Detected in some" "Daudi: 4.9;HEL: 4.1;HMC-1: 18.9;U-698: 12.7" "Cancer enriched" "Detected in single" 6 "testis cancer: 2.5" "Not detected" "Not detected" "Group enriched" "Detected in many" 7 "basophil: 19.2;eosinophil: 16.2;memory B-cell: 14.9;naive B-cell: 15.1;NK-cell: 8.7" "Group enriched" "Detected in many" 7 "B-cells: 15.1;granulocytes: 19.2;NK-cells: 8.7" "Not detected" "Not detected" "Not detected" "Not detected" CAB009719 Uncertain "CAB009719: AB_2082784" "unprognostic (9.45e-4)" "unprognostic (5.40e-3)" "unprognostic (8.50e-3)" "unprognostic (8.19e-3)" "unprognostic (3.55e-3)" "unprognostic (9.34e-6)" "unprognostic (5.58e-3)" "unprognostic (6.96e-3)" "unprognostic (1.74e-1)" "unprognostic (7.87e-2)" "unprognostic (1.53e-1)" "unprognostic (4.93e-2)" "unprognostic (1.04e-3)" "unprognostic (3.67e-1)" "unprognostic (1.80e-1)" "unprognostic (3.75e-2)" "unprognostic (4.91e-2)" 0.3 0.2 0.2 18.5 0.2 1.8 0.2 0.2 0.2 0.2 0.4 0.0 0.0 0.1 0.2 0.1 1.8 0.2 0.3 0.3 0.2 0.2 0.4 0.3 0.6 27.7 0.2 0.0 0.2 0.2 0.0 0.2 0.0 0.0 0.4 0.3 0.3 3.1 0.0 1.8 0.2 5.5 0.0 0.2 29.7 0.4 0.4 0.0 3.0 0.6 0.6 31.1 1.5 0.3 15.1 0.8 19.2 0.1 8.7 2.0 0.9 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.1 0.1 0.0 0.0 0.0 18.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 12.7 0.0 0.1 0.0 19.2 0.1 16.2 1.7 0.0 2.0 14.9 0.1 1.5 0.2 15.1 0.1 0.9 0.6 8.7 0.1 0.8 0.1 0.9 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.0 0.0 COMT ENSG00000093010 Catechol-O-methyltransferase P21964 22 19941607-19969975 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Catecholamine metabolism, Neurotransmitter degradation" "Methyltransferase, Transferase" "FDA approved drug targets, Schizophrenia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 139.3" "Cell line enhanced" "Detected in many" "MCF7: 118.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001169, CAB011233" Enhanced Supported "Endoplasmic reticulum,Vesicles" 560000 Vesicles "Endoplasmic reticulum" "CAB011233: , HPA001169: AB_1078402" "unprognostic (5.20e-2)" "unprognostic (2.73e-2)" "unprognostic (3.08e-2)" "prognostic favourable (3.68e-4)" "unprognostic (2.99e-2)" "unprognostic (2.32e-3)" "unprognostic (5.54e-3)" "unprognostic (9.14e-2)" "unprognostic (1.39e-1)" "unprognostic (1.40e-1)" "unprognostic (2.14e-3)" "prognostic favourable (5.67e-4)" "prognostic unfavourable (9.76e-4)" "unprognostic (2.27e-1)" "unprognostic (7.09e-2)" "unprognostic (3.97e-1)" "unprognostic (1.07e-2)" 18.6 49.0 29.4 14.3 28.8 24.3 27.8 19.6 32.9 22.4 23.4 42.4 36.1 21.0 19.8 33.8 58.1 19.4 36.8 28.1 28.9 22.3 31.1 139.3 30.9 17.0 29.0 18.4 36.3 27.2 14.1 12.7 59.0 23.3 25.7 8.9 24.9 67.3 30.9 21.5 27.7 28.6 15.5 41.0 17.8 24.8 18.2 23.7 11.5 19.2 44.0 32.0 36.3 28.0 11.2 55.1 10.9 60.0 12.9 15.6 28.0 19.0 19.6 2.2 19.4 22.1 19.7 0.8 21.6 27.3 18.5 21.3 16.6 22.2 7.7 9.6 30.9 26.1 3.7 23.2 4.9 16.6 24.7 13.7 10.5 38.7 41.3 22.8 5.5 25.0 28.7 16.1 16.0 17.4 55.4 16.4 15.0 118.0 8.9 41.0 4.8 6.6 13.5 19.4 10.6 19.6 60.5 9.5 8.3 7.2 61.3 17.8 13.2 64.3 20.8 33.2 12.7 10.9 16.2 6.0 2.5 6.3 35.8 30.9 22.8 10.2 60.0 10.9 15.6 39.9 12.8 11.2 10.8 12.6 47.7 10.7 9.6 10.6 2.4 12.9 26.6 55.1 13.3 28.0 29.4 28.8 19.6 32.9 28.9 22.3 29.0 18.4 23.3 23.7 CPS1 ENSG00000021826 "Carbamoyl-phosphate synthase 1" P31327 2 210477682-210679107 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Urea cycle" "Allosteric enzyme, Ligase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "liver: 298.3" "Cell line enhanced" "Detected in many" "HeLa: 88.4;SK-BR-3: 26.7" "Cancer enriched" "Detected in many" 8 "liver cancer: 136.1" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Not detected" "Not detected" "CAB003781, HPA021400" Enhanced Supported Nucleoli 2100000 Nucleoli "CAB003781: , HPA021400: AB_1847197" "unprognostic (1.67e-2)" "unprognostic (3.72e-2)" "unprognostic (4.02e-2)" "unprognostic (7.21e-7)" "unprognostic (3.81e-2)" "unprognostic (2.52e-1)" "prognostic favourable (6.93e-5)" "unprognostic (1.23e-2)" "unprognostic (2.65e-1)" "unprognostic (1.35e-2)" "unprognostic (5.38e-2)" "unprognostic (1.94e-3)" "unprognostic (2.38e-4)" "unprognostic (5.90e-2)" "unprognostic (1.13e-1)" "unprognostic (3.14e-2)" "unprognostic (3.74e-2)" 0.4 0.1 0.5 0.3 1.6 0.0 0.8 0.3 0.7 0.4 0.2 0.7 0.3 31.5 0.3 0.7 0.5 0.2 0.4 0.3 0.5 0.4 0.6 298.3 0.2 0.3 1.5 0.8 0.7 0.2 0.0 0.4 1.1 1.4 0.3 0.0 0.6 0.2 0.2 0.3 0.3 17.2 0.4 2.3 0.3 0.2 1.3 0.5 0.0 0.4 0.4 0.1 0.2 0.4 0.3 0.0 0.0 0.0 0.0 0.8 0.0 0.3 2.3 6.2 4.2 4.1 7.2 6.6 2.2 2.7 2.6 4.1 0.6 0.0 1.0 0.1 2.4 1.1 0.2 3.7 6.6 0.0 1.9 3.9 88.4 5.5 1.3 2.0 0.0 3.7 2.8 5.2 5.3 0.2 3.9 0.3 4.3 1.1 0.1 0.2 2.4 0.6 0.2 5.7 0.5 5.6 0.0 0.1 0.4 15.5 26.7 3.0 0.0 0.6 2.9 6.8 2.1 2.0 4.8 0.0 0.3 0.0 4.5 4.3 3.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.6 0.3 0.7 0.5 0.4 1.5 0.8 1.4 0.5 CPT1A "CPT1, CPT1-L, L-CPT1" ENSG00000110090 "Carnitine palmitoyltransferase 1A" P50416 11 68754620-68844410 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Fatty acid metabolism, Lipid metabolism, Transport" "Acyltransferase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008835 Supported Supported Mitochondria 790000 Mitochondria "HPA008835: AB_1078563" "prognostic unfavourable (3.84e-4)" "unprognostic (1.38e-3)" "unprognostic (3.04e-3)" "unprognostic (2.46e-2)" "unprognostic (1.45e-1)" "unprognostic (7.25e-2)" "unprognostic (2.17e-1)" "unprognostic (4.99e-2)" "unprognostic (2.72e-1)" "unprognostic (1.47e-2)" "unprognostic (2.92e-2)" "unprognostic (2.34e-1)" "prognostic favourable (2.67e-7)" "unprognostic (9.76e-2)" "unprognostic (1.06e-1)" "unprognostic (1.49e-1)" "unprognostic (2.46e-3)" 18.0 18.3 9.9 9.9 12.1 15.8 24.4 7.0 10.3 12.8 31.9 8.2 14.1 33.7 17.0 7.2 11.2 12.8 14.7 14.6 12.0 6.6 30.6 62.0 13.1 10.1 10.5 8.6 17.0 24.4 16.9 13.8 8.7 10.8 15.6 22.0 19.7 12.9 11.4 6.9 10.3 33.4 16.9 8.7 18.9 16.8 10.4 9.0 17.9 13.2 7.5 7.6 11.3 30.2 2.5 11.9 10.6 8.6 5.7 8.8 2.5 8.3 14.8 2.1 14.5 9.5 8.6 0.6 6.7 5.5 5.3 1.1 0.5 28.3 0.0 24.8 17.6 27.5 18.8 4.0 1.6 13.4 1.8 20.5 16.2 6.8 14.2 11.9 24.9 8.9 1.9 10.6 6.4 18.8 2.1 16.9 4.8 24.0 9.7 21.1 0.2 15.8 27.1 0.3 36.5 12.5 20.9 0.3 9.5 18.5 35.7 5.9 31.9 11.6 18.8 11.6 0.2 23.2 9.6 13.2 16.8 8.5 12.2 8.8 12.6 9.2 7.8 10.6 8.8 8.6 5.1 2.3 5.5 5.3 5.0 2.5 3.4 7.0 3.8 5.7 7.2 11.9 2.9 2.5 9.9 12.1 7.0 10.3 12.0 6.6 10.5 8.6 10.8 9.0 CPT2 "CPT1, CPTASE" ENSG00000157184 "Carnitine palmitoyltransferase 2" P23786 1 53196429-53214197 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism, Transport" "Acyltransferase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 69.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA028201, HPA028202, HPA028214" Enhanced Supported Nucleoplasm,Nucleoli,Mitochondria "Nucleoplasm, Nucleoli, Mitochondria" "HPA028201: AB_10599177, HPA028202: AB_10599942, HPA028214: AB_10601958" "unprognostic (2.43e-1)" "unprognostic (2.27e-1)" "prognostic favourable (5.27e-4)" "unprognostic (6.48e-2)" "unprognostic (1.88e-1)" "unprognostic (9.34e-2)" "unprognostic (6.48e-2)" "unprognostic (1.75e-2)" "unprognostic (2.86e-1)" "unprognostic (1.67e-1)" "unprognostic (3.00e-2)" "unprognostic (8.97e-2)" "prognostic favourable (1.46e-12)" "unprognostic (4.00e-2)" "unprognostic (2.06e-1)" "unprognostic (1.79e-2)" "unprognostic (2.95e-2)" 7.5 15.5 5.3 6.8 6.1 2.3 6.5 4.0 7.2 5.1 15.4 9.4 10.7 16.6 5.1 7.6 10.5 5.4 11.3 21.4 4.3 4.5 19.8 69.0 6.9 8.3 5.7 3.7 5.3 15.9 10.7 11.5 18.1 6.4 6.0 15.6 13.8 11.8 12.2 13.6 6.0 18.9 5.5 5.2 10.3 10.1 11.2 4.7 9.7 8.3 7.2 10.3 8.0 4.9 5.9 12.4 10.0 13.1 4.8 8.0 6.5 7.8 3.3 7.7 7.5 6.6 3.9 8.8 4.9 5.0 7.1 6.6 1.6 6.7 13.5 7.5 2.3 7.9 14.3 11.3 6.0 7.4 8.4 7.7 4.5 1.3 9.8 7.3 7.4 8.4 9.7 5.1 4.4 4.8 9.8 4.8 4.4 4.6 5.7 6.0 14.4 8.8 6.6 7.3 14.3 8.8 7.4 11.5 7.7 9.8 12.5 18.5 14.5 15.6 4.7 4.0 3.2 7.0 4.0 14.9 9.1 8.3 5.1 8.4 5.8 4.1 8.4 10.0 5.1 12.6 6.2 4.5 4.9 5.9 12.4 5.9 8.0 5.5 5.1 4.8 13.1 6.4 7.0 6.5 5.3 6.1 4.0 7.2 4.3 4.5 5.7 3.7 6.4 4.7 CRBN "MRT2, MRT2A" ENSG00000113851 Cereblon Q96SW2 3 3144628-3179727 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA045910 Approved "HPA045910: AB_10960409" "unprognostic (1.26e-1)" "unprognostic (4.14e-2)" "unprognostic (4.27e-2)" "unprognostic (4.05e-2)" "unprognostic (1.85e-2)" "unprognostic (3.31e-2)" "unprognostic (1.21e-1)" "unprognostic (6.40e-3)" "unprognostic (2.15e-1)" "unprognostic (2.38e-1)" "unprognostic (1.23e-1)" "unprognostic (4.79e-2)" "unprognostic (2.17e-3)" "unprognostic (1.70e-1)" "unprognostic (5.95e-2)" "unprognostic (2.28e-2)" "unprognostic (1.47e-2)" 22.9 17.3 30.9 12.4 29.0 28.1 26.2 41.8 36.6 19.1 19.1 15.3 15.8 15.9 19.7 18.5 15.4 16.8 15.5 22.0 27.6 27.1 23.1 25.6 18.3 18.8 31.4 25.2 25.0 17.3 20.4 23.4 21.4 38.6 20.7 17.7 9.5 27.4 18.9 31.8 17.9 20.3 24.7 37.1 21.2 16.6 33.5 33.1 18.3 24.0 12.9 15.3 20.2 17.9 13.0 10.9 65.3 14.3 26.2 25.5 26.1 7.2 6.0 19.0 8.2 23.0 22.9 8.0 8.2 13.9 10.8 14.6 8.8 10.7 7.8 12.1 10.1 7.0 11.5 13.6 11.8 13.7 18.3 20.1 12.0 11.0 15.6 18.0 13.1 17.5 18.2 11.7 8.9 14.5 11.7 17.0 9.4 10.5 15.8 18.0 15.8 14.9 14.4 11.4 18.5 12.7 11.4 8.4 13.9 9.0 12.5 19.5 16.7 13.4 9.2 11.0 5.8 15.7 10.5 19.5 31.6 19.7 17.2 16.6 13.4 65.3 12.6 25.9 18.1 14.2 19.2 13.0 24.4 19.3 10.9 10.1 25.5 21.0 7.2 26.2 14.3 5.7 16.7 26.1 30.9 29.0 41.8 36.6 27.6 27.1 31.4 25.2 38.6 33.1 CRHR1 "CRF-R, CRF1, CRHR" ENSG00000120088 "Corticotropin releasing hormone receptor 1" P34998 17 45784280-45835828 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "brain: 23.2;pituitary gland: 16.5" "Group enriched" "Detected in some" 4 "RT4: 7.9;SH-SY5Y: 4.9" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" CAB025251 Enhanced "Intracellular and membrane" "CAB025251: " "unprognostic (4.59e-2)" "unprognostic (1.43e-2)" "unprognostic (2.59e-7)" "unprognostic (1.76e-1)" "unprognostic (2.71e-1)" "unprognostic (3.94e-2)" "unprognostic (2.48e-1)" "unprognostic (4.55e-4)" "unprognostic (1.65e-2)" "unprognostic (2.21e-1)" "unprognostic (3.33e-4)" "unprognostic (2.07e-5)" "unprognostic (3.26e-1)" "unprognostic (1.49e-1)" "unprognostic (1.59e-1)" 0.8 0.6 14.7 0.5 5.1 0.5 1.5 23.2 11.5 1.4 0.6 1.1 0.0 0.8 2.7 1.1 0.5 1.6 0.7 0.5 3.2 2.2 0.6 0.5 0.6 0.5 1.8 5.2 0.6 0.5 0.6 16.5 0.6 2.9 1.3 0.6 1.9 1.2 2.5 0.6 1.4 1.0 1.2 1.0 0.5 0.5 1.0 2.8 0.0 0.9 0.0 0.5 1.4 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.9 1.6 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.7 5.1 23.2 11.5 3.2 2.2 1.8 5.2 2.9 2.8 CSF1R "C-FMS, CD115, CSFR, FMS" ENSG00000182578 "Colony stimulating factor 1 receptor" P07333 5 150053291-150113372 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Immunity, Inflammatory response, Innate immunity" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 82.5;lymphoid tissue: 82.6" "Group enriched" "Detected in some" 5 "BEWO: 50.6;SK-BR-3: 19.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "intermediate monocyte: 60.7;non-classical monocyte: 82.5" "Lineage enriched" "Detected in many" 4 "monocytes: 82.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008970, HPA012323" Uncertain Supported "Vesicles,Plasma membrane" "Intracellular and membrane" 1500000000 "Vesicles, Plasma membrane" "CAB008970: , HPA012323: AB_1848977" "unprognostic (3.82e-2)" "unprognostic (1.31e-1)" "unprognostic (1.86e-3)" "unprognostic (9.83e-2)" "unprognostic (1.20e-1)" "unprognostic (7.33e-2)" "unprognostic (1.03e-1)" "unprognostic (1.45e-1)" "unprognostic (9.37e-2)" "unprognostic (1.11e-2)" "unprognostic (2.49e-1)" "unprognostic (1.65e-1)" "prognostic unfavourable (1.08e-4)" "unprognostic (3.67e-2)" "prognostic unfavourable (4.92e-4)" "unprognostic (1.72e-2)" "unprognostic (4.61e-2)" 20.9 12.4 18.2 28.1 18.9 1.8 7.7 2.8 13.5 9.3 8.3 25.4 1.1 9.2 5.9 13.1 8.4 7.9 16.1 8.7 16.4 13.7 7.8 15.1 13.7 25.4 21.3 6.0 5.3 5.2 5.9 6.4 52.1 17.1 8.5 8.4 16.8 8.0 8.7 3.0 5.8 14.5 16.2 25.8 82.6 9.0 4.9 23.0 3.1 4.2 2.9 8.2 16.4 4.7 0.0 19.1 2.9 82.5 0.0 0.1 13.9 1.7 0.0 0.0 0.0 0.8 0.2 50.6 0.1 0.0 0.0 0.0 1.5 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 0.1 0.0 19.3 0.0 0.0 7.2 0.0 0.3 0.0 0.0 1.3 0.0 0.1 0.0 2.6 0.9 0.0 0.4 18.1 0.5 0.1 60.7 0.0 0.0 0.0 0.0 19.1 0.0 0.0 0.0 2.9 0.0 82.5 1.4 0.0 13.9 18.2 18.9 2.8 13.4 16.4 13.7 21.3 6.0 17.1 23.0 CYP11A1 "CYP11A, P450SCC" ENSG00000140459 "Cytochrome P450 family 11 subfamily A member 1" P05108 15 74337759-74367740 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Steroidogenesis, Sterol metabolism" "Monooxygenase, Oxidoreductase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "adrenal gland: 145.3;placenta: 157.2" "Group enriched" "Detected in some" 4 "BEWO: 43.1;HEL: 34.2" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in single" 36 "basal ganglia: 14.8" "Cell type enriched" "Detected in single" 37 "basophil: 15.8" "Lineage enriched" "Detected in single" 37 "granulocytes: 15.8" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "midbrain: 6.9" HPA016436 Enhanced "HPA016436: AB_1847423" "unprognostic (8.89e-2)" "unprognostic (6.96e-2)" "unprognostic (4.95e-3)" "unprognostic (9.31e-2)" "unprognostic (9.42e-4)" "unprognostic (1.90e-1)" "unprognostic (1.55e-3)" "unprognostic (8.06e-2)" "unprognostic (3.04e-1)" "unprognostic (2.95e-1)" "unprognostic (1.77e-2)" "unprognostic (5.45e-2)" "unprognostic (9.66e-4)" "unprognostic (2.40e-2)" "unprognostic (2.74e-1)" "unprognostic (3.04e-2)" "unprognostic (7.95e-2)" 0.4 145.3 0.4 0.1 14.8 0.0 0.4 0.3 0.3 0.2 0.2 7.6 0.1 0.0 0.3 0.5 1.5 0.3 0.0 0.3 0.3 0.2 0.1 0.7 0.1 0.0 0.3 0.2 9.2 0.1 0.0 0.4 157.2 0.2 0.2 0.0 0.3 0.1 0.6 0.3 0.1 0.1 0.3 0.3 5.7 0.1 20.4 0.1 0.0 0.1 0.3 0.7 0.2 0.2 0.0 0.0 15.8 0.0 0.4 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.3 43.1 0.1 0.0 0.3 0.1 0.0 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.2 0.0 0.1 34.2 1.0 0.3 0.2 0.0 0.2 1.5 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 8.7 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 15.8 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.4 14.8 0.3 0.3 0.3 0.2 0.3 0.2 0.2 0.1 CYP11B1 "CPN1, CYP11B, FHI, P450C11" ENSG00000160882 "Cytochrome P450 family 11 subfamily B member 1" P15538 8 142872356-142879846 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroidogenesis" "Monooxygenase, Oxidoreductase" "Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 781 "adrenal gland: 224.9" "Group enriched" "Detected in some" 8 "SCLC-21H: 3.0;SH-SY5Y: 1.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA049171, HPA056348, HPA057752" Supported "HPA049171: , HPA056348: , HPA057752: " 0.0 224.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CYP17A1 "CPT7, CYP17, P450C17, S17AH" ENSG00000148795 "Cytochrome P450 family 17 subfamily A member 1" P05093 10 102830531-102837533 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Steroidogenesis "Lyase, Monooxygenase, Oxidoreductase" "Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "adrenal gland: 425.4" "Group enriched" "Detected in some" 4 "HMC-1: 7.8;SCLC-21H: 3.1" "Cancer enriched" "Detected in many" 5 "liver cancer: 22.7" "Region enriched" "Detected in single" 103 "basal ganglia: 19.7" "Cell type enhanced" "Detected in single" "neutrophil: 1.2" "Lineage enhanced" "Detected in single" "granulocytes: 1.2" "Not detected" "Not detected" "Not detected" "Not detected" HPA048533 Enhanced "Intracellular and membrane" "HPA048533: " "unprognostic (1.07e-2)" "unprognostic (8.84e-2)" "unprognostic (3.01e-2)" "unprognostic (9.08e-2)" "unprognostic (1.91e-1)" "unprognostic (6.29e-2)" "unprognostic (2.92e-3)" "unprognostic (2.39e-4)" "unprognostic (8.26e-2)" "unprognostic (2.35e-1)" "unprognostic (5.92e-3)" "unprognostic (1.13e-1)" "prognostic favourable (5.43e-7)" "unprognostic (1.07e-1)" "unprognostic (5.56e-2)" "unprognostic (1.66e-2)" "unprognostic (2.94e-4)" 0.0 425.4 0.0 0.1 19.7 0.0 0.0 0.1 0.1 0.1 0.0 78.5 0.0 0.0 0.1 0.3 0.1 0.1 0.0 0.1 0.0 0.0 6.4 1.7 0.1 0.0 0.0 0.0 3.2 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 82.3 0.0 0.1 2.2 0.0 0.0 0.1 0.0 0.0 0.0 1.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 7.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.1 3.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.2 0.0 0.0 0.0 0.0 19.7 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 CYP19A1 "ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM" ENSG00000137869 "Cytochrome P450 family 19 subfamily A member 1" P11511 15 51208057-51338610 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Monooxygenase, Oxidoreductase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 49 "placenta: 440.1" "Cell line enhanced" "Detected in some" "ASC TERT1: 44.8;HDLM-2: 7.8;HSkMC: 15.0" "Low cancer specificity" "Detected in single" "Region enriched" "Detected in single" 8 "basal ganglia: 5.9" "Cell type enriched" "Detected in single" 17 "neutrophil: 1.7" "Lineage enriched" "Detected in single" 17 "granulocytes: 1.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000355, HPA051194" Enhanced Approved Mitochondria Mitochondria "CAB000355: , HPA051194: " "unprognostic (9.41e-2)" "unprognostic (7.44e-2)" "unprognostic (9.52e-5)" "unprognostic (6.81e-2)" "unprognostic (2.72e-1)" "unprognostic (4.25e-4)" "unprognostic (5.18e-5)" "unprognostic (1.54e-3)" "unprognostic (2.38e-2)" "unprognostic (2.52e-1)" "unprognostic (1.97e-1)" "unprognostic (5.37e-2)" "unprognostic (1.54e-5)" "unprognostic (2.52e-3)" "unprognostic (2.11e-1)" "unprognostic (1.40e-2)" "unprognostic (1.11e-1)" 9.0 4.6 0.2 0.2 5.9 0.1 2.1 0.2 0.3 0.9 0.3 0.3 0.2 0.4 0.2 0.3 0.3 0.2 0.3 1.3 0.2 0.7 0.3 0.2 0.6 0.2 0.2 0.2 4.4 0.6 0.1 0.2 440.1 0.2 0.5 0.1 0.2 0.9 1.4 0.8 2.3 0.2 0.7 0.5 0.5 0.1 3.0 0.2 0.3 3.0 0.2 0.2 1.2 0.5 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 44.8 2.8 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 7.8 0.0 0.3 0.1 3.7 0.2 0.0 0.0 15.0 0.0 0.1 1.8 0.0 0.0 0.3 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 1.4 0.6 0.0 0.3 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.2 5.9 0.2 0.3 0.2 0.7 0.2 0.2 0.2 0.2 CYP51A1 "CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1" ENSG00000001630 "Cytochrome P450 family 51 subfamily A member 1" Q16850 7 92112151-92142952 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cholesterol biosynthesis, Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism" "Monooxygenase, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 80.9" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041325, HPA043508" Enhanced Enhanced "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA041325: AB_2677411, HPA043508: AB_2678520" "unprognostic (6.68e-2)" "prognostic unfavourable (6.12e-4)" "unprognostic (3.48e-2)" "unprognostic (1.18e-2)" "unprognostic (7.82e-2)" "unprognostic (3.60e-2)" "unprognostic (1.02e-1)" "unprognostic (1.97e-1)" "unprognostic (9.84e-2)" "unprognostic (1.36e-1)" "unprognostic (9.75e-2)" "unprognostic (1.34e-1)" "unprognostic (1.59e-9)" "unprognostic (1.82e-1)" "unprognostic (2.73e-1)" "unprognostic (5.13e-2)" "unprognostic (1.09e-3)" 10.3 27.0 16.7 8.1 22.1 10.5 15.5 13.3 32.0 11.8 21.1 32.9 6.3 33.1 9.1 15.3 23.4 7.1 10.3 9.9 18.6 20.8 18.6 80.9 22.2 5.0 17.2 13.7 21.0 20.2 32.4 11.9 8.8 47.1 18.2 16.9 17.1 11.0 7.7 4.3 12.8 28.8 8.3 43.7 7.3 18.1 35.7 19.5 2.3 14.1 18.7 10.0 9.0 13.2 14.2 14.1 3.5 13.9 6.7 10.7 7.1 24.6 12.1 30.5 19.5 21.5 35.2 4.3 8.4 25.4 10.9 29.8 29.0 45.1 21.5 13.3 14.4 21.6 26.6 53.0 12.7 9.0 18.8 6.2 12.9 21.8 29.3 12.6 9.3 25.5 24.1 42.5 44.8 11.1 23.2 49.6 12.8 25.2 2.7 11.7 22.8 12.1 8.7 6.3 48.5 49.4 41.8 21.5 14.4 17.8 35.4 26.0 12.8 15.2 13.2 15.0 16.7 21.6 10.9 16.9 15.0 19.6 11.5 16.8 19.1 1.8 9.7 3.5 10.7 13.9 7.1 14.2 7.6 8.4 14.1 10.7 7.2 9.2 1.5 6.7 8.3 12.4 5.8 7.1 16.7 22.1 13.3 32.0 18.6 20.8 17.2 13.7 47.1 19.5 CYSLTR1 "CysLT(1), CysLT1, CYSLT1R" ENSG00000173198 "Cysteinyl leukotriene receptor 1" Q9Y271 X 78271464-78327691 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 33.9;esophagus: 24.6" "Cell line enhanced" "Detected in some" "HL-60: 11.3;Karpas-707: 7.4;NB-4: 15.9;RPMI-8226: 24.1;THP-1: 14.9;U-937: 16.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "eosinophil: 33.9" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA010546 Approved "HPA010546: AB_1078268" "unprognostic (9.48e-2)" "unprognostic (6.01e-5)" "unprognostic (4.72e-3)" "unprognostic (3.04e-1)" "unprognostic (6.30e-2)" "unprognostic (2.80e-3)" "unprognostic (2.52e-1)" "unprognostic (8.19e-2)" "unprognostic (1.19e-1)" "unprognostic (2.53e-2)" "unprognostic (4.55e-1)" "unprognostic (2.43e-1)" "unprognostic (4.41e-4)" "unprognostic (5.82e-2)" "unprognostic (3.56e-2)" "unprognostic (9.87e-2)" "unprognostic (8.94e-2)" 7.3 2.0 1.7 7.8 1.7 2.8 5.4 0.8 2.2 3.0 3.3 1.7 2.9 2.2 2.3 4.4 24.6 2.3 5.6 3.1 2.3 1.9 4.8 2.7 6.9 19.5 3.8 0.8 1.7 2.0 1.7 1.5 3.3 2.9 3.7 4.8 3.1 5.4 0.8 1.7 3.1 7.1 4.2 5.1 22.8 5.2 2.3 4.0 4.7 4.5 4.8 11.3 9.8 3.5 8.1 7.4 33.9 11.9 4.1 3.7 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 11.3 4.7 0.0 0.0 0.0 0.0 0.0 0.0 7.4 0.0 0.0 0.0 15.9 0.0 0.0 3.2 0.0 24.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 14.9 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 16.4 0.0 5.8 6.3 33.9 0.0 10.9 0.0 8.1 2.4 0.1 4.8 5.8 3.7 0.0 18.4 4.1 11.9 7.4 0.5 2.8 1.7 1.7 0.8 2.2 2.3 1.9 3.8 0.8 2.9 4.0 CYSLTR2 "CysLT(2), CYSLT2R" ENSG00000152207 "Cysteinyl leukotriene receptor 2" Q9NS75 13 48653711-48711226 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 37.2;ductus deferens: 25.1;placenta: 22.6;seminal vesicle: 22.4" "Cell line enriched" "Detected in single" 77 "HDLM-2: 43.7" "Group enriched" "Detected in many" 6 "melanoma: 1.8;renal cancer: 6.6;thyroid cancer: 7.7" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 12 "eosinophil: 37.2" "Lineage enriched" "Detected in many" 12 "granulocytes: 37.2" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA046528 Uncertain "HPA046528: " "unprognostic (9.83e-3)" "unprognostic (2.72e-3)" "unprognostic (1.05e-2)" "unprognostic (6.81e-2)" "unprognostic (2.94e-2)" "unprognostic (3.11e-2)" "unprognostic (1.11e-1)" "unprognostic (7.41e-3)" "unprognostic (8.33e-2)" "unprognostic (1.83e-1)" "unprognostic (5.44e-2)" "unprognostic (5.93e-2)" "unprognostic (1.88e-3)" "unprognostic (3.79e-2)" "unprognostic (4.44e-2)" "unprognostic (2.35e-2)" "unprognostic (1.18e-2)" 2.0 11.4 3.4 3.9 4.2 0.7 1.0 1.6 8.0 0.9 1.0 1.1 25.1 2.1 1.3 1.7 0.7 3.4 1.6 11.5 4.1 3.4 1.8 1.0 1.5 4.4 3.3 1.5 5.4 0.5 0.7 2.3 22.6 3.7 3.4 1.1 2.9 0.7 22.4 0.5 1.3 2.5 0.7 2.3 6.9 1.1 1.0 2.9 1.0 1.1 0.5 1.5 1.0 1.2 0.0 0.9 37.2 3.2 0.4 0.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 43.7 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.2 1.0 37.2 0.2 3.2 0.0 0.0 0.4 0.0 0.9 0.0 0.5 0.1 0.1 0.4 2.0 0.0 0.3 0.4 3.4 4.2 1.6 8.0 4.1 3.4 3.3 1.5 3.7 2.9 DBH DBM ENSG00000123454 "Dopamine beta-hydroxylase" P09172 9 133636360-133659344 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Catecholamine biosynthesis" "Monooxygenase, Oxidoreductase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "adrenal gland: 86.6;brain: 36.2;liver: 35.6" "Cell line enriched" "Detected in single" 340 "SH-SY5Y: 201.2" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 45 "pons and medulla: 36.2" "Cell type enhanced" "Detected in single" "naive CD4 T-cell: 2.0" "Lineage enriched" "Detected in single" 21 "T-cells: 2.0" "Region enriched" "Detected in some" 6 "pons and medulla: 23.2" "Region enriched" "Detected in single" 37 "pons and medulla: 25.1" "HPA002130, HPA005960, HPA070789" Enhanced Supported "Endoplasmic reticulum,Vesicles" "Intracellular and membrane" 2000000000 Vesicles "Endoplasmic reticulum" "HPA002130: AB_2666554, HPA005960: AB_1078628, HPA070789: AB_2686312" "unprognostic (1.93e-3)" "unprognostic (7.52e-3)" "unprognostic (8.53e-2)" "unprognostic (2.10e-2)" "unprognostic (2.18e-3)" "unprognostic (3.38e-3)" "unprognostic (3.39e-3)" "unprognostic (3.97e-2)" "unprognostic (1.71e-1)" "unprognostic (8.99e-2)" "unprognostic (5.80e-2)" "unprognostic (7.69e-2)" "unprognostic (2.81e-7)" "unprognostic (9.31e-2)" "unprognostic (6.77e-2)" "unprognostic (1.49e-2)" "unprognostic (5.06e-3)" 0.7 86.6 0.1 0.3 0.1 0.0 0.0 0.1 0.8 0.3 0.0 1.9 0.7 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.5 35.6 0.3 0.6 0.0 0.0 0.1 1.3 0.0 0.6 0.4 36.2 0.8 0.0 1.0 0.2 5.9 0.0 0.0 0.2 0.0 1.4 0.4 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.8 0.5 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.2 201.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.8 0.0 0.1 0.0 0.0 36.2 0.0 DCK ENSG00000156136 "Deoxycytidine kinase" P27707 4 70992538-71030914 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 80.9" "Cell line enhanced" "Detected in all" "Daudi: 59.7;U-698: 48.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA059609, HPA062773" Enhanced Supported Nucleoplasm Nucleoplasm "HPA059609: , HPA062773: " "unprognostic (9.16e-2)" "unprognostic (2.44e-1)" "unprognostic (5.24e-3)" "unprognostic (4.77e-2)" "unprognostic (3.95e-1)" "unprognostic (6.45e-2)" "prognostic unfavourable (6.90e-7)" "unprognostic (3.04e-2)" "unprognostic (7.19e-2)" "unprognostic (8.28e-2)" "unprognostic (4.51e-1)" "unprognostic (1.33e-1)" "unprognostic (3.37e-2)" "unprognostic (4.47e-2)" "unprognostic (6.82e-2)" "unprognostic (1.33e-1)" "unprognostic (2.27e-2)" 8.0 8.3 11.9 30.9 16.8 17.2 6.9 11.4 14.8 5.6 8.6 10.4 2.6 7.6 7.5 4.4 8.8 5.5 6.1 5.5 12.3 13.1 5.8 4.8 9.7 42.8 11.7 10.3 6.0 5.0 3.6 4.2 7.9 11.1 5.9 10.4 6.4 6.3 4.0 6.8 7.9 12.4 7.5 17.6 17.5 8.2 5.6 8.6 80.9 8.3 3.8 39.9 9.5 6.5 27.9 34.2 17.5 12.7 18.5 24.9 25.1 6.6 4.4 9.7 5.7 3.0 5.3 5.6 17.2 6.4 13.6 11.4 2.9 14.5 59.7 7.4 7.1 3.9 8.6 5.4 18.4 12.6 5.3 12.3 5.1 4.5 3.1 24.6 15.9 2.7 6.6 8.3 5.0 7.7 4.9 22.7 15.5 3.8 30.4 9.7 4.7 5.4 25.8 19.7 4.7 6.8 4.6 8.6 9.2 6.4 12.7 7.5 5.7 12.9 6.2 15.4 11.6 12.9 9.2 8.6 5.6 48.4 10.7 15.4 11.4 13.1 10.7 17.5 16.2 12.7 20.3 27.9 21.8 20.0 14.3 26.4 23.4 23.5 5.4 18.5 12.1 34.2 24.9 25.1 11.9 16.8 11.4 14.8 12.3 13.1 11.7 10.3 11.1 8.6 DDC AADC ENSG00000132437 "Dopa decarboxylase" P20711 7 50458436-50565457 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Catecholamine biosynthesis" "Decarboxylase, Lyase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "intestine: 90.1;kidney: 68.1" "Group enriched" "Detected in some" 8 "CACO-2: 17.4;Hep G2: 15.3;SCLC-21H: 44.0;SH-SY5Y: 45.7" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in some" 4 "midbrain: 7.9;pons and medulla: 3.4" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 10 "midbrain: 90.4;pons and medulla: 40.7" HPA017742 Enhanced Approved "Actin filaments" 380000 "Actin filaments" "HPA017742: AB_1847832" "unprognostic (1.04e-1)" "unprognostic (3.68e-2)" "unprognostic (2.57e-2)" "unprognostic (3.49e-5)" "unprognostic (1.17e-1)" "unprognostic (1.03e-1)" "unprognostic (1.28e-1)" "unprognostic (5.15e-2)" "unprognostic (4.69e-2)" "unprognostic (5.44e-2)" "unprognostic (9.36e-3)" "unprognostic (5.24e-2)" "unprognostic (1.76e-3)" "unprognostic (1.60e-1)" "unprognostic (3.55e-1)" "unprognostic (7.65e-2)" "unprognostic (1.16e-1)" 0.3 10.9 0.3 3.0 0.7 0.0 0.3 0.3 0.4 0.3 36.7 0.4 0.3 33.5 0.3 1.8 0.3 0.0 0.7 0.3 0.3 1.3 68.1 11.7 0.7 0.3 7.9 0.3 0.4 9.8 0.0 0.3 0.3 3.4 0.4 8.1 0.4 0.3 0.3 0.3 0.1 90.1 0.3 0.3 0.3 4.3 0.6 0.5 0.3 0.3 0.4 0.3 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 17.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.3 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 44.0 45.7 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.7 0.3 0.4 0.3 1.3 7.9 0.3 3.4 0.5 DDR2 "NTRKR3, TKT, TYRO10" ENSG00000162733 "Discoidin domain receptor tyrosine kinase 2" Q16832 1 162631373-162787400 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Osteogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 60.6;ASC TERT1: 59.9;BJ hTERT+: 44.3;fHDF/TERT166: 31.7;HSkMC: 42.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 1.1;MAIT T-cell: 1.3" "Lineage enriched" "Detected in single" 5 "T-cells: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA070112 Supported "Plasma membrane,Actin filaments" 850000 "Plasma membrane, Actin filaments" "HPA070112: " "unprognostic (4.12e-2)" "unprognostic (2.73e-1)" "unprognostic (6.97e-3)" "unprognostic (4.52e-2)" "unprognostic (1.17e-1)" "unprognostic (8.16e-2)" "unprognostic (1.81e-1)" "unprognostic (1.19e-1)" "unprognostic (6.62e-2)" "unprognostic (2.24e-2)" "unprognostic (1.00e-1)" "unprognostic (1.15e-1)" "prognostic unfavourable (1.73e-7)" "unprognostic (1.56e-3)" "unprognostic (8.26e-3)" "unprognostic (7.57e-2)" "unprognostic (4.10e-3)" 42.1 43.5 4.7 10.9 6.9 0.2 15.6 7.9 7.1 30.3 30.4 9.0 18.6 3.3 24.2 17.7 25.0 13.4 16.6 15.4 7.9 4.7 4.0 3.3 8.9 5.1 12.9 3.4 26.4 2.2 2.1 4.0 6.6 12.7 21.8 9.1 30.7 6.4 19.3 5.2 6.1 10.1 34.3 19.7 3.4 14.1 8.3 7.5 0.0 8.6 12.8 4.1 29.0 18.3 0.1 0.2 0.0 0.0 0.2 1.3 0.0 0.1 0.0 0.0 16.0 60.6 59.9 0.2 23.6 44.3 10.3 14.9 0.0 0.0 0.0 0.0 31.7 0.0 0.0 0.1 14.1 12.7 0.1 0.0 0.0 0.0 26.3 0.0 0.0 42.5 0.1 18.2 0.4 11.8 0.1 5.0 9.4 0.0 0.0 0.0 0.1 0.1 0.0 6.7 0.1 0.0 0.0 0.0 9.7 0.0 0.0 0.8 0.0 0.0 0.6 16.5 3.6 8.3 3.2 0.7 1.3 0.0 14.9 0.0 16.7 0.0 0.0 0.0 1.1 0.0 1.3 0.0 0.8 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 4.7 6.9 7.9 7.1 7.9 4.7 12.9 3.4 12.7 7.5 DHFR ENSG00000228716 "Dihydrofolate reductase" P00374 5 80626228-80654983 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Methotrexate resistance, One-carbon metabolism" "Oxidoreductase, RNA-binding" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "CAB037129, HPA051465" Uncertain Supported Mitochondria Mitochondria "CAB037129: AB_439683, HPA051465: " "unprognostic (1.44e-2)" "unprognostic (1.03e-2)" "unprognostic (2.24e-3)" "unprognostic (2.91e-3)" "unprognostic (3.27e-1)" "unprognostic (1.32e-1)" "unprognostic (2.83e-2)" "unprognostic (2.35e-2)" "unprognostic (2.02e-2)" "unprognostic (4.19e-3)" "unprognostic (1.83e-2)" "unprognostic (2.55e-1)" "unprognostic (1.15e-2)" "unprognostic (1.82e-2)" "unprognostic (2.49e-1)" "unprognostic (1.57e-1)" "unprognostic (1.09e-1)" 17.7 6.1 16.0 11.6 13.9 28.3 10.9 10.2 14.0 7.5 12.6 18.1 11.7 14.5 5.9 9.0 9.8 4.7 6.9 9.7 17.3 14.4 13.1 35.5 8.6 23.2 18.9 9.4 7.5 4.9 9.6 7.2 8.5 13.0 5.9 15.5 8.6 8.0 8.4 10.4 5.9 14.5 7.3 25.3 9.1 7.4 10.5 11.5 13.4 9.2 2.3 22.8 7.9 6.1 2.4 3.3 3.5 2.6 2.1 4.0 2.1 19.6 13.6 34.6 25.6 6.6 6.9 12.7 15.7 12.1 27.4 31.7 12.9 23.7 39.8 6.9 9.1 13.8 44.4 20.3 44.4 17.6 27.4 19.1 22.6 12.0 1.4 22.2 8.5 4.8 2.1 24.5 2.7 13.2 21.4 30.6 27.7 19.7 54.7 9.0 17.4 8.0 35.5 67.9 39.4 15.7 12.5 28.3 19.8 22.2 10.4 11.2 20.5 22.0 7.9 8.7 13.2 24.3 30.0 14.4 28.8 43.1 19.4 45.2 22.3 0.8 1.2 1.1 2.3 2.6 1.1 2.1 2.7 3.2 1.9 2.4 2.1 2.7 3.5 2.1 1.7 3.3 4.0 2.1 16.0 13.9 10.2 14.0 17.3 14.4 18.9 9.4 13.0 11.5 DHODH ENSG00000102967 "Dihydroorotate dehydrogenase (quinone)" Q02127 16 72008588-72027664 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Pyrimidine biosynthesis" Oxidoreductase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "liver: 72.4" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010123, HPA011942" Approved Enhanced Nucleoplasm,Mitochondria,Cytosol Mitochondria "Nucleoplasm, Cytosol" "HPA010123: AB_1847648, HPA011942: AB_1847649" "unprognostic (4.88e-2)" "unprognostic (1.10e-1)" "unprognostic (1.90e-1)" "unprognostic (2.12e-2)" "unprognostic (1.41e-3)" "unprognostic (2.10e-1)" "unprognostic (4.27e-2)" "unprognostic (1.31e-2)" "unprognostic (1.26e-1)" "unprognostic (2.68e-1)" "unprognostic (2.14e-1)" "unprognostic (6.40e-2)" "unprognostic (9.26e-3)" "unprognostic (1.98e-1)" "unprognostic (1.97e-1)" "unprognostic (1.14e-1)" "unprognostic (1.81e-1)" 5.9 4.2 4.7 8.8 5.1 2.9 5.0 2.7 5.0 5.9 4.4 6.1 1.4 3.4 6.6 2.3 5.1 5.2 2.3 11.5 4.3 3.0 6.6 72.4 3.4 5.5 4.8 2.7 6.2 9.9 7.1 4.0 2.6 5.2 3.9 4.8 5.9 6.0 4.4 11.7 4.0 3.0 7.5 4.0 3.5 3.4 4.3 5.4 4.0 3.6 7.1 5.1 3.5 3.3 11.2 13.4 3.9 8.1 9.3 12.9 6.8 7.3 15.4 4.5 7.4 2.4 3.2 8.5 6.3 2.5 9.6 7.4 12.1 6.8 16.6 8.6 3.4 7.8 8.8 6.8 11.3 3.7 8.3 9.1 7.5 11.8 6.8 12.6 6.7 3.1 7.0 11.6 12.2 6.9 13.9 3.0 5.8 19.6 11.9 12.1 10.1 6.0 15.1 5.9 17.5 5.8 4.9 5.3 6.3 8.5 9.1 4.1 8.1 6.4 3.0 8.8 5.5 8.3 9.2 5.8 10.8 28.1 4.6 13.8 8.0 3.9 8.1 0.9 9.3 7.7 12.7 11.2 8.9 9.0 13.3 10.6 12.4 12.9 2.1 9.3 5.6 13.4 7.1 6.8 4.7 5.1 2.7 5.0 4.3 3.0 4.8 2.7 5.2 5.4 DNMT1 "CXXC9, DNMT, MCMT" ENSG00000130816 "DNA methyltransferase 1" P26358 19 10133345-10231286 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chromatin regulator, DNA-binding, Methyltransferase, Repressor, Transferase" "Deafness, Disease mutation, FDA approved drug targets, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002694, CAB005876" Enhanced Supported Nucleoplasm Nucleoplasm "CAB005876: AB_731983, HPA002694: AB_1847810" "unprognostic (3.51e-1)" "unprognostic (1.20e-2)" "unprognostic (1.26e-2)" "unprognostic (1.40e-1)" "unprognostic (3.62e-1)" "unprognostic (7.59e-3)" "prognostic unfavourable (1.46e-4)" "unprognostic (2.90e-1)" "unprognostic (4.23e-3)" "unprognostic (1.10e-2)" "unprognostic (1.07e-1)" "unprognostic (1.11e-2)" "unprognostic (1.28e-3)" "unprognostic (7.81e-3)" "unprognostic (1.73e-1)" "unprognostic (8.11e-2)" "unprognostic (1.46e-1)" 12.1 7.6 9.8 20.2 10.8 31.9 11.5 27.1 14.4 12.0 8.6 10.0 4.3 8.1 12.1 8.0 12.0 11.5 7.8 8.0 9.3 8.1 6.9 9.2 11.8 29.7 12.5 7.9 11.1 6.2 10.2 8.8 32.5 8.7 8.3 10.7 7.8 9.3 6.5 6.8 10.8 11.3 11.2 9.1 11.0 9.0 19.9 12.6 31.4 9.5 8.8 28.8 11.4 9.7 12.6 19.0 10.2 13.4 25.0 18.2 6.8 24.0 15.2 19.5 16.5 7.3 7.5 41.8 16.3 13.0 23.5 23.6 14.7 13.1 40.3 10.2 10.0 15.9 21.4 12.7 24.1 15.8 31.9 58.4 13.6 7.6 3.1 23.8 23.7 5.0 2.4 20.5 8.1 12.7 23.1 24.9 17.5 16.0 34.7 32.4 25.5 22.2 35.2 20.4 22.2 7.4 15.3 20.8 16.1 19.8 8.9 6.4 9.3 12.1 9.6 39.5 13.5 23.9 24.1 20.4 21.2 47.7 11.5 22.2 30.6 10.2 13.4 3.3 18.2 13.2 15.9 7.9 14.6 12.5 11.3 12.6 16.6 12.3 3.1 25.0 7.9 19.0 12.9 6.8 9.8 10.8 27.1 14.4 9.3 8.1 12.5 7.9 8.7 12.6 DPEP1 ENSG00000015413 "Dipeptidase 1" P16444 16 89613308-89638456 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Dipeptidase, Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 11 "intestine: 161.7;kidney: 52.2;pancreas: 100.5" "Cell line enhanced" "Detected in some" "CACO-2: 5.1;Hep G2: 19.9;HHSteC: 9.0;U-937: 28.3" "Cancer enriched" "Detected in many" 8 "colorectal cancer: 107.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA009426, HPA012783" Enhanced Approved "Nucleoplasm,Cell Junctions" "Intracellular and membrane" 270000 "Nucleoplasm, Cell Junctions" "HPA009426: AB_1847842, HPA012783: AB_1847843" "unprognostic (3.31e-2)" "unprognostic (3.86e-1)" "unprognostic (1.37e-1)" "unprognostic (1.95e-2)" "unprognostic (1.91e-2)" "unprognostic (4.93e-2)" "unprognostic (1.04e-1)" "unprognostic (1.89e-1)" "unprognostic (3.45e-2)" "unprognostic (5.18e-1)" "unprognostic (8.68e-2)" "unprognostic (1.27e-1)" "prognostic favourable (6.84e-4)" "unprognostic (6.12e-3)" "unprognostic (1.92e-1)" "unprognostic (5.23e-2)" "unprognostic (3.93e-2)" 0.1 0.4 0.1 0.9 0.1 0.0 0.1 0.1 0.1 1.5 53.6 0.1 0.4 16.1 0.2 3.4 0.3 0.1 0.9 0.1 0.1 0.1 52.2 0.1 0.3 0.9 0.1 0.1 0.2 100.5 0.0 0.2 0.1 0.2 0.1 0.0 0.2 0.3 0.4 0.1 0.4 161.7 0.1 0.1 0.9 0.2 9.8 0.1 0.2 0.1 0.1 0.5 0.6 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.5 0.1 0.0 1.1 0.1 2.8 0.0 0.0 0.0 0.0 5.1 0.1 0.0 1.8 0.0 0.0 0.1 0.0 0.0 1.3 0.4 0.0 0.0 19.9 9.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.6 0.7 0.0 0.0 0.0 1.8 0.0 0.0 0.5 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 0.1 0.1 0.0 28.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 DPP4 "ADCP2, CD26, DPPIV" ENSG00000197635 "Dipeptidyl peptidase 4" P27487 2 161992241-162074542 "CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion" "Aminopeptidase, Hydrolase, Protease, Receptor, Serine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 133.1;parathyroid gland: 75.5" "Cell line enhanced" "Detected in some" "ASC diff: 41.8;ASC TERT1: 42.4;BJ hTERT+: 38.9;RPTEC TERT1: 56.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in many" "MAIT T-cell: 26.7" "Lineage enriched" "Detected in many" 10 "T-cells: 26.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" CAB045970 Enhanced "Secreted in other tissues" 170000000 "CAB045970: AB_11140529" "unprognostic (4.47e-2)" "unprognostic (4.47e-2)" "unprognostic (8.89e-2)" "unprognostic (3.36e-1)" "unprognostic (7.25e-2)" "unprognostic (5.40e-2)" "unprognostic (2.78e-1)" "unprognostic (3.54e-2)" "unprognostic (3.58e-1)" "unprognostic (4.73e-1)" "unprognostic (2.36e-1)" "prognostic unfavourable (1.98e-4)" "prognostic favourable (1.35e-6)" "unprognostic (4.68e-2)" "unprognostic (6.33e-2)" "prognostic favourable (4.99e-4)" "unprognostic (1.21e-2)" 9.5 2.9 0.3 3.2 0.5 0.0 5.0 0.3 1.4 2.2 50.0 0.2 36.9 19.1 2.2 3.5 1.2 1.2 5.2 2.1 0.4 0.3 29.1 12.2 5.4 2.1 0.4 0.2 2.7 1.8 75.5 0.3 24.0 0.2 21.1 2.8 0.6 46.9 38.8 2.4 4.4 133.1 0.9 0.8 5.0 1.2 0.6 0.1 6.2 1.0 1.4 1.1 1.0 2.6 0.1 2.1 0.3 0.0 2.6 26.7 2.5 0.0 0.0 0.1 0.0 41.8 42.4 0.1 7.7 38.9 2.1 7.6 7.8 0.2 0.0 2.9 13.4 0.2 0.1 0.0 1.3 2.4 0.1 0.0 0.0 11.7 17.1 0.0 0.0 4.8 0.0 13.1 0.1 1.2 0.0 0.0 0.7 0.0 0.7 0.1 0.4 16.0 0.0 0.0 0.1 56.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 6.9 4.5 0.2 0.2 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 3.2 0.0 26.7 0.1 8.3 5.2 0.6 0.0 8.3 3.3 0.3 2.6 0.0 2.1 0.9 2.5 0.3 0.5 0.3 1.4 0.4 0.3 0.4 0.2 0.2 0.1 DPYD DPD ENSG00000188641 "Dihydropyrimidine dehydrogenase" Q12882 1 97077743-97995000 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" Oxidoreductase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033241, HPA045210" Uncertain 1300000 "CAB033241: AB_2094323, HPA045210: " "unprognostic (2.33e-2)" "unprognostic (1.69e-1)" "unprognostic (9.82e-3)" "unprognostic (1.04e-1)" "unprognostic (1.13e-2)" "unprognostic (8.81e-2)" "unprognostic (2.86e-1)" "unprognostic (3.05e-1)" "unprognostic (1.56e-1)" "unprognostic (9.29e-2)" "prognostic unfavourable (6.27e-4)" "unprognostic (6.54e-2)" "unprognostic (5.32e-2)" "unprognostic (1.43e-1)" "unprognostic (3.43e-2)" "unprognostic (3.71e-1)" "unprognostic (2.25e-1)" 24.9 15.4 8.8 17.0 20.9 7.4 18.4 2.0 11.2 17.9 15.6 20.3 6.4 17.0 13.7 10.8 19.0 13.5 20.5 13.3 8.3 6.1 10.5 52.2 26.0 25.7 25.3 7.1 20.4 9.7 15.5 18.4 8.0 13.9 11.6 8.4 6.2 16.7 11.6 6.7 7.7 22.4 15.5 15.0 27.7 12.0 6.0 22.2 27.4 13.5 10.0 10.4 16.3 19.6 2.6 14.3 28.3 28.1 5.7 7.3 8.0 7.8 2.2 2.9 0.0 16.0 27.6 0.0 12.8 11.6 11.9 8.8 0.0 3.3 4.1 18.8 11.8 1.9 0.0 3.0 21.9 4.1 2.6 3.5 4.2 0.0 7.1 1.5 0.2 21.7 1.1 9.5 10.9 9.7 0.1 13.3 6.2 0.0 8.2 2.2 0.3 2.7 0.0 13.7 6.5 14.6 0.0 4.1 3.2 10.9 0.9 0.1 0.0 3.6 11.1 25.9 1.8 20.8 25.1 1.1 0.0 0.0 3.8 4.5 20.4 6.3 28.1 1.7 5.5 13.0 7.3 0.9 6.5 5.3 14.3 2.6 6.2 5.4 28.3 5.7 10.7 0.4 7.0 8.0 8.8 20.9 2.0 11.2 8.3 6.1 25.3 7.1 13.9 22.2 DRD1 ENSG00000184845 "Dopamine receptor D1" P21728 5 175440039-175444208 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "brain: 34.5" "Cell line enriched" "Detected in some" 5 "RT4: 23.6" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in many" 5 "basal ganglia: 34.5" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 9 "basal ganglia: 147.4" "Region enriched" "Detected in many" 13 "basal ganglia: 95.6" HPA013393 Supported "HPA013393: AB_1847833" "unprognostic (2.74e-2)" "unprognostic (6.36e-3)" "unprognostic (2.02e-1)" "unprognostic (1.07e-1)" "unprognostic (7.63e-3)" "unprognostic (1.28e-1)" "unprognostic (1.15e-6)" "unprognostic (6.69e-2)" "unprognostic (1.05e-1)" "unprognostic (1.24e-1)" "unprognostic (1.49e-1)" "unprognostic (2.74e-2)" "unprognostic (8.60e-4)" "unprognostic (5.86e-2)" "unprognostic (5.43e-1)" "unprognostic (6.00e-3)" "unprognostic (1.10e-2)" 0.7 1.5 1.9 0.2 34.5 0.0 0.1 0.1 12.0 0.7 0.7 0.4 0.0 0.5 0.4 0.7 0.7 0.6 1.1 0.3 1.0 0.6 0.7 2.6 1.8 0.1 0.5 1.6 0.3 0.0 0.0 0.1 2.5 0.3 2.7 0.9 2.1 0.1 1.2 0.1 0.1 0.3 0.4 0.1 0.4 0.4 0.1 6.8 0.1 0.1 0.0 0.4 1.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.6 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 34.5 0.1 5.3 1.0 0.6 0.5 1.6 0.3 6.8 DRD2 ENSG00000149295 "Dopamine receptor D2" P14416 11 113409615-113475691 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "adrenal gland: 17.3;brain: 52.0;pituitary gland: 51.6" "Cell line enriched" "Detected in some" 9 "SCLC-21H: 44.2" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in many" 5 "basal ganglia: 52.0" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 10 "basal ganglia: 183.8" "Group enriched" "Detected in many" 9 "basal ganglia: 126.7;midbrain: 41.7" "HPA015139, HPA015691" Supported Supported "HPA015139: , HPA015691: AB_1847834" "unprognostic (8.49e-2)" "unprognostic (2.11e-1)" "unprognostic (1.69e-1)" "unprognostic (1.29e-4)" "unprognostic (2.32e-2)" "unprognostic (1.15e-1)" "unprognostic (1.97e-2)" "unprognostic (5.89e-2)" "unprognostic (4.40e-2)" "unprognostic (8.33e-4)" "unprognostic (1.10e-1)" "unprognostic (6.65e-3)" "unprognostic (2.29e-1)" "unprognostic (1.71e-1)" "unprognostic (4.82e-2)" "unprognostic (8.49e-3)" 0.6 17.3 0.9 0.5 52.0 0.2 2.1 0.2 3.3 1.3 0.6 1.5 0.0 0.3 2.3 0.4 0.9 2.1 0.6 0.5 0.3 4.1 0.3 0.2 0.6 0.2 9.9 0.2 0.3 0.4 0.3 51.6 0.2 2.4 1.5 0.9 3.9 5.1 1.7 1.7 0.3 0.5 3.2 0.2 0.2 0.5 1.6 9.5 0.0 0.2 0.0 0.3 0.3 0.3 0.0 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.8 0.0 0.5 0.0 0.0 0.0 1.5 0.2 0.0 0.0 0.5 0.0 0.0 4.7 0.0 0.0 0.0 44.2 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.9 52.0 0.2 3.3 0.3 4.1 9.9 0.2 2.4 9.5 DRD5 "DRD1B, DRD1L2" ENSG00000169676 "Dopamine receptor D5" P21918 4 9781680-9784009 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Dystonia, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 8.4;lymphoid tissue: 3.5;stomach 1: 10.9" "Cell line enhanced" "Detected in some" "REH: 3.6;THP-1: 2.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA048930 Supported "HPA048930: " "unprognostic (2.03e-2)" "unprognostic (2.63e-1)" "unprognostic (9.73e-2)" "unprognostic (4.27e-2)" "unprognostic (4.44e-3)" "unprognostic (1.98e-2)" "unprognostic (1.32e-4)" "unprognostic (5.09e-4)" "unprognostic (6.51e-2)" "unprognostic (1.46e-1)" "unprognostic (7.36e-3)" 0.2 0.2 2.8 3.5 4.1 0.1 0.2 0.0 8.4 0.1 0.9 0.0 0.0 0.9 0.1 0.1 0.3 0.3 0.1 0.1 3.2 3.2 0.2 0.1 0.4 0.2 1.9 0.8 0.1 0.2 0.1 1.0 0.1 7.4 0.6 0.2 0.4 0.2 0.2 0.1 0.2 0.2 0.2 0.6 0.1 10.9 1.3 1.0 0.0 0.2 0.0 0.2 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.8 0.0 3.6 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.7 0.0 2.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 4.1 0.0 8.4 3.2 3.2 1.9 0.8 7.4 1.0 EDNRA ENSG00000151617 "Endothelin receptor type A" P25101 4 147480917-147544954 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 62.6;seminal vesicle: 52.3" "Cell line enhanced" "Detected in some" "ASC diff: 7.2;ASC TERT1: 14.2;HHSteC: 7.3;LHCN-M2: 16.8;SH-SY5Y: 12.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013774, CAB018957" Uncertain Uncertain "Plasma membrane,Cytosol" Cytosol "Plasma membrane" "CAB018957: AB_2039838, HPA013774: AB_1847994" "unprognostic (3.08e-2)" "unprognostic (6.28e-2)" "unprognostic (1.78e-1)" "unprognostic (3.42e-1)" "unprognostic (1.07e-2)" "unprognostic (1.39e-1)" "unprognostic (3.20e-2)" "unprognostic (7.20e-2)" "unprognostic (2.75e-3)" "unprognostic (1.47e-2)" "unprognostic (1.34e-3)" "unprognostic (2.88e-1)" "prognostic unfavourable (1.50e-7)" "prognostic unfavourable (3.93e-4)" "unprognostic (6.20e-3)" "unprognostic (3.11e-2)" "unprognostic (2.53e-3)" 7.6 2.6 1.3 1.4 1.8 0.0 7.2 0.6 2.4 62.6 2.6 1.0 21.7 1.5 37.3 14.2 4.7 13.3 7.3 15.1 1.3 1.3 3.1 1.4 12.7 2.0 1.8 1.0 23.5 0.9 1.9 2.2 5.9 2.7 21.5 1.5 10.3 4.1 52.3 4.8 3.2 1.8 19.4 1.6 11.5 4.4 9.1 1.4 2.9 5.0 6.0 2.6 14.7 18.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 4.1 0.0 7.2 14.2 0.0 2.1 2.8 0.3 0.1 0.1 0.0 0.0 0.0 0.7 0.0 0.3 0.5 0.2 0.0 1.5 0.0 2.4 0.0 7.3 0.0 0.0 5.5 0.4 0.4 0.0 0.0 0.0 1.1 16.8 0.2 0.0 0.1 1.2 0.8 0.0 0.7 0.1 1.1 0.8 0.0 12.7 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.6 0.0 0.0 1.1 0.3 0.0 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.8 0.6 2.4 1.3 1.3 1.8 1.0 2.7 1.4 EDNRB "ETB, HSCR, HSCR2" ENSG00000136160 "Endothelin receptor type B" P24530 13 77895481-77975529 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Albinism, Deafness, Disease mutation, FDA approved drug targets, Hirschsprung disease, Waardenburg syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 67.5" "Cell line enhanced" "Detected in some" "AF22: 24.6;ASC diff: 18.7;SK-MEL-30: 22.6;U-266/70: 14.8;WM-115: 47.1" "Group enriched" "Detected in all" 7 "glioma: 41.1;melanoma: 127.7;renal cancer: 28.2" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 21 "classical monocyte: 2.0;intermediate monocyte: 2.1" "Lineage enriched" "Detected in single" 21 "monocytes: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017842, HPA027546" Approved Supported "Plasma membrane,Cytosol" "Plasma membrane" Cytosol "CAB017842: , HPA027546: " "unprognostic (7.75e-2)" "unprognostic (6.73e-2)" "unprognostic (1.41e-3)" "unprognostic (2.59e-2)" "unprognostic (8.37e-2)" "unprognostic (2.45e-3)" "unprognostic (4.17e-3)" "unprognostic (5.43e-2)" "unprognostic (1.02e-1)" "unprognostic (1.38e-2)" "unprognostic (3.40e-2)" "unprognostic (3.01e-2)" "prognostic favourable (7.20e-5)" "unprognostic (1.59e-2)" "unprognostic (3.86e-2)" "unprognostic (4.58e-2)" "unprognostic (6.77e-3)" 25.4 23.2 22.2 10.3 29.8 0.8 23.1 10.3 30.7 8.1 7.2 13.6 2.3 10.9 7.7 3.6 4.9 6.0 8.5 23.7 16.7 16.4 22.3 26.5 28.4 15.6 24.2 8.1 4.9 6.4 7.7 6.3 67.5 33.2 14.9 7.7 51.0 13.4 4.4 6.7 5.1 11.9 7.4 33.4 16.0 5.8 3.1 12.4 0.0 17.6 2.0 2.9 10.9 8.2 0.0 0.0 0.0 2.1 0.0 0.0 0.4 1.9 0.0 24.6 0.0 18.7 0.7 0.3 0.0 0.0 0.0 0.0 9.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 1.3 0.0 0.0 4.9 0.0 0.0 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 22.6 0.0 0.1 0.1 0.2 0.0 0.0 0.1 14.8 8.3 0.0 0.4 0.0 47.1 0.0 2.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 22.2 29.8 10.3 11.9 16.7 16.4 24.2 8.1 33.2 12.4 EGFR "ERBB, ERBB1" ENSG00000146648 "Epidermal growth factor receptor" P00533 7 55019021-55211628 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Host-virus interaction" "Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 102.3" "Cell line enriched" "Detected in many" 12 "A-431: 337.7" "Cancer enhanced" "Detected in all" "glioma: 136.0" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000035, HPA001200, HPA018530, CAB068186, CAB073534" Enhanced Enhanced "Plasma membrane,Cell Junctions" "Secreted to blood" 93000000 "Plasma membrane, Cell Junctions" "CAB000035: , CAB068186: , CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044" "unprognostic (2.62e-2)" "unprognostic (9.56e-3)" "unprognostic (1.59e-1)" "unprognostic (7.51e-2)" "unprognostic (1.08e-1)" "unprognostic (1.27e-2)" "unprognostic (6.11e-2)" "unprognostic (4.88e-2)" "unprognostic (2.85e-2)" "unprognostic (3.30e-3)" "unprognostic (1.78e-3)" "unprognostic (1.04e-1)" "unprognostic (1.93e-3)" "unprognostic (6.98e-3)" "unprognostic (1.72e-1)" "unprognostic (6.62e-2)" "prognostic unfavourable (2.04e-5)" 16.2 8.4 4.9 7.5 6.8 0.1 39.8 5.1 8.5 13.8 7.8 3.3 10.7 3.6 8.2 11.7 15.6 8.8 8.5 4.8 6.8 2.7 7.6 23.5 14.2 2.3 4.1 3.9 10.4 10.1 1.8 2.1 102.3 5.6 10.9 6.7 9.2 15.4 12.9 10.7 32.5 6.3 15.5 3.5 3.3 7.8 5.5 5.9 3.2 12.8 15.5 8.0 10.2 28.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 337.7 4.3 1.1 1.5 6.9 4.3 1.1 3.3 4.5 2.0 1.6 0.8 3.7 0.2 0.8 2.8 13.5 0.0 14.9 2.5 0.1 0.2 0.0 1.8 0.2 1.8 0.0 0.0 2.1 13.7 5.2 27.9 0.2 0.0 0.0 4.4 0.2 0.0 0.0 0.3 2.2 0.0 0.6 0.0 2.5 3.6 0.0 1.3 2.8 3.4 0.6 0.3 0.7 1.0 1.9 0.5 14.6 3.1 0.0 0.3 0.1 2.5 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 6.8 5.1 6.6 6.8 2.7 4.1 3.9 5.6 5.9 EPCAM "17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1" ENSG00000119888 "Epithelial cell adhesion molecule" P16422 2 47345158-47387601 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Tumor antigen" "Cancer-related genes, Disease mutation, FDA approved drug targets, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 303.2" "Cell line enhanced" "Detected in many" "A-431: 58.3;CACO-2: 75.6;CAPAN-2: 106.4;RPTEC TERT1: 45.4;SCLC-21H: 41.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.9" "Lineage enriched" "Detected in single" 5 "dendritic cells: 1.9" "Not detected" "Not detected" "Low region specificity" "Detected in some" "CAB003809, HPA026761, CAB030012, CAB055098, HPA067463" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB003809: AB_562285, CAB030012: AB_756075, CAB055098: AB_2335685, HPA026761: AB_1848198, HPA067463: " "unprognostic (6.79e-2)" "unprognostic (2.28e-1)" "unprognostic (1.59e-2)" "unprognostic (1.16e-2)" "unprognostic (1.61e-1)" "unprognostic (3.49e-2)" "unprognostic (2.01e-1)" "unprognostic (3.61e-2)" "unprognostic (3.40e-1)" "prognostic favourable (3.30e-4)" "unprognostic (5.27e-2)" "unprognostic (3.28e-2)" "prognostic favourable (1.04e-6)" "unprognostic (6.38e-3)" "unprognostic (1.28e-1)" "unprognostic (6.45e-3)" "unprognostic (6.08e-2)" 0.4 2.1 1.8 49.8 3.0 0.2 8.9 0.6 1.0 10.8 155.8 0.7 31.5 66.8 4.4 35.2 2.8 10.2 41.6 0.4 1.7 2.7 60.2 1.2 22.6 0.4 1.2 0.4 3.8 54.1 19.8 38.7 2.2 0.9 9.0 70.5 0.7 47.2 25.0 0.5 2.0 303.2 1.7 1.4 0.5 15.3 5.5 0.9 1.7 83.6 4.2 4.1 4.1 2.1 0.2 1.9 0.4 0.2 0.0 0.0 0.6 58.3 0.6 0.0 0.1 0.0 0.0 37.0 0.0 0.0 0.0 0.0 75.6 106.4 0.0 16.4 0.1 27.5 0.5 6.9 0.2 0.0 6.7 0.0 0.3 29.7 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 17.4 0.0 0.0 29.8 0.0 2.8 19.1 3.8 0.0 0.0 14.8 45.4 25.8 41.1 0.3 0.4 21.7 0.0 18.3 0.1 0.0 0.0 0.7 0.2 0.1 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 1.9 0.0 0.6 1.8 3.0 0.6 1.0 1.7 2.7 1.2 0.4 0.9 0.9 EPHA2 ECK ENSG00000142627 "EPH receptor A2" P29317 1 16124337-16156087 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Angiogenesis, Apoptosis, Cell adhesion, Differentiation, Host-virus interaction" "Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cataract, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 51.2" "Cell line enhanced" "Detected in many" "CAPAN-2: 41.9;EFO-21: 40.4;PC-3: 48.0;U-251 MG: 49.2;WM-115: 53.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 115 "plasmacytoid DC: 11.4" "Lineage enriched" "Detected in single" 115 "dendritic cells: 11.4" "Low region specificity" "Detected in all" CAB010464 Supported "Nuclear speckles,Golgi apparatus,Plasma membrane,Cell Junctions" "Plasma membrane, Cell Junctions" "Nuclear speckles, Golgi apparatus" "CAB010464: AB_631436" "unprognostic (9.41e-2)" "unprognostic (1.67e-1)" "unprognostic (4.13e-2)" "unprognostic (1.67e-2)" "unprognostic (6.22e-2)" "unprognostic (9.12e-2)" "unprognostic (5.24e-2)" "unprognostic (1.29e-3)" "unprognostic (2.52e-2)" "unprognostic (7.05e-3)" "unprognostic (1.52e-3)" "unprognostic (2.77e-1)" "unprognostic (2.65e-2)" "unprognostic (2.08e-1)" "unprognostic (1.73e-1)" "unprognostic (4.77e-3)" "unprognostic (4.40e-2)" 6.7 3.4 1.3 3.1 2.6 0.0 5.2 0.5 2.1 12.1 4.9 1.6 1.9 4.3 7.8 3.8 51.2 4.6 16.7 6.4 1.1 0.8 5.7 8.2 6.6 4.7 2.7 1.3 4.5 10.2 2.2 2.8 8.9 3.4 5.8 2.6 5.4 31.0 2.8 3.4 12.7 13.1 2.7 3.0 2.8 6.8 2.4 1.2 1.2 5.7 21.8 25.5 15.2 18.5 0.0 11.4 0.0 0.0 0.0 0.0 0.0 15.4 31.3 8.7 4.2 0.6 0.7 5.1 9.3 13.3 17.0 10.8 13.0 41.9 0.0 40.4 5.3 6.3 2.0 21.6 5.9 0.0 1.4 0.0 9.1 8.3 11.1 0.0 0.0 1.0 8.1 9.2 20.5 18.1 0.0 0.0 10.7 4.9 0.0 0.0 4.2 48.0 0.0 7.9 0.0 18.0 8.0 0.0 1.3 18.2 4.4 1.2 0.6 0.1 22.3 6.1 16.3 0.4 49.2 0.0 0.1 0.1 4.7 0.0 53.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.4 0.0 0.0 1.3 2.6 0.5 2.1 1.1 0.8 2.7 1.3 3.4 1.2 ERBB2 "CD340, HER-2, HER2, NEU, NGL" ENSG00000141736 "Erb-b2 receptor tyrosine kinase 2" P04626 17 39687914-39730426 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" "Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enriched" "Detected in many" 27 "SK-BR-3: 263.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 8.8" "Lineage enriched" "Detected in many" 4 "T-cells: 8.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555" Enhanced Supported "Plasma membrane,Cytosol" 430000 "Plasma membrane" Cytosol "CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: , HPA001060: , HPA001338: , HPA001383: AB_1078500" "unprognostic (1.97e-1)" "unprognostic (6.60e-3)" "unprognostic (6.21e-2)" "prognostic unfavourable (8.99e-8)" "unprognostic (2.96e-2)" "unprognostic (1.40e-2)" "unprognostic (1.97e-2)" "unprognostic (9.04e-2)" "unprognostic (1.79e-2)" "unprognostic (1.20e-3)" "prognostic unfavourable (9.17e-4)" "unprognostic (3.92e-1)" "prognostic favourable (2.41e-14)" "unprognostic (9.29e-2)" "unprognostic (1.40e-1)" "unprognostic (3.75e-2)" "unprognostic (1.96e-1)" 5.8 2.4 5.2 10.4 7.0 0.1 20.1 4.2 7.0 19.1 46.5 9.1 55.2 21.6 14.9 18.7 40.9 22.7 26.6 24.8 6.3 3.1 37.5 21.5 17.6 3.7 5.1 5.6 19.3 16.2 27.7 8.1 60.8 7.5 23.6 16.6 15.9 28.7 58.1 8.9 35.3 47.2 10.9 4.5 4.0 17.1 6.5 3.7 2.8 35.7 20.8 22.9 19.7 20.3 1.3 0.3 2.1 0.4 0.9 8.8 2.2 3.1 3.8 4.2 2.7 5.1 3.6 5.7 2.2 3.7 4.9 4.2 2.8 8.6 0.2 4.6 5.1 9.8 0.2 5.1 2.3 0.4 3.2 0.1 3.0 4.5 3.0 0.0 0.0 3.5 4.8 3.0 1.8 2.0 0.4 0.1 3.6 4.8 0.5 0.2 7.6 0.9 0.3 1.7 0.4 5.0 9.8 0.8 0.2 4.2 263.9 1.3 7.4 0.1 0.2 2.5 3.3 3.2 1.4 0.4 0.2 0.2 0.2 0.0 8.2 1.6 0.4 0.8 8.8 0.3 0.7 0.9 0.5 2.5 0.3 1.3 1.0 2.5 2.1 0.9 0.2 0.2 0.4 2.2 5.2 7.0 4.2 7.0 6.3 3.1 5.1 5.6 7.5 3.7 ERBB4 "ALS19, HER4" ENSG00000178568 "Erb-b2 receptor tyrosine kinase 4" Q15303 2 211375717-212538841 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Lactation, Transcription, Transcription regulation" "Activator, Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "fallopian tube: 24.5" "Cell line enhanced" "Detected in some" "AF22: 9.4;EFO-21: 7.0;HEK 293: 5.2;RPTEC TERT1: 7.7;SCLC-21H: 4.3;T-47d: 6.9" "Cancer enhanced" "Detected in many" "breast cancer: 4.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000276, HPA012016, CAB025522" Enhanced 140000 "CAB000276: , CAB025522: , HPA012016: AB_1846541" "unprognostic (1.48e-1)" "unprognostic (3.28e-1)" "unprognostic (4.31e-3)" "unprognostic (1.76e-3)" "unprognostic (3.59e-1)" "unprognostic (2.75e-1)" "unprognostic (2.88e-1)" "unprognostic (9.56e-2)" "unprognostic (2.07e-1)" "unprognostic (4.67e-3)" "unprognostic (1.07e-1)" "unprognostic (3.61e-1)" "unprognostic (7.14e-3)" "unprognostic (1.49e-3)" "unprognostic (1.41e-1)" "unprognostic (1.14e-1)" "unprognostic (4.11e-2)" 1.6 1.9 15.1 1.2 15.0 1.0 13.4 18.6 14.1 7.8 1.1 7.6 8.8 1.1 1.5 1.2 1.3 24.5 1.2 7.0 14.3 6.5 11.9 1.1 2.9 1.2 7.8 10.7 1.3 2.4 10.8 5.1 1.3 8.8 1.7 1.1 2.0 9.7 18.1 3.8 1.8 1.2 1.1 7.3 1.2 1.5 7.6 12.0 0.0 4.5 1.1 1.2 1.4 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 9.4 0.2 0.0 0.0 0.0 0.0 0.3 0.5 0.1 0.0 0.0 0.0 7.0 1.0 0.4 0.2 0.0 0.0 0.1 5.2 0.0 1.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 7.7 0.4 4.3 0.2 0.0 0.1 0.1 6.9 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.1 15.0 18.6 14.1 14.3 6.5 7.8 10.7 8.8 12.0 ESR1 "ER-alpha, Era, ESR, NR3A1" ENSG00000091831 "Estrogen receptor 1" P03372 6 151656691-152129619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 64.5;endometrium 1: 68.9" "Group enriched" "Detected in some" 9 "MCF7: 24.3;T-47d: 31.5" "Group enriched" "Detected in many" 9 "breast cancer: 40.2;endometrial cancer: 24.3;ovarian cancer: 8.7" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "CAB000037, HPA000449, HPA000450, CAB055099, CAB072858" Enhanced Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "CAB000037: AB_563706, CAB055099: AB_2101946, CAB072858: , HPA000449: AB_1078753, HPA000450: AB_1078754" "unprognostic (8.28e-2)" "unprognostic (3.02e-2)" "unprognostic (1.43e-2)" "prognostic favourable (5.47e-7)" "unprognostic (4.79e-1)" "unprognostic (2.43e-3)" "unprognostic (4.10e-5)" "unprognostic (9.92e-2)" "unprognostic (2.20e-1)" "unprognostic (7.17e-2)" "unprognostic (7.35e-2)" "unprognostic (3.45e-1)" "unprognostic (1.20e-2)" "unprognostic (7.91e-3)" "unprognostic (6.45e-2)" "unprognostic (1.25e-1)" "unprognostic (1.52e-1)" 3.0 0.9 0.5 1.6 0.5 0.2 16.2 0.8 0.4 64.5 1.5 0.2 2.2 0.1 68.9 27.7 1.1 26.7 1.9 1.1 0.5 0.8 1.5 6.6 3.6 1.6 0.4 0.1 14.2 0.4 0.0 9.3 0.9 0.6 3.6 0.1 2.6 1.6 4.1 2.0 0.6 0.5 20.8 0.4 1.6 0.3 1.9 0.4 1.9 1.3 2.2 2.5 3.8 23.7 0.6 1.0 0.0 0.8 0.3 2.5 1.0 0.3 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.6 0.0 24.3 0.0 0.0 0.0 0.0 0.7 0.0 0.4 0.0 1.8 0.0 0.0 0.0 0.3 0.0 31.5 0.0 0.0 0.1 0.1 0.3 0.0 2.9 0.5 0.0 0.1 0.2 0.0 0.0 0.8 0.0 0.3 0.2 1.0 0.6 1.3 0.4 1.0 0.4 2.5 0.9 0.0 0.3 0.0 0.0 0.3 1.0 0.5 0.5 0.8 0.4 0.5 0.8 0.4 0.1 0.6 0.4 ESR2 "ER-beta, Erb, NR3A2" ENSG00000140009 "Estrogen receptor 2" Q92731 14 64084232-64338112 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 19.1;testis: 30.2;vagina: 14.3" "Cell line enhanced" "Detected in some" "U-266/70: 10.5;U-698: 17.2" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Region enriched" "Detected in many" 5 "cerebellum: 17.8" CAB079300 Enhanced "CAB079300: " "unprognostic (7.63e-3)" "unprognostic (2.28e-3)" "unprognostic (8.27e-3)" "unprognostic (5.41e-2)" "unprognostic (2.91e-2)" "unprognostic (1.06e-1)" "unprognostic (1.80e-1)" "unprognostic (4.38e-2)" "unprognostic (1.95e-1)" "unprognostic (8.75e-2)" "unprognostic (2.57e-2)" "unprognostic (1.65e-1)" "unprognostic (3.03e-5)" "unprognostic (1.57e-1)" "unprognostic (1.66e-1)" "unprognostic (4.21e-2)" "unprognostic (5.89e-2)" 2.1 9.4 0.2 2.3 0.8 1.0 3.7 0.8 0.6 1.3 2.9 0.6 0.2 1.4 1.7 0.7 1.7 1.1 0.6 1.0 1.1 0.4 1.4 0.7 1.3 2.8 0.2 0.2 19.1 2.5 0.0 1.6 0.7 1.4 2.2 1.5 0.5 1.5 0.9 1.4 1.2 1.5 0.6 1.0 3.0 1.3 30.2 0.6 5.0 0.6 0.2 2.9 1.8 14.3 2.4 4.0 1.1 0.3 0.4 1.3 0.2 0.7 0.3 0.7 0.6 0.0 0.1 1.3 0.1 0.0 0.1 0.1 0.2 0.8 2.8 0.1 0.0 1.0 0.9 0.0 0.1 0.7 0.3 0.3 0.7 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.2 0.2 0.6 4.0 0.1 0.7 0.4 0.2 0.7 0.4 0.5 0.3 0.2 0.1 1.3 2.4 0.7 0.5 0.2 1.1 0.8 0.0 0.4 0.5 0.9 0.2 0.1 10.5 3.2 17.2 0.2 0.1 0.7 0.3 0.3 1.0 0.8 0.2 0.6 1.7 0.6 1.1 0.1 2.4 1.3 1.0 1.1 0.4 0.2 4.0 0.5 0.2 0.2 0.8 0.8 0.6 1.1 0.4 0.2 0.2 1.4 0.6 ESRRG NR3B3 ENSG00000196482 "Estrogen related receptor gamma" P62508 1 216503246-217137755 "FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 49.5;parathyroid gland: 37.2;placenta: 40.8" "Group enriched" "Detected in some" 4 "RPMI-8226: 15.1;SH-SY5Y: 28.8" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 5 "pons and medulla: 49.5" "Cell type enhanced" "Detected in single" "neutrophil: 1.5" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044678 Uncertain Approved Nucleoplasm Nucleoplasm "HPA044678: AB_10963215" "unprognostic (6.48e-2)" "unprognostic (1.11e-1)" "unprognostic (7.06e-2)" "unprognostic (7.32e-2)" "unprognostic (2.34e-1)" "unprognostic (5.48e-2)" "unprognostic (1.66e-1)" "unprognostic (1.13e-1)" "unprognostic (4.55e-2)" "unprognostic (2.88e-1)" "unprognostic (2.35e-1)" "unprognostic (1.79e-2)" "prognostic favourable (1.13e-11)" "unprognostic (3.04e-1)" "unprognostic (2.55e-1)" "unprognostic (3.65e-4)" "unprognostic (2.05e-1)" 0.5 5.1 2.8 0.4 3.3 0.2 2.9 6.9 10.3 1.4 0.7 0.7 2.2 4.0 0.5 1.5 1.4 2.1 0.8 8.3 3.2 2.6 22.0 0.8 0.7 0.4 6.8 1.7 0.8 4.4 37.2 9.9 40.8 49.5 2.6 0.4 10.7 11.0 2.4 6.3 1.5 3.7 0.9 2.6 1.0 22.2 1.0 1.5 0.0 4.6 7.2 0.4 1.0 0.7 0.4 0.2 1.5 0.0 0.2 0.1 0.0 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.8 0.1 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.1 0.0 0.0 15.1 2.3 1.7 5.4 28.8 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.4 0.1 0.1 1.5 0.2 0.0 0.2 0.0 0.0 2.8 3.3 6.9 10.3 3.2 2.6 6.8 1.7 49.5 1.5 F12 ENSG00000131187 "Coagulation factor XII" P00748 5 177402140-177409576 "Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Fibrinolysis, Hemostasis" "Hydrolase, Protease, Serine protease" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 26 "liver: 180.1" "Cell line enhanced" "Detected in some" "HDLM-2: 8.6;MCF7: 10.9;PC-3: 8.1;SH-SY5Y: 5.5;U-937: 5.6" "Cancer enriched" "Detected in many" 21 "liver cancer: 171.0" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "classical monocyte: 2.5;eosinophil: 6.9" "Group enriched" "Detected in many" 5 "granulocytes: 6.9;monocytes: 2.5" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA003825 Approved "Secreted to blood" 1040000 6600000000 "HPA003825: AB_1078790" "unprognostic (9.75e-2)" "unprognostic (1.71e-1)" "unprognostic (2.93e-1)" "unprognostic (4.47e-2)" "unprognostic (1.01e-1)" "unprognostic (2.32e-1)" "prognostic favourable (4.63e-5)" "unprognostic (6.97e-2)" "unprognostic (1.26e-2)" "unprognostic (3.96e-2)" "unprognostic (4.41e-1)" "unprognostic (6.54e-2)" "prognostic unfavourable (7.09e-4)" "unprognostic (4.11e-2)" "unprognostic (3.69e-1)" "unprognostic (3.40e-6)" "unprognostic (6.48e-2)" 0.1 0.0 0.1 0.1 0.1 0.7 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.2 180.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.5 1.0 6.9 2.5 0.7 0.3 1.0 0.8 2.0 0.0 0.5 0.0 0.0 0.2 0.0 0.1 0.0 0.0 2.3 1.3 0.0 0.4 0.0 1.4 0.7 0.4 0.0 8.6 1.8 1.3 0.3 0.9 0.2 0.7 3.0 0.2 1.3 0.1 0.4 0.2 0.4 3.2 0.0 10.9 0.1 2.6 0.0 8.1 0.6 0.2 1.8 1.1 0.0 2.5 5.5 0.3 1.0 0.7 0.4 0.0 0.0 0.2 1.1 0.0 0.3 0.5 0.0 0.1 0.1 5.6 0.6 0.0 2.5 6.9 0.3 0.1 0.2 0.5 0.3 0.2 0.1 0.2 0.0 0.1 0.9 0.7 0.9 1.0 0.0 1.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 F2 ENSG00000180210 "Coagulation factor II, thrombin" P00734 11 46719180-46739506 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase, Blood coagulation, Hemostasis" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 593 "liver: 324.8" "Cell line enriched" "Detected in some" 21 "Hep G2: 76.5" "Cancer enriched" "Detected in some" 110 "liver cancer: 508.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB016780, CAB018650, HPA051476, HPA054698" Enhanced "Secreted to blood" 107500000000 43000000000 "CAB016780: , CAB018650: AB_2246689, HPA051476: , HPA054698: " "unprognostic (1.98e-1)" "unprognostic (2.52e-1)" "unprognostic (2.64e-2)" "unprognostic (1.85e-1)" "unprognostic (2.29e-1)" "unprognostic (2.81e-1)" "unprognostic (2.23e-2)" "unprognostic (3.94e-2)" "unprognostic (5.79e-2)" "unprognostic (8.29e-2)" "unprognostic (4.46e-2)" "prognostic unfavourable (6.75e-12)" "unprognostic (5.65e-3)" "unprognostic (5.80e-2)" "unprognostic (1.54e-3)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 324.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 76.5 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.5 0.0 0.5 0.0 0.1 0.4 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 F2R "CF2R, PAR-1, PAR1, TR" ENSG00000181104 "Coagulation factor II thrombin receptor" P25116 5 76716043-76735781 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "Blood coagulation, Hemostasis" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 67.5" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 71.1;WM-115: 67.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "gdT-cell: 17.6" "Lineage enriched" "Detected in many" 4 "T-cells: 17.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB008973, CAB012962" Approved "CAB008973: , CAB012962: AB_2533198" "unprognostic (3.03e-1)" "unprognostic (7.76e-2)" "unprognostic (5.55e-2)" "unprognostic (7.76e-2)" "unprognostic (7.14e-2)" "unprognostic (3.46e-1)" "unprognostic (2.51e-1)" "unprognostic (3.75e-2)" "unprognostic (5.37e-2)" "unprognostic (1.36e-1)" "unprognostic (1.36e-1)" "unprognostic (2.22e-1)" "prognostic unfavourable (2.21e-7)" "unprognostic (2.72e-3)" "unprognostic (1.30e-1)" "unprognostic (1.12e-1)" "unprognostic (6.74e-3)" 12.3 11.2 1.5 7.5 2.2 1.1 8.9 0.8 3.5 11.7 14.0 3.3 20.1 5.9 17.6 8.6 9.3 3.5 20.8 19.2 1.4 1.7 19.5 22.6 24.4 10.4 1.5 1.8 6.2 4.0 1.6 4.7 32.0 2.5 9.6 5.1 9.6 26.4 14.0 7.2 23.7 15.5 8.4 3.5 67.5 4.5 16.6 1.4 4.0 9.1 11.4 13.5 10.7 4.7 0.4 0.2 0.8 0.3 4.2 17.6 6.4 1.0 3.3 10.4 1.7 19.8 34.6 0.5 5.8 19.9 3.8 13.9 0.7 9.1 0.0 9.9 2.4 2.5 4.4 3.5 7.3 0.8 3.7 22.7 0.7 2.8 29.9 0.1 0.9 19.5 11.8 7.3 2.0 71.1 4.2 4.3 7.8 0.4 1.7 0.0 3.3 18.2 3.2 6.2 0.8 18.0 0.1 1.2 5.6 1.7 0.0 8.5 0.1 0.2 32.5 24.2 5.4 0.2 10.7 11.6 3.4 0.0 6.4 0.4 67.0 0.5 0.2 0.3 17.6 0.3 4.4 0.4 4.1 12.1 0.0 0.1 0.7 9.1 0.8 4.2 0.1 0.2 0.4 6.4 1.5 2.2 0.8 2.1 1.4 1.7 1.5 1.8 2.5 1.4 FADS1 "D5D, FADS6, FADSD5, LLCDL1, TU12" ENSG00000149485 "Fatty acid desaturase 1" O60427 11 61799625-61829318 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Electron transport, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transport" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC TERT1: 97.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042705 Approved "HPA042705: AB_10795709" "unprognostic (8.28e-2)" "unprognostic (3.54e-1)" "unprognostic (1.29e-1)" "unprognostic (1.99e-1)" "unprognostic (8.17e-3)" "unprognostic (1.40e-1)" "unprognostic (1.99e-2)" "unprognostic (3.23e-3)" "unprognostic (7.88e-2)" "unprognostic (1.94e-2)" "unprognostic (4.10e-2)" "unprognostic (2.00e-1)" "prognostic unfavourable (1.95e-9)" "unprognostic (2.29e-2)" "unprognostic (3.59e-2)" "prognostic unfavourable (2.79e-4)" "prognostic unfavourable (1.33e-4)" 15.1 51.6 26.7 14.4 21.8 6.6 7.6 12.5 41.4 9.6 4.8 46.1 12.9 4.6 14.8 5.6 4.6 8.5 11.1 16.6 23.2 21.8 6.5 38.3 14.9 11.5 16.2 25.4 23.2 7.8 34.4 11.3 15.3 27.1 15.2 4.3 23.0 4.9 13.5 8.9 7.7 3.8 15.4 18.6 6.1 5.7 9.0 21.8 3.3 4.5 1.9 6.9 8.7 7.8 4.2 14.9 3.8 21.1 3.6 6.6 7.3 11.6 30.6 29.2 7.3 57.6 97.6 8.5 7.4 36.0 12.8 21.4 9.3 26.0 0.4 8.1 10.9 15.3 23.4 20.6 9.5 2.1 3.3 18.4 35.2 16.8 31.0 4.0 1.9 43.8 6.8 28.5 13.9 11.4 10.1 21.7 12.6 3.2 13.7 4.0 16.9 11.3 15.1 28.9 40.6 14.7 5.2 14.9 16.4 18.6 0.3 16.2 6.9 17.7 10.7 13.3 13.5 13.3 8.9 20.8 18.8 9.4 7.8 18.9 10.8 3.8 18.0 3.2 6.6 21.1 1.4 1.3 2.3 2.7 14.9 4.2 1.3 3.2 1.4 3.6 8.9 12.5 1.4 7.3 26.7 21.8 12.5 25.5 23.2 21.8 16.2 25.4 27.1 21.8 FADS2 "D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13" ENSG00000134824 "Fatty acid desaturase 2" O95864 11 61792980-61867354 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Electron transport, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transport" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "ductus deferens: 204.5;seminal vesicle: 98.8" "Cell line enhanced" "Detected in many" "ASC TERT1: 148.0;HBEC3-KT: 88.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006741 Approved "HPA006741: AB_1078796" "unprognostic (2.37e-2)" "unprognostic (1.02e-1)" "unprognostic (8.34e-2)" "unprognostic (4.33e-3)" "unprognostic (4.63e-2)" "unprognostic (2.42e-2)" "unprognostic (4.51e-2)" "unprognostic (4.35e-3)" "unprognostic (2.01e-1)" "unprognostic (4.21e-2)" "unprognostic (8.95e-3)" "unprognostic (7.80e-2)" "prognostic unfavourable (1.00e-7)" "unprognostic (6.19e-2)" "unprognostic (1.34e-1)" "unprognostic (1.41e-2)" "prognostic unfavourable (3.42e-4)" 7.1 85.9 34.3 10.0 31.7 7.5 20.2 10.1 48.5 23.7 4.9 28.6 204.5 9.3 19.9 10.3 3.2 8.9 6.6 8.2 24.4 29.9 3.8 38.0 9.7 6.7 28.1 20.1 8.6 3.1 41.5 11.8 12.8 26.4 32.0 4.3 16.7 5.0 98.8 3.0 26.1 3.6 39.3 17.9 3.3 3.6 10.4 24.0 8.4 2.5 3.2 9.2 10.6 6.5 3.5 13.3 6.9 9.0 6.3 9.4 3.8 1.3 52.1 77.4 42.7 70.5 148.0 20.2 8.7 78.7 12.8 35.1 3.3 17.5 0.3 1.2 19.2 1.5 50.6 88.5 5.5 0.6 1.0 29.6 10.4 7.6 55.6 1.8 1.7 55.6 2.7 46.6 4.2 37.8 1.6 24.0 5.9 1.3 16.6 9.8 33.7 13.7 22.5 1.3 72.8 50.9 0.4 23.0 28.0 5.7 0.1 2.2 2.1 21.8 15.3 1.4 13.9 0.9 1.2 11.2 9.8 3.9 1.4 9.8 15.7 4.5 5.7 6.9 9.4 9.0 2.2 1.6 3.5 5.0 10.5 3.5 2.0 4.4 3.1 6.3 7.5 13.3 3.0 3.8 34.3 31.7 10.1 25.2 24.4 29.9 28.1 20.1 26.4 24.0 FASN "FAS, SDR27X1" ENSG00000169710 "Fatty acid synthase" P49327 17 82078333-82098332 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" "Hydrolase, Lyase, Multifunctional enzyme, Oxidoreductase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adipose tissue: 147.6" "Cell line enhanced" "Detected in many" "SK-BR-3: 152.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005192, HPA006461, CAB015417, HPA056108" Enhanced Enhanced "Plasma membrane,Cytosol" 1600000 "Plasma membrane, Cytosol" "CAB005192: AB_2101095, CAB015417: AB_2231427, HPA006461: AB_1848437, HPA056108: AB_2683039" "unprognostic (3.35e-2)" "prognostic unfavourable (1.42e-5)" "unprognostic (9.69e-3)" "unprognostic (4.09e-2)" "unprognostic (3.46e-3)" "unprognostic (1.55e-2)" "unprognostic (3.09e-2)" "unprognostic (4.74e-3)" "unprognostic (3.15e-1)" "unprognostic (3.15e-1)" "unprognostic (2.87e-3)" "unprognostic (1.05e-1)" "prognostic unfavourable (7.16e-5)" "unprognostic (4.50e-2)" "unprognostic (9.62e-2)" "unprognostic (1.35e-2)" "unprognostic (7.03e-3)" 147.6 7.8 8.2 14.2 11.5 11.1 57.5 19.1 23.0 6.6 27.7 17.0 14.1 8.2 4.7 14.2 17.1 4.3 19.4 6.3 7.9 6.7 3.7 30.8 26.8 9.8 7.3 11.5 6.4 10.4 6.7 15.3 8.4 21.7 28.8 3.4 7.6 16.9 10.8 7.5 17.2 6.5 4.6 8.4 5.1 11.9 6.6 8.8 1.9 5.1 10.7 5.4 8.0 6.6 0.5 1.4 0.0 0.8 0.2 1.9 0.8 23.1 24.3 11.3 7.8 18.3 12.4 24.2 4.6 6.0 4.9 9.0 25.4 15.8 7.7 3.8 3.5 19.4 10.9 21.3 0.9 3.6 47.4 16.0 18.2 33.9 5.2 8.6 2.4 11.9 5.6 12.5 2.9 5.5 24.1 6.9 1.7 40.1 9.4 13.7 21.9 14.2 8.3 6.4 15.3 5.5 29.7 28.1 15.6 6.8 152.8 12.4 27.2 16.5 9.6 7.2 14.8 5.9 11.0 9.3 2.0 8.0 4.3 9.4 10.6 0.0 0.8 0.0 1.2 0.5 0.7 0.5 1.9 1.4 1.4 0.2 0.7 0.6 0.0 0.2 0.4 1.1 0.6 0.8 8.2 11.5 19.1 23.0 7.9 6.7 7.3 11.5 21.7 8.8 FCER1A FCE1A ENSG00000179639 "Fc fragment of IgE receptor Ia" P12319 1 159289714-159308224 "FDA approved drug targets, Predicted membrane proteins" "IgE-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 18 "blood: 494.6" "Cell line enriched" "Detected in some" 94 "HEL: 97.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 7 "basophil: 494.6" "Lineage enriched" "Detected in many" 7 "granulocytes: 494.6" "Low region specificity" "Detected in all" "CAB022102, HPA036051, CAB055526" Approved "CAB022102: , CAB055526: , HPA036051: " "unprognostic (1.78e-2)" "unprognostic (2.26e-2)" "unprognostic (7.32e-2)" "unprognostic (7.51e-2)" "unprognostic (1.32e-2)" "unprognostic (1.44e-3)" "unprognostic (7.19e-2)" "unprognostic (1.97e-3)" "unprognostic (2.44e-1)" "unprognostic (7.20e-2)" "unprognostic (8.54e-2)" "unprognostic (2.74e-1)" "prognostic favourable (1.20e-4)" "unprognostic (1.68e-2)" "unprognostic (1.18e-1)" "unprognostic (2.70e-1)" "unprognostic (3.39e-2)" 5.8 1.4 1.6 3.6 0.8 6.0 9.2 0.9 1.3 8.0 3.4 1.1 3.4 3.2 10.6 5.6 12.1 2.0 25.4 4.1 4.3 1.3 3.6 2.4 27.8 0.6 1.0 5.3 1.5 2.6 0.5 1.9 0.5 2.7 9.4 5.4 6.5 5.9 4.7 1.2 17.9 4.1 6.0 2.8 3.5 2.3 1.5 6.8 2.4 2.5 19.7 16.2 3.8 4.9 0.0 75.4 494.6 0.3 0.4 0.1 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 97.8 0.0 0.0 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 494.6 0.3 0.9 0.0 0.1 0.1 0.0 0.1 0.0 75.4 0.0 0.0 0.1 0.4 0.4 0.2 10.4 0.0 3.0 1.6 0.8 0.9 1.3 4.3 1.3 1.0 5.3 2.7 6.8 FCER1G ENSG00000158869 "Fc fragment of IgE receptor Ig" P30273 1 161215234-161220699 "FDA approved drug targets, Predicted membrane proteins" "Immunity, Innate immunity" "IgE-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 262.7;lymphoid tissue: 176.3" "Cell line enhanced" "Detected in some" "HEL: 17.1;HMC-1: 70.0;THP-1: 61.6;U-266/84: 18.9;U-937: 19.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 262.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022108, HPA026872" Supported 9800000 "CAB022108: , HPA026872: AB_1848473" "unprognostic (3.71e-2)" "unprognostic (2.52e-2)" "unprognostic (2.40e-2)" "unprognostic (8.73e-3)" "unprognostic (1.46e-1)" "unprognostic (4.28e-2)" "unprognostic (3.10e-3)" "unprognostic (1.84e-1)" "unprognostic (3.25e-1)" "unprognostic (9.63e-2)" "unprognostic (2.28e-2)" "unprognostic (5.67e-2)" "prognostic unfavourable (1.83e-6)" "unprognostic (1.99e-1)" "unprognostic (6.28e-2)" "unprognostic (2.04e-2)" "unprognostic (7.87e-2)" 62.6 20.5 12.1 49.5 22.4 71.5 17.6 2.4 10.8 10.6 14.6 14.1 1.3 8.0 7.2 15.9 6.9 20.5 18.8 21.2 15.3 11.2 18.9 35.9 71.2 124.8 23.4 4.5 11.4 7.4 2.9 7.9 38.1 17.0 9.7 21.3 9.7 12.8 7.4 11.9 5.7 13.6 28.5 33.3 176.3 10.9 11.6 16.0 6.5 11.5 6.7 14.7 22.4 10.5 0.9 135.4 73.5 262.7 66.6 2.0 132.1 0.0 0.0 0.1 0.3 0.4 0.1 0.0 0.1 0.0 0.1 0.2 0.5 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.3 17.1 0.1 3.3 0.0 3.5 70.0 1.4 0.7 0.5 0.0 0.1 0.0 1.6 0.5 0.1 0.3 8.3 0.3 0.0 0.0 1.5 0.1 0.1 0.0 0.0 0.2 0.1 0.0 0.6 0.0 61.6 0.1 0.4 0.1 0.2 0.2 0.7 18.9 0.2 0.4 19.3 0.1 64.3 129.8 12.1 0.5 210.3 0.6 0.9 0.4 0.4 97.1 0.3 0.7 2.0 73.5 66.6 262.7 135.4 0.8 132.1 12.1 22.4 2.4 10.8 15.3 11.2 23.4 4.5 17.0 16.0 FDPS ENSG00000160752 "Farnesyl diphosphate synthase" P14324 1 155308748-155320666 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Cholesterol biosynthesis, Cholesterol metabolism, Host-virus interaction, Isoprene biosynthesis, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism" Transferase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HBEC3-KT: 147.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028200 Approved Approved Nucleoplasm,Cytosol 2000000 Cytosol Nucleoplasm "HPA028200: AB_10612109" "unprognostic (1.23e-1)" "unprognostic (8.46e-3)" "unprognostic (2.47e-2)" "unprognostic (6.57e-2)" "unprognostic (4.58e-2)" "unprognostic (2.84e-2)" "prognostic unfavourable (7.35e-4)" "unprognostic (4.21e-2)" "unprognostic (6.78e-3)" "unprognostic (1.64e-3)" "unprognostic (7.19e-2)" "unprognostic (2.25e-2)" "unprognostic (1.11e-2)" "unprognostic (8.25e-2)" "unprognostic (2.07e-1)" "unprognostic (5.65e-2)" "unprognostic (8.44e-2)" 21.0 57.8 19.3 17.6 26.5 16.5 19.8 12.8 32.2 19.0 25.0 22.6 14.5 45.9 18.0 21.7 41.4 16.7 18.8 19.6 18.6 23.4 23.7 100.8 25.7 19.2 19.5 24.3 15.2 27.5 15.6 12.3 20.2 47.3 16.5 29.7 20.5 29.2 12.9 15.7 29.3 32.3 18.9 23.0 17.7 23.4 15.1 16.5 25.1 19.5 41.7 27.3 13.7 20.8 41.1 39.7 49.4 37.1 45.3 45.5 48.3 35.6 19.4 71.3 25.7 16.7 61.3 25.4 17.0 33.7 27.2 44.3 31.4 84.9 27.2 41.4 14.9 39.8 42.4 147.8 25.5 14.8 30.4 15.8 34.6 37.8 27.5 25.5 18.1 43.6 23.4 43.2 21.7 47.3 28.1 73.3 28.3 38.3 32.6 24.8 42.8 28.4 28.2 30.9 75.4 71.6 23.8 27.7 23.7 17.5 31.9 29.4 23.0 69.4 34.4 15.2 18.7 9.4 31.1 31.1 23.9 48.5 14.8 27.2 23.9 30.5 36.0 49.4 39.4 37.1 35.0 41.1 34.8 39.8 39.7 34.2 31.5 39.3 16.5 45.3 27.2 31.4 45.5 48.3 19.3 26.5 12.8 32.2 18.6 23.4 19.5 24.3 47.3 16.5 FGF1 "AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1" ENSG00000113578 "Fibroblast growth factor 1" P05230 5 142592178-142698070 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 65.0;heart muscle: 35.5;kidney: 41.5" "Cell line enhanced" "Detected in some" "BJ: 19.3;BJ hTERT+: 14.4;BJ hTERT+ SV40 Large T+: 16.0;BJ hTERT+ SV40 Large T+ RasG12V: 20.2;HBF TERT88: 28.8;hTEC/SVTERT24-B: 20.1;LHCN-M2: 13.4;U-2 OS: 14.4" "Cancer enriched" "Detected in many" 12 "glioma: 33.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003265, CAB017519" Enhanced Supported Nucleoplasm "Secreted in other tissues" Nucleoplasm "CAB017519: AB_629473, HPA003265: AB_1848522" "unprognostic (1.25e-2)" "unprognostic (2.43e-1)" "unprognostic (1.06e-1)" "unprognostic (3.41e-3)" "unprognostic (2.55e-2)" "unprognostic (3.52e-1)" "unprognostic (2.77e-1)" "unprognostic (2.39e-1)" "unprognostic (3.63e-1)" "unprognostic (1.57e-2)" "unprognostic (1.89e-1)" "unprognostic (1.54e-1)" "prognostic favourable (2.59e-5)" "unprognostic (3.72e-4)" "unprognostic (2.49e-1)" "prognostic favourable (3.45e-5)" "unprognostic (3.01e-4)" 7.3 3.5 44.2 2.0 43.1 1.5 9.7 10.5 59.9 1.8 1.7 65.0 0.0 1.6 3.1 8.7 2.3 2.1 2.7 35.5 47.4 33.0 41.5 2.0 2.9 1.4 62.6 13.8 1.5 1.4 3.4 1.6 2.3 36.3 2.2 1.8 0.8 5.8 2.6 2.3 2.0 1.7 2.6 57.7 5.5 1.1 2.2 48.6 0.0 4.9 0.8 2.2 1.7 0.4 1.2 1.0 1.8 0.6 0.1 2.3 0.2 2.3 0.1 0.1 0.7 0.5 1.5 0.8 19.3 14.4 16.0 20.2 0.1 0.1 0.5 1.4 6.6 0.3 0.0 1.5 28.8 0.1 0.0 0.0 0.3 0.1 0.2 0.0 0.2 0.7 0.5 20.1 1.2 0.0 0.0 0.7 13.4 0.3 0.0 0.4 0.6 0.6 0.1 0.6 0.2 0.6 0.1 0.5 1.0 0.0 0.4 0.2 0.0 0.1 0.4 2.6 14.4 0.3 9.1 0.3 0.1 0.1 3.6 0.1 0.7 0.3 0.3 1.8 2.3 0.1 1.8 0.4 0.8 0.9 0.2 1.2 0.9 1.9 1.7 0.1 0.6 1.0 0.5 0.2 44.2 43.1 10.5 22.6 47.4 33.0 62.6 13.8 36.3 48.6 FGF2 FGFB ENSG00000138685 "Fibroblast growth factor 2" P09038 4 122826708-122898236 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins, Transporters" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 56.5;BJ hTERT+: 33.1;fHDF/TERT166: 61.3;hTERT-HME1: 33.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000125, HPA065502" Enhanced Supported "Nucleoplasm,Nuclear bodies" "Secreted in other tissues" "Nucleoplasm, Nuclear bodies" "CAB000125: , HPA065502: " "unprognostic (1.53e-2)" "unprognostic (3.12e-1)" "unprognostic (1.08e-1)" "unprognostic (7.42e-2)" "unprognostic (2.10e-1)" "unprognostic (3.33e-1)" "unprognostic (6.98e-2)" "unprognostic (1.25e-1)" "unprognostic (2.82e-1)" "unprognostic (1.79e-1)" "prognostic unfavourable (9.85e-4)" "unprognostic (3.37e-1)" "unprognostic (4.61e-3)" "unprognostic (2.36e-1)" "unprognostic (1.81e-1)" "unprognostic (4.45e-2)" "unprognostic (3.45e-3)" 28.1 3.8 19.4 6.9 21.3 0.7 12.1 6.5 15.3 10.2 14.2 10.3 1.9 2.6 17.9 6.3 6.4 10.1 9.4 5.6 17.1 11.0 5.5 2.9 8.3 2.5 9.9 10.7 16.8 2.4 10.1 4.0 8.1 18.6 10.3 5.6 7.5 4.6 11.9 2.0 2.3 4.1 16.2 17.3 1.9 7.6 3.0 12.3 0.0 3.1 3.8 2.7 7.5 14.5 0.8 0.8 0.5 0.5 0.3 1.0 0.0 1.2 3.1 1.7 6.8 4.3 7.2 0.0 56.5 33.1 23.7 13.8 0.0 0.1 0.0 6.6 61.3 0.2 1.8 0.1 23.9 4.4 0.8 0.0 6.4 0.0 12.8 0.3 0.0 3.9 0.3 23.4 33.8 2.6 1.7 1.9 6.1 0.0 0.0 0.0 5.1 1.3 0.0 0.9 0.0 7.5 0.0 1.0 0.9 10.9 0.0 0.4 0.0 0.1 2.3 19.6 3.8 7.2 4.8 3.3 3.6 0.0 5.6 0.0 2.0 0.5 0.5 0.4 0.3 0.4 0.2 0.4 0.5 0.4 0.2 0.8 0.7 1.0 0.4 0.3 0.4 0.8 0.7 0.0 19.4 21.3 6.5 15.3 17.1 11.0 9.9 10.7 18.6 12.3 FGFR1 "BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM" ENSG00000077782 "Fibroblast growth factor receptor 1" P11362 8 38411138-38468834 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Transcription, Transcription regulation" "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AN3-CA: 109.2;BJ hTERT+: 49.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033614, HPA056402" Approved 120000000 "CAB033614: AB_783377, HPA056402: " "unprognostic (9.53e-2)" "unprognostic (7.33e-2)" "unprognostic (2.44e-1)" "unprognostic (1.35e-2)" "unprognostic (4.23e-3)" "unprognostic (7.02e-2)" "unprognostic (6.59e-2)" "unprognostic (2.77e-1)" "unprognostic (1.81e-1)" "unprognostic (3.99e-2)" "unprognostic (7.97e-3)" "unprognostic (4.59e-2)" "unprognostic (7.69e-2)" "unprognostic (6.87e-3)" "unprognostic (5.60e-2)" "unprognostic (4.59e-3)" "unprognostic (1.05e-3)" 41.1 8.6 12.5 14.5 12.2 7.2 39.5 45.0 10.5 36.0 31.5 10.1 11.6 5.5 29.3 20.6 22.9 29.4 32.4 31.7 12.8 10.1 11.8 5.4 18.6 9.7 11.4 14.3 42.0 51.2 11.5 22.3 28.4 20.0 28.2 10.8 35.8 14.0 31.6 12.0 12.9 14.4 52.4 15.6 4.5 16.4 16.4 8.5 11.3 12.6 13.0 9.8 39.6 41.2 1.6 0.7 1.8 1.1 0.8 5.7 0.7 2.4 9.3 40.3 109.2 25.1 17.9 26.6 24.8 49.8 17.3 18.0 6.0 1.4 0.3 6.9 23.8 0.0 19.1 1.2 20.0 6.5 4.2 0.0 1.5 5.9 14.1 5.8 0.1 16.2 0.1 14.0 2.8 16.6 2.2 0.1 8.1 2.8 17.0 1.9 28.4 3.9 15.7 4.2 0.0 8.4 0.0 1.6 3.6 4.4 0.2 1.0 2.2 1.1 10.4 11.3 6.2 31.2 5.9 0.4 0.7 0.0 13.4 0.3 5.9 1.4 1.1 0.4 5.7 0.3 3.9 0.7 2.7 3.7 0.1 1.6 1.5 4.1 1.8 0.8 0.5 0.7 2.2 0.7 12.5 12.2 45.0 10.5 12.8 10.1 11.4 14.3 20.0 8.5 FGFR2 "BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25" ENSG00000066468 "Fibroblast growth factor receptor 2" P21802 10 121478334-121598458 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Apoptosis "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 74.8" "Cell line enhanced" "Detected in some" "AN3-CA: 57.8;BEWO: 19.4;CACO-2: 15.1;HaCaT: 17.4;HAP1: 18.7;NTERA-2: 18.5;T-47d: 15.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 15 "basophil: 10.8;eosinophil: 4.6" "Lineage enriched" "Detected in single" 35 "granulocytes: 10.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010886, HPA035305" Uncertain Supported "Nucleoplasm,Vesicles,Cell Junctions" "Secreted - unknown location" 500000 "Cell Junctions" "Nucleoplasm, Vesicles" "CAB010886: AB_259379, HPA035305: AB_10672862" "unprognostic (5.53e-2)" "prognostic favourable (8.79e-4)" "unprognostic (1.08e-1)" "unprognostic (5.23e-2)" "unprognostic (1.73e-1)" "prognostic favourable (9.32e-4)" "unprognostic (1.53e-1)" "unprognostic (4.96e-3)" "unprognostic (1.74e-1)" "unprognostic (1.56e-1)" "unprognostic (1.07e-1)" "unprognostic (3.74e-2)" "unprognostic (1.01e-1)" "unprognostic (6.11e-2)" "unprognostic (2.54e-1)" "unprognostic (6.93e-2)" "unprognostic (2.25e-1)" 2.1 8.8 16.4 3.0 30.3 0.0 9.9 15.8 21.3 6.8 14.1 55.7 5.6 4.2 22.0 6.6 10.2 12.5 12.5 1.4 20.6 11.1 11.4 16.1 13.1 1.0 41.2 13.3 7.4 12.8 25.5 2.5 6.2 30.2 11.7 8.7 16.4 23.8 24.3 0.4 45.4 4.7 18.3 74.8 0.5 9.3 2.9 32.1 0.8 23.4 1.6 3.4 6.9 8.5 0.1 0.1 10.8 0.1 0.1 0.3 0.0 2.2 0.1 9.0 57.8 0.0 0.0 19.4 0.1 0.0 0.0 0.0 15.1 0.3 0.0 4.1 0.9 17.4 18.7 4.0 0.0 0.0 4.0 0.0 0.0 0.3 0.4 0.0 3.8 0.0 8.4 0.0 0.2 0.0 0.0 0.0 0.0 3.5 0.0 0.0 18.5 0.0 0.0 0.0 2.2 5.6 4.9 0.1 0.1 0.1 10.6 0.0 15.5 0.0 0.0 0.1 2.8 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 10.8 0.1 4.6 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.1 0.5 0.1 0.0 0.1 0.0 0.0 16.4 30.3 15.8 21.3 20.6 11.1 41.2 13.3 30.2 32.1 FGFR3 "ACH, CD333, CEK2, JTK4" ENSG00000068078 "Fibroblast growth factor receptor 3" P22607 4 1793293-1808872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Apoptosis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "skin 1: 131.7" "Cell line enhanced" "Detected in many" "CACO-2: 19.1;HaCaT: 14.9;Hep G2: 32.1;NTERA-2: 15.6;RT4: 19.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004231, HPA067204" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" 670000 "Endoplasmic reticulum" "CAB004231: AB_627596, HPA067204: " "unprognostic (1.34e-1)" "unprognostic (5.29e-3)" "unprognostic (1.49e-1)" "prognostic unfavourable (3.77e-4)" "unprognostic (5.90e-2)" "unprognostic (1.24e-3)" "unprognostic (7.22e-2)" "unprognostic (2.54e-1)" "unprognostic (1.99e-1)" "unprognostic (2.17e-1)" "unprognostic (1.38e-1)" "unprognostic (2.88e-2)" "unprognostic (1.30e-1)" "unprognostic (9.11e-3)" "unprognostic (1.98e-1)" "unprognostic (4.74e-2)" "unprognostic (1.97e-1)" 1.5 1.5 24.7 1.7 30.3 1.6 4.2 10.2 22.0 4.1 4.9 15.8 3.4 9.9 1.8 2.7 26.9 2.0 5.0 2.0 21.6 11.7 9.6 7.4 4.5 1.3 17.6 21.5 1.1 23.0 1.2 3.0 5.6 15.1 3.7 3.8 1.7 3.8 9.0 1.7 131.7 7.4 1.3 9.0 2.1 4.9 8.1 10.6 0.1 1.3 8.5 7.3 8.5 10.1 0.1 0.6 0.1 0.1 0.2 0.3 0.0 0.0 1.5 9.0 2.6 0.0 0.1 9.2 1.0 0.1 0.4 0.2 19.1 0.4 0.0 7.6 0.3 14.9 2.6 0.1 0.1 0.1 9.6 5.9 1.5 32.1 0.0 0.0 0.1 0.0 5.0 0.1 0.0 0.0 6.4 0.0 0.0 9.5 0.3 0.2 15.6 0.0 0.5 0.5 0.1 1.3 19.1 2.6 0.7 0.8 1.6 0.0 8.9 1.1 0.4 0.0 0.9 0.2 0.6 0.0 0.0 0.0 0.1 0.7 0.5 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.6 0.1 0.0 24.7 30.3 10.2 22.0 21.6 11.7 17.6 21.5 15.1 10.6 FGFR4 "CD334, JTK2" ENSG00000160867 "Fibroblast growth factor receptor 4" P22455 5 177086886-177098144 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 33.6;kidney: 37.7;liver: 45.3" "Group enriched" "Detected in many" 4 "CACO-2: 42.0;Hep G2: 42.0;RH-30: 67.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "neutrophil: 3.0" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB005196, HPA027273, HPA027369, HPA028251" Approved "Intracellular and membrane" 4300000 "CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221" "unprognostic (1.96e-1)" "unprognostic (2.10e-2)" "unprognostic (1.12e-1)" "unprognostic (9.06e-3)" "unprognostic (2.87e-1)" "unprognostic (1.95e-2)" "unprognostic (7.85e-3)" "unprognostic (9.19e-2)" "unprognostic (4.25e-1)" "unprognostic (4.46e-2)" "unprognostic (1.16e-1)" "unprognostic (3.48e-2)" "unprognostic (1.78e-1)" "unprognostic (1.71e-3)" "unprognostic (2.41e-1)" "unprognostic (5.75e-2)" "unprognostic (4.68e-2)" 0.5 5.7 0.7 14.3 0.6 0.1 1.6 2.6 0.5 2.8 10.4 0.9 0.7 13.5 0.9 4.8 1.6 1.7 33.6 0.7 0.8 0.3 37.7 45.3 25.3 2.5 0.7 1.0 13.6 26.0 0.0 0.7 1.3 0.8 4.0 3.7 2.0 1.6 0.3 4.3 0.5 17.3 1.6 0.8 11.2 5.4 2.9 0.4 0.3 0.8 2.3 0.7 1.9 3.6 1.1 0.9 3.0 1.1 0.4 0.4 0.0 0.7 11.8 0.2 2.9 0.0 0.0 5.8 0.0 0.0 0.0 0.0 42.0 1.6 1.2 5.5 0.0 0.6 2.3 0.4 0.0 0.7 2.8 0.1 0.6 42.0 1.3 0.1 1.0 0.2 0.0 2.1 0.0 0.0 3.9 0.1 0.9 9.6 0.0 0.8 7.1 1.0 1.9 67.6 7.1 5.7 0.1 0.4 0.7 0.4 3.0 1.4 2.9 0.6 0.2 0.0 5.7 0.0 0.1 0.4 0.4 0.7 0.0 0.2 0.5 1.5 1.1 0.4 0.4 0.3 0.3 1.1 0.4 0.0 0.1 0.6 0.4 0.4 3.0 0.4 0.3 0.9 0.2 0.0 0.7 0.6 2.6 0.5 0.8 0.3 0.7 1.0 0.8 0.4 FKBP1A "FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE" ENSG00000088832 "FK506 binding protein 1A" P62942 20 1368978-1393172 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Isomerase, Rotamase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HUVEC TERT2: 149.0;TIME: 172.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Group enriched" "Detected in all" 4 "dendritic cells: 63.6;granulocytes: 88.4;monocytes: 94.3" "CAB004639, HPA051798" Uncertain 16000000 "CAB004639: AB_425434, HPA051798: " "unprognostic (4.09e-2)" "unprognostic (2.29e-1)" "unprognostic (5.22e-3)" "unprognostic (1.28e-2)" "unprognostic (2.66e-1)" "unprognostic (7.18e-3)" "prognostic unfavourable (3.44e-7)" "unprognostic (7.05e-3)" "unprognostic (2.76e-1)" "unprognostic (8.81e-2)" "unprognostic (5.12e-3)" "unprognostic (6.65e-2)" "prognostic unfavourable (6.69e-5)" "unprognostic (1.97e-2)" "unprognostic (2.06e-1)" "unprognostic (1.21e-1)" "unprognostic (1.47e-1)" 106.0 42.4 67.3 55.0 114.8 44.4 63.5 15.8 55.8 33.2 39.7 22.1 33.8 32.7 45.5 45.9 42.7 33.8 32.0 36.4 51.7 30.6 41.9 41.7 59.2 84.1 26.0 36.5 41.7 57.7 20.6 21.7 65.0 22.5 34.4 49.4 21.4 30.8 40.6 38.9 31.5 37.1 56.0 23.3 68.0 33.0 21.1 28.4 47.4 62.2 39.7 48.3 48.1 37.0 13.3 63.6 88.4 94.3 14.5 18.6 84.3 69.9 19.4 15.5 22.4 52.4 65.7 20.4 44.5 30.2 35.7 33.1 19.3 27.2 28.6 14.3 41.4 32.2 19.9 81.3 46.9 8.2 21.7 29.4 9.1 36.8 32.2 34.1 16.3 38.2 26.0 32.9 34.0 149.0 26.9 14.7 41.9 8.7 33.3 47.0 33.2 38.0 28.6 27.0 34.7 46.0 17.7 25.8 19.5 22.0 44.3 73.6 17.4 29.1 172.6 132.5 22.2 28.2 32.8 7.4 15.9 30.0 22.8 34.6 29.3 23.9 79.4 88.4 11.5 94.3 10.2 12.8 13.9 13.2 63.6 13.3 14.8 14.2 77.9 14.5 90.3 31.6 18.6 84.3 67.3 114.8 15.8 55.8 51.7 30.6 26.0 36.5 22.5 28.4 FLT1 "FLT, VEGFR1" ENSG00000102755 "Fms related tyrosine kinase 1" P17948 13 28300344-28495145 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Chemotaxis, Differentiation" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 8 "placenta: 155.3" "Cell line enhanced" "Detected in some" "BJ: 17.0;BJ hTERT+: 13.5;HMC-1: 84.6;HUVEC TERT2: 15.3;WM-115: 30.3" "Cancer enhanced" "Detected in all" "renal cancer: 28.7" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "memory B-cell: 1.1;naive B-cell: 3.7;neutrophil: 2.1" "Group enriched" "Detected in many" 5 "B-cells: 3.7;granulocytes: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011740, HPA014290, CAB068189, CAB068190" Enhanced Supported "Plasma membrane,Actin filaments" "Secreted to blood" 875697 54000 "Plasma membrane, Actin filaments" "CAB068189: , CAB068190: , HPA011740: AB_1858737, HPA014290: AB_1858738" "unprognostic (3.33e-2)" "unprognostic (3.52e-3)" "unprognostic (1.13e-3)" "unprognostic (5.02e-2)" "unprognostic (3.65e-1)" "unprognostic (5.03e-2)" "unprognostic (8.25e-2)" "unprognostic (2.27e-3)" "unprognostic (9.91e-2)" "unprognostic (6.61e-2)" "unprognostic (2.33e-1)" "unprognostic (1.57e-1)" "prognostic unfavourable (2.19e-4)" "unprognostic (4.20e-2)" "unprognostic (6.00e-2)" "unprognostic (1.57e-1)" "unprognostic (6.32e-2)" 18.9 4.0 9.9 4.0 14.3 1.2 13.5 8.0 15.9 7.1 4.6 3.5 1.7 3.5 7.2 2.2 3.4 4.0 6.9 18.3 11.4 7.3 10.3 7.6 12.3 2.5 10.3 3.2 5.1 5.4 13.4 3.7 155.3 13.8 5.1 3.1 9.1 3.0 5.0 12.5 2.6 3.4 7.3 9.6 7.2 4.6 6.8 10.2 0.0 19.1 3.8 2.8 7.6 9.2 3.7 0.5 2.1 0.1 0.2 0.4 0.2 0.0 0.0 0.0 0.1 0.1 0.2 0.0 17.0 13.5 6.2 3.6 0.0 0.0 0.0 0.0 2.2 0.0 1.6 0.0 11.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 84.6 0.1 0.0 0.0 0.2 15.3 0.4 0.0 0.0 0.0 1.0 0.8 9.0 0.0 0.6 0.0 0.0 0.0 0.0 1.9 0.1 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.2 0.0 0.0 0.5 0.2 0.0 0.1 0.0 30.3 0.2 0.1 0.1 0.1 0.1 0.0 1.1 0.1 0.1 0.0 3.7 0.4 0.4 2.1 0.2 0.1 0.5 0.2 0.2 9.9 14.3 8.0 15.9 11.4 7.3 10.3 3.2 13.8 10.2 FLT3 "CD135, FLK2, STK1" ENSG00000122025 "Fms related tyrosine kinase 3" P36888 13 28003274-28100592 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 29.9;brain: 19.3;lymphoid tissue: 15.0" "Group enriched" "Detected in some" 11 "REH: 27.8;THP-1: 17.1" "Cancer enhanced" "Detected in some" "breast cancer: 1.8" "Region enhanced" "Detected in many" "cerebellum: 19.3" "Group enriched" "Detected in some" 11 "myeloid DC: 29.9;plasmacytoid DC: 12.1" "Lineage enriched" "Detected in many" 16 "dendritic cells: 29.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA047539 Approved "Endoplasmic reticulum" 180000 "Endoplasmic reticulum" "HPA047539: " "unprognostic (2.19e-3)" "unprognostic (3.16e-3)" "unprognostic (6.54e-3)" "unprognostic (9.96e-2)" "unprognostic (3.88e-1)" "unprognostic (3.96e-7)" "unprognostic (7.99e-3)" "unprognostic (1.65e-2)" "unprognostic (5.37e-2)" "unprognostic (1.01e-2)" "unprognostic (1.96e-1)" "unprognostic (1.03e-1)" "unprognostic (4.56e-2)" "unprognostic (3.65e-1)" "unprognostic (3.91e-2)" "unprognostic (2.51e-1)" "unprognostic (2.22e-1)" 0.9 0.6 0.6 7.2 1.1 7.5 2.6 19.3 3.5 0.9 1.2 0.1 0.1 0.4 0.8 0.8 1.0 1.2 4.6 0.5 0.9 1.7 2.8 0.7 2.7 15.0 1.8 1.1 0.5 5.7 0.0 0.4 0.0 7.4 0.6 1.4 0.1 2.3 0.6 0.4 1.2 3.0 1.3 4.4 8.8 0.9 1.2 0.0 8.2 0.6 0.0 5.8 2.4 0.7 0.1 29.9 1.4 1.8 0.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.0 0.5 0.0 27.8 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 17.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.8 1.4 0.0 0.3 0.0 0.1 0.0 0.0 29.9 0.0 0.0 0.0 0.0 0.8 0.0 12.1 0.0 1.2 0.6 1.1 19.3 3.5 0.9 1.7 1.8 1.1 7.4 0.0 FLT4 "PCL, VEGFR3" ENSG00000037280 "Fms related tyrosine kinase 4" P35916 5 180601506-180649624 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Angiogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 56.3" "Cell line enhanced" "Detected in some" "AN3-CA: 8.3;BEWO: 10.2;HEK 293: 12.6;HL-60: 7.4;HUVEC TERT2: 8.1;T-47d: 12.0;TIME: 12.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 5 "MAIT T-cell: 7.7" "Lineage enriched" "Detected in single" 35 "T-cells: 7.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000099, HPA046519, HPA067906" Approved Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Secreted to blood" 270000000 "Plasma membrane" "Nucleoplasm, Cell Junctions" "CAB000099: , HPA046519: , HPA067906: " "unprognostic (7.35e-2)" "unprognostic (1.63e-1)" "unprognostic (9.45e-3)" "unprognostic (3.81e-1)" "unprognostic (9.26e-2)" "unprognostic (3.20e-3)" "unprognostic (1.13e-2)" "unprognostic (1.80e-2)" "unprognostic (2.19e-1)" "unprognostic (1.70e-1)" "unprognostic (2.13e-2)" "unprognostic (3.69e-1)" "unprognostic (1.88e-2)" "unprognostic (9.41e-3)" "unprognostic (1.83e-1)" "unprognostic (8.26e-2)" "unprognostic (1.32e-1)" 14.8 7.1 1.6 4.9 6.0 0.7 28.5 1.3 2.7 6.3 7.3 1.9 2.1 3.1 7.3 6.2 5.7 9.2 5.3 6.4 1.7 0.9 11.7 10.2 14.1 23.6 2.0 0.8 5.8 2.3 2.3 6.2 56.3 2.1 4.9 1.4 6.7 3.3 4.4 4.8 2.8 4.7 4.7 1.5 14.5 2.4 3.5 2.0 0.3 19.4 4.4 2.3 6.1 14.7 0.0 0.1 0.2 0.0 0.0 7.7 0.2 0.1 2.0 2.7 8.3 0.0 0.0 10.2 0.2 0.1 0.0 0.0 0.3 0.3 0.2 0.8 0.1 0.3 2.8 0.1 0.2 0.1 12.6 1.0 0.4 0.4 0.1 7.4 0.2 0.2 0.0 0.1 0.3 8.1 0.3 0.3 1.7 4.5 0.1 0.4 5.8 0.5 6.5 0.0 0.1 0.1 0.2 0.2 0.9 0.1 0.2 0.0 12.0 0.2 12.7 0.1 5.9 0.2 0.1 0.2 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.9 0.0 7.7 0.0 0.4 1.6 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.1 0.0 0.2 1.6 6.0 1.3 2.7 1.7 0.9 2.0 0.8 2.1 2.0 FRK "GTK, PTK5, RAK" ENSG00000111816 "Fyn related Src family tyrosine kinase" P42685 6 115931149-116060758 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "FDA approved drug targets, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 41.4" "Cell line enhanced" "Detected in many" "RT4: 10.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB025217, HPA030479" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB025217: , HPA030479: " "unprognostic (7.70e-3)" "unprognostic (1.99e-2)" "unprognostic (1.11e-1)" "unprognostic (4.68e-3)" "unprognostic (1.96e-1)" "unprognostic (3.49e-2)" "unprognostic (2.09e-1)" "unprognostic (1.58e-1)" "unprognostic (4.23e-2)" "unprognostic (5.82e-3)" "unprognostic (1.45e-1)" "unprognostic (7.54e-2)" "prognostic favourable (9.66e-7)" "unprognostic (1.52e-2)" "unprognostic (1.34e-1)" "unprognostic (2.02e-2)" "unprognostic (1.10e-1)" 1.5 2.2 0.8 3.0 1.3 1.3 2.6 0.5 0.8 6.4 21.4 0.2 10.2 6.8 1.6 9.0 10.5 2.8 7.3 3.3 1.2 0.8 23.7 19.6 5.6 0.6 1.5 0.5 2.4 5.9 0.3 3.8 2.7 0.8 4.1 5.5 0.8 9.2 6.1 2.9 2.0 41.4 2.5 2.4 1.0 5.5 1.8 0.5 1.2 1.0 5.2 7.4 5.0 3.6 2.2 1.2 3.8 1.2 1.4 2.3 0.3 3.2 5.3 0.8 1.3 0.4 0.4 1.0 0.8 0.2 0.1 0.1 4.1 5.1 1.3 4.9 0.8 7.7 0.4 1.5 0.2 4.4 0.5 1.8 4.6 3.5 0.3 1.2 1.1 0.3 2.2 0.5 0.6 0.3 0.9 3.3 1.3 1.8 1.0 0.8 1.4 0.9 1.5 4.6 1.6 6.5 10.1 1.1 1.2 1.1 6.8 0.7 2.1 1.0 1.3 1.5 1.6 1.2 0.8 5.0 3.5 2.3 1.5 0.8 1.0 3.2 1.0 1.0 1.9 0.6 2.3 1.1 1.4 1.7 0.4 2.2 1.1 1.4 3.8 1.4 1.2 1.2 1.0 0.3 0.8 1.3 0.5 0.7 1.2 0.8 1.5 0.5 0.8 0.5 FTH1 "FHC, FTH, FTHL6, PIG15, PLIF" ENSG00000167996 "Ferritin heavy chain 1" P02794 11 61959718-61967660 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Iron storage" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 756.2" "Cell line enhanced" "Detected in all" "ASC diff: 547.1;HHSteC: 570.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 756.2" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" CAB008623 Approved Approved Microtubules 9000000 Microtubules "CAB008623: " "unprognostic (7.15e-2)" "unprognostic (1.52e-2)" "unprognostic (2.27e-1)" "unprognostic (2.00e-2)" "unprognostic (2.53e-1)" "prognostic unfavourable (7.56e-5)" "prognostic unfavourable (6.18e-4)" "unprognostic (3.08e-2)" "unprognostic (2.48e-2)" "unprognostic (6.65e-2)" "unprognostic (2.44e-2)" "unprognostic (8.13e-2)" "prognostic unfavourable (5.20e-5)" "unprognostic (2.99e-1)" "unprognostic (4.89e-2)" "unprognostic (3.44e-1)" "unprognostic (5.83e-2)" 155.1 118.0 177.6 138.9 92.6 162.0 302.9 38.5 163.7 104.2 142.4 97.8 72.0 72.2 81.6 102.4 88.8 70.6 83.5 236.1 124.7 91.2 113.5 128.2 297.3 394.0 118.5 110.6 81.7 150.8 49.7 46.7 70.1 77.5 60.9 138.5 79.5 180.5 65.1 124.1 42.5 110.0 140.0 182.1 84.4 81.0 67.8 88.2 58.5 100.3 64.1 48.9 106.7 94.0 69.5 163.3 756.2 424.5 30.7 69.2 284.2 64.4 181.0 27.6 73.0 547.1 265.0 152.3 59.1 254.1 60.4 61.0 21.9 89.5 7.5 375.8 170.2 110.4 24.6 48.9 39.2 30.7 12.1 37.5 250.9 142.9 570.0 17.6 59.0 358.9 240.3 120.5 226.6 75.5 55.9 86.0 210.8 87.2 19.7 28.8 47.2 306.1 19.6 34.1 53.6 308.6 175.5 23.5 29.7 203.3 22.4 96.2 39.8 23.7 84.1 188.8 45.2 83.5 37.1 14.9 51.2 23.1 257.4 7.8 44.9 401.9 297.7 247.4 40.8 367.6 40.2 68.6 58.3 40.4 163.3 69.5 49.3 38.2 756.2 30.7 424.5 121.2 69.2 284.2 177.6 92.6 38.5 163.7 124.7 91.2 118.5 110.6 77.5 88.2 FTL "MGC71996, NBIA3" ENSG00000087086 "Ferritin light chain" P02792 19 48965301-48966878 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Iron storage" "Cancer-related genes, Cataract, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 1149.4" "Cell line enhanced" "Detected in all" "HHSteC: 570.4;HSkMC: 477.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Group enriched" "Detected in all" 4 "granulocytes: 1149.4;monocytes: 890.5" "CAB020769, HPA041602" Enhanced Approved Cytosol 240000000 Cytosol "CAB020769: , HPA041602: " "unprognostic (2.95e-1)" "unprognostic (2.64e-2)" "unprognostic (1.31e-1)" "unprognostic (1.56e-3)" "unprognostic (7.48e-2)" "unprognostic (5.28e-2)" "unprognostic (2.16e-3)" "unprognostic (6.17e-3)" "unprognostic (1.18e-1)" "unprognostic (1.08e-1)" "unprognostic (2.66e-1)" "unprognostic (2.96e-1)" "prognostic unfavourable (4.40e-5)" "unprognostic (1.32e-1)" "unprognostic (2.43e-2)" "unprognostic (2.30e-2)" "unprognostic (1.87e-2)" 326.0 111.3 147.1 113.6 130.9 179.8 321.8 25.8 101.3 105.7 107.5 134.7 58.2 120.5 54.9 85.4 85.0 71.3 214.6 140.8 111.7 88.2 295.2 526.9 391.6 444.6 139.4 49.6 126.8 108.0 27.0 63.6 166.3 89.0 108.0 92.3 114.4 59.4 75.4 75.6 48.3 159.4 149.2 194.5 317.9 105.2 53.9 74.5 45.1 130.0 57.5 67.5 159.8 172.1 147.8 231.2 1149.4 890.5 41.5 86.1 674.1 18.5 282.8 21.2 32.4 367.1 381.0 38.0 48.2 283.8 69.5 156.5 61.9 75.4 14.1 92.8 287.8 11.1 17.4 28.5 62.8 190.6 11.2 37.5 73.8 404.9 570.4 88.0 126.2 477.2 38.7 118.2 52.1 100.6 69.3 29.6 137.1 4.5 24.3 51.4 38.5 28.9 20.3 14.4 145.7 44.1 11.8 27.2 15.8 126.6 6.9 26.3 4.0 184.1 75.2 76.1 40.0 97.6 65.9 128.1 282.4 13.2 80.7 92.8 133.0 488.0 642.5 675.8 63.9 890.5 72.6 147.8 71.3 68.3 231.2 132.2 86.1 74.8 1149.4 41.5 768.3 97.2 83.8 674.1 147.1 130.9 25.8 101.3 111.7 88.2 139.4 49.6 89.0 74.5 FXYD2 "ATP1G1, HOMG2, MGC12372" ENSG00000137731 "FXYD domain containing ion transport regulator 2" P54710 11 117800844-117828698 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" "Disease mutation, FDA approved drug targets, Primary hypomagnesemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "kidney: 258.1;pancreas: 68.9;salivary gland: 91.7" "Group enriched" "Detected in some" 29 "MOLT-4: 137.7;RPTEC TERT1: 315.9" "Cancer enriched" "Detected in some" 8 "renal cancer: 49.9" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "memory CD8 T-cell: 14.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Region enriched" "Detected in single" 9 "midbrain: 2.6" "HPA064218, HPA068838" Supported Approved Mitochondria 26000 Mitochondria "HPA064218: , HPA068838: " "unprognostic (4.11e-4)" "unprognostic (1.14e-2)" "unprognostic (1.63e-1)" "unprognostic (1.36e-3)" "unprognostic (1.09e-3)" "unprognostic (2.30e-2)" "unprognostic (3.65e-2)" "unprognostic (4.62e-1)" "unprognostic (4.01e-2)" "unprognostic (4.91e-2)" "unprognostic (1.24e-2)" "unprognostic (2.64e-1)" "prognostic favourable (3.23e-9)" "unprognostic (3.22e-3)" "unprognostic (4.38e-2)" "unprognostic (4.62e-1)" "unprognostic (3.00e-2)" 0.3 0.2 0.2 0.2 0.1 0.0 0.7 0.2 0.2 0.2 0.2 0.1 0.0 0.0 0.3 2.8 0.3 0.3 54.7 0.2 0.1 0.2 258.1 2.2 0.2 0.6 0.1 0.0 0.4 68.9 0.0 0.3 0.6 0.1 0.3 0.0 0.1 91.7 0.1 0.1 0.2 0.3 0.1 0.1 0.4 0.2 0.2 0.0 9.5 0.2 0.3 0.4 0.2 0.6 0.4 3.2 0.0 1.1 8.4 14.1 2.0 0.0 7.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 137.7 0.0 0.0 0.0 0.0 0.0 0.2 315.9 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 1.0 0.0 1.1 0.2 1.8 14.1 0.2 0.4 5.1 4.1 0.0 8.4 0.0 3.2 1.6 2.0 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.0 0.1 0.0 GAA ENSG00000171298 "Glucosidase alpha, acid" P10253 17 80101556-80119879 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Glycosidase, Hydrolase" "Disease mutation, FDA approved drug targets, Glycogen storage disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 23.8;eosinophil: 8.4;intermediate monocyte: 20.0;myeloid DC: 15.6;neutrophil: 10.8;non-classical monocyte: 24.7" "Group enriched" "Detected in all" 9 "dendritic cells: 15.6;granulocytes: 10.8;monocytes: 24.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026970, HPA029126" Enhanced 3000000 "HPA026970: AB_2672065, HPA029126: AB_2672918" "unprognostic (1.13e-1)" "unprognostic (1.11e-1)" "prognostic unfavourable (7.66e-4)" "unprognostic (2.94e-2)" "unprognostic (1.14e-2)" "unprognostic (7.96e-2)" "unprognostic (2.05e-2)" "unprognostic (1.19e-1)" "unprognostic (2.90e-1)" "unprognostic (1.43e-1)" "unprognostic (1.29e-2)" "unprognostic (2.76e-1)" "unprognostic (1.46e-1)" "unprognostic (7.02e-2)" "unprognostic (2.38e-1)" "unprognostic (1.78e-2)" "unprognostic (1.18e-1)" 27.5 19.6 13.8 17.0 14.8 11.3 18.6 14.3 23.0 14.9 16.5 23.4 21.7 19.4 20.1 50.9 13.9 18.2 23.5 21.4 13.5 17.6 27.9 44.2 34.0 30.2 18.1 16.1 14.6 29.4 28.8 24.7 84.1 14.9 22.3 7.2 21.9 27.5 22.1 26.3 18.3 15.4 17.2 16.6 35.8 17.4 30.7 14.6 13.9 21.9 14.9 13.5 24.0 13.4 1.4 15.6 10.8 24.7 1.1 1.8 9.8 11.3 22.1 4.4 14.3 13.7 13.8 28.5 7.1 13.1 5.4 4.4 6.5 18.5 4.1 18.9 5.6 4.8 1.3 8.2 1.3 5.2 16.5 0.0 3.7 23.4 23.9 0.5 13.5 29.6 11.8 10.2 3.5 9.6 4.0 17.1 4.0 26.1 1.8 2.6 9.0 15.5 9.8 15.0 6.9 4.4 11.9 5.0 14.5 9.3 10.4 12.7 29.6 16.2 6.1 20.1 10.8 14.5 2.6 40.8 11.3 1.2 6.4 10.5 12.6 0.1 23.8 8.4 1.5 20.0 1.8 1.3 1.2 1.6 15.6 1.4 1.4 0.9 10.8 1.1 24.7 3.8 0.8 9.8 13.8 14.8 14.3 23.0 13.5 17.6 18.1 16.1 14.9 14.6 GABBR1 "GPRC3A, hGB1a" ENSG00000204681 "Gamma-aminobutyric acid type B receptor subunit 1" Q9UBS5 6 29555629-29633976 "FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 53.8" "Cell line enhanced" "Detected in many" "AN3-CA: 8.0;HEL: 7.7;U-2 OS: 8.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive B-cell: 1.8;plasmacytoid DC: 1.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA050483, HPA058459" Uncertain Approved Centrosome "Intracellular and membrane" Centrosome "HPA050483: , HPA058459: " "unprognostic (1.01e-1)" "unprognostic (2.07e-3)" "unprognostic (3.22e-3)" "unprognostic (2.93e-3)" "unprognostic (3.37e-1)" "unprognostic (2.65e-1)" "unprognostic (7.95e-4)" "unprognostic (5.44e-2)" "unprognostic (4.24e-2)" "unprognostic (1.14e-1)" "prognostic favourable (2.54e-5)" "unprognostic (1.23e-3)" "prognostic unfavourable (3.77e-10)" "unprognostic (3.82e-2)" "unprognostic (2.26e-1)" "unprognostic (3.87e-2)" "unprognostic (2.55e-2)" 14.0 7.4 33.6 7.0 47.2 8.2 4.2 29.1 53.8 6.9 5.6 17.3 3.0 2.3 18.1 1.9 2.9 7.9 4.1 4.6 24.8 21.4 2.9 2.0 6.9 6.6 15.6 33.7 7.8 5.1 1.8 5.8 5.0 22.3 12.8 3.2 4.4 13.0 13.3 8.5 18.3 6.1 5.5 14.9 24.2 6.1 4.3 15.4 0.0 3.9 0.1 5.2 4.0 5.9 1.8 1.7 0.0 0.5 0.0 0.4 0.3 2.9 0.0 1.9 8.0 0.9 2.1 2.1 2.0 0.8 1.8 0.5 2.3 0.1 1.4 2.0 0.0 2.4 0.9 0.0 0.0 7.2 3.4 7.7 3.4 0.0 1.2 0.3 4.0 0.0 0.0 1.6 0.0 1.0 6.6 0.0 0.3 1.9 0.7 0.1 0.6 1.1 3.5 0.7 0.1 0.3 0.0 0.5 1.3 0.5 0.0 3.3 1.5 1.1 4.5 3.2 8.3 0.3 3.7 7.0 0.7 0.0 1.8 3.5 0.9 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.4 0.3 1.8 0.0 0.0 0.0 0.0 0.5 1.7 0.0 0.3 33.6 47.2 29.1 53.8 24.8 21.4 15.6 33.7 22.3 15.4 GABBR2 "GABABR2, GPR51, GPRC3B, HG20" ENSG00000136928 "Gamma-aminobutyric acid type B receptor subunit 2" O75899 9 98288082-98709197 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "brain: 52.7" "Cell line enhanced" "Detected in some" "BJ: 10.9;fHDF/TERT166: 5.4;HUVEC TERT2: 22.5;U-138 MG: 8.8" "Group enriched" "Detected in many" 10 "glioma: 7.2;thyroid cancer: 11.6;urothelial cancer: 3.9" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013820, HPA031684, CAB079065" Enhanced Approved "CAB079065: , HPA013820: AB_1849364, HPA031684: " "unprognostic (2.00e-1)" "unprognostic (7.56e-2)" "unprognostic (3.75e-1)" "unprognostic (3.09e-5)" "unprognostic (2.52e-1)" "unprognostic (1.16e-1)" "unprognostic (2.81e-2)" "unprognostic (1.42e-1)" "unprognostic (2.66e-1)" "unprognostic (4.43e-2)" "unprognostic (1.43e-2)" "unprognostic (2.06e-1)" "unprognostic (1.76e-2)" "unprognostic (3.52e-2)" "unprognostic (1.91e-1)" "unprognostic (2.68e-2)" "unprognostic (3.45e-2)" 0.9 4.4 13.6 1.0 14.6 0.8 0.9 19.7 52.7 0.8 0.9 2.1 0.0 0.8 1.1 1.1 0.9 0.8 0.9 0.9 14.6 11.1 0.9 0.9 1.0 0.9 7.6 17.6 0.8 0.8 0.9 0.3 0.9 10.3 0.9 0.8 0.6 0.9 0.9 3.2 0.9 0.8 1.0 2.2 0.9 1.0 1.3 0.2 0.0 2.3 0.0 1.1 1.5 0.1 0.7 0.7 1.7 1.1 1.7 1.0 0.4 0.0 0.0 0.0 0.0 0.1 0.1 1.0 10.9 2.2 2.3 4.2 0.0 0.1 0.0 0.7 5.4 0.0 0.1 0.2 0.8 0.0 0.4 0.0 0.0 0.0 1.0 0.0 0.0 0.3 0.0 0.8 0.2 22.5 0.2 0.1 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.1 0.6 3.1 0.0 0.0 2.8 0.0 0.0 0.1 1.0 8.8 0.6 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 1.7 0.4 0.8 0.6 0.7 1.0 0.7 0.7 0.7 0.4 0.6 0.8 0.9 1.2 1.7 1.1 0.7 1.0 0.4 13.6 14.6 19.7 35.0 14.6 11.1 7.6 17.6 10.3 0.2 GABRA1 EJM5 ENSG00000022355 "Gamma-aminobutyric acid type A receptor alpha1 subunit" P14867 5 161847063-161899981 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 22 "brain: 58.6" "Cell line enhanced" "Detected in some" "HEL: 3.6;SCLC-21H: 1.1;U-2 OS: 1.5;U-87 MG: 2.3;WM-115: 1.2" "Cancer enriched" "Detected in single" 5 "glioma: 1.1" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022502, HPA055746" Enhanced Supported "CAB022502: , HPA055746: " "unprognostic (2.58e-2)" "unprognostic (4.78e-3)" "unprognostic (1.84e-1)" "unprognostic (3.31e-1)" "unprognostic (2.43e-1)" 1.0 2.6 8.5 1.0 21.9 1.0 1.0 35.2 58.6 1.0 1.0 1.8 0.0 1.1 1.0 1.0 1.0 1.0 1.0 1.0 10.5 8.8 1.0 1.0 1.0 1.0 6.7 22.0 1.0 1.0 1.0 0.1 1.0 7.4 1.2 1.0 0.2 1.0 1.1 1.0 1.0 1.0 1.0 1.3 1.1 1.5 1.1 0.0 0.0 1.0 0.0 1.3 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 3.6 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.1 0.0 0.0 2.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.5 21.9 35.2 49.8 10.5 8.8 6.7 22.0 7.4 0.0 GABRA2 ENSG00000151834 "Gamma-aminobutyric acid type A receptor alpha2 subunit" P47869 4 46248427-46475230 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 52.6" "Cell line enhanced" "Detected in some" "U-2 OS: 9.4;U-87 MG: 4.4;WM-115: 5.0" "Cancer enhanced" "Detected in some" "glioma: 0.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 1.0" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB079061 Supported "Intracellular and membrane" "CAB079061: " "unprognostic (2.03e-2)" "unprognostic (2.77e-1)" "unprognostic (2.45e-4)" "unprognostic (6.87e-3)" "unprognostic (2.65e-1)" "unprognostic (2.08e-1)" "unprognostic (1.01e-1)" "unprognostic (4.09e-1)" "unprognostic (6.90e-3)" "unprognostic (8.83e-2)" "unprognostic (2.22e-5)" "unprognostic (1.75e-1)" "unprognostic (1.15e-1)" "unprognostic (2.67e-1)" "unprognostic (3.04e-2)" 2.2 1.3 38.5 1.4 34.4 1.2 1.9 10.4 52.6 1.7 4.5 4.9 0.0 2.0 1.4 11.7 1.7 1.0 1.6 1.0 38.9 7.7 8.8 1.4 1.0 1.4 3.7 31.0 1.9 1.0 0.9 0.6 1.5 10.5 1.0 3.5 0.0 1.2 1.9 1.0 1.3 7.7 1.3 6.9 2.3 1.6 1.5 7.1 0.0 1.1 0.0 1.4 1.2 0.8 0.2 0.3 1.0 0.1 0.1 0.1 0.0 0.5 0.5 0.1 0.6 0.0 0.0 0.5 0.3 0.0 0.0 0.0 2.1 0.6 0.2 0.5 0.0 0.8 0.0 0.0 0.1 0.5 0.5 0.1 0.7 0.2 0.8 0.1 0.2 0.0 0.0 0.2 0.2 0.0 0.8 0.2 0.0 0.4 0.0 0.3 0.9 0.1 0.0 0.6 0.4 0.1 0.6 0.2 0.0 0.1 0.3 0.0 0.3 0.4 0.1 0.5 9.4 0.5 0.1 0.7 1.2 0.2 4.4 0.4 5.0 1.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.9 0.1 0.1 0.3 0.0 0.0 38.5 34.4 10.4 31.4 38.9 7.7 3.7 31.0 10.5 7.1 GABRA3 ENSG00000011677 "Gamma-aminobutyric acid type A receptor alpha3 subunit" P34903 X 152166234-152451358 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 30.1" "Cell line enhanced" "Detected in some" "HMC-1: 7.8;Karpas-707: 13.2;PC-3: 7.6;U-2 OS: 6.5;U-266/70: 7.1;U-266/84: 11.7;U-87 MG: 7.7" "Cancer enriched" "Detected in many" 7 "testis cancer: 16.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 1.5" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA000839 Approved Supported "HPA000839: AB_1078929" "unprognostic (9.63e-3)" "unprognostic (2.04e-1)" "unprognostic (2.02e-1)" "unprognostic (1.18e-2)" "unprognostic (7.07e-2)" "unprognostic (5.42e-2)" "unprognostic (2.34e-6)" "unprognostic (1.24e-1)" "unprognostic (2.70e-1)" "unprognostic (2.39e-2)" "unprognostic (2.63e-2)" "unprognostic (1.73e-1)" "unprognostic (7.29e-6)" "unprognostic (7.42e-3)" "unprognostic (6.20e-2)" "unprognostic (8.13e-2)" 0.7 0.7 7.7 0.6 15.2 0.7 0.7 1.3 30.1 2.2 0.8 3.3 0.0 0.8 1.2 0.8 1.3 0.7 0.7 0.7 10.9 15.9 0.7 0.7 0.7 0.7 4.7 10.5 0.6 0.7 0.6 0.9 5.2 6.2 0.8 0.8 0.4 0.7 1.8 0.8 1.1 0.9 0.8 2.1 0.7 0.7 1.8 1.1 0.0 0.7 0.0 0.9 1.8 0.4 0.0 0.1 1.5 0.3 0.3 0.2 0.0 0.0 0.8 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.0 0.0 0.0 0.0 7.8 0.0 0.0 0.0 0.0 0.0 1.3 13.2 0.0 0.0 0.0 0.0 2.4 7.6 0.0 0.0 0.0 0.0 0.0 0.2 4.8 0.0 4.9 0.4 0.1 1.2 0.0 5.0 6.5 0.3 1.4 7.1 11.7 0.0 7.7 0.0 4.9 1.5 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.3 0.3 0.1 0.2 0.0 7.7 15.2 1.3 28.4 10.9 15.9 4.7 10.5 6.2 1.1 GABRA5 ENSG00000186297 "Gamma-aminobutyric acid type A receptor alpha5 subunit" P31644 15 26866363-26949207 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 21 "brain: 52.6" "Group enriched" "Detected in some" 12 "A549: 25.8;HAP1: 8.9;NTERA-2: 10.7;U-2 OS: 9.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA077031, CAB079022" Supported Supported "Plasma membrane" "Plasma membrane" "CAB079022: , HPA077031: " "unprognostic (6.33e-2)" "unprognostic (8.94e-3)" "unprognostic (1.04e-1)" "unprognostic (2.50e-1)" "unprognostic (1.81e-1)" "unprognostic (3.75e-1)" "unprognostic (9.50e-3)" "unprognostic (2.57e-1)" "unprognostic (7.63e-2)" "unprognostic (8.50e-2)" "unprognostic (1.44e-2)" 0.8 0.8 12.0 0.8 48.2 0.8 0.8 0.1 52.6 0.8 0.8 0.8 0.0 0.8 0.8 0.7 2.5 0.8 1.5 0.9 20.9 6.0 0.9 0.8 0.8 0.8 2.3 15.2 0.7 0.7 0.7 0.1 0.8 1.0 1.0 0.7 0.0 0.7 0.9 0.7 0.8 0.7 1.4 0.3 0.8 1.1 1.4 2.0 1.3 0.9 0.0 1.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.8 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 8.9 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 10.7 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 9.3 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.0 48.2 0.1 26.0 20.9 6.0 2.3 15.2 1.0 2.0 GABRA6 ENSG00000145863 "Gamma-aminobutyric acid type A receptor alpha6 subunit" Q16445 5 161547063-161702593 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 23 "brain: 96.4" "Group enriched" "Detected in some" 9 "AF22: 1.0;PC-3: 1.4;TIME: 1.0;U-266/70: 2.4" "Not detected" "Not detected" "Region enriched" "Detected in some" 36 "cerebellum: 96.4" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 40 "cerebellum: 1204.9" "Region enriched" "Detected in single" 44 "cerebellum: 189.6" CAB022462 Approved "CAB022462: " "unprognostic (3.79e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 96.4 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 96.4 0.1 0.0 0.0 0.0 0.0 2.6 0.0 GABRB1 ENSG00000163288 "Gamma-aminobutyric acid type A receptor beta1 subunit" P18505 4 46993723-47426444 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 34.5;pituitary gland: 14.7" "Cell line enhanced" "Detected in some" "CACO-2: 2.3;REH: 4.1;SCLC-21H: 1.1;U-87 MG: 6.7" "Cancer enhanced" "Detected in single" "glioma: 0.7" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051297 Uncertain "HPA051297: " "unprognostic (3.11e-2)" "unprognostic (7.56e-3)" "unprognostic (5.10e-2)" "unprognostic (1.83e-1)" "unprognostic (1.11e-1)" "unprognostic (4.98e-3)" "unprognostic (8.16e-3)" "unprognostic (6.22e-2)" "unprognostic (2.72e-2)" "unprognostic (2.34e-1)" 1.0 1.3 19.9 1.0 34.5 0.9 1.0 14.7 27.9 1.0 1.2 2.7 0.0 1.6 1.2 1.0 1.0 1.2 1.2 6.0 16.3 4.2 1.8 1.1 1.1 0.9 2.8 18.5 1.1 0.9 0.9 14.7 1.3 5.6 1.0 1.2 0.0 0.9 0.9 0.9 0.9 1.3 1.0 3.4 1.0 1.0 1.1 6.7 0.0 1.3 0.0 0.9 0.9 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.6 0.0 0.0 0.0 6.7 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.9 34.5 14.7 16.6 16.3 4.2 2.8 18.5 5.6 6.7 GABRB2 ENSG00000145864 "Gamma-aminobutyric acid type A receptor beta2 subunit" P47870 5 161288429-161549044 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 48.7" "Cell line enriched" "Detected in some" 10 "SCLC-21H: 22.8" "Cancer enriched" "Detected in some" 20 "thyroid cancer: 10.2" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001964, HPA067632" Enhanced "CAB001964: , HPA067632: " "unprognostic (5.46e-2)" "unprognostic (1.03e-1)" "unprognostic (3.29e-1)" "unprognostic (2.26e-6)" "unprognostic (2.33e-2)" "unprognostic (6.65e-2)" "unprognostic (3.58e-2)" "unprognostic (1.82e-1)" "unprognostic (1.01e-2)" "unprognostic (1.22e-1)" "unprognostic (5.19e-3)" "unprognostic (2.24e-4)" "unprognostic (1.22e-1)" "unprognostic (1.33e-2)" "unprognostic (1.58e-1)" "unprognostic (7.18e-3)" "unprognostic (1.04e-2)" 1.2 3.6 7.7 0.8 19.2 0.7 0.9 48.7 45.4 1.3 1.5 0.9 0.0 2.0 0.9 5.8 0.8 1.2 0.8 0.9 8.1 4.6 2.8 0.7 1.8 0.8 3.7 16.3 0.9 0.9 0.8 0.5 1.0 4.3 0.9 2.2 0.1 1.3 1.5 0.8 0.8 1.4 0.9 1.1 3.4 1.2 1.5 1.8 0.0 1.3 0.0 0.8 0.8 0.3 0.4 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 22.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.2 0.1 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 7.7 19.2 48.7 34.1 8.1 4.6 3.7 16.3 4.3 1.8 GABRD ENSG00000187730 "Gamma-aminobutyric acid type A receptor delta subunit" O14764 1 2019298-2030758 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 25 "brain: 87.0" "Cell line enhanced" "Detected in some" "EFO-21: 2.8;HMC-1: 2.5;MCF7: 8.2;NB-4: 5.2;SH-SY5Y: 3.1" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 87.0" "Cell type enriched" "Detected in single" 5 "plasmacytoid DC: 1.2" "Lineage enriched" "Detected in single" 5 "dendritic cells: 1.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA044371 Enhanced Uncertain "Golgi apparatus,Vesicles" "Golgi apparatus, Vesicles" "HPA044371: " "unprognostic (4.28e-2)" "unprognostic (1.90e-1)" "unprognostic (5.95e-8)" "unprognostic (6.34e-3)" "unprognostic (2.66e-3)" "unprognostic (1.04e-2)" "unprognostic (3.44e-3)" "unprognostic (2.14e-1)" "unprognostic (4.53e-2)" "unprognostic (1.12e-1)" "unprognostic (3.77e-2)" "unprognostic (1.99e-1)" "prognostic unfavourable (4.12e-8)" "unprognostic (1.72e-1)" "unprognostic (1.76e-1)" "unprognostic (2.77e-1)" "unprognostic (5.16e-2)" 1.2 3.4 8.8 0.9 16.8 1.0 1.0 87.0 40.0 1.0 1.2 1.7 0.0 0.9 1.3 1.2 1.3 1.0 1.5 1.7 6.0 1.7 1.1 0.9 1.4 1.3 3.3 11.1 0.9 0.9 1.4 0.7 1.2 17.1 1.0 1.0 0.0 1.1 0.9 1.3 1.4 1.0 1.4 1.4 1.0 1.0 3.3 1.5 0.0 1.6 0.0 1.0 1.2 0.1 0.0 1.2 0.2 0.1 0.0 0.0 0.8 0.0 0.7 0.0 1.7 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.8 0.0 0.0 1.4 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.2 0.0 5.2 2.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 3.1 0.1 0.0 0.0 1.1 1.1 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.2 0.0 0.8 8.8 16.8 87.0 40.0 6.0 1.7 3.3 11.1 17.1 1.5 GABRE ENSG00000102287 "Gamma-aminobutyric acid type A receptor epsilon subunit" P78334 X 151953124-151974680 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "placenta: 36.4;vagina: 27.7" "Cell line enhanced" "Detected in some" "ASC diff: 4.3;EFO-21: 14.6;HeLa: 6.5;SiHa: 6.9" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 5 "hypothalamus: 21.8" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA045918 Uncertain "HPA045918: AB_10961281" "unprognostic (1.33e-2)" "unprognostic (6.75e-2)" "unprognostic (3.50e-3)" "unprognostic (1.39e-3)" "unprognostic (2.43e-1)" "unprognostic (7.52e-2)" "unprognostic (5.06e-3)" "unprognostic (1.27e-1)" "unprognostic (3.58e-2)" "unprognostic (1.55e-1)" "unprognostic (6.44e-2)" "unprognostic (6.73e-2)" "prognostic unfavourable (4.05e-11)" "unprognostic (1.96e-2)" "unprognostic (1.39e-1)" "unprognostic (2.29e-2)" "unprognostic (5.28e-2)" 14.8 1.0 1.5 2.2 2.8 0.3 16.5 1.0 1.6 8.9 5.8 0.0 2.2 1.4 6.0 4.1 5.0 1.5 4.2 16.3 1.0 21.8 1.1 0.9 2.3 0.7 1.1 0.6 1.6 2.5 0.4 4.1 36.4 4.5 5.9 0.8 3.8 2.0 6.3 0.9 5.6 10.1 2.5 1.1 0.9 1.0 0.9 0.4 0.0 2.5 5.9 3.5 2.9 27.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 4.3 0.0 0.0 0.6 0.0 1.1 0.5 2.2 0.8 0.0 14.6 3.0 2.3 0.0 0.8 0.7 0.0 0.5 1.6 6.5 0.8 0.2 0.0 0.2 1.0 0.6 1.2 0.3 0.6 0.5 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 6.9 1.0 0.0 0.0 0.0 1.2 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 2.8 1.0 1.3 1.0 21.8 1.1 0.6 4.5 0.4 GABRG1 ENSG00000163285 "Gamma-aminobutyric acid type A receptor gamma1 subunit" Q8N1C3 4 46035769-46124081 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in many" 9 "brain: 35.7" "Cell line enhanced" "Detected in some" "Karpas-707: 1.3;THP-1: 2.6;U-2 OS: 1.8;U-266/70: 5.3" "Cancer enriched" "Detected in single" 8 "glioma: 0.6" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035622 Approved "HPA035622: AB_10603669" "unprognostic (2.50e-1)" "unprognostic (2.20e-1)" "unprognostic (6.06e-2)" "unprognostic (1.46e-2)" "unprognostic (7.39e-4)" "unprognostic (1.23e-1)" "unprognostic (1.28e-1)" "unprognostic (1.99e-1)" 1.5 1.5 20.3 1.2 25.9 1.2 1.3 26.4 35.7 1.3 1.3 12.2 0.0 1.4 1.4 1.3 1.3 1.7 1.3 1.2 26.0 14.6 1.4 1.4 1.2 1.3 10.2 14.0 3.9 1.2 1.3 1.6 1.2 17.9 1.2 1.3 0.0 1.2 1.3 1.2 1.2 1.4 1.4 17.8 1.4 1.3 1.8 17.8 0.0 1.5 0.0 1.2 1.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 2.6 0.0 0.3 1.8 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.3 25.9 26.4 18.5 26.0 14.6 10.2 14.0 17.9 17.8 GABRG2 ENSG00000113327 "Gamma-aminobutyric acid type A receptor gamma2 subunit" P18507 5 162000057-162162977 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 47.1" "Cell line enhanced" "Detected in many" "CACO-2: 10.7;Karpas-707: 8.5;RPMI-8226: 10.3;U-266/70: 17.9;U-266/84: 14.1" "Cancer enhanced" "Detected in single" "glioma: 1.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 7.3" "Group enriched" "Detected in many" 5 "B-cells: 2.9;granulocytes: 7.3;T-cells: 3.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB079060 Supported "CAB079060: " "unprognostic (2.88e-2)" "unprognostic (1.56e-2)" "unprognostic (6.31e-3)" "unprognostic (3.07e-3)" "unprognostic (1.52e-1)" 1.1 5.7 9.7 1.2 28.8 3.3 0.9 21.7 47.1 0.7 1.5 1.1 0.0 2.2 1.2 1.3 1.3 1.3 3.8 1.6 10.6 19.6 1.0 1.2 1.9 1.2 7.5 19.1 1.5 1.0 0.8 5.3 2.9 17.6 1.0 1.3 0.6 1.3 0.8 1.2 3.3 1.9 1.6 2.6 1.2 3.3 1.7 1.8 0.0 1.8 0.0 1.3 1.5 0.3 2.9 0.7 7.3 0.3 0.9 3.2 0.2 3.6 1.7 2.0 0.3 0.0 0.0 2.1 0.6 0.0 0.0 0.0 10.7 4.7 0.7 5.3 0.0 1.6 1.2 0.0 0.0 0.8 1.1 0.0 2.1 1.3 0.0 0.2 0.5 0.3 0.0 0.0 0.0 0.0 1.8 8.5 0.0 2.5 0.4 0.1 6.1 2.9 0.4 0.1 10.3 0.0 3.4 0.9 0.8 0.3 0.6 3.4 5.7 5.7 0.2 0.3 4.5 0.3 0.5 17.9 14.1 0.5 0.2 0.4 0.4 7.3 0.3 0.6 0.4 0.3 2.7 2.9 0.7 0.6 0.0 2.5 3.2 0.7 1.6 0.9 0.2 0.7 0.6 0.2 9.7 28.8 21.7 38.1 10.6 19.6 7.5 19.1 17.6 1.8 GABRG3 ENSG00000182256 "Gamma-aminobutyric acid type A receptor gamma3 subunit" Q99928 15 26971282-27541991 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "brain: 15.3;prostate: 13.5;testis: 16.6" "Cell line enhanced" "Detected in some" "K-562: 4.9;PC-3: 6.3;SK-MEL-30: 4.1;U-2 OS: 2.9;U-266/70: 3.8;U-87 MG: 16.8" "Cancer enhanced" "Detected in single" "prostate cancer: 1.5" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA054010 Supported "HPA054010: " "unprognostic (1.23e-1)" "unprognostic (1.67e-1)" "unprognostic (1.02e-2)" "unprognostic (3.50e-2)" "unprognostic (2.61e-1)" "unprognostic (2.33e-3)" "unprognostic (1.30e-1)" "unprognostic (2.39e-2)" "unprognostic (5.15e-2)" "unprognostic (2.95e-1)" "unprognostic (4.41e-1)" "unprognostic (1.43e-5)" "unprognostic (1.52e-1)" "unprognostic (1.32e-1)" "unprognostic (2.03e-2)" "unprognostic (1.83e-1)" 0.5 1.3 2.2 0.8 10.4 0.5 1.2 3.1 15.3 2.2 0.5 0.8 0.0 0.4 0.7 4.4 0.5 1.3 0.5 0.4 3.0 5.8 1.0 0.6 0.5 1.5 1.0 7.8 0.5 0.4 0.4 6.4 0.5 2.7 13.5 0.5 4.0 1.5 3.4 0.5 0.9 0.4 0.6 0.8 2.3 0.4 16.6 0.5 0.3 3.3 0.0 1.9 0.4 0.7 0.8 0.3 0.9 0.4 0.3 0.3 0.0 0.0 0.1 1.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.4 0.4 6.3 0.0 0.0 1.1 0.0 0.0 0.1 1.1 0.0 0.0 4.1 0.0 0.0 0.0 0.0 2.9 0.0 0.0 3.8 0.0 0.0 16.8 0.1 0.0 0.4 0.4 0.1 0.1 0.1 0.2 0.3 0.1 0.1 0.0 0.8 0.3 0.1 0.9 0.3 0.1 0.3 0.1 0.0 2.2 10.4 3.1 15.3 3.0 5.8 1.0 7.8 2.7 0.5 GABRP ENSG00000094755 "Gamma-aminobutyric acid type A receptor pi subunit" O00591 5 170763350-170814047 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 37.0;lymphoid tissue: 57.7" "Cell line enhanced" "Detected in many" "A-431: 44.6;EFO-21: 52.2;HeLa: 31.3;PC-3: 71.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "basophil: 10.1" "Group enriched" "Detected in many" 6 "granulocytes: 10.1;monocytes: 6.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB014883 Uncertain "CAB014883: " "unprognostic (3.98e-3)" "prognostic favourable (3.37e-4)" "unprognostic (8.34e-2)" "unprognostic (1.57e-1)" "unprognostic (8.90e-2)" "unprognostic (1.27e-1)" "unprognostic (7.89e-2)" "unprognostic (4.97e-3)" "unprognostic (3.72e-1)" "unprognostic (4.93e-3)" "unprognostic (1.30e-3)" "unprognostic (2.30e-1)" "unprognostic (1.40e-2)" "unprognostic (1.60e-1)" "unprognostic (1.82e-1)" "unprognostic (5.92e-3)" "unprognostic (6.52e-3)" 1.5 0.5 0.5 1.3 0.5 1.1 31.6 0.5 1.1 18.5 1.7 0.6 2.6 2.6 30.4 9.9 37.0 2.2 8.6 1.0 0.5 0.4 6.9 3.8 2.5 0.5 0.5 0.5 1.1 4.3 0.0 2.4 5.5 0.6 6.8 0.4 0.8 25.5 3.2 2.0 10.0 3.9 0.5 0.5 0.8 5.0 1.0 0.5 2.5 0.6 3.1 57.7 1.2 20.0 0.9 1.1 10.1 6.1 0.2 1.3 3.1 44.6 2.0 2.2 1.5 0.1 0.9 5.2 0.8 0.3 0.1 0.1 8.0 5.1 0.7 52.2 0.2 16.2 1.3 0.1 0.1 0.7 1.6 2.9 31.3 1.1 0.1 1.0 2.5 0.3 0.6 0.6 0.4 0.3 12.0 5.7 0.1 1.4 1.9 1.0 18.4 71.4 2.8 1.4 1.7 3.0 2.4 1.8 0.8 16.5 0.8 0.5 0.9 0.5 1.9 4.1 15.2 3.4 3.3 2.2 1.3 1.3 0.5 2.9 0.6 10.1 2.3 6.8 0.5 1.7 1.3 0.3 0.5 0.4 0.7 0.9 0.7 0.6 5.4 0.2 6.1 1.1 0.7 3.1 0.5 0.5 0.5 0.6 0.5 0.4 0.5 0.5 0.6 0.5 GALNT8 GALNAC-T8 ENSG00000130035 "Polypeptide N-acetylgalactosaminyltransferase 8" "Q9NY28, P17658" 12 4720341-4851927 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Glycosyltransferase, Ion channel, Potassium channel, Transferase, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 12.7;intestine: 33.2;testis: 18.5" "Group enriched" "Detected in some" 4 "Karpas-707: 26.3;NTERA-2: 9.3;U-266/84: 7.5" "Cancer enhanced" "Detected in some" "testis cancer: 2.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 3.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "HPA012638, HPA073461" Enhanced Approved "Golgi apparatus,Vesicles" "Intracellular and membrane" "Golgi apparatus, Vesicles" "HPA012638: AB_2294503, HPA073461: " "unprognostic (2.36e-2)" "unprognostic (1.95e-1)" "unprognostic (1.13e-2)" "unprognostic (1.75e-2)" "unprognostic (6.24e-2)" "unprognostic (2.87e-1)" "unprognostic (2.59e-2)" "unprognostic (3.79e-1)" "unprognostic (2.72e-1)" "unprognostic (5.76e-2)" "unprognostic (8.06e-5)" "unprognostic (1.16e-2)" "unprognostic (6.67e-5)" "unprognostic (5.18e-2)" "unprognostic (2.59e-2)" "unprognostic (2.53e-1)" "unprognostic (1.33e-2)" 1.1 2.2 5.3 2.2 6.5 0.5 3.1 1.4 12.7 1.0 15.5 9.4 0.0 7.2 0.9 0.4 0.7 1.2 1.1 3.7 8.0 1.7 1.2 0.8 0.9 1.0 5.7 9.6 1.6 0.9 0.2 3.7 0.5 6.0 1.1 33.2 0.1 1.0 0.9 0.7 0.9 14.7 2.1 3.5 1.2 1.3 18.5 11.5 0.0 0.8 0.5 0.9 1.2 0.9 1.0 0.7 0.1 0.1 0.9 3.0 0.0 0.0 0.0 1.4 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.7 0.0 0.0 0.2 0.8 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 26.3 0.0 0.0 0.2 0.1 9.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.3 7.5 0.7 0.0 0.0 0.0 0.0 0.1 0.0 1.8 0.0 0.4 0.3 0.7 1.2 0.0 1.0 0.0 0.1 0.1 0.9 0.0 0.7 3.0 0.0 5.3 6.5 1.4 12.7 8.0 1.7 5.7 9.6 6.0 11.5 GAMT "PIG2, TP53I2" ENSG00000130005 "Guanidinoacetate N-methyltransferase" Q14353 19 1397026-1401570 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Methyltransferase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 73.0;skeletal muscle: 222.2" "Cell line enhanced" "Detected in many" "Hep G2: 51.2" "Cancer enriched" "Detected in all" 5 "liver cancer: 173.2" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051806 Approved 38000 "HPA051806: " "unprognostic (3.25e-1)" "unprognostic (7.74e-3)" "unprognostic (3.22e-2)" "unprognostic (6.32e-2)" "unprognostic (4.35e-2)" "unprognostic (1.86e-1)" "unprognostic (2.92e-2)" "unprognostic (2.80e-2)" "unprognostic (1.14e-1)" "unprognostic (2.27e-1)" "unprognostic (3.41e-2)" "unprognostic (7.10e-2)" "unprognostic (6.36e-2)" "prognostic unfavourable (6.57e-4)" "unprognostic (1.78e-1)" "unprognostic (1.82e-1)" "unprognostic (1.54e-2)" 5.1 4.6 9.1 1.5 8.7 2.2 3.2 5.1 11.4 2.3 1.4 15.1 5.1 1.3 2.0 31.3 5.3 3.8 2.6 10.8 9.2 7.7 8.0 73.0 1.5 2.0 8.7 5.2 3.8 47.0 5.4 4.9 1.6 5.9 5.6 1.1 4.5 9.1 4.7 222.2 6.0 1.4 2.1 8.8 2.1 3.2 7.7 4.5 5.6 3.3 26.7 2.8 1.9 1.7 15.7 23.0 6.9 2.6 8.0 21.6 7.7 6.2 7.1 7.6 17.2 9.6 11.7 10.4 7.5 12.5 9.7 8.8 16.0 4.5 3.3 5.3 8.9 2.7 12.0 4.6 2.6 23.8 13.7 10.2 5.9 51.2 5.7 0.2 3.5 13.0 1.6 10.3 0.0 2.1 14.5 8.0 15.8 6.4 29.8 3.5 8.6 22.6 29.9 6.8 23.8 11.4 5.8 2.5 17.9 0.5 4.3 9.2 19.8 14.2 3.6 10.7 11.1 0.6 3.4 36.3 7.0 5.6 9.9 13.5 12.2 1.6 1.2 6.9 9.9 1.6 13.9 10.6 13.7 12.2 5.4 15.7 21.6 16.1 0.8 8.0 2.6 23.0 7.5 7.7 9.1 8.7 5.1 11.4 9.2 7.7 8.7 5.2 5.9 4.5 GANAB "G2AN, GIIA, GluII, KIAA0088" ENSG00000089597 "Glucosidase II alpha subunit" Q14697 11 62624826-62646726 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Glycosidase, Hydrolase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026874, HPA061426" Enhanced Approved "Endoplasmic reticulum" "Intracellular and membrane" 37000000 "Endoplasmic reticulum" "HPA026874: AB_1849745, HPA061426: AB_2684516" "unprognostic (2.12e-1)" "unprognostic (5.95e-3)" "unprognostic (4.35e-2)" "unprognostic (2.12e-1)" "unprognostic (1.20e-2)" "unprognostic (3.65e-2)" "prognostic unfavourable (1.27e-5)" "unprognostic (5.80e-3)" "unprognostic (1.09e-1)" "unprognostic (1.79e-1)" "unprognostic (1.68e-3)" "unprognostic (5.91e-2)" "unprognostic (1.01e-3)" "unprognostic (3.81e-2)" "unprognostic (1.82e-2)" "unprognostic (1.39e-1)" "prognostic unfavourable (9.54e-4)" 33.6 34.6 16.2 23.3 20.7 17.9 30.1 19.9 31.0 38.9 31.5 29.8 43.4 26.0 44.0 38.6 29.2 34.2 33.8 32.6 17.2 16.5 35.9 91.5 31.4 30.2 21.7 19.5 49.0 51.4 56.6 27.3 61.1 20.0 29.4 32.6 33.7 43.5 40.7 28.2 24.5 39.8 37.4 19.5 37.4 31.2 27.7 20.2 41.8 45.6 25.2 34.0 36.0 29.4 14.6 17.5 16.5 18.8 22.5 20.0 17.6 42.3 37.2 46.5 84.3 71.9 62.8 50.4 47.8 71.8 66.2 57.2 31.0 78.9 29.0 96.8 84.4 58.0 56.1 53.7 68.7 23.4 24.2 28.7 51.0 12.9 53.0 44.5 36.1 60.9 34.8 65.8 69.2 61.3 40.6 52.5 59.5 37.2 23.1 14.5 39.4 30.2 30.8 55.7 73.0 32.5 34.7 24.6 33.4 68.3 44.4 50.8 58.1 37.9 46.1 66.3 42.4 52.0 44.4 52.7 60.9 22.2 72.8 23.9 64.5 16.5 15.0 14.4 20.0 18.8 20.0 14.6 13.8 15.9 17.5 13.1 17.9 16.3 7.0 22.5 16.4 11.6 13.0 17.6 16.2 20.7 19.9 31.0 17.2 16.5 21.7 19.5 20.0 20.2 GANC ENSG00000214013 "Glucosidase alpha, neutral C" Q8TET4 15 42273233-42356935 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Glycosidase, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA016949 Approved Approved "Nucleoplasm,Actin filaments" "Nucleoplasm, Actin filaments" "HPA016949: AB_1849465" "unprognostic (8.83e-2)" "unprognostic (1.68e-1)" "unprognostic (2.24e-1)" "unprognostic (3.04e-3)" "unprognostic (2.51e-2)" "unprognostic (9.85e-2)" "unprognostic (2.49e-2)" "prognostic favourable (9.76e-4)" "unprognostic (1.73e-1)" "unprognostic (1.43e-1)" "unprognostic (1.66e-2)" "unprognostic (1.46e-1)" "unprognostic (1.14e-1)" "unprognostic (1.05e-2)" "unprognostic (3.14e-1)" "unprognostic (1.55e-2)" "unprognostic (3.74e-2)" 13.3 14.0 12.5 17.3 20.7 17.6 14.4 16.6 14.2 15.8 14.3 25.6 15.4 11.7 17.9 26.0 20.7 12.9 13.0 12.4 13.4 10.4 13.5 18.0 30.5 13.8 25.0 13.7 18.8 13.1 17.4 20.5 10.8 19.8 13.1 17.8 18.3 20.4 13.7 23.9 13.9 15.4 15.9 25.1 15.5 13.1 24.5 22.6 17.4 16.8 12.3 18.3 16.2 16.3 17.6 12.2 9.3 10.1 4.0 7.4 4.7 6.1 3.2 7.9 8.5 9.6 13.5 5.0 13.6 14.7 15.0 12.6 4.7 4.4 3.4 7.4 13.7 12.9 9.4 14.5 10.4 8.4 4.3 8.4 8.5 9.1 8.1 8.1 7.3 9.1 8.7 6.1 10.4 10.1 8.7 9.5 11.8 1.3 5.4 9.0 4.8 4.1 10.5 9.2 11.7 11.3 5.8 5.9 8.4 7.6 6.7 4.8 2.5 19.3 9.2 15.8 4.2 13.0 8.1 10.3 13.6 6.9 7.4 15.0 8.7 9.3 9.3 7.4 3.7 10.1 5.0 16.2 5.7 6.9 12.2 17.6 7.4 4.4 5.0 4.0 8.1 9.6 5.5 4.7 12.5 20.7 16.6 14.2 13.4 10.4 25.0 13.7 19.8 22.6 GAPDH GAPD ENSG00000111640 "Glyceraldehyde-3-phosphate dehydrogenase" P04406 12 6533927-6538374 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Glycolysis, Translation regulation" "Oxidoreductase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "skeletal muscle: 1236.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB005197, CAB016392, HPA040067, HPA061280" Supported Supported "Nuclear membrane,Vesicles,Plasma membrane,Cytosol" 2200000000 "Plasma membrane, Cytosol" "Nuclear membrane, Vesicles" "CAB005197: AB_641107, CAB016392: AB_627678, HPA040067: AB_10965903, HPA061280: AB_2684463" "unprognostic (3.03e-1)" "unprognostic (2.62e-3)" "unprognostic (3.58e-2)" "unprognostic (4.20e-1)" "unprognostic (9.73e-3)" "unprognostic (1.77e-3)" "prognostic unfavourable (1.79e-6)" "unprognostic (2.89e-3)" "unprognostic (2.86e-1)" "unprognostic (2.06e-2)" "unprognostic (9.50e-3)" "unprognostic (4.52e-1)" "prognostic unfavourable (6.25e-10)" "unprognostic (2.33e-1)" "unprognostic (4.28e-1)" "unprognostic (1.40e-1)" "unprognostic (1.26e-2)" 50.0 59.4 104.1 57.6 101.0 195.5 38.4 58.0 151.3 49.4 73.3 80.7 24.0 75.8 37.3 46.8 146.9 50.2 58.0 215.1 95.0 95.5 88.4 221.0 41.3 90.1 111.8 58.0 62.0 27.0 66.1 46.1 98.2 115.9 48.3 76.7 74.5 60.8 63.2 1236.8 54.4 74.4 68.0 95.6 50.7 41.1 36.4 35.9 101.9 38.3 238.7 105.3 89.5 50.5 57.9 171.0 110.0 201.6 60.5 108.8 271.9 196.0 345.9 99.8 155.5 97.4 160.6 217.5 149.0 212.2 218.1 227.7 244.1 134.6 229.2 29.5 175.6 111.7 92.7 345.6 151.4 201.0 100.7 126.8 217.1 207.3 131.3 204.9 102.1 134.3 112.9 214.3 242.1 240.0 68.1 48.3 247.7 391.1 233.5 107.9 368.8 115.3 189.9 177.7 109.1 248.1 239.9 70.7 113.5 131.5 343.1 197.9 53.6 144.8 149.7 170.2 205.7 87.8 257.4 109.8 79.8 295.4 360.8 129.9 266.3 110.0 201.6 37.0 74.1 103.2 65.3 57.9 77.9 74.4 171.0 32.2 44.1 51.2 106.5 60.5 92.3 25.2 108.8 271.9 104.1 101.0 58.0 151.3 95.0 95.5 111.8 58.0 115.9 35.9 GART "GARS-AIRS-GART, PGFT, PRGS" ENSG00000159131 "Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase" P22102 21 33503931-33543491 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Purine biosynthesis" "Ligase, Multifunctional enzyme, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002119, HPA005779" Approved Uncertain Nucleoplasm,Mitochondria,Cytosol 1300000 "Nucleoplasm, Mitochondria, Cytosol" "HPA002119: AB_1849482, HPA005779: AB_1849484" "unprognostic (3.77e-2)" "unprognostic (2.25e-2)" "unprognostic (4.51e-3)" "unprognostic (1.72e-2)" "unprognostic (2.30e-2)" "prognostic unfavourable (5.05e-5)" "prognostic unfavourable (9.82e-5)" "unprognostic (2.50e-2)" "unprognostic (2.76e-3)" "unprognostic (2.92e-1)" "prognostic unfavourable (2.19e-4)" "unprognostic (1.98e-3)" "prognostic unfavourable (3.95e-6)" "unprognostic (1.36e-2)" "unprognostic (2.31e-1)" "unprognostic (2.28e-1)" "unprognostic (1.57e-1)" 24.9 24.7 16.0 20.0 22.3 14.2 22.2 14.5 20.3 16.2 20.1 20.5 13.3 18.9 21.7 15.9 28.1 19.9 14.3 19.3 16.4 14.9 19.2 33.6 18.3 24.4 21.9 14.6 21.0 30.6 21.6 22.9 23.1 21.0 16.4 26.9 19.5 18.6 16.1 33.2 17.6 19.1 23.5 17.9 21.4 21.9 47.0 21.7 40.8 20.0 19.4 32.8 21.6 17.6 18.7 19.5 9.7 20.9 27.1 21.1 13.3 30.0 14.3 21.2 23.5 15.6 16.1 23.8 19.5 16.5 22.8 24.2 27.1 25.6 40.0 11.6 13.0 15.9 44.4 30.6 33.3 21.0 26.4 60.3 17.1 17.7 21.3 33.5 15.9 14.2 21.4 26.9 39.6 21.5 70.1 25.7 20.6 14.4 35.3 22.5 46.2 16.9 29.5 39.5 56.6 18.3 16.1 22.6 20.3 27.0 21.3 25.2 27.0 21.5 15.8 15.5 18.6 13.4 20.8 25.6 35.4 43.7 16.3 39.5 22.9 5.3 15.2 9.7 17.3 20.9 21.1 18.7 16.9 17.9 19.5 14.4 17.7 17.4 7.0 27.1 17.7 14.7 20.6 13.3 16.0 22.3 14.5 20.3 16.4 14.9 21.9 14.6 21.0 21.7 GGCX VKCFD1 ENSG00000115486 "Gamma-glutamyl carboxylase" P38435 2 85544723-85561547 "Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins" Lyase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "liver: 74.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA018284 Approved "HPA018284: AB_1849641" "unprognostic (4.88e-3)" "unprognostic (1.13e-2)" "unprognostic (1.22e-2)" "prognostic unfavourable (1.82e-6)" "unprognostic (5.67e-2)" "unprognostic (1.85e-3)" "unprognostic (2.96e-2)" "unprognostic (3.77e-2)" "unprognostic (5.64e-2)" "unprognostic (2.18e-2)" "unprognostic (6.45e-3)" "unprognostic (5.23e-2)" "unprognostic (8.17e-3)" "unprognostic (7.85e-2)" "unprognostic (2.59e-1)" "unprognostic (7.63e-3)" "unprognostic (9.38e-2)" 7.1 7.8 4.8 4.2 6.3 1.6 10.8 6.3 6.6 6.4 4.9 5.4 8.3 4.0 6.3 8.1 6.5 5.9 7.0 6.8 5.4 3.6 9.0 74.8 8.1 5.4 5.4 5.0 7.0 11.4 15.1 5.6 13.8 5.9 6.3 5.5 5.8 7.4 7.9 6.8 4.9 5.5 7.2 5.1 4.5 6.0 3.6 5.7 3.4 8.5 5.3 5.4 7.3 6.0 0.9 4.9 6.0 7.2 2.2 3.2 3.2 6.8 11.1 7.9 8.8 40.0 11.4 17.6 12.2 14.4 9.0 12.8 19.0 8.4 2.4 12.5 20.0 11.1 5.6 15.4 10.0 4.3 7.7 4.4 7.4 18.0 14.9 2.7 4.2 14.1 9.1 18.2 12.5 12.7 5.3 3.6 26.1 8.9 1.4 2.1 3.7 9.6 2.6 18.6 6.1 12.5 13.1 3.0 5.0 10.9 21.6 11.3 10.5 2.7 11.6 11.6 10.2 11.2 8.3 2.8 7.8 2.0 11.1 2.8 16.2 6.0 7.2 3.6 3.2 7.2 3.0 0.7 1.3 1.2 4.9 0.9 3.2 3.0 3.2 2.2 4.4 4.0 1.9 3.2 4.8 6.3 6.3 6.6 5.4 3.6 5.4 5.0 5.9 5.7 GGPS1 GGPPS1 ENSG00000152904 "Geranylgeranyl diphosphate synthase 1" O95749 1 235327350-235344532 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Isoprene biosynthesis" Transferase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029472 Enhanced "HPA029472: AB_10696206" "unprognostic (7.45e-2)" "unprognostic (3.18e-2)" "unprognostic (1.25e-1)" "unprognostic (2.23e-2)" "unprognostic (1.43e-1)" "unprognostic (3.10e-3)" "prognostic unfavourable (6.69e-4)" "unprognostic (4.50e-2)" "unprognostic (3.66e-2)" "unprognostic (3.77e-3)" "unprognostic (2.66e-2)" "unprognostic (8.77e-3)" "unprognostic (1.95e-2)" "unprognostic (1.99e-1)" "unprognostic (3.35e-2)" "unprognostic (1.41e-1)" "unprognostic (1.70e-2)" 24.5 24.8 26.8 16.2 25.7 6.8 33.4 30.1 28.7 24.9 23.1 19.9 21.8 19.8 22.8 30.3 24.1 20.9 19.2 21.8 25.4 25.8 26.4 20.0 18.9 18.3 24.4 22.0 23.5 16.0 19.0 29.3 24.2 25.8 29.0 23.2 15.9 27.8 21.9 26.8 19.0 20.6 24.9 28.3 20.4 20.1 42.5 25.6 22.6 27.9 21.2 20.0 26.9 17.9 28.5 22.2 33.9 35.9 22.1 31.3 26.0 17.6 9.6 24.0 18.1 18.7 27.1 9.4 15.7 22.0 10.4 14.7 7.4 28.2 12.0 22.9 17.3 14.4 12.7 16.2 13.8 12.1 23.7 10.1 9.1 12.5 21.1 12.4 8.7 17.6 29.3 14.1 19.1 18.4 24.2 10.8 13.7 10.3 15.5 14.9 20.5 5.0 9.6 7.5 13.6 29.0 9.6 19.3 26.7 11.8 27.1 22.6 33.8 19.9 15.5 12.5 9.4 21.1 14.7 18.9 22.8 14.6 15.8 14.1 22.4 26.6 22.8 33.9 24.8 26.8 24.9 28.5 31.3 26.4 22.2 23.4 29.2 26.5 20.6 22.1 35.9 18.4 30.0 26.0 26.8 25.7 30.1 28.7 25.4 25.8 24.4 22.0 25.8 25.6 GLRA1 STHE ENSG00000145888 "Glycine receptor alpha 1" P23415 5 151822513-151924842 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "brain: 31.7" "Cell line enhanced" "Detected in single" "HeLa: 1.3" "Not detected" "Not detected" "Region enriched" "Detected in many" 10 "pons and medulla: 31.7" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "hypothalamus: 11.0;midbrain: 18.1;pons and medulla: 27.6" "Region enhanced" "Detected in many" "pons and medulla: 54.9" "HPA016502, CAB079042" Uncertain Supported "CAB079042: , HPA016502: AB_1849819" "unprognostic (3.17e-1)" "unprognostic (2.47e-1)" "unprognostic (3.85e-7)" "unprognostic (8.24e-2)" "unprognostic (9.45e-3)" 0.3 3.2 1.2 0.1 0.7 0.2 0.1 3.2 0.9 0.1 0.2 0.0 0.0 0.5 0.1 0.1 0.1 0.1 0.1 0.3 0.1 2.7 0.2 0.1 0.1 0.1 2.7 0.0 0.1 2.2 0.1 0.1 0.2 31.7 0.1 0.1 1.6 0.1 0.1 0.6 0.1 0.1 0.1 12.6 0.1 0.1 0.2 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.7 3.2 0.9 0.1 2.7 2.7 0.0 31.7 0.0 GLRA2 GLR ENSG00000101958 "Glycine receptor alpha 2" P23416 X 14529298-14731812 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 14 "brain: 21.0;intestine: 11.1" "Cell line enriched" "Detected in single" 33 "AN3-CA: 19.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB070422 Approved "CAB070422: AB_11153055" "unprognostic (2.52e-1)" "unprognostic (3.13e-1)" "unprognostic (5.52e-2)" "unprognostic (1.90e-1)" "unprognostic (5.74e-2)" "unprognostic (1.81e-2)" "unprognostic (3.39e-1)" "unprognostic (5.82e-2)" "unprognostic (7.95e-3)" "unprognostic (1.13e-1)" "unprognostic (2.76e-1)" "unprognostic (6.69e-2)" 0.4 0.5 14.5 0.7 13.2 0.7 0.5 21.0 10.8 0.4 4.1 0.1 0.0 0.7 0.5 0.5 0.4 0.8 0.7 0.4 3.6 13.9 0.5 0.5 0.4 0.5 1.6 8.4 0.9 0.5 0.4 0.5 0.8 10.1 0.4 11.1 1.1 0.8 0.5 0.5 0.8 0.9 0.7 6.5 0.5 0.5 0.9 0.8 0.0 0.5 0.0 0.4 0.4 0.1 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 19.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.5 13.2 21.0 10.4 3.6 13.9 1.6 8.4 10.1 0.8 GLRB ENSG00000109738 "Glycine receptor beta" P48167 4 157076057-157172090 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 43.1;parathyroid gland: 37.0" "Cell line enhanced" "Detected in many" "AN3-CA: 18.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 18 "plasmacytoid DC: 1.7" "Lineage enriched" "Detected in single" 18 "dendritic cells: 1.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA052363 Approved "HPA052363: " "unprognostic (7.36e-2)" "unprognostic (6.53e-2)" "unprognostic (1.44e-1)" "unprognostic (2.59e-3)" "unprognostic (5.65e-2)" "unprognostic (1.18e-1)" "unprognostic (9.47e-2)" "unprognostic (1.52e-1)" "unprognostic (1.19e-2)" "unprognostic (2.99e-2)" "unprognostic (6.81e-2)" "unprognostic (1.48e-1)" "prognostic favourable (4.89e-4)" "unprognostic (4.32e-3)" "unprognostic (1.85e-1)" "unprognostic (5.61e-2)" "unprognostic (1.66e-2)" 4.5 7.2 12.6 1.5 20.9 0.7 10.3 15.9 43.1 9.4 2.3 2.8 0.1 1.1 3.3 5.4 1.5 7.4 3.5 9.9 18.3 17.3 4.1 1.6 3.4 0.8 11.1 21.3 1.8 14.2 37.0 6.7 2.9 16.5 6.5 1.4 0.7 16.7 5.2 3.3 1.5 1.2 4.0 6.1 0.6 2.2 1.9 4.5 0.0 1.5 0.5 0.7 1.9 1.4 0.0 1.7 0.0 0.0 0.0 0.0 0.0 5.0 2.2 6.1 18.5 12.0 4.9 0.0 10.1 6.5 5.0 9.4 0.0 15.7 0.0 2.4 10.2 0.0 4.6 1.6 9.4 0.0 6.1 3.1 2.4 0.2 5.5 3.9 0.0 4.3 1.4 8.7 1.3 4.4 0.0 0.0 9.0 0.0 0.4 0.0 0.4 1.3 0.0 8.4 0.0 13.4 0.9 6.7 4.1 0.0 4.8 0.8 4.4 1.0 6.6 3.0 8.8 5.0 9.8 0.0 0.0 0.0 7.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 12.6 20.9 15.9 43.1 18.3 17.3 11.1 21.3 16.5 4.5 GNRHR "GRHR, LHRHR" ENSG00000109163 "Gonadotropin releasing hormone receptor" P30968 4 67739328-67754360 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets, Hypogonadotropic hypogonadism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "pituitary gland: 56.6" "Cell line enhanced" "Detected in some" "K-562: 3.0" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "naive B-cell: 1.3" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" HPA013424 Enhanced "HPA013424: " "unprognostic (2.77e-1)" "unprognostic (1.58e-1)" "unprognostic (4.05e-1)" "unprognostic (1.78e-1)" "unprognostic (4.65e-1)" "unprognostic (8.75e-3)" "unprognostic (3.09e-2)" "unprognostic (1.34e-1)" "unprognostic (1.90e-1)" "unprognostic (1.01e-1)" "unprognostic (6.84e-2)" "unprognostic (1.63e-1)" "unprognostic (9.03e-2)" "unprognostic (3.23e-2)" "unprognostic (9.67e-2)" "unprognostic (1.22e-3)" "unprognostic (3.99e-2)" 0.1 3.9 0.1 0.4 0.2 0.2 0.1 0.3 1.7 0.3 0.1 0.1 0.1 0.7 0.1 0.1 1.6 0.0 0.2 0.2 0.2 0.2 0.1 0.1 0.1 1.1 0.1 0.1 0.2 0.3 0.0 56.6 0.1 0.5 0.2 0.0 0.1 0.3 0.1 0.2 0.9 0.1 0.1 0.1 0.2 0.3 0.3 0.1 0.2 1.0 0.1 0.4 0.1 0.5 1.3 0.2 0.0 0.0 0.4 0.3 0.0 0.2 1.5 1.5 1.6 0.0 0.0 0.6 0.3 0.0 0.0 0.0 0.5 1.7 1.2 0.2 0.0 0.5 0.0 0.0 0.0 0.3 0.5 0.2 0.3 0.7 0.0 1.1 0.4 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.7 0.6 0.4 0.9 0.0 0.6 1.2 0.6 0.0 0.0 0.8 2.0 0.0 0.3 0.0 0.3 0.2 1.0 0.1 0.2 0.6 0.2 1.1 0.3 0.6 1.4 0.8 0.9 0.0 0.0 0.0 0.2 0.0 0.2 0.5 0.1 0.0 0.0 1.3 0.1 0.3 0.0 0.4 0.0 0.2 0.0 0.0 0.1 0.2 0.3 0.3 0.2 0.2 0.1 0.1 0.5 0.1 GRIA1 "GluA1, GLUR1, GLURA" ENSG00000155511 "Glutamate ionotropic receptor AMPA type subunit 1" P42261 5 153489615-153813869 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 52.6" "Cell line enhanced" "Detected in some" "AF22: 13.4;ASC diff: 4.1;BJ: 6.4;LHCN-M2: 9.4;U-266/70: 6.8" "Cancer enriched" "Detected in some" 15 "glioma: 9.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001965, HPA035202" Enhanced "CAB001965: , HPA035202: " "unprognostic (2.51e-1)" "unprognostic (4.76e-3)" "unprognostic (1.97e-1)" "unprognostic (4.20e-2)" "unprognostic (6.95e-2)" "unprognostic (2.43e-1)" "unprognostic (2.61e-1)" "unprognostic (1.18e-2)" "unprognostic (2.04e-1)" "unprognostic (2.35e-2)" "unprognostic (5.14e-4)" "unprognostic (7.97e-2)" "unprognostic (2.96e-2)" "unprognostic (1.01e-1)" "unprognostic (1.70e-1)" "unprognostic (2.80e-1)" "unprognostic (7.61e-2)" 1.8 1.6 44.9 1.2 23.1 1.0 1.5 23.6 52.6 1.4 1.2 3.7 0.0 1.3 1.2 2.0 1.2 1.2 1.1 2.0 50.4 13.4 1.1 1.1 9.5 1.0 4.8 20.0 1.3 1.4 1.2 0.5 1.1 4.6 1.1 1.2 0.7 1.1 1.7 1.1 1.1 1.3 2.3 2.3 1.1 1.2 2.1 5.2 0.0 1.1 0.0 1.1 1.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.4 0.0 4.1 2.8 0.0 6.4 3.3 0.4 0.1 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.1 9.4 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.8 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 44.9 23.1 23.6 24.3 50.4 13.4 4.8 20.0 4.6 5.2 GRIK1 "GluK1, GLUR5" ENSG00000171189 "Glutamate ionotropic receptor kainate type subunit 1" P39086 21 29536933-29940033 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 23.7;brain: 44.2;retina: 12.0" "Cell line enhanced" "Detected in some" "Daudi: 4.4" "Group enriched" "Detected in some" 7 "glioma: 4.5;prostate cancer: 0.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA014623 Uncertain "HPA014623: AB_1850305" "unprognostic (1.39e-1)" "unprognostic (6.54e-2)" "unprognostic (1.32e-1)" "unprognostic (1.04e-2)" "unprognostic (1.03e-3)" "unprognostic (1.56e-1)" "unprognostic (1.07e-1)" "unprognostic (2.12e-3)" "unprognostic (1.25e-1)" "unprognostic (8.77e-2)" "unprognostic (4.89e-3)" "unprognostic (1.20e-3)" "unprognostic (1.47e-8)" "unprognostic (2.09e-1)" "unprognostic (2.68e-1)" "unprognostic (1.09e-1)" "unprognostic (3.15e-3)" 0.8 23.7 9.8 0.9 10.2 0.7 4.1 6.6 18.3 1.2 1.2 2.9 0.0 0.7 0.7 4.3 1.2 0.7 0.8 0.6 10.0 13.4 0.6 0.8 0.8 0.9 7.1 7.6 1.1 0.6 0.6 0.3 1.3 44.2 5.3 1.5 12.0 0.7 0.8 0.8 2.1 1.3 0.8 2.6 0.8 0.7 1.4 2.7 0.0 0.7 0.0 0.6 1.0 0.6 0.4 0.3 1.6 1.1 0.2 0.4 0.0 0.2 0.4 0.8 0.3 0.0 0.0 0.4 0.5 0.0 0.0 0.0 0.2 0.7 4.4 0.0 0.0 0.2 0.0 0.0 0.0 0.8 0.4 1.3 1.0 0.2 0.0 1.0 0.7 0.0 0.0 0.0 0.0 0.0 0.9 1.8 0.0 0.0 0.4 1.0 1.0 0.3 0.2 1.1 0.3 0.0 0.4 0.1 0.3 0.1 1.0 0.1 0.5 1.0 0.4 0.6 0.9 0.2 0.2 0.5 0.9 0.2 0.7 0.7 1.7 0.0 1.1 0.6 0.1 0.8 0.0 0.2 0.1 0.0 0.3 0.4 0.3 0.1 1.6 0.2 0.5 0.1 0.4 0.0 9.8 10.2 6.6 18.3 10.0 13.4 7.1 7.6 44.2 2.7 GRIN1 "GluN1, NMDAR1" ENSG00000176884 "Glutamate ionotropic receptor NMDA type subunit 1" Q05586 9 137138390-137168762 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 38 "brain: 97.5" "Cell line enhanced" "Detected in some" "REH: 3.0;RPMI-8226: 4.3;SCLC-21H: 9.8;SH-SY5Y: 6.8" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067773 Enhanced "HPA067773: " "unprognostic (3.58e-2)" "unprognostic (4.51e-1)" "unprognostic (2.68e-2)" "unprognostic (5.48e-4)" "unprognostic (5.20e-2)" "unprognostic (1.25e-1)" "unprognostic (2.34e-2)" "unprognostic (2.81e-2)" "unprognostic (6.46e-3)" "unprognostic (1.51e-1)" "unprognostic (1.69e-1)" "unprognostic (1.78e-1)" "unprognostic (1.21e-3)" "unprognostic (4.47e-2)" "unprognostic (1.44e-1)" "unprognostic (3.56e-3)" "unprognostic (4.72e-2)" 1.7 2.0 23.6 2.0 47.5 1.7 1.8 28.1 97.5 1.8 2.0 3.2 0.0 2.2 1.7 1.8 1.7 1.7 1.7 1.7 29.1 26.4 1.8 1.7 1.8 1.8 15.4 37.9 1.7 1.8 1.8 0.0 1.7 22.0 2.2 1.8 0.7 2.5 1.8 1.7 1.8 2.2 1.8 4.7 1.8 1.8 1.9 6.3 0.0 1.7 0.0 1.8 1.8 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.7 0.0 0.1 0.0 0.0 0.4 1.0 0.0 0.1 0.0 1.2 0.0 0.0 0.0 1.5 0.1 0.0 0.2 0.2 0.0 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.9 0.0 0.0 0.1 0.0 3.0 0.0 4.3 0.0 0.0 9.8 6.8 0.1 0.5 0.0 2.4 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 23.6 47.5 28.1 87.9 29.1 26.4 15.4 37.9 22.0 6.3 GRIN2A "GluN2A, NMDAR2A" ENSG00000183454 "Glutamate ionotropic receptor NMDA type subunit 2A" Q12879 16 9753404-10182754 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 25.2" "Cell line enhanced" "Detected in some" "fHDF/TERT166: 7.7;RPMI-8226: 2.9;U-138 MG: 8.4" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB022725 Enhanced "CAB022725: " "unprognostic (6.43e-2)" "unprognostic (2.47e-1)" "unprognostic (5.97e-2)" "unprognostic (3.21e-2)" "unprognostic (3.13e-2)" "unprognostic (1.59e-2)" "unprognostic (1.62e-1)" "unprognostic (2.10e-1)" "unprognostic (2.08e-1)" "unprognostic (5.39e-2)" "unprognostic (1.47e-1)" "unprognostic (1.69e-1)" "unprognostic (3.75e-3)" "unprognostic (4.79e-3)" "unprognostic (2.05e-1)" "unprognostic (3.92e-3)" "unprognostic (3.33e-2)" 0.9 1.0 5.4 0.5 5.9 0.4 0.6 8.5 25.2 0.6 0.7 1.5 0.0 0.9 0.8 4.5 2.1 4.1 0.5 4.0 8.0 1.9 0.9 0.4 1.0 0.5 1.7 10.3 0.5 0.6 0.4 0.3 0.4 1.4 0.5 0.7 1.4 0.7 1.0 0.5 1.2 0.7 0.9 1.2 0.4 1.1 5.2 0.8 0.0 0.8 0.0 0.7 0.6 0.5 0.6 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.1 1.8 0.5 1.4 0.0 0.1 0.0 0.0 7.7 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 8.4 0.8 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 5.4 5.9 8.5 17.9 8.0 1.9 1.7 10.3 1.4 0.8 GRIN2B "GluN2B, NMDAR2B" ENSG00000273079 "Glutamate ionotropic receptor NMDA type subunit 2B" Q13224 12 13437942-13981957 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 19 "brain: 36.5" "Cell line enhanced" "Detected in some" "A549: 1.4;AF22: 3.3;CACO-2: 3.8;Daudi: 1.5;NTERA-2: 4.8;RPTEC TERT1: 4.6" "Not detected" "Not detected" "Group enriched" "Detected in many" 6 "amygdala: 19.5;basal ganglia: 26.0;cerebral cortex: 36.5;hippocampal formation: 19.6;olfactory region: 15.0" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA069762 Approved "HPA069762: " "unprognostic (2.01e-2)" "unprognostic (4.07e-2)" "unprognostic (7.89e-2)" "unprognostic (3.77e-3)" "unprognostic (3.39e-3)" "unprognostic (9.36e-2)" "unprognostic (5.92e-2)" "unprognostic (1.77e-2)" "unprognostic (6.85e-2)" "unprognostic (2.24e-1)" "unprognostic (4.68e-2)" "unprognostic (4.12e-2)" "unprognostic (4.48e-5)" "unprognostic (2.43e-1)" "unprognostic (8.76e-2)" "unprognostic (1.63e-1)" "unprognostic (2.37e-1)" 1.9 0.9 19.5 0.8 26.0 0.8 0.9 0.9 36.5 0.8 1.9 1.9 0.0 0.8 0.8 0.8 0.9 0.8 0.8 0.8 19.6 3.5 1.0 1.6 0.8 1.4 1.8 15.0 0.9 0.8 0.8 0.4 0.9 2.6 0.8 1.2 0.0 0.8 0.8 0.8 0.8 1.8 0.8 0.8 0.9 1.0 1.5 3.6 0.0 0.8 0.0 1.0 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 1.4 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.5 26.0 0.9 36.5 19.6 3.5 1.8 15.0 2.6 3.6 GRIN2D "EB11, GluN2D, NMDAR2D, NR2D" ENSG00000105464 "Glutamate ionotropic receptor NMDA type subunit 2D" O15399 19 48394875-48444931 "Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.9" "Cell line enhanced" "Detected in many" "A549: 12.7;EFO-21: 8.8;HMC-1: 21.6;NB-4: 12.7;SK-BR-3: 11.3" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in single" "classical monocyte: 1.2" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009006 Approved "CAB009006: AB_2279191" "unprognostic (9.96e-2)" "unprognostic (6.98e-2)" "unprognostic (1.17e-1)" "unprognostic (5.08e-3)" "unprognostic (1.46e-1)" "unprognostic (4.17e-1)" "unprognostic (1.43e-4)" "unprognostic (7.84e-2)" "unprognostic (2.72e-1)" "unprognostic (2.23e-3)" "unprognostic (1.57e-1)" "unprognostic (1.80e-1)" "unprognostic (6.66e-13)" "unprognostic (2.15e-2)" "unprognostic (1.92e-2)" "unprognostic (1.26e-3)" "unprognostic (1.14e-1)" 0.5 0.1 4.1 1.1 1.7 0.1 0.1 2.0 5.0 0.1 0.6 1.8 0.0 0.1 0.0 0.2 1.1 0.3 2.4 6.9 0.0 0.0 0.4 0.3 3.1 0.0 0.0 1.4 0.0 3.2 0.8 0.0 0.5 0.1 0.1 1.0 2.8 0.4 1.1 0.4 0.7 1.6 1.0 0.1 0.5 0.1 0.0 0.8 0.0 1.2 0.0 0.0 0.0 1.0 12.7 0.3 0.0 1.0 2.7 7.5 1.5 0.0 0.4 0.1 0.9 7.4 0.3 8.8 0.8 0.1 0.1 0.1 0.2 1.3 0.3 3.8 0.2 1.6 1.4 0.3 21.6 1.0 0.0 0.7 0.0 0.3 7.1 0.4 0.0 2.2 0.0 12.7 0.4 0.2 0.0 0.0 0.1 0.2 0.0 1.3 1.2 0.5 11.3 0.1 0.0 4.8 4.2 0.0 0.1 0.0 0.0 2.0 2.3 0.0 0.0 1.4 0.1 0.0 1.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 GSR ENSG00000104687 "Glutathione-disulfide reductase" P00390 8 30678061-30727999 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001538, CAB008632" Approved Supported "Plasma membrane,Cytosol" 110000000 Cytosol "Plasma membrane" "CAB008632: AB_1616690, HPA001538: AB_1078986" "unprognostic (1.23e-1)" "prognostic favourable (3.37e-4)" "prognostic favourable (4.08e-5)" "unprognostic (2.89e-3)" "unprognostic (1.62e-1)" "unprognostic (3.50e-1)" "prognostic unfavourable (3.26e-5)" "unprognostic (3.61e-2)" "unprognostic (1.01e-1)" "unprognostic (4.15e-2)" "unprognostic (2.83e-2)" "unprognostic (6.92e-3)" "prognostic favourable (1.80e-4)" "unprognostic (2.31e-3)" "unprognostic (2.26e-1)" "unprognostic (1.01e-1)" "unprognostic (1.29e-1)" 8.9 14.4 6.8 10.7 9.1 7.9 6.2 9.1 11.8 18.6 18.7 7.1 18.4 20.4 13.2 12.0 19.4 8.8 17.3 11.9 5.0 5.7 27.9 17.8 10.8 9.7 4.9 6.0 11.8 17.6 22.9 7.2 8.9 6.8 16.4 17.2 10.9 12.0 17.4 14.7 6.5 31.8 9.3 4.5 13.6 17.7 7.9 4.2 17.0 9.2 11.8 12.0 23.9 14.5 2.5 4.7 19.0 5.7 2.6 7.3 2.1 12.0 51.0 8.3 6.4 8.9 10.0 8.0 5.4 11.8 7.7 10.3 15.0 6.4 23.6 26.7 6.9 13.6 12.5 11.7 8.4 6.1 11.6 23.7 17.6 50.1 24.0 7.2 38.3 16.6 7.4 11.5 4.6 10.9 19.6 10.5 17.3 11.0 25.5 8.5 14.7 9.1 9.8 9.5 11.4 15.2 30.6 6.3 8.1 7.4 17.3 12.9 7.5 8.2 14.7 3.2 8.9 7.6 8.0 5.8 6.4 15.1 10.2 10.2 10.5 19.0 4.6 11.5 4.2 4.2 7.3 2.5 3.8 4.6 4.7 2.0 2.4 3.1 6.5 2.6 5.7 2.9 3.2 2.1 6.8 9.1 9.1 11.8 5.0 5.7 4.9 6.0 6.8 4.2 GSS ENSG00000100983 "Glutathione synthetase" P48637 20 34928433-34956027 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Glutathione biosynthesis" Ligase "Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054508, HPA059315" Enhanced Supported Nucleoplasm 23000000 Nucleoplasm "HPA054508: AB_2682509, HPA059315: AB_2683976" "unprognostic (5.80e-2)" "unprognostic (1.50e-1)" "unprognostic (1.14e-1)" "unprognostic (7.21e-2)" "unprognostic (3.63e-2)" "unprognostic (5.68e-2)" "prognostic unfavourable (7.21e-5)" "unprognostic (2.90e-2)" "unprognostic (8.52e-2)" "unprognostic (3.64e-1)" "unprognostic (6.49e-2)" "unprognostic (1.50e-1)" "prognostic favourable (7.31e-6)" "unprognostic (3.35e-3)" "unprognostic (1.96e-1)" "unprognostic (1.42e-3)" "unprognostic (1.52e-1)" 12.9 29.8 14.7 13.2 21.0 16.0 16.2 9.2 27.6 12.7 26.9 17.2 28.9 20.0 11.5 47.5 25.6 18.5 18.3 14.6 15.0 15.9 30.5 30.9 12.1 11.7 15.1 15.1 11.6 10.3 17.5 15.6 27.2 15.3 18.6 27.6 15.4 19.1 19.4 10.7 19.1 21.4 12.9 13.3 13.3 15.7 16.8 9.2 17.0 18.0 12.0 21.0 14.4 13.9 7.3 24.3 7.9 21.3 15.2 18.3 14.9 18.0 21.9 10.8 15.1 12.6 13.1 15.4 15.4 14.3 24.3 20.2 40.3 22.1 12.8 20.6 15.8 17.2 15.7 39.3 20.6 5.9 8.9 50.4 14.0 40.0 17.7 12.7 17.8 13.7 42.1 22.9 38.7 17.2 24.4 10.5 29.5 19.9 20.2 18.0 6.4 28.4 18.6 21.7 30.4 34.8 18.5 21.2 12.4 27.2 25.5 20.3 31.3 11.6 13.5 28.0 15.9 18.4 13.3 10.7 9.9 14.1 23.8 14.0 16.6 7.9 20.3 4.6 18.0 21.3 16.1 7.3 14.5 18.3 24.3 5.2 16.9 14.3 5.3 15.2 19.0 13.5 17.5 14.9 14.7 21.0 9.2 27.6 15.0 15.9 15.1 15.1 15.3 9.2 GUCY1A2 "GC-SA2, GUC1A2" ENSG00000152402 "Guanylate cyclase 1 soluble subunit alpha 2" P33402 11 106674012-107018524 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "cGMP biosynthesis" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 23.0;placenta: 23.6" "Cell line enhanced" "Detected in some" "BJ hTERT+: 12.2;BJ hTERT+ SV40 Large T+ RasG12V: 14.3;HBF TERT88: 7.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009534 Uncertain "CAB009534: AB_2279509" "unprognostic (7.53e-2)" "unprognostic (6.67e-2)" "unprognostic (7.99e-2)" "unprognostic (1.10e-1)" "unprognostic (1.08e-1)" "unprognostic (1.22e-2)" "unprognostic (1.23e-2)" "unprognostic (1.24e-1)" "unprognostic (6.53e-3)" "unprognostic (9.70e-3)" "unprognostic (8.00e-2)" "unprognostic (2.03e-1)" "prognostic unfavourable (3.02e-5)" "unprognostic (2.48e-4)" "unprognostic (1.62e-1)" "unprognostic (3.50e-2)" "unprognostic (1.09e-2)" 5.5 3.3 4.6 1.3 10.9 0.6 3.9 4.3 10.7 19.2 1.5 1.2 1.1 0.9 23.0 5.0 1.3 8.4 2.6 3.8 4.6 4.0 3.2 2.8 11.8 1.6 3.7 5.3 3.9 6.2 1.8 1.5 23.6 5.5 3.2 1.3 1.4 1.4 10.1 4.1 1.4 1.2 18.0 2.4 7.9 1.0 2.8 5.4 0.0 2.4 3.0 1.0 2.2 5.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 4.3 0.0 0.2 2.6 2.3 0.3 12.2 1.6 14.3 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 7.6 0.0 1.2 0.0 0.1 0.0 0.2 0.0 1.7 0.7 0.0 1.9 0.2 0.9 0.0 0.0 0.0 0.2 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.5 3.7 0.0 0.8 0.8 0.2 4.7 3.9 3.2 0.8 1.3 0.0 0.0 0.0 0.1 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 10.9 4.3 9.9 4.6 4.0 3.7 5.3 5.5 5.4 GUCY2C "GUC2C, STAR" ENSG00000070019 "Guanylate cyclase 2C" P25092 12 14612632-14696585 "Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters" "cGMP biosynthesis" "Lyase, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 19 "intestine: 85.1" "Cell line enhanced" "Detected in some" "AN3-CA: 3.7;BEWO: 2.2;CACO-2: 3.1;CAPAN-2: 4.5;SiHa: 4.2" "Group enriched" "Detected in many" 5 "colorectal cancer: 23.9;stomach cancer: 9.1" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "memory B-cell: 4.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA037655, HPA073759" Uncertain Uncertain Vesicles Vesicles "HPA037655: AB_10672388, HPA073759: " "unprognostic (1.08e-1)" "unprognostic (2.12e-1)" "unprognostic (3.58e-2)" "unprognostic (2.11e-2)" "unprognostic (1.60e-2)" "unprognostic (5.67e-3)" "prognostic unfavourable (1.37e-5)" "unprognostic (9.14e-2)" "unprognostic (1.49e-2)" "unprognostic (2.95e-1)" "unprognostic (1.58e-1)" "unprognostic (5.40e-2)" "unprognostic (2.35e-4)" "unprognostic (8.02e-2)" "unprognostic (1.64e-1)" "unprognostic (1.33e-1)" "unprognostic (1.98e-1)" 0.2 0.1 0.2 3.4 0.2 0.0 0.2 0.2 0.2 0.2 38.8 0.2 0.2 28.0 0.3 0.2 0.4 0.2 0.3 0.4 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.5 0.0 0.2 0.2 0.2 0.2 17.5 0.2 0.5 0.2 0.2 1.0 85.1 0.3 0.2 0.2 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 4.3 0.7 2.7 1.7 0.0 0.0 0.6 1.1 0.1 0.0 3.7 0.0 0.0 2.2 0.1 0.0 0.0 0.0 3.1 4.5 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.7 0.0 0.4 0.4 0.0 0.0 0.0 0.5 0.1 0.6 0.0 0.5 4.2 0.3 0.0 0.3 0.1 0.0 0.0 0.0 0.9 0.1 1.3 0.8 1.3 0.0 0.0 0.1 0.0 1.7 0.0 0.0 0.5 0.0 4.3 0.0 0.0 0.7 2.3 0.0 0.0 2.7 0.0 0.0 0.7 0.0 0.6 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 HBA1 HBA-T3 ENSG00000206172 "Hemoglobin subunit alpha 1" P69905 16 176680-177522 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "bone marrow: 1020.7" "Group enriched" "Detected in some" 37 "HEL: 243.0;K-562: 171.3" "Cancer enhanced" "Detected in many" "glioma: 6.3" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 11.7;plasmacytoid DC: 7.4" "Group enriched" "Detected in many" 4 "dendritic cells: 7.4;granulocytes: 11.7" "CAB032534, HPA043780" Enhanced 17000000000 "CAB032534: AB_2294993, HPA043780: " "unprognostic (1.16e-1)" "unprognostic (1.45e-2)" "unprognostic (8.87e-2)" "unprognostic (9.78e-3)" "unprognostic (3.02e-1)" "unprognostic (1.44e-1)" "unprognostic (1.67e-1)" "unprognostic (1.35e-1)" "unprognostic (6.21e-3)" "unprognostic (1.92e-2)" "unprognostic (1.64e-1)" "unprognostic (1.02e-2)" "unprognostic (3.59e-2)" "unprognostic (3.79e-1)" "unprognostic (6.61e-2)" "unprognostic (2.67e-2)" "unprognostic (9.56e-2)" 12.6 8.8 7.1 5.0 6.6 1020.7 5.0 7.9 10.0 2.2 3.2 3.0 2.2 1.3 2.2 4.1 2.8 4.8 4.0 16.9 5.2 5.1 20.6 15.7 30.3 8.1 10.1 5.8 4.9 2.2 0.9 7.5 104.1 3.3 4.8 1.4 4.5 6.7 3.3 9.4 1.9 2.2 5.1 7.9 101.4 1.6 6.7 2.2 2.2 9.3 2.2 2.2 3.4 9.4 0.6 7.4 11.7 0.5 0.9 2.1 186.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.4 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 243.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 171.3 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 5.6 0.0 0.0 0.5 0.3 0.2 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 3.3 1.9 0.0 0.0 0.6 0.2 0.7 0.7 0.4 0.7 2.1 11.7 0.9 0.0 7.4 0.0 186.1 7.1 6.6 7.9 10.0 5.2 5.1 10.1 5.8 3.3 2.2 HBA2 HBA-T2 ENSG00000188536 "Hemoglobin subunit alpha 2" P69905 16 172876-173710 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 427.1;bone marrow: 1094.2" "Group enriched" "Detected in some" 18 "HEL: 157.4;K-562: 42.2" "Cancer enhanced" "Detected in all" "glioma: 59.7" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "eosinophil: 9.8;neutrophil: 33.6;plasmacytoid DC: 15.7" "Group enriched" "Detected in many" 8 "dendritic cells: 15.7;granulocytes: 33.6" "CAB038417, HPA043780" Enhanced 17000000000 "CAB038417: , HPA043780: " "unprognostic (1.57e-1)" "unprognostic (7.02e-2)" "unprognostic (2.59e-2)" "unprognostic (2.13e-1)" "unprognostic (3.59e-1)" "unprognostic (3.18e-1)" "unprognostic (3.39e-2)" "unprognostic (2.12e-1)" "unprognostic (4.99e-2)" "unprognostic (4.43e-1)" "unprognostic (1.09e-2)" "unprognostic (1.19e-2)" "unprognostic (1.72e-3)" "unprognostic (1.36e-1)" "unprognostic (2.11e-1)" "unprognostic (4.73e-2)" "unprognostic (8.92e-2)" 15.4 11.8 7.2 6.9 7.3 1094.2 7.6 4.1 4.1 4.1 4.1 4.1 4.1 1.1 4.1 4.1 4.1 7.7 5.8 19.5 5.8 6.2 24.3 17.7 38.4 4.1 11.2 4.1 4.1 4.1 0.5 8.9 128.7 4.1 4.1 1.3 4.1 9.2 5.6 17.7 0.9 4.1 4.1 9.3 98.3 1.9 4.1 4.1 4.1 12.5 4.1 4.1 4.1 20.1 1.4 15.7 33.6 0.9 1.5 3.0 427.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 157.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 42.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.0 0.1 1.6 1.3 0.1 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.9 9.8 3.0 0.0 0.1 1.4 0.3 0.2 1.4 0.8 0.8 2.6 33.6 1.5 0.0 15.7 0.0 427.1 7.2 7.3 4.1 4.1 5.8 6.2 11.2 4.1 4.1 4.1 HBB "beta-globin, CD113t-C" ENSG00000244734 "Hemoglobin subunit beta" P68871 11 5225464-5229395 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Hypotensive agent, Vasoactive" "Congenital dyserythropoietic anemia, Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 7 "bone marrow: 3646.7" "Cell line enhanced" "Detected in some" "HEL: 5.4;SCLC-21H: 4.7;SH-SY5Y: 5.9;U-266/70: 21.8;U-266/84: 3.6" "Cancer enhanced" "Detected in all" "glioma: 244.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 7 "neutrophil: 19.3;plasmacytoid DC: 9.9" "Group enriched" "Detected in many" 12 "dendritic cells: 9.9;granulocytes: 19.3" "CAB009526, HPA043234" Enhanced 15000000000 "CAB009526: AB_2143058, HPA043234: " "unprognostic (2.41e-1)" "unprognostic (8.55e-2)" "unprognostic (2.40e-1)" "unprognostic (4.40e-2)" "unprognostic (1.14e-1)" "unprognostic (3.22e-1)" "unprognostic (4.88e-2)" "unprognostic (7.46e-2)" "unprognostic (2.91e-2)" "unprognostic (1.76e-1)" "unprognostic (1.91e-1)" "unprognostic (8.11e-3)" "unprognostic (2.40e-2)" "unprognostic (5.81e-2)" "unprognostic (1.42e-1)" "unprognostic (8.87e-3)" "unprognostic (6.41e-2)" 32.7 20.0 20.9 10.1 21.0 3646.7 43.4 6.5 10.7 9.2 11.3 7.2 3.4 3.2 7.3 11.1 36.6 28.4 30.4 38.9 17.9 17.4 45.0 37.6 305.8 7.0 31.6 10.8 82.6 28.4 2.9 18.6 236.8 23.7 23.1 7.5 32.0 17.4 12.8 29.5 3.8 3.9 12.0 26.5 216.8 4.0 9.3 3.8 5.6 46.4 20.2 7.6 124.5 256.7 0.6 9.9 19.3 0.6 1.2 1.1 523.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.2 2.1 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.3 0.3 0.0 0.0 4.7 5.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 21.8 3.6 0.0 0.0 0.0 0.0 2.2 0.6 1.9 0.9 0.0 0.1 0.6 0.2 0.0 0.9 0.4 0.4 1.1 19.3 1.2 0.1 9.9 0.0 523.2 20.9 21.0 6.5 10.7 17.9 17.4 31.6 10.8 23.7 3.8 HCAR2 "GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG" ENSG00000182782 "Hydroxycarboxylic acid receptor 2" Q8TDS4 12 122701293-122703343 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" Apoptosis "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 50.9" "Cell line enriched" "Detected in some" 6 "HaCaT: 50.7" "Group enriched" "Detected in many" 8 "cervical cancer: 12.6;head and neck cancer: 16.1;lung cancer: 6.4;urothelial cancer: 9.2" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in some" 6 "neutrophil: 50.9" "Lineage enriched" "Detected in many" 8 "granulocytes: 50.9" HPA028660 Approved Supported "Cell Junctions" "Cell Junctions" "HPA028660: AB_10602139" "unprognostic (5.43e-2)" "unprognostic (1.27e-1)" "unprognostic (1.77e-1)" "unprognostic (2.05e-1)" "unprognostic (6.65e-2)" "unprognostic (1.33e-1)" "unprognostic (3.33e-3)" "unprognostic (7.26e-2)" "unprognostic (2.17e-1)" "unprognostic (1.77e-2)" "unprognostic (7.10e-2)" "unprognostic (7.33e-2)" "unprognostic (4.83e-4)" "unprognostic (5.76e-2)" "unprognostic (5.07e-2)" "unprognostic (1.54e-1)" "unprognostic (4.63e-2)" 16.1 0.2 0.4 6.4 0.5 13.2 8.3 0.2 0.7 5.8 3.6 0.3 6.2 0.4 0.8 1.6 26.0 0.4 1.1 1.2 0.8 0.2 1.9 1.8 11.3 0.7 3.3 0.2 1.2 0.2 4.4 0.9 8.2 1.0 8.6 0.0 0.3 9.7 10.7 0.7 17.8 0.7 0.4 0.9 16.5 0.8 2.8 1.1 1.1 0.4 13.5 21.5 3.5 8.3 0.0 0.5 50.9 6.6 0.0 0.0 0.3 1.8 0.1 0.0 0.0 0.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 50.7 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 8.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 9.0 0.6 0.6 0.0 1.5 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 50.9 0.0 6.6 0.0 0.0 0.3 0.4 0.5 0.2 0.7 0.8 0.2 3.3 0.2 1.0 1.1 HCAR3 "GPR109B, HCA3, HM74" ENSG00000255398 "Hydroxycarboxylic acid receptor 3" P49019 12 122714756-122716892 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 47.7" "Group enriched" "Detected in some" 5 "HaCaT: 7.1;RT4: 27.3" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 5 "midbrain: 3.5" "Group enriched" "Detected in some" 6 "basophil: 12.1;neutrophil: 47.7;non-classical monocyte: 21.3" "Group enriched" "Detected in many" 49 "granulocytes: 47.7;monocytes: 21.3" HPA028660 Approved Approved "Cell Junctions" "Cell Junctions" "HPA028660: AB_10602139" "unprognostic (2.32e-1)" "unprognostic (5.82e-2)" "unprognostic (8.23e-2)" "unprognostic (2.27e-1)" "unprognostic (1.17e-1)" "unprognostic (9.17e-2)" "unprognostic (1.64e-3)" "unprognostic (1.60e-1)" "unprognostic (6.29e-2)" "unprognostic (9.87e-2)" "unprognostic (1.50e-2)" "unprognostic (2.80e-1)" "unprognostic (1.23e-1)" "unprognostic (2.30e-2)" "unprognostic (2.83e-1)" "unprognostic (1.16e-1)" "unprognostic (9.28e-2)" 4.8 0.2 0.6 7.9 0.3 20.8 4.0 0.4 0.5 2.3 0.9 0.2 2.2 0.1 0.4 0.4 18.2 0.5 0.5 1.0 0.3 0.3 0.9 2.5 10.2 3.5 3.5 0.0 1.6 0.2 6.6 1.1 3.0 0.7 4.2 0.0 0.3 2.9 4.3 0.6 13.9 0.3 0.4 1.2 21.6 0.5 1.6 0.4 0.3 0.5 12.0 14.9 5.7 7.2 0.0 0.7 47.7 21.3 0.0 0.0 0.6 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 7.1 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 27.3 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.1 12.1 0.5 0.2 0.0 4.4 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 47.7 0.0 21.3 0.0 0.0 0.6 0.6 0.3 0.4 0.5 0.3 0.3 3.5 0.0 0.7 0.4 HCRTR1 OX1R ENSG00000121764 "Hypocretin receptor 1" O43613 1 31617686-31632518 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 8.0" "Cell line enhanced" "Detected in some" "HeLa: 1.7;HUVEC TERT2: 2.9;TIME: 1.6" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "naive B-cell: 1.1" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA014018 Approved "HPA014018: AB_1854810" "unprognostic (2.96e-2)" "unprognostic (2.34e-2)" "unprognostic (7.86e-3)" "unprognostic (3.72e-3)" "unprognostic (2.42e-1)" "unprognostic (3.45e-3)" "unprognostic (2.54e-5)" "unprognostic (3.58e-2)" "unprognostic (4.17e-2)" "unprognostic (1.19e-1)" "unprognostic (2.28e-1)" "unprognostic (2.93e-1)" "unprognostic (3.77e-3)" "unprognostic (2.16e-2)" "unprognostic (1.02e-1)" "unprognostic (1.43e-1)" "unprognostic (1.07e-1)" 3.3 4.3 0.9 0.3 1.4 1.6 2.7 0.7 4.5 0.1 0.3 0.0 0.0 0.2 0.6 0.3 0.7 0.5 0.8 1.8 0.8 4.6 0.5 0.1 0.2 0.6 1.1 0.0 0.5 0.3 0.0 1.7 2.3 8.0 0.5 0.2 0.7 0.5 0.0 2.4 1.1 0.5 0.0 0.5 0.6 0.4 0.4 0.0 0.0 2.9 0.8 0.2 0.6 0.1 1.1 0.2 0.0 0.2 0.2 0.5 0.1 0.4 0.0 0.3 0.1 0.0 0.0 0.7 0.5 0.0 0.0 0.0 0.0 0.6 0.6 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.3 1.7 0.0 0.0 1.0 0.4 0.0 0.0 0.5 0.0 2.9 0.4 0.2 0.0 0.5 0.1 0.1 0.1 0.0 1.1 0.1 0.0 0.0 0.7 0.1 0.4 0.3 0.2 0.0 0.2 0.0 1.6 0.1 0.2 0.3 0.4 0.5 0.1 0.2 0.0 0.6 1.0 0.0 0.2 0.0 0.5 0.2 0.0 0.1 0.2 0.0 0.1 1.1 0.1 0.1 0.0 0.2 0.1 0.2 0.0 0.1 0.9 1.4 0.7 4.5 0.8 4.6 1.1 0.0 8.0 0.0 HCRTR2 OX2R ENSG00000137252 "Hypocretin receptor 2" O43614 6 55106460-55282620 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 17.4" "Cell line enriched" "Detected in single" 6 "AF22: 4.7" "Not detected" "Not detected" "Region enriched" "Detected in many" 4 "pons and medulla: 17.4" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA054516 Enhanced "HPA054516: " "unprognostic (4.86e-1)" "unprognostic (2.69e-2)" "unprognostic (1.86e-2)" "unprognostic (2.32e-1)" "unprognostic (7.45e-2)" "unprognostic (7.39e-2)" 0.1 0.2 1.7 0.0 1.3 0.0 0.1 0.6 2.2 0.1 0.1 0.3 0.0 0.0 0.1 0.5 0.0 0.1 0.1 1.1 0.9 4.2 3.7 0.1 0.4 0.1 2.6 1.7 1.7 0.0 0.0 0.3 2.2 17.4 0.0 0.1 0.5 0.0 0.0 0.0 0.1 0.2 0.1 0.5 0.0 0.0 1.5 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 1.7 1.3 0.6 2.2 0.9 4.2 2.6 1.7 17.4 0.0 HDAC1 "GON-10, HD1, RPD3L1" ENSG00000116478 "Histone deacetylase 1" Q13547 1 32292086-32333635 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005017, HPA029693, CAB068191" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB005017: AB_2248344, CAB068191: , HPA029693: AB_10601659" "unprognostic (2.51e-2)" "unprognostic (9.10e-2)" "unprognostic (2.92e-1)" "unprognostic (2.98e-1)" "unprognostic (9.15e-2)" "unprognostic (3.57e-3)" "prognostic unfavourable (5.76e-7)" "unprognostic (9.57e-2)" "unprognostic (5.02e-2)" "unprognostic (3.47e-2)" "unprognostic (7.06e-2)" "unprognostic (4.44e-2)" "prognostic unfavourable (1.04e-5)" "unprognostic (6.86e-2)" "unprognostic (3.78e-1)" "unprognostic (7.16e-2)" "unprognostic (1.72e-1)" 13.8 22.8 12.8 33.5 14.8 15.0 21.1 5.1 13.0 21.9 35.7 16.0 34.8 22.2 24.6 17.5 40.6 21.0 43.8 12.4 12.5 8.5 21.1 21.5 17.2 33.3 14.7 8.6 27.7 20.5 17.2 27.1 24.4 12.2 25.2 33.9 18.0 27.8 31.3 6.6 16.9 32.7 22.1 13.3 32.6 27.8 20.0 16.7 59.4 36.8 21.2 51.1 26.0 25.1 47.7 32.1 59.8 44.6 42.4 49.2 54.7 29.5 18.0 11.6 23.1 6.8 8.1 24.2 20.9 23.5 28.1 26.0 33.0 53.3 45.6 38.9 23.1 34.6 35.7 28.5 31.2 42.6 35.5 31.4 21.7 25.3 16.1 55.6 45.6 14.7 15.7 21.7 14.4 21.3 41.1 18.2 12.3 22.5 63.3 31.3 26.9 46.2 43.8 27.6 20.3 30.4 42.8 9.1 11.5 35.0 23.6 44.0 27.8 43.3 24.6 18.7 22.0 5.7 51.0 11.1 23.8 62.5 15.4 46.2 24.3 37.0 27.7 59.8 43.2 35.5 35.4 47.7 42.4 46.1 32.1 44.3 49.2 45.7 19.9 42.4 44.6 20.1 42.5 54.7 12.8 14.8 5.1 13.0 12.5 8.5 14.7 8.6 12.2 16.7 HDAC10 DKFZP761B039 ENSG00000100429 "Histone deacetylase 10" Q969S8 22 50245183-50251405 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Autophagy, DNA damage, DNA recombination, DNA repair" Hydrolase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 18.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB045977 Supported "CAB045977: AB_11124034" "unprognostic (1.53e-1)" "prognostic favourable (4.46e-4)" "unprognostic (1.43e-2)" "prognostic favourable (2.45e-5)" "unprognostic (2.71e-2)" "unprognostic (3.70e-2)" "unprognostic (6.15e-3)" "unprognostic (5.48e-2)" "unprognostic (3.28e-1)" "unprognostic (2.56e-2)" "prognostic favourable (9.25e-4)" "unprognostic (4.93e-2)" "prognostic unfavourable (4.74e-11)" "unprognostic (2.21e-2)" "unprognostic (2.52e-2)" "unprognostic (1.43e-2)" "unprognostic (1.38e-3)" 8.9 9.3 10.1 14.7 10.3 16.9 6.8 10.9 8.8 8.6 13.9 4.7 14.6 12.9 7.7 13.5 10.2 7.9 13.1 4.0 8.4 6.1 11.4 15.1 8.2 12.5 4.9 8.8 7.8 15.0 6.4 13.2 7.0 6.1 10.2 3.7 8.8 18.6 12.9 9.2 12.1 14.2 7.1 4.4 17.1 14.2 2.4 4.7 16.1 9.3 7.6 19.2 8.2 7.7 1.1 3.1 5.4 4.2 1.1 1.9 2.5 4.1 2.3 0.6 3.4 3.0 2.3 7.6 2.7 2.4 1.6 0.9 4.3 4.5 2.7 3.9 2.1 6.9 1.4 4.1 0.3 3.4 3.9 5.8 6.1 7.2 5.2 6.8 18.9 4.9 3.0 1.5 0.9 2.9 4.0 4.1 1.4 12.8 3.8 17.0 1.4 5.1 9.1 2.2 16.7 2.5 7.0 1.8 4.5 2.8 1.0 4.8 7.8 11.0 4.7 2.7 3.9 4.6 1.6 5.1 1.7 2.3 4.4 4.3 2.1 0.8 4.0 5.4 1.9 4.2 1.6 1.0 0.9 1.2 3.1 1.1 0.8 1.0 2.0 1.1 2.3 2.7 1.6 2.5 10.1 10.3 10.9 8.8 8.4 6.1 4.9 8.8 6.1 4.7 HDAC2 "RPD3, YAF1" ENSG00000196591 "Histone deacetylase 2" Q92769 6 113933028-114011308 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005054, HPA011727" Supported Enhanced Nucleoplasm Nucleoplasm "CAB005054: AB_562295, HPA011727: AB_1850540" "prognostic unfavourable (7.07e-4)" "unprognostic (1.44e-1)" "unprognostic (2.67e-1)" "unprognostic (2.56e-2)" "unprognostic (2.61e-2)" "unprognostic (1.89e-2)" "prognostic unfavourable (5.39e-10)" "unprognostic (2.03e-1)" "unprognostic (2.63e-2)" "unprognostic (9.00e-2)" "unprognostic (2.01e-1)" "unprognostic (3.92e-1)" "unprognostic (1.84e-2)" "unprognostic (1.96e-1)" "unprognostic (2.42e-1)" "unprognostic (9.80e-2)" "unprognostic (3.51e-1)" 25.8 33.8 25.8 30.1 31.3 34.9 58.7 32.8 36.5 32.1 30.7 25.6 32.2 22.0 38.7 36.7 36.3 32.7 23.3 27.6 26.5 26.9 31.6 22.2 29.9 41.5 29.6 26.5 39.2 31.5 31.7 45.1 38.1 27.9 32.1 36.1 17.5 29.3 39.0 33.9 30.8 26.1 36.1 31.1 30.7 29.9 47.4 27.4 64.0 35.1 31.3 32.5 33.1 47.3 27.0 35.7 28.2 32.6 26.3 32.6 24.3 24.2 16.7 78.2 44.9 20.2 23.0 32.8 28.9 23.7 34.2 41.0 44.3 17.9 20.0 24.2 26.0 19.1 53.0 29.3 57.6 28.5 36.6 48.2 21.7 25.6 26.9 48.9 21.8 18.6 19.7 36.4 34.2 39.8 62.0 20.4 56.5 20.3 43.8 44.3 44.2 23.1 29.8 39.0 18.4 35.3 29.3 52.3 44.4 22.9 21.6 24.1 15.7 57.1 32.1 21.8 25.1 22.8 47.9 16.2 21.3 47.9 18.5 47.2 36.9 23.1 27.6 28.2 21.1 26.6 28.1 27.0 25.9 22.7 35.7 22.3 32.6 29.7 16.3 26.3 32.6 30.9 24.5 24.3 25.8 31.3 32.8 36.5 26.5 26.9 29.6 26.5 27.9 27.4 HDAC3 "HD3, RPD3, RPD3-2" ENSG00000171720 "Histone deacetylase 3" O15379 5 141620876-141636870 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005583, HPA052052, CAB072336" Supported Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "CAB005583: AB_562296, CAB072336: , HPA052052: " "unprognostic (6.65e-2)" "unprognostic (1.96e-1)" "prognostic favourable (3.39e-4)" "unprognostic (1.17e-1)" "unprognostic (1.24e-1)" "unprognostic (1.07e-1)" "unprognostic (1.19e-2)" "unprognostic (3.16e-1)" "unprognostic (5.56e-2)" "unprognostic (2.45e-2)" "prognostic favourable (3.95e-4)" "unprognostic (1.12e-1)" "prognostic unfavourable (2.65e-6)" "unprognostic (1.85e-1)" "unprognostic (1.63e-2)" "unprognostic (2.28e-3)" "unprognostic (2.17e-1)" 15.9 28.8 19.6 12.2 17.6 18.1 18.6 22.6 20.8 15.6 14.1 11.2 13.1 10.6 17.3 17.6 22.8 16.3 14.0 16.8 18.0 8.9 14.5 23.3 24.4 36.4 13.4 14.2 17.3 24.7 20.9 17.3 14.3 18.8 13.6 14.4 13.6 17.5 13.7 24.5 26.7 15.2 17.2 10.8 20.1 15.5 11.9 12.6 18.5 14.4 9.6 23.7 17.5 17.0 22.1 46.7 16.4 22.6 14.1 23.1 16.9 21.1 14.3 26.6 40.4 25.8 20.6 17.3 15.4 33.9 35.0 50.2 30.7 18.1 30.7 20.0 20.0 18.3 26.8 36.1 43.4 26.2 28.8 24.0 13.2 17.4 18.2 28.9 22.0 17.5 23.3 20.3 26.4 22.5 23.4 16.4 22.1 20.0 32.0 25.0 23.5 11.4 23.2 27.9 22.1 18.7 21.3 22.3 18.1 20.4 21.2 25.4 22.6 18.3 11.3 21.7 13.6 16.6 25.2 13.4 16.4 28.9 18.3 27.5 18.6 13.2 22.4 16.4 15.9 22.6 20.8 22.1 19.8 19.2 46.7 20.1 21.7 18.0 9.5 14.1 19.0 23.9 23.1 16.9 19.6 17.6 22.6 20.8 18.0 8.9 13.4 14.2 18.8 12.6 HDAC4 "BDMR, HA6116, HD4, HDAC-4, HDAC-A, HDACA, KIAA0288" ENSG00000068024 "Histone deacetylase 4" P56524 2 239048168-239401654 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Autism spectrum disorder, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 54.6" "Cell line enhanced" "Detected in many" "MOLT-4: 31.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "basophil: 10.5;classical monocyte: 7.4;neutrophil: 28.3" "Group enriched" "Detected in many" 8 "granulocytes: 28.3;monocytes: 7.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004431, HPA048723" Approved Supported "Nucleoplasm,Nuclear speckles,Cytosol" "Nuclear speckles" "Nucleoplasm, Cytosol" "CAB004431: AB_627706, HPA048723: " "unprognostic (1.54e-1)" "unprognostic (1.76e-2)" "unprognostic (1.33e-1)" "unprognostic (1.18e-3)" "unprognostic (2.43e-2)" "unprognostic (2.39e-3)" "unprognostic (3.06e-4)" "unprognostic (1.00e-1)" "unprognostic (1.24e-1)" "prognostic unfavourable (6.33e-4)" "prognostic favourable (1.13e-4)" "unprognostic (1.40e-1)" "unprognostic (4.82e-3)" "unprognostic (2.40e-1)" "unprognostic (3.26e-2)" "unprognostic (1.32e-2)" "unprognostic (6.04e-2)" 7.9 6.8 6.1 6.8 5.2 17.1 4.6 6.4 12.3 11.3 21.4 4.6 4.3 2.5 10.2 6.4 8.8 9.0 24.6 5.2 5.0 6.0 3.2 3.1 4.2 4.3 6.1 5.4 8.5 5.8 4.9 8.3 2.5 5.2 7.5 4.8 8.3 3.7 7.3 54.6 6.9 6.5 15.8 4.2 5.4 7.0 8.1 4.3 6.5 4.8 13.2 5.6 10.2 4.6 0.5 1.7 28.3 7.4 2.1 1.2 0.4 4.3 4.3 5.5 6.6 3.1 5.3 6.5 4.5 3.1 3.6 3.4 2.0 7.8 2.0 1.8 3.9 4.3 3.8 1.8 1.8 12.0 2.0 3.2 5.3 6.3 4.2 4.9 2.9 3.6 4.6 6.6 5.3 3.8 4.5 4.6 1.7 5.3 31.6 6.7 4.3 2.2 8.2 10.4 3.2 4.1 5.5 4.4 7.8 6.3 2.8 11.1 1.5 13.4 6.1 4.2 0.3 7.2 6.1 3.3 3.1 3.9 6.1 6.8 8.3 10.5 7.4 1.1 0.9 2.4 1.1 0.5 0.9 0.8 0.8 0.5 0.5 1.0 28.3 2.1 1.0 1.7 1.2 0.4 6.1 5.2 6.4 7.5 5.0 6.0 6.1 5.4 5.2 4.3 HDAC5 "FLJ90614, KIAA0600, NY-CO-9" ENSG00000108840 "Histone deacetylase 5" Q9UQL6 17 44076746-44123702 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019400, HPA030991" Approved Supported "Nuclear speckles,Golgi apparatus,Cytosol" "Nuclear speckles" "Golgi apparatus, Cytosol" "CAB019400: AB_2116626, HPA030991: AB_10795286" "unprognostic (1.30e-2)" "prognostic favourable (6.14e-4)" "unprognostic (6.65e-2)" "unprognostic (8.06e-2)" "unprognostic (3.49e-1)" "unprognostic (3.52e-2)" "prognostic unfavourable (3.12e-5)" "unprognostic (8.80e-3)" "unprognostic (3.80e-2)" "unprognostic (2.37e-2)" "unprognostic (4.91e-3)" "unprognostic (4.30e-1)" "prognostic favourable (3.30e-5)" "unprognostic (1.51e-2)" "unprognostic (3.11e-1)" "unprognostic (6.00e-2)" "unprognostic (1.76e-2)" 15.6 17.6 24.9 7.9 15.8 13.2 18.1 35.9 25.8 16.5 8.8 19.6 9.5 8.4 15.0 11.9 20.1 16.9 11.3 24.4 22.1 24.2 8.6 6.3 13.6 8.8 24.7 22.1 24.5 16.1 28.2 17.5 23.0 19.3 13.6 5.5 11.7 14.2 11.9 42.6 34.0 9.7 12.4 20.5 13.8 9.3 10.3 18.1 7.6 15.0 9.8 8.2 14.9 20.4 7.6 9.4 17.9 13.6 3.5 4.9 5.0 3.5 2.3 6.4 1.5 12.4 9.7 23.1 9.6 24.0 4.8 7.9 5.1 3.8 5.6 3.9 22.8 2.9 7.5 4.1 2.0 8.7 12.2 10.9 7.7 11.7 5.3 3.5 15.4 13.7 7.1 5.5 6.9 3.9 8.1 11.4 27.8 2.7 5.8 10.7 7.0 5.5 22.5 17.9 14.4 0.5 1.6 16.7 8.8 2.8 11.8 13.0 16.8 20.7 2.1 12.1 7.8 2.8 4.8 18.8 15.7 6.7 7.0 4.4 5.7 7.1 7.3 7.7 4.9 11.6 3.5 6.6 3.9 4.9 9.4 7.6 4.1 3.5 17.9 3.5 13.6 8.3 3.5 5.0 24.9 15.8 35.9 25.8 22.1 24.2 24.7 22.1 19.3 18.1 HDAC6 "FLJ16239, HD6, JM21, KIAA0901, PPP1R90" ENSG00000094631 "Histone deacetylase 6" Q9UBN7 X 48801377-48824982 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Autophagy, Transcription, Transcription regulation" "Actin-binding, Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003714, CAB004236, HPA026321" Supported Supported Nucleoplasm 39000 Nucleoplasm "CAB004236: AB_627708, HPA003714: AB_1850544, HPA026321: AB_1850546" "unprognostic (9.53e-2)" "unprognostic (1.59e-1)" "unprognostic (2.66e-2)" "unprognostic (2.42e-2)" "unprognostic (2.82e-2)" "unprognostic (4.11e-3)" "unprognostic (2.17e-2)" "unprognostic (1.16e-1)" "unprognostic (7.68e-2)" "unprognostic (2.83e-1)" "unprognostic (1.16e-3)" "unprognostic (2.33e-2)" "unprognostic (6.10e-2)" "unprognostic (1.47e-1)" "unprognostic (6.60e-2)" "unprognostic (2.34e-1)" "prognostic favourable (3.34e-4)" 14.6 13.7 23.4 12.8 29.8 19.0 14.4 34.2 30.1 12.7 14.1 24.4 14.9 16.9 16.0 14.7 13.1 15.7 11.7 11.9 21.7 24.8 32.8 43.3 15.1 13.9 27.2 22.4 18.7 15.5 26.7 24.4 15.1 27.0 12.3 15.9 15.1 12.2 15.3 18.2 11.3 16.1 15.0 20.9 15.3 14.2 24.7 22.4 19.0 15.7 9.5 14.0 11.7 12.1 5.7 9.7 6.3 12.4 4.0 5.8 5.0 16.0 13.6 26.7 10.2 10.8 9.8 18.1 7.7 6.5 14.8 14.6 13.1 13.7 15.4 7.4 8.7 11.5 16.2 8.2 12.8 14.4 10.2 21.1 16.2 13.4 10.2 9.7 32.7 14.2 13.3 11.6 14.0 12.3 23.1 17.1 9.3 5.6 13.8 15.3 9.9 13.0 11.9 28.8 15.9 8.5 6.9 13.8 13.6 15.4 4.6 9.2 19.3 9.1 10.0 11.5 14.9 15.8 7.3 15.8 15.6 11.2 11.7 12.5 11.4 0.0 5.8 6.3 5.8 9.7 4.1 4.3 4.0 4.2 8.6 5.7 3.9 3.7 2.9 4.0 12.4 9.7 4.4 5.0 23.4 29.8 34.2 30.1 21.7 24.8 27.2 22.4 27.0 22.4 HDAC7 "DKFZP586J0917, HDAC7A" ENSG00000061273 "Histone deacetylase 7" Q8WUI4 12 47782722-47833132 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 85.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "neutrophil: 10.5" "Lineage enriched" "Detected in many" 5 "granulocytes: 10.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004775 Supported Cytosol Cytosol "HPA004775: AB_1850548" "unprognostic (3.83e-1)" "unprognostic (9.49e-3)" "unprognostic (1.37e-2)" "unprognostic (4.46e-2)" "unprognostic (6.56e-3)" "unprognostic (2.22e-2)" "unprognostic (2.50e-3)" "unprognostic (1.26e-1)" "prognostic unfavourable (5.16e-4)" "unprognostic (1.28e-1)" "unprognostic (2.07e-1)" "unprognostic (2.38e-2)" "prognostic unfavourable (8.25e-4)" "unprognostic (6.24e-2)" "unprognostic (4.38e-2)" "unprognostic (9.69e-2)" "prognostic favourable (4.65e-4)" 26.0 21.6 8.2 22.7 10.8 17.3 24.4 8.4 10.7 28.2 20.7 8.7 15.4 8.0 27.9 21.5 19.2 25.2 22.1 16.5 10.3 4.3 17.7 5.1 27.6 21.1 8.2 8.0 25.4 8.9 23.7 11.5 17.5 10.0 20.1 4.1 17.6 16.3 18.9 12.5 19.7 13.9 24.9 10.3 23.1 14.9 9.5 11.5 85.8 20.9 12.9 21.0 24.8 25.0 1.4 0.6 10.5 1.9 1.7 1.5 1.8 14.0 9.6 10.0 16.3 7.8 21.9 9.0 13.9 10.8 10.1 6.6 12.8 13.4 28.3 46.2 12.6 13.1 2.3 10.8 3.7 13.2 4.8 9.6 9.4 2.9 8.5 3.0 0.4 14.3 3.8 10.0 5.4 20.8 10.2 11.6 6.4 6.1 27.8 7.5 14.0 10.7 21.4 5.3 10.2 4.3 9.2 2.8 6.8 10.6 4.9 5.0 4.6 4.1 23.5 20.7 22.5 16.8 9.8 26.2 19.0 22.5 8.5 14.3 6.7 0.0 1.9 0.0 1.5 0.8 1.5 1.4 1.3 1.1 0.6 1.1 1.5 1.0 10.5 1.7 0.7 0.5 0.6 1.8 8.2 10.8 8.4 10.7 10.3 4.3 8.2 8.0 10.0 11.5 HDAC8 "HDACL1, MRXS6, RPD3, WTS" ENSG00000147099 "Histone deacetylase 8" Q9BY41 X 72329516-72573103 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Disease mutation, FDA approved drug targets, Mental retardation, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048560 Supported Approved "Nucleoplasm,Plasma membrane" "Nucleoplasm, Plasma membrane" "HPA048560: " "unprognostic (1.42e-1)" "unprognostic (6.62e-3)" "unprognostic (3.20e-2)" "unprognostic (9.24e-3)" "unprognostic (1.10e-1)" "unprognostic (1.10e-1)" "unprognostic (4.64e-2)" "unprognostic (6.03e-2)" "unprognostic (1.58e-1)" "unprognostic (2.81e-2)" "unprognostic (3.17e-2)" "unprognostic (9.68e-2)" "unprognostic (8.42e-2)" "unprognostic (2.33e-3)" "unprognostic (9.10e-2)" "unprognostic (7.15e-3)" "unprognostic (2.12e-3)" 9.6 22.5 14.7 9.9 16.2 10.2 12.4 31.4 20.6 12.6 10.4 13.9 11.5 8.6 12.3 28.2 11.0 9.4 9.4 12.6 15.0 15.2 16.8 18.6 10.2 9.6 14.9 9.4 12.8 15.9 13.6 22.0 11.2 19.3 13.3 12.8 14.3 12.2 10.3 10.4 9.3 8.4 13.1 12.2 9.5 10.7 3.6 14.0 8.0 15.0 8.2 11.9 10.4 10.1 9.4 12.8 19.7 13.2 7.7 11.4 7.7 12.3 16.9 12.4 17.2 17.0 12.7 8.6 7.1 13.9 11.0 12.5 12.2 12.7 8.6 22.7 9.8 9.0 23.1 13.9 14.7 14.1 16.4 11.3 21.7 14.2 9.3 18.8 20.1 13.3 10.3 13.5 10.1 16.9 12.6 24.1 14.7 15.5 8.8 24.7 17.2 24.4 12.1 16.0 15.4 19.2 13.0 8.9 19.4 16.9 13.5 17.3 6.8 16.1 12.7 9.1 13.1 13.0 8.0 9.2 14.7 10.9 12.3 20.8 11.7 7.2 13.2 19.7 8.8 11.8 6.9 9.4 9.5 7.3 12.8 9.1 7.6 7.1 0.7 7.7 10.5 4.8 11.4 7.7 14.7 16.2 31.4 20.6 15.0 15.2 14.9 9.4 19.3 14.0 HDAC9 "HD7, HDAC, HDAC7B, KIAA0744, MITR" ENSG00000048052 "Histone deacetylase 9" Q9UKV0 7 18086949-19002416 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HAP1: 54.3;hTERT-HME1: 26.0;SH-SY5Y: 21.7;U-698: 21.5;WM-115: 22.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "myeloid DC: 29.5" "Group enriched" "Detected in many" 9 "B-cells: 21.8;dendritic cells: 29.5;monocytes: 9.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028926 Uncertain Approved Nucleoplasm Nucleoplasm "HPA028926: AB_10602327" "unprognostic (2.06e-2)" "unprognostic (2.67e-1)" "unprognostic (2.30e-1)" "unprognostic (1.17e-1)" "unprognostic (2.74e-1)" "unprognostic (5.54e-2)" "unprognostic (2.20e-2)" "unprognostic (2.32e-1)" "unprognostic (2.21e-1)" "unprognostic (2.45e-1)" "unprognostic (5.01e-1)" "unprognostic (7.58e-2)" "unprognostic (1.29e-1)" "unprognostic (3.94e-2)" "unprognostic (1.32e-1)" "unprognostic (1.02e-1)" "unprognostic (6.87e-3)" 10.7 13.5 12.6 10.7 16.2 5.9 8.4 19.1 16.9 11.6 7.4 11.3 7.5 3.8 17.8 6.7 4.7 10.5 7.5 14.9 13.1 12.0 3.9 3.1 5.7 18.9 13.9 14.9 3.0 2.7 3.0 17.7 6.8 11.2 12.5 6.2 9.7 6.9 16.5 15.5 3.8 8.4 14.4 17.6 17.4 9.1 8.7 18.2 2.9 5.5 5.4 19.3 7.1 9.6 21.8 29.5 0.5 9.7 2.0 2.1 4.5 12.3 0.0 2.0 0.0 0.3 2.8 0.0 0.7 7.3 3.1 5.3 0.1 4.0 5.3 13.7 8.2 1.8 54.3 1.0 8.0 0.0 0.3 0.0 0.0 0.0 0.0 1.0 0.0 1.0 1.0 9.6 26.0 0.1 0.0 8.3 4.2 0.0 0.5 1.0 6.6 1.2 1.5 0.8 3.1 1.7 3.3 3.9 21.7 0.1 0.1 3.9 0.2 4.9 0.5 11.3 3.6 0.6 7.0 9.6 4.1 21.5 2.9 0.5 22.2 0.1 9.7 0.0 1.7 6.7 1.7 21.8 0.6 0.8 29.5 16.3 0.0 0.9 0.5 2.0 3.8 6.4 2.1 4.5 12.6 16.2 19.1 16.9 13.1 12.0 13.9 14.9 11.2 18.2 HMGCR ENSG00000113161 "3-hydroxy-3-methylglutaryl-CoA reductase" P04035 5 75336329-75362104 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cholesterol biosynthesis, Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008338, CAB016797" Approved "CAB016797: , HPA008338: AB_10960401" "unprognostic (5.07e-2)" "unprognostic (1.65e-2)" "unprognostic (3.65e-3)" "unprognostic (1.02e-2)" "unprognostic (1.65e-3)" "unprognostic (1.02e-1)" "unprognostic (1.45e-1)" "unprognostic (4.41e-2)" "unprognostic (5.45e-2)" "unprognostic (1.90e-2)" "unprognostic (1.41e-1)" "unprognostic (3.99e-2)" "prognostic favourable (9.42e-6)" "unprognostic (2.44e-1)" "unprognostic (2.55e-2)" "unprognostic (3.64e-3)" "unprognostic (4.37e-2)" 5.6 28.9 12.4 8.7 31.1 12.1 16.4 14.4 36.3 13.9 23.0 10.9 7.1 18.9 9.0 14.4 35.0 6.5 8.2 4.0 21.8 16.5 12.1 53.5 12.1 7.0 9.8 19.4 15.2 8.4 16.2 11.4 9.2 29.6 12.4 19.7 7.8 12.4 4.5 3.4 36.1 19.0 6.8 17.0 7.9 14.6 14.0 8.8 13.9 12.5 23.2 12.4 6.2 18.1 4.3 12.5 23.2 11.0 9.5 6.5 5.1 15.8 6.3 63.7 21.9 13.5 26.1 16.0 4.6 12.8 9.4 20.9 23.5 39.2 14.2 16.7 7.4 20.1 33.0 53.7 9.9 4.8 12.1 10.8 9.5 18.1 19.9 9.0 8.0 16.9 31.6 32.6 16.2 7.5 11.6 21.8 14.7 10.4 16.6 9.1 27.2 4.7 11.7 19.0 20.3 38.5 37.2 22.1 10.0 10.1 10.5 9.1 10.3 23.8 8.7 5.1 7.6 5.4 7.8 7.0 8.8 19.6 7.4 17.7 10.5 6.7 11.0 6.3 6.1 6.9 5.1 4.3 4.6 6.4 12.5 4.2 4.5 6.2 23.2 9.5 7.4 3.9 6.5 5.1 12.4 31.1 14.4 36.3 21.8 16.5 9.8 19.4 29.6 8.8 HMMR "CD168, RHAMM" ENSG00000072571 "Hyaluronan mediated motility receptor" O75330 5 163460203-163491945 "CD markers, FDA approved drug targets, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 54.5;testis: 16.7" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "T-reg: 4.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB002433, HPA040025, HPA043926, HPA061524" Enhanced Enhanced Microtubules,Centrosome,Cytosol Microtubules "Centrosome, Cytosol" "CAB002433: AB_564080, HPA040025: , HPA043926: , HPA061524: " "unprognostic (3.53e-3)" "unprognostic (1.01e-1)" "unprognostic (3.38e-3)" "unprognostic (8.88e-3)" "unprognostic (2.12e-1)" "prognostic unfavourable (5.52e-4)" "prognostic unfavourable (1.93e-7)" "prognostic unfavourable (1.09e-4)" "unprognostic (5.68e-2)" "unprognostic (2.50e-1)" "prognostic unfavourable (3.71e-5)" "unprognostic (1.02e-1)" "unprognostic (0.00e+0)" "unprognostic (1.65e-2)" "unprognostic (4.98e-2)" "unprognostic (2.39e-1)" "unprognostic (1.77e-2)" 1.6 1.4 0.6 13.4 0.6 11.4 2.4 0.4 0.9 1.7 5.0 0.6 0.6 4.5 0.6 2.3 6.4 0.5 0.9 1.6 0.8 0.7 1.4 1.8 2.5 10.9 1.0 0.4 0.6 1.1 0.6 0.5 6.9 1.1 0.7 5.6 0.4 1.6 0.2 1.4 2.3 4.8 1.4 1.9 8.6 2.6 16.7 0.3 54.5 0.7 5.6 10.8 1.8 2.1 1.2 1.8 0.6 0.7 1.5 4.8 0.8 21.1 13.3 27.1 14.5 1.4 2.6 20.2 20.1 9.8 25.2 22.9 27.0 40.8 35.1 19.2 6.2 24.4 31.3 19.0 43.0 31.8 9.7 21.0 9.5 13.1 0.4 18.6 19.4 0.7 1.1 23.6 18.5 14.3 19.8 28.8 26.2 7.7 19.6 10.6 23.4 14.5 21.4 36.3 17.6 9.8 5.7 22.7 12.6 29.9 9.4 11.4 27.6 14.9 9.3 18.1 15.3 14.4 26.9 15.5 25.9 28.3 11.9 28.8 17.3 0.5 0.7 0.0 0.5 0.3 0.9 1.2 1.0 0.6 0.9 0.9 0.4 0.7 0.6 1.5 0.0 1.8 4.8 0.8 0.6 0.6 0.4 0.9 0.8 0.7 1.0 0.4 1.1 0.3 HPD "4-HPPD, 4HPPD, GLOD3, PPD" ENSG00000158104 "4-hydroxyphenylpyruvate dioxygenase" P32754 12 121839527-121863596 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Phenylalanine catabolism, Tyrosine catabolism" "Dioxygenase, Oxidoreductase" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "liver: 267.5" "Cell line enriched" "Detected in some" 30 "Hep G2: 104.7" "Cancer enriched" "Detected in many" 100 "liver cancer: 540.9" "Region enriched" "Detected in single" 29 "pons and medulla: 13.7" "Group enriched" "Detected in many" 4 "eosinophil: 9.8;neutrophil: 4.8;plasmacytoid DC: 5.0" "Group enriched" "Detected in many" 5 "dendritic cells: 5.0;granulocytes: 9.8" "Region enriched" "Detected in single" 8 "amygdala: 0.4" "Low region specificity" "Detected in many" "HPA038321, HPA038322" Enhanced Uncertain "Nuclear speckles" 23000000 "Nuclear speckles" "HPA038321: AB_2675957, HPA038322: AB_10670778" "unprognostic (3.01e-2)" "unprognostic (2.30e-1)" "unprognostic (4.81e-3)" "unprognostic (1.42e-3)" "unprognostic (1.10e-2)" "unprognostic (9.08e-2)" "unprognostic (1.13e-2)" "unprognostic (8.84e-2)" "unprognostic (5.58e-2)" "unprognostic (6.14e-3)" "unprognostic (9.72e-3)" "unprognostic (8.61e-3)" "unprognostic (7.16e-2)" "unprognostic (1.97e-1)" "unprognostic (4.12e-1)" "unprognostic (3.06e-2)" "unprognostic (2.34e-1)" 0.1 0.5 0.0 0.1 0.1 0.0 0.4 0.1 0.3 0.2 0.1 2.1 0.3 0.0 0.3 0.4 0.1 0.7 0.2 0.3 0.4 0.0 51.3 267.5 0.2 0.4 0.1 0.0 0.7 0.7 0.0 0.1 0.0 13.7 0.5 0.0 3.8 0.0 0.8 0.2 0.0 0.1 0.4 0.2 0.2 0.1 0.8 0.1 0.0 0.1 0.1 0.1 0.6 0.2 0.1 5.0 9.8 1.4 0.0 0.3 0.3 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 1.1 104.7 2.5 0.3 3.5 0.8 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.2 0.0 0.1 2.1 0.0 0.0 0.3 0.1 0.0 0.3 0.0 0.0 0.3 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.2 0.0 0.0 0.8 9.8 0.0 1.0 0.1 0.1 0.1 0.1 1.3 0.1 0.3 0.2 4.8 0.0 1.4 5.0 0.0 0.3 0.0 0.1 0.1 0.3 0.4 0.0 0.1 0.0 13.7 0.1 HPRT1 "HGPRT, HPRT" ENSG00000165704 "Hypoxanthine phosphoribosyltransferase 1" P00492 X 134460153-134520513 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Purine salvage" "Glycosyltransferase, Transferase" "Disease mutation, FDA approved drug targets, Gout" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006360, CAB012200" Enhanced Supported Cytosol 15000000 Cytosol "CAB012200: AB_297217, HPA006360: AB_1079082" "unprognostic (2.02e-1)" "unprognostic (2.18e-1)" "unprognostic (1.46e-1)" "unprognostic (2.32e-3)" "unprognostic (8.55e-2)" "prognostic unfavourable (1.35e-5)" "unprognostic (1.58e-2)" "unprognostic (4.77e-3)" "unprognostic (4.93e-2)" "unprognostic (2.02e-2)" "unprognostic (7.05e-2)" "unprognostic (1.38e-3)" "unprognostic (6.00e-2)" "unprognostic (2.12e-1)" "unprognostic (2.04e-1)" "unprognostic (2.70e-2)" "unprognostic (1.51e-1)" 7.9 14.9 31.0 12.6 30.2 25.3 11.3 24.2 49.8 7.5 13.7 5.8 9.8 11.0 7.9 36.2 10.3 9.4 8.1 12.8 27.6 37.3 18.4 24.7 7.3 15.9 23.5 28.9 9.8 20.2 9.9 18.6 8.8 34.4 8.8 13.2 9.7 7.1 9.5 10.7 8.0 14.2 9.5 9.8 8.7 17.1 39.7 4.9 13.7 12.3 8.6 15.9 10.8 7.5 13.5 19.7 10.1 18.5 19.9 29.3 12.6 31.0 15.0 4.2 8.7 9.5 13.7 12.8 16.6 16.0 21.3 28.0 13.4 19.9 35.2 37.9 10.8 19.1 27.4 22.8 36.8 29.2 51.3 19.1 21.3 13.6 9.4 41.0 17.6 10.1 8.6 18.9 30.3 24.5 14.6 0.9 16.6 31.7 31.6 35.6 8.7 40.3 19.0 21.6 36.1 25.6 15.1 26.9 14.7 12.0 9.7 11.3 8.3 17.2 12.1 14.5 10.9 41.4 41.2 13.4 23.2 0.2 17.8 45.6 7.9 2.2 11.6 10.1 11.6 18.5 16.7 12.3 17.3 15.3 19.7 13.5 14.3 15.1 2.9 19.9 17.2 8.2 29.3 12.6 31.0 30.2 24.2 49.8 27.6 37.3 23.5 28.9 34.4 4.9 HRH1 ENSG00000196639 "Histamine receptor H1" P35367 3 11137093-11263557 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC TERT1: 17.4;hTEC/SVTERT24-B: 17.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "T-reg: 3.5" "Group enriched" "Detected in many" 7 "granulocytes: 1.2;T-cells: 3.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029740 Uncertain Supported "Plasma membrane,Cytosol" "Plasma membrane" Cytosol "HPA029740: AB_10601578" "unprognostic (4.60e-3)" "unprognostic (3.41e-2)" "unprognostic (6.37e-3)" "unprognostic (9.55e-2)" "unprognostic (3.32e-2)" "unprognostic (1.07e-2)" "unprognostic (9.60e-3)" "unprognostic (4.00e-3)" "unprognostic (7.54e-2)" "unprognostic (4.98e-2)" "prognostic unfavourable (1.27e-5)" "unprognostic (1.43e-1)" "unprognostic (1.70e-2)" "unprognostic (1.66e-1)" "unprognostic (3.13e-2)" "unprognostic (7.19e-2)" "unprognostic (1.20e-1)" 9.1 4.4 7.3 4.6 4.4 0.2 9.6 0.5 10.6 8.0 13.5 1.3 2.4 3.8 6.2 7.2 5.7 10.6 9.9 7.0 5.1 4.0 3.3 1.1 8.2 1.8 2.2 2.1 8.7 2.1 1.7 1.2 5.5 3.2 7.2 7.2 2.0 3.4 6.1 3.0 8.0 10.5 9.2 8.6 1.4 3.3 2.4 2.0 0.1 2.5 7.2 3.1 11.2 16.2 0.1 0.3 1.2 0.2 0.1 3.5 0.1 1.5 3.4 0.0 0.0 1.6 17.4 2.4 2.6 8.7 7.8 5.3 0.6 12.5 0.0 7.8 6.0 9.8 0.0 3.5 10.6 5.5 0.0 0.8 5.6 0.0 5.2 2.4 1.4 6.0 2.2 17.5 6.2 10.8 0.0 0.0 3.4 0.0 0.0 1.1 0.0 3.2 0.2 0.9 0.3 13.9 2.0 0.1 0.0 3.7 2.7 0.0 0.0 1.9 16.1 8.8 5.5 8.9 13.0 0.0 0.9 0.0 13.4 2.2 7.5 0.4 0.2 0.0 0.1 0.2 0.0 0.0 1.3 0.5 0.3 0.1 0.1 0.1 1.2 0.1 0.0 0.1 3.5 0.1 7.3 4.4 0.5 8.4 5.1 4.0 2.2 2.1 3.2 2.0 HRH2 ENSG00000113749 "Histamine receptor H2" P25021 5 175658030-175710756 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "blood: 45.7;bone marrow: 30.1" "Group enriched" "Detected in some" 4 "RPMI-8226: 35.4;SK-MEL-30: 10.6;THP-1: 9.8;U-937: 11.8" "Cancer enhanced" "Detected in many" "renal cancer: 4.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 45.7" "Group enriched" "Detected in many" 5 "granulocytes: 45.7;monocytes: 13.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA013770 Approved "HPA013770: AB_1851086" "unprognostic (8.56e-3)" "unprognostic (1.62e-1)" "unprognostic (6.66e-2)" "unprognostic (5.96e-2)" "unprognostic (3.49e-2)" "unprognostic (1.80e-1)" "unprognostic (1.20e-1)" "unprognostic (4.77e-2)" "unprognostic (9.93e-2)" "unprognostic (5.76e-2)" "unprognostic (1.52e-1)" "unprognostic (2.35e-1)" "unprognostic (3.71e-3)" "unprognostic (2.01e-2)" "unprognostic (1.97e-2)" "unprognostic (1.97e-3)" "unprognostic (1.77e-2)" 7.9 1.5 5.9 11.1 11.6 30.1 2.8 1.0 12.1 3.9 2.8 0.9 0.5 5.9 2.3 1.3 1.6 2.7 2.6 18.6 3.4 1.7 2.4 1.2 5.4 12.3 2.3 4.9 1.6 1.6 0.3 1.3 9.5 2.4 3.0 1.3 0.6 1.7 4.8 1.2 2.1 7.2 3.5 4.4 9.9 10.3 1.2 5.6 9.9 1.8 0.2 3.0 2.8 2.0 0.0 6.4 45.7 13.1 0.6 2.3 3.7 0.0 0.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 2.7 1.6 0.0 3.8 0.0 35.4 0.0 0.2 0.2 0.0 0.0 0.0 10.6 0.0 9.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 11.8 2.4 28.9 12.9 13.6 0.0 12.0 0.1 0.0 1.1 0.2 6.4 0.0 2.3 1.4 45.7 0.6 13.1 5.0 0.8 3.7 5.9 11.6 1.0 12.1 3.4 1.7 2.3 4.9 2.4 5.6 HSD3B1 "HSD3B, HSDB3, SDR11E1" ENSG00000203857 "Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1" P14060 1 119507198-119515054 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Lipid metabolism, Steroid metabolism, Steroidogenesis" "Isomerase, Multifunctional enzyme, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 19 "placenta: 231.4" "Cell line enriched" "Detected in some" 9 "CACO-2: 37.0" "Cancer enhanced" "Detected in single" "urothelial cancer: 1.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA043261, HPA043264, HPA044028" Supported Approved "Nucleoli,Endoplasmic reticulum,Cytokinetic bridge" "Nucleoli, Endoplasmic reticulum" "Cytokinetic bridge" "HPA043261: , HPA043264: , HPA044028: " "unprognostic (1.53e-1)" "unprognostic (7.11e-2)" "unprognostic (1.15e-1)" "unprognostic (1.04e-1)" "prognostic favourable (4.59e-5)" 0.1 0.6 0.0 0.0 0.3 0.0 0.7 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.1 0.5 0.0 0.0 231.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 4.5 11.9 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.1 0.0 0.0 0.0 37.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 4.1 0.4 0.5 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 HSD3B2 SDR11E2 ENSG00000203859 "Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2" P26439 1 119414931-119423035 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Steroidogenesis "Isomerase, Multifunctional enzyme, Oxidoreductase" "Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "adrenal gland: 223.2" "Cell line enhanced" "Detected in some" "SCLC-21H: 1.5;SH-SY5Y: 1.4;SK-MEL-30: 5.1;TIME: 1.2;WM-115: 3.2" "Cancer enhanced" "Detected in single" "testis cancer: 0.6" "Region enriched" "Detected in single" 198 "basal ganglia: 19.8" "Not detected" "Not detected" "Not detected" "Not detected" "HPA043261, HPA043264, HPA044028" Supported Uncertain "Nucleoli,Endoplasmic reticulum,Cytokinetic bridge" "Nucleoli, Endoplasmic reticulum" "Cytokinetic bridge" "HPA043261: , HPA043264: , HPA044028: " "unprognostic (3.56e-1)" "unprognostic (1.85e-1)" "unprognostic (2.80e-1)" "unprognostic (2.72e-2)" "unprognostic (8.87e-2)" "unprognostic (3.91e-2)" "unprognostic (3.43e-2)" "unprognostic (1.94e-1)" "unprognostic (6.51e-2)" "unprognostic (1.97e-2)" "unprognostic (1.55e-1)" 0.0 223.2 0.0 0.8 19.8 0.0 0.0 0.0 0.0 0.0 0.5 43.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.9 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 3.6 0.2 0.0 0.0 0.0 1.9 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.1 0.0 0.0 0.0 1.5 1.4 0.0 0.0 5.1 0.0 0.0 1.2 0.2 0.1 0.1 0.7 0.0 0.0 0.0 0.8 0.0 3.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HTR1A "5-HT1A, ADRB2RL1, ADRBRL1" ENSG00000178394 "5-hydroxytryptamine receptor 1A" P08908 5 63960356-63962507 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 24 "brain: 21.5;ovary: 10.4" "Group enriched" "Detected in some" 32 "NTERA-2: 5.3;SCLC-21H: 4.3" "Not detected" "Not detected" "Group enriched" "Detected in many" 6 "amygdala: 14.7;cerebral cortex: 10.7;hippocampal formation: 21.5" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA018073 Uncertain "HPA018073: AB_1856704" "unprognostic (1.81e-1)" 0.2 0.4 14.7 0.2 1.0 0.2 0.2 0.1 10.7 0.2 0.2 0.0 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.5 21.5 2.4 0.2 0.2 0.3 0.2 0.7 2.7 10.4 0.2 0.2 0.1 0.2 0.9 0.3 0.2 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.5 0.2 0.2 0.6 0.0 0.0 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.7 1.0 0.1 10.7 21.5 2.4 0.7 2.7 0.9 0.0 HTR1B "5-HT1B, 5-HT1DB, HTR1D2, S12" ENSG00000135312 "5-hydroxytryptamine receptor 1B" P28222 6 77461753-77463773 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 11.8;placenta: 14.2;stomach 1: 10.2" "Group enriched" "Detected in some" 15 "HUVEC TERT2: 40.8;TIME: 18.0" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in many" "basal ganglia: 11.8" "Cell type enriched" "Detected in single" 17 "basophil: 1.6" "Lineage enriched" "Detected in single" 17 "granulocytes: 1.6" "Region enriched" "Detected in many" 4 "basal ganglia: 34.5" HPA028808 Enhanced Supported "Plasma membrane" "Plasma membrane" "HPA028808: " "unprognostic (3.86e-2)" "unprognostic (3.56e-1)" "unprognostic (7.68e-2)" "unprognostic (2.58e-1)" "unprognostic (1.88e-1)" "unprognostic (1.18e-2)" "unprognostic (2.67e-1)" "unprognostic (2.11e-1)" "unprognostic (8.96e-2)" "unprognostic (4.03e-1)" "unprognostic (1.77e-2)" "unprognostic (1.24e-1)" "unprognostic (1.10e-3)" "unprognostic (3.08e-2)" "unprognostic (2.81e-2)" "unprognostic (1.34e-1)" "unprognostic (1.02e-1)" 2.2 1.5 1.3 1.1 11.8 0.3 2.4 0.4 3.7 2.9 0.6 0.1 0.0 0.6 1.1 1.0 1.4 0.8 2.8 0.4 1.0 2.1 0.9 0.3 1.1 0.3 1.2 0.9 1.1 0.5 0.3 0.5 14.2 3.0 1.6 0.4 0.3 1.3 1.2 0.9 0.5 0.4 4.1 0.6 0.4 10.2 1.5 0.6 0.0 0.5 0.0 0.3 2.6 1.4 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 1.9 0.9 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.1 0.4 1.0 40.8 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 11.8 0.4 3.7 1.0 2.1 1.2 0.9 3.0 0.6 HTR1E 5-HT1E ENSG00000168830 "5-hydroxytryptamine receptor 1E" P28566 6 86937306-87016683 "FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 16.4;ovary: 13.3" "Group enriched" "Detected in some" 22 "PC-3: 2.9;SH-SY5Y: 11.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA004931 Approved "HPA004931: AB_1856706" "unprognostic (2.25e-2)" "unprognostic (1.32e-1)" "unprognostic (6.29e-2)" "unprognostic (4.52e-2)" "unprognostic (1.25e-1)" 0.5 0.6 8.9 0.6 13.3 0.5 0.5 5.4 16.4 1.6 0.5 0.0 0.0 0.5 5.1 1.1 0.6 0.5 0.8 0.5 4.1 2.8 0.5 0.5 0.5 0.5 1.8 11.4 13.3 0.8 0.5 0.3 0.5 2.2 1.1 0.5 0.0 0.5 1.2 0.5 0.5 0.5 2.9 0.6 0.5 3.6 1.4 1.5 0.0 2.7 0.0 0.5 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.3 11.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.9 13.3 5.4 16.4 4.1 2.8 1.8 11.4 2.2 1.5 HTR1F "5-HT1F, HTR1EL" ENSG00000179097 "5-hydroxytryptamine receptor 1F" P30939 3 87990696-87993835 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "placenta: 5.7" "Group enriched" "Detected in some" 6 "A549: 1.2;K-562: 4.4;LHCN-M2: 4.3" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 16 "basophil: 3.2" "Lineage enriched" "Detected in single" 16 "granulocytes: 3.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA005555 Uncertain "HPA005555: AB_1856708" "unprognostic (1.66e-1)" "unprognostic (2.62e-1)" "unprognostic (2.58e-1)" "unprognostic (9.03e-2)" "unprognostic (1.09e-1)" "unprognostic (1.01e-2)" "unprognostic (4.78e-1)" "unprognostic (1.58e-1)" "unprognostic (2.77e-2)" "unprognostic (2.24e-1)" "unprognostic (1.33e-1)" "unprognostic (9.80e-2)" "unprognostic (2.67e-6)" "unprognostic (1.25e-4)" "unprognostic (1.55e-2)" "unprognostic (3.33e-2)" "unprognostic (3.31e-2)" 2.8 0.5 0.7 0.0 0.6 1.5 1.6 0.0 1.8 1.4 0.0 0.0 1.2 0.3 0.1 0.4 0.1 0.3 0.6 0.4 0.6 0.0 0.9 0.1 0.8 0.4 0.7 0.3 1.4 5.7 0.4 0.0 0.1 1.0 0.6 0.4 0.0 1.3 0.3 1.7 0.0 0.3 1.5 0.5 0.6 0.7 0.1 0.2 3.2 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 4.4 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 HTR2A "5-HT2A, HTR2" ENSG00000102468 "5-hydroxytryptamine receptor 2A" P28223 13 46831550-46897076 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "Behavior, Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "brain: 30.4" "Cell line enhanced" "Detected in some" "ASC diff: 3.7;ASC TERT1: 9.1;BEWO: 2.8;HEL: 2.8;U-138 MG: 4.6;U-2 OS: 2.9;U-87 MG: 2.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 8 "neutrophil: 1.2;plasmacytoid DC: 1.2" "Group enriched" "Detected in many" 8 "dendritic cells: 1.2;granulocytes: 1.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA014011 Enhanced "HPA014011: AB_1856709" "unprognostic (8.01e-2)" "unprognostic (2.71e-2)" "unprognostic (9.49e-2)" "unprognostic (7.40e-2)" "unprognostic (2.78e-1)" "unprognostic (1.99e-1)" "unprognostic (2.70e-2)" "unprognostic (4.31e-2)" "unprognostic (5.27e-2)" "unprognostic (3.97e-2)" "unprognostic (2.61e-1)" "unprognostic (2.90e-1)" "unprognostic (9.94e-5)" "unprognostic (4.78e-3)" "unprognostic (2.54e-1)" "unprognostic (2.91e-2)" "unprognostic (8.28e-2)" 1.9 1.0 9.5 1.7 13.5 0.6 1.3 0.6 30.4 1.6 1.2 1.2 0.0 1.1 1.6 0.6 1.4 1.1 2.9 1.5 3.8 5.1 0.7 0.6 1.0 0.6 3.3 13.3 1.0 0.6 0.6 0.5 0.6 1.8 0.9 1.6 2.0 0.6 1.5 0.9 0.7 1.1 4.4 1.2 0.6 1.0 1.5 0.7 0.0 0.7 0.0 0.8 1.9 1.5 0.1 1.2 1.2 0.0 0.0 0.1 1.5 0.0 0.0 0.0 0.0 3.7 9.1 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.1 0.1 0.8 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 1.0 0.1 4.6 2.9 0.0 0.2 0.1 0.0 0.0 2.2 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 1.2 0.0 0.0 1.2 0.0 1.5 9.5 13.5 0.6 26.4 3.8 5.1 3.3 13.3 1.8 0.7 HTR2B "5-HT(2B), 5-HT2B" ENSG00000135914 "5-hydroxytryptamine receptor 2B" P41595 2 231108230-231125118 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 26.0" "Group enriched" "Detected in some" 4 "HHSteC: 6.8;HSkMC: 13.0;SK-MEL-30: 23.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 12 "basophil: 3.8;T-reg: 2.9" "Group enriched" "Detected in many" 29 "granulocytes: 3.8;T-cells: 2.9" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA012867, HPA063658" Enhanced Supported Nucleoplasm Nucleoplasm "HPA012867: AB_1856710, HPA063658: " "unprognostic (1.86e-1)" "unprognostic (3.55e-2)" "unprognostic (1.20e-3)" "unprognostic (1.45e-2)" "unprognostic (1.12e-1)" "unprognostic (1.16e-1)" "unprognostic (1.53e-2)" "unprognostic (1.00e-1)" "unprognostic (1.33e-2)" "unprognostic (1.15e-4)" "unprognostic (3.59e-1)" "unprognostic (2.17e-2)" "unprognostic (1.42e-3)" "unprognostic (7.44e-4)" "unprognostic (1.81e-1)" "unprognostic (1.17e-1)" "unprognostic (1.14e-2)" 2.3 17.9 0.2 5.8 0.3 0.7 4.1 0.3 0.6 17.8 7.3 0.2 1.7 1.0 14.9 9.5 5.7 1.9 0.8 4.6 0.3 0.3 5.6 2.5 1.8 0.5 0.3 0.4 4.3 0.3 0.3 0.4 26.0 0.9 2.6 1.5 1.8 0.5 1.0 0.2 0.2 6.3 12.8 0.3 0.4 5.2 3.3 0.3 2.4 6.8 1.0 0.4 4.9 0.8 0.0 0.1 3.8 0.0 0.0 2.9 0.0 0.1 0.2 0.0 0.1 0.4 3.6 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 6.8 0.1 0.2 13.0 0.0 0.0 0.0 2.4 0.1 0.0 0.0 0.1 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.1 0.0 0.1 23.8 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.8 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 2.9 0.0 0.2 0.3 0.3 0.6 0.3 0.3 0.3 0.4 0.9 0.3 HTR3A "5-HT3A, 5-HT3R, HTR3" ENSG00000166736 "5-hydroxytryptamine receptor 3A" P46098 11 113974881-113990313 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 11.1;lymphoid tissue: 12.0;salivary gland: 8.6" "Cell line enhanced" "Detected in some" "CAPAN-2: 6.1;Daudi: 5.9;NTERA-2: 3.7;SCLC-21H: 19.6" "Cancer enriched" "Detected in many" 7 "ovarian cancer: 15.2" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 13 "memory B-cell: 4.1;naive B-cell: 9.7;plasmacytoid DC: 11.1" "Group enriched" "Detected in many" 104 "B-cells: 9.7;dendritic cells: 11.1" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 16 "amygdala: 3.3;cerebral cortex: 4.0;hippocampal formation: 4.2" HPA069442 Supported "HPA069442: " "unprognostic (6.46e-3)" "prognostic favourable (6.26e-4)" "unprognostic (1.09e-1)" "prognostic unfavourable (1.26e-4)" "unprognostic (3.36e-3)" "unprognostic (8.36e-3)" "unprognostic (1.65e-5)" "unprognostic (1.46e-2)" "unprognostic (8.87e-2)" "unprognostic (6.21e-2)" "unprognostic (6.80e-3)" "unprognostic (3.00e-2)" "unprognostic (1.65e-2)" "unprognostic (8.72e-2)" "unprognostic (2.01e-1)" "unprognostic (3.79e-1)" "unprognostic (3.40e-2)" 0.3 0.5 2.2 4.4 3.9 0.0 0.3 0.3 0.9 0.3 2.5 0.3 0.3 1.0 0.3 0.3 0.8 0.0 0.3 0.3 2.1 0.0 0.3 0.3 0.3 9.7 0.3 0.3 0.3 3.7 0.0 0.3 0.3 0.3 0.3 0.6 0.3 8.6 0.3 0.3 0.6 2.0 1.0 0.3 3.0 0.9 0.3 0.3 0.7 0.3 0.3 12.0 0.3 0.3 9.7 11.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 5.9 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.6 0.0 0.0 0.0 19.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.6 9.7 0.0 0.0 0.0 0.0 0.0 11.1 0.0 0.2 2.2 3.9 0.3 0.9 2.1 0.0 0.3 0.3 0.3 0.3 HTR3B 5-HT3B ENSG00000149305 "5-hydroxytryptamine receptor 3B" O95264 11 113904677-113946565 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 8.7" "Low cell line specificity" "Detected in many" "Not detected" "Not detected" "Region enriched" "Detected in many" 4 "cerebral cortex: 8.7" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Region enhanced" "Detected in single" "hypothalamus: 0.4" "Low region specificity" "Detected in many" HPA039559 Approved "HPA039559: AB_10672779" "unprognostic (1.60e-2)" "unprognostic (8.37e-2)" "unprognostic (2.84e-1)" "unprognostic (3.28e-1)" "unprognostic (1.71e-1)" "unprognostic (2.46e-1)" 0.2 0.2 1.0 0.8 2.1 2.4 0.2 0.4 8.7 0.3 0.4 0.2 0.0 0.3 0.5 1.6 2.6 0.2 0.2 0.2 1.2 0.7 1.0 0.2 0.2 0.5 0.8 1.4 0.3 0.3 0.1 0.2 0.2 0.0 0.2 0.5 0.0 0.5 0.1 0.5 1.2 0.5 0.1 0.7 0.5 0.3 1.5 0.0 0.0 0.5 0.0 0.5 0.3 0.6 1.6 1.3 2.9 0.9 1.9 0.9 0.1 0.4 1.4 0.8 0.7 1.6 0.9 1.2 0.1 0.2 0.2 0.2 0.9 0.9 1.9 0.5 0.5 0.5 0.6 0.6 0.8 0.5 0.7 0.6 1.9 1.8 0.3 1.5 1.4 1.1 0.5 0.2 0.0 0.2 0.7 1.5 0.3 0.2 0.9 1.6 0.4 0.2 0.8 1.4 0.9 0.9 0.7 0.7 2.7 0.5 1.6 1.1 0.6 0.4 1.8 1.4 1.1 1.4 1.0 1.1 0.7 1.3 0.9 0.5 0.8 1.6 0.9 0.3 0.9 0.5 0.7 1.3 0.8 0.6 0.5 1.6 0.9 0.9 2.9 1.9 0.3 1.3 0.7 0.1 1.0 2.1 0.4 8.7 1.2 0.7 0.8 1.4 0.0 0.0 HTR3E ENSG00000186038 "5-hydroxytryptamine receptor 3E" A5X5Y0 3 184097064-184106995 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "intestine: 7.0" "Cell line enriched" "Detected in single" 6 "RH-30: 5.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA049764 Enhanced "HPA049764: " "unprognostic (4.12e-2)" "unprognostic (5.86e-2)" "unprognostic (2.15e-1)" "unprognostic (4.57e-4)" "unprognostic (3.61e-3)" "unprognostic (1.15e-1)" "unprognostic (3.16e-1)" "unprognostic (4.47e-1)" "unprognostic (3.32e-1)" "unprognostic (2.67e-1)" "unprognostic (4.16e-2)" 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 5.7 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.0 1.1 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 HTR4 5-HT4 ENSG00000164270 "5-hydroxytryptamine receptor 4" Q13639 5 148451032-148677235 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "brain: 18.1;heart muscle: 7.2;intestine: 14.6;pituitary gland: 5.9" "Cell line enriched" "Detected in single" 5 "Karpas-707: 2.6" "Not detected" "Not detected" "Region enhanced" "Detected in many" "basal ganglia: 18.1" "Cell type enriched" "Detected in single" 8 "T-reg: 1.5" "Lineage enriched" "Detected in single" 15 "T-cells: 1.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA040591 Enhanced "HPA040591: " "unprognostic (1.12e-1)" "unprognostic (4.60e-2)" "unprognostic (7.74e-2)" "unprognostic (2.37e-1)" "unprognostic (5.02e-2)" "unprognostic (3.77e-2)" "unprognostic (4.68e-2)" "unprognostic (1.10e-2)" "unprognostic (1.13e-1)" "unprognostic (1.46e-1)" "unprognostic (3.40e-2)" "unprognostic (2.25e-1)" "unprognostic (4.49e-2)" "unprognostic (8.83e-5)" 0.4 1.4 1.9 1.1 18.1 0.1 0.2 0.1 3.2 0.6 4.3 0.0 0.0 8.0 0.3 0.1 0.3 0.4 1.5 7.2 5.2 0.6 0.1 0.2 0.3 0.2 0.5 1.3 0.2 0.1 0.1 5.9 0.1 0.1 0.1 4.9 0.0 0.2 0.2 0.2 0.2 14.6 1.1 0.3 0.2 0.2 0.2 2.4 0.0 0.2 0.0 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.5 0.0 1.9 18.1 0.1 3.2 5.2 0.6 0.5 1.3 0.1 2.4 HTR6 "5-HT6, 5-HT6R" ENSG00000158748 "5-hydroxytryptamine receptor 6" P50406 1 19665287-19679562 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "brain: 24.6" "Cell line enhanced" "Detected in some" "MCF7: 1.2;NTERA-2: 2.4;SH-SY5Y: 6.5" "Cancer enhanced" "Detected in single" "renal cancer: 0.6" "Group enriched" "Detected in many" 5 "basal ganglia: 24.6;cerebral cortex: 6.6" "Cell type enhanced" "Detected in some" "MAIT T-cell: 1.4;naive CD4 T-cell: 1.1" "Lineage enriched" "Detected in single" 14 "T-cells: 1.4" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 9.5" HPA068165 Uncertain "HPA068165: " "unprognostic (2.34e-2)" "unprognostic (1.84e-1)" "unprognostic (7.19e-3)" "unprognostic (3.84e-5)" "unprognostic (1.38e-4)" "unprognostic (2.69e-2)" "unprognostic (1.36e-1)" "unprognostic (2.80e-2)" "unprognostic (1.03e-1)" "unprognostic (5.33e-3)" "unprognostic (8.63e-2)" "unprognostic (5.47e-4)" "unprognostic (1.28e-1)" "unprognostic (2.49e-1)" "unprognostic (6.13e-3)" "unprognostic (2.02e-1)" 0.4 0.5 1.2 1.4 24.6 0.4 0.4 0.2 6.6 0.6 0.4 0.0 0.0 0.6 0.6 0.5 0.5 0.6 0.5 0.4 1.4 1.0 0.3 0.3 0.3 1.4 0.5 2.2 0.3 0.3 0.3 0.4 0.3 0.4 0.4 0.3 0.0 0.5 0.3 0.3 0.8 0.5 0.5 0.2 0.4 0.5 0.8 3.2 0.0 0.3 0.0 2.7 0.6 0.2 0.0 0.0 0.0 0.0 0.0 1.4 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 2.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 1.4 0.0 1.0 0.5 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.2 0.2 1.2 24.6 0.2 6.6 1.4 1.0 0.5 2.2 0.4 3.2 HTR7 5-HT7 ENSG00000148680 "5-hydroxytryptamine receptor 7" P34969 10 90740823-90857698 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 30.8;testis: 14.3" "Cell line enhanced" "Detected in some" "HBEC3-KT: 8.1;hTCEpi: 7.3;hTERT-HME1: 24.5;LHCN-M2: 9.8;U-87 MG: 7.5;WM-115: 9.3" "Group enriched" "Detected in some" 5 "cervical cancer: 0.9;head and neck cancer: 3.3;lung cancer: 0.9;urothelial cancer: 1.3" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 12 "myeloid DC: 4.6" "Lineage enriched" "Detected in single" 12 "dendritic cells: 4.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB022708, HPA073617" Approved Supported "Nuclear speckles,Plasma membrane,Cytosol" "Plasma membrane" "Nuclear speckles, Cytosol" "CAB022708: , HPA073617: " "unprognostic (1.17e-1)" "unprognostic (1.24e-2)" "unprognostic (4.72e-2)" "unprognostic (1.33e-1)" "unprognostic (5.51e-3)" "unprognostic (1.71e-2)" "unprognostic (1.89e-1)" "unprognostic (1.44e-1)" "unprognostic (1.15e-1)" "unprognostic (4.58e-3)" "unprognostic (3.32e-1)" "unprognostic (1.45e-1)" "unprognostic (2.89e-1)" "unprognostic (1.23e-3)" "unprognostic (1.38e-1)" "unprognostic (1.84e-2)" "unprognostic (6.49e-2)" 1.0 0.5 2.4 1.1 2.5 0.5 0.7 0.3 4.3 0.6 0.8 1.7 1.2 0.8 0.4 0.3 1.0 0.4 1.3 0.6 9.9 5.1 0.3 0.6 0.5 0.7 1.7 1.8 0.4 1.4 30.8 0.2 0.5 3.1 1.0 1.2 0.4 0.6 0.3 1.7 0.9 2.2 3.6 1.5 1.3 1.5 14.3 1.0 0.0 0.3 0.1 0.6 3.5 2.1 0.0 4.6 0.0 0.3 0.0 0.2 0.1 0.2 0.0 0.0 0.0 0.1 0.7 0.0 0.5 0.2 0.5 0.7 0.0 0.9 0.0 0.0 0.1 3.3 0.9 8.1 2.0 0.0 0.1 0.0 0.0 0.0 3.8 0.0 0.4 5.8 7.3 2.4 24.5 0.0 0.0 0.0 9.8 0.0 0.0 0.1 0.9 1.2 0.7 0.1 0.0 0.0 0.9 0.3 0.0 0.3 0.0 3.8 0.0 0.2 0.2 4.5 0.0 0.0 6.8 0.0 0.0 0.0 7.5 0.0 9.3 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.1 4.6 0.0 0.2 0.2 0.0 0.0 0.3 0.0 0.1 0.1 2.4 2.5 0.3 4.3 9.9 5.1 1.7 1.8 3.1 1.0 ICAM1 "BB2, CD54" ENSG00000090339 "Intercellular adhesion molecule 1" P05362 19 10270835-10286615 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 68.3;lung: 91.3" "Cell line enhanced" "Detected in many" "HHSteC: 31.1;Karpas-707: 88.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA002126, CAB002142, HPA004877" Enhanced Uncertain "Plasma membrane,Cytosol" 3100000000 "Plasma membrane, Cytosol" "CAB002142: AB_563596, HPA002126: AB_1078470, HPA004877: AB_1846317" "prognostic favourable (7.09e-4)" "unprognostic (1.88e-1)" "unprognostic (1.94e-1)" "unprognostic (2.63e-2)" "unprognostic (3.25e-3)" "unprognostic (3.05e-1)" "unprognostic (1.45e-2)" "unprognostic (3.48e-1)" "unprognostic (3.18e-2)" "unprognostic (1.09e-2)" "unprognostic (1.49e-2)" "unprognostic (1.79e-1)" "prognostic unfavourable (1.32e-6)" "unprognostic (2.77e-1)" "unprognostic (2.16e-2)" "unprognostic (2.25e-1)" "unprognostic (3.70e-3)" 26.1 8.6 4.0 41.0 4.1 36.5 15.0 1.0 4.5 5.6 10.0 2.7 1.6 6.1 8.5 7.7 7.9 10.7 19.8 16.3 2.6 2.1 10.9 68.3 91.3 32.8 5.4 1.7 12.4 7.2 2.5 4.0 9.3 6.8 10.4 6.6 10.6 7.2 3.6 13.9 6.9 7.9 8.0 7.8 42.2 7.3 6.5 3.6 8.3 11.6 13.7 13.4 14.8 17.1 2.2 13.3 22.2 14.2 7.9 5.6 8.9 8.2 0.1 1.5 0.0 0.4 0.9 2.1 1.7 18.5 4.1 12.5 2.7 9.3 7.6 25.8 0.7 1.7 0.3 0.0 8.7 22.7 0.0 0.7 0.2 11.3 31.1 0.2 4.5 10.9 0.7 2.6 4.0 2.1 2.8 88.5 0.3 0.6 0.1 6.4 0.5 4.7 0.2 0.0 28.1 7.0 0.0 0.0 0.2 11.4 0.6 18.1 1.4 0.5 6.4 4.2 0.4 2.3 0.1 27.0 27.8 4.7 6.8 4.9 6.2 2.2 13.9 2.6 3.0 14.2 5.6 2.2 2.4 3.6 13.3 0.9 1.0 2.2 22.2 7.9 7.9 7.5 3.4 8.9 4.0 4.1 1.0 4.5 2.6 2.1 5.4 1.7 6.8 3.6 IDE ENSG00000119912 "Insulin degrading enzyme" P14735 10 92451684-92574076 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Allosteric enzyme, Host cell receptor for virus entry, Hydrolase, Metalloprotease, Protease, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063478 Approved "Intracellular and membrane" 140000 "HPA063478: " "unprognostic (1.70e-1)" "unprognostic (6.40e-2)" "prognostic favourable (3.69e-4)" "prognostic favourable (3.53e-4)" "unprognostic (2.54e-1)" "unprognostic (1.78e-1)" "unprognostic (2.51e-1)" "unprognostic (3.79e-1)" "unprognostic (8.88e-2)" "unprognostic (2.57e-1)" "unprognostic (6.58e-2)" "unprognostic (7.79e-2)" "unprognostic (6.81e-2)" "unprognostic (9.24e-3)" "unprognostic (6.13e-2)" "unprognostic (3.89e-2)" "unprognostic (3.91e-1)" 9.8 13.1 6.9 11.7 8.8 6.0 19.8 8.6 9.4 10.5 9.9 6.5 17.5 7.4 10.2 15.9 13.0 8.4 9.6 13.6 5.8 5.3 13.3 21.3 7.9 9.2 8.9 5.1 7.7 15.7 19.4 11.1 9.4 7.6 11.6 10.0 10.5 11.0 17.2 31.1 45.2 10.7 14.3 8.8 9.9 10.3 18.1 7.5 13.5 12.0 13.9 10.7 11.5 9.8 7.4 11.3 3.8 13.7 7.7 10.6 5.5 12.2 18.1 14.1 29.0 13.8 11.6 7.8 10.8 25.7 11.4 9.7 18.4 14.5 17.3 16.0 15.8 15.8 18.6 11.9 7.5 20.7 11.4 8.6 15.1 16.1 12.1 26.2 13.6 8.2 11.6 13.4 19.4 19.2 16.0 12.3 12.9 8.2 8.7 10.3 11.2 7.2 12.1 13.2 11.0 16.8 22.9 6.6 9.2 14.6 10.5 9.5 15.0 7.4 17.8 7.4 8.4 7.7 13.9 11.3 14.1 18.5 10.8 21.0 5.1 2.3 8.2 3.8 6.7 11.4 5.9 7.4 7.9 6.5 11.3 5.3 6.0 6.4 0.5 7.7 13.7 4.4 10.6 5.5 6.9 8.8 8.6 9.4 5.8 5.3 8.9 5.1 7.6 7.5 IDH2 ENSG00000182054 "Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial" P48735 15 90083045-90102504 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Glyoxylate bypass, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 126.2;skeletal muscle: 190.7" "Cell line enhanced" "Detected in all" "MOLT-4: 68.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007831 Enhanced Supported Mitochondria 53000000 Mitochondria "HPA007831: AB_1851397" "unprognostic (2.45e-2)" "prognostic favourable (5.15e-5)" "unprognostic (2.92e-1)" "unprognostic (1.53e-1)" "unprognostic (3.53e-1)" "unprognostic (8.46e-2)" "unprognostic (3.83e-2)" "unprognostic (2.55e-3)" "unprognostic (1.86e-2)" "unprognostic (1.89e-2)" "unprognostic (2.76e-1)" "unprognostic (4.90e-2)" "unprognostic (2.19e-3)" "unprognostic (3.92e-3)" "unprognostic (4.46e-1)" "unprognostic (1.30e-2)" "unprognostic (2.58e-2)" 5.4 2.0 14.9 10.1 16.6 22.6 8.8 4.9 19.1 6.4 16.2 13.8 12.4 16.1 5.9 15.3 23.7 6.0 9.4 126.2 10.2 9.3 25.0 93.2 6.9 15.8 14.4 12.0 3.0 25.1 8.4 3.3 15.1 11.9 13.3 14.5 6.0 28.0 21.9 190.7 11.0 13.9 15.8 11.0 7.5 27.9 1.2 7.6 28.2 3.4 69.0 13.6 11.0 8.6 16.8 32.8 17.2 56.3 22.2 29.5 31.2 10.2 5.8 30.2 30.0 4.2 5.2 25.7 12.8 19.5 12.1 13.0 2.7 8.9 12.2 3.6 10.6 3.5 4.4 3.9 5.8 23.9 2.9 20.8 2.2 20.3 5.1 14.2 21.1 10.8 2.2 2.9 2.3 24.8 3.1 10.5 9.3 29.8 68.3 22.1 9.0 2.4 57.9 21.7 36.3 18.7 12.3 43.6 22.1 15.9 63.6 5.1 51.3 43.9 5.9 21.7 3.1 2.8 5.9 17.3 3.2 1.4 6.9 30.0 12.5 9.0 26.4 17.2 26.1 48.0 12.4 16.8 18.7 29.5 32.8 9.8 10.2 18.2 5.1 22.2 56.3 17.8 15.9 31.2 14.9 16.6 4.9 19.1 10.2 9.3 14.4 12.0 11.9 7.6 IDH3A ENSG00000166411 "Isocitrate dehydrogenase 3 (NAD(+)) alpha" P50213 15 78131498-78171949 "Citric acid cycle related proteins, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Tricarboxylic acid cycle" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "plasmacytoid DC: 47.2" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041465, HPA062971" Supported Enhanced Mitochondria 2000000 Mitochondria "HPA041465: AB_10794377, HPA062971: AB_2684913" "unprognostic (2.33e-1)" "unprognostic (1.21e-1)" "unprognostic (5.76e-3)" "unprognostic (2.26e-1)" "unprognostic (1.02e-1)" "unprognostic (4.01e-1)" "unprognostic (2.29e-1)" "unprognostic (6.47e-2)" "unprognostic (1.69e-2)" "unprognostic (2.30e-1)" "unprognostic (3.05e-1)" "unprognostic (1.42e-1)" "prognostic favourable (6.49e-8)" "unprognostic (1.40e-1)" "unprognostic (3.08e-2)" "unprognostic (4.49e-2)" "unprognostic (3.39e-2)" 14.6 18.1 18.0 13.0 25.3 6.5 7.7 16.1 29.5 9.9 17.6 11.9 6.1 24.5 11.2 5.9 12.0 8.4 6.5 41.5 16.6 16.8 15.2 10.4 8.8 11.0 20.6 18.1 8.0 9.2 18.5 12.4 8.4 29.0 10.1 18.8 10.4 11.2 11.9 47.7 11.1 23.8 11.9 18.1 10.1 8.9 11.5 13.8 16.2 8.1 26.5 16.4 11.1 10.3 10.1 47.2 6.1 17.0 5.5 6.0 7.4 15.9 21.9 4.0 13.9 10.0 10.2 8.7 19.0 9.3 15.5 11.8 15.5 9.7 34.0 14.1 11.1 24.1 36.9 14.7 14.4 14.9 12.2 13.1 23.7 7.0 8.5 25.4 18.8 7.7 9.1 15.1 15.9 9.7 16.8 14.0 9.8 15.2 18.6 6.8 4.9 8.2 10.8 17.0 10.6 12.9 21.7 15.9 6.1 21.8 31.2 17.6 12.4 13.8 10.0 18.3 17.0 24.1 30.6 16.0 35.6 18.1 12.9 24.3 14.3 4.2 9.4 2.7 5.3 17.0 5.7 9.2 5.2 4.8 14.2 10.1 5.6 6.0 6.1 5.5 16.6 47.2 5.6 7.4 18.0 25.3 16.1 29.5 16.6 16.8 20.6 18.1 29.0 13.8 IFNG ENSG00000111537 "Interferon gamma" P01579 12 68154768-68159747 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Antiviral defense, Growth regulation" Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 14.4;lung: 14.5" "Cell line enhanced" "Detected in some" "Karpas-707: 2.2;U-266/70: 2.2;U-698: 1.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 5 "gdT-cell: 7.3;memory CD4 T-cell: 3.3;memory CD8 T-cell: 8.6;naive CD8 T-cell: 5.2" "Lineage enriched" "Detected in many" 7 "T-cells: 8.6" "Low region specificity" "Detected in single" CAB010344 Approved "Secreted to blood" 400 "CAB010344: AB_2123447" "unprognostic (2.16e-4)" "unprognostic (1.93e-3)" "unprognostic (9.21e-2)" "unprognostic (1.04e-4)" "unprognostic (5.14e-1)" "unprognostic (3.96e-3)" "unprognostic (1.33e-1)" "unprognostic (3.17e-4)" "unprognostic (7.79e-2)" "unprognostic (7.97e-3)" "unprognostic (1.63e-2)" "unprognostic (5.36e-2)" "unprognostic (7.62e-9)" "unprognostic (3.54e-2)" "unprognostic (5.36e-1)" "unprognostic (6.32e-2)" "unprognostic (7.38e-3)" 2.4 0.9 0.3 4.5 0.3 14.4 0.5 0.1 1.0 1.4 0.9 0.5 0.0 0.2 0.6 1.4 1.3 0.2 0.6 1.0 0.3 0.3 0.7 4.1 14.5 8.5 1.5 0.4 0.4 0.2 0.0 0.5 0.8 0.6 1.2 0.4 1.1 1.4 0.2 1.7 0.3 0.7 0.7 1.3 4.1 0.8 0.2 0.0 0.8 1.3 3.1 4.7 2.2 0.6 0.5 0.0 0.2 0.0 1.2 8.6 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 7.3 0.0 0.0 0.0 3.3 8.6 0.0 0.5 0.8 5.2 0.2 1.2 0.0 0.0 0.2 1.1 0.3 0.3 0.1 1.0 0.3 0.3 1.5 0.4 0.6 0.0 IKBKB "IKK-beta, IKK2, IKKB, NFKBIKB" ENSG00000104365 "Inhibitor of nuclear factor kappa B kinase subunit beta" O14920 8 42271302-42332653 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001249, CAB004447" Enhanced Approved Cytosol Cytosol "CAB004447: AB_627785, HPA001249: AB_1079126" "unprognostic (1.04e-1)" "unprognostic (2.30e-2)" "unprognostic (1.31e-1)" "unprognostic (1.73e-3)" "unprognostic (1.26e-1)" "unprognostic (1.27e-3)" "unprognostic (1.95e-1)" "unprognostic (1.25e-3)" "unprognostic (1.75e-1)" "unprognostic (1.55e-1)" "unprognostic (3.27e-1)" "unprognostic (1.73e-1)" "unprognostic (1.20e-2)" "unprognostic (1.89e-2)" "unprognostic (9.20e-2)" "unprognostic (3.02e-1)" "prognostic favourable (1.46e-6)" 9.1 10.8 10.9 17.0 16.7 9.3 10.0 26.1 16.9 10.3 10.3 12.4 11.4 4.7 15.3 13.2 17.9 16.4 14.9 7.9 13.1 6.9 12.4 9.9 14.9 12.2 20.3 7.9 9.6 13.3 18.0 13.6 11.2 11.9 14.0 10.9 10.5 11.4 9.7 17.6 22.2 9.8 16.4 10.5 18.7 10.8 8.3 18.6 12.9 14.3 8.4 17.1 18.1 12.8 12.6 14.8 14.1 9.6 11.9 11.2 5.8 3.6 13.1 3.7 6.4 14.5 12.6 4.8 3.2 11.5 9.7 8.5 3.0 6.8 7.2 5.6 8.9 4.2 5.1 13.0 12.5 7.0 5.8 10.1 6.1 2.3 11.1 1.9 10.6 8.4 9.9 9.3 14.4 14.3 8.5 3.5 21.2 4.2 7.0 3.2 3.6 4.1 7.2 6.4 4.2 10.9 3.3 1.1 2.1 2.1 3.6 5.3 4.8 8.5 7.4 6.8 3.6 5.3 2.3 2.1 2.2 5.1 8.1 4.8 7.7 14.1 9.6 10.4 10.1 7.6 10.3 9.4 10.5 11.2 8.9 12.6 10.2 10.4 11.4 11.9 9.0 14.8 9.9 5.8 10.9 16.7 26.1 16.9 13.1 6.9 20.3 7.9 11.9 18.6 IMPDH1 "LCA11, RP10, sWSS2608" ENSG00000106348 "Inosine monophosphate dehydrogenase 1" P20839 7 128392277-128410252 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "GMP biosynthesis, Purine biosynthesis" "DNA-binding, Oxidoreductase, RNA-binding" "Disease mutation, FDA approved drug targets, Leber congenital amaurosis, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 88.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "classical monocyte: 21.6;eosinophil: 20.2;intermediate monocyte: 26.2;myeloid DC: 15.1;neutrophil: 49.9;non-classical monocyte: 31.0" "Group enriched" "Detected in all" 5 "dendritic cells: 15.1;granulocytes: 49.9;monocytes: 31.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001400 Approved Supported "Cytosol,Rods & Rings" Cytosol "Rods & Rings" "HPA001400: AB_1079139" "unprognostic (2.84e-1)" "prognostic unfavourable (3.87e-4)" "unprognostic (2.23e-2)" "unprognostic (6.45e-2)" "prognostic unfavourable (7.31e-5)" "unprognostic (6.03e-2)" "prognostic unfavourable (1.12e-7)" "unprognostic (1.24e-1)" "unprognostic (7.45e-3)" "unprognostic (1.03e-2)" "unprognostic (1.79e-1)" "unprognostic (2.50e-1)" "prognostic unfavourable (1.78e-12)" "unprognostic (1.65e-1)" "unprognostic (1.19e-1)" "unprognostic (1.10e-1)" "prognostic unfavourable (3.72e-5)" 26.0 7.4 7.5 20.7 8.5 24.5 37.1 7.7 10.2 11.3 10.9 3.6 12.4 5.2 8.5 6.5 14.6 9.1 7.6 12.6 7.6 5.0 7.5 3.5 14.8 31.2 5.1 5.8 10.7 20.3 5.2 12.0 7.2 9.9 12.1 6.3 19.5 20.6 11.4 3.5 11.9 8.8 12.3 6.4 25.1 20.6 7.1 5.6 3.9 5.5 11.2 9.7 14.2 9.9 4.1 15.1 49.9 31.0 2.8 6.4 11.7 25.1 21.6 3.2 24.2 13.7 10.0 9.2 17.2 10.9 14.8 9.6 15.7 8.1 16.0 5.9 25.6 19.3 18.3 24.3 7.4 5.8 20.4 10.6 16.0 11.1 12.5 13.9 5.0 11.8 11.6 15.0 14.9 17.4 10.5 12.1 4.9 17.3 9.7 37.4 18.3 25.4 11.7 6.0 33.2 6.5 8.1 13.0 13.1 11.1 88.5 15.6 10.0 27.0 15.9 24.9 9.1 13.0 12.2 9.1 8.4 20.6 12.7 30.9 15.1 2.3 21.6 20.2 5.9 26.2 6.4 4.1 4.7 5.1 15.1 2.4 2.8 3.4 49.9 2.8 31.0 1.5 5.2 11.7 7.5 8.5 7.7 10.2 7.6 5.0 5.1 5.8 9.9 5.6 IMPDH2 ENSG00000178035 "Inosine monophosphate dehydrogenase 2" P12268 3 49024325-49029408 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "GMP biosynthesis, Purine biosynthesis" "DNA-binding, Oxidoreductase, RNA-binding" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001400, CAB020717" Approved Enhanced "Cytosol,Rods & Rings" 19000 Cytosol "Rods & Rings" "CAB020717: , HPA001400: AB_1079139" "unprognostic (2.09e-2)" "unprognostic (2.91e-1)" "unprognostic (5.96e-2)" "unprognostic (1.20e-1)" "unprognostic (7.31e-3)" "unprognostic (1.56e-1)" "prognostic unfavourable (3.22e-4)" "unprognostic (1.30e-1)" "unprognostic (2.65e-1)" "unprognostic (2.17e-1)" "unprognostic (5.44e-2)" "unprognostic (4.24e-2)" "unprognostic (1.30e-1)" "unprognostic (3.85e-1)" "unprognostic (5.80e-2)" "unprognostic (2.24e-1)" "unprognostic (4.47e-2)" 25.0 21.5 16.1 25.7 15.4 23.9 47.0 9.7 21.1 34.7 24.9 15.1 19.1 18.9 29.5 19.8 40.1 51.9 33.3 29.3 13.0 11.2 21.4 29.4 19.9 52.5 18.1 13.0 89.0 88.8 19.1 16.6 23.2 15.6 33.2 31.7 10.8 22.1 22.2 61.4 40.7 17.8 34.1 15.2 23.7 22.2 15.3 15.4 31.2 29.8 51.3 33.4 30.3 32.1 31.6 18.8 6.2 16.8 21.6 34.8 16.0 39.6 22.9 31.8 32.8 47.6 86.9 30.9 27.5 44.6 66.4 56.6 39.8 35.8 72.4 19.7 33.1 27.7 65.6 55.9 58.2 19.0 21.9 53.6 33.8 36.4 40.8 56.8 22.1 77.2 61.6 63.4 115.3 46.6 32.0 41.0 53.4 32.2 48.0 39.5 41.2 46.3 21.0 33.5 71.0 37.8 25.7 20.6 20.3 29.9 33.8 49.7 41.9 25.3 23.4 29.1 54.0 70.7 70.5 39.8 28.7 34.7 33.6 63.4 28.4 6.2 10.1 4.0 17.0 16.8 31.7 31.6 23.3 19.6 18.8 31.1 34.8 28.6 4.4 21.6 13.9 14.5 15.5 16.0 16.1 15.4 9.7 21.1 13.0 11.2 18.1 13.0 15.6 15.4 INSR CD220 ENSG00000171105 "Insulin receptor" P06213 19 7112255-7294034 "CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Carbohydrate metabolism" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Diabetes mellitus, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 64.5" "Cell line enhanced" "Detected in many" "Karpas-707: 30.6;U-266/70: 22.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 7 "dendritic cells: 8.8;granulocytes: 5.1;monocytes: 10.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036302, HPA036303" Uncertain Approved "Vesicles,Plasma membrane" 72000 Vesicles "Plasma membrane" "HPA036302: , HPA036303: " "unprognostic (4.64e-2)" "unprognostic (2.42e-1)" "unprognostic (9.65e-3)" "unprognostic (9.70e-2)" "unprognostic (1.44e-1)" "unprognostic (1.15e-2)" "unprognostic (2.58e-1)" "unprognostic (5.09e-2)" "unprognostic (1.97e-1)" "unprognostic (3.05e-1)" "unprognostic (9.29e-2)" "unprognostic (1.86e-1)" "unprognostic (6.33e-2)" "unprognostic (3.45e-3)" "unprognostic (2.43e-1)" "unprognostic (2.75e-1)" "unprognostic (8.82e-2)" 13.9 14.7 7.1 3.5 8.2 4.5 12.0 12.0 8.2 10.3 15.2 11.7 10.6 8.4 15.5 6.1 4.7 13.1 7.7 17.7 6.4 5.8 18.7 32.5 5.3 2.2 10.1 4.9 28.3 64.5 11.6 11.6 26.2 8.0 10.5 8.9 11.0 12.0 10.6 15.1 7.3 16.0 10.6 6.8 47.3 8.7 6.9 9.7 2.2 17.1 5.0 3.2 11.3 16.0 1.1 8.8 5.1 10.5 0.8 0.7 1.3 3.7 2.1 1.9 2.9 10.6 3.7 6.4 2.1 1.9 1.2 1.2 5.3 4.3 4.7 5.3 3.8 1.0 4.6 0.9 0.7 0.0 3.7 0.0 1.5 11.5 4.6 2.2 3.8 5.7 2.4 0.1 2.8 2.1 5.7 30.6 0.9 1.7 1.6 3.8 1.8 3.3 16.3 1.1 4.1 0.1 15.5 3.7 2.8 3.8 2.0 2.1 0.9 10.8 2.0 2.2 1.4 4.7 2.8 22.6 12.3 10.9 2.6 3.8 0.0 2.0 8.2 5.1 0.2 7.8 0.3 0.8 0.3 0.1 8.8 1.1 0.7 0.1 1.7 0.8 10.5 7.4 0.0 1.3 7.1 8.2 12.0 8.2 6.4 5.8 10.1 4.9 8.0 9.7 ITGA2B "CD41, CD41B, GP2B, PPP1R93" ENSG00000005961 "Integrin subunit alpha 2b" P08514 17 44372180-44389505 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.5;epididymis: 25.2;lymphoid tissue: 22.8" "Group enriched" "Detected in some" 13 "HEL: 69.4;HMC-1: 118.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 10 "basophil: 28.5" "Lineage enriched" "Detected in single" 54 "granulocytes: 28.5" "Low region specificity" "Detected in single" "CAB018611, HPA031168, HPA031169, HPA031170, HPA031171" Enhanced Approved "Plasma membrane" 1100000000 "Plasma membrane" "CAB018611: AB_2265153, HPA031168: AB_10670151, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773" "unprognostic (6.11e-2)" "unprognostic (3.23e-2)" "unprognostic (1.23e-1)" "unprognostic (4.85e-2)" "unprognostic (1.59e-2)" "unprognostic (3.98e-3)" "unprognostic (4.23e-5)" "unprognostic (1.25e-1)" "unprognostic (1.33e-2)" "unprognostic (7.22e-2)" "unprognostic (2.97e-3)" "unprognostic (1.30e-1)" "unprognostic (8.83e-9)" "unprognostic (7.82e-2)" "unprognostic (1.85e-1)" "unprognostic (1.95e-1)" "unprognostic (2.25e-1)" 0.7 0.2 1.4 0.4 1.0 15.2 0.6 3.8 2.4 1.2 0.9 0.4 0.4 0.1 1.1 25.2 0.7 1.9 1.4 10.6 0.9 1.6 1.0 0.4 6.5 0.5 0.7 0.8 2.1 2.5 0.1 2.5 1.9 1.1 0.6 0.3 0.6 0.4 1.6 0.8 0.1 0.6 0.4 0.8 22.8 0.2 3.0 0.4 0.4 5.2 1.0 0.6 0.7 1.9 0.0 0.5 28.5 0.2 0.0 0.2 11.1 0.0 0.1 0.7 0.0 0.0 0.0 2.8 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.4 69.4 0.0 0.6 0.0 0.0 118.6 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 7.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.6 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 28.5 0.2 2.1 0.1 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 2.8 0.0 0.0 0.5 0.0 11.1 1.4 1.0 3.8 2.4 0.9 1.6 0.7 0.8 1.1 0.4 ITGAL "CD11A, LFA-1" ENSG00000005844 "Integrin subunit alpha L" P20701 16 30472658-30523185 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Phagocytosis" "Integrin, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 36.7;lymphoid tissue: 74.6" "Cell line enriched" "Detected in some" 4 "HMC-1: 119.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" CAB025011 Enhanced "Intracellular and membrane" 1100000 "CAB025011: " "unprognostic (1.10e-2)" "unprognostic (4.26e-3)" "unprognostic (3.72e-3)" "prognostic favourable (5.63e-5)" "unprognostic (2.88e-1)" "prognostic favourable (3.34e-4)" "unprognostic (1.63e-1)" "unprognostic (5.69e-3)" "prognostic favourable (5.57e-4)" "unprognostic (3.37e-2)" "unprognostic (4.98e-2)" "unprognostic (1.84e-1)" "prognostic unfavourable (2.69e-5)" "unprognostic (2.89e-1)" "unprognostic (3.05e-2)" "unprognostic (1.39e-1)" "unprognostic (1.71e-2)" 2.8 1.1 1.8 29.8 2.0 15.1 1.8 0.6 1.5 1.3 3.0 2.7 0.5 2.4 1.7 1.4 2.2 2.6 4.9 1.4 1.3 1.3 2.6 6.7 16.2 29.0 3.1 1.4 1.4 1.2 0.0 1.4 1.7 1.7 2.0 3.4 1.9 6.6 0.7 0.8 1.0 12.7 1.4 4.7 44.1 3.5 0.8 2.7 74.6 2.8 2.0 41.8 4.4 1.9 2.1 7.5 7.2 36.7 9.5 22.5 11.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.2 119.0 0.0 0.0 0.0 0.0 0.0 0.0 26.7 0.0 0.0 7.9 0.7 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 4.2 0.0 0.0 0.0 0.0 0.0 7.5 2.5 0.0 0.1 0.8 0.0 3.1 8.4 6.5 22.5 16.9 11.2 2.1 8.8 16.2 7.5 1.3 4.9 11.4 7.2 9.5 36.7 3.0 6.3 11.5 1.8 2.0 0.6 1.5 1.3 1.3 3.1 1.4 1.7 2.7 ITGB3 "CD61, GP3A, GPIIIa" ENSG00000259207 "Integrin subunit beta 3" P05106 17 47253846-47311816 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "thyroid gland: 36.6" "Cell line enhanced" "Detected in some" "EFO-21: 45.5;HEL: 40.3;RPTEC TERT1: 26.2;U-87 MG: 20.6;WM-115: 65.7" "Group enriched" "Detected in many" 6 "melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 19 "basophil: 2.8;neutrophil: 2.8" "Lineage enriched" "Detected in single" 19 "granulocytes: 2.8" HPA027852 Approved Supported "Nucleoplasm,Plasma membrane" "Intracellular and membrane" 710000000 "Plasma membrane" Nucleoplasm "HPA027852: AB_10601760" "unprognostic (1.13e-2)" "unprognostic (1.97e-3)" "unprognostic (2.47e-1)" "unprognostic (3.00e-2)" "unprognostic (1.91e-2)" "unprognostic (6.04e-3)" "unprognostic (3.70e-1)" "unprognostic (3.00e-1)" "unprognostic (1.44e-1)" "unprognostic (3.85e-1)" "unprognostic (6.35e-2)" "unprognostic (7.22e-2)" "unprognostic (1.36e-1)" "unprognostic (1.03e-2)" "unprognostic (2.72e-2)" "unprognostic (1.48e-1)" "unprognostic (1.17e-3)" 10.0 0.6 1.0 6.2 2.5 2.7 7.0 0.4 1.6 4.6 13.6 0.9 2.4 2.2 9.7 5.7 6.4 6.4 2.8 8.5 0.7 0.6 16.0 3.7 5.2 1.2 2.3 0.1 4.6 0.6 0.7 1.6 23.5 1.6 6.4 4.8 1.8 2.5 11.5 4.9 2.4 5.0 17.0 1.8 9.5 3.6 2.6 0.6 0.2 36.6 1.9 0.9 11.0 7.8 0.1 0.0 2.8 0.1 0.0 0.0 9.5 0.0 0.4 0.1 0.0 2.3 1.0 0.0 1.2 6.0 2.6 2.4 0.0 0.0 0.1 45.5 0.3 0.0 0.0 0.0 3.4 0.8 0.0 40.3 0.1 0.0 1.9 0.0 0.0 0.9 0.0 15.2 0.3 11.3 0.1 0.0 0.5 0.0 0.2 0.0 0.0 0.1 0.0 1.0 0.0 26.2 0.0 0.0 0.1 1.5 0.0 8.2 0.0 0.0 12.3 0.5 0.6 0.3 2.8 0.0 0.0 0.2 20.6 0.0 65.7 2.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.8 0.0 0.0 0.0 0.0 9.5 1.0 2.5 0.4 1.6 0.7 0.6 2.3 0.1 1.6 0.6 JAK1 "JAK1A, JAK1B, JTK3" ENSG00000162434 "Janus kinase 1" P23458 1 64833229-64966504 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 69.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013088 Approved "CAB013088: " "prognostic favourable (9.63e-4)" "unprognostic (1.24e-1)" "prognostic favourable (2.81e-4)" "unprognostic (5.10e-2)" "unprognostic (1.16e-1)" "unprognostic (4.21e-2)" "unprognostic (1.53e-1)" "unprognostic (7.00e-3)" "unprognostic (8.40e-2)" "unprognostic (7.88e-3)" "unprognostic (1.66e-2)" "unprognostic (8.84e-2)" "prognostic favourable (2.67e-4)" "unprognostic (2.35e-1)" "unprognostic (2.04e-1)" "unprognostic (7.30e-2)" "unprognostic (3.51e-1)" 46.7 20.4 15.5 31.1 16.5 21.2 56.6 24.3 20.4 27.3 27.1 16.3 16.5 13.8 28.2 22.0 27.0 20.7 27.7 27.3 15.3 16.5 31.4 38.3 36.5 61.4 15.6 14.1 33.3 29.1 28.3 39.8 22.9 25.1 26.0 22.2 18.1 19.8 21.3 45.1 29.7 29.3 30.7 16.3 52.7 20.9 17.3 15.0 62.7 29.0 17.9 42.5 37.2 29.3 20.2 15.4 34.9 17.1 68.1 27.5 25.8 10.9 14.4 6.0 0.6 69.4 39.3 7.8 17.2 25.4 14.3 16.9 4.7 6.1 16.7 13.4 30.5 6.2 4.0 13.3 20.4 22.1 6.4 22.7 7.5 10.2 25.6 8.7 15.8 34.5 18.5 21.6 22.6 44.6 8.2 17.9 15.8 6.3 4.7 5.8 4.1 8.6 6.8 17.3 6.1 36.9 19.4 4.2 12.7 23.6 11.1 10.1 23.5 5.4 40.4 17.2 7.7 38.9 9.1 11.2 5.1 13.3 16.0 11.5 7.7 31.2 10.9 31.5 22.8 15.2 27.5 20.2 22.0 25.7 15.4 16.1 24.3 20.7 34.9 68.1 17.1 10.5 26.5 25.8 15.5 16.5 24.3 20.4 15.3 16.5 15.6 14.1 25.1 15.0 JAK2 JTK10 ENSG00000096968 "Janus kinase 2" O60674 9 4984390-5128183 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 5 "ASC diff: 18.9;HDLM-2: 26.7;HEL: 54.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 40.8" "Lineage enriched" "Detected in all" 4 "granulocytes: 40.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013089, HPA040820, HPA043870" Approved Supported "Nucleoplasm,Plasma membrane,Focal adhesion sites" Nucleoplasm "Plasma membrane, Focal adhesion sites" "CAB013089: AB_2533647, HPA040820: , HPA043870: " "unprognostic (2.24e-3)" "unprognostic (2.76e-2)" "unprognostic (1.50e-2)" "unprognostic (7.67e-2)" "unprognostic (5.50e-2)" "unprognostic (3.09e-2)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (1.09e-1)" "unprognostic (5.49e-3)" "unprognostic (1.58e-1)" "unprognostic (1.72e-2)" "unprognostic (3.85e-1)" "unprognostic (4.53e-2)" "unprognostic (3.43e-2)" "unprognostic (1.96e-1)" "unprognostic (7.37e-3)" 19.8 8.8 11.5 19.0 10.5 19.0 17.7 14.7 14.4 17.8 10.6 7.0 10.3 7.2 14.8 13.6 12.4 13.4 14.6 27.6 10.3 6.7 7.7 5.6 16.1 19.4 7.0 10.5 15.9 6.7 10.1 7.5 12.0 10.0 12.0 7.4 9.4 7.2 7.4 14.4 19.0 12.3 10.4 11.7 21.5 14.1 10.1 9.0 13.6 8.6 6.5 13.5 13.9 15.6 2.1 9.6 40.8 7.5 3.4 2.1 2.5 2.5 1.4 1.4 2.5 18.9 4.9 0.4 3.4 2.9 2.6 1.7 0.1 0.8 0.1 0.8 2.0 0.8 1.5 2.1 1.9 26.7 0.5 54.8 2.9 0.7 3.9 3.7 2.8 4.0 0.9 1.1 1.8 2.4 3.9 6.4 4.7 0.9 0.9 5.2 1.3 1.7 1.9 2.7 0.7 2.0 1.3 1.6 0.9 1.0 1.5 1.0 0.7 6.5 5.0 4.0 1.3 4.1 2.4 1.2 2.2 0.5 5.2 1.8 2.0 40.8 7.5 13.4 2.1 7.3 1.7 2.1 1.6 1.2 9.6 1.9 0.9 1.1 7.1 3.4 5.8 3.6 1.6 2.5 11.5 10.5 14.7 14.4 10.3 6.7 7.0 10.5 10.0 9.0 JAK3 "JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK" ENSG00000105639 "Janus kinase 3" P52333 19 17824780-17848071 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 68.3" "Cell line enhanced" "Detected in some" "HDLM-2: 20.1;HEL: 9.0;HMC-1: 9.2;Karpas-707: 23.5;U-266/70: 9.1;U-266/84: 13.5;U-937: 13.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA070314 Enhanced Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA070314: " "unprognostic (5.59e-3)" "prognostic favourable (6.42e-5)" "unprognostic (5.71e-2)" "unprognostic (2.34e-1)" "unprognostic (6.13e-3)" "unprognostic (1.11e-3)" "unprognostic (4.21e-2)" "unprognostic (2.60e-1)" "unprognostic (2.38e-2)" "unprognostic (2.36e-1)" "unprognostic (3.58e-2)" "unprognostic (1.94e-1)" "prognostic unfavourable (2.89e-14)" "unprognostic (2.28e-1)" "unprognostic (2.21e-2)" "unprognostic (4.43e-2)" "unprognostic (7.61e-2)" 6.8 1.7 4.0 24.5 8.5 12.0 2.7 2.4 3.1 1.9 2.3 1.0 0.0 2.2 1.7 2.0 2.5 3.5 3.6 4.3 2.7 2.8 3.8 2.0 8.4 68.3 7.5 0.0 11.0 2.0 0.4 2.3 4.1 5.3 3.0 2.4 1.6 6.1 1.5 0.7 1.3 9.5 2.5 8.4 36.1 3.2 1.8 5.8 20.9 3.4 1.7 28.8 5.3 2.4 7.4 4.5 16.9 9.6 8.4 15.0 6.8 0.1 0.3 0.3 1.0 0.4 1.4 0.2 0.5 0.0 0.0 0.1 0.0 0.9 0.4 1.9 0.4 0.1 0.0 0.2 0.0 20.1 0.0 9.0 0.0 0.8 0.7 0.0 9.2 5.0 0.2 0.0 0.0 0.2 0.0 23.5 0.0 0.4 3.6 0.0 0.1 0.7 4.6 0.0 0.4 0.5 0.0 0.0 0.3 0.1 0.2 0.0 2.0 1.3 0.4 0.0 0.4 0.0 0.0 9.1 13.5 2.5 0.1 13.7 0.2 1.2 4.9 0.2 12.6 9.6 14.5 6.5 15.0 13.1 4.5 7.4 14.9 13.0 16.9 8.4 8.8 3.7 11.8 6.8 4.0 8.5 2.4 3.1 2.7 2.8 7.5 0.0 5.3 5.8 JUN "AP-1, c-Jun" ENSG00000177606 "Jun proto-oncogene, AP-1 transcription factor subunit" P05412 1 58780788-58784327 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RH-30: 71.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003801, CAB007780, HPA059474" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB003801: AB_365485, CAB007780: AB_562268, HPA059474: " "unprognostic (2.06e-2)" "unprognostic (1.76e-2)" "unprognostic (1.34e-1)" "unprognostic (7.85e-2)" "unprognostic (1.60e-1)" "unprognostic (1.70e-1)" "unprognostic (4.11e-2)" "unprognostic (5.21e-2)" "unprognostic (1.24e-1)" "unprognostic (5.00e-2)" "unprognostic (2.14e-1)" "unprognostic (2.82e-1)" "unprognostic (5.15e-2)" "unprognostic (1.45e-1)" "unprognostic (2.83e-1)" "unprognostic (2.37e-1)" "unprognostic (2.81e-3)" 64.5 29.4 26.7 33.7 17.2 68.4 61.7 19.5 20.6 60.0 32.7 30.8 28.4 13.3 40.5 21.8 34.1 72.6 48.5 31.3 20.2 12.4 21.2 39.3 55.1 14.3 15.3 12.0 49.8 48.7 15.0 16.7 21.6 24.1 48.6 16.7 40.5 59.4 39.3 32.2 51.3 28.6 40.7 17.6 22.9 47.0 18.2 18.1 9.0 61.0 35.2 23.3 41.5 33.1 7.4 1.3 4.0 5.1 3.2 2.5 1.2 16.0 2.3 5.2 1.0 8.3 9.4 0.1 20.5 7.5 14.5 8.8 4.2 1.2 0.6 9.9 12.7 5.6 0.4 6.6 9.2 12.7 37.3 0.2 0.9 4.7 6.8 1.1 3.7 10.1 17.1 18.7 7.8 10.8 5.6 9.3 5.6 3.0 1.0 9.0 4.1 14.6 0.4 71.1 3.2 13.6 1.5 14.4 4.2 14.2 14.9 6.0 5.3 0.6 19.0 33.1 15.0 12.0 25.6 20.7 3.3 1.2 34.5 2.1 9.4 1.2 5.1 2.0 2.4 1.1 1.3 4.1 1.2 2.5 1.3 7.4 0.3 1.7 4.0 3.2 0.4 0.2 0.9 1.2 26.7 17.2 19.5 20.6 20.2 12.4 15.3 12.0 24.1 18.1 KCNA1 "AEMK, HUK1, Kv1.1, MBK1, RBK1" ENSG00000111262 "Potassium voltage-gated channel subfamily A member 1" Q09470 12 4909893-4918256 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 24.1" "Group enriched" "Detected in some" 11 "LHCN-M2: 2.3;NTERA-2: 2.0;SCLC-21H: 3.8;U-2 OS: 3.7" "Not detected" "Not detected" "Group enriched" "Detected in all" 4 "basal ganglia: 13.7;cerebellum: 23.8;cerebral cortex: 21.1;pons and medulla: 24.1" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074471 Approved "HPA074471: " "unprognostic (6.39e-3)" "unprognostic (2.64e-1)" "unprognostic (1.09e-1)" "unprognostic (8.44e-2)" "unprognostic (1.33e-1)" "unprognostic (1.79e-2)" "unprognostic (4.69e-3)" "unprognostic (2.48e-1)" "unprognostic (8.77e-5)" "unprognostic (6.30e-2)" "unprognostic (1.08e-4)" 0.8 0.7 1.5 0.7 13.7 0.7 1.3 23.8 21.1 1.6 0.9 0.9 0.0 0.9 1.0 0.7 0.7 0.7 0.9 0.7 4.6 1.1 0.7 0.7 0.8 0.7 2.2 3.5 0.7 0.7 4.0 0.6 0.7 24.1 0.7 0.9 0.0 1.9 0.8 0.7 0.8 0.8 1.1 1.1 0.7 1.0 0.7 1.4 0.2 2.0 0.0 0.7 0.9 0.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 13.7 23.8 21.1 4.6 1.1 2.2 3.5 24.1 1.4 KCNA10 Kv1.8 ENSG00000143105 "Potassium voltage-gated channel subfamily A member 10" Q16322 1 110517217-110519175 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in single" "testis: 3.2" "Cell line enhanced" "Detected in some" "U-2 OS: 1.4;U-87 MG: 1.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 4 "basal ganglia: 0.2" "HPA015061, CAB022564" Uncertain Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB022564: , HPA015061: AB_1855573" "unprognostic (2.96e-2)" 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.1 3.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.4 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KCNA2 "HK4, Kv1.2" ENSG00000177301 "Potassium voltage-gated channel subfamily A member 2" P16389 1 110519837-110631474 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 28.0" "Cell line enhanced" "Detected in some" "Karpas-707: 10.6;SCLC-21H: 2.7;U-2 OS: 2.4;U-266/70: 3.5;U-266/84: 5.3;WM-115: 2.9" "Cancer enhanced" "Detected in some" "glioma: 1.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 4.1" "Lineage enriched" "Detected in single" 8 "T-cells: 4.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB001976 Enhanced "CAB001976: " "unprognostic (1.84e-2)" "unprognostic (9.70e-3)" "unprognostic (1.97e-1)" "unprognostic (2.98e-1)" "unprognostic (7.17e-3)" "unprognostic (6.68e-3)" "unprognostic (5.05e-3)" "unprognostic (2.02e-1)" "unprognostic (1.29e-1)" "unprognostic (4.50e-3)" "unprognostic (3.08e-3)" "unprognostic (2.93e-4)" "unprognostic (2.15e-1)" "unprognostic (3.55e-1)" "unprognostic (6.41e-2)" "unprognostic (2.83e-1)" 3.2 1.4 7.1 2.2 13.1 0.8 1.2 17.2 28.0 1.2 1.6 3.1 0.0 1.4 1.0 1.3 1.7 1.1 1.6 1.6 7.2 6.1 0.9 0.9 1.0 1.9 7.2 14.5 1.1 1.9 0.8 1.4 0.7 21.1 1.8 2.0 1.4 1.8 2.4 2.1 1.6 1.6 1.6 2.8 1.3 1.3 2.5 3.8 0.3 5.3 0.0 3.5 1.4 0.5 0.5 0.0 0.0 0.0 0.0 4.1 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.6 0.0 0.0 0.0 0.0 0.9 0.0 0.5 0.0 1.4 0.0 0.0 2.7 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.1 2.4 0.0 0.0 3.5 5.3 0.2 0.1 0.0 2.9 0.0 0.0 0.0 0.4 0.0 0.3 0.5 1.8 1.3 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.0 4.1 0.1 7.1 13.1 17.2 26.3 7.2 6.1 7.2 14.5 21.1 3.8 KCNA3 "HLK3, HPCN3, Kv1.3, MK3" ENSG00000177272 "Potassium voltage-gated channel subfamily A member 3" P22001 1 110672465-110675033 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 59.4" "Cell line enhanced" "Detected in some" "HDLM-2: 12.4;Karpas-707: 25.6;U-266/70: 18.5;U-266/84: 16.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 7 "B-cells: 3.3;T-cells: 11.5" "Low region specificity" "Detected in all" HPA016625 Approved "HPA016625: " "unprognostic (2.17e-2)" "unprognostic (5.07e-3)" "unprognostic (3.92e-3)" "unprognostic (1.20e-2)" "unprognostic (2.35e-1)" "unprognostic (1.76e-5)" "unprognostic (1.70e-4)" "unprognostic (8.48e-2)" "unprognostic (1.49e-2)" "unprognostic (5.92e-4)" "unprognostic (1.81e-2)" "unprognostic (3.96e-2)" "unprognostic (1.39e-1)" "unprognostic (3.13e-2)" "unprognostic (2.99e-2)" "unprognostic (1.73e-1)" "unprognostic (1.40e-1)" 1.9 1.3 4.0 7.8 5.7 5.6 1.3 5.0 5.6 1.7 3.1 0.5 0.0 3.2 1.1 0.4 1.1 1.3 2.3 1.4 3.5 4.3 1.5 1.3 7.8 14.5 1.5 3.1 1.3 0.9 0.4 1.8 0.9 3.1 1.1 2.6 0.5 3.7 0.3 0.5 0.8 5.9 0.7 1.9 7.7 5.3 1.4 1.5 59.4 2.1 0.3 10.9 5.8 1.3 3.3 1.0 0.0 0.7 0.9 11.5 2.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 12.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.6 0.0 0.0 5.3 0.0 0.5 0.0 0.0 0.0 5.1 0.0 0.0 3.6 0.3 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.4 0.0 0.0 18.5 16.6 6.4 0.0 1.5 0.0 0.0 0.7 0.0 7.2 0.0 8.2 2.3 10.8 11.5 1.0 3.3 8.5 6.4 0.0 0.9 0.1 0.5 9.5 2.9 4.0 5.7 5.0 5.6 3.5 4.3 1.5 3.1 3.1 1.5 KCNA4 "HK1, HPCN2, KCNA4L, Kv1.4" ENSG00000182255 "Potassium voltage-gated channel subfamily A member 4" P22459 11 30009741-30017023 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Cataract, Disease mutation, Dystonia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "adrenal gland: 16.5;brain: 39.0" "Cell line enhanced" "Detected in some" "U-2 OS: 1.6;WM-115: 2.1" "Not detected" "Not detected" "Region enhanced" "Detected in many" "basal ganglia: 39.0" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB001977, HPA016422" Approved "CAB001977: , HPA016422: AB_1855574" "unprognostic (1.12e-2)" "unprognostic (1.80e-2)" "unprognostic (1.31e-2)" "unprognostic (2.73e-2)" "unprognostic (1.00e-1)" "unprognostic (4.09e-3)" "unprognostic (2.24e-1)" "unprognostic (1.15e-2)" "unprognostic (6.71e-2)" "unprognostic (1.17e-1)" 2.2 16.5 9.8 0.6 39.0 0.6 0.6 0.2 12.2 0.6 0.6 0.8 1.8 0.7 1.1 0.9 0.6 0.8 0.6 5.9 6.1 2.7 1.2 0.6 2.4 0.6 1.6 6.2 0.6 0.6 0.6 2.8 1.2 10.5 0.6 0.6 0.0 0.6 1.7 0.6 0.8 0.6 0.8 0.6 0.6 1.0 0.7 5.9 0.0 0.6 0.0 0.6 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.1 0.0 0.1 0.0 0.0 0.6 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 39.0 0.2 12.2 6.1 2.7 1.6 6.2 10.5 5.9 KCNA5 "HK2, HPCN1, Kv1.5" ENSG00000130037 "Potassium voltage-gated channel subfamily A member 5" P22460 12 5043989-5046788 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Atrial fibrillation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 33.0" "Cell line enriched" "Detected in single" 21 "NTERA-2: 9.8" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 134 "plasmacytoid DC: 13.3" "Lineage enriched" "Detected in single" 134 "dendritic cells: 13.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA021516, CAB022562" Approved "CAB022562: , HPA021516: " "unprognostic (3.87e-1)" "unprognostic (9.91e-3)" "unprognostic (1.94e-1)" "unprognostic (3.23e-1)" "unprognostic (2.64e-1)" "unprognostic (7.06e-3)" "unprognostic (1.20e-1)" "unprognostic (4.61e-3)" "unprognostic (1.34e-1)" "unprognostic (2.14e-1)" "unprognostic (2.37e-2)" "unprognostic (5.08e-3)" "unprognostic (6.73e-4)" "unprognostic (1.92e-3)" "unprognostic (1.90e-1)" "unprognostic (2.86e-2)" "unprognostic (3.08e-2)" 3.4 1.4 1.9 0.9 8.6 0.7 1.2 0.4 2.3 1.6 3.3 7.2 0.0 1.1 1.7 2.6 7.6 2.1 2.3 33.0 3.5 5.8 1.9 0.8 2.3 0.9 2.3 2.2 3.2 2.4 0.6 7.5 3.4 8.8 3.7 1.3 7.2 0.9 2.0 5.3 0.6 1.1 3.0 3.9 1.2 3.3 0.8 4.9 0.0 1.1 3.4 1.2 4.5 3.4 0.0 13.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.3 0.0 0.0 1.9 8.6 0.4 2.3 3.5 5.8 2.3 2.2 8.8 4.9 KCNB1 Kv2.1 ENSG00000158445 "Potassium voltage-gated channel subfamily B member 1" Q14721 20 49293394-49484297 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Exocytosis, Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 25.9;retina: 22.4" "Cell line enhanced" "Detected in some" "ASC diff: 3.5;CACO-2: 5.0;hTCEpi: 3.1;U-2 OS: 4.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB001979, HPA042434" Enhanced "CAB001979: , HPA042434: " "unprognostic (4.51e-1)" "unprognostic (1.72e-1)" "unprognostic (6.54e-3)" "unprognostic (4.87e-2)" "unprognostic (1.94e-1)" "unprognostic (1.82e-1)" "unprognostic (8.09e-2)" "unprognostic (6.22e-2)" "unprognostic (5.31e-1)" "unprognostic (8.32e-2)" "unprognostic (1.87e-3)" "unprognostic (1.37e-1)" "unprognostic (1.31e-2)" "unprognostic (2.07e-3)" "unprognostic (8.17e-2)" "unprognostic (9.35e-2)" "unprognostic (5.25e-4)" 16.9 3.6 11.4 1.3 14.6 0.8 2.4 8.1 25.9 2.3 5.1 1.8 0.7 1.2 6.8 2.3 3.9 9.0 1.9 1.9 6.6 5.3 1.3 3.5 1.2 0.8 3.3 12.5 1.2 1.2 0.9 2.5 1.0 2.5 4.8 1.9 22.4 1.7 6.5 6.2 1.1 1.8 9.6 1.2 1.2 3.9 1.5 2.4 0.0 1.0 0.1 0.8 4.0 0.9 0.4 0.3 1.2 0.2 0.3 0.7 0.0 0.0 0.1 0.8 0.0 3.5 0.3 0.1 0.0 0.4 0.4 0.0 5.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.3 0.1 0.2 0.0 0.1 0.0 0.0 2.5 0.0 0.6 3.1 0.0 0.1 0.0 0.0 1.9 1.1 0.3 0.0 2.3 0.1 0.9 0.0 0.9 0.0 0.0 0.0 2.3 1.8 1.6 2.3 0.0 1.6 0.0 0.0 2.2 4.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.3 0.2 0.0 0.1 0.1 0.3 0.2 0.0 0.4 0.7 0.2 1.2 0.3 0.1 0.3 0.1 0.0 11.4 14.6 8.1 25.9 6.6 5.3 3.3 12.5 2.5 2.4 KCNB2 Kv2.2 ENSG00000182674 "Potassium voltage-gated channel subfamily B member 2" Q92953 8 72537391-72938349 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 9.7;lymphoid tissue: 8.6;pituitary gland: 9.2" "Group enriched" "Detected in some" 5 "HaCaT: 3.2;HDLM-2: 3.0;HEK 293: 7.4;SCLC-21H: 6.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA065970 Approved "Nucleoli,Plasma membrane,Midbody" "Plasma membrane" "Nucleoli, Midbody" "HPA065970: " "unprognostic (9.87e-3)" "unprognostic (1.71e-1)" "unprognostic (7.57e-2)" "unprognostic (1.10e-3)" "unprognostic (1.22e-1)" "unprognostic (1.34e-1)" "unprognostic (1.44e-2)" "unprognostic (2.72e-1)" "unprognostic (6.93e-5)" "unprognostic (5.53e-3)" "unprognostic (3.30e-2)" "unprognostic (1.62e-1)" "unprognostic (3.35e-2)" "unprognostic (3.26e-1)" 0.8 1.9 3.8 0.6 5.3 0.4 0.7 0.3 9.7 0.5 0.7 0.0 0.0 1.2 0.4 0.4 1.1 2.1 0.5 0.4 7.1 3.1 0.5 0.4 0.6 0.5 0.9 7.8 0.4 2.4 0.4 9.2 0.5 3.2 0.7 0.7 4.2 0.5 0.5 0.4 0.4 1.6 0.5 1.6 8.6 2.4 1.7 0.4 0.9 0.4 0.0 0.9 0.6 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 3.0 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 6.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 5.3 0.3 9.7 7.1 3.1 0.9 7.8 3.2 0.4 KCNC1 Kv3.1 ENSG00000129159 "Potassium voltage-gated channel subfamily C member 1" P48547 11 17734774-17856804 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "brain: 67.5" "Cell line enhanced" "Detected in some" "RH-30: 7.4;SCLC-21H: 7.0;SH-SY5Y: 4.3" "Cancer enhanced" "Detected in some" "glioma: 1.1" "Region enhanced" "Detected in all" "cerebellum: 67.5" "Cell type enhanced" "Detected in some" "basophil: 5.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047634, HPA048249" Enhanced Approved "Nucleoplasm,Nuclear membrane,Vesicles,Cytosol" "Nucleoplasm, Nuclear membrane" "Vesicles, Cytosol" "HPA047634: , HPA048249: " "unprognostic (1.79e-2)" "unprognostic (2.68e-1)" "unprognostic (1.33e-1)" "unprognostic (4.09e-3)" "unprognostic (1.12e-1)" "unprognostic (8.02e-2)" "unprognostic (2.40e-1)" "unprognostic (1.27e-1)" "unprognostic (8.37e-2)" "unprognostic (2.14e-1)" "unprognostic (7.04e-5)" "unprognostic (5.89e-2)" "unprognostic (7.32e-4)" "unprognostic (1.29e-1)" "unprognostic (5.44e-2)" "unprognostic (1.05e-2)" "unprognostic (7.83e-2)" 0.7 2.3 8.2 1.0 10.0 2.9 0.9 67.5 33.3 3.0 1.0 1.0 0.0 1.4 1.5 0.6 1.1 0.9 1.3 0.6 5.6 4.9 0.9 1.1 1.0 1.2 3.3 12.6 1.1 0.9 0.6 1.4 0.7 19.5 1.2 0.8 0.7 1.2 0.7 1.7 1.8 1.2 0.8 1.9 1.0 1.3 2.9 2.0 0.0 1.5 0.0 0.8 2.4 0.5 1.7 0.8 5.8 0.8 0.7 1.1 0.3 0.4 0.1 3.0 1.2 0.5 0.0 0.1 0.0 0.0 0.1 0.0 0.2 1.0 0.0 0.2 0.0 1.1 1.8 0.0 0.3 0.3 2.1 0.6 2.9 0.2 0.3 0.5 0.2 0.0 0.0 0.0 0.1 0.0 0.5 1.4 0.0 0.5 0.5 1.1 1.5 0.0 0.7 7.4 0.9 0.0 0.4 7.0 4.3 0.4 0.4 0.0 0.6 0.5 0.1 0.2 2.3 0.3 0.3 0.5 0.6 1.0 0.5 0.3 0.9 5.8 0.7 1.1 1.1 0.7 0.7 0.7 0.9 0.5 0.2 1.7 0.7 0.8 3.8 0.7 0.8 0.8 0.4 0.3 8.2 10.0 67.5 33.3 5.6 4.9 3.3 12.6 19.5 2.0 KCNC2 Kv3.2 ENSG00000166006 "Potassium voltage-gated channel subfamily C member 2" Q96PR1 12 75040077-75209868 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 39.3" "Cell line enhanced" "Detected in single" "Karpas-707: 1.0" "Group enriched" "Detected in some" 8 "breast cancer: 1.5;prostate cancer: 4.6" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA019664, CAB022571" Uncertain Supported "Plasma membrane,Cytosol" Cytosol "Plasma membrane" "CAB022571: , HPA019664: AB_1855578" "unprognostic (2.01e-1)" "unprognostic (1.14e-1)" "unprognostic (2.68e-1)" "unprognostic (5.58e-3)" "unprognostic (4.46e-2)" "unprognostic (3.39e-2)" 0.7 0.7 8.7 0.7 12.9 0.7 3.3 0.4 39.3 0.7 0.8 1.9 0.0 0.7 0.9 0.9 0.7 0.7 0.7 0.7 7.4 10.4 0.7 0.9 0.7 0.7 4.7 13.5 0.7 0.7 0.7 6.0 0.7 19.1 4.4 0.8 1.3 1.1 0.7 0.7 0.7 0.8 0.7 1.0 0.7 0.7 1.0 0.6 0.0 0.7 0.0 0.7 0.7 0.2 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 8.7 12.9 0.4 27.3 7.4 10.4 4.7 13.5 19.1 0.6 KCNC3 "Kv3.3, SCA13" ENSG00000131398 "Potassium voltage-gated channel subfamily C member 3" Q14003 19 50311937-50333515 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 32.1;parathyroid gland: 31.1;thyroid gland: 23.9" "Cell line enhanced" "Detected in some" "CACO-2: 8.7;CAPAN-2: 7.6;HDLM-2: 7.9;HMC-1: 20.9;K-562: 7.7;SK-BR-3: 14.2;T-47d: 13.5;U-2 OS: 9.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.1" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA018041 Approved "HPA018041: AB_1855579" "unprognostic (8.05e-2)" "unprognostic (2.34e-2)" "unprognostic (3.01e-4)" "unprognostic (4.41e-2)" "unprognostic (3.84e-2)" "unprognostic (1.91e-2)" "unprognostic (2.79e-2)" "unprognostic (1.12e-2)" "unprognostic (1.46e-1)" "unprognostic (1.59e-1)" "unprognostic (3.94e-3)" "unprognostic (2.10e-5)" "prognostic unfavourable (1.23e-4)" "unprognostic (1.68e-2)" "unprognostic (1.45e-1)" "unprognostic (2.85e-2)" "unprognostic (1.19e-1)" 1.4 2.2 7.2 5.4 9.4 1.4 2.3 32.1 31.2 3.1 1.1 3.4 3.0 1.8 4.5 5.8 1.1 12.8 1.4 1.7 6.9 4.2 10.6 2.5 4.5 4.7 4.0 6.6 0.6 3.7 31.1 9.7 2.4 15.6 2.4 1.4 3.0 2.3 15.1 1.2 2.1 1.8 1.7 3.8 6.5 2.1 2.4 2.9 1.1 23.9 0.0 3.4 1.8 1.0 0.4 1.1 0.0 0.8 0.0 0.0 0.0 0.0 0.4 0.0 1.4 0.0 0.0 4.1 0.0 0.0 0.0 0.0 8.7 7.6 0.7 1.0 0.0 1.1 0.2 0.0 0.0 7.9 1.8 0.0 0.0 1.7 0.0 0.0 20.9 0.1 0.0 0.0 0.0 0.1 7.7 0.0 0.0 2.7 0.1 0.0 1.1 3.3 0.0 0.1 0.0 0.5 0.2 0.0 1.4 1.6 14.2 0.0 13.5 2.1 0.1 0.0 9.3 0.0 0.0 0.0 0.1 0.4 0.3 1.7 0.0 0.0 0.4 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 7.2 9.4 32.1 31.2 6.9 4.2 4.0 6.6 15.6 2.9 KCND1 Kv4.1 ENSG00000102057 "Potassium voltage-gated channel subfamily D member 1" Q9NSA2 X 48961378-48971569 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 16.8" "Cell line enhanced" "Detected in many" "HSkMC: 13.6;NB-4: 10.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 1.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000524, HPA001066" Approved Uncertain Nucleoplasm Nucleoplasm "HPA000524: , HPA001066: AB_1079662" "unprognostic (6.00e-2)" "unprognostic (2.58e-1)" "unprognostic (1.01e-4)" "unprognostic (2.19e-4)" "unprognostic (1.41e-1)" "unprognostic (3.79e-2)" "unprognostic (2.79e-1)" "unprognostic (8.13e-3)" "unprognostic (1.13e-2)" "unprognostic (2.41e-3)" "prognostic favourable (2.66e-6)" "unprognostic (2.61e-1)" "unprognostic (4.30e-11)" "unprognostic (3.13e-2)" "unprognostic (3.49e-1)" "unprognostic (7.64e-2)" "unprognostic (2.22e-3)" 4.9 2.4 4.2 3.4 4.7 6.0 2.2 16.8 7.8 5.1 2.2 6.3 1.9 2.0 5.0 3.8 1.4 7.4 6.3 2.9 6.9 2.5 2.5 1.8 3.0 3.1 3.1 3.5 4.6 1.4 1.8 3.0 2.5 10.4 3.3 2.1 2.6 1.2 6.0 0.7 1.6 2.6 6.6 6.5 4.2 2.5 3.0 2.7 1.1 2.3 0.5 3.6 3.0 3.0 0.6 1.3 1.4 0.1 0.0 0.8 0.1 0.4 2.0 0.8 4.8 6.6 5.2 1.6 1.0 4.2 2.9 1.9 1.3 0.6 1.6 3.5 3.2 0.6 0.8 0.4 2.8 2.7 3.2 1.5 2.0 0.1 2.4 0.4 3.0 13.6 1.8 5.3 0.6 1.0 1.1 3.7 2.1 3.6 0.4 10.8 2.6 0.7 1.3 0.9 1.6 3.2 1.5 0.5 2.2 0.9 0.0 2.2 2.1 1.6 2.5 0.6 2.7 0.6 0.2 3.0 3.9 3.9 1.8 3.9 2.1 0.0 0.1 0.0 0.5 0.0 0.3 0.6 0.2 0.8 0.0 0.1 0.2 0.0 1.4 0.0 0.0 1.3 0.0 0.1 4.2 4.7 16.8 7.8 6.9 2.5 3.1 3.5 10.4 2.7 KCND2 "KIAA1044, Kv4.2, RK5" ENSG00000184408 "Potassium voltage-gated channel subfamily D member 2" Q9NZV8 7 120273668-120750331 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 41.1" "Cell line enhanced" "Detected in some" "ASC TERT1: 6.4;HSkMC: 4.0;NTERA-2: 3.1;RT4: 3.2;SCLC-21H: 16.2" "Cancer enhanced" "Detected in many" "glioma: 6.2" "Region enhanced" "Detected in all" "cerebellum: 41.1" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029068 Enhanced "HPA029068: AB_10601436" "unprognostic (4.22e-1)" "unprognostic (2.79e-4)" "unprognostic (3.79e-2)" "unprognostic (3.40e-1)" "unprognostic (1.23e-1)" "unprognostic (3.91e-2)" "unprognostic (4.98e-3)" "unprognostic (9.07e-3)" "unprognostic (1.03e-1)" "unprognostic (1.14e-1)" "unprognostic (9.77e-3)" "unprognostic (1.51e-1)" "unprognostic (4.51e-4)" "unprognostic (4.07e-5)" "unprognostic (2.71e-2)" "unprognostic (2.92e-2)" "unprognostic (1.83e-3)" 2.9 1.0 3.9 1.0 6.7 0.3 1.9 41.1 20.6 2.4 0.7 1.5 0.0 0.7 5.6 0.5 0.5 1.7 7.0 0.5 3.7 5.4 0.3 0.4 0.6 0.5 4.2 3.6 5.9 0.6 2.5 6.6 0.8 12.1 0.5 0.6 0.0 0.7 1.7 0.5 0.3 0.5 3.7 3.7 0.3 0.5 2.9 4.5 0.0 0.8 1.1 0.3 2.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.7 6.4 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.1 2.5 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.6 0.0 0.0 4.0 0.0 0.0 0.0 0.1 0.0 0.4 0.2 0.0 0.0 0.0 3.1 0.2 0.0 0.0 0.0 0.0 3.2 16.2 0.0 0.0 0.0 0.0 0.2 0.8 0.0 0.5 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 6.7 41.1 5.3 3.7 5.4 4.2 3.6 12.1 4.5 KCND3 "KSHIVB, Kv4.3, SCA19, SCA22" ENSG00000171385 "Potassium voltage-gated channel subfamily D member 3" Q9UK17 1 111770662-111989155 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Brugada syndrome, Disease mutation, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 25.9" "Cell line enriched" "Detected in some" 4 "SCLC-21H: 16.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029452 Approved "HPA029452: AB_10602239" "unprognostic (1.11e-2)" "unprognostic (1.73e-3)" "unprognostic (1.71e-1)" "unprognostic (2.60e-2)" "unprognostic (1.37e-1)" "unprognostic (2.42e-1)" "unprognostic (1.41e-1)" "unprognostic (9.48e-2)" "unprognostic (1.15e-1)" "unprognostic (9.17e-2)" "unprognostic (1.86e-2)" "unprognostic (1.40e-1)" "unprognostic (7.44e-2)" "unprognostic (3.64e-1)" "unprognostic (1.23e-1)" "unprognostic (2.51e-3)" "unprognostic (6.64e-3)" 3.3 0.8 6.8 3.1 6.9 0.0 2.1 25.9 11.9 1.3 2.5 1.3 1.3 0.3 4.1 9.6 3.2 3.4 4.2 5.5 5.6 5.6 1.3 11.6 1.3 1.3 8.9 5.7 1.3 2.2 4.1 1.5 1.3 1.6 9.2 1.6 1.9 1.3 10.0 2.8 5.1 1.3 7.7 1.3 2.0 1.7 1.3 1.3 1.3 1.3 2.3 1.3 3.7 1.3 0.5 0.4 1.2 0.3 0.9 0.3 0.7 0.0 0.0 0.3 0.0 0.5 0.1 0.1 0.4 0.0 0.0 0.0 0.8 0.1 0.0 1.6 0.6 0.5 0.6 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.0 1.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.2 0.3 0.0 0.0 0.1 0.0 0.0 0.3 16.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.5 0.2 0.1 0.3 0.1 0.1 0.1 0.1 0.3 0.4 0.5 0.3 0.2 1.2 0.9 0.3 0.3 0.1 0.7 6.8 6.9 25.9 9.3 5.6 5.6 8.9 5.7 1.6 1.3 KCNJ1 "Kir1.1, ROMK1" ENSG00000151704 "Potassium voltage-gated channel subfamily J member 1" P48048 11 128836315-128867373 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Bartter syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 51 "kidney: 123.2" "Cell line enriched" "Detected in some" 40 "RPTEC TERT1: 50.6" "Cancer enriched" "Detected in some" 7 "renal cancer: 3.4" "Region enriched" "Detected in single" 4 "basal ganglia: 2.3" "Cell type enhanced" "Detected in single" "memory B-cell: 1.3" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" HPA026962 Enhanced "HPA026962: AB_10601934" "unprognostic (1.75e-1)" "unprognostic (4.38e-2)" "unprognostic (1.14e-1)" "unprognostic (3.19e-1)" "unprognostic (7.55e-2)" "unprognostic (1.29e-1)" "unprognostic (3.01e-2)" "unprognostic (2.69e-1)" "unprognostic (1.46e-1)" "unprognostic (2.44e-2)" "unprognostic (6.47e-2)" "unprognostic (2.78e-1)" "unprognostic (6.05e-2)" "unprognostic (4.99e-2)" "unprognostic (1.61e-1)" "unprognostic (1.28e-1)" "unprognostic (7.81e-3)" 0.1 0.0 0.5 0.2 2.3 0.0 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.0 0.1 0.5 0.1 0.0 0.1 0.1 0.1 0.0 123.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 1.3 0.0 0.0 0.4 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 50.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.2 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.4 0.9 1.3 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 2.3 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 KCNJ11 "BIR, Kir6.2" ENSG00000187486 "Potassium voltage-gated channel subfamily J member 11" Q14654 11 17385859-17389331 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Diabetes mellitus, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "skeletal muscle: 63.1" "Cell line enhanced" "Detected in many" "Daudi: 7.1;HEK 293: 13.4;MCF7: 10.7;SCLC-21H: 9.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" HPA048891 Approved "HPA048891: " "unprognostic (1.95e-2)" "unprognostic (6.18e-3)" "unprognostic (7.79e-2)" "unprognostic (2.26e-1)" "unprognostic (1.77e-1)" "unprognostic (1.25e-1)" "unprognostic (4.81e-5)" "unprognostic (1.83e-3)" "unprognostic (5.45e-2)" "unprognostic (8.09e-3)" "unprognostic (3.72e-3)" "unprognostic (9.23e-3)" "prognostic favourable (1.56e-4)" "unprognostic (4.05e-2)" "unprognostic (2.10e-2)" "unprognostic (1.67e-1)" "unprognostic (4.75e-2)" 2.5 1.1 2.9 1.0 7.8 0.8 2.7 13.6 7.8 1.0 1.1 0.7 4.9 1.4 1.1 2.1 1.7 1.1 1.1 6.2 3.5 2.4 1.3 0.9 1.3 1.2 2.7 5.2 0.8 8.7 2.7 3.3 0.7 3.5 2.5 1.0 0.1 1.2 7.6 63.1 1.0 1.1 0.8 1.7 1.0 4.6 0.8 1.9 0.0 4.1 4.5 1.0 0.9 1.1 0.8 0.4 1.4 0.3 0.8 0.4 0.4 1.5 2.3 0.3 4.0 0.0 0.0 1.6 0.0 0.0 0.0 0.1 2.5 0.2 7.1 0.2 0.0 0.3 4.8 0.1 0.3 1.6 13.4 3.6 0.9 0.8 0.1 0.4 0.3 0.1 0.3 0.0 0.1 0.0 3.7 3.8 0.0 10.7 0.7 0.1 1.0 0.3 1.4 1.7 2.0 0.4 0.9 9.1 0.8 0.0 3.5 0.0 4.6 0.2 0.0 0.0 1.2 0.0 0.1 0.2 6.0 0.9 0.0 1.0 0.0 1.4 0.3 0.2 0.4 0.3 0.3 0.7 0.4 0.4 0.1 0.8 0.4 0.4 1.3 0.8 0.1 0.4 0.3 0.4 2.9 7.8 13.6 7.8 3.5 2.4 2.7 5.2 3.5 1.9 KCNJ12 "hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v" ENSG00000184185 "Potassium voltage-gated channel subfamily J member 12" Q14500 17 21376197-21419872 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 39.4;skeletal muscle: 47.8" "Cell line enhanced" "Detected in some" "EFO-21: 3.7;HeLa: 6.2;PC-3: 6.5;SCLC-21H: 7.6;SiHa: 3.8;U-2197: 6.6" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 7 "cerebellum: 39.4" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA027021 Approved Uncertain "Nucleoplasm,Golgi apparatus,Cytosol" "Golgi apparatus" "Nucleoplasm, Cytosol" "HPA027021: AB_10602912" "unprognostic (3.81e-3)" "unprognostic (2.69e-2)" "unprognostic (8.60e-2)" "prognostic unfavourable (7.84e-5)" "unprognostic (2.29e-1)" "unprognostic (1.73e-2)" "unprognostic (3.80e-2)" "unprognostic (1.54e-2)" "unprognostic (4.39e-2)" "unprognostic (4.91e-2)" "unprognostic (8.12e-2)" "unprognostic (1.16e-1)" "unprognostic (4.22e-2)" "unprognostic (2.23e-1)" "unprognostic (1.51e-1)" "unprognostic (5.90e-2)" "unprognostic (9.70e-3)" 1.2 1.3 1.9 0.9 2.9 0.7 0.9 39.4 5.8 1.2 0.8 1.1 0.5 0.5 0.8 1.4 1.5 2.1 0.7 5.1 0.9 1.4 1.2 0.5 1.3 0.4 1.3 3.4 0.7 0.5 10.6 0.7 0.7 4.0 0.9 0.6 1.7 0.6 0.9 47.8 6.0 0.6 1.0 0.9 1.3 0.9 1.3 0.9 0.0 1.0 7.5 1.1 0.8 1.5 0.0 0.9 0.0 0.5 0.0 0.1 0.0 0.0 1.1 0.4 2.3 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.2 0.0 0.0 3.7 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.2 6.2 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.3 0.0 0.0 0.5 0.1 0.1 0.0 1.5 6.5 0.0 1.0 1.7 0.0 0.0 7.6 0.4 3.8 0.0 1.6 0.0 0.0 2.9 0.0 0.5 6.6 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.9 0.1 0.0 1.9 2.9 39.4 5.8 0.9 1.4 1.3 3.4 4.0 0.9 KCNJ8 Kir6.1 ENSG00000121361 "Potassium voltage-gated channel subfamily J member 8" Q15842 12 21764955-21775581 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 60.1;pancreas: 47.6" "Cell line enhanced" "Detected in some" "CACO-2: 41.5;HSkMC: 8.4;SH-SY5Y: 14.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 12 "eosinophil: 4.5" "Lineage enriched" "Detected in single" 45 "granulocytes: 4.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031066 Uncertain "HPA031066: AB_10602240" "unprognostic (8.12e-3)" "unprognostic (1.89e-1)" "prognostic unfavourable (9.29e-4)" "unprognostic (7.81e-2)" "unprognostic (8.71e-2)" "unprognostic (2.34e-1)" "unprognostic (3.15e-2)" "unprognostic (1.27e-1)" "unprognostic (1.36e-2)" "unprognostic (3.90e-2)" "unprognostic (3.66e-3)" "unprognostic (2.88e-2)" "prognostic unfavourable (1.62e-6)" "unprognostic (4.70e-3)" "unprognostic (9.61e-2)" "unprognostic (1.73e-2)" "unprognostic (3.54e-3)" 14.6 12.9 3.2 2.7 3.4 0.0 14.7 1.7 5.1 7.7 6.6 2.3 3.6 2.0 10.6 4.5 6.7 5.9 6.3 60.1 2.2 1.7 6.4 29.7 12.4 3.5 2.9 3.0 12.4 47.6 1.7 3.8 4.9 3.7 10.6 1.6 8.8 2.9 15.7 15.0 2.4 3.8 13.2 2.6 3.8 6.5 3.4 2.8 0.9 8.4 7.0 1.2 11.4 5.6 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.2 1.3 0.0 5.1 3.4 0.0 5.6 4.5 6.4 3.3 41.5 0.0 0.0 0.0 0.1 0.0 0.2 0.0 1.9 0.0 2.0 1.3 0.0 0.0 0.1 0.0 0.0 8.4 0.0 2.5 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.5 0.0 0.0 0.0 0.0 0.0 0.0 4.1 1.8 0.0 1.7 0.1 0.0 0.0 0.1 0.0 0.1 0.3 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 3.4 1.7 5.1 2.2 1.7 2.9 3.0 3.7 2.8 KCNK9 "K2p9.1, TASK-3, TASK3" ENSG00000169427 "Potassium two pore domain channel subfamily K member 9" Q9NPC2 8 139600838-139703056 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "adrenal gland: 9.4;brain: 15.4" "Group enriched" "Detected in some" 7 "PC-3: 6.5;SCLC-21H: 2.8;SH-SY5Y: 2.1" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in many" "cerebellum: 15.4" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA075842 Approved "Plasma membrane" "Plasma membrane" "HPA075842: " "unprognostic (1.84e-2)" "unprognostic (2.57e-1)" "unprognostic (1.58e-1)" "unprognostic (8.96e-8)" "unprognostic (1.91e-1)" "unprognostic (8.17e-3)" "unprognostic (2.19e-3)" "unprognostic (1.65e-1)" "unprognostic (3.87e-1)" "unprognostic (1.69e-1)" "unprognostic (1.00e-2)" "unprognostic (3.21e-1)" "unprognostic (5.12e-6)" "unprognostic (2.94e-2)" "unprognostic (1.64e-1)" "unprognostic (9.99e-3)" "unprognostic (1.76e-1)" 0.2 9.4 0.5 0.5 1.0 0.1 0.1 15.4 7.7 1.3 0.5 0.0 0.0 0.1 0.3 0.1 0.2 0.3 0.1 0.2 1.6 1.4 0.1 0.1 0.1 0.1 0.7 1.7 0.1 0.1 0.1 1.1 0.2 6.6 0.1 0.2 0.2 0.1 0.1 1.4 0.1 0.1 0.6 0.6 0.1 0.3 0.5 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0 2.8 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 1.0 15.4 3.7 1.6 1.4 0.7 1.7 6.6 0.0 KCNMA1 "KCa1.1, mSLO1, SLO" ENSG00000156113 "Potassium calcium-activated channel subfamily M alpha 1" Q12791 10 76869601-77638369 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 27.2;hTERT-HME1: 32.0;PC-3: 43.5;U-138 MG: 31.3;U-87 MG: 30.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "intermediate monocyte: 5.5;memory B-cell: 1.7;non-classical monocyte: 3.7" "Group enriched" "Detected in many" 5 "B-cells: 1.7;monocytes: 5.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054648 Approved "HPA054648: " "unprognostic (1.25e-1)" "unprognostic (2.23e-2)" "unprognostic (1.86e-2)" "unprognostic (5.29e-2)" "unprognostic (9.43e-2)" "unprognostic (2.25e-1)" "unprognostic (1.77e-1)" "unprognostic (2.81e-2)" "unprognostic (1.87e-1)" "unprognostic (1.34e-1)" "unprognostic (4.12e-3)" "unprognostic (1.20e-1)" "unprognostic (2.26e-2)" "unprognostic (1.42e-2)" "unprognostic (5.19e-2)" "unprognostic (1.42e-2)" "unprognostic (3.99e-3)" 6.0 8.1 12.5 8.8 13.6 1.1 7.1 8.2 18.5 36.3 39.0 5.7 27.9 4.8 54.0 19.7 20.7 18.3 15.6 2.7 10.8 8.2 2.0 6.6 4.0 6.2 7.4 16.5 7.0 4.1 0.7 10.1 3.3 10.1 30.1 13.2 6.6 24.0 47.6 37.1 1.8 8.6 55.1 6.8 10.4 14.8 2.6 4.9 0.4 1.4 2.7 2.5 21.7 12.6 1.7 0.6 0.3 5.5 0.0 0.0 0.3 0.0 8.1 0.0 0.1 1.3 7.0 0.1 27.2 24.3 6.6 3.2 1.8 0.1 0.0 0.2 20.3 0.0 0.0 15.9 4.0 16.1 0.1 0.0 0.0 0.0 12.7 0.0 0.1 4.9 2.9 10.5 32.0 2.6 0.0 0.0 11.6 0.3 0.5 0.0 0.5 43.5 0.0 1.0 0.0 4.2 0.0 2.5 0.3 0.0 0.6 0.0 3.3 0.0 17.6 31.3 3.5 5.6 24.0 0.0 0.0 0.0 30.6 0.0 12.2 0.0 0.2 0.0 0.0 5.5 0.0 1.7 0.0 0.0 0.6 0.3 0.0 0.0 0.3 0.0 3.7 0.0 0.0 0.3 12.5 13.6 8.2 18.5 10.8 8.2 7.4 16.5 10.1 4.9 KCNMB2 ENSG00000197584 "Potassium calcium-activated channel subfamily M regulatory beta subunit 2" Q9Y691 3 178272932-178844429 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "epididymis: 36.8" "Cell line enhanced" "Detected in some" "BJ hTERT+: 6.3;fHDF/TERT166: 2.5;SCLC-21H: 8.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" CAB022649 Uncertain "CAB022649: " "unprognostic (9.52e-2)" "unprognostic (1.13e-1)" "unprognostic (6.82e-2)" "unprognostic (2.07e-1)" "unprognostic (2.19e-2)" "unprognostic (1.04e-2)" "unprognostic (2.43e-2)" "unprognostic (6.97e-2)" "unprognostic (6.74e-2)" "unprognostic (2.15e-1)" "unprognostic (3.58e-3)" "unprognostic (3.57e-2)" "unprognostic (1.71e-2)" "unprognostic (2.07e-1)" "unprognostic (1.68e-1)" "unprognostic (6.89e-4)" "unprognostic (7.85e-2)" 0.7 6.3 7.8 0.5 6.2 0.4 1.3 1.8 11.2 2.5 1.9 2.2 4.4 1.0 7.2 36.8 0.9 14.3 0.9 7.4 13.2 4.5 4.1 0.6 1.6 0.4 4.7 4.9 16.3 4.5 0.4 10.2 0.5 6.2 1.1 0.9 0.5 0.6 1.9 0.6 0.7 0.9 3.0 3.2 1.9 3.6 0.6 3.2 0.0 1.1 0.0 0.4 0.6 1.5 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 6.3 0.0 0.0 0.4 0.0 0.0 1.4 2.5 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.0 1.7 0.0 1.0 8.3 0.0 0.0 0.5 0.0 1.4 0.0 0.3 0.0 0.1 0.0 0.0 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.8 6.2 1.8 11.2 13.2 4.5 4.7 4.9 6.2 3.2 KCNMB3 "KCNMB2, KCNMBL" ENSG00000171121 "Potassium calcium-activated channel subfamily M regulatory beta subunit 3" Q9NPA1 3 179236691-179267002 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HEL: 10.9;NB-4: 7.4" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA015665, HPA019185" Approved Approved Nucleoplasm,Mitochondria Nucleoplasm Mitochondria "HPA015665: AB_1852142, HPA019185: AB_1852144" "unprognostic (2.50e-1)" "unprognostic (1.32e-1)" "unprognostic (6.76e-5)" "unprognostic (2.65e-2)" "unprognostic (2.22e-2)" "unprognostic (2.08e-1)" "unprognostic (4.59e-3)" "unprognostic (1.14e-1)" "unprognostic (9.15e-3)" "unprognostic (5.09e-2)" "unprognostic (1.87e-2)" "unprognostic (1.95e-5)" "unprognostic (5.93e-10)" "unprognostic (7.22e-2)" "unprognostic (4.72e-1)" "unprognostic (8.69e-2)" "unprognostic (3.49e-2)" 3.0 2.0 0.7 2.9 0.7 1.2 3.3 0.2 0.6 1.8 2.0 1.9 2.0 2.3 0.7 1.0 2.4 1.8 1.0 0.9 2.2 4.0 1.2 2.9 1.1 1.6 5.3 3.7 2.1 6.6 2.9 2.2 2.7 1.4 0.5 0.6 2.2 1.9 1.5 5.9 2.6 4.5 2.4 2.6 1.9 1.5 3.5 0.3 2.3 0.4 3.6 1.0 0.0 3.0 0.7 1.2 0.0 1.4 1.1 1.9 0.8 0.5 1.3 0.6 6.4 2.6 0.1 3.0 0.6 1.1 0.0 0.2 1.5 3.7 0.4 10.9 2.9 2.5 1.2 0.2 3.6 1.9 0.6 0.9 0.0 1.1 0.4 0.1 1.5 1.8 0.1 7.4 0.0 2.3 3.2 0.0 0.1 1.0 2.0 1.5 0.4 0.9 1.2 0.7 3.0 6.0 0.7 0.6 1.0 0.3 0.9 1.0 0.4 3.5 0.6 4.2 0.8 2.3 0.4 0.5 1.0 0.3 0.6 3.5 0.6 0.8 0.1 2.1 0.4 0.7 1.9 3.6 0.1 0.3 0.9 0.0 KCNMB4 ENSG00000135643 "Potassium calcium-activated channel subfamily M regulatory beta subunit 4" Q86W47 12 70366276-70434292 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 24.4;brain: 37.7" "Cell line enhanced" "Detected in many" "NTERA-2: 9.0;RH-30: 9.7;RT4: 10.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive CD8 T-cell: 2.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA072287 Enhanced Approved Approved Cytosol Cytosol "HPA072287: " "unprognostic (3.90e-1)" "unprognostic (1.72e-2)" "unprognostic (2.69e-2)" "unprognostic (2.62e-2)" "unprognostic (6.98e-2)" "unprognostic (1.13e-3)" "unprognostic (1.85e-1)" "unprognostic (2.48e-2)" "unprognostic (3.50e-1)" "unprognostic (2.95e-2)" "unprognostic (3.75e-1)" "unprognostic (2.47e-2)" "unprognostic (2.19e-2)" "unprognostic (1.96e-1)" "unprognostic (1.78e-1)" "unprognostic (4.62e-2)" "unprognostic (1.05e-2)" 4.4 24.4 19.8 2.6 24.6 1.3 2.6 13.8 37.7 3.5 5.0 28.4 1.0 2.5 3.2 2.8 2.6 3.3 3.2 5.9 25.9 10.4 5.8 1.8 4.6 2.8 28.6 19.3 5.4 1.5 1.3 1.4 4.9 11.6 2.9 2.9 2.0 3.8 4.5 4.2 4.9 3.0 2.8 15.2 2.8 1.8 3.8 26.0 0.8 3.3 0.0 2.6 2.4 2.1 1.7 0.6 0.3 0.3 0.2 2.8 0.5 0.0 0.4 5.7 3.2 0.3 0.3 0.6 0.7 1.0 0.3 0.9 0.2 2.1 2.8 0.3 0.0 0.1 6.2 0.9 0.2 1.3 3.5 1.4 1.3 3.2 0.0 0.1 0.1 1.7 0.1 0.0 0.0 0.2 0.0 0.0 1.1 0.8 2.0 0.5 9.0 6.5 2.9 9.7 0.2 0.3 10.6 2.8 3.5 0.9 1.1 0.1 3.2 0.1 0.1 0.4 1.5 0.1 0.4 2.0 0.0 2.8 0.5 0.0 0.9 0.3 0.3 0.0 0.3 0.3 0.3 0.6 0.6 0.6 0.6 1.7 2.2 2.8 0.3 0.2 0.1 0.2 0.6 0.5 19.8 24.6 13.8 19.1 25.9 10.4 28.6 19.3 11.6 26.0 KCNN1 "hSK1, KCa2.1" ENSG00000105642 "Potassium calcium-activated channel subfamily N member 1" Q92952 19 17951293-18000080 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Transport" "Calmodulin-binding, Ion channel" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in many" 12 "brain: 32.5" "Cell line enriched" "Detected in some" 12 "REH: 57.4" "Cancer enhanced" "Detected in some" "testis cancer: 3.5" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 4 "basophil: 2.3" "Lineage enriched" "Detected in single" 9 "granulocytes: 2.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA065938 Approved "Actin filaments,Cytosol" "Actin filaments, Cytosol" "HPA065938: " "unprognostic (7.55e-2)" "unprognostic (4.03e-2)" "unprognostic (1.82e-1)" "unprognostic (7.80e-2)" "unprognostic (1.90e-1)" "unprognostic (8.94e-5)" "unprognostic (3.92e-3)" "unprognostic (1.01e-1)" "unprognostic (8.42e-2)" "unprognostic (3.59e-1)" "unprognostic (2.71e-3)" "unprognostic (3.38e-1)" "unprognostic (5.21e-3)" "unprognostic (2.70e-2)" "unprognostic (1.14e-1)" "unprognostic (7.24e-3)" "unprognostic (3.24e-1)" 0.8 0.9 25.8 1.5 11.3 0.9 0.8 3.3 27.0 1.6 1.0 0.5 0.1 1.0 1.7 1.0 1.0 0.9 1.0 1.3 32.5 3.3 0.9 0.8 0.8 1.0 5.0 8.7 2.6 0.9 0.7 0.2 0.8 4.1 1.2 0.8 0.0 1.5 1.3 1.0 0.9 1.2 0.9 1.2 0.9 0.9 2.8 1.6 0.0 0.9 0.0 1.0 0.9 0.0 0.2 0.2 2.3 0.1 0.1 0.2 0.0 0.0 0.2 0.1 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 2.0 0.0 0.1 0.1 0.9 1.8 0.1 0.0 0.0 0.0 4.9 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.7 0.0 57.4 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 2.3 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.2 0.5 0.1 0.0 0.2 0.0 0.0 25.8 11.3 3.3 22.4 32.5 3.3 5.0 8.7 4.1 1.6 KCNN2 "hSK2, KCa2.2" ENSG00000080709 "Potassium calcium-activated channel subfamily N member 2" Q9H2S1 5 114360945-114496500 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Transport" "Calmodulin-binding, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 25.3;brain: 23.1;liver: 33.2" "Group enriched" "Detected in some" 5 "BJ: 14.7;NTERA-2: 5.6;SK-MEL-30: 10.4;THP-1: 18.3;U-937: 6.5" "Group enriched" "Detected in some" 7 "glioma: 3.5;melanoma: 3.2;prostate cancer: 12.6" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA038221 Uncertain Uncertain Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA038221: AB_10673044" "unprognostic (9.22e-3)" "unprognostic (1.90e-1)" "unprognostic (2.04e-1)" "unprognostic (5.65e-2)" "unprognostic (1.43e-1)" "unprognostic (1.40e-1)" "unprognostic (2.94e-1)" "unprognostic (1.42e-1)" "unprognostic (1.11e-2)" "unprognostic (1.56e-1)" "unprognostic (1.09e-1)" "unprognostic (1.15e-1)" "unprognostic (1.66e-1)" "unprognostic (1.23e-2)" "unprognostic (4.61e-1)" "unprognostic (3.16e-1)" "unprognostic (4.25e-1)" 0.8 25.3 12.6 0.8 7.3 0.6 1.1 21.7 15.0 1.7 1.2 9.5 0.0 0.9 3.9 0.9 0.8 1.0 1.0 7.7 23.1 3.6 4.8 33.2 2.5 0.9 4.5 16.9 1.4 3.8 1.0 16.0 0.6 9.1 11.7 1.3 4.2 1.1 5.4 9.9 2.1 0.9 2.8 8.4 1.1 1.1 3.8 6.5 0.0 0.9 0.0 0.8 2.4 1.1 0.3 0.3 0.8 0.3 0.1 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.8 14.7 2.2 0.3 0.1 0.0 0.2 0.0 0.5 0.0 0.0 2.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 1.2 5.6 0.0 0.1 0.0 0.7 0.2 0.1 1.8 0.0 0.0 0.1 10.4 0.2 18.3 0.2 0.0 0.4 1.6 0.0 0.1 0.0 0.1 1.8 6.5 0.5 0.5 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.3 0.3 0.1 0.3 0.8 0.1 0.3 0.3 0.1 0.0 12.6 7.3 21.7 15.0 23.1 3.6 4.5 16.9 9.1 6.5 KCNN3 "hSK3, KCa2.3, SKCA3" ENSG00000143603 "Potassium calcium-activated channel subfamily N member 3" Q9UGI6 1 154697455-154870280 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Transport" "Calmodulin-binding, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 26.7" "Cell line enhanced" "Detected in some" "Daudi: 17.7;HMC-1: 12.3;Karpas-707: 30.3;RPMI-8226: 8.2;U-266/70: 29.2;U-698: 9.8" "Cancer enhanced" "Detected in many" "glioma: 5.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 5.8;memory B-cell: 4.8" "Group enriched" "Detected in many" 9 "B-cells: 4.8;granulocytes: 5.8;monocytes: 2.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA057127 Enhanced Approved Nucleoplasm Nucleoplasm "HPA057127: " "unprognostic (2.09e-1)" "unprognostic (2.91e-2)" "unprognostic (3.41e-2)" "unprognostic (1.04e-1)" "unprognostic (7.22e-2)" "unprognostic (4.06e-2)" "unprognostic (2.19e-2)" "unprognostic (2.03e-1)" "unprognostic (3.43e-2)" "unprognostic (9.51e-2)" "unprognostic (4.07e-3)" "unprognostic (4.89e-2)" "prognostic unfavourable (1.97e-4)" "unprognostic (1.71e-2)" "unprognostic (1.54e-1)" "unprognostic (6.93e-2)" "unprognostic (1.80e-2)" 1.7 2.5 20.6 6.5 21.7 1.0 1.8 5.7 26.7 9.3 9.1 12.4 1.1 5.4 12.6 1.7 3.5 10.3 3.1 4.0 21.6 8.0 3.5 1.0 3.1 5.8 12.0 10.9 2.1 1.0 1.5 2.6 0.7 13.3 3.4 4.6 0.1 2.7 2.7 8.5 1.1 3.9 10.6 8.1 5.0 4.4 1.3 15.5 0.2 3.7 3.5 9.2 8.3 4.9 4.8 0.4 5.8 2.7 0.0 0.0 0.4 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.7 1.4 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 12.3 0.2 0.0 0.1 0.0 0.4 0.0 30.3 0.3 0.0 0.1 0.0 0.3 1.1 0.0 7.5 8.2 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.0 29.2 3.8 9.8 0.3 0.0 2.8 5.8 0.0 0.0 0.0 0.2 0.0 4.8 0.0 0.0 0.4 1.1 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.4 20.6 21.7 5.7 10.3 21.6 8.0 12.0 10.9 13.3 15.5 KCNN4 "hIKCa1, hKCa4, hSK4, IK, KCa3.1" ENSG00000104783 "Potassium calcium-activated channel subfamily N member 4" O15554 19 43766533-43781257 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Immunity, Ion transport, Transport" "Calmodulin-binding, Ion channel" "Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 45.7;salivary gland: 82.3" "Cell line enhanced" "Detected in many" "CAPAN-2: 27.8;SK-BR-3: 27.5;WM-115: 70.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Region enhanced" "Detected in single" "olfactory region: 2.3" "Low region specificity" "Detected in some" "HPA053841, HPA059622" Approved "HPA053841: , HPA059622: " "unprognostic (1.23e-2)" "unprognostic (3.22e-2)" "unprognostic (4.29e-1)" "unprognostic (3.74e-3)" "prognostic unfavourable (2.68e-4)" "unprognostic (1.98e-2)" "unprognostic (7.33e-2)" "unprognostic (1.42e-2)" "unprognostic (2.48e-3)" "unprognostic (4.12e-2)" "prognostic unfavourable (4.56e-4)" "unprognostic (9.96e-3)" "prognostic unfavourable (1.05e-14)" "unprognostic (3.70e-2)" "unprognostic (2.17e-2)" "unprognostic (7.50e-2)" "prognostic favourable (1.75e-4)" 3.0 0.1 0.5 12.2 2.5 6.5 5.6 0.4 0.5 8.0 5.7 0.7 6.4 2.0 0.9 2.9 2.6 2.6 8.8 0.6 1.4 0.5 0.8 0.3 2.6 5.7 1.7 0.6 1.3 0.3 0.0 0.3 45.7 1.5 11.0 3.8 0.8 82.3 6.8 0.7 10.8 10.0 2.0 1.1 8.4 13.6 0.9 1.0 9.1 0.7 3.6 17.3 10.3 2.4 18.7 14.4 1.9 15.8 0.0 6.9 5.2 5.1 9.5 0.0 0.0 0.0 0.8 13.5 0.2 0.7 0.5 0.1 0.1 27.8 1.4 2.2 0.2 4.1 0.0 9.8 1.4 9.3 0.0 6.8 12.5 0.2 0.0 0.0 0.1 0.0 1.2 0.6 4.4 0.0 1.5 0.8 0.1 5.0 1.4 5.2 0.0 10.3 4.6 0.1 5.1 8.5 14.4 0.0 0.0 13.8 27.5 8.1 0.0 5.5 0.3 3.8 19.7 0.1 11.1 0.0 0.3 0.6 13.1 1.2 70.6 1.9 10.2 0.0 0.3 15.8 0.4 18.7 5.1 2.6 14.4 9.4 3.4 3.2 0.5 0.0 8.6 0.4 6.9 5.2 0.5 2.5 0.4 0.5 1.4 0.5 1.7 0.6 1.5 1.0 KCNQ1 "JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1" ENSG00000053918 "Potassium voltage-gated channel subfamily Q member 1" P51787 11 2444684-2849110 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Calmodulin-binding, Ion channel, Potassium channel, Voltage-gated channel" "Atrial fibrillation, Deafness, Diabetes mellitus, Disease mutation, FDA approved drug targets, Long QT syndrome, Short QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 78.2;ductus deferens: 88.1;seminal vesicle: 83.6" "Cell line enhanced" "Detected in some" "HMC-1: 22.3;RPMI-8226: 15.0;U-266/70: 8.9;U-937: 8.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB018656, HPA048553" Enhanced "CAB018656: AB_2131551, HPA048553: " "unprognostic (6.02e-2)" "unprognostic (2.48e-1)" "unprognostic (6.39e-3)" "unprognostic (4.38e-1)" "unprognostic (1.86e-1)" "unprognostic (1.83e-1)" "unprognostic (3.46e-2)" "unprognostic (7.36e-2)" "unprognostic (8.07e-2)" "unprognostic (8.81e-2)" "unprognostic (1.58e-1)" "unprognostic (5.39e-2)" "unprognostic (2.46e-3)" "prognostic favourable (9.85e-4)" "unprognostic (3.99e-2)" "unprognostic (4.19e-2)" "unprognostic (5.27e-2)" 3.0 78.2 1.0 5.1 1.0 3.4 3.1 0.6 1.2 5.0 13.7 4.1 88.1 14.2 1.9 15.9 1.5 2.1 12.2 10.7 1.5 1.0 13.8 1.0 11.4 5.8 1.2 0.8 1.6 25.6 5.6 2.7 1.8 1.8 7.5 4.6 2.5 9.5 83.6 0.8 1.0 18.4 1.5 1.4 5.5 31.2 3.6 1.5 1.6 36.2 0.9 4.8 5.5 3.6 1.2 5.6 5.3 4.7 0.0 1.7 1.4 0.0 0.1 0.0 4.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 1.6 1.0 3.7 0.0 0.1 0.5 0.0 0.0 0.2 1.0 0.0 2.6 0.3 0.2 0.0 22.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.5 0.8 0.2 0.1 0.0 15.0 5.6 1.8 0.5 4.1 0.5 0.0 0.0 0.1 5.7 0.0 0.0 0.2 0.1 0.0 8.9 0.0 0.0 0.0 8.8 0.0 1.6 4.7 4.7 0.0 2.6 0.1 1.2 0.6 0.1 5.6 0.6 1.7 1.7 5.3 0.0 3.7 1.9 0.5 1.4 1.0 1.0 0.6 1.2 1.5 1.0 1.2 0.8 1.8 1.5 KCNQ2 "BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2" ENSG00000075043 "Potassium voltage-gated channel subfamily Q member 2" O43526 20 63400210-63472677 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 50.8" "Cell line enhanced" "Detected in some" "AF22: 8.3;AN3-CA: 13.7;NTERA-2: 7.6;SCLC-21H: 26.9;SH-SY5Y: 47.2" "Cancer enriched" "Detected in some" 9 "glioma: 8.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 2.2;T-reg: 1.5" "Lineage enriched" "Detected in single" 22 "T-cells: 2.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016642, HPA057112" Enhanced Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA016642: AB_1855555, HPA057112: " "unprognostic (2.35e-1)" "unprognostic (1.41e-1)" "unprognostic (2.22e-4)" "unprognostic (8.21e-6)" "unprognostic (6.18e-2)" "unprognostic (7.58e-2)" "unprognostic (6.06e-2)" "unprognostic (3.16e-1)" "unprognostic (1.73e-1)" "unprognostic (1.92e-1)" "unprognostic (9.96e-2)" "unprognostic (9.39e-2)" "unprognostic (1.43e-5)" "unprognostic (4.36e-2)" "unprognostic (1.02e-1)" "unprognostic (1.81e-1)" "unprognostic (2.70e-2)" 1.2 10.0 18.7 1.3 21.4 1.2 1.2 24.1 50.8 1.2 1.3 2.4 0.0 1.3 1.2 1.3 1.2 1.7 1.7 1.2 15.4 10.0 1.2 1.2 1.2 1.2 8.4 14.1 1.2 1.9 1.2 9.2 1.2 8.9 2.8 1.2 0.0 1.2 1.2 1.2 1.2 1.3 1.2 2.6 1.2 1.3 6.9 4.2 0.0 1.2 0.0 1.2 1.2 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 8.3 13.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 7.6 0.0 0.0 0.0 0.0 0.0 0.0 26.9 47.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.8 0.9 0.0 0.0 0.0 0.0 1.5 0.0 18.7 21.4 24.1 31.2 15.4 10.0 8.4 14.1 8.9 4.2 KDR "CD309, FLK1, VEGFR, VEGFR2" ENSG00000128052 "Kinase insert domain receptor" P35968 4 55078259-55125595 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Angiogenesis, Differentiation, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 9 "HUVEC TERT2: 31.8;TIME: 35.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB004028 Enhanced Supported "Plasma membrane" "Intracellular and membrane" 7400000 "Plasma membrane" "CAB004028: AB_2212507" "unprognostic (1.61e-1)" "unprognostic (2.03e-1)" "unprognostic (9.65e-2)" "unprognostic (1.97e-1)" "unprognostic (9.63e-2)" "unprognostic (1.22e-2)" "unprognostic (1.78e-3)" "unprognostic (2.59e-2)" "unprognostic (1.19e-2)" "unprognostic (1.10e-1)" "unprognostic (8.79e-3)" "unprognostic (1.34e-1)" "prognostic unfavourable (7.26e-4)" "unprognostic (4.00e-2)" "unprognostic (2.30e-1)" "unprognostic (3.22e-1)" "unprognostic (1.86e-1)" 19.7 6.2 1.8 4.4 3.1 0.4 20.5 1.1 2.2 11.4 6.0 1.8 11.5 2.3 28.8 10.2 5.2 9.5 6.2 12.1 2.3 1.7 7.8 10.4 13.2 14.1 3.1 2.9 6.0 8.1 8.0 6.8 34.5 3.9 9.5 1.4 27.6 7.1 10.3 5.3 3.0 3.8 7.7 2.6 4.4 4.2 5.3 1.2 0.5 20.0 5.3 3.0 4.4 12.0 0.1 0.1 0.7 0.0 0.2 0.2 0.1 0.0 0.0 1.7 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 3.7 0.0 0.0 0.3 0.0 0.0 0.2 31.8 0.0 0.0 0.2 0.0 0.0 0.0 0.8 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 35.9 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.4 0.0 0.1 0.1 0.0 0.7 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.1 1.8 3.1 1.1 2.2 2.3 1.7 3.1 2.9 3.9 1.2 KEAP1 "INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454" ENSG00000079999 "Kelch like ECH associated protein 1" Q14145 19 10486120-10503741 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005558, CAB025337" Approved Supported "Nucleoplasm,Centriolar satellite,Cytosol" "Nucleoplasm, Centriolar satellite" Cytosol "CAB025337: , HPA005558: AB_1079175" "unprognostic (1.98e-1)" "prognostic favourable (3.28e-4)" "unprognostic (1.61e-1)" "unprognostic (1.02e-1)" "unprognostic (1.42e-1)" "unprognostic (1.63e-2)" "unprognostic (2.64e-2)" "unprognostic (1.46e-1)" "unprognostic (1.48e-1)" "unprognostic (5.22e-3)" "unprognostic (2.04e-1)" "unprognostic (9.99e-2)" "unprognostic (1.29e-1)" "unprognostic (7.71e-3)" "unprognostic (5.06e-1)" "unprognostic (8.18e-2)" "unprognostic (1.60e-2)" 16.0 13.7 13.5 10.4 14.3 9.1 12.4 13.2 15.1 13.1 15.7 15.4 13.8 13.6 11.0 12.7 26.3 15.1 12.7 19.7 13.9 13.7 13.2 22.0 10.8 15.5 16.7 7.4 11.8 14.3 11.1 10.2 11.5 14.3 13.9 8.8 11.8 11.3 13.9 63.9 16.8 13.8 11.6 16.5 11.3 10.6 12.2 13.8 13.1 14.5 29.1 16.1 14.5 11.2 14.6 23.7 21.3 19.8 21.0 30.8 19.6 17.2 31.7 8.8 11.7 18.1 15.5 9.4 14.7 11.0 15.1 13.6 22.5 17.4 24.6 38.8 16.3 15.5 17.4 11.5 7.5 23.8 19.1 37.2 9.4 26.6 17.5 19.4 20.2 16.0 15.6 17.0 7.9 14.3 22.7 45.6 13.1 23.9 14.1 53.4 25.6 26.7 25.6 11.0 28.7 9.8 20.7 24.2 12.6 20.5 13.8 12.7 11.9 26.0 17.6 24.4 13.1 27.3 17.8 26.6 33.3 24.1 18.8 23.2 17.9 16.1 19.8 21.3 30.8 17.0 29.3 14.6 21.5 28.3 23.7 5.7 13.5 19.1 10.9 21.0 16.6 16.3 25.4 19.6 13.5 14.3 13.2 12.8 13.9 13.7 16.7 7.4 14.3 13.8 KIT "C-Kit, CD117, PBT, SCFR" ENSG00000157404 "KIT proto-oncogene receptor tyrosine kinase" P10721 4 54657918-54740715 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 65.5" "Group enriched" "Detected in some" 13 "HEL: 47.7;HMC-1: 100.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7" "Group enriched" "Detected in many" 6 "granulocytes: 12.7;NK-cells: 9.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003288, HPA004471, CAB068253, CAB072867, HPA073252" Enhanced Supported Supported "Plasma membrane" 48000000 "Plasma membrane" "CAB003288: AB_2335702, CAB068253: , CAB072867: , HPA004471: AB_1078431, HPA073252: " "unprognostic (1.55e-2)" "unprognostic (1.91e-1)" "unprognostic (4.04e-2)" "unprognostic (8.19e-2)" "unprognostic (3.96e-2)" "unprognostic (2.18e-2)" "unprognostic (2.33e-2)" "unprognostic (1.97e-2)" "unprognostic (3.60e-2)" "unprognostic (1.64e-1)" "unprognostic (2.20e-1)" "unprognostic (1.92e-2)" "prognostic favourable (5.63e-4)" "unprognostic (1.34e-3)" "unprognostic (1.87e-1)" "unprognostic (1.29e-2)" "unprognostic (2.30e-1)" 8.1 1.6 9.5 6.6 11.8 3.7 65.5 18.3 12.0 12.1 10.3 6.5 10.2 5.8 8.9 4.2 9.9 2.5 15.5 2.4 36.0 4.4 9.4 1.1 13.8 3.8 3.6 6.0 28.5 2.1 1.3 2.3 6.2 5.7 9.6 10.4 20.7 12.9 6.9 1.3 14.6 8.9 10.2 3.9 3.2 12.8 4.0 4.5 0.4 28.9 4.3 4.9 9.8 12.5 0.0 1.8 12.7 0.9 9.7 1.9 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.6 0.9 2.5 3.2 0.0 0.0 0.0 0.0 1.4 0.0 0.5 0.0 2.1 0.0 1.1 47.7 0.0 0.0 0.0 0.0 100.2 0.0 0.0 0.0 0.0 5.6 0.6 0.1 0.0 0.0 0.2 0.4 1.3 0.0 0.1 0.0 0.0 0.0 4.7 1.2 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 12.7 0.0 10.0 0.1 0.0 1.9 0.0 0.3 0.7 1.8 0.0 0.0 0.0 0.8 9.7 0.9 0.0 0.0 0.1 9.5 11.8 18.3 12.0 36.0 4.4 3.6 6.0 5.7 4.5 KRT12 K12 ENSG00000187242 "Keratin 12" Q99456 17 40861303-40867210 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Corneal dystrophy, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 3.3;retina: 3.6;skin 1: 1.9" "Cell line enriched" "Detected in single" 6 "HeLa: 3.7" "Low cancer specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "HPA055217, HPA055835" Enhanced "HPA055217: AB_2682742, HPA055835: AB_2682935" "unprognostic (1.89e-1)" "unprognostic (2.40e-2)" "unprognostic (1.01e-1)" "unprognostic (4.82e-1)" "unprognostic (2.19e-1)" "unprognostic (2.04e-1)" "unprognostic (1.74e-2)" "unprognostic (5.52e-2)" "unprognostic (9.41e-3)" "unprognostic (3.49e-1)" "unprognostic (1.73e-1)" "unprognostic (3.94e-3)" "unprognostic (2.01e-2)" "unprognostic (1.27e-1)" "unprognostic (2.60e-4)" "unprognostic (6.31e-3)" 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.9 0.1 3.3 0.1 0.1 1.3 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 1.0 3.6 0.1 0.1 0.1 1.9 3.3 0.1 0.1 0.1 0.4 0.7 0.1 1.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.1 3.7 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.3 0.2 0.3 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.9 0.1 0.0 0.1 0.1 0.1 0.1 KRT2 "KRT2A, KRTE" ENSG00000172867 "Keratin 2" P35908 12 52644558-52652164 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Disease mutation, FDA approved drug targets, Ichthyosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 15 "skin 1: 289.9" "Group enriched" "Detected in some" 6 "HEL: 6.5;HMC-1: 2.8" "Group enriched" "Detected in some" 35 "head and neck cancer: 4.7;melanoma: 23.4" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "naive CD4 T-cell: 4.4;naive CD8 T-cell: 2.1" "Lineage enriched" "Detected in single" 45 "T-cells: 4.4" "Group enriched" "Detected in some" 6 "amygdala: 1.8;hippocampal formation: 2.9" "Low region specificity" "Detected in single" "HPA006299, CAB037321" Enhanced Approved "Golgi apparatus,Intermediate filaments,Cytosol" 14000000000 "Intermediate filaments, Cytosol" "Golgi apparatus" "CAB037321: , HPA006299: AB_1079180" "unprognostic (1.22e-1)" "unprognostic (1.60e-1)" "unprognostic (1.34e-1)" "unprognostic (2.56e-1)" "unprognostic (8.47e-3)" "unprognostic (1.69e-2)" "unprognostic (1.84e-1)" "unprognostic (3.59e-1)" "unprognostic (2.12e-1)" "unprognostic (4.76e-2)" "unprognostic (3.56e-7)" "unprognostic (6.43e-2)" "unprognostic (5.98e-3)" "unprognostic (6.69e-2)" "unprognostic (3.46e-1)" 0.1 0.0 0.1 0.1 0.1 0.0 9.5 0.1 0.1 18.3 0.1 0.1 0.1 0.0 2.0 0.1 0.4 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 4.4 289.9 0.1 0.1 0.1 0.1 0.0 0.1 0.1 6.8 0.1 19.2 1.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 4.4 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.5 0.0 0.0 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.4 0.0 0.0 4.4 2.1 0.0 0.0 0.0 0.0 0.0 0.8 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 LCK ENSG00000182866 "LCK proto-oncogene, Src family tyrosine kinase" P06239 1 32251239-32286165 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Host-virus interaction" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "blood: 112.2;lymphoid tissue: 153.0" "Group enriched" "Detected in some" 6 "MOLT-4: 98.9;U-698: 57.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 14 "gdT-cell: 83.4;MAIT T-cell: 77.5;memory CD4 T-cell: 86.1;memory CD8 T-cell: 90.2;naive CD4 T-cell: 97.0;naive CD8 T-cell: 91.3;NK-cell: 42.8;T-reg: 112.2" "Group enriched" "Detected in many" 13 "NK-cells: 42.8;T-cells: 112.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003494, CAB003816" Enhanced Approved "Golgi apparatus" "Golgi apparatus" "CAB003816: AB_562158, HPA003494: AB_1852751" "unprognostic (6.38e-3)" "unprognostic (5.45e-3)" "unprognostic (8.39e-2)" "prognostic favourable (2.96e-6)" "unprognostic (2.20e-2)" "prognostic favourable (2.91e-4)" "unprognostic (4.78e-3)" "unprognostic (1.33e-2)" "prognostic favourable (5.65e-5)" "unprognostic (3.07e-2)" "unprognostic (3.80e-2)" "unprognostic (2.83e-1)" "prognostic unfavourable (2.60e-5)" "unprognostic (8.15e-2)" "unprognostic (4.05e-2)" "unprognostic (7.39e-2)" "unprognostic (1.17e-2)" 2.6 0.7 0.4 28.2 0.5 3.8 1.3 0.3 0.5 1.7 3.9 0.5 0.9 2.2 1.1 4.5 2.3 1.6 3.8 1.0 0.4 0.4 3.0 2.3 6.6 34.9 0.9 0.5 1.2 0.8 0.0 0.8 0.7 0.6 2.2 1.9 1.3 8.4 1.3 0.9 1.0 16.5 0.7 1.0 28.9 3.5 0.7 0.5 153.0 2.9 1.5 27.1 5.8 2.1 6.1 0.5 2.5 0.3 42.8 112.2 109.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 12.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 98.9 0.0 1.1 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 57.0 0.0 0.0 0.0 0.6 0.3 0.4 83.4 0.3 77.5 4.0 86.1 90.2 0.3 6.1 97.0 91.3 2.5 42.8 0.3 0.5 112.2 109.3 0.4 0.5 0.3 0.5 0.4 0.4 0.9 0.5 0.6 0.5 LDHA ENSG00000134333 "Lactate dehydrogenase A" P00338 11 18394388-18408425 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes, Disease mutation, FDA approved drug targets, Glycogen storage disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 249.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015336, CAB069404" Uncertain Supported Vesicles,Cytosol 300000000 Cytosol Vesicles "CAB015336: AB_2134947, CAB069404: " "unprognostic (8.83e-2)" "prognostic unfavourable (2.78e-5)" "unprognostic (3.81e-2)" "unprognostic (1.73e-1)" "unprognostic (3.43e-3)" "unprognostic (4.66e-3)" "prognostic unfavourable (3.26e-8)" "prognostic unfavourable (2.27e-6)" "unprognostic (1.08e-1)" "unprognostic (1.88e-2)" "prognostic unfavourable (8.09e-6)" "unprognostic (1.76e-2)" "prognostic unfavourable (9.69e-9)" "unprognostic (4.15e-2)" "unprognostic (1.89e-1)" "unprognostic (3.07e-1)" "unprognostic (1.05e-2)" 84.2 56.4 24.5 52.6 32.5 64.0 56.0 22.3 40.2 38.1 53.5 13.5 9.1 60.5 24.9 36.2 77.7 29.0 31.6 59.4 24.4 33.0 100.1 249.1 37.1 59.4 29.7 25.7 49.7 34.1 10.5 16.4 49.7 44.3 33.3 51.2 45.9 46.3 37.0 199.6 70.2 128.3 50.7 35.5 45.0 31.2 25.9 23.9 45.0 56.4 90.6 60.1 81.9 44.8 27.6 76.5 29.1 61.2 32.8 52.2 72.1 131.7 82.0 3.1 46.2 72.2 49.3 44.0 127.5 135.5 112.0 166.7 36.6 21.7 99.7 41.9 128.8 106.6 82.0 195.4 242.9 34.0 48.5 34.5 74.9 62.8 17.8 85.1 25.9 49.2 90.1 44.0 44.1 66.1 48.6 48.0 131.1 34.9 70.0 53.9 19.8 102.6 45.4 32.7 83.5 178.0 30.6 24.6 30.4 69.1 57.0 23.6 26.8 20.3 59.5 140.3 50.9 122.1 1.5 38.2 55.9 95.9 200.8 44.1 47.2 28.9 53.1 29.1 38.1 61.2 42.6 27.6 50.2 40.1 76.5 19.2 32.8 33.3 18.1 32.8 59.5 25.8 52.2 72.1 24.5 32.5 22.3 40.2 24.4 33.0 29.7 25.7 44.3 23.9 LDHB ENSG00000111716 "Lactate dehydrogenase B" P07195 12 21635342-21757857 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 255.8;kidney: 233.1" "Cell line enhanced" "Detected in many" "RPTEC TERT1: 318.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Lineage enriched" "Detected in all" 4 "T-cells: 145.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004641, HPA019007" Enhanced Supported Cytosol 780000000 Cytosol "CAB004641: AB_425525, HPA019007: " "unprognostic (2.93e-1)" "unprognostic (9.20e-3)" "unprognostic (6.10e-2)" "unprognostic (1.11e-1)" "unprognostic (5.39e-3)" "unprognostic (1.36e-3)" "unprognostic (1.61e-2)" "unprognostic (1.72e-2)" "unprognostic (5.34e-2)" "unprognostic (8.40e-2)" "unprognostic (2.91e-1)" "unprognostic (6.41e-2)" "prognostic favourable (2.51e-4)" "unprognostic (1.31e-1)" "unprognostic (1.71e-1)" "unprognostic (2.55e-1)" "unprognostic (9.32e-2)" 70.9 60.2 79.5 33.3 79.6 40.8 33.4 52.4 80.1 24.9 31.8 30.6 13.2 11.8 38.7 27.3 25.6 34.4 32.3 255.8 58.8 69.9 233.1 9.8 27.7 52.3 91.6 62.3 68.0 54.8 41.8 19.4 40.1 84.9 34.9 39.4 26.8 21.8 42.2 29.7 8.6 18.0 42.9 52.9 23.8 47.5 16.4 47.6 59.1 48.5 56.3 58.7 49.7 21.8 28.1 32.9 33.0 15.3 33.7 145.1 93.2 32.7 88.0 77.4 50.9 55.5 61.8 90.0 45.8 45.8 64.1 63.5 139.3 0.1 116.1 30.1 30.8 16.5 106.4 84.9 81.7 29.7 74.1 119.5 84.1 0.1 53.1 111.5 51.7 70.6 30.4 56.1 76.4 73.1 65.3 17.5 70.5 0.1 94.7 135.0 223.2 38.2 85.6 108.0 93.6 318.2 146.3 24.9 57.7 21.0 32.6 79.0 0.2 87.5 28.4 43.2 56.7 30.7 86.3 15.5 20.9 152.5 47.9 53.4 51.2 33.0 15.3 1.8 28.5 9.4 47.5 28.1 110.7 59.4 28.3 17.7 145.1 92.2 2.5 33.7 6.7 32.9 105.4 93.2 79.5 79.6 52.4 80.1 58.8 69.9 91.6 62.3 84.9 47.6 LHCGR "HHG, LCGR, LGR2, LHR, ULG5" ENSG00000138039 "Luteinizing hormone/choriogonadotropin receptor" P22888 2 48686775-48755730 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 10.3;testis: 18.8" "Group enriched" "Detected in some" 5 "AF22: 2.8;HSkMC: 1.0;NTERA-2: 1.6" "Not detected" "Not detected" "Region enhanced" "Detected in some" "basal ganglia: 6.1" "Not detected" "Not detected" "Not detected" "Not detected" CAB009814 Uncertain "CAB009814: AB_2135467" "unprognostic (8.57e-2)" "unprognostic (1.08e-1)" "unprognostic (1.54e-1)" "unprognostic (1.41e-1)" "unprognostic (3.14e-2)" "unprognostic (2.97e-2)" "unprognostic (2.24e-2)" "unprognostic (5.22e-2)" 3.6 2.9 0.3 1.4 6.1 0.0 1.6 0.3 0.4 0.2 0.5 0.2 0.0 0.2 0.4 0.3 2.1 0.2 1.8 0.6 0.7 0.4 0.9 0.1 0.4 0.1 2.6 0.0 5.0 0.1 0.0 2.7 0.1 1.4 0.4 0.2 0.3 1.0 0.1 0.2 0.6 0.3 1.0 10.3 0.1 0.6 18.8 0.0 0.4 2.2 0.1 0.1 0.4 0.8 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.3 6.1 0.3 0.4 0.7 0.4 2.6 0.0 1.4 0.0 LIPF "HGL, HLAL" ENSG00000182333 "Lipase F, gastric type" P07098 10 88664441-88678814 "Enzymes, FDA approved drug targets, Predicted secreted proteins" "Lipid degradation, Lipid metabolism" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 24 "stomach 1: 762.9" "Cell line enhanced" "Detected in some" "HMC-1: 6.2;MOLT-4: 4.9;NTERA-2: 5.2;REH: 3.0;THP-1: 9.8;U-2 OS: 3.5;U-266/70: 4.8" "Cancer enriched" "Detected in some" 75 "stomach cancer: 278.5" "Region enhanced" "Detected in single" "cerebral cortex: 1.9" "Cell type enriched" "Detected in single" 16 "eosinophil: 1.5" "Lineage enriched" "Detected in single" 16 "granulocytes: 1.5" "Region enriched" "Detected in single" 51 "olfactory region: 9.9" HPA045930 Enhanced "Secreted to digestive system" "HPA045930: AB_10959518" "unprognostic (1.53e-1)" "unprognostic (1.83e-1)" 0.1 0.0 0.1 0.1 0.5 0.0 0.1 0.1 1.9 0.1 0.2 28.2 0.1 8.2 0.1 0.1 31.6 0.1 0.6 0.1 0.1 0.0 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.3 0.1 0.1 0.1 0.0 0.1 9.9 0.1 0.1 0.0 0.1 0.1 0.1 0.1 762.9 0.1 0.1 0.2 0.1 1.1 0.1 0.1 0.1 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.1 5.2 0.0 3.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 0.0 0.0 3.5 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.1 1.9 0.1 0.0 0.1 0.1 0.1 0.1 LPL LIPD ENSG00000175445 "Lipoprotein lipase" P06858 8 19901717-19967258 "Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Lipid degradation, Lipid metabolism" "Heparin-binding, Hydrolase" "Disease mutation, FDA approved drug targets, Hyperlipidemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 178.6;breast: 146.2;heart muscle: 121.4" "Cell line enriched" "Detected in some" 5 "AF22: 89.3" "Cancer enhanced" "Detected in all" "glioma: 39.2" "Region enhanced" "Detected in many" "basal ganglia: 16.3" "Cell type enhanced" "Detected in some" "non-classical monocyte: 7.1" "Lineage enriched" "Detected in many" 5 "monocytes: 7.1" "Region enhanced" "Detected in many" "basal ganglia: 40.6" "Region enriched" "Detected in all" 4 "basal ganglia: 64.0" HPA048749 Supported Vesicles "Secreted to blood" 880000 Vesicles "HPA048749: " "unprognostic (5.52e-2)" "unprognostic (3.16e-1)" "unprognostic (6.41e-2)" "unprognostic (3.03e-1)" "unprognostic (4.14e-2)" "unprognostic (1.01e-2)" "unprognostic (1.88e-4)" "unprognostic (1.05e-1)" "unprognostic (6.78e-2)" "unprognostic (8.20e-2)" "unprognostic (2.54e-2)" "unprognostic (5.28e-1)" "unprognostic (1.18e-1)" "unprognostic (4.20e-3)" "unprognostic (4.16e-3)" "unprognostic (1.19e-1)" "prognostic unfavourable (6.07e-4)" 178.6 4.3 2.0 11.4 16.3 0.6 146.2 3.9 8.0 1.0 16.9 0.3 27.3 0.8 1.3 1.1 1.1 0.7 8.2 121.4 2.8 2.3 4.8 0.6 20.7 7.0 4.5 0.7 2.7 1.8 32.6 0.9 7.1 1.7 0.9 1.8 8.4 9.2 85.1 53.8 1.8 3.1 1.3 2.8 0.8 1.8 0.7 3.4 0.0 2.7 9.7 1.0 3.2 6.1 0.0 0.7 1.3 7.1 0.0 0.1 0.4 0.0 0.0 89.3 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 17.6 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.1 0.0 0.0 0.0 14.2 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.8 0.0 0.7 0.0 0.0 0.0 0.0 0.0 7.2 0.0 1.6 1.3 0.0 2.8 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.4 2.0 16.3 3.9 2.3 2.8 2.3 4.5 0.7 1.7 3.4 MAOA ENSG00000189221 "Monoamine oxidase A" P21397 X 43654907-43746824 "Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins" "Catecholamine metabolism, Neurotransmitter degradation" Oxidoreductase "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 39.5;HHSteC: 74.2;HSkMC: 18.6;hTCEpi: 20.9;RT4: 30.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "classical monocyte: 1.0;MAIT T-cell: 1.3" "Group enriched" "Detected in many" 10 "monocytes: 1.0;T-cells: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009437, HPA054807, HPA059299" Enhanced Enhanced Mitochondria,Cytosol Mitochondria Cytosol "CAB009437: AB_2137260, HPA054807: , HPA059299: " "unprognostic (9.54e-3)" "unprognostic (1.63e-1)" "unprognostic (7.99e-2)" "unprognostic (3.07e-1)" "unprognostic (6.75e-2)" "unprognostic (3.32e-1)" "unprognostic (9.51e-2)" "unprognostic (6.89e-3)" "unprognostic (2.21e-1)" "unprognostic (4.29e-2)" "unprognostic (3.94e-1)" "unprognostic (3.54e-1)" "unprognostic (1.45e-3)" "unprognostic (1.16e-2)" "unprognostic (1.47e-1)" "unprognostic (4.04e-2)" "unprognostic (2.98e-3)" 72.3 11.0 8.2 10.2 7.8 0.3 35.2 3.3 6.1 12.4 85.7 2.8 10.7 53.6 12.5 6.2 36.6 12.0 14.7 37.8 6.7 8.3 77.8 45.9 34.4 5.2 11.1 6.1 14.2 24.4 9.6 1.5 79.8 8.7 26.2 39.9 6.2 49.1 12.9 12.5 11.2 90.1 23.6 3.4 2.1 19.3 5.5 4.7 0.0 68.6 9.7 3.9 35.3 35.1 0.0 0.0 0.1 1.0 0.0 1.3 0.1 0.0 0.8 0.1 2.3 39.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 4.0 1.4 5.3 0.0 0.0 0.5 1.6 0.1 4.2 74.2 0.0 4.0 18.6 20.9 0.0 10.9 4.7 0.0 0.1 1.3 0.6 0.0 0.1 0.3 1.2 0.0 0.0 0.1 5.3 30.6 0.7 1.8 0.0 0.0 0.0 0.1 0.0 2.0 0.0 2.0 0.1 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 1.0 0.0 0.0 0.0 1.3 0.0 0.1 0.3 0.0 0.0 0.1 0.6 0.1 0.0 0.0 0.0 0.0 0.1 8.2 7.8 3.3 6.1 6.7 8.3 11.1 6.1 8.7 4.7 MAOB ENSG00000069535 "Monoamine oxidase B" P27338 X 43766611-43882447 "Enzymes, FDA approved drug targets, Predicted membrane proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 104.9" "Group enriched" "Detected in some" 7 "Hep G2: 20.2;SiHa: 39.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 5 "naive CD8 T-cell: 1.0" "Lineage enriched" "Detected in single" 6 "T-cells: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002328, CAB037200" Enhanced 3600000 "CAB037200: AB_1841012, HPA002328: AB_1854062" "unprognostic (1.19e-2)" "unprognostic (1.36e-1)" "unprognostic (5.16e-2)" "unprognostic (1.85e-2)" "unprognostic (4.39e-2)" "unprognostic (2.69e-2)" "unprognostic (5.61e-2)" "unprognostic (4.37e-2)" "unprognostic (1.56e-1)" "unprognostic (1.04e-2)" "unprognostic (1.20e-1)" "unprognostic (1.54e-2)" "unprognostic (9.74e-2)" "unprognostic (5.35e-3)" "unprognostic (1.48e-2)" "unprognostic (3.53e-1)" "unprognostic (1.90e-3)" 25.0 18.2 24.8 3.9 34.8 0.5 16.5 5.5 24.5 12.0 18.9 20.3 15.6 24.9 38.0 20.0 11.4 34.9 15.4 32.4 21.2 46.9 41.8 104.9 10.9 2.3 24.4 19.9 56.0 4.1 15.6 8.9 9.4 26.8 30.1 6.3 3.0 38.0 55.9 34.8 3.0 30.5 35.9 39.1 1.3 8.4 5.2 21.3 0.2 1.8 8.2 2.8 12.1 8.5 0.0 0.0 0.0 0.1 0.0 1.0 1.2 0.0 0.5 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 2.6 2.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 4.4 20.2 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 1.8 0.0 0.0 0.0 0.1 2.0 0.0 0.0 0.5 39.0 0.0 0.2 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 1.2 24.8 34.8 5.5 24.5 21.2 46.9 24.4 19.9 26.8 21.3 MAP1A MAP1L ENSG00000166963 "Microtubule associated protein 1A" P78559 15 43510958-43531620 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "brain: 103.6" "Cell line enhanced" "Detected in many" "ASC diff: 21.4;BJ hTERT+: 21.1;fHDF/TERT166: 31.5;hTEC/SVTERT24-B: 20.0;U-87 MG: 42.4" "Cancer enhanced" "Detected in many" "glioma: 18.1" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 74 "plasmacytoid DC: 12.3" "Lineage enriched" "Detected in single" 74 "dendritic cells: 12.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039063, HPA039064, HPA066488" Enhanced Approved Cytosol Cytosol "HPA039063: AB_2676327, HPA039064: AB_10673302, HPA066488: " "unprognostic (1.60e-1)" "unprognostic (1.31e-1)" "unprognostic (3.29e-2)" "unprognostic (1.86e-3)" "unprognostic (4.45e-2)" "unprognostic (3.58e-2)" "unprognostic (5.66e-2)" "unprognostic (1.12e-1)" "unprognostic (2.65e-2)" "unprognostic (1.13e-3)" "unprognostic (8.36e-3)" "unprognostic (3.45e-3)" "prognostic unfavourable (6.59e-5)" "unprognostic (5.83e-2)" "unprognostic (2.53e-1)" "prognostic unfavourable (1.09e-5)" "prognostic unfavourable (1.66e-5)" 5.2 7.9 43.6 5.4 42.8 2.5 4.3 24.5 103.6 10.5 5.4 18.3 1.0 3.0 5.6 4.3 4.8 9.1 5.9 14.8 40.9 30.2 2.8 1.9 3.4 2.7 34.7 31.3 7.1 2.7 4.1 4.4 4.4 56.2 6.7 5.3 3.1 2.5 9.6 4.5 3.1 3.2 14.5 21.4 2.6 2.7 5.4 12.6 6.5 3.7 0.1 2.7 6.3 2.8 0.0 12.3 0.0 0.0 0.0 0.1 0.2 0.1 0.8 3.8 2.2 21.4 14.7 0.0 12.2 21.1 3.6 3.5 1.4 0.0 0.0 5.3 31.5 0.1 5.1 0.0 2.1 1.8 0.5 4.7 1.2 0.1 2.0 0.1 2.0 11.0 0.0 20.0 0.1 2.7 7.8 0.1 14.6 0.1 8.6 0.2 2.8 0.3 2.3 11.1 0.0 0.0 0.0 12.0 3.6 0.4 0.0 0.1 0.7 0.2 0.5 11.7 3.9 3.9 0.1 0.0 0.5 1.7 42.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.3 0.1 0.2 43.6 42.8 24.5 63.1 40.9 30.2 34.7 31.3 56.2 12.6 MAP2 "MAP2A, MAP2B, MAP2C" ENSG00000078018 "Microtubule associated protein 2" P11137 2 209424058-209734118 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Calmodulin-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 122.3" "Cell line enhanced" "Detected in some" "AF22: 74.6;NTERA-2: 26.7;SCLC-21H: 37.5;SH-SY5Y: 21.0" "Cancer enhanced" "Detected in many" "glioma: 30.4" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 13 "memory B-cell: 2.6;naive B-cell: 3.4" "Lineage enriched" "Detected in single" 15 "B-cells: 3.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001984, HPA008273, HPA012828" Enhanced Supported "CAB001984: , HPA008273: AB_1853945, HPA012828: AB_1853946" "unprognostic (2.47e-2)" "unprognostic (2.81e-1)" "unprognostic (2.58e-2)" "prognostic unfavourable (1.98e-6)" "unprognostic (2.29e-2)" "unprognostic (1.79e-1)" "unprognostic (1.13e-2)" "unprognostic (6.06e-2)" "unprognostic (1.31e-1)" "unprognostic (9.84e-2)" "unprognostic (1.09e-2)" "unprognostic (1.60e-1)" "unprognostic (1.23e-1)" "unprognostic (2.69e-3)" "unprognostic (2.54e-1)" "unprognostic (7.28e-2)" "unprognostic (4.10e-5)" 4.6 9.2 62.1 2.1 63.1 1.5 4.9 24.7 122.3 4.4 2.5 3.8 0.0 2.0 2.9 4.0 5.6 2.8 6.3 6.2 73.6 53.8 3.9 3.7 9.3 2.4 31.0 48.8 6.4 8.2 12.5 14.7 1.9 35.4 6.5 2.5 7.6 4.9 4.7 2.2 12.1 2.0 3.2 19.9 2.4 2.6 5.4 11.4 0.0 12.2 0.4 2.9 2.8 1.5 3.4 0.1 0.0 0.0 0.0 0.2 0.3 0.6 0.1 74.6 0.0 1.0 0.5 0.0 0.4 0.5 0.1 0.5 0.0 4.0 0.0 0.4 0.9 1.0 5.7 0.4 0.2 0.0 0.3 0.2 2.3 0.0 9.4 0.0 0.0 0.8 2.4 0.0 1.4 1.9 0.0 0.7 0.0 0.2 0.0 0.0 26.7 0.1 0.0 0.1 0.0 0.9 0.0 37.5 21.0 1.5 0.2 0.9 2.0 0.0 0.0 0.0 0.4 0.0 1.0 0.5 0.0 0.0 3.9 0.0 11.1 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.1 0.0 0.0 3.4 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.3 62.1 63.1 24.7 79.6 73.6 53.8 31.0 48.8 35.4 11.4 MAP2K1 "MAPKK1, MEK1, PRKMK1" ENSG00000169032 "Mitogen-activated protein kinase kinase 1" Q02750 15 66386817-66492312 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003834, HPA026430" Approved Enhanced "Plasma membrane,Cytosol" 62000 "Plasma membrane, Cytosol" "CAB003834: AB_562310, HPA026430: AB_1853742" "unprognostic (4.05e-2)" "unprognostic (1.23e-2)" "unprognostic (2.07e-1)" "unprognostic (4.92e-2)" "prognostic unfavourable (1.95e-4)" "unprognostic (1.81e-3)" "unprognostic (5.78e-2)" "unprognostic (9.91e-3)" "unprognostic (1.11e-1)" "unprognostic (1.77e-1)" "unprognostic (1.45e-1)" "unprognostic (7.62e-3)" "unprognostic (1.20e-1)" "unprognostic (2.71e-1)" "unprognostic (1.96e-1)" "unprognostic (1.15e-1)" "unprognostic (9.40e-3)" 28.6 16.9 33.9 19.1 54.1 29.0 23.6 32.5 48.4 12.5 12.1 8.4 10.2 10.0 11.8 16.5 22.0 10.6 14.4 19.1 49.2 26.4 15.3 53.1 16.4 23.3 17.6 31.2 13.5 11.7 23.4 12.0 15.4 17.2 14.4 12.9 9.1 13.2 12.4 39.5 12.3 10.9 16.9 17.4 14.5 10.8 7.8 12.6 12.6 12.3 9.7 27.9 13.6 18.7 4.6 16.2 5.5 8.2 8.4 7.9 2.7 33.1 15.6 31.5 13.1 19.0 14.3 18.2 24.1 20.6 26.2 23.4 23.5 27.3 30.5 29.9 19.8 29.6 29.4 35.2 30.8 24.5 17.5 9.8 16.4 12.7 15.4 12.9 14.6 11.0 21.8 18.9 28.1 20.4 17.3 39.0 38.1 12.8 10.3 16.8 16.1 13.7 11.7 19.5 27.1 25.4 14.3 19.4 10.8 19.5 15.3 20.2 13.8 11.0 28.1 34.1 20.9 24.0 35.7 24.2 43.0 19.4 36.0 22.8 15.9 3.2 8.2 5.5 7.4 8.2 6.7 3.0 6.6 6.9 8.3 4.6 7.9 4.9 3.9 8.4 7.3 16.2 4.9 2.7 33.9 54.1 32.5 46.9 49.2 26.4 17.6 31.2 17.2 12.6 MAP2K2 "MEK2, PRKMK2" ENSG00000126934 "Mitogen-activated protein kinase kinase 2" P36507 19 4090321-4124129 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB003835, HPA051993" Supported Supported Cytosol Cytosol "CAB003835: AB_562312, HPA051993: " "unprognostic (4.39e-1)" "prognostic favourable (3.72e-4)" "unprognostic (4.24e-1)" "unprognostic (1.26e-3)" "unprognostic (2.58e-1)" "prognostic favourable (7.98e-4)" "unprognostic (2.08e-3)" "unprognostic (2.11e-1)" "unprognostic (2.65e-1)" "unprognostic (1.06e-1)" "unprognostic (7.45e-3)" "unprognostic (4.95e-2)" "unprognostic (1.32e-1)" "prognostic favourable (5.43e-5)" "unprognostic (2.91e-2)" "unprognostic (2.25e-1)" "unprognostic (4.90e-2)" 23.9 33.0 35.6 27.6 36.1 46.7 30.2 31.2 43.4 22.6 38.8 24.6 27.0 70.9 21.8 23.2 32.8 21.7 27.9 41.4 33.1 31.0 22.7 42.0 24.1 44.5 34.4 29.2 30.8 46.0 18.9 29.7 21.3 26.1 25.7 24.3 21.7 41.5 24.0 134.9 27.4 56.7 19.0 25.2 25.9 28.3 42.0 20.9 44.1 26.2 42.2 29.1 20.0 26.9 11.4 10.7 28.3 10.6 11.3 12.1 4.5 36.2 40.0 21.9 30.7 30.3 36.6 21.9 23.9 32.0 32.7 29.7 34.6 19.7 31.0 22.6 27.2 26.2 17.1 25.5 25.4 26.3 20.8 11.3 21.8 38.2 46.5 20.8 23.9 40.4 24.9 22.9 30.6 28.9 21.6 61.3 27.5 45.4 41.1 29.2 25.1 29.1 31.5 14.4 35.4 28.5 23.3 29.7 29.6 21.9 30.4 74.5 23.4 35.7 25.5 26.9 23.3 68.6 36.8 61.7 37.3 21.7 41.7 37.5 45.9 15.2 9.1 28.3 11.9 10.6 9.7 8.9 9.7 12.1 10.7 11.4 8.9 11.6 14.4 11.3 8.7 6.0 9.2 4.5 35.6 36.1 31.2 43.4 33.1 31.0 34.4 29.2 26.1 20.9 MAP4 ENSG00000047849 "Microtubule associated protein 4" P27816 3 47850690-48089272 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 131.5;skeletal muscle: 197.9" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038149, HPA038150" Enhanced Enhanced "Plasma membrane,Microtubules,Cytosol" 120000 "Plasma membrane, Microtubules, Cytosol" "HPA038149: AB_10672471, HPA038150: AB_10672505" "unprognostic (2.51e-1)" "unprognostic (4.48e-1)" "unprognostic (2.72e-1)" "unprognostic (1.95e-2)" "unprognostic (3.36e-1)" "unprognostic (4.57e-1)" "prognostic unfavourable (1.82e-4)" "unprognostic (6.82e-2)" "unprognostic (1.46e-2)" "unprognostic (5.02e-2)" "unprognostic (2.23e-2)" "unprognostic (1.30e-2)" "unprognostic (2.25e-2)" "unprognostic (8.89e-2)" "unprognostic (6.45e-2)" "unprognostic (1.88e-1)" "unprognostic (1.21e-3)" 39.3 14.8 60.5 18.2 50.9 6.3 16.4 29.3 56.0 26.9 26.4 80.8 15.8 13.6 25.8 27.4 27.0 24.6 20.1 110.2 63.7 57.5 20.8 13.8 22.7 12.4 86.8 26.1 26.8 18.9 14.6 9.3 24.0 59.5 21.8 18.8 25.2 14.0 34.9 197.9 25.1 15.2 35.0 131.5 18.3 16.2 21.2 41.8 7.3 15.4 31.3 14.2 24.3 18.1 9.9 8.9 6.3 19.7 10.7 13.4 6.7 21.9 17.6 22.1 16.7 32.6 58.2 9.3 41.2 45.0 34.9 39.2 14.8 13.8 18.6 9.6 62.1 14.7 28.2 37.3 39.2 26.8 11.9 12.6 19.7 19.1 44.3 8.7 10.2 48.6 46.7 42.3 51.9 45.7 16.2 21.6 27.4 12.4 12.3 10.6 13.3 36.5 6.6 20.8 23.1 22.3 18.4 8.8 13.7 31.6 12.8 21.8 9.4 8.1 61.7 33.0 25.5 34.4 26.3 15.2 11.8 8.8 42.4 10.7 31.2 6.3 5.3 2.8 13.4 9.0 6.5 9.9 9.0 10.9 5.7 9.4 4.3 6.7 2.2 10.7 19.7 8.9 10.2 6.7 60.5 50.9 29.3 51.8 63.7 57.5 86.8 26.1 59.5 41.8 MAPK1 "ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2" ENSG00000100030 "Mitogen-activated protein kinase 1" P28482 22 21754500-21867680 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Kinase, Repressor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 80.3" "Cell line enhanced" "Detected in all" "K-562: 79.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003995, CAB004229, HPA005700, HPA030069" Approved 250000 "CAB004229: AB_627547, HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035" "unprognostic (9.41e-3)" "unprognostic (2.68e-1)" "unprognostic (2.50e-3)" "unprognostic (4.17e-1)" "unprognostic (4.44e-3)" "unprognostic (1.72e-1)" "prognostic unfavourable (4.95e-4)" "unprognostic (2.29e-1)" "unprognostic (1.67e-1)" "unprognostic (1.58e-1)" "unprognostic (8.43e-3)" "unprognostic (1.04e-1)" "unprognostic (1.35e-2)" "unprognostic (2.08e-1)" "unprognostic (1.94e-1)" "unprognostic (1.41e-1)" "unprognostic (6.49e-2)" 16.1 21.1 32.9 18.3 80.3 20.2 13.6 31.0 54.5 18.6 18.5 23.2 9.6 13.7 17.4 10.6 25.7 16.9 14.9 22.8 32.4 23.4 21.7 16.4 19.9 16.6 18.4 23.6 16.0 19.8 27.4 10.9 17.2 27.6 16.4 19.9 14.2 15.8 17.8 28.2 17.5 15.1 22.8 20.4 19.8 17.2 24.2 21.5 19.5 23.0 11.1 21.4 17.7 15.3 2.5 3.2 13.5 4.9 7.0 13.7 2.5 19.3 12.2 15.7 9.0 18.7 18.9 6.0 21.4 20.0 19.2 18.6 9.7 10.3 10.7 10.6 28.6 18.4 18.5 17.1 25.1 43.1 17.3 19.4 11.5 11.4 15.4 27.3 20.1 14.0 13.7 23.2 21.5 26.2 79.5 12.2 23.4 7.9 17.6 6.0 5.9 12.1 19.4 39.0 2.9 11.0 15.9 12.9 7.1 23.1 14.0 12.5 10.5 9.2 22.9 16.1 21.0 18.4 13.6 11.7 14.3 16.7 15.2 13.3 17.4 1.0 4.0 5.8 13.7 4.6 3.9 2.0 2.9 4.9 3.2 2.5 2.8 5.1 13.5 7.0 4.9 3.2 2.7 2.5 32.9 80.3 31.0 54.5 32.4 23.4 18.4 23.6 27.6 21.5 MAPK11 "p38-2, p38Beta, PRKM11, SAPK2" ENSG00000185386 "Mitogen-activated protein kinase 11" Q15759 22 50263713-50270767 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Stress response, Transcription, Transcription regulation" "Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "memory B-cell: 1.1" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012961, HPA045069" Approved Approved Mitochondria Mitochondria "CAB012961: AB_2533144, HPA045069: " "unprognostic (1.11e-1)" "unprognostic (1.28e-1)" "unprognostic (1.49e-2)" "unprognostic (1.92e-1)" "unprognostic (1.18e-2)" "unprognostic (1.64e-3)" "unprognostic (1.02e-1)" "unprognostic (5.84e-2)" "unprognostic (5.89e-2)" "unprognostic (2.46e-1)" "unprognostic (4.96e-3)" "unprognostic (2.18e-1)" "prognostic unfavourable (6.02e-6)" "unprognostic (9.84e-2)" "unprognostic (4.25e-2)" "unprognostic (9.16e-2)" "unprognostic (2.10e-2)" 20.4 5.7 14.2 7.5 17.3 0.8 8.2 22.0 23.7 6.6 2.7 2.8 1.0 1.9 8.2 6.2 5.3 7.0 8.8 8.8 11.7 9.1 5.0 1.5 8.5 8.5 7.2 19.9 5.3 3.1 6.4 10.9 8.4 6.6 7.2 2.7 4.1 5.7 8.0 5.0 6.4 2.6 9.8 5.5 7.3 4.6 3.1 4.1 0.9 4.5 5.3 6.1 6.0 4.4 1.1 0.0 0.0 0.3 0.0 0.9 0.0 1.7 4.2 4.6 17.3 6.1 9.2 0.1 6.4 4.6 4.3 1.7 1.6 3.2 0.0 5.8 6.0 4.2 3.0 2.6 0.3 8.9 2.1 6.1 5.5 0.4 7.0 1.5 9.5 12.8 7.6 1.2 0.5 9.4 4.9 16.7 4.2 7.4 0.3 5.6 0.4 4.8 16.7 0.1 5.9 6.5 0.0 4.3 11.5 5.5 2.3 4.6 7.6 4.8 14.7 12.9 10.8 0.9 2.4 0.7 1.9 7.1 6.5 1.7 10.8 0.0 0.0 0.0 0.0 0.3 0.0 1.1 0.4 0.2 0.0 0.5 0.0 0.6 0.0 0.0 0.0 0.0 0.9 0.0 14.2 17.3 22.0 23.7 11.7 9.1 7.2 19.9 6.6 4.1 MAPK3 "ERK1, p44erk1, p44mapk, PRKM3" ENSG00000102882 "Mitogen-activated protein kinase 3" P27361 16 30114105-30123506 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Cell cycle, Host-virus interaction" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "eosinophil: 25.1;neutrophil: 11.3" "Lineage enriched" "Detected in many" 8 "granulocytes: 25.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002683, HPA003995, HPA005700, HPA030069" Approved Approved Nucleoplasm Nucleoplasm "CAB002683: , HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035" "unprognostic (5.03e-2)" "unprognostic (4.62e-2)" "unprognostic (3.46e-2)" "unprognostic (1.60e-1)" "unprognostic (4.70e-3)" "unprognostic (2.75e-1)" "prognostic unfavourable (1.11e-4)" "unprognostic (2.09e-2)" "unprognostic (3.59e-2)" "unprognostic (1.12e-1)" "unprognostic (1.55e-1)" "unprognostic (3.51e-2)" "unprognostic (8.78e-2)" "unprognostic (1.45e-1)" "unprognostic (3.01e-2)" "unprognostic (2.38e-1)" "unprognostic (1.19e-2)" 24.9 18.5 63.3 15.3 43.2 15.6 21.1 24.8 52.0 21.3 45.1 30.4 6.3 39.7 24.2 11.4 44.1 28.7 25.6 21.2 37.1 34.0 13.4 8.8 23.3 13.1 33.8 27.4 32.7 13.0 26.1 15.2 27.6 27.6 20.1 36.7 26.2 17.1 18.3 13.9 18.7 49.2 24.0 27.8 15.9 33.7 11.6 19.5 8.4 20.5 18.7 26.0 18.2 22.2 1.4 1.5 25.1 2.7 0.8 3.1 1.4 13.7 7.5 16.1 9.1 40.5 53.8 9.0 10.3 25.6 16.4 19.6 9.0 27.8 13.9 10.2 28.8 5.1 13.5 12.1 16.0 26.3 15.7 4.3 8.3 15.0 40.7 3.1 11.9 33.1 7.0 18.7 8.4 41.6 5.8 17.9 21.6 36.3 14.3 5.0 4.3 6.6 17.0 9.6 31.2 14.9 8.7 14.2 10.1 5.9 20.8 6.0 13.6 7.6 29.4 10.8 9.3 12.3 3.5 20.3 9.3 7.1 21.6 6.7 7.6 2.4 2.7 25.1 0.9 1.9 1.4 1.3 2.1 1.6 1.4 1.4 1.5 1.6 11.3 0.8 1.0 1.5 3.1 1.4 63.3 43.2 24.8 52.0 37.1 34.0 33.8 27.4 27.6 19.5 MAPT "DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau" ENSG00000186868 "Microtubule associated protein tau" P10636 17 45894382-46028334 "Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Alzheimer disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 89.9;skeletal muscle: 43.7" "Cell line enhanced" "Detected in some" "HDLM-2: 27.3;SCLC-21H: 9.8;T-47d: 12.4" "Group enriched" "Detected in many" 11 "breast cancer: 9.5;glioma: 13.3;prostate cancer: 3.0;renal cancer: 4.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 1.7" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000151, HPA048895, HPA069524, HPA069570, CAB072344" Enhanced Supported "Nuclear speckles,Plasma membrane" "Plasma membrane" "Nuclear speckles" "CAB000151: , CAB072344: , HPA048895: , HPA069524: , HPA069570: " "unprognostic (1.78e-3)" "unprognostic (7.51e-2)" "unprognostic (3.71e-2)" "unprognostic (8.40e-5)" "unprognostic (1.40e-1)" "unprognostic (1.31e-2)" "unprognostic (4.06e-5)" "unprognostic (6.04e-2)" "unprognostic (2.19e-2)" "unprognostic (3.49e-2)" "unprognostic (3.88e-3)" "unprognostic (2.65e-1)" "unprognostic (1.72e-3)" "unprognostic (6.53e-2)" "unprognostic (3.43e-1)" "unprognostic (1.85e-2)" "unprognostic (5.47e-2)" 3.8 7.1 28.9 2.4 31.2 2.1 8.8 40.1 89.9 2.4 2.7 21.4 1.7 2.5 2.6 2.3 6.4 2.5 2.8 6.5 28.7 29.7 15.3 2.2 2.4 2.3 22.6 35.2 2.3 2.8 8.5 8.8 5.2 29.1 5.1 2.5 2.2 8.1 5.3 43.7 4.6 2.8 2.5 13.6 2.2 2.3 6.5 27.7 0.0 2.3 3.1 2.3 3.2 0.8 0.0 0.0 0.3 0.1 0.5 1.7 0.1 0.8 0.3 0.2 2.6 0.0 0.5 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 1.3 0.1 0.0 27.3 1.4 0.0 0.0 2.5 0.0 0.0 0.1 0.0 0.3 0.0 0.1 0.0 0.2 1.3 0.0 4.1 0.5 0.1 0.0 1.1 0.0 2.2 2.7 0.0 3.5 9.8 4.6 1.0 0.0 0.9 12.4 0.0 0.0 0.2 0.3 0.6 0.1 0.5 0.1 0.0 0.2 0.5 0.3 0.0 0.1 0.3 0.8 0.0 0.6 0.0 0.4 1.2 0.0 0.0 0.9 0.9 0.0 0.5 0.1 0.0 1.7 0.1 28.9 31.2 40.1 46.3 28.7 29.7 22.6 35.2 29.1 27.7 MC2R ACTHR ENSG00000185231 "Melanocortin 2 receptor" Q01718 18 13882044-13915707 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "adrenal gland: 31.7;pituitary gland: 14.3" "Cell line enhanced" "Detected in some" "HeLa: 1.8;MCF7: 3.7" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "basophil: 1.3" "Lineage enriched" "Detected in single" 4 "granulocytes: 1.3" "Not detected" "Not detected" "Not detected" "Not detected" HPA079148 Enhanced "HPA079148: " "unprognostic (2.09e-1)" "unprognostic (3.63e-2)" "unprognostic (1.85e-2)" 0.0 31.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 14.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.1 0.0 0.0 0.3 0.0 0.1 0.1 1.3 0.3 0.1 0.1 0.0 0.2 0.0 0.1 0.3 0.1 0.3 1.1 0.2 0.0 0.1 0.3 0.1 0.2 0.0 0.0 0.4 0.3 0.1 0.9 0.1 0.0 0.5 0.0 1.8 0.2 0.0 0.2 0.0 0.0 0.9 0.0 0.6 0.0 0.1 0.4 0.0 3.7 0.0 0.0 0.6 0.1 0.2 0.5 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.3 0.0 0.2 0.3 0.5 0.0 0.2 0.2 0.0 0.1 0.4 0.0 1.3 0.1 0.0 0.1 0.3 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.5 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 MDH2 ENSG00000146701 "Malate dehydrogenase 2" P40926 7 76048051-76067508 "Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Tricarboxylic acid cycle" Oxidoreductase "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 175.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019714, HPA019716, HPA019848, HPA026720" Enhanced Enhanced Mitochondria 47000000 Mitochondria "HPA019714: AB_1853678, HPA019716: AB_1853680, HPA019848: AB_1853683, HPA026720: AB_1853685" "unprognostic (3.20e-2)" "unprognostic (2.85e-1)" "unprognostic (1.11e-1)" "unprognostic (1.43e-2)" "unprognostic (5.55e-3)" "unprognostic (8.94e-2)" "unprognostic (6.45e-2)" "unprognostic (3.77e-2)" "unprognostic (3.60e-1)" "unprognostic (2.02e-2)" "unprognostic (1.40e-1)" "unprognostic (9.70e-2)" "prognostic favourable (1.49e-5)" "unprognostic (8.57e-2)" "unprognostic (9.64e-2)" "unprognostic (5.68e-2)" "unprognostic (2.66e-1)" 18.1 39.1 17.4 15.4 20.6 18.3 22.2 15.3 34.4 14.9 27.0 13.5 16.9 32.5 16.6 13.5 31.8 19.4 17.6 103.1 17.1 18.8 29.1 101.9 13.8 26.6 17.4 21.9 17.3 35.5 16.8 16.9 17.5 20.5 17.9 24.3 15.0 26.8 21.5 175.8 24.6 26.7 21.9 12.8 21.1 22.3 17.6 9.5 22.4 20.1 76.2 23.8 19.9 17.8 37.1 52.8 22.1 45.3 30.1 45.6 44.7 28.6 47.0 17.0 42.6 19.5 21.4 29.3 19.3 24.9 27.6 25.0 41.3 34.5 43.4 8.7 25.4 29.3 43.7 28.8 19.8 30.9 63.2 24.1 25.3 38.1 24.0 37.4 24.9 27.0 25.7 26.8 40.1 25.7 75.8 25.4 25.5 64.9 32.4 66.1 37.9 59.3 26.5 21.0 62.4 25.8 37.9 42.7 38.9 19.3 96.8 39.7 55.0 42.3 19.8 27.8 26.3 30.0 38.3 28.5 23.5 48.0 24.1 48.0 42.1 22.1 38.9 18.2 32.7 43.5 34.2 37.1 36.9 35.3 52.8 32.1 36.0 33.1 10.2 30.1 45.3 47.1 45.6 44.7 17.4 20.6 15.3 34.4 17.1 18.8 17.4 21.9 20.5 9.5 MET "DFNB97, HGFR, RCCP2" ENSG00000105976 "MET proto-oncogene, receptor tyrosine kinase" P08581 7 116672390-116798386 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "A-431: 45.4;CAPAN-2: 49.6;EFO-21: 43.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in many" 5 "amygdala: 3.5;basal ganglia: 9.9;cerebral cortex: 7.6;hippocampal formation: 8.0;olfactory region: 9.1" "Low region specificity" "Detected in many" "CAB005282, CAB018577, HPA055607" Approved Supported "Plasma membrane,Cytosol" "Secreted to blood" 178550000 70000000 "Plasma membrane, Cytosol" "CAB005282: AB_631940, CAB018577: AB_649068, HPA055607: " "unprognostic (1.60e-2)" "unprognostic (7.71e-2)" "unprognostic (2.53e-2)" "unprognostic (1.58e-1)" "unprognostic (3.57e-3)" "prognostic unfavourable (6.75e-4)" "unprognostic (1.68e-1)" "unprognostic (3.22e-2)" "unprognostic (3.81e-2)" "unprognostic (2.52e-2)" "prognostic unfavourable (1.21e-7)" "unprognostic (1.86e-1)" "unprognostic (1.25e-1)" "unprognostic (5.53e-2)" "unprognostic (8.88e-2)" "unprognostic (2.01e-2)" "unprognostic (2.20e-1)" 16.2 1.1 1.8 4.5 2.3 4.3 11.2 0.9 15.2 9.9 6.5 2.4 2.4 4.4 7.5 5.2 5.1 4.6 12.3 5.4 5.7 1.8 20.1 30.2 15.6 1.4 3.6 2.1 2.0 9.3 0.7 8.1 24.4 2.6 8.0 6.6 34.1 12.2 8.4 12.8 7.2 8.6 4.0 2.3 5.7 10.6 2.7 2.4 0.5 21.4 7.0 2.1 10.1 15.0 0.2 0.3 1.2 0.2 0.3 0.4 0.0 45.4 26.1 0.0 0.1 2.0 2.0 1.8 26.0 10.6 14.0 11.8 5.4 49.6 2.0 43.3 16.3 12.0 4.5 24.7 28.7 0.1 5.6 0.0 27.1 4.7 0.3 0.0 0.0 2.6 9.8 9.1 30.1 9.6 0.9 0.2 25.9 1.0 0.0 0.0 3.9 26.7 0.0 22.0 0.0 24.6 5.2 3.8 0.0 10.7 3.4 10.1 0.0 0.2 17.7 20.9 7.4 11.0 20.1 0.5 4.0 0.2 23.0 0.0 2.9 1.1 0.2 0.4 0.4 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 1.2 0.3 0.1 0.3 0.1 0.0 1.8 2.3 0.9 15.2 5.7 1.8 3.6 2.1 2.6 2.4 METAP2 "MAP2, MNPEP, p67" ENSG00000111142 "Methionyl aminopeptidase 2" P50579 12 95473520-95515839 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Aminopeptidase, Hydrolase, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013025, HPA019095" Enhanced Supported "Plasma membrane,Cytosol" 22000 "Plasma membrane, Cytosol" "CAB013025: AB_2533993, HPA019095: AB_1853823" "unprognostic (1.91e-1)" "unprognostic (1.02e-1)" "unprognostic (5.92e-2)" "unprognostic (2.44e-1)" "unprognostic (3.27e-2)" "unprognostic (2.57e-2)" "prognostic unfavourable (4.51e-6)" "unprognostic (1.25e-1)" "unprognostic (2.28e-2)" "unprognostic (1.40e-2)" "unprognostic (8.53e-2)" "unprognostic (1.66e-1)" "unprognostic (1.49e-1)" "unprognostic (2.51e-1)" "unprognostic (1.07e-1)" "unprognostic (2.95e-2)" "unprognostic (1.03e-1)" 24.2 36.4 25.8 49.9 33.7 39.1 25.1 25.9 32.3 23.9 26.2 16.3 102.5 16.6 28.7 25.4 30.1 22.5 21.7 30.7 29.6 24.0 26.0 46.8 22.1 32.6 29.1 23.4 29.4 31.9 21.0 36.1 25.1 42.9 24.2 24.0 10.1 22.1 140.7 94.4 28.7 19.7 26.1 48.2 25.2 22.2 26.3 27.7 32.1 24.1 29.0 55.2 33.4 37.3 39.4 31.8 21.3 27.1 25.7 32.0 16.2 33.2 28.1 30.1 23.3 18.3 29.4 23.1 32.8 23.0 32.4 23.0 40.8 16.0 97.0 20.7 23.4 21.5 33.8 25.1 37.3 23.0 29.1 43.4 21.4 28.7 19.6 53.7 21.3 25.4 26.9 30.6 30.1 34.4 56.1 11.0 24.0 21.9 39.7 36.7 36.8 42.0 31.3 26.0 31.8 22.2 35.4 23.4 30.7 29.2 23.9 28.7 28.8 25.6 29.5 18.6 18.1 20.8 34.6 15.9 41.4 104.0 10.6 30.3 23.4 21.3 27.1 11.1 23.8 19.1 29.2 39.4 26.7 26.6 24.4 37.6 32.0 29.7 1.2 25.7 22.3 31.8 25.3 16.2 25.8 33.7 25.9 32.3 29.6 24.0 29.1 23.4 42.9 27.7 MGAM MGA ENSG00000257335 Maltase-glucoamylase O43451 7 141907813-142106747 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Glycosidase, Hydrolase, Multifunctional enzyme" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "intestine: 155.5" "Cell line enhanced" "Detected in some" "A549: 3.6;BJ hTERT+: 3.2;HL-60: 5.3;U-937: 8.5;WM-115: 2.0" "Cancer enriched" "Detected in some" 7 "renal cancer: 4.9" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 8 "neutrophil: 14.1" "Lineage enriched" "Detected in single" 104 "granulocytes: 14.1" "Region enriched" "Detected in single" 12 "olfactory region: 3.1" HPA002270 Enhanced 68000 "HPA002270: AB_1079366" "unprognostic (1.02e-2)" "unprognostic (1.45e-1)" "unprognostic (1.13e-1)" "unprognostic (6.95e-3)" "unprognostic (2.80e-1)" "unprognostic (7.81e-2)" "unprognostic (7.32e-3)" "unprognostic (3.83e-2)" "unprognostic (4.97e-1)" "unprognostic (2.17e-2)" "unprognostic (6.86e-2)" "unprognostic (1.99e-1)" "prognostic favourable (6.16e-5)" "unprognostic (1.82e-1)" "unprognostic (2.82e-1)" "unprognostic (1.34e-3)" "unprognostic (3.03e-1)" 0.9 0.2 0.3 0.8 0.2 6.9 0.3 0.2 0.2 0.2 59.4 0.1 7.6 25.2 0.2 36.0 0.2 1.0 0.1 0.3 0.2 0.2 8.7 0.4 2.1 0.1 0.3 0.1 0.2 0.2 0.0 0.2 0.1 0.1 0.6 0.0 0.1 0.2 3.2 0.2 0.1 155.5 0.1 0.3 8.3 0.7 4.3 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.0 0.0 14.1 0.1 0.0 0.0 0.0 0.0 3.6 0.2 0.1 0.0 0.0 0.4 0.1 3.2 0.3 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 1.4 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.3 0.3 0.0 0.4 0.1 0.0 0.0 0.0 0.3 1.0 0.4 0.1 0.3 0.0 0.1 0.0 8.5 2.0 0.0 0.1 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.1 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.2 0.2 0.2 0.3 0.1 0.1 0.1 MME "CALLA, CD10, NEP" ENSG00000196549 "Membrane metalloendopeptidase" P08473 3 155024124-155183729 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 61.1;intestine: 136.0;kidney: 64.9" "Cell line enhanced" "Detected in many" "ASC TERT1: 95.0;BJ hTERT+: 142.9;HSkMC: 92.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 129 "neutrophil: 61.1" "Lineage enriched" "Detected in single" 129 "granulocytes: 61.1" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 26.8" "CAB000013, HPA052583, HPA056072" Enhanced 99000 "CAB000013: AB_563478, HPA052583: AB_2681872, HPA056072: AB_2683027" "unprognostic (1.36e-1)" "unprognostic (1.02e-3)" "unprognostic (8.52e-2)" "unprognostic (2.95e-1)" "unprognostic (2.78e-2)" "unprognostic (6.52e-3)" "unprognostic (1.20e-1)" "unprognostic (1.67e-2)" "unprognostic (8.67e-2)" "unprognostic (1.96e-1)" "unprognostic (7.30e-3)" "unprognostic (1.31e-1)" "unprognostic (2.71e-3)" "unprognostic (1.50e-1)" "unprognostic (7.29e-2)" "unprognostic (1.06e-2)" "unprognostic (1.37e-2)" 26.5 0.4 0.4 3.4 7.4 1.9 14.7 0.4 0.7 4.8 65.6 0.1 18.4 74.0 2.8 8.1 0.7 0.9 8.5 1.8 0.3 0.4 64.9 11.5 13.7 3.0 2.1 0.2 0.9 0.6 0.0 0.6 35.0 8.6 18.3 0.4 1.3 3.7 11.3 11.7 1.4 136.0 0.6 0.9 2.7 0.7 1.0 1.2 13.2 1.0 5.3 2.3 3.4 4.9 0.1 0.4 61.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 38.6 95.0 0.2 21.2 142.9 10.8 28.1 0.0 0.0 23.4 0.0 18.8 0.0 0.7 0.8 26.1 0.0 0.1 0.0 0.0 0.0 30.9 0.0 0.0 92.1 0.1 5.8 41.6 8.2 0.0 0.0 17.3 0.1 0.0 0.1 0.9 0.1 38.8 18.2 0.1 0.6 0.2 0.0 0.2 0.0 0.0 4.1 0.0 0.0 23.3 46.7 0.1 15.9 3.7 0.0 0.0 30.8 5.6 0.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 61.1 0.0 0.0 0.4 0.0 0.0 0.4 7.4 0.4 0.7 0.3 0.4 2.1 0.2 8.6 1.2 MMP1 CLG ENSG00000196611 "Matrix metallopeptidase 1" P03956 11 102789920-102798160 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Collagen degradation, Host-virus interaction" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 62.4;stomach 1: 27.2" "Cell line enhanced" "Detected in some" "BJ hTERT+: 88.1;HBF TERT88: 87.3;HUVEC TERT2: 229.4;WM-115: 113.0" "Cancer enhanced" "Detected in many" "head and neck cancer: 344.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA004920 Approved Vesicles "Secreted to extracellular matrix" 430000 Vesicles "HPA004920: " "unprognostic (4.11e-3)" "prognostic unfavourable (4.66e-4)" "unprognostic (4.20e-3)" "unprognostic (1.19e-3)" "unprognostic (6.46e-2)" "unprognostic (6.50e-2)" "prognostic unfavourable (4.22e-6)" "unprognostic (7.83e-3)" "unprognostic (2.94e-2)" "unprognostic (5.44e-2)" "unprognostic (1.11e-3)" "unprognostic (1.75e-1)" "prognostic unfavourable (9.86e-10)" "unprognostic (1.67e-2)" "unprognostic (1.49e-1)" "unprognostic (1.26e-2)" "unprognostic (5.11e-2)" 0.2 0.1 0.3 12.3 0.3 0.0 0.9 0.3 0.3 0.3 2.7 0.3 0.2 3.2 4.8 0.2 3.3 0.1 62.4 0.4 0.2 0.1 0.7 1.3 4.7 0.2 0.2 0.2 0.2 1.6 0.0 0.2 8.6 0.5 0.7 3.0 0.3 2.0 0.2 0.2 0.3 8.8 0.2 0.4 1.8 27.2 2.2 0.2 0.4 0.3 1.3 0.9 11.0 0.2 0.0 0.0 0.6 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.9 88.1 36.0 9.4 0.7 0.0 0.0 0.4 21.1 0.3 0.0 12.3 87.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 37.0 3.1 229.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.1 0.0 0.0 11.9 29.9 0.0 1.3 0.1 0.0 0.0 0.0 0.7 0.0 113.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 1.9 0.3 0.3 0.3 0.3 0.2 0.1 0.2 0.2 0.5 0.2 MMP10 STMY2 ENSG00000166670 "Matrix metallopeptidase 10" P09238 11 102770503-102780628 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "endometrium 1: 89.4" "Cell line enhanced" "Detected in some" "BJ: 12.3;HUVEC TERT2: 15.8;SCLC-21H: 5.0" "Cancer enhanced" "Detected in many" "head and neck cancer: 102.2" "Region enriched" "Detected in single" 9 "pons and medulla: 2.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB002159 Uncertain Approved "Plasma membrane,Cytosol" "Secreted to extracellular matrix" Cytosol "Plasma membrane" "CAB002159: AB_564103" "unprognostic (8.76e-2)" "unprognostic (3.38e-1)" "unprognostic (1.98e-3)" "unprognostic (2.72e-3)" "unprognostic (7.17e-3)" "unprognostic (1.52e-2)" "unprognostic (5.67e-8)" "unprognostic (2.08e-3)" "unprognostic (2.20e-1)" "unprognostic (1.75e-1)" "unprognostic (1.67e-2)" "unprognostic (2.67e-1)" "unprognostic (6.99e-5)" "unprognostic (2.66e-2)" "unprognostic (7.98e-2)" "unprognostic (5.46e-2)" "prognostic favourable (7.12e-4)" 0.1 0.1 0.0 2.6 0.2 0.1 0.1 0.0 0.3 1.7 0.5 0.0 0.0 0.4 89.4 0.1 0.2 0.1 0.5 0.1 0.0 0.1 0.1 3.6 11.0 0.1 0.0 0.0 0.5 0.3 0.1 0.9 19.8 2.8 3.2 0.2 0.0 2.9 0.1 0.1 0.1 0.7 0.1 0.0 0.2 3.3 0.5 0.0 1.2 0.1 0.0 1.9 0.6 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.2 0.0 0.0 0.2 12.3 0.7 0.1 0.1 0.3 0.0 0.0 3.6 1.9 2.8 0.0 1.4 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.4 0.6 15.8 0.7 0.0 0.0 0.0 0.0 0.3 2.9 1.7 0.0 0.0 0.0 0.0 0.7 5.0 0.0 2.5 0.0 0.0 0.0 0.0 2.0 3.8 1.2 0.4 0.5 0.0 0.0 0.0 0.6 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.1 0.0 0.0 2.8 0.0 MMP11 STMY3 ENSG00000099953 "Matrix metallopeptidase 11" P24347 22 23768226-23784316 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "endometrium 1: 44.1;placenta: 119.6" "Cell line enhanced" "Detected in some" "AN3-CA: 18.9;BJ hTERT+: 5.1;REH: 7.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 7.8" "Group enriched" "Detected in many" 5 "B-cells: 2.4;dendritic cells: 7.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002593, HPA068864" Approved "Secreted to extracellular matrix" "CAB002593: , HPA068864: " "unprognostic (1.06e-1)" "unprognostic (3.08e-1)" "unprognostic (1.83e-1)" "unprognostic (1.84e-3)" "unprognostic (2.77e-2)" "unprognostic (6.73e-2)" "unprognostic (2.14e-2)" "unprognostic (5.15e-1)" "unprognostic (2.73e-2)" "unprognostic (2.20e-1)" "unprognostic (1.89e-3)" "unprognostic (7.04e-2)" "prognostic unfavourable (2.62e-4)" "unprognostic (8.05e-2)" "unprognostic (6.78e-2)" "unprognostic (1.10e-1)" "unprognostic (1.68e-2)" 1.7 0.6 0.2 1.0 0.6 0.1 1.6 1.0 0.5 13.4 1.8 0.4 0.4 1.9 44.1 1.1 0.8 2.2 2.0 3.1 0.5 0.0 1.7 0.5 0.7 1.8 0.4 0.2 7.7 1.1 0.2 0.3 119.6 0.5 1.4 1.0 0.8 2.5 0.4 0.5 2.0 4.0 2.7 0.3 0.9 0.7 3.4 0.2 2.6 0.5 0.6 0.9 1.6 2.1 2.4 7.8 0.0 0.0 0.0 1.0 0.1 0.1 0.0 2.3 18.9 2.9 4.2 0.0 0.2 5.1 0.6 0.4 0.0 0.6 0.6 3.5 1.3 0.1 1.0 0.0 0.2 0.0 0.3 0.0 0.0 1.0 2.1 0.0 0.0 2.7 0.4 0.5 0.0 3.0 0.3 0.0 0.7 0.1 0.0 0.0 0.7 0.1 7.9 0.0 0.2 0.3 0.0 3.0 5.1 1.9 0.3 0.0 1.8 0.0 1.3 0.3 0.0 0.8 0.0 0.1 0.1 2.5 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 2.4 1.0 0.3 0.0 0.0 0.0 7.8 0.0 0.1 0.2 0.6 1.0 0.5 0.5 0.0 0.4 0.2 0.5 0.2 MMP13 CLG3 ENSG00000137745 "Matrix metallopeptidase 13" P45452 11 102942995-102955734 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lung: 12.6;vagina: 10.8" "Group enriched" "Detected in some" 5 "HaCaT: 19.1;PC-3: 7.2" "Cancer enhanced" "Detected in many" "head and neck cancer: 70.9" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" CAB002742 Supported "Secreted to extracellular matrix" "CAB002742: " "unprognostic (8.98e-3)" "unprognostic (1.54e-1)" "unprognostic (4.75e-2)" "unprognostic (4.57e-2)" "unprognostic (3.05e-2)" "unprognostic (1.59e-3)" "unprognostic (1.32e-1)" "unprognostic (6.35e-3)" "unprognostic (1.69e-1)" "unprognostic (7.55e-3)" "unprognostic (2.24e-1)" "unprognostic (1.73e-8)" "unprognostic (2.12e-2)" "unprognostic (3.14e-1)" "unprognostic (4.14e-2)" "unprognostic (4.33e-2)" 0.5 0.1 0.0 0.8 0.0 1.3 0.4 0.0 0.2 1.3 0.1 0.0 0.0 0.6 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.1 12.6 0.1 0.0 0.0 0.1 0.0 0.0 3.1 0.1 0.1 1.2 0.0 0.0 0.6 0.0 0.0 1.0 0.5 0.0 0.0 0.1 0.1 1.9 0.0 1.4 0.0 0.0 0.1 4.6 10.8 1.0 0.7 2.7 0.5 1.9 1.3 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.3 0.0 0.0 0.0 19.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.5 0.1 0.0 0.0 7.2 0.0 0.0 0.1 0.0 1.9 0.0 0.1 0.1 2.2 0.0 0.0 0.0 0.0 2.7 1.4 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 2.7 0.5 0.6 1.3 0.4 1.0 0.5 0.7 0.8 0.3 1.0 0.6 1.1 1.9 1.9 0.3 0.7 0.4 0.5 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.1 0.0 MMP14 MT1-MMP ENSG00000157227 "Matrix metallopeptidase 14" P50281 14 22836557-22849027 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 98.0;HHSteC: 92.7;HSkMC: 94.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009918, HPA051432" Approved Approved "Intermediate filaments,Cytosol" 570000 Cytosol "Intermediate filaments" "CAB009918: AB_2250767, HPA051432: " "unprognostic (1.34e-1)" "unprognostic (1.37e-1)" "unprognostic (1.11e-2)" "unprognostic (2.81e-1)" "unprognostic (4.28e-2)" "unprognostic (1.12e-2)" "unprognostic (3.05e-3)" "unprognostic (5.91e-3)" "unprognostic (1.95e-1)" "prognostic unfavourable (9.48e-4)" "unprognostic (3.82e-3)" "unprognostic (7.31e-2)" "prognostic unfavourable (1.34e-4)" "unprognostic (5.02e-2)" "unprognostic (6.69e-2)" "unprognostic (1.00e-2)" "unprognostic (3.41e-3)" 60.9 10.5 2.4 16.6 4.7 0.2 64.2 2.2 3.2 56.3 35.0 8.2 12.7 12.0 53.1 24.1 47.0 21.9 39.6 17.5 3.4 1.8 16.8 9.0 29.8 16.9 5.8 2.9 39.3 11.2 34.4 4.7 73.5 16.4 39.1 11.3 27.1 24.4 16.7 20.4 37.0 22.9 28.5 20.7 22.5 18.2 26.3 4.6 5.4 22.3 14.6 16.7 52.5 53.9 0.1 0.7 0.0 0.7 0.0 0.0 0.1 7.9 0.1 2.4 0.1 98.0 62.3 45.0 25.1 50.6 7.6 13.6 2.3 29.9 0.1 14.0 26.4 20.3 0.0 26.1 9.8 0.1 0.1 3.7 0.1 0.5 92.7 0.0 0.1 94.2 15.8 31.7 27.2 46.0 0.1 0.2 17.9 0.1 0.0 9.0 1.5 4.3 0.3 8.6 0.0 6.9 13.7 0.0 0.0 16.4 0.0 54.4 0.1 8.1 40.7 61.9 5.3 18.0 28.6 0.1 0.1 0.1 37.7 0.0 35.8 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.4 4.7 2.2 3.2 3.4 1.8 5.8 2.9 16.4 4.6 MMP15 "MT2-MMP, MTMMP2, SMCP-2" ENSG00000102996 "Matrix metallopeptidase 15" P51511 16 58025566-58046901 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 43.2" "Cell line enhanced" "Detected in many" "BEWO: 36.8;Hep G2: 19.1;SK-BR-3: 18.5;WM-115: 30.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 30 "plasmacytoid DC: 2.9" "Lineage enriched" "Detected in single" 30 "dendritic cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002611, HPA040390" Uncertain Approved "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Nucleoplasm "CAB002611: , HPA040390: " "unprognostic (1.76e-2)" "unprognostic (7.32e-2)" "unprognostic (2.69e-1)" "unprognostic (6.85e-2)" "unprognostic (3.09e-1)" "unprognostic (1.68e-1)" "unprognostic (6.88e-3)" "unprognostic (1.40e-1)" "unprognostic (3.02e-2)" "unprognostic (1.24e-2)" "unprognostic (4.81e-2)" "unprognostic (1.81e-1)" "prognostic favourable (8.54e-8)" "unprognostic (3.63e-2)" "unprognostic (1.36e-1)" "unprognostic (1.28e-1)" "prognostic favourable (3.08e-4)" 5.9 2.3 2.0 5.5 3.0 0.1 7.7 3.7 7.2 3.3 19.5 4.2 16.3 22.6 2.9 1.7 2.5 3.6 15.9 17.6 2.3 3.7 8.4 26.4 6.1 2.0 2.5 2.2 2.1 10.3 7.3 5.2 28.5 10.4 3.6 8.2 9.5 4.7 14.7 3.4 2.3 43.2 3.4 3.4 5.2 14.7 28.0 2.1 1.1 26.8 2.5 2.2 3.3 4.2 0.0 2.9 0.0 0.0 0.0 0.0 0.0 5.7 4.3 2.3 11.8 2.4 0.1 36.8 0.5 0.3 2.1 0.4 3.4 14.8 0.0 7.0 0.6 8.1 1.9 1.7 0.6 0.0 3.9 0.0 1.9 19.1 3.1 0.1 7.7 1.2 3.0 0.3 0.9 1.4 4.7 0.0 0.7 2.8 0.2 0.9 6.7 1.2 2.8 0.3 3.1 6.5 2.1 0.6 4.1 7.7 18.5 3.5 2.0 3.1 1.3 0.1 3.7 1.4 0.5 0.0 0.0 0.1 0.7 0.9 30.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 2.0 3.0 3.7 7.2 2.3 3.7 2.5 2.2 10.4 2.1 MMP16 "C8orf57, DKFZp761D112, MT3-MMP" ENSG00000156103 "Matrix metallopeptidase 16" P51512 8 88032009-88328025 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 15.9" "Cell line enhanced" "Detected in many" "AN3-CA: 20.0;HUVEC TERT2: 8.7;SH-SY5Y: 11.1;U-138 MG: 9.5;WM-115: 19.5" "Cancer enhanced" "Detected in many" "glioma: 4.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023693 Uncertain Approved Vesicles,Cytosol "Secreted to extracellular matrix" Cytosol Vesicles "HPA023693: AB_1854025" "unprognostic (2.58e-1)" "unprognostic (2.42e-2)" "unprognostic (1.38e-1)" "unprognostic (1.87e-1)" "unprognostic (7.09e-2)" "unprognostic (3.31e-2)" "unprognostic (2.39e-3)" "unprognostic (1.45e-3)" "unprognostic (2.46e-1)" "unprognostic (2.61e-1)" "unprognostic (9.42e-2)" "unprognostic (2.92e-1)" "unprognostic (2.09e-8)" "unprognostic (6.90e-3)" "unprognostic (1.16e-1)" "unprognostic (3.62e-1)" "unprognostic (2.19e-3)" 2.4 1.3 11.0 1.4 6.8 0.5 4.9 8.3 15.9 5.3 2.2 2.9 0.7 0.8 4.9 2.1 1.7 2.1 7.3 2.7 8.7 6.9 0.8 0.9 1.0 1.0 5.5 9.1 3.3 2.1 1.5 1.7 3.0 6.3 3.2 1.7 0.6 1.2 2.4 0.7 1.1 1.3 4.0 4.6 1.5 1.4 1.5 5.5 0.0 3.2 0.7 1.0 2.6 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 5.4 20.0 0.7 1.4 0.0 7.3 1.0 2.1 1.2 0.0 0.0 0.0 0.0 3.3 0.0 3.9 0.0 2.5 0.0 2.3 0.0 0.0 0.0 1.7 0.0 0.3 1.0 0.0 3.0 0.9 8.7 0.0 0.7 1.1 0.0 0.0 0.0 1.1 2.0 0.2 0.4 0.0 0.4 0.0 0.1 11.1 0.0 0.0 0.1 0.8 0.0 4.8 9.5 5.4 0.1 2.7 0.0 0.0 0.0 3.8 0.0 19.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.0 6.8 8.3 14.1 8.7 6.9 5.5 9.1 6.3 5.5 MMP19 "MMP18, RASI-1" ENSG00000123342 "Matrix metallopeptidase 19" Q99542 12 55835433-55842966 "Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins" "Angiogenesis, Collagen degradation, Differentiation" "Developmental protein, Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 60.7" "Cell line enriched" "Detected in many" 6 "BEWO: 55.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 16 "classical monocyte: 3.2;myeloid DC: 1.0" "Group enriched" "Detected in many" 16 "dendritic cells: 1.0;monocytes: 3.2" "Region enriched" "Detected in single" 6 "olfactory region: 8.8" "Low region specificity" "Detected in all" HPA070804 Approved "Endoplasmic reticulum,Vesicles" "Secreted to extracellular matrix" 800000 "Endoplasmic reticulum, Vesicles" "HPA070804: " "unprognostic (2.61e-1)" "unprognostic (6.56e-2)" "unprognostic (2.28e-2)" "unprognostic (2.42e-1)" "unprognostic (4.77e-3)" "unprognostic (4.77e-3)" "unprognostic (2.01e-2)" "unprognostic (4.03e-2)" "unprognostic (2.85e-2)" "unprognostic (4.30e-2)" "unprognostic (2.37e-1)" "unprognostic (2.09e-1)" "prognostic unfavourable (8.56e-9)" "unprognostic (5.06e-3)" "unprognostic (1.28e-3)" "unprognostic (2.73e-2)" "unprognostic (4.00e-2)" 60.7 1.9 0.2 10.9 0.7 0.0 9.9 0.2 0.5 7.6 3.9 0.4 1.4 0.8 12.7 6.0 3.6 11.8 30.3 4.7 0.6 0.1 4.1 3.0 14.0 15.5 0.5 0.2 7.4 8.1 0.0 0.5 24.5 1.0 2.9 2.8 3.1 2.0 3.5 2.1 2.7 4.1 7.7 0.8 27.4 5.0 2.9 0.2 2.7 3.3 1.8 7.1 5.9 3.5 0.0 1.0 0.1 3.2 0.0 0.0 0.6 0.8 0.0 0.0 0.0 6.2 7.9 55.9 5.9 6.9 2.4 2.8 0.3 0.2 0.0 0.0 8.2 0.0 0.0 1.8 3.3 0.3 0.0 0.0 0.0 0.1 5.1 0.0 0.2 8.2 0.2 1.5 1.5 0.4 0.1 0.0 8.0 0.0 0.0 0.0 0.2 0.0 0.0 1.4 0.0 1.0 2.8 0.0 0.0 0.1 0.0 0.0 0.0 0.1 9.5 1.5 3.3 0.0 0.2 0.0 0.0 0.0 4.3 0.0 0.0 0.0 3.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.2 0.7 0.2 0.5 0.6 0.1 0.5 0.2 1.0 0.2 MMP2 "CLG4, CLG4A, TBE-1" ENSG00000087245 "Matrix metallopeptidase 2" P08253 16 55389700-55506691 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Angiogenesis, Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 335.4;ASC TERT1: 97.7;HSkMC: 83.3;U-138 MG: 91.2;U-87 MG: 106.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001939, CAB002788" Approved Approved Vesicles "Secreted to extracellular matrix" 160000000 Vesicles "CAB002788: , HPA001939: AB_1079395" "unprognostic (7.26e-2)" "unprognostic (1.36e-3)" "unprognostic (1.66e-1)" "unprognostic (2.14e-3)" "unprognostic (5.03e-2)" "unprognostic (1.20e-1)" "unprognostic (1.74e-1)" "unprognostic (9.36e-3)" "unprognostic (4.81e-3)" "unprognostic (3.79e-2)" "unprognostic (4.59e-3)" "unprognostic (6.12e-2)" "unprognostic (1.28e-3)" "unprognostic (1.59e-2)" "unprognostic (8.00e-2)" "unprognostic (8.98e-2)" "unprognostic (4.63e-2)" 197.5 9.0 1.2 13.2 1.6 0.0 136.4 0.8 1.4 74.3 74.4 2.4 36.9 5.6 85.0 123.0 52.3 25.7 115.4 54.0 0.9 0.5 9.4 3.5 38.9 3.9 1.5 1.1 71.0 6.5 0.7 2.2 58.9 2.2 66.8 18.7 36.4 18.6 20.4 68.6 68.2 22.6 57.1 1.8 12.4 20.5 57.0 1.1 1.3 20.6 31.8 9.1 84.1 105.3 0.0 0.0 0.9 0.7 0.0 0.0 0.0 0.3 0.2 11.1 0.1 335.4 97.7 18.2 28.7 65.9 5.8 4.6 0.0 0.1 0.0 23.1 50.5 3.1 0.0 0.2 3.3 0.0 0.0 0.0 0.7 0.1 31.7 0.0 0.8 83.3 0.0 29.8 0.2 37.4 0.0 0.1 19.3 0.0 0.0 0.4 8.8 0.0 0.0 2.6 0.0 0.9 0.4 0.1 20.2 5.3 0.0 0.1 0.0 2.0 52.7 91.2 8.7 17.5 3.7 0.0 0.0 0.1 106.8 1.5 16.6 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.0 0.0 1.2 1.6 0.8 1.4 0.9 0.5 1.5 1.1 2.2 1.1 MMP24 MT5-MMP ENSG00000125966 "Matrix metallopeptidase 24" Q9Y5R2 20 35226654-35277000 "Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion" "Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 38.5" "Cell line enhanced" "Detected in some" "A549: 19.6;CACO-2: 29.9;EFO-21: 8.8;RPTEC TERT1: 13.5;U-2 OS: 10.1" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 5 "cerebellum: 38.5" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Region enriched" "Detected in all" 5 "cerebellum: 91.3" "HPA049280, HPA078816" Approved Approved "Nucleoli,Plasma membrane" "Secreted to extracellular matrix" "Nucleoli, Plasma membrane" "HPA049280: , HPA078816: " "unprognostic (1.52e-3)" "unprognostic (1.36e-1)" "unprognostic (1.18e-1)" "unprognostic (4.51e-4)" "unprognostic (2.47e-2)" "unprognostic (7.61e-3)" "unprognostic (1.22e-1)" "unprognostic (4.59e-2)" "unprognostic (2.32e-2)" "unprognostic (8.82e-2)" "unprognostic (9.20e-3)" "unprognostic (7.12e-2)" "prognostic favourable (8.17e-11)" "unprognostic (3.32e-2)" "unprognostic (5.63e-2)" "unprognostic (1.69e-2)" "unprognostic (9.90e-4)" 1.6 1.3 4.0 0.4 7.8 0.6 0.4 38.5 8.9 0.7 0.3 1.3 0.2 2.8 1.6 0.9 0.2 2.8 0.6 1.0 2.7 3.2 8.6 0.9 6.1 0.3 1.8 1.5 0.9 8.0 0.0 3.8 0.6 1.7 2.2 0.1 0.5 0.4 6.0 0.2 1.5 1.7 2.5 0.9 0.6 0.7 0.4 1.4 0.2 0.8 0.2 0.2 0.5 0.2 0.8 0.4 2.2 0.8 0.6 1.2 0.3 0.3 19.6 0.0 0.1 0.1 0.0 0.6 1.1 1.2 2.1 1.1 29.9 5.3 0.0 8.8 1.3 0.3 4.6 0.0 0.9 0.1 0.2 1.0 0.5 0.3 0.0 0.0 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.3 0.2 0.2 0.1 0.1 7.5 1.3 0.0 0.1 0.0 13.5 0.1 7.8 5.4 1.4 0.5 0.2 0.3 0.1 0.3 4.2 10.1 1.0 0.4 0.1 0.1 0.0 0.9 0.1 0.6 1.0 0.6 0.1 1.0 0.7 1.2 0.6 0.7 0.8 0.4 0.8 0.6 0.6 2.2 0.6 0.8 0.2 0.0 0.3 4.0 7.8 38.5 5.3 2.7 3.2 1.8 1.5 1.7 1.4 MMP25 "MMP20, MMPL1, MT6-MMP" ENSG00000008516 "Matrix metallopeptidase 25" Q9NPA2 16 3046681-3060726 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 17.6;bone marrow: 25.6;lymphoid tissue: 54.1" "Cell line enriched" "Detected in some" 12 "HMC-1: 49.3" "Cancer enhanced" "Detected in many" "testis cancer: 7.1" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 6 "basophil: 10.2;eosinophil: 6.0;neutrophil: 17.6" "Lineage enriched" "Detected in many" 10 "granulocytes: 17.6" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" CAB025177 Uncertain "Secreted to blood" "CAB025177: " "unprognostic (4.51e-3)" "unprognostic (9.28e-3)" "unprognostic (7.57e-2)" "unprognostic (2.95e-3)" "unprognostic (2.26e-1)" "prognostic favourable (1.09e-5)" "unprognostic (1.36e-1)" "unprognostic (7.39e-3)" "unprognostic (7.63e-3)" "unprognostic (2.29e-2)" "unprognostic (1.51e-1)" "unprognostic (2.53e-2)" "unprognostic (2.37e-3)" "unprognostic (1.17e-2)" "unprognostic (8.30e-2)" "unprognostic (4.01e-1)" "unprognostic (2.02e-1)" 4.0 0.3 0.6 12.3 0.4 25.6 0.8 0.5 0.6 0.8 1.1 0.2 0.0 1.0 0.4 0.5 0.8 3.8 1.1 2.8 0.5 0.4 0.7 2.5 10.7 54.1 1.8 0.0 0.6 0.8 0.0 0.5 2.0 1.1 0.6 1.0 1.0 0.9 0.0 2.4 0.6 1.8 0.5 0.4 43.9 1.1 0.7 0.5 4.1 0.7 0.9 4.2 1.5 2.5 0.0 0.3 17.6 0.2 1.7 0.5 0.1 0.2 0.1 0.6 1.5 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.3 0.3 0.2 0.0 0.6 0.3 0.0 0.0 3.9 0.8 0.1 0.1 0.0 0.0 0.1 49.3 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.5 0.2 3.0 1.4 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.3 3.5 0.1 0.1 0.4 0.1 0.0 1.2 0.1 0.1 0.0 0.9 0.1 10.2 0.2 6.0 0.3 0.0 0.5 0.0 0.2 0.2 0.0 0.0 0.3 0.2 17.6 1.7 0.0 0.3 0.3 0.1 0.6 0.4 0.5 0.6 0.5 0.4 1.8 0.0 1.1 0.5 MMP27 ENSG00000137675 "Matrix metallopeptidase 27" Q9H306 11 102691487-102705806 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 10.4;tongue: 10.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 7 "neutrophil: 1.0" "Lineage enriched" "Detected in single" 7 "granulocytes: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" HPA069097 Approved "Intracellular and membrane" "HPA069097: " "unprognostic (3.99e-2)" "unprognostic (2.37e-4)" "unprognostic (1.25e-3)" "unprognostic (1.63e-1)" "unprognostic (4.60e-1)" 3.2 0.0 0.0 0.0 0.5 2.4 10.4 0.0 0.0 1.5 0.8 0.0 0.0 0.3 0.9 4.7 0.8 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.6 0.0 5.1 0.0 0.8 5.4 2.6 2.0 0.0 0.1 0.4 0.4 0.0 0.9 0.1 10.0 2.2 0.4 0.3 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MMP28 "EPILYSIN, MM28, MMP-25, MMP-28" ENSG00000271447 "Matrix metallopeptidase 28" Q9H239 17 35756249-35795707 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enriched" "Detected in some" 9 "HaCaT: 28.1" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 7.2;naive CD8 T-cell: 5.9" "Lineage enriched" "Detected in many" 5 "T-cells: 7.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA057288, HPA057890" Approved "Nucleoplasm,Focal adhesion sites" "Secreted to extracellular matrix" Nucleoplasm "Focal adhesion sites" "HPA057288: , HPA057890: " "unprognostic (7.99e-3)" "unprognostic (3.27e-1)" "unprognostic (2.20e-1)" "unprognostic (1.01e-1)" "unprognostic (7.52e-2)" "unprognostic (1.63e-1)" "unprognostic (6.90e-2)" "unprognostic (1.09e-2)" "unprognostic (1.51e-1)" "unprognostic (1.99e-1)" "prognostic unfavourable (6.28e-6)" "unprognostic (9.37e-2)" "unprognostic (1.31e-1)" "unprognostic (8.87e-2)" "unprognostic (1.74e-1)" "unprognostic (1.76e-2)" "unprognostic (3.27e-3)" 8.0 1.6 1.8 2.7 3.7 0.5 4.3 0.0 5.1 1.7 7.3 1.6 1.4 3.0 3.2 4.8 4.3 1.5 12.3 0.5 2.8 0.8 0.2 10.3 0.4 0.0 2.9 0.1 1.3 0.5 0.0 0.7 1.3 2.9 4.1 2.7 0.1 2.1 0.6 4.5 9.3 4.3 0.2 0.6 7.2 13.4 0.2 0.0 4.2 4.4 2.5 5.5 2.2 1.1 1.5 0.1 0.2 1.3 7.2 0.9 0.1 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.1 0.7 0.0 28.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 1.1 0.0 0.0 0.0 2.5 0.0 0.1 0.2 0.0 0.1 0.0 0.2 0.1 0.2 0.0 0.2 0.6 0.0 0.0 0.0 1.6 0.2 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 2.0 1.1 0.4 1.7 0.1 0.9 7.2 5.9 0.1 1.3 0.2 1.5 0.0 0.9 MMP3 "STMY, STMY1" ENSG00000149968 "Matrix metallopeptidase 3" P08254 11 102835801-102843803 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "epididymis: 177.5;salivary gland: 73.4" "Group enriched" "Detected in some" 17 "BJ: 98.9;BJ hTERT+: 269.1;fHDF/TERT166: 116.5" "Cancer enhanced" "Detected in many" "head and neck cancer: 59.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA007875 Uncertain Supported Vesicles "Secreted to extracellular matrix" 170000 Vesicles "HPA007875: AB_1079396" "unprognostic (2.27e-1)" "prognostic unfavourable (9.73e-4)" "unprognostic (1.63e-3)" "unprognostic (5.11e-3)" "unprognostic (3.78e-1)" "unprognostic (5.11e-2)" "unprognostic (5.26e-6)" "unprognostic (3.46e-2)" "unprognostic (7.14e-2)" "unprognostic (2.87e-1)" "prognostic unfavourable (4.09e-4)" "unprognostic (3.26e-2)" "unprognostic (1.22e-15)" "unprognostic (3.17e-1)" "unprognostic (1.55e-1)" "unprognostic (3.43e-2)" "unprognostic (2.34e-1)" 19.1 0.0 0.2 14.4 0.3 0.0 6.9 0.2 0.5 0.2 1.5 0.3 0.2 1.8 28.3 177.5 0.2 0.0 1.4 0.2 0.2 0.0 0.3 0.5 0.4 0.2 0.2 0.2 0.3 0.2 0.0 0.2 0.2 0.2 1.2 1.7 0.2 73.4 1.5 7.3 12.6 0.7 5.9 0.2 0.2 2.8 1.4 0.2 0.2 0.6 1.5 0.9 7.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 98.9 269.1 1.7 0.5 0.0 0.0 0.0 0.0 116.5 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 7.9 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 9.2 0.8 0.1 0.0 0.0 0.0 0.0 3.8 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.2 0.5 0.2 0.0 0.2 0.2 0.2 0.2 MMP7 "MPSL1, PUMP-1" ENSG00000137673 "Matrix metallopeptidase 7" P09237 11 102520508-102530753 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 93.0;kidney: 129.5;salivary gland: 79.3" "Cell line enhanced" "Detected in some" "A549: 22.6;CAPAN-2: 126.5;EFO-21: 30.0;RPTEC TERT1: 54.7" "Cancer enhanced" "Detected in all" "pancreatic cancer: 352.1" "Region enriched" "Detected in single" 5 "pons and medulla: 1.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB025869, HPA051358" Supported Approved Nucleoplasm,Vesicles "Secreted to extracellular matrix" "Nucleoplasm, Vesicles" "CAB025869: , HPA051358: " "unprognostic (1.06e-3)" "unprognostic (9.51e-2)" "unprognostic (4.15e-2)" "unprognostic (1.38e-1)" "unprognostic (7.70e-3)" "unprognostic (7.28e-2)" "prognostic unfavourable (2.53e-4)" "prognostic unfavourable (3.38e-4)" "unprognostic (3.96e-2)" "unprognostic (5.63e-2)" "unprognostic (6.59e-3)" "unprognostic (1.51e-1)" "unprognostic (6.36e-3)" "unprognostic (1.42e-2)" "unprognostic (5.54e-2)" "unprognostic (1.48e-1)" "unprognostic (1.46e-1)" 6.8 0.2 0.2 1.2 0.2 0.0 28.8 0.2 0.2 5.2 0.2 0.2 2.1 0.0 17.2 12.3 3.3 16.4 93.0 0.2 0.2 0.2 129.5 1.4 5.0 0.9 0.2 0.2 3.9 23.5 0.0 0.7 2.7 1.3 42.0 0.0 0.2 79.3 6.7 0.2 7.8 0.3 0.5 0.2 0.2 0.9 9.4 0.2 1.2 0.3 1.4 4.5 19.9 0.8 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 22.6 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 126.5 0.0 30.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 54.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.2 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 1.3 0.2 MMP8 CLG1 ENSG00000118113 "Matrix metallopeptidase 8" P22894 11 102711795-102727050 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "bone marrow: 119.3" "Cell line enriched" "Detected in some" 8 "WM-115: 39.2" "Cancer enriched" "Detected in single" 17 "melanoma: 5.7" "Region enhanced" "Detected in single" "cerebral cortex: 1.7" "Group enriched" "Detected in some" 32 "neutrophil: 1.4;non-classical monocyte: 4.9" "Group enriched" "Detected in many" 32 "granulocytes: 1.4;monocytes: 4.9" "Not detected" "Not detected" "Not detected" "Not detected" "HPA021221, HPA022935" Enhanced "Secreted to extracellular matrix" 83000 "HPA021221: AB_1854043, HPA022935: AB_1854044" "unprognostic (3.03e-1)" "unprognostic (8.49e-5)" "unprognostic (1.08e-2)" "unprognostic (3.95e-3)" "unprognostic (1.80e-1)" "unprognostic (1.01e-2)" "unprognostic (7.68e-3)" "unprognostic (1.27e-1)" "unprognostic (4.92e-2)" "unprognostic (6.64e-3)" "unprognostic (2.45e-6)" "unprognostic (2.33e-4)" "unprognostic (1.33e-1)" "unprognostic (4.97e-1)" "unprognostic (2.30e-2)" 1.9 0.1 0.2 0.2 0.4 119.3 0.3 0.1 1.7 0.1 0.2 0.0 0.0 0.1 0.6 0.1 0.1 0.1 0.1 9.0 0.2 0.3 0.4 0.8 12.6 2.6 0.3 0.0 0.9 0.9 0.1 0.6 1.4 0.2 0.1 0.1 0.1 0.3 0.1 0.6 0.3 0.1 0.2 0.3 18.7 0.2 0.1 0.1 5.2 1.9 0.0 0.1 0.2 7.6 0.0 0.0 1.4 4.9 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 4.9 0.0 0.0 1.7 0.2 0.4 0.1 1.7 0.2 0.3 0.3 0.0 0.2 0.1 MMP9 CLG4B ENSG00000100985 "Matrix metallopeptidase 9" P14780 20 46008908-46016561 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adipose tissue: 64.0;blood: 63.2;bone marrow: 89.4;lymphoid tissue: 80.1" "Cell line enriched" "Detected in some" 12 "NB-4: 87.3" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 141 "neutrophil: 63.2" "Lineage enriched" "Detected in single" 339 "granulocytes: 63.2" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201" Enhanced Approved Cytosol "Secreted to blood" 57000000 Cytosol "CAB000348: , CAB068199: , CAB068200: , CAB068201: , HPA001238: AB_1079398, HPA063909: AB_2685150" "unprognostic (4.62e-2)" "unprognostic (1.64e-1)" "unprognostic (2.85e-2)" "prognostic favourable (2.55e-4)" "unprognostic (6.65e-3)" "unprognostic (2.82e-1)" "prognostic unfavourable (7.19e-4)" "unprognostic (1.54e-1)" "unprognostic (8.57e-2)" "unprognostic (3.21e-2)" "unprognostic (4.15e-2)" "unprognostic (1.96e-1)" "prognostic unfavourable (4.05e-5)" "unprognostic (4.65e-1)" "unprognostic (9.85e-3)" "unprognostic (2.48e-2)" "unprognostic (2.17e-3)" 64.0 0.5 0.6 38.6 0.7 89.4 4.3 0.4 0.6 0.8 1.2 0.1 0.0 2.8 0.6 0.2 0.9 1.5 0.6 4.0 0.5 0.6 1.4 2.0 13.3 80.1 0.6 0.0 2.7 1.4 0.0 0.8 2.6 0.5 0.6 0.8 0.5 12.5 0.0 1.3 1.3 4.2 0.3 0.5 53.7 2.5 2.7 0.0 23.6 1.3 2.3 44.5 4.5 2.9 0.0 0.0 63.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.8 0.0 7.3 0.0 0.1 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.9 0.0 87.3 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.3 0.0 2.6 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 63.2 0.0 0.0 0.0 0.0 0.0 0.6 0.7 0.4 0.6 0.5 0.6 0.6 0.0 0.5 0.0 MRC1 "bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1" ENSG00000260314 "Mannose receptor C-type 1" P22897 10 17809344-17911170 "CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Endocytosis, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 44.8;lymphoid tissue: 37.8" "Group enriched" "Detected in some" 19 "MOLT-4: 17.2;TIME: 16.0" "Low cancer specificity" "Detected in all" "Cell type enriched" "Detected in single" 15 "myeloid DC: 8.2" "Lineage enriched" "Detected in single" 15 "dendritic cells: 8.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in some" "HPA004114, HPA045134, CAB068203" Enhanced 130000000 "CAB068203: , HPA004114: AB_1846270, HPA045134: AB_2679228" "unprognostic (2.20e-1)" "unprognostic (2.07e-1)" "unprognostic (1.03e-2)" "unprognostic (2.58e-1)" "unprognostic (5.62e-2)" "unprognostic (4.30e-1)" "unprognostic (6.36e-3)" "unprognostic (1.35e-1)" "unprognostic (1.05e-2)" "unprognostic (6.05e-2)" "unprognostic (5.61e-2)" "unprognostic (4.12e-1)" "unprognostic (2.94e-2)" "unprognostic (4.97e-2)" "unprognostic (3.05e-2)" "unprognostic (1.74e-2)" "unprognostic (7.02e-2)" 34.8 8.3 0.3 6.2 1.2 0.0 19.8 0.7 0.6 5.2 11.2 0.6 0.9 2.2 4.5 10.4 4.2 1.3 7.9 13.4 0.9 12.4 16.4 44.8 37.8 1.0 0.0 3.6 5.1 1.8 2.4 15.4 3.1 5.5 5.1 7.0 0.7 1.9 5.1 0.0 6.5 8.2 1.4 30.6 2.2 7.1 0.8 0.8 6.5 3.5 0.7 7.5 5.1 0.0 8.2 0.1 0.5 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.2 0.0 0.1 0.0 0.1 0.3 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.1 0.0 8.2 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.4 0.2 MS4A1 "B1, Bp35, CD20, MS4A2" ENSG00000156738 "Membrane spanning 4-domains A1" P11836 11 60455752-60470760 "CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "B-cell activation" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 77.7;intestine: 46.1;lymphoid tissue: 134.1" "Group enriched" "Detected in some" 25 "Daudi: 120.0;U-698: 60.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 105 "memory B-cell: 77.7;naive B-cell: 77.7" "Lineage enriched" "Detected in single" 105 "B-cells: 77.7" "Not detected" "Not detected" "Low region specificity" "Detected in some" "CAB000015, HPA014341, HPA014391" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB000015: AB_2282030, HPA014341: AB_1846265, HPA014391: AB_1846264" "prognostic favourable (4.34e-5)" "unprognostic (4.45e-4)" "unprognostic (1.19e-4)" "unprognostic (2.04e-3)" "unprognostic (1.06e-1)" "unprognostic (5.53e-7)" "unprognostic (2.46e-3)" "unprognostic (1.85e-3)" "unprognostic (3.06e-2)" "unprognostic (2.89e-4)" "unprognostic (6.96e-2)" "unprognostic (2.84e-2)" "unprognostic (3.96e-5)" "unprognostic (2.23e-1)" "unprognostic (8.04e-2)" "unprognostic (1.44e-1)" "unprognostic (1.30e-1)" 1.6 0.3 0.3 79.0 0.3 3.6 0.6 0.3 0.3 0.5 2.0 0.0 0.0 0.2 0.4 0.5 7.0 0.4 1.3 0.7 0.3 0.3 2.0 0.9 2.7 81.2 0.3 0.1 0.3 0.4 0.0 0.4 0.4 0.1 1.1 1.7 0.6 14.5 0.2 0.3 0.3 46.1 0.1 0.4 90.7 2.6 0.6 0.0 15.7 2.5 2.7 134.1 6.4 0.8 77.7 0.0 0.2 0.0 0.7 0.6 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 120.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 60.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 77.7 0.3 0.6 0.0 77.7 0.0 0.2 0.2 0.7 0.0 0.0 0.0 3.5 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.1 0.1 0.0 MTNR1B ENSG00000134640 "Melatonin receptor 1B" P49286 11 92969720-92985066 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 3.0;lymphoid tissue: 1.9;placenta: 4.5;testis: 2.0" "Group enriched" "Detected in some" 8 "AF22: 1.1;U-138 MG: 1.4;WM-115: 1.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "midbrain: 0.8;pons and medulla: 1.2" HPA074024 Supported "HPA074024: " "unprognostic (3.61e-1)" "unprognostic (1.43e-1)" 0.1 0.0 0.3 0.0 3.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 2.0 0.0 1.9 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MTOR "FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1" ENSG00000198793 "Mechanistic target of rapamycin kinase" P42345 1 11106535-11262507 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB069425, HPA071227" Approved Approved Vesicles,Cytosol "Vesicles, Cytosol" "CAB069425: , HPA071227: " "unprognostic (3.18e-1)" "unprognostic (1.50e-1)" "unprognostic (1.20e-1)" "unprognostic (2.45e-3)" "unprognostic (5.50e-2)" "unprognostic (2.55e-2)" "unprognostic (1.39e-1)" "unprognostic (1.68e-1)" "unprognostic (1.18e-1)" "unprognostic (8.24e-3)" "unprognostic (3.48e-2)" "unprognostic (1.88e-1)" "prognostic favourable (1.49e-5)" "unprognostic (1.27e-1)" "unprognostic (2.45e-1)" "unprognostic (6.60e-2)" "unprognostic (7.55e-2)" 11.3 13.9 18.7 13.0 22.5 12.3 14.9 25.2 25.2 11.3 14.5 18.2 10.4 11.2 13.8 23.6 13.1 10.5 15.7 14.2 14.5 13.6 15.8 19.4 10.8 14.3 14.0 14.4 10.7 16.6 26.5 16.0 12.5 15.5 15.2 17.1 14.4 14.2 15.2 24.6 16.5 13.6 15.2 10.4 15.4 13.1 38.6 13.1 16.6 13.2 9.9 15.7 11.7 10.2 3.9 4.0 3.0 6.4 2.6 5.6 2.3 15.2 13.8 18.7 14.1 22.6 10.8 9.3 12.9 12.4 17.2 17.0 14.2 14.1 16.9 11.1 15.2 18.2 25.2 19.7 22.3 13.5 18.4 22.5 28.6 17.9 14.2 21.9 16.8 13.8 15.0 24.6 25.0 21.8 25.1 14.6 12.0 17.4 15.1 16.7 14.1 13.1 15.2 22.0 11.3 15.2 13.8 18.9 13.8 27.6 14.9 16.9 12.1 13.0 23.2 15.1 13.7 11.5 17.2 14.4 13.4 33.3 10.9 23.7 15.8 0.7 2.9 3.0 5.2 6.4 4.3 3.9 3.0 2.7 4.0 3.4 3.6 3.1 2.0 2.6 3.3 3.1 5.6 2.3 18.7 22.5 25.2 25.2 14.5 13.6 14.0 14.4 15.5 13.1 MTR cblG ENSG00000116984 "5-methyltetrahydrofolate-homocysteine methyltransferase" Q99707 1 236795281-236903981 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Amino-acid biosynthesis, Methionine biosynthesis" "Methyltransferase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA044474, HPA054915" Approved Supported Cytosol Cytosol "HPA044474: AB_10966696, HPA054915: " "unprognostic (2.12e-1)" "unprognostic (1.03e-1)" "unprognostic (6.96e-2)" "unprognostic (1.99e-1)" "unprognostic (1.35e-1)" "unprognostic (1.76e-1)" "unprognostic (4.87e-1)" "unprognostic (1.02e-1)" "unprognostic (2.48e-2)" "unprognostic (3.34e-1)" "unprognostic (5.73e-2)" "unprognostic (1.63e-1)" "unprognostic (1.67e-2)" "unprognostic (8.84e-3)" "unprognostic (1.88e-1)" "prognostic unfavourable (5.75e-4)" "unprognostic (8.10e-2)" 14.5 11.4 9.9 13.2 13.5 7.6 13.6 14.8 14.4 16.9 16.4 16.2 16.0 7.5 18.1 27.3 10.4 18.4 16.3 21.9 9.4 9.8 21.2 9.5 11.7 14.3 12.6 12.8 24.7 20.8 27.4 12.4 17.5 13.0 14.0 8.9 17.7 11.1 17.3 27.0 15.4 11.7 23.3 12.1 13.9 14.9 20.1 12.1 20.8 22.4 11.1 13.2 18.4 14.4 3.3 1.6 3.0 2.0 2.3 5.8 2.1 9.9 6.7 8.2 6.8 15.3 14.1 9.7 8.7 7.8 9.6 10.0 6.3 7.6 22.1 8.1 9.8 6.9 10.6 7.8 11.5 10.2 9.1 13.0 8.9 11.6 10.3 20.6 8.1 20.1 4.9 12.7 12.2 12.7 18.7 10.4 8.0 6.9 10.7 6.6 11.0 3.6 11.7 14.6 14.2 6.9 11.5 6.7 18.7 9.8 7.2 8.8 10.2 8.4 16.4 15.9 6.1 12.2 11.2 22.6 7.0 12.9 10.3 13.0 15.6 2.7 1.6 3.0 3.2 2.0 5.8 2.7 4.2 4.5 1.5 3.3 5.0 4.0 0.1 2.3 1.5 1.6 2.9 2.1 9.9 13.5 14.8 14.4 9.4 9.8 12.6 12.8 13.0 12.1 MTTP "ABL, MTP" ENSG00000138823 "Microsomal triglyceride transfer protein" P55157 4 99563761-99623999 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins" "Lipid transport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 49 "intestine: 211.4;liver: 60.8" "Group enriched" "Detected in some" 6 "AF22: 12.5;Hep G2: 13.7" "Cancer enriched" "Detected in many" 13 "liver cancer: 28.7" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "naive B-cell: 1.0" "Lineage enriched" "Detected in single" 10 "B-cells: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in single" "HPA051170, HPA054862" Uncertain Approved Cytosol "Intracellular and membrane" 450000 Cytosol "HPA051170: , HPA054862: " "unprognostic (1.66e-2)" "unprognostic (1.14e-1)" "unprognostic (5.64e-2)" "unprognostic (5.33e-2)" "unprognostic (3.49e-3)" "unprognostic (7.38e-2)" "unprognostic (1.05e-1)" "unprognostic (2.74e-2)" "unprognostic (1.08e-1)" "unprognostic (3.66e-2)" "unprognostic (1.00e-2)" "unprognostic (1.62e-1)" "unprognostic (1.27e-3)" "unprognostic (2.02e-2)" "unprognostic (3.64e-1)" "unprognostic (1.53e-2)" "unprognostic (1.31e-1)" 0.1 0.1 0.3 0.0 0.3 0.0 0.1 0.1 0.2 0.0 53.2 0.2 0.1 53.4 0.0 0.0 0.2 0.2 0.4 0.4 0.3 0.4 2.7 60.8 0.1 0.0 0.4 0.1 1.1 0.1 0.0 0.3 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.1 0.1 211.4 0.7 0.4 0.1 0.2 1.8 0.2 0.1 0.1 0.1 0.0 0.3 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 12.5 0.0 0.0 0.1 1.1 0.1 0.0 0.0 0.3 0.5 0.0 0.4 0.2 0.0 0.0 0.1 0.0 0.0 2.3 0.2 0.3 0.1 13.7 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.1 0.6 0.6 0.3 0.3 0.2 1.2 0.0 0.0 0.8 0.9 0.2 0.1 0.4 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.1 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.1 0.2 0.3 0.4 0.4 0.1 0.3 0.2 MUT ENSG00000146085 "Methylmalonyl-CoA mutase" P22033 6 49430360-49463191 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Isomerase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 96.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035971, HPA035972" Enhanced Approved Mitochondria,Cytosol 110000 Cytosol Mitochondria "HPA035971: AB_10696648, HPA035972: AB_2674895" "unprognostic (1.34e-2)" "unprognostic (1.12e-1)" "unprognostic (1.17e-2)" "unprognostic (3.72e-2)" "unprognostic (3.18e-3)" "unprognostic (1.20e-1)" "unprognostic (1.16e-2)" "unprognostic (1.16e-2)" "unprognostic (3.62e-2)" "unprognostic (1.89e-2)" "unprognostic (6.57e-2)" "unprognostic (9.89e-2)" "prognostic favourable (8.71e-13)" "unprognostic (5.38e-2)" "unprognostic (3.78e-1)" "unprognostic (6.01e-3)" "unprognostic (1.91e-1)" 10.7 14.3 10.9 5.7 13.4 4.1 9.7 10.0 12.1 8.9 12.7 8.6 9.0 13.6 8.7 8.6 13.2 8.4 7.5 16.6 10.1 10.0 25.5 96.5 7.8 5.7 11.8 9.5 13.1 15.7 15.8 13.5 7.5 12.0 11.2 11.2 8.0 9.3 9.2 13.7 9.0 14.7 11.8 9.7 6.4 10.9 9.1 9.9 8.2 11.2 9.1 5.8 12.8 8.1 9.4 8.9 14.0 15.2 14.2 12.0 6.7 13.2 4.7 14.3 16.6 28.5 27.1 7.9 11.9 15.7 12.6 18.7 5.4 6.9 12.3 9.5 12.7 7.6 15.9 8.4 17.8 10.5 11.5 6.5 10.8 14.2 20.8 8.3 6.3 16.4 12.6 12.8 15.0 12.1 11.9 14.8 14.8 8.3 9.7 8.3 6.1 3.5 8.8 17.9 17.0 14.6 12.8 13.3 9.2 13.1 9.4 19.7 8.2 13.4 8.7 11.8 8.7 15.9 16.0 5.9 6.6 10.6 16.6 9.9 10.2 14.0 7.5 12.5 7.9 9.9 9.9 9.4 9.5 9.9 8.9 8.3 12.0 9.0 4.3 14.2 15.2 6.3 11.9 6.7 10.9 13.4 10.0 12.1 10.1 10.0 11.8 9.5 12.0 9.9 NDUFV3 CI-10k ENSG00000160194 "NADH:ubiquinone oxidoreductase subunit V3" P56181 21 42879644-42913304 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Electron transport, Respiratory chain, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 129.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019791, HPA020463, HPA030427, CAB034142" Enhanced Enhanced Mitochondria Mitochondria "CAB034142: AB_2298212, HPA019791: AB_1854357, HPA020463: AB_1854358, HPA030427: AB_10603024" "unprognostic (1.62e-1)" "unprognostic (2.17e-3)" "unprognostic (1.31e-1)" "unprognostic (1.04e-1)" "unprognostic (1.10e-1)" "unprognostic (1.11e-2)" "unprognostic (4.69e-1)" "unprognostic (2.97e-2)" "unprognostic (1.05e-1)" "unprognostic (3.13e-1)" "unprognostic (3.85e-3)" "unprognostic (1.54e-1)" "unprognostic (1.45e-1)" "unprognostic (6.56e-2)" "unprognostic (9.30e-3)" "unprognostic (2.14e-1)" "unprognostic (1.94e-1)" 18.1 14.1 16.9 11.1 17.2 15.8 14.6 11.8 23.2 12.0 15.9 11.9 14.6 15.2 15.1 15.7 15.6 12.7 15.4 54.9 14.2 11.0 15.1 24.3 10.8 12.5 14.0 18.6 16.0 17.7 13.2 13.1 11.6 19.2 13.6 11.4 12.2 19.4 21.8 129.5 15.4 13.5 16.9 16.0 13.3 14.3 20.3 13.3 6.6 11.6 18.5 10.6 13.3 11.8 9.9 22.9 16.0 22.8 10.5 8.8 10.3 9.6 11.3 11.0 18.0 13.6 11.8 13.6 19.2 11.0 11.4 9.6 20.7 11.9 10.7 15.2 7.1 10.5 12.8 16.9 7.5 6.1 15.4 35.2 13.3 16.2 21.3 12.0 18.5 13.3 14.7 11.6 18.4 14.4 27.9 13.9 13.1 18.9 8.0 18.2 14.3 22.4 13.8 8.0 33.4 15.4 12.8 8.0 8.4 19.2 22.8 12.7 19.5 15.9 16.9 10.8 7.5 13.8 13.6 20.8 13.7 12.1 14.1 21.6 16.2 3.7 21.4 16.0 8.0 22.8 8.1 8.1 7.6 6.7 22.9 9.9 8.8 7.7 3.8 10.5 19.6 11.3 8.8 10.3 16.9 17.2 11.8 23.2 14.2 11.0 14.0 18.6 19.2 13.3 NFKB1 "KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50" ENSG00000109320 "Nuclear factor kappa B subunit 1" P19838 4 102501329-102617302 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004031, HPA027305" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB004031: AB_330564, HPA027305: AB_1854429" "unprognostic (1.06e-1)" "unprognostic (1.61e-2)" "unprognostic (4.37e-2)" "unprognostic (2.38e-2)" "unprognostic (1.60e-1)" "unprognostic (1.20e-1)" "unprognostic (2.04e-2)" "unprognostic (8.98e-2)" "unprognostic (1.96e-1)" "unprognostic (9.03e-3)" "unprognostic (2.28e-1)" "unprognostic (2.71e-1)" "prognostic favourable (1.76e-4)" "unprognostic (1.84e-2)" "unprognostic (6.75e-3)" "unprognostic (1.74e-1)" "unprognostic (6.92e-3)" 19.8 14.7 8.2 37.7 12.0 44.5 26.6 12.4 10.3 18.2 17.1 10.4 10.4 10.7 17.5 11.2 20.5 16.4 20.3 14.5 7.5 5.1 13.2 15.8 26.9 46.0 11.4 4.8 17.5 14.3 10.2 8.7 13.7 10.0 18.8 14.6 10.8 17.7 13.5 17.1 19.6 16.7 16.0 10.1 30.0 14.6 9.3 12.5 37.5 14.7 16.3 26.7 18.4 22.7 5.8 10.4 5.5 7.1 14.3 10.6 3.5 16.9 9.5 5.1 7.8 16.0 14.4 6.3 9.7 28.8 12.1 12.4 10.5 24.3 27.7 8.8 15.3 13.5 10.2 17.0 16.7 25.0 6.0 11.8 7.7 11.3 15.0 21.0 25.1 11.9 12.0 11.8 16.4 15.2 11.4 20.4 8.7 11.9 1.8 11.5 3.1 8.8 14.8 12.2 12.5 11.3 23.9 3.5 5.8 17.9 25.0 9.8 5.1 15.7 19.4 16.5 8.6 8.9 13.6 9.0 6.2 26.9 10.5 10.8 23.3 5.2 5.4 4.9 3.4 7.1 6.0 5.6 8.4 5.6 10.4 5.8 10.6 8.9 5.5 14.3 5.9 7.4 4.5 3.5 8.2 12.0 12.4 10.3 7.5 5.1 11.4 4.8 10.0 12.5 NISCH "I-1, IRAS, KIAA0975" ENSG00000010322 Nischarin Q9Y2I1 3 52455118-52493071 "FDA approved drug targets, Predicted intracellular proteins" Apoptosis Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023189 Approved "HPA023189: AB_1854495" "unprognostic (6.66e-2)" "unprognostic (1.58e-1)" "unprognostic (1.59e-3)" "unprognostic (4.11e-3)" "unprognostic (1.64e-1)" "unprognostic (8.08e-3)" "unprognostic (1.60e-2)" "unprognostic (6.56e-3)" "unprognostic (4.96e-2)" "unprognostic (8.33e-3)" "prognostic favourable (1.91e-4)" "unprognostic (1.40e-2)" "unprognostic (5.10e-2)" "unprognostic (1.19e-1)" "unprognostic (2.94e-2)" "unprognostic (1.47e-1)" "unprognostic (7.05e-3)" 16.5 24.9 29.7 14.3 36.1 18.1 16.7 84.5 47.5 24.1 16.4 21.4 22.1 12.9 24.4 19.5 14.1 20.9 16.4 14.1 24.7 18.8 14.9 11.8 17.1 15.9 13.2 35.6 30.7 21.8 23.3 55.3 21.0 20.8 29.8 11.4 27.0 26.5 30.2 12.2 42.5 14.8 20.9 13.3 16.8 14.8 27.3 13.9 16.3 17.1 7.8 12.6 21.9 19.5 5.8 6.6 6.5 8.3 6.1 8.1 6.4 7.5 8.0 24.9 20.3 18.6 20.7 20.5 16.4 10.9 13.2 13.5 11.9 11.5 10.6 4.6 22.7 10.2 13.2 17.9 7.8 10.8 14.2 19.2 27.9 11.6 17.0 11.2 17.2 32.4 14.4 14.2 12.1 21.2 10.1 11.9 12.3 10.8 20.1 25.0 15.2 13.7 12.0 6.8 12.4 15.0 15.2 10.5 18.4 17.8 4.7 11.4 14.7 19.0 23.1 18.6 17.8 18.8 11.7 19.8 11.3 13.5 12.8 18.4 11.3 6.3 8.3 6.5 6.4 7.6 6.3 4.7 5.4 8.1 4.5 5.8 6.5 6.5 2.9 6.1 1.1 6.6 5.8 6.4 29.7 36.1 84.5 47.5 24.7 18.8 13.2 35.6 20.8 13.9 NNMT ENSG00000166741 "Nicotinamide N-methyltransferase" P40261 11 114257787-114313285 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Methyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 97.7" "Cell line enhanced" "Detected in many" "HSkMC: 67.4;LHCN-M2: 40.0;RPTEC TERT1: 103.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA059180 Approved Approved "Nucleoplasm,Golgi apparatus,Cytosol" 15000 "Golgi apparatus" "Nucleoplasm, Cytosol" "HPA059180: " "unprognostic (1.62e-1)" "unprognostic (2.33e-2)" "unprognostic (1.61e-2)" "unprognostic (6.14e-2)" "unprognostic (3.51e-1)" "prognostic unfavourable (2.07e-4)" "unprognostic (1.76e-1)" "unprognostic (5.84e-2)" "unprognostic (2.71e-2)" "unprognostic (2.48e-2)" "unprognostic (1.20e-1)" "unprognostic (1.69e-2)" "prognostic unfavourable (1.02e-6)" "prognostic unfavourable (1.75e-4)" "unprognostic (1.11e-1)" "unprognostic (3.37e-3)" "unprognostic (2.77e-2)" 23.7 1.4 0.6 8.8 0.9 0.1 14.6 0.6 1.7 13.1 8.5 0.7 4.9 0.5 15.8 8.7 12.0 8.3 15.3 8.2 1.6 0.0 4.7 97.7 10.0 3.4 1.1 0.6 11.2 2.0 0.6 2.6 8.6 3.3 9.6 3.3 1.6 3.6 6.7 18.3 8.2 4.3 12.4 1.5 5.8 5.1 7.3 0.6 1.3 5.3 2.2 3.1 10.9 35.3 0.6 0.1 0.7 0.2 0.0 0.9 0.0 0.0 4.7 0.0 4.2 24.3 31.6 0.0 6.0 15.9 9.6 19.1 0.0 6.5 0.0 21.4 12.2 0.0 0.0 2.1 9.7 0.0 0.0 0.0 7.4 0.0 33.1 0.0 0.0 67.4 23.3 6.8 10.1 13.2 0.0 0.0 40.0 0.0 0.0 0.0 0.0 0.1 0.0 26.8 0.0 103.7 0.0 0.0 0.0 30.0 0.0 0.0 0.0 0.0 9.3 5.5 22.1 8.5 1.0 0.0 0.0 0.0 1.6 0.0 0.4 0.0 0.2 0.0 0.2 0.1 0.9 0.2 0.0 0.2 0.1 0.6 0.0 0.2 0.7 0.0 0.0 0.1 0.0 0.0 0.6 0.9 0.6 1.7 1.6 0.0 1.1 0.6 3.3 0.6 NNT ENSG00000112992 "Nicotinamide nucleotide transhydrogenase" Q13423 5 43602692-43707405 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 100.0" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004829, CAB004975, HPA066564" Enhanced Approved Mitochondria 1100000 Mitochondria "CAB004975: AB_425908, HPA004829: AB_1079495, HPA066564: " "unprognostic (1.51e-1)" "unprognostic (1.07e-1)" "unprognostic (3.33e-2)" "unprognostic (4.81e-2)" "unprognostic (5.02e-2)" "unprognostic (1.81e-1)" "unprognostic (4.04e-2)" "unprognostic (1.96e-3)" "unprognostic (2.20e-2)" "unprognostic (3.98e-2)" "unprognostic (1.65e-1)" "unprognostic (8.33e-2)" "prognostic favourable (1.22e-15)" "unprognostic (8.24e-2)" "unprognostic (1.11e-1)" "unprognostic (2.76e-2)" "unprognostic (2.58e-1)" 10.8 10.5 11.7 8.3 14.0 7.3 9.1 8.3 19.0 7.6 11.2 7.3 8.8 9.2 7.1 8.8 7.9 5.4 7.1 62.1 10.8 8.2 26.0 48.5 7.2 9.6 9.2 10.3 5.8 12.2 15.6 6.2 5.8 10.0 8.5 12.1 6.7 14.4 7.8 100.0 6.0 8.9 14.7 6.1 6.5 13.6 4.2 6.1 14.0 14.0 32.6 8.7 10.9 6.2 11.4 25.5 13.1 18.5 18.2 19.1 13.5 8.3 6.1 14.2 26.4 16.5 18.4 4.4 8.3 14.2 10.3 9.3 7.1 13.7 8.5 10.4 15.8 7.9 56.2 2.0 10.9 13.5 15.1 12.3 33.0 8.6 9.6 20.6 18.3 15.8 6.3 5.9 8.4 20.3 8.8 34.1 24.4 5.6 22.1 11.1 2.8 5.5 24.8 33.5 30.5 19.5 7.3 21.0 17.4 30.6 0.4 18.9 21.4 20.7 11.1 15.1 14.6 6.3 4.0 18.4 18.9 13.1 3.1 27.4 9.7 9.3 14.2 13.1 14.4 18.4 14.8 11.4 15.6 14.5 25.5 10.3 14.6 13.3 2.4 18.2 18.5 9.2 19.1 13.5 11.7 14.0 8.3 19.0 10.8 8.2 9.2 10.3 10.0 6.1 NOD2 "BLAU, CARD15, CD, CLR16.3, IBD1, NLRC2, PSORAS1" ENSG00000167207 "Nucleotide binding oligomerization domain containing 2" Q9HC29 16 50693588-50734041 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins" "Immunity, Innate immunity" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HMC-1: 11.6;T-47d: 5.5;THP-1: 6.7;U-266/70: 15.4;U-266/84: 6.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "classical monocyte: 15.3;eosinophil: 3.9;intermediate monocyte: 9.1;myeloid DC: 15.5;neutrophil: 6.3;non-classical monocyte: 5.8" "Group enriched" "Detected in many" 6 "dendritic cells: 15.5;granulocytes: 6.3;monocytes: 15.3" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "HPA041985, HPA054494" Enhanced Approved "Golgi apparatus,Cytosol" "Golgi apparatus, Cytosol" "HPA041985: AB_2677780, HPA054494: AB_2682505" "unprognostic (1.01e-1)" "unprognostic (4.38e-1)" "unprognostic (1.07e-1)" "unprognostic (1.02e-3)" "unprognostic (9.91e-3)" "unprognostic (5.84e-2)" "unprognostic (5.90e-3)" "unprognostic (1.23e-1)" "unprognostic (4.17e-1)" "unprognostic (3.88e-2)" "unprognostic (6.94e-3)" "unprognostic (1.48e-2)" "unprognostic (2.31e-9)" "unprognostic (4.38e-2)" "unprognostic (1.08e-2)" "unprognostic (1.53e-1)" "unprognostic (1.13e-1)" 2.6 0.6 0.9 6.2 0.5 13.2 1.7 0.5 1.5 5.7 1.0 0.7 0.9 1.5 1.8 2.6 12.6 1.1 3.7 3.2 1.2 0.5 0.8 1.9 7.6 8.0 1.6 0.0 1.4 0.4 0.0 1.0 2.6 1.4 1.8 1.0 1.2 5.5 0.4 1.4 14.2 1.3 1.9 3.2 4.7 1.4 2.2 0.9 1.0 0.9 12.1 8.3 4.0 10.6 0.0 15.5 6.3 15.3 1.9 1.0 6.8 0.5 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.2 0.0 11.6 0.0 2.6 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 2.1 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.1 0.1 0.0 1.4 0.0 5.5 6.7 0.0 0.0 0.0 0.0 0.0 15.4 6.6 0.0 0.2 0.1 0.0 2.0 15.3 3.9 0.2 9.1 0.5 0.0 1.0 0.9 15.5 0.0 0.1 0.3 6.3 1.9 5.8 0.6 0.6 6.8 0.9 0.5 0.5 1.5 1.2 0.5 1.6 0.0 1.4 0.9 NOS1 "nNOS, NOS" ENSG00000089250 "Nitric oxide synthase 1" P29475 12 117208142-117452170 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 13.4;skeletal muscle: 36.3" "Cell line enhanced" "Detected in some" "HaCaT: 6.2;RH-30: 12.8;RPTEC TERT1: 8.0;U-2 OS: 2.5" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002167, HPA058312, HPA069509" Enhanced Supported "Nucleoplasm,Plasma membrane" "Plasma membrane" Nucleoplasm "CAB002167: AB_564073, HPA058312: , HPA069509: " "unprognostic (1.63e-1)" "unprognostic (3.14e-2)" "unprognostic (2.18e-2)" "unprognostic (6.64e-3)" "unprognostic (4.91e-2)" "unprognostic (2.74e-1)" "unprognostic (2.54e-1)" "unprognostic (9.12e-3)" "unprognostic (2.51e-1)" "unprognostic (1.10e-1)" "unprognostic (1.07e-1)" "unprognostic (7.56e-2)" "unprognostic (1.01e-1)" "unprognostic (3.73e-2)" "unprognostic (1.34e-1)" "unprognostic (5.97e-4)" "unprognostic (1.87e-1)" 0.5 0.6 3.8 3.5 13.4 0.7 0.6 4.4 4.8 0.7 2.0 1.1 0.0 0.5 0.6 0.7 1.3 0.8 0.5 0.5 2.8 4.4 1.9 0.5 1.4 0.6 2.4 1.6 0.5 1.9 0.4 0.8 0.4 5.9 1.6 0.9 0.6 3.8 0.6 36.3 2.2 0.6 0.8 1.2 0.5 0.5 0.9 3.0 0.0 0.6 0.0 0.5 0.9 0.6 0.9 0.6 2.1 0.5 0.8 0.5 0.0 0.0 0.4 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.3 0.0 6.2 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.2 1.4 0.0 12.8 0.1 8.0 0.0 0.3 1.3 0.0 0.0 0.0 0.1 0.0 0.1 0.1 2.5 0.0 0.0 0.1 0.0 0.1 0.3 0.1 0.0 2.1 0.5 0.5 0.5 0.4 0.4 0.7 0.4 0.3 0.2 0.9 0.5 0.5 1.9 0.8 0.5 0.6 0.3 0.0 3.8 13.4 4.4 4.8 2.8 4.4 2.4 1.6 5.9 3.0 NOS2 "HEP-NOS, iNOS, NOS, NOS2A" ENSG00000007171 "Nitric oxide synthase 2" P35228 17 27756766-27800499 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 20.8;lymphoid tissue: 15.6" "Group enriched" "Detected in some" 8 "CACO-2: 16.6;SCLC-21H: 13.6" "Cancer enhanced" "Detected in many" "colorectal cancer: 16.0" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB002014 Enhanced "CAB002014: " "unprognostic (1.95e-3)" "unprognostic (3.08e-3)" "unprognostic (4.75e-3)" "unprognostic (4.42e-3)" "unprognostic (3.49e-1)" "unprognostic (2.13e-2)" "unprognostic (5.61e-2)" "unprognostic (5.09e-2)" "unprognostic (9.91e-3)" "unprognostic (1.93e-1)" "unprognostic (2.39e-2)" "unprognostic (1.34e-1)" "unprognostic (6.04e-2)" "unprognostic (8.02e-2)" "unprognostic (3.68e-1)" "unprognostic (8.69e-2)" "unprognostic (4.03e-2)" 1.0 0.7 1.6 15.6 1.6 0.0 0.5 1.5 7.3 0.4 6.8 0.0 0.0 11.8 0.4 0.0 1.0 0.5 0.4 0.7 1.3 1.1 1.7 0.2 3.8 1.8 1.0 2.2 1.0 0.3 0.1 2.1 3.4 0.4 0.9 9.0 1.2 0.2 0.2 0.7 0.4 20.8 1.7 0.8 0.2 0.3 0.4 0.2 0.2 0.5 5.3 1.7 5.4 0.3 0.4 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.1 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 16.6 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 13.6 0.9 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.6 1.5 7.3 1.3 1.1 1.0 2.2 0.4 0.2 NOS3 "ECNOS, eNOS" ENSG00000164867 "Nitric oxide synthase 3" P29474 7 150990995-151014588 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 70.6" "Cell line enhanced" "Detected in some" "BEWO: 11.2;HUVEC TERT2: 21.5;K-562: 7.6;TIME: 39.2" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in all" 5 "basal ganglia: 32.4;cerebral cortex: 12.4;hippocampal formation: 18.8;pons and medulla: 35.3" "Low cell type specificity" "Detected in many" "Lineage enriched" "Detected in many" 5 "T-cells: 5.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB002168 Enhanced "CAB002168: AB_564072" "unprognostic (6.53e-2)" "unprognostic (3.36e-1)" "unprognostic (1.63e-2)" "unprognostic (8.46e-2)" "unprognostic (2.96e-2)" "unprognostic (1.47e-1)" "unprognostic (1.35e-1)" "unprognostic (1.36e-1)" "unprognostic (6.97e-2)" "unprognostic (2.56e-1)" "unprognostic (9.40e-2)" "unprognostic (2.36e-1)" "prognostic unfavourable (3.63e-4)" "unprognostic (1.25e-2)" "unprognostic (6.63e-2)" "unprognostic (1.05e-1)" "unprognostic (1.01e-1)" 11.4 4.5 3.1 7.5 32.4 1.9 25.6 1.8 12.4 4.6 3.2 1.7 1.0 4.0 8.3 2.5 4.7 5.0 6.6 35.2 18.8 3.4 5.5 5.4 14.0 10.3 4.7 1.7 4.5 4.1 2.7 4.8 11.5 35.3 5.2 2.5 5.2 3.0 3.2 6.0 4.9 4.0 5.4 25.9 70.6 3.6 4.5 1.6 0.0 5.9 2.1 2.4 5.1 7.3 1.1 0.5 0.7 0.4 0.5 5.3 1.2 0.2 0.0 0.6 1.9 0.0 0.0 11.2 0.0 0.0 0.0 0.0 0.1 1.0 0.2 1.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 1.0 0.1 2.9 0.3 0.2 5.0 0.0 0.1 0.0 0.0 21.5 7.6 1.8 0.0 0.0 0.1 0.2 0.8 0.0 1.4 0.0 0.8 0.0 0.1 0.2 0.2 0.1 0.7 0.0 0.1 0.6 39.2 0.1 0.4 0.1 0.0 1.2 4.0 1.0 0.0 3.5 0.0 0.3 0.3 0.2 2.5 0.4 1.5 0.8 3.9 2.2 0.5 1.1 5.3 2.1 0.7 0.5 0.4 0.5 4.4 1.2 3.1 32.4 1.8 12.4 18.8 3.4 4.7 1.7 35.3 1.6 NOXO1 "P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28" ENSG00000196408 "NADPH oxidase organizer 1" Q8NFA2 16 1978917-1984192 "FDA approved drug targets, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 7.0;intestine: 10.5;lymphoid tissue: 10.6" "Cell line enhanced" "Detected in some" "CAPAN-2: 6.6;HaCaT: 3.8;MOLT-4: 3.3;SCLC-21H: 3.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "neutrophil: 1.3" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA071540 Enhanced "HPA071540: " "unprognostic (3.74e-1)" "unprognostic (1.10e-1)" "unprognostic (1.73e-2)" 0.5 0.0 1.1 10.6 3.1 0.3 0.5 7.0 2.0 0.9 10.5 0.5 0.5 4.6 0.5 1.5 2.2 0.2 2.8 0.5 1.0 0.9 0.5 2.2 1.0 0.5 0.6 0.5 0.5 0.5 0.3 0.8 0.5 0.5 0.5 8.6 0.5 4.9 0.5 0.5 0.6 4.2 0.6 0.5 0.5 0.3 4.8 0.5 1.4 0.5 0.5 4.1 1.1 0.5 0.7 0.2 1.3 0.0 0.0 0.3 0.0 0.4 1.0 1.1 0.3 0.6 0.0 0.0 0.1 0.3 0.9 0.5 0.8 6.6 0.6 0.5 0.0 3.8 0.0 0.3 0.0 1.2 0.0 0.0 1.9 0.0 0.1 0.0 0.6 1.1 0.2 1.0 0.4 0.0 0.3 0.0 0.0 0.3 3.3 0.1 0.0 0.0 0.5 1.0 0.1 0.8 0.0 3.5 0.0 1.4 1.3 0.2 2.6 1.0 0.0 0.7 0.1 0.0 1.6 0.2 0.6 1.5 0.6 0.1 0.4 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.7 0.0 0.0 1.3 0.0 0.0 0.2 0.0 0.0 1.1 3.1 7.0 2.0 1.0 0.9 0.6 0.5 0.5 0.5 NPC1L1 SLC65A2 ENSG00000015520 "NPC1 like intracellular cholesterol transporter 1" Q9UHC9 7 44512535-44541315 "FDA approved drug targets, Predicted membrane proteins" "Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "intestine: 77.0;liver: 29.8" "Group enriched" "Detected in some" 7 "CACO-2: 6.7;Hep G2: 16.8;SCLC-21H: 14.4" "Group enriched" "Detected in many" 5 "liver cancer: 8.5;pancreatic cancer: 7.8;stomach cancer: 4.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in single" "cerebral cortex: 0.7" "Low region specificity" "Detected in all" "CAB070127, CAB070128" Enhanced "CAB070127: AB_10002744, CAB070128: AB_10000815" "unprognostic (2.96e-2)" "unprognostic (2.23e-1)" "unprognostic (7.57e-3)" "unprognostic (8.43e-2)" "unprognostic (1.62e-1)" "unprognostic (2.07e-1)" "unprognostic (9.40e-2)" "unprognostic (6.75e-2)" "unprognostic (1.44e-1)" "unprognostic (1.96e-2)" "unprognostic (4.51e-2)" "unprognostic (7.59e-2)" "unprognostic (8.08e-10)" "unprognostic (1.64e-2)" "unprognostic (2.83e-1)" "unprognostic (3.62e-2)" "unprognostic (5.83e-2)" 0.5 0.1 0.1 0.0 0.2 0.0 0.4 0.5 0.2 0.3 42.0 0.0 0.0 30.5 0.4 0.3 0.3 0.3 11.4 0.1 0.1 0.1 0.7 29.8 0.2 0.0 0.1 0.0 0.5 1.4 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.1 0.2 77.0 0.0 0.1 0.1 0.8 0.7 0.0 0.0 0.1 0.0 0.0 0.3 0.5 0.2 0.0 0.6 0.2 0.4 0.5 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.2 0.0 0.0 0.0 0.0 6.7 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 16.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.1 0.0 14.4 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 0.0 0.5 0.0 0.0 0.1 0.1 0.1 0.0 0.2 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.0 0.1 0.2 0.5 0.2 0.1 0.1 0.1 0.0 0.0 0.0 NPR1 "ANPa, ANPRA, GUCY2A, NPRA" ENSG00000169418 "Natriuretic peptide receptor 1" P16066 1 153678637-153693992 "Enzymes, FDA approved drug targets, Predicted membrane proteins" "cGMP biosynthesis" "Lyase, Receptor, Vasoactive" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 98.4" "Cell line enriched" "Detected in some" 6 "ASC diff: 59.1" "Cancer enhanced" "Detected in all" "ovarian cancer: 39.2" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 5 "olfactory region: 23.0" "Region enhanced" "Detected in many" "olfactory region: 11.1" HPA031087 Approved "Nucleoplasm,Nucleoli,Plasma membrane" Nucleoli "Nucleoplasm, Plasma membrane" "HPA031087: AB_10601975" "unprognostic (2.54e-1)" "unprognostic (3.03e-3)" "unprognostic (6.31e-2)" "prognostic unfavourable (3.97e-4)" "unprognostic (1.55e-1)" "unprognostic (6.60e-2)" "unprognostic (1.54e-2)" "unprognostic (2.03e-1)" "unprognostic (2.46e-1)" "unprognostic (3.27e-2)" "prognostic favourable (2.49e-4)" "unprognostic (1.27e-1)" "unprognostic (6.69e-2)" "unprognostic (1.16e-2)" "unprognostic (1.09e-1)" "unprognostic (4.06e-1)" "unprognostic (1.74e-2)" 41.1 4.3 0.5 5.9 0.9 0.1 98.4 0.5 0.8 8.1 8.2 0.3 7.3 1.2 16.8 11.1 8.7 25.0 9.3 19.6 0.9 0.5 28.7 3.7 34.8 8.6 0.7 0.0 19.5 4.2 7.8 4.5 11.8 2.5 4.9 1.5 2.0 2.0 9.0 6.9 3.4 4.6 15.6 2.2 1.2 5.0 6.4 0.2 0.8 7.6 5.1 1.1 11.6 26.5 0.0 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 59.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 9.8 0.0 7.1 0.0 0.0 0.1 0.0 0.1 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 5.5 0.0 0.0 0.7 0.0 0.0 0.0 0.6 0.0 2.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.9 0.5 0.8 0.9 0.5 0.7 0.0 2.5 0.2 NR1H4 "FXR, HRR-1, HRR1, RIP14" ENSG00000012504 "Nuclear receptor subfamily 1 group H member 4" Q96RI1 12 100473708-100564413 "Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters" "Immunity, Inflammatory response, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Disease mutation, FDA approved drug targets, Intrahepatic cholestasis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "liver: 109.4" "Group enriched" "Detected in some" 32 "Hep G2: 17.9;HHSteC: 10.8;RPTEC TERT1: 29.0" "Group enriched" "Detected in some" 11 "liver cancer: 18.7;renal cancer: 12.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA047699 Approved Nucleoplasm Nucleoplasm "HPA047699: AB_10965320" "unprognostic (1.78e-1)" "unprognostic (1.81e-1)" "unprognostic (6.68e-2)" "unprognostic (2.49e-1)" "unprognostic (1.60e-1)" "unprognostic (9.39e-2)" "unprognostic (2.01e-1)" "unprognostic (1.88e-2)" "unprognostic (1.16e-1)" "unprognostic (2.43e-1)" "unprognostic (3.77e-3)" 0.1 11.3 0.1 1.4 0.4 0.0 0.2 0.1 0.2 0.2 5.8 0.4 0.1 11.3 0.1 0.4 0.1 0.1 7.0 0.1 0.1 0.0 25.0 109.4 0.6 2.4 0.1 0.1 7.7 2.7 0.0 2.9 0.2 0.3 0.5 0.4 0.6 0.1 0.1 0.1 0.0 19.5 0.3 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.3 0.3 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.9 10.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.1 0.2 0.1 0.0 0.1 0.1 0.3 0.1 NR1I2 "BXR, ONR1, PAR2, PXR, SXR" ENSG00000144852 "Nuclear receptor subfamily 1 group I member 2" O75469 3 119780484-119818485 "FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "blood: 7.1;intestine: 15.4;liver: 22.2" "Cell line enriched" "Detected in some" 4 "Hep G2: 17.3" "Group enriched" "Detected in some" 24 "colorectal cancer: 9.0;liver cancer: 5.7;pancreatic cancer: 2.6;stomach cancer: 2.7" "Cell type enriched" "Detected in single" 18 "NK-cell: 7.1" "Lineage enriched" "Detected in single" 18 "NK-cells: 7.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA029309, HPA055121, HPA073926" Enhanced Nucleoplasm Nucleoplasm "HPA029309: , HPA055121: , HPA073926: " "unprognostic (6.76e-3)" "unprognostic (2.25e-1)" "unprognostic (5.84e-2)" "unprognostic (1.24e-4)" "unprognostic (4.51e-2)" "unprognostic (4.52e-2)" "unprognostic (4.03e-3)" "unprognostic (3.97e-2)" "unprognostic (5.78e-2)" "unprognostic (5.05e-2)" "unprognostic (5.21e-2)" "unprognostic (3.60e-2)" "unprognostic (5.51e-6)" "unprognostic (4.86e-1)" "unprognostic (6.95e-2)" "unprognostic (3.13e-1)" "unprognostic (6.12e-3)" 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 5.6 15.4 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.3 0.0 22.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 15.1 0.0 0.0 0.1 0.7 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 7.1 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.3 0.1 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 1.6 0.5 0.0 0.0 0.0 0.0 0.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.3 0.1 NR3C1 "GR, GRL" ENSG00000113580 "Nuclear receptor subfamily 3 group C member 1" P04150 5 143277931-143435512 "Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Apoptosis, Cell cycle, Cell division, Chromosome partition, Mitosis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Receptor, RNA-binding" "Disease mutation, FDA approved drug targets, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004248, CAB010435" Supported Supported Nucleoplasm,Mitochondria,Cytosol "Nucleoplasm, Cytosol" Mitochondria "CAB010435: AB_2155784, HPA004248: AB_1078976" "unprognostic (1.38e-1)" "unprognostic (1.93e-1)" "unprognostic (1.17e-1)" "prognostic unfavourable (3.64e-5)" "unprognostic (1.43e-2)" "unprognostic (2.74e-1)" "unprognostic (4.19e-1)" "unprognostic (1.39e-1)" "unprognostic (2.46e-2)" "unprognostic (3.87e-2)" "unprognostic (2.15e-1)" "unprognostic (6.85e-2)" "prognostic unfavourable (1.72e-6)" "unprognostic (9.06e-3)" "unprognostic (1.02e-1)" "unprognostic (2.43e-3)" "unprognostic (2.45e-2)" 27.7 8.6 13.5 26.1 14.9 29.6 23.5 30.1 19.2 14.9 14.2 17.0 10.5 13.0 14.7 12.9 18.2 13.7 14.7 17.4 13.4 14.1 13.5 27.3 22.0 16.1 18.3 12.8 15.5 12.5 21.9 18.9 31.9 13.6 14.3 10.3 14.2 12.0 15.2 40.4 18.3 14.8 16.8 17.2 17.5 13.4 7.3 18.2 37.1 18.0 15.1 18.2 14.8 32.2 11.1 13.6 33.7 11.8 10.9 9.6 7.3 10.0 20.5 1.5 0.0 13.5 15.1 1.8 15.8 18.9 13.6 15.8 1.5 13.5 8.9 7.2 23.1 9.6 0.1 12.4 16.9 5.0 7.0 2.3 27.8 4.4 12.7 9.2 7.1 10.9 16.1 22.4 21.9 5.1 3.3 34.0 12.0 3.6 5.4 6.6 4.1 4.3 1.9 14.3 18.9 4.0 0.7 2.7 2.1 27.6 4.0 6.6 1.8 13.3 12.1 33.2 6.6 15.8 11.9 6.9 6.2 14.0 17.4 9.5 11.5 25.4 9.8 17.9 9.3 11.8 7.7 7.6 9.6 8.9 13.6 11.1 9.2 8.9 33.7 10.9 10.5 12.4 5.8 7.3 13.5 14.9 30.1 19.2 13.4 14.1 18.3 12.8 13.6 18.2 NR3C2 "MLR, MR" ENSG00000151623 "Nuclear receptor subfamily 3 group C member 2" P08235 4 148078762-148444698 "Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HUVEC TERT2: 7.1;Karpas-707: 7.7;PC-3: 7.1;RPTEC TERT1: 9.6;TIME: 9.4;U-138 MG: 5.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 4.8" "Lineage enriched" "Detected in single" 6 "T-cells: 4.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009155, HPA074979" Enhanced Supported Nucleoplasm Nucleoplasm "CAB009155: AB_2155949, HPA074979: " "unprognostic (2.75e-3)" "unprognostic (2.63e-2)" "unprognostic (6.70e-3)" "unprognostic (1.52e-1)" "unprognostic (4.09e-1)" "unprognostic (7.82e-3)" "unprognostic (1.04e-2)" "unprognostic (1.11e-2)" "unprognostic (1.14e-1)" "unprognostic (4.35e-2)" "unprognostic (4.97e-2)" "unprognostic (2.39e-1)" "prognostic favourable (3.10e-11)" "unprognostic (1.42e-1)" "unprognostic (1.87e-1)" "unprognostic (1.57e-1)" "unprognostic (1.27e-1)" 7.0 5.6 9.0 12.9 9.5 1.5 7.2 16.8 14.5 8.2 23.4 8.2 6.5 9.7 7.2 4.8 3.8 7.1 10.2 9.7 12.7 6.5 13.8 9.6 8.2 4.2 7.5 7.7 17.0 8.6 22.5 16.7 2.4 5.7 5.9 28.4 12.1 16.9 9.6 12.1 4.6 26.5 8.6 6.5 5.7 9.0 4.8 6.5 2.2 21.7 7.6 5.0 10.7 5.6 0.8 0.0 0.0 0.4 0.1 4.8 0.4 0.0 0.0 0.0 0.0 0.5 0.4 0.5 0.0 0.1 0.0 0.5 0.0 0.1 1.6 3.0 1.2 0.0 1.6 0.8 0.1 0.3 2.9 0.3 0.7 0.0 0.1 1.9 0.4 0.1 0.0 0.1 0.0 7.1 0.0 7.7 2.4 0.0 0.0 0.0 0.1 7.1 0.6 0.0 0.1 9.6 0.1 0.1 0.1 0.0 1.6 0.7 0.9 0.0 9.4 5.1 3.0 0.2 0.9 0.0 0.0 0.2 1.7 0.7 1.2 0.0 0.0 0.0 1.5 0.0 4.8 0.4 1.8 1.2 0.0 0.8 2.9 2.9 0.0 0.1 0.4 0.0 0.5 0.4 9.0 9.5 16.8 14.5 12.7 6.5 7.5 7.7 5.7 6.5 NTRK1 "MTC, TRK, TRKA" ENSG00000198400 "Neurotrophic receptor tyrosine kinase 1" P04629 1 156815640-156881850 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "adrenal gland: 15.8;blood: 32.3;brain: 28.3" "Cell line enriched" "Detected in some" 4 "HMC-1: 41.1" "Cancer enhanced" "Detected in some" "glioma: 1.3" "Region enriched" "Detected in many" 5 "pons and medulla: 28.3" "Cell type enriched" "Detected in single" 127 "basophil: 32.3" "Lineage enriched" "Detected in single" 323 "granulocytes: 32.3" "Region enhanced" "Detected in some" "basal ganglia: 8.2" "Low region specificity" "Detected in all" "CAB004606, HPA035799, HPA076570" Approved Approved Vesicles,Cytosol 140000 "Vesicles, Cytosol" "CAB004606: AB_628397, HPA035799: , HPA076570: " "unprognostic (5.89e-3)" "unprognostic (7.56e-2)" "unprognostic (2.74e-2)" "unprognostic (5.99e-3)" "unprognostic (7.26e-2)" "unprognostic (1.43e-3)" "unprognostic (1.56e-1)" "unprognostic (7.42e-3)" "unprognostic (7.63e-2)" "unprognostic (1.35e-1)" "unprognostic (6.73e-2)" "unprognostic (2.29e-2)" "unprognostic (3.18e-11)" "unprognostic (2.18e-3)" "unprognostic (3.79e-2)" "unprognostic (1.07e-1)" "unprognostic (4.89e-1)" 1.0 15.8 0.5 0.8 6.0 0.9 0.4 0.0 0.7 0.9 1.1 0.1 0.0 0.8 1.6 2.0 0.7 0.6 2.1 1.5 0.0 1.2 2.9 0.2 1.9 0.3 2.1 0.6 0.3 0.3 0.3 1.1 0.5 28.3 2.2 0.2 3.1 1.2 0.5 0.7 0.2 0.4 1.1 1.2 0.2 1.0 2.4 1.5 0.4 0.3 0.0 0.4 0.7 0.8 0.0 0.0 32.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 5.6 0.0 6.6 0.0 0.0 0.0 0.0 41.1 0.0 0.0 0.0 0.0 0.0 2.1 0.7 0.0 0.0 0.0 1.1 0.0 0.6 1.2 0.0 0.1 0.0 0.0 0.7 9.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 1.6 0.2 0.0 0.0 0.0 0.0 32.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 6.0 0.0 0.6 0.0 1.2 2.1 0.6 28.3 1.5 ODC1 ODC ENSG00000115758 "Ornithine decarboxylase 1" P11926 2 10439968-10448504 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Polyamine biosynthesis" "Decarboxylase, Lyase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001536, CAB035996" Approved Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB035996: , HPA001536: AB_1079521" "unprognostic (2.33e-1)" "unprognostic (3.41e-1)" "unprognostic (7.25e-3)" "unprognostic (5.21e-3)" "unprognostic (4.22e-2)" "unprognostic (2.70e-1)" "prognostic unfavourable (3.07e-5)" "unprognostic (3.06e-2)" "unprognostic (4.18e-2)" "unprognostic (6.27e-2)" "unprognostic (3.04e-1)" "unprognostic (6.65e-2)" "unprognostic (1.67e-3)" "unprognostic (1.18e-1)" "unprognostic (1.05e-1)" "unprognostic (2.26e-2)" "unprognostic (5.86e-2)" 13.2 8.2 11.6 33.5 11.1 41.8 9.1 7.2 11.8 11.7 17.4 11.5 33.8 8.6 22.9 21.6 16.5 16.5 30.0 33.8 9.7 10.6 31.5 48.7 14.2 42.3 11.3 6.5 29.2 48.7 13.4 35.4 6.9 11.2 26.3 20.7 18.2 11.0 27.2 64.2 9.6 14.9 26.2 10.2 20.4 19.2 54.6 6.3 31.0 16.4 19.8 39.6 16.1 14.6 13.4 10.8 2.4 2.4 1.2 4.4 3.0 18.6 15.0 20.9 24.7 3.7 11.2 48.5 27.0 13.4 25.6 11.9 79.7 8.7 98.9 13.6 16.5 3.4 63.9 30.7 31.2 37.6 26.7 45.1 25.8 48.6 30.4 76.2 10.8 7.5 8.3 57.9 72.7 20.5 75.0 32.2 14.2 12.3 75.4 30.0 38.1 49.0 53.8 65.7 66.6 15.5 13.7 29.2 24.9 33.9 10.4 13.7 7.0 34.2 14.3 20.8 42.9 26.8 58.0 15.0 45.4 89.9 18.7 50.5 12.8 0.0 1.3 2.4 2.7 2.4 3.2 13.4 3.8 4.4 3.0 11.0 2.7 4.3 0.5 1.2 1.5 10.8 3.8 3.0 11.6 11.1 7.2 11.8 9.7 10.6 11.3 6.5 11.2 6.3 OGDH E1k ENSG00000105953 "Oxoglutarate dehydrogenase" Q02218 7 44606572-44709066 "Citric acid cycle related proteins, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Glycolysis Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 99.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019514, HPA020347" Supported Enhanced Mitochondria 53000 Mitochondria "HPA019514: AB_1854772, HPA020347: AB_1854773" "unprognostic (1.96e-2)" "unprognostic (1.40e-1)" "unprognostic (4.39e-1)" "unprognostic (5.64e-3)" "unprognostic (3.02e-3)" "unprognostic (1.20e-1)" "unprognostic (3.45e-1)" "unprognostic (7.58e-2)" "unprognostic (1.74e-1)" "unprognostic (1.52e-2)" "unprognostic (3.38e-1)" "unprognostic (3.30e-2)" "prognostic favourable (2.22e-14)" "unprognostic (1.53e-1)" "unprognostic (1.62e-1)" "unprognostic (2.23e-2)" "unprognostic (5.88e-3)" 18.9 20.8 12.3 14.5 18.5 8.7 11.0 14.3 23.7 10.1 19.4 15.9 13.5 29.0 16.2 11.1 19.5 11.1 11.8 73.9 11.3 12.8 28.8 14.8 13.0 11.1 14.2 11.7 9.8 13.0 25.5 11.0 14.5 22.2 12.3 13.3 22.3 23.7 15.9 99.3 15.6 35.5 16.4 10.1 12.1 14.9 11.3 11.0 11.3 17.8 39.8 15.8 13.0 10.8 7.2 13.4 7.5 20.4 11.2 25.7 11.6 10.8 22.8 13.7 20.8 21.2 23.3 13.4 17.0 16.6 19.4 16.9 20.8 22.5 47.8 20.2 24.7 33.8 27.0 25.4 18.9 27.9 7.1 14.5 46.2 10.2 10.8 17.9 16.3 21.6 19.3 27.4 19.7 26.2 16.7 14.3 20.4 15.3 17.7 10.3 12.6 25.8 17.0 9.6 53.7 22.2 32.4 23.4 11.2 24.6 34.1 10.6 20.2 18.0 20.6 14.0 12.6 24.2 19.6 13.0 24.9 26.4 25.3 20.3 25.3 4.8 12.1 7.3 11.7 17.7 12.8 7.2 13.5 11.7 13.4 5.9 5.8 7.0 7.5 11.2 20.4 6.6 25.7 11.6 12.3 18.5 14.3 23.7 11.3 12.8 14.2 11.7 22.2 11.0 OPRD1 ENSG00000116329 "Opioid receptor delta 1" P41143 1 28812142-28871267 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 8.7" "Group enriched" "Detected in some" 12 "RH-30: 14.5;SCLC-21H: 5.7;SH-SY5Y: 5.8;WM-115: 19.3" "Cancer enhanced" "Detected in single" "melanoma: 1.0" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA070831 Approved "HPA070831: " "unprognostic (1.44e-1)" "unprognostic (4.07e-1)" "unprognostic (1.25e-1)" "unprognostic (3.89e-2)" "unprognostic (2.68e-1)" "unprognostic (5.84e-3)" "unprognostic (6.28e-3)" "unprognostic (5.92e-2)" "unprognostic (1.82e-2)" "unprognostic (5.95e-3)" "unprognostic (4.28e-3)" "unprognostic (2.98e-1)" "unprognostic (1.52e-7)" "unprognostic (1.44e-2)" "unprognostic (1.28e-1)" "unprognostic (1.26e-1)" "unprognostic (2.18e-3)" 0.4 2.4 5.5 0.6 3.9 1.9 0.4 0.4 8.7 0.4 0.6 0.0 0.0 0.5 0.4 0.4 0.4 0.4 0.6 0.4 3.0 1.3 0.4 0.4 0.5 0.7 0.6 5.9 0.5 1.3 0.2 0.5 0.5 4.7 0.4 0.5 0.1 1.0 0.2 3.2 1.0 0.6 0.4 0.4 0.7 0.8 0.8 0.2 0.0 0.6 0.0 0.2 0.4 0.4 1.2 1.1 3.1 0.5 1.1 0.7 0.1 0.0 0.1 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.5 0.2 0.2 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.1 0.0 0.2 0.9 0.0 0.0 14.5 0.1 0.0 0.0 5.7 5.8 0.0 0.1 0.9 0.1 0.1 0.0 0.1 0.3 0.2 0.0 0.2 0.0 0.2 0.1 0.3 19.3 3.1 0.5 0.6 0.6 0.3 0.4 0.6 0.6 0.5 0.1 1.2 0.6 0.7 2.5 1.1 0.3 1.1 0.3 0.1 5.5 3.9 0.4 8.7 3.0 1.3 0.6 5.9 4.7 0.2 OPRK1 "KOR, OPRK" ENSG00000082556 "Opioid receptor kappa 1" P41145 8 53225716-53251697 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 18.0;prostate: 6.7" "Cell line enriched" "Detected in some" 5 "U-937: 21.6" "Cancer enhanced" "Detected in some" "prostate cancer: 1.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 1.2" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA067549 Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane" "Nucleoplasm, Cytosol" "HPA067549: " "unprognostic (1.01e-1)" "unprognostic (1.17e-2)" "unprognostic (8.70e-3)" "unprognostic (3.73e-2)" "unprognostic (6.74e-2)" "unprognostic (2.22e-3)" "unprognostic (8.09e-2)" "unprognostic (9.71e-2)" "unprognostic (4.28e-3)" "unprognostic (3.29e-1)" "unprognostic (3.35e-2)" "unprognostic (9.54e-4)" "unprognostic (1.61e-1)" 0.7 0.7 15.9 0.3 18.0 0.4 0.3 2.2 8.8 0.4 0.4 0.3 0.0 0.4 0.4 0.6 0.5 0.7 0.4 0.8 4.5 6.2 0.3 0.5 0.8 0.4 1.7 5.8 0.4 0.3 0.4 0.8 2.8 3.1 6.7 0.4 0.0 0.3 0.4 3.8 0.4 0.5 0.5 0.5 0.6 0.3 2.8 1.6 0.2 0.9 0.0 0.3 0.3 0.1 0.2 0.8 1.2 0.2 0.1 0.4 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.3 21.6 0.1 1.2 0.2 0.1 0.4 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.4 0.1 0.1 0.8 0.0 0.0 15.9 18.0 2.2 8.8 4.5 6.2 1.7 5.8 3.1 1.6 OPRM1 MOR1 ENSG00000112038 "Opioid receptor mu 1" P35372 6 154010496-154246867 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 37.9" "Cell line enriched" "Detected in single" 24 "SH-SY5Y: 12.8" "Not detected" "Not detected" "Region enhanced" "Detected in many" "cerebellum: 37.9" "Cell type enhanced" "Detected in single" "neutrophil: 2.1" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA014509, HPA067435" Enhanced Supported "HPA014509: AB_1854801, HPA067435: " "unprognostic (7.34e-2)" "unprognostic (6.91e-2)" 0.5 3.4 7.0 0.6 17.5 1.8 0.9 37.9 7.6 0.5 0.6 0.8 0.0 0.6 0.7 1.4 3.7 0.5 1.0 0.5 2.6 2.3 0.5 0.5 0.5 0.9 0.6 9.3 0.8 0.7 0.4 0.6 0.5 5.2 0.7 0.4 0.0 0.6 0.2 0.9 1.8 0.5 0.3 1.9 0.6 1.0 8.0 0.5 0.0 1.0 0.0 0.3 0.5 0.5 0.5 0.2 2.1 0.1 0.1 0.7 0.0 0.1 0.0 0.2 0.4 0.0 0.2 0.2 0.2 0.0 0.1 0.0 0.2 0.4 0.4 0.1 0.0 0.3 0.3 0.2 0.1 0.2 0.1 0.1 0.4 0.1 0.0 0.3 0.5 0.1 0.5 0.0 0.1 0.1 0.1 0.3 0.3 0.2 0.1 0.0 0.1 0.0 0.2 0.2 0.0 0.1 0.1 0.3 12.8 0.0 0.0 0.3 0.3 0.1 0.3 0.4 0.1 0.3 0.1 0.4 0.2 0.1 0.3 0.1 0.0 0.2 0.1 0.6 0.6 0.0 0.7 0.2 0.3 0.5 0.1 0.5 0.4 0.1 2.1 0.1 0.0 0.2 0.3 0.0 7.0 17.5 37.9 7.6 2.6 2.3 0.6 9.3 5.2 0.5 P2RX4 P2X4 ENSG00000135124 "Purinergic receptor P2X 4" Q99571 12 121209857-121234106 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA039494 Enhanced "HPA039494: AB_10969132" "unprognostic (4.02e-3)" "unprognostic (1.06e-1)" "unprognostic (5.43e-2)" "prognostic favourable (6.30e-10)" "unprognostic (2.98e-2)" "unprognostic (2.52e-1)" "unprognostic (2.06e-3)" "unprognostic (1.68e-1)" "unprognostic (1.21e-1)" "unprognostic (5.42e-2)" "unprognostic (7.71e-2)" "unprognostic (2.18e-1)" "unprognostic (1.81e-2)" "unprognostic (1.13e-1)" "unprognostic (6.06e-2)" "unprognostic (1.42e-2)" "unprognostic (4.76e-3)" 14.1 7.8 4.9 6.5 4.7 4.8 13.8 24.0 8.1 11.3 16.3 8.8 5.5 13.4 6.3 5.5 5.6 8.4 8.6 6.1 3.9 3.4 10.2 13.2 11.6 16.1 6.0 3.5 9.9 22.7 15.7 8.4 25.9 5.8 7.7 13.9 7.0 15.7 9.5 2.3 4.1 17.6 8.4 6.8 11.5 11.2 4.2 5.0 4.2 7.1 2.8 7.1 7.8 5.8 2.7 6.1 17.1 14.2 5.6 6.1 7.2 2.2 6.3 0.1 7.9 4.1 3.8 19.7 2.4 12.7 3.3 5.8 3.7 9.3 1.6 7.1 7.7 0.9 2.1 1.2 1.6 7.9 4.6 1.0 0.1 3.3 9.9 2.8 17.0 4.6 2.5 3.2 4.3 11.4 2.8 5.9 2.5 11.9 1.5 2.0 2.0 5.1 1.6 11.4 12.2 1.1 3.9 2.0 3.8 5.5 3.2 21.3 16.0 5.3 0.6 4.5 3.8 0.4 1.3 8.4 9.6 1.5 9.2 3.5 4.4 17.1 13.0 2.1 4.2 14.2 4.2 2.7 6.1 3.4 6.1 1.5 4.5 2.2 0.1 5.6 12.2 1.4 3.9 7.2 4.9 4.7 24.0 8.1 3.9 3.4 6.0 3.5 5.8 5.0 P2RY12 "HORK3, P2Y12, SP1999" ENSG00000169313 "Purinergic receptor P2Y12" Q9H244 3 151337380-151384812 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "Blood coagulation, Hemostasis" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 46.0" "Cell line enhanced" "Detected in some" "HSkMC: 1.7;Karpas-707: 1.1;REH: 1.9" "Cancer enriched" "Detected in many" 14 "glioma: 17.3" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 12.4" "Group enriched" "Detected in many" 13 "dendritic cells: 5.0;monocytes: 12.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013796, HPA014518" Enhanced "HPA013796: AB_1854884, HPA014518: " "unprognostic (2.39e-2)" "unprognostic (1.60e-3)" "unprognostic (5.93e-2)" "unprognostic (1.77e-1)" "unprognostic (2.41e-2)" "unprognostic (2.52e-2)" "unprognostic (8.09e-2)" "unprognostic (1.72e-3)" "unprognostic (6.46e-2)" "unprognostic (8.64e-4)" "unprognostic (4.84e-2)" "unprognostic (5.96e-2)" "unprognostic (2.03e-1)" "unprognostic (8.92e-2)" "unprognostic (1.65e-1)" "unprognostic (3.52e-2)" "unprognostic (4.04e-1)" 7.4 4.3 15.3 2.2 14.2 0.8 4.3 2.3 46.0 2.0 2.0 13.4 0.0 1.6 1.1 1.1 1.7 3.2 2.7 1.8 14.3 11.6 1.1 2.7 2.9 9.2 21.1 10.0 2.2 0.9 2.0 0.9 2.7 16.8 1.4 1.8 0.2 3.1 2.9 0.6 0.8 3.1 2.1 24.9 5.3 1.5 0.6 18.8 0.0 0.9 0.0 8.6 1.9 0.9 0.6 5.0 0.3 12.4 0.0 0.0 2.0 0.0 0.0 0.2 0.2 0.0 0.3 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.3 0.0 0.3 1.7 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.3 0.0 0.1 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.3 0.3 0.3 0.0 2.9 0.0 0.0 12.4 0.0 0.6 0.0 0.0 5.0 0.6 0.0 0.0 0.3 0.0 3.3 0.5 0.0 2.0 15.3 14.2 2.3 14.6 14.3 11.6 21.1 10.0 16.8 18.8 P2RY2 P2U ENSG00000175591 "Purinergic receptor P2Y2" P41231 11 73218298-73236352 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.1;skeletal muscle: 29.5" "Cell line enhanced" "Detected in many" "HaCaT: 16.1;HL-60: 15.2;MCF7: 12.1;NB-4: 12.4;PC-3: 12.6;SK-BR-3: 14.0;THP-1: 35.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "eosinophil: 28.1" "Group enriched" "Detected in many" 12 "granulocytes: 28.1;monocytes: 10.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" CAB022642 Uncertain Uncertain Cytosol Cytosol "CAB022642: " "unprognostic (1.24e-1)" "unprognostic (1.13e-1)" "unprognostic (6.36e-2)" "unprognostic (7.97e-3)" "unprognostic (6.50e-4)" "unprognostic (2.04e-2)" "unprognostic (4.66e-3)" "unprognostic (8.93e-2)" "unprognostic (2.87e-1)" "unprognostic (4.17e-2)" "prognostic unfavourable (2.19e-5)" "unprognostic (9.69e-2)" "unprognostic (4.92e-4)" "unprognostic (1.34e-1)" "unprognostic (2.82e-1)" "unprognostic (1.05e-1)" "unprognostic (8.57e-3)" 0.4 2.3 0.9 1.4 1.2 10.8 1.3 0.3 1.1 5.5 3.1 1.1 0.3 2.2 1.3 2.3 20.0 1.2 2.8 11.7 0.6 0.3 0.9 2.6 2.9 1.5 1.2 0.6 1.7 1.7 6.1 1.1 10.3 1.0 1.7 2.4 3.3 4.0 1.6 29.5 3.4 10.8 0.4 0.4 6.6 0.6 0.7 0.6 0.6 20.2 20.6 12.8 2.1 10.9 0.0 1.6 28.1 10.4 0.0 0.0 1.2 3.5 3.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 8.2 2.8 0.0 5.5 0.2 16.1 0.4 7.5 0.0 0.0 0.3 1.2 0.2 1.5 0.0 15.2 0.0 0.0 3.5 1.2 0.2 0.7 0.6 0.0 0.0 12.1 0.0 12.4 0.2 12.6 0.0 0.0 0.5 1.2 8.6 0.0 0.0 0.2 14.0 0.0 6.5 35.6 5.2 0.0 0.1 0.0 0.0 0.5 0.2 0.0 0.0 2.7 0.0 0.2 3.4 28.1 0.0 10.4 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.1 0.0 6.2 0.0 0.0 1.2 0.9 1.2 0.3 1.1 0.6 0.3 1.2 0.6 1.0 0.6 PAH PH ENSG00000171759 "Phenylalanine hydroxylase" P00439 12 102836885-102958410 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Phenylalanine catabolism" "Allosteric enzyme, Monooxygenase, Oxidoreductase" "Disease mutation, FDA approved drug targets, Phenylketonuria" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "kidney: 65.1;liver: 220.0" "Cell line enriched" "Detected in some" 31 "Hep G2: 71.1" "Cancer enriched" "Detected in some" 17 "liver cancer: 94.7" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Low region specificity" "Detected in some" "HPA028407, HPA031642" Enhanced Approved "Endoplasmic reticulum,Vesicles" "Endoplasmic reticulum, Vesicles" "HPA028407: AB_10601241, HPA031642: AB_2673974" "unprognostic (1.16e-1)" "unprognostic (1.52e-1)" "unprognostic (4.47e-2)" "unprognostic (9.13e-3)" "unprognostic (5.19e-2)" "unprognostic (5.99e-2)" "prognostic favourable (4.30e-4)" "unprognostic (1.27e-1)" "unprognostic (6.60e-2)" "unprognostic (4.45e-3)" "unprognostic (1.94e-3)" "unprognostic (1.83e-1)" "unprognostic (1.10e-2)" "unprognostic (3.51e-1)" "unprognostic (1.64e-1)" "unprognostic (3.96e-2)" "unprognostic (1.68e-2)" 0.1 1.3 0.5 0.0 0.5 0.0 0.1 0.2 1.0 0.0 0.1 0.6 0.0 0.0 0.0 0.1 0.0 0.1 20.3 0.1 0.8 0.3 65.1 220.0 0.0 0.0 0.3 0.7 0.1 1.7 0.0 1.6 0.0 0.8 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.8 0.1 0.0 2.8 0.4 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 71.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.2 1.0 0.8 0.3 0.3 0.7 0.8 0.4 PARP1 "ADPRT, PARP, PPOL" ENSG00000143799 "Poly(ADP-ribose) polymerase 1" P09874 1 226360691-226408079 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Transcription, Transcription regulation" "DNA-binding, Glycosyltransferase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727" Supported Supported Enhanced Nucleoplasm 39000 Nucleoplasm "CAB000147: AB_430876, CAB003839: AB_365493, CAB003840: AB_562187, CAB075726: , CAB075727: , HPA045168: " "unprognostic (2.02e-1)" "unprognostic (9.40e-2)" "unprognostic (7.44e-3)" "unprognostic (1.32e-1)" "unprognostic (4.29e-1)" "unprognostic (9.22e-2)" "prognostic unfavourable (3.40e-4)" "unprognostic (2.20e-1)" "unprognostic (3.62e-2)" "unprognostic (1.39e-1)" "unprognostic (2.13e-1)" "unprognostic (1.66e-1)" "prognostic unfavourable (1.35e-5)" "unprognostic (2.38e-2)" "unprognostic (1.82e-1)" "unprognostic (3.14e-2)" "unprognostic (2.64e-1)" 17.3 16.6 31.2 35.7 31.2 14.3 15.3 21.1 29.2 14.3 21.8 37.4 10.3 15.0 18.2 13.0 18.1 15.0 10.8 24.2 27.8 21.9 13.4 24.8 14.1 56.3 40.7 21.8 14.6 28.1 62.6 22.9 28.7 30.4 22.0 19.2 16.3 17.0 24.7 47.3 11.7 19.6 25.5 49.1 32.7 15.9 22.5 34.8 29.5 14.5 16.5 70.2 19.9 13.7 53.0 16.5 9.0 17.5 11.1 21.8 11.5 28.5 15.3 42.6 30.1 11.2 9.2 24.3 18.9 16.9 25.8 21.2 24.3 14.0 83.2 28.3 11.5 21.5 58.5 18.6 22.7 34.9 81.7 32.2 20.4 15.9 6.7 53.4 15.6 9.1 7.4 20.7 14.7 20.0 51.2 42.5 13.3 13.6 17.1 19.3 78.4 30.4 51.8 73.0 76.9 12.1 20.4 42.9 37.6 24.6 27.6 15.5 23.2 33.5 15.2 13.7 22.7 18.5 35.4 17.3 29.0 71.5 11.4 18.1 30.7 9.0 6.7 6.9 18.3 11.3 21.6 46.8 19.4 18.0 14.3 53.0 15.2 16.4 1.0 11.1 17.5 16.5 21.8 11.5 31.2 31.2 21.1 28.4 27.8 21.9 40.7 21.8 30.4 34.8 PARP2 ADPRTL2 ENSG00000129484 "Poly(ADP-ribose) polymerase 2" Q9UGN5 14 20343582-20357905 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Glycosyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA052003 Approved Supported Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "HPA052003: " "unprognostic (3.93e-1)" "unprognostic (7.92e-2)" "unprognostic (4.12e-1)" "unprognostic (1.24e-1)" "unprognostic (3.40e-2)" "unprognostic (7.30e-2)" "prognostic unfavourable (6.48e-4)" "unprognostic (1.97e-2)" "unprognostic (4.43e-2)" "unprognostic (9.35e-3)" "unprognostic (1.44e-2)" "unprognostic (1.42e-2)" "unprognostic (3.37e-3)" "unprognostic (2.83e-1)" "unprognostic (9.19e-2)" "unprognostic (1.91e-1)" "unprognostic (2.89e-2)" 11.5 16.6 23.6 8.9 28.5 20.9 15.2 36.7 31.3 12.0 11.7 16.8 9.3 11.2 18.8 16.8 10.7 14.7 8.9 14.0 19.2 17.8 14.0 15.0 12.0 11.8 16.6 30.8 20.2 11.8 11.6 14.6 11.3 22.1 11.3 12.9 10.8 10.5 12.9 25.9 15.1 10.8 14.6 13.9 11.4 11.6 20.4 17.4 6.0 11.7 13.9 15.2 9.3 10.4 6.7 5.6 1.8 5.0 6.9 12.3 4.9 20.2 14.8 22.8 17.1 7.6 7.2 16.6 22.5 12.3 28.6 35.5 13.9 19.4 15.0 10.2 7.1 19.0 30.3 10.3 33.9 12.0 14.8 13.7 17.9 23.3 6.8 28.3 7.9 5.0 8.8 17.8 19.7 14.7 14.5 20.5 19.6 12.5 14.5 12.2 12.5 23.1 18.2 31.0 9.7 11.4 10.6 15.8 10.9 25.1 14.0 6.6 12.9 9.6 10.0 17.5 26.5 12.0 18.2 19.2 24.5 19.9 7.3 12.6 19.3 1.8 5.0 0.5 9.5 4.5 12.3 6.7 8.9 8.3 5.4 4.6 9.6 9.3 0.1 6.9 2.5 5.6 5.2 4.9 23.6 28.5 36.7 31.3 19.2 17.8 16.6 30.8 22.1 17.4 PARP3 "ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3" ENSG00000041880 "Poly(ADP-ribose) polymerase family member 3" Q9Y6F1 3 51942345-51948867 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "Glycosyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020984, HPA067657" Supported Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA020984: , HPA067657: " "prognostic favourable (6.39e-5)" "unprognostic (1.25e-1)" "unprognostic (1.54e-2)" "unprognostic (2.85e-2)" "unprognostic (7.31e-2)" "unprognostic (1.56e-1)" "unprognostic (4.13e-1)" "unprognostic (3.53e-2)" "unprognostic (2.26e-1)" "unprognostic (2.01e-1)" "unprognostic (7.44e-3)" "unprognostic (4.30e-1)" "prognostic favourable (1.25e-8)" "unprognostic (5.63e-2)" "unprognostic (1.77e-1)" "unprognostic (1.40e-2)" "unprognostic (4.65e-3)" 15.2 29.2 11.2 14.6 17.1 2.8 13.6 5.7 18.8 7.5 17.3 10.6 14.3 26.9 10.3 14.1 10.8 12.1 16.2 12.4 11.6 12.3 17.3 22.3 13.3 9.7 12.0 14.2 8.2 3.9 34.2 9.8 6.2 12.2 12.1 10.7 13.2 14.0 18.1 14.6 6.1 26.3 18.9 8.7 12.8 15.8 4.5 10.2 2.9 17.0 9.6 10.3 15.1 8.9 9.0 2.9 1.7 4.1 6.6 4.9 2.3 6.0 3.3 1.0 9.0 8.7 16.5 2.5 9.8 15.9 12.2 13.7 1.9 15.9 8.2 2.6 16.2 0.9 2.5 8.9 5.9 20.0 0.6 4.2 6.7 6.3 9.5 2.5 5.8 13.1 5.5 7.7 5.2 6.1 1.7 7.7 9.3 1.5 2.2 6.3 1.3 9.6 3.5 1.5 7.0 7.4 6.6 1.0 3.4 9.9 2.8 5.3 3.4 2.8 13.7 24.5 5.1 3.6 5.9 11.8 14.3 3.5 15.8 7.4 7.6 0.0 2.6 1.7 3.6 4.1 3.4 9.0 4.2 2.8 2.9 4.3 4.9 4.9 0.1 6.6 2.0 1.2 4.3 2.3 11.2 17.1 5.7 18.8 11.6 12.3 12.0 14.2 12.2 10.2 PDE10A ENSG00000112541 "Phosphodiesterase 10A" Q9Y233 6 165327287-165986603 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Allosteric enzyme, Hydrolase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 36.8" "Cell line enhanced" "Detected in some" "LHCN-M2: 13.7;RH-30: 8.0;RT4: 8.4;SH-SY5Y: 8.4;TIME: 14.2;U-2 OS: 7.7" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in all" "basal ganglia: 36.8" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 11 "basal ganglia: 307.0" "Group enriched" "Detected in all" 4 "basal ganglia: 155.2;cerebellum: 80.7" "CAB045998, HPA047200" Supported "CAB045998: AB_2162589, HPA047200: " "unprognostic (1.02e-1)" "unprognostic (3.63e-2)" "unprognostic (3.58e-2)" "unprognostic (2.91e-1)" "unprognostic (1.20e-1)" "unprognostic (1.25e-1)" "unprognostic (1.76e-1)" "unprognostic (1.23e-1)" "unprognostic (9.36e-2)" "unprognostic (6.03e-2)" "unprognostic (3.79e-2)" "unprognostic (9.24e-2)" "prognostic unfavourable (4.44e-7)" "unprognostic (3.59e-3)" "unprognostic (2.37e-2)" "unprognostic (3.44e-2)" "unprognostic (5.90e-3)" 3.1 1.9 1.7 1.0 36.8 0.0 3.4 4.5 6.9 2.2 1.0 1.1 4.3 0.8 2.9 7.5 0.7 3.1 3.2 3.6 2.6 2.1 8.8 0.9 4.3 1.4 2.7 1.1 3.4 0.8 1.2 2.5 5.3 1.7 2.6 0.5 0.6 0.7 4.9 0.9 0.6 0.8 4.3 1.1 2.5 1.2 8.7 16.0 0.0 12.2 1.0 0.8 7.3 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 6.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.2 0.7 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 3.3 0.0 7.6 0.0 0.5 0.0 0.0 0.1 0.0 0.6 0.0 7.4 0.0 0.0 13.7 0.1 1.1 0.0 1.5 5.5 1.7 8.0 0.0 7.2 8.4 2.2 8.4 0.0 0.0 0.4 0.0 0.0 14.2 0.0 7.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 36.8 4.5 6.9 2.6 2.1 2.7 1.1 1.7 16.0 PDE11A ENSG00000128655 "Phosphodiesterase 11A" Q9HCR9 2 177623252-178072755 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Allosteric enzyme, Hydrolase" "Cushing syndrome, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "prostate: 20.8" "Cell line enhanced" "Detected in some" "CAPAN-2: 3.7;fHDF/TERT166: 5.5;HAP1: 3.1;Hep G2: 6.2" "Cancer enhanced" "Detected in some" "prostate cancer: 1.7" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" HPA034560 Approved "Intracellular and membrane" "HPA034560: AB_10602140" "unprognostic (1.02e-1)" "unprognostic (4.73e-2)" "unprognostic (1.02e-1)" "unprognostic (9.61e-3)" "unprognostic (2.34e-2)" "unprognostic (1.43e-2)" "unprognostic (1.30e-1)" "unprognostic (2.28e-2)" "unprognostic (2.23e-1)" "unprognostic (3.91e-1)" "unprognostic (9.95e-2)" "unprognostic (2.80e-2)" "unprognostic (5.06e-2)" "unprognostic (1.04e-1)" "unprognostic (1.75e-1)" "unprognostic (4.11e-4)" "unprognostic (1.64e-3)" 2.9 0.5 1.3 0.7 1.0 0.2 2.5 0.2 0.8 4.2 3.1 0.1 0.0 1.2 1.9 1.5 0.3 0.4 5.4 2.6 1.6 2.0 4.0 11.8 0.5 0.0 3.3 0.0 0.5 7.8 9.8 13.6 0.0 1.2 20.8 0.5 5.6 8.5 1.2 7.5 0.3 7.6 1.7 5.6 0.1 0.4 3.8 0.0 0.1 13.2 0.7 0.1 0.6 0.3 1.0 0.8 2.2 0.9 0.9 0.7 0.2 0.1 1.0 0.5 0.2 0.2 0.0 0.2 2.5 0.4 0.1 0.8 0.5 3.7 0.1 1.5 5.5 0.2 3.1 0.1 0.1 0.0 2.0 2.4 0.2 6.2 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.6 0.9 0.3 1.2 0.1 0.5 0.1 0.5 0.0 1.1 0.1 0.7 1.7 0.0 0.2 0.4 0.3 0.0 0.0 0.3 0.6 0.2 0.3 0.5 0.0 0.0 1.0 0.1 0.2 1.6 0.7 1.1 0.7 0.6 0.5 0.7 0.6 0.7 0.4 1.0 0.6 0.7 2.2 0.9 0.9 0.8 0.7 0.2 1.3 1.0 0.2 0.7 1.6 2.0 3.3 0.0 1.2 0.0 PDE1A ENSG00000115252 "Phosphodiesterase 1A" P54750 2 182140036-182523192 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Calmodulin-binding, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 66.0;kidney: 37.1" "Group enriched" "Detected in some" 5 "ASC diff: 22.3;HHSteC: 13.2;HSkMC: 28.2" "Cancer enhanced" "Detected in many" "thyroid cancer: 13.0" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "myeloid DC: 1.4" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in many" 6 "amygdala: 118.0;basal ganglia: 76.2;cerebral cortex: 161.5;hippocampal formation: 155.8;hypothalamus: 47.8" "Low region specificity" "Detected in many" HPA022151 Approved Approved Nucleoplasm Nucleoplasm "HPA022151: AB_1855118" "unprognostic (3.63e-1)" "unprognostic (7.21e-2)" "unprognostic (1.32e-1)" "unprognostic (8.61e-2)" "unprognostic (1.58e-1)" "unprognostic (3.02e-1)" "unprognostic (3.84e-1)" "unprognostic (3.82e-1)" "unprognostic (1.02e-1)" "unprognostic (5.38e-2)" "unprognostic (2.78e-1)" "unprognostic (2.86e-1)" "unprognostic (5.55e-3)" "unprognostic (2.50e-3)" "unprognostic (5.96e-2)" "unprognostic (1.37e-1)" "unprognostic (1.40e-3)" 7.6 3.9 13.8 3.6 11.5 0.5 4.1 66.0 25.3 11.5 8.8 6.2 1.7 2.6 7.3 6.7 4.7 7.4 18.2 11.8 12.6 4.1 37.1 3.2 3.1 1.8 7.1 15.7 9.2 2.0 1.3 2.3 1.3 6.9 3.8 5.6 3.0 1.8 4.8 2.4 2.1 4.6 11.8 10.1 2.6 4.6 24.6 9.0 0.0 35.1 2.6 1.1 8.3 9.0 0.0 1.4 0.8 0.2 0.0 0.0 0.0 0.0 0.1 2.2 0.0 22.3 1.8 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 2.7 0.0 3.1 0.0 13.2 0.0 0.0 28.2 0.0 0.0 0.0 0.0 0.0 4.3 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.2 0.0 3.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 13.8 11.5 66.0 25.3 12.6 4.1 7.1 15.7 6.9 9.0 PDE1B PDES1B ENSG00000123360 "Phosphodiesterase 1B" Q01064 12 54549350-54579239 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 52.6" "Cell line enhanced" "Detected in some" "HDLM-2: 11.3;HL-60: 6.3;HMC-1: 12.1;NB-4: 8.0;THP-1: 7.7;U-937: 6.4" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in all" "basal ganglia: 52.6" "Cell type enriched" "Detected in single" 4 "naive CD4 T-cell: 1.6" "Lineage enriched" "Detected in single" 4 "T-cells: 1.6" "Region enriched" "Detected in all" 6 "basal ganglia: 895.2" "Region enriched" "Detected in all" 7 "basal ganglia: 253.8" HPA018492 Enhanced "HPA018492: AB_1855119" "unprognostic (2.90e-1)" "unprognostic (1.51e-1)" "unprognostic (7.67e-4)" "unprognostic (5.63e-3)" "unprognostic (7.02e-2)" "unprognostic (7.51e-2)" "unprognostic (1.97e-1)" "unprognostic (9.39e-2)" "unprognostic (1.14e-1)" "unprognostic (5.11e-2)" "unprognostic (3.84e-3)" "unprognostic (2.70e-2)" "prognostic unfavourable (4.77e-6)" "unprognostic (6.64e-4)" "unprognostic (2.14e-1)" "unprognostic (3.09e-1)" "unprognostic (2.83e-2)" 12.3 1.4 9.9 4.6 52.6 5.6 2.7 3.1 19.4 2.6 3.7 1.4 0.0 1.2 3.9 2.5 1.7 2.4 2.9 1.9 3.7 3.8 1.3 1.6 2.9 1.6 3.0 9.3 12.5 0.6 11.0 0.5 0.5 5.8 1.0 1.7 0.5 1.3 2.1 0.7 1.0 2.6 4.9 1.2 4.8 2.5 1.1 7.7 0.0 2.7 0.0 1.1 2.8 1.1 0.2 0.3 0.1 0.3 0.1 1.6 0.4 0.0 0.0 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.0 0.1 0.0 0.0 1.8 0.0 0.0 11.3 0.3 4.6 0.0 0.0 0.0 6.3 12.1 0.7 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.7 8.0 3.3 0.0 2.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 7.7 0.0 0.0 0.2 0.0 0.0 0.0 0.1 2.4 0.0 6.4 1.2 0.0 0.3 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.2 1.6 0.0 0.1 0.1 0.0 0.0 0.0 0.4 9.9 52.6 3.1 19.4 3.7 3.8 3.0 9.3 5.8 7.7 PDE1C Hcam3 ENSG00000154678 "Phosphodiesterase 1C" Q14123 7 31751179-32299329 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Calmodulin-binding, Hydrolase" "Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 33.6;heart muscle: 56.2" "Cell line enhanced" "Detected in some" "BJ: 15.0;fHDF/TERT166: 48.3;U-251 MG: 26.1;WM-115: 34.5" "Cancer enhanced" "Detected in some" "glioma: 1.7" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA052375 Approved Nucleoplasm Nucleoplasm "HPA052375: " "unprognostic (1.29e-2)" "unprognostic (2.20e-5)" "unprognostic (1.68e-2)" "unprognostic (1.20e-3)" "unprognostic (2.29e-1)" "unprognostic (5.65e-2)" "unprognostic (4.06e-3)" "unprognostic (2.75e-1)" "unprognostic (6.79e-3)" "unprognostic (6.49e-2)" "unprognostic (3.88e-5)" "unprognostic (7.03e-2)" "unprognostic (3.09e-3)" "unprognostic (5.76e-2)" "unprognostic (5.80e-2)" "unprognostic (1.49e-1)" "unprognostic (1.06e-3)" 2.9 2.7 10.6 3.2 27.7 0.9 5.1 2.4 17.1 1.2 2.7 30.1 0.0 2.3 3.1 6.8 7.4 8.4 2.4 56.2 14.8 7.5 4.0 1.0 5.0 1.4 31.1 12.0 4.9 2.7 1.3 1.3 4.0 16.3 2.9 2.7 7.9 2.6 4.2 1.4 0.9 2.8 10.4 17.1 1.4 3.8 4.2 33.6 0.0 3.9 0.2 1.0 7.6 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 5.2 0.0 0.2 0.1 0.0 15.0 6.1 7.1 5.8 0.0 0.0 0.0 0.0 48.3 0.4 0.0 0.0 9.2 0.0 0.0 0.4 0.4 0.0 0.0 0.0 10.8 0.6 0.0 1.4 0.0 2.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 7.2 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 8.0 2.9 0.1 26.1 0.0 0.0 0.0 0.7 0.1 34.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.6 27.7 2.4 17.1 14.8 7.5 31.1 12.0 16.3 33.6 PDE2A ENSG00000186642 "Phosphodiesterase 2A" O00408 11 72576141-72674591 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 48.0;lymphoid tissue: 65.4" "Cell line enriched" "Detected in some" 8 "HeLa: 105.0" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in all" 4 "amygdala: 30.4;basal ganglia: 34.2;cerebral cortex: 48.0;hippocampal formation: 18.0;olfactory region: 27.0" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "B-cells: 3.7;T-cells: 9.6" "Group enriched" "Detected in many" 5 "amygdala: 111.5;basal ganglia: 166.3;cerebral cortex: 98.9;hippocampal formation: 120.9" "CAB009752, HPA031192" Enhanced Supported Cytosol Cytosol "CAB009752: AB_2268159, HPA031192: " "unprognostic (1.92e-1)" "unprognostic (1.52e-3)" "unprognostic (4.58e-2)" "unprognostic (1.49e-1)" "unprognostic (1.26e-1)" "unprognostic (2.50e-1)" "prognostic favourable (1.76e-6)" "unprognostic (3.06e-2)" "unprognostic (1.35e-1)" "unprognostic (3.01e-3)" "unprognostic (3.13e-3)" "unprognostic (1.50e-2)" "unprognostic (1.77e-2)" "unprognostic (2.85e-3)" "unprognostic (6.31e-2)" "unprognostic (7.72e-2)" "unprognostic (7.96e-4)" 27.8 18.4 30.4 3.0 34.2 2.5 25.4 1.0 48.0 8.9 7.7 3.8 1.9 3.5 9.4 4.9 10.2 11.6 12.0 11.3 18.0 6.1 7.0 10.4 5.1 3.8 3.8 27.0 3.4 2.4 4.4 3.4 6.6 6.7 4.8 5.2 3.0 2.3 6.3 6.6 4.8 4.2 10.3 2.1 65.4 4.2 2.9 7.4 0.1 7.0 3.9 2.2 8.3 11.2 3.7 1.2 0.2 1.0 0.1 9.6 1.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 2.5 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 105.0 0.1 0.2 0.0 1.6 0.0 0.2 0.5 4.3 2.3 0.1 0.1 0.0 0.0 0.0 0.0 1.5 2.9 0.0 0.0 0.2 0.0 0.0 9.4 0.5 0.0 0.0 0.4 0.0 0.0 13.4 0.0 2.0 0.7 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 0.8 0.0 9.6 1.0 5.6 3.7 5.7 5.6 1.2 2.5 3.7 3.0 0.2 0.1 0.5 0.0 2.3 1.9 30.4 34.2 1.0 48.0 18.0 6.1 3.8 27.0 6.7 7.4 PDE3A CGI-PDE ENSG00000172572 "Phosphodiesterase 3A" Q14432 12 20369245-20684381 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins" Hydrolase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 62.2" "Cell line enhanced" "Detected in some" "AF22: 7.7;HEL: 14.2;HeLa: 38.7;HUVEC TERT2: 6.9;SH-SY5Y: 14.5;U-138 MG: 11.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Region enhanced" "Detected in many" "cerebellum: 35.4" "HPA014492, HPA074258" Uncertain Approved "Plasma membrane" 23000 "Plasma membrane" "HPA014492: AB_1855120, HPA074258: " "unprognostic (2.59e-2)" "unprognostic (2.94e-2)" "unprognostic (1.25e-1)" "unprognostic (3.23e-1)" "unprognostic (2.27e-1)" "unprognostic (1.21e-1)" "unprognostic (3.50e-2)" "unprognostic (1.67e-2)" "unprognostic (8.14e-2)" "unprognostic (1.49e-1)" "unprognostic (4.25e-1)" "unprognostic (3.37e-1)" "prognostic unfavourable (1.72e-6)" "unprognostic (5.58e-2)" "unprognostic (5.94e-2)" "unprognostic (4.28e-2)" "unprognostic (2.76e-4)" 7.1 1.0 1.7 4.7 2.0 0.0 3.8 3.5 1.4 7.8 15.9 1.0 2.0 2.1 7.8 3.5 9.1 4.9 5.5 62.2 1.6 1.4 3.7 1.8 3.9 3.3 1.9 1.1 7.1 6.5 1.0 2.8 13.8 2.7 6.3 9.0 12.0 7.8 4.2 2.0 1.4 21.4 6.0 1.8 2.1 5.5 2.3 0.7 0.0 2.8 1.9 0.9 4.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 7.7 0.0 1.8 1.3 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 14.2 38.7 0.2 0.6 0.0 0.0 1.8 0.0 0.4 0.0 6.9 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.1 0.0 0.0 0.0 2.1 0.0 0.1 14.5 0.0 0.0 0.0 0.0 0.0 0.2 11.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 1.7 2.0 3.5 1.4 1.6 1.4 1.9 1.1 2.7 0.7 PDE3B HcGIP1 ENSG00000152270 "Phosphodiesterase 3B" Q13370 11 14643723-14872044 "Enzymes, FDA approved drug targets, Predicted membrane proteins" Angiogenesis Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 42.6" "Cell line enhanced" "Detected in many" "HL-60: 13.3;Karpas-707: 15.4;THP-1: 16.3;U-266/70: 17.4" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 6 "cerebellum: 19.2" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 6 "granulocytes: 5.0;T-cells: 8.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA056111 Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA056111: " "unprognostic (1.05e-1)" "unprognostic (2.86e-2)" "unprognostic (4.12e-2)" "unprognostic (2.76e-3)" "unprognostic (4.25e-1)" "unprognostic (1.84e-3)" "unprognostic (3.40e-2)" "unprognostic (3.24e-2)" "unprognostic (5.39e-2)" "unprognostic (1.20e-1)" "prognostic favourable (7.91e-4)" "unprognostic (1.77e-1)" "unprognostic (2.33e-2)" "unprognostic (1.39e-2)" "unprognostic (3.42e-1)" "unprognostic (2.47e-1)" "unprognostic (9.03e-3)" 42.6 1.0 2.3 12.6 2.2 6.7 17.0 19.2 3.0 2.9 21.8 0.9 0.8 2.2 0.9 1.4 2.6 1.0 6.9 4.7 2.2 2.1 2.4 18.2 10.2 14.1 1.6 1.6 0.9 7.3 0.3 5.1 5.5 1.5 10.7 8.1 1.9 16.5 1.3 0.8 0.9 6.3 9.7 2.1 8.7 3.0 12.5 0.8 7.8 1.2 2.3 7.1 10.5 4.5 0.3 0.4 5.0 1.2 0.1 8.7 1.8 0.0 1.5 3.3 5.4 6.6 0.0 1.3 0.4 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.1 11.1 0.1 8.1 10.0 2.3 13.3 0.0 0.5 0.0 0.0 0.3 0.0 11.7 15.4 0.0 0.1 2.6 6.5 4.5 2.4 6.4 1.5 10.0 0.0 1.1 5.1 9.5 1.3 8.6 2.9 0.0 16.3 0.0 0.0 0.8 0.0 0.0 17.4 5.3 0.4 0.1 2.3 1.0 0.0 0.7 2.9 1.4 0.7 2.9 0.3 4.2 3.2 0.4 0.2 8.7 7.5 5.0 0.1 1.2 0.1 4.2 1.8 2.3 2.2 19.2 3.0 2.2 2.1 1.6 1.6 1.5 0.8 PDE4A DPDE2 ENSG00000065989 "Phosphodiesterase 4A" P27815 19 10416773-10469631 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 38.5;testis: 31.8" "Cell line enhanced" "Detected in many" "HMC-1: 21.6;NB-4: 24.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017632, HPA043310, HPA076091" Uncertain Supported "Plasma membrane" "Plasma membrane" "CAB017632: AB_1127109, HPA043310: , HPA076091: " "unprognostic (1.29e-2)" "unprognostic (3.98e-2)" "unprognostic (8.91e-2)" "unprognostic (1.82e-1)" "unprognostic (7.00e-2)" "unprognostic (6.84e-2)" "unprognostic (1.54e-2)" "unprognostic (4.39e-2)" "unprognostic (7.91e-2)" "unprognostic (1.52e-2)" "unprognostic (6.90e-2)" "unprognostic (2.41e-1)" "unprognostic (2.27e-2)" "unprognostic (1.64e-2)" "unprognostic (2.57e-2)" "unprognostic (1.67e-1)" "unprognostic (2.15e-1)" 6.4 2.5 9.0 4.2 13.9 3.4 6.3 15.0 38.5 8.4 4.3 3.2 0.4 2.0 4.4 1.1 3.1 4.8 5.0 4.1 12.4 6.9 2.8 1.9 7.7 2.0 5.3 19.4 1.7 9.8 17.3 2.3 4.9 34.7 3.7 3.0 3.1 7.1 4.0 26.1 2.2 2.7 4.7 3.6 4.1 6.1 31.8 4.5 0.0 5.4 1.0 1.9 4.6 3.5 0.2 3.3 5.9 4.4 5.3 2.0 1.3 0.0 1.4 0.3 3.9 11.4 6.8 2.2 3.2 6.5 0.4 1.1 3.4 3.1 1.4 9.6 8.4 0.3 2.2 0.4 0.2 3.7 3.2 13.4 4.7 3.7 7.4 2.2 21.6 5.0 0.4 3.6 0.0 3.1 10.5 3.2 2.3 0.9 1.3 24.9 1.7 2.8 8.8 2.2 11.5 0.5 0.8 2.5 0.9 0.2 0.1 3.5 0.5 4.4 6.5 4.9 6.3 3.3 2.0 6.4 0.5 7.1 2.1 0.1 3.9 5.9 2.6 5.1 1.5 4.4 0.8 0.2 0.5 2.0 3.3 0.1 0.1 0.7 0.2 5.3 4.4 0.2 1.2 1.3 9.0 13.9 15.0 38.5 12.4 6.9 5.3 19.4 34.7 4.5 PDE4B DPDE4 ENSG00000184588 "Phosphodiesterase 4B" Q07343 1 65792514-66374579 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 48.2" "Cell line enhanced" "Detected in many" "AN3-CA: 23.9;HUVEC TERT2: 35.9;NTERA-2: 21.8;SK-MEL-30: 21.6;TIME: 20.0;U-266/84: 18.8" "Cancer enhanced" "Detected in all" "glioma: 18.9" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 36.6" "Group enriched" "Detected in all" 5 "B-cells: 16.1;granulocytes: 36.6;T-cells: 13.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003005 Uncertain Approved "Golgi apparatus,Cytosol" "Golgi apparatus" Cytosol "HPA003005: AB_1079587" "unprognostic (7.86e-2)" "unprognostic (3.13e-1)" "unprognostic (4.62e-2)" "unprognostic (2.90e-1)" "unprognostic (3.21e-1)" "unprognostic (3.33e-3)" "unprognostic (1.35e-1)" "unprognostic (1.15e-3)" "unprognostic (1.04e-2)" "unprognostic (6.10e-2)" "unprognostic (8.78e-2)" "unprognostic (4.24e-2)" "prognostic unfavourable (5.04e-4)" "unprognostic (2.89e-2)" "unprognostic (3.54e-1)" "unprognostic (9.04e-3)" "unprognostic (8.33e-3)" 14.9 2.9 21.5 28.4 29.0 48.2 15.0 12.7 31.9 6.4 6.6 39.2 0.7 3.9 6.7 2.1 3.9 3.5 8.1 16.1 20.7 18.8 3.7 8.7 10.0 15.9 36.3 14.2 2.0 1.7 1.7 3.4 13.1 32.2 18.3 8.6 6.6 15.9 10.3 28.2 6.2 8.5 9.5 37.4 18.5 4.2 3.2 36.9 2.3 5.5 5.5 14.7 16.1 3.9 16.1 2.6 36.6 2.8 4.4 13.3 3.7 0.0 6.8 13.5 23.9 0.7 0.7 0.0 4.4 5.2 4.2 5.5 0.0 0.0 2.0 0.1 8.2 0.0 0.1 0.0 4.1 5.8 0.0 0.1 1.9 0.0 0.5 4.8 0.0 1.4 0.2 2.1 0.1 35.9 0.0 1.3 1.8 0.1 0.0 2.8 21.8 0.3 0.9 2.4 1.3 3.3 0.0 0.1 10.4 0.0 1.1 21.6 0.1 1.7 20.0 3.3 0.8 1.8 0.7 0.6 18.8 7.3 3.4 5.0 1.4 2.7 2.8 8.4 4.4 2.4 8.4 15.4 8.3 6.2 2.4 16.1 9.4 6.5 36.6 4.4 2.1 2.6 13.3 3.7 21.5 29.0 12.7 24.6 20.7 18.8 36.3 14.2 32.2 36.9 PDE4C DPDE1 ENSG00000105650 "Phosphodiesterase 4C" Q08493 19 18208652-18248200 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "tongue: 28.6" "Cell line enhanced" "Detected in some" "BEWO: 5.9;Hep G2: 3.9;U-87 MG: 8.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" HPA048975 Approved "HPA048975: " "unprognostic (4.20e-2)" "unprognostic (4.02e-2)" "unprognostic (1.20e-1)" "unprognostic (1.27e-1)" "unprognostic (5.22e-4)" "unprognostic (1.44e-2)" "unprognostic (7.70e-2)" "unprognostic (1.15e-1)" "unprognostic (4.01e-2)" "unprognostic (5.69e-2)" "unprognostic (2.50e-3)" "unprognostic (2.21e-1)" "unprognostic (7.25e-10)" "unprognostic (2.73e-2)" "unprognostic (2.65e-1)" "unprognostic (9.21e-2)" "unprognostic (2.45e-2)" 2.0 1.3 1.8 1.5 2.8 1.0 2.0 0.8 6.1 4.1 4.4 1.5 3.1 1.5 6.4 6.8 1.3 4.2 5.6 4.2 1.6 1.9 4.1 2.0 4.1 0.5 1.7 5.1 2.0 0.8 0.3 3.5 7.0 2.8 5.8 1.3 2.5 1.3 5.4 13.4 0.6 4.1 3.4 0.7 2.3 5.2 2.6 1.1 0.4 1.2 28.6 0.7 1.8 3.3 1.3 0.6 3.5 0.7 1.0 0.7 0.2 0.1 0.3 0.2 0.3 0.1 0.3 5.9 0.1 0.0 0.2 0.3 1.2 0.2 0.2 0.6 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.2 0.4 3.9 0.2 0.2 0.5 0.7 0.1 2.5 0.0 0.0 0.9 2.0 0.1 0.4 0.2 0.3 0.1 0.2 0.2 0.3 0.4 0.1 0.2 0.2 0.8 0.3 0.5 0.0 0.5 0.3 0.0 0.4 0.2 0.7 0.1 1.3 0.6 0.2 8.8 0.2 0.3 3.4 0.7 1.0 0.6 0.4 0.5 0.5 0.5 0.4 0.2 1.3 0.5 0.7 3.5 1.0 0.4 0.6 0.3 0.2 1.8 2.8 0.8 6.1 1.6 1.9 1.7 5.1 2.8 1.1 PDE4D DPDE3 ENSG00000113448 "Phosphodiesterase 4D" Q08499 5 58969038-60522120 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 60.0" "Cell line enhanced" "Detected in many" "A549: 24.8;AN3-CA: 28.5;HeLa: 41.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "eosinophil: 28.1" "Lineage enriched" "Detected in many" 5 "granulocytes: 28.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA045895 Approved Supported "Plasma membrane,Cytosol" "Plasma membrane" Cytosol "HPA045895: AB_10960275" "unprognostic (1.14e-1)" "unprognostic (8.73e-3)" "unprognostic (4.35e-2)" "unprognostic (7.87e-2)" "unprognostic (5.97e-2)" "unprognostic (2.03e-1)" "unprognostic (8.10e-4)" "unprognostic (1.17e-1)" "unprognostic (6.59e-2)" "unprognostic (1.84e-1)" "unprognostic (2.71e-1)" "unprognostic (2.65e-1)" "prognostic favourable (4.00e-5)" "unprognostic (1.51e-1)" "unprognostic (8.20e-2)" "unprognostic (1.77e-2)" "unprognostic (2.56e-2)" 8.2 1.9 4.4 6.8 8.6 46.2 5.3 4.2 13.0 13.5 18.6 1.4 14.7 4.1 17.1 14.0 10.3 6.6 12.7 15.5 4.5 5.8 12.8 3.4 11.1 3.7 5.2 6.6 5.3 2.9 7.0 9.0 11.8 2.7 18.2 11.2 8.6 24.4 16.5 60.0 5.1 7.5 35.8 5.0 3.8 10.2 2.6 2.8 4.4 6.2 11.3 9.5 20.0 11.2 6.1 0.7 28.1 1.1 0.1 0.8 0.5 0.0 24.8 5.2 28.5 0.9 1.8 4.1 0.6 0.7 1.4 2.0 9.7 0.8 1.9 0.1 0.2 4.2 0.0 1.1 2.4 1.1 2.8 3.6 41.0 2.1 3.8 1.7 0.2 3.8 0.9 3.9 0.7 2.9 0.0 0.6 2.4 1.7 1.3 4.0 0.9 1.3 0.4 6.5 4.1 6.5 9.3 0.9 3.3 6.5 11.0 5.6 0.8 3.7 3.4 0.3 0.1 4.9 1.3 1.4 0.0 0.2 4.2 6.8 1.1 2.0 1.1 28.1 0.8 0.0 0.8 6.1 0.7 0.3 0.7 6.1 0.5 0.4 1.5 0.1 0.1 0.0 0.4 0.5 4.4 8.6 4.2 13.0 4.5 5.8 5.2 6.6 2.7 2.8 PDE5A ENSG00000138735 "Phosphodiesterase 5A" O76074 4 119494395-119628991 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Allosteric enzyme, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ hTERT+: 24.3;HHSteC: 35.0" "Cancer enhanced" "Detected in all" "thyroid cancer: 27.3" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA004729, HPA012873" Approved Approved "Centriolar satellite,Cytosol" 3100000 Cytosol "Centriolar satellite" "HPA004729: AB_1079588, HPA012873: AB_1855124" "unprognostic (6.95e-2)" "prognostic favourable (5.20e-4)" "unprognostic (1.28e-1)" "unprognostic (1.56e-1)" "unprognostic (1.25e-1)" "unprognostic (3.66e-2)" "unprognostic (7.36e-2)" "unprognostic (2.58e-2)" "unprognostic (2.29e-2)" "unprognostic (6.97e-2)" "unprognostic (2.05e-2)" "unprognostic (2.54e-1)" "unprognostic (2.16e-2)" "unprognostic (1.52e-2)" "unprognostic (8.98e-2)" "unprognostic (8.71e-3)" "prognostic unfavourable (1.17e-4)" 12.3 4.9 2.0 28.2 2.3 0.4 8.1 3.0 2.3 21.3 28.0 1.7 20.1 6.5 17.3 21.4 30.7 10.7 13.3 5.3 2.0 2.8 3.8 1.2 11.4 4.1 2.4 3.4 10.0 7.8 5.1 3.4 8.9 4.4 31.8 11.7 20.2 8.5 23.7 6.8 4.2 15.6 45.6 2.0 2.1 9.1 7.6 1.2 0.9 9.1 8.1 2.2 25.9 15.9 1.5 0.5 1.4 0.4 0.6 2.1 4.2 8.0 0.4 5.7 0.6 1.9 2.9 1.0 5.4 24.3 0.2 0.5 0.5 0.7 0.8 0.2 6.7 2.9 1.8 0.8 0.7 0.2 3.7 9.0 1.4 0.4 35.0 1.9 0.9 3.2 1.7 0.6 0.0 0.7 1.0 1.5 0.8 0.4 2.4 0.3 1.2 1.4 0.3 2.9 2.1 2.1 2.4 2.2 4.5 6.3 7.9 0.6 1.4 1.0 1.2 3.2 2.8 1.7 0.7 2.1 1.0 0.7 3.1 0.5 0.4 0.0 0.3 0.0 0.6 0.1 2.1 1.5 1.3 0.4 0.2 1.0 0.6 0.9 1.4 0.6 0.4 0.5 0.4 4.2 2.0 2.3 3.0 2.3 2.0 2.8 2.4 3.4 4.4 1.2 PDE6A "PDEA, RP43" ENSG00000132915 "Phosphodiesterase 6A" P16499 5 149857955-149944793 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Sensory transduction, Vision" Hydrolase "Disease mutation, FDA approved drug targets, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "retina: 153.4" "Cell line enriched" "Detected in some" 4 "CACO-2: 7.4" "Not detected" "Not detected" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "HPA016970, HPA074677" Enhanced "HPA016970: AB_1855125, HPA074677: AB_2732264" "unprognostic (6.85e-2)" "unprognostic (8.84e-2)" "unprognostic (1.70e-2)" "unprognostic (4.11e-2)" "unprognostic (1.12e-2)" "unprognostic (5.72e-2)" "unprognostic (4.39e-3)" "unprognostic (8.83e-2)" "unprognostic (6.54e-2)" "unprognostic (5.91e-3)" "unprognostic (1.77e-2)" "unprognostic (9.21e-2)" "unprognostic (7.57e-5)" "unprognostic (9.93e-2)" "unprognostic (3.08e-1)" "unprognostic (1.31e-1)" "unprognostic (2.26e-2)" 0.2 2.3 0.2 0.2 0.2 0.9 0.2 0.3 0.2 0.2 1.8 0.2 0.3 0.2 0.2 20.1 2.4 0.1 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 4.6 0.2 0.2 0.2 1.0 153.4 1.4 0.2 0.2 1.6 0.2 0.2 0.2 0.2 0.1 3.1 0.2 0.2 0.4 0.3 0.5 0.2 0.2 1.5 0.8 3.3 0.8 1.2 0.8 0.1 0.4 0.7 0.6 0.5 0.3 0.3 0.6 0.3 0.1 0.4 0.1 7.4 0.8 0.9 1.3 0.2 0.7 0.2 0.4 0.5 0.6 0.3 1.0 1.1 0.6 0.2 0.7 0.6 0.3 1.1 0.9 0.6 0.2 0.3 1.4 1.4 0.3 0.4 0.9 0.5 0.5 0.3 0.8 0.7 0.5 0.9 0.8 1.1 0.0 0.7 0.2 1.0 0.5 1.4 0.8 1.6 0.8 0.5 0.6 0.3 0.5 0.8 0.8 0.6 3.3 0.8 0.5 0.6 0.4 0.5 0.7 0.6 0.5 0.2 1.5 0.7 0.8 2.8 1.2 0.5 0.8 0.4 0.1 0.2 0.2 0.3 0.2 0.2 0.0 0.2 0.2 0.2 0.2 PDE6B "CSNB3, CSNBAD2, PDEB, rd1, RP40" ENSG00000133256 "Phosphodiesterase 6B" P35913 4 625584-670782 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Sensory transduction, Vision" Hydrolase "Congenital stationary night blindness, Disease mutation, FDA approved drug targets, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 30.2;retina: 64.2" "Cell line enhanced" "Detected in some" "EFO-21: 8.0;MOLT-4: 20.5;REH: 11.1;SCLC-21H: 14.0;SH-SY5Y: 8.2;U-266/84: 15.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "HPA054148, HPA059929" Enhanced Approved Cytosol Cytosol "HPA054148: , HPA059929: " "unprognostic (2.43e-2)" "unprognostic (1.33e-4)" "unprognostic (2.45e-4)" "unprognostic (7.18e-3)" "unprognostic (1.88e-2)" "unprognostic (5.04e-3)" "unprognostic (7.32e-3)" "prognostic favourable (5.34e-4)" "unprognostic (9.70e-2)" "unprognostic (1.14e-1)" "unprognostic (1.37e-2)" "unprognostic (2.33e-2)" "unprognostic (4.09e-2)" "unprognostic (1.67e-2)" "unprognostic (2.26e-1)" "unprognostic (2.41e-3)" "unprognostic (1.85e-1)" 1.6 1.9 12.1 4.6 19.1 6.7 3.8 2.3 13.2 2.3 1.3 30.2 1.5 0.8 2.5 3.9 1.4 9.6 3.2 5.2 18.1 10.2 4.6 0.7 4.2 12.0 29.6 9.8 2.6 1.4 9.1 3.2 2.6 14.5 2.5 1.0 64.2 3.5 2.9 0.7 1.8 2.2 2.1 20.2 8.7 2.5 3.6 22.4 4.3 11.4 0.2 8.3 4.1 1.1 16.5 14.1 11.2 5.8 10.2 13.1 7.1 0.0 0.2 0.8 0.4 0.2 0.3 0.2 0.0 0.0 0.5 1.4 0.0 0.1 0.2 8.0 0.2 0.1 1.7 0.4 0.0 0.1 0.0 0.6 0.2 0.0 4.1 0.1 0.3 0.5 0.1 2.4 0.0 0.7 0.1 0.6 0.0 0.2 20.5 0.2 6.5 0.2 11.1 0.2 0.4 1.4 0.9 14.0 8.2 0.0 0.3 0.1 0.4 0.0 0.2 0.1 0.8 0.1 0.3 5.4 15.2 0.2 0.2 0.2 0.1 11.2 4.2 0.6 11.5 5.8 10.5 10.0 7.7 7.9 6.6 16.5 12.2 13.1 1.1 10.2 5.6 14.1 11.4 7.1 12.1 19.1 2.3 10.0 18.1 10.2 29.6 9.8 14.5 22.4 PDE7A HCP1 ENSG00000205268 "Phosphodiesterase 7A" Q13946 8 65717510-65842322 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 87.5;skeletal muscle: 48.3" "Cell line enhanced" "Detected in many" "Karpas-707: 32.1;MOLT-4: 53.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018770, HPA027340" Approved "CAB018770: AB_677329, HPA027340: AB_1855127" "unprognostic (2.76e-1)" "unprognostic (2.94e-2)" "unprognostic (1.36e-1)" "unprognostic (1.17e-2)" "unprognostic (2.15e-1)" "unprognostic (7.11e-2)" "prognostic unfavourable (5.64e-4)" "unprognostic (1.44e-2)" "unprognostic (6.94e-2)" "unprognostic (1.54e-1)" "unprognostic (1.76e-2)" "unprognostic (1.56e-1)" "prognostic unfavourable (1.35e-4)" "unprognostic (3.08e-2)" "unprognostic (1.26e-1)" "unprognostic (5.06e-2)" "unprognostic (2.03e-2)" 6.9 1.4 4.4 22.7 4.6 12.3 10.0 7.3 4.3 7.1 4.1 5.8 5.9 5.6 3.6 8.2 3.6 3.8 6.1 21.0 4.3 3.6 13.4 2.7 10.1 27.7 4.3 2.7 3.4 9.2 1.4 7.5 4.0 4.6 7.3 5.0 3.3 11.7 12.6 48.3 4.3 13.6 4.0 3.4 16.3 6.2 4.8 5.5 87.5 13.0 25.4 22.4 5.4 4.7 7.7 2.2 5.3 0.7 2.1 12.6 1.8 4.0 3.6 15.9 7.4 2.3 2.0 6.7 3.0 2.6 3.9 3.7 4.4 2.7 11.4 0.7 1.9 4.5 5.8 6.4 4.1 13.4 3.0 8.3 5.7 3.1 1.1 6.6 3.3 2.9 10.8 2.5 7.6 3.8 6.1 32.1 2.6 2.3 53.5 8.2 16.9 1.6 20.0 2.4 2.9 2.6 8.1 7.9 9.0 3.2 1.6 1.6 8.7 17.1 2.4 5.4 6.7 3.8 2.4 15.7 6.7 19.8 5.5 13.9 2.9 0.2 0.7 5.3 3.7 0.6 6.0 6.7 5.7 3.7 1.5 7.7 12.6 9.6 2.6 2.1 0.1 2.2 4.5 1.8 4.4 4.6 7.3 4.3 4.3 3.6 4.3 2.7 4.6 5.5 PDE7B ENSG00000171408 "Phosphodiesterase 7B" Q9NP56 6 135851696-136195574 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 7.1;ASC TERT1: 8.5;EFO-21: 13.1;HeLa: 7.6;HSkMC: 18.3;HUVEC TERT2: 8.5;U-2197: 9.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive B-cell: 4.3" "Low lineage specificity" "Detected in many" "Region enriched" "Detected in all" 5 "basal ganglia: 112.3" "Low region specificity" "Detected in all" HPA023967 Uncertain Approved Nucleoplasm Nucleoplasm "HPA023967: AB_1855128" "unprognostic (3.18e-1)" "unprognostic (3.47e-1)" "unprognostic (2.34e-1)" "unprognostic (1.79e-3)" "unprognostic (3.34e-1)" "unprognostic (3.22e-4)" "unprognostic (1.37e-2)" "unprognostic (3.00e-1)" "unprognostic (2.80e-1)" "unprognostic (6.73e-3)" "unprognostic (1.11e-2)" "unprognostic (7.85e-2)" "prognostic favourable (1.59e-4)" "unprognostic (3.14e-3)" "unprognostic (2.68e-2)" "unprognostic (1.43e-1)" "unprognostic (3.34e-2)" 5.8 4.3 7.3 4.0 21.9 0.8 3.6 1.6 12.8 6.2 4.0 2.3 25.2 3.6 14.2 4.9 2.8 4.2 6.1 7.9 5.1 7.4 9.6 6.4 3.3 2.8 6.4 4.2 22.7 1.6 3.7 8.7 2.2 5.9 6.8 5.0 5.4 5.0 28.5 7.2 1.5 3.7 13.5 5.3 2.3 5.2 2.9 7.1 7.7 8.3 6.1 1.9 10.6 5.1 4.3 2.6 0.6 0.9 0.7 1.8 0.3 0.0 4.4 0.1 0.0 7.1 8.5 0.0 0.4 2.3 1.7 0.9 0.0 0.0 0.0 13.1 2.8 0.0 0.0 0.0 0.6 0.0 0.1 0.0 7.6 0.0 3.1 0.1 0.0 18.3 0.0 3.4 0.0 8.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 3.0 0.5 3.1 2.9 0.1 0.1 0.0 1.5 0.0 1.8 0.0 9.1 0.0 0.1 0.0 0.0 0.5 0.0 0.7 0.2 0.9 0.6 0.2 0.2 0.1 1.5 0.4 0.2 2.6 4.3 1.8 1.0 0.3 0.7 0.1 0.2 0.2 0.3 7.3 21.9 1.6 12.8 5.1 7.4 6.4 4.2 5.9 7.1 PDE8A HsT19550 ENSG00000073417 "Phosphodiesterase 8A" O60658 15 84980440-85139145 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RT4: 39.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" HPA007722 Approved Approved "Golgi apparatus" "Golgi apparatus" "HPA007722: AB_1855130" "unprognostic (1.68e-1)" "unprognostic (2.83e-2)" "unprognostic (4.81e-2)" "unprognostic (4.97e-2)" "unprognostic (6.25e-2)" "unprognostic (3.47e-2)" "unprognostic (2.97e-2)" "unprognostic (3.94e-2)" "unprognostic (1.03e-1)" "unprognostic (2.45e-1)" "unprognostic (8.99e-3)" "unprognostic (2.75e-2)" "unprognostic (3.42e-1)" "unprognostic (3.72e-1)" "unprognostic (4.26e-1)" "unprognostic (1.31e-1)" "unprognostic (1.94e-2)" 14.3 16.6 14.0 8.5 18.7 2.6 9.8 2.6 14.8 11.4 21.0 35.5 9.1 13.2 9.0 8.2 5.9 8.8 14.3 7.8 17.2 9.8 21.7 26.2 10.5 5.4 23.3 12.1 12.0 12.7 17.6 7.1 10.1 20.1 6.9 19.8 12.6 8.2 9.2 5.6 6.2 11.7 10.7 17.6 6.7 10.8 10.6 25.5 2.2 11.2 4.8 5.0 11.9 10.6 1.3 1.7 1.7 4.5 0.6 3.2 0.6 12.6 21.1 3.6 2.4 15.2 8.1 4.3 8.4 9.5 7.6 8.8 4.7 7.5 2.5 6.7 11.4 9.0 15.3 6.7 10.2 4.6 9.1 3.4 13.7 6.8 11.0 1.9 5.1 8.1 4.1 8.9 8.5 9.7 6.7 8.3 6.8 10.6 1.1 1.9 1.7 3.9 1.5 2.9 3.5 6.0 39.5 8.4 6.4 8.4 9.2 24.6 3.0 3.8 7.6 17.8 6.2 6.3 13.8 4.0 7.1 2.7 12.1 7.9 5.0 0.0 2.4 1.7 1.1 2.2 2.1 0.8 1.8 1.9 1.7 1.3 2.2 0.9 0.2 0.6 4.5 0.0 3.2 0.6 14.0 18.7 2.6 14.8 17.2 9.8 23.3 12.1 20.1 25.5 PDE8B ENSG00000113231 "Phosphodiesterase 8B" O95263 5 77210449-77429807 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "Cushing syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "thyroid gland: 67.7" "Group enriched" "Detected in some" 4 "BJ hTERT+: 12.1;HeLa: 27.8;SK-BR-3: 7.4" "Cancer enriched" "Detected in many" 6 "thyroid cancer: 35.7" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "HPA036911, HPA036912" Supported Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA036911: , HPA036912: AB_10670377" "unprognostic (1.30e-1)" "unprognostic (7.95e-2)" "unprognostic (3.35e-2)" "unprognostic (7.61e-4)" "unprognostic (1.59e-2)" "unprognostic (1.41e-1)" "unprognostic (2.66e-2)" "unprognostic (4.48e-2)" "unprognostic (1.71e-1)" "unprognostic (3.26e-2)" "unprognostic (3.98e-2)" "unprognostic (2.44e-1)" "unprognostic (9.04e-3)" "unprognostic (3.40e-2)" "unprognostic (3.76e-2)" "unprognostic (1.98e-1)" "unprognostic (3.19e-2)" 6.8 2.5 9.9 0.7 14.2 0.4 3.8 1.1 16.3 6.3 1.2 2.3 0.3 1.2 11.3 3.2 1.1 10.1 2.1 7.9 8.2 9.2 3.1 1.2 2.2 0.7 5.4 8.3 1.9 4.2 0.3 3.8 13.1 8.6 10.5 0.8 2.0 5.3 7.1 0.4 0.7 1.3 10.3 2.3 0.4 1.5 1.5 5.7 0.3 67.7 0.3 0.7 0.8 1.4 0.2 0.8 1.4 2.3 0.4 0.4 0.1 0.3 3.3 1.3 0.3 1.2 0.0 0.5 1.1 12.1 0.2 0.1 1.3 0.2 0.5 0.2 0.1 0.9 0.1 0.0 0.2 0.2 1.0 0.7 27.8 0.3 0.0 0.5 0.5 0.5 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.2 0.6 0.7 0.8 0.1 0.8 1.4 0.7 0.0 0.3 3.7 1.0 1.6 7.4 0.8 1.6 1.1 0.6 0.4 0.2 0.2 0.6 0.9 0.5 0.6 1.6 0.7 0.4 0.0 0.3 1.4 0.3 2.2 0.1 0.2 0.2 0.3 0.8 0.2 0.4 0.0 0.3 0.4 2.3 0.5 0.1 0.1 9.9 14.2 1.1 16.3 8.2 9.2 5.4 8.3 8.6 5.7 PDE9A ENSG00000160191 "Phosphodiesterase 9A" O76083 21 42653636-42775509 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 16.1;EFO-21: 16.2;MCF7: 12.0;NB-4: 17.9;NTERA-2: 22.1;SCLC-21H: 12.3" "Cancer enhanced" "Detected in all" "prostate cancer: 31.5" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 6.8" "Group enriched" "Detected in many" 4 "NK-cells: 1.7;T-cells: 6.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA011380 Enhanced Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "HPA011380: AB_1855132" "unprognostic (5.75e-2)" "unprognostic (9.92e-3)" "unprognostic (3.50e-1)" "unprognostic (1.08e-1)" "unprognostic (1.44e-1)" "unprognostic (1.40e-1)" "unprognostic (5.06e-2)" "unprognostic (3.99e-2)" "unprognostic (6.02e-2)" "unprognostic (1.60e-1)" "unprognostic (1.25e-2)" "unprognostic (5.01e-2)" "unprognostic (1.90e-2)" "unprognostic (4.01e-3)" "unprognostic (1.97e-1)" "unprognostic (6.55e-2)" "unprognostic (1.79e-1)" 6.1 6.6 9.9 6.8 15.2 0.8 9.4 13.7 9.0 3.7 37.1 11.9 14.0 3.0 5.7 18.8 6.1 10.3 7.7 3.5 6.2 7.7 13.2 2.5 4.7 4.6 10.0 4.9 4.1 4.0 4.7 6.0 9.6 6.9 33.2 15.8 9.7 8.8 15.9 2.3 3.8 26.1 22.3 8.0 15.9 8.4 1.5 8.9 4.9 5.2 2.1 4.1 12.6 4.0 0.5 0.9 1.0 0.1 1.7 6.8 0.5 0.0 1.5 16.1 1.9 0.0 0.6 0.3 0.0 0.0 0.0 0.0 1.7 9.7 0.0 16.2 0.0 0.0 1.4 5.2 0.0 0.0 5.5 0.0 0.0 3.2 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 12.0 0.8 17.9 22.1 0.0 0.0 0.0 0.6 11.0 4.4 12.3 7.3 2.7 0.0 0.2 0.1 9.9 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.1 0.0 0.0 0.0 0.8 0.1 0.0 0.0 2.1 0.6 0.2 0.5 6.8 1.7 1.0 1.7 0.1 0.9 2.2 0.5 9.9 15.2 13.7 6.7 6.2 7.7 10.0 4.9 6.9 8.9 PDGFRA "CD140a, GAS9, PDGFR2" ENSG00000134853 "Platelet derived growth factor receptor alpha" P16234 4 54229097-54298247 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Chemotaxis, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 81.5" "Cell line enhanced" "Detected in some" "ASC diff: 81.0;ASC TERT1: 37.9;BJ hTERT+: 47.0;fHDF/TERT166: 32.7;HHSteC: 27.4;HSkMC: 68.9" "Cancer enhanced" "Detected in all" "glioma: 30.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004947, CAB018143" Supported Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Intracellular and membrane" 150000 "Nucleoplasm, Plasma membrane, Cell Junctions" "CAB018143: AB_2162351, HPA004947: " "unprognostic (1.67e-1)" "unprognostic (9.35e-2)" "unprognostic (4.59e-3)" "unprognostic (1.60e-1)" "unprognostic (8.92e-2)" "prognostic favourable (9.33e-4)" "unprognostic (1.24e-1)" "unprognostic (2.00e-2)" "unprognostic (1.46e-1)" "unprognostic (2.18e-2)" "unprognostic (2.18e-1)" "unprognostic (7.01e-2)" "prognostic unfavourable (9.79e-6)" "unprognostic (9.58e-3)" "unprognostic (9.87e-2)" "unprognostic (2.16e-2)" "unprognostic (1.72e-3)" 35.0 12.4 12.6 16.1 7.6 0.9 17.2 2.4 20.1 33.2 19.1 9.2 6.4 9.6 27.6 14.6 21.9 22.5 16.2 15.3 8.9 7.4 22.8 8.4 24.1 26.9 9.2 4.0 81.5 6.8 1.6 2.1 25.1 7.2 18.6 15.2 19.2 8.5 8.3 11.9 7.0 17.4 19.7 8.8 51.6 13.6 19.0 9.3 0.5 11.3 12.8 4.3 35.9 24.6 0.9 0.4 2.5 0.4 0.3 0.8 0.3 0.0 0.0 0.2 0.1 81.0 37.9 0.1 4.2 47.0 0.0 0.1 11.2 0.0 0.1 0.1 32.7 0.1 3.2 0.0 0.0 0.4 0.1 0.1 0.1 0.2 27.4 0.0 0.0 68.9 0.0 5.3 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.6 0.1 0.1 0.0 0.0 0.0 0.3 0.1 6.6 0.0 0.1 0.0 0.1 0.0 0.1 14.8 0.5 16.2 0.0 0.0 0.0 0.1 0.4 0.0 0.3 2.5 0.4 0.2 0.5 0.2 0.2 0.6 0.8 0.4 0.0 0.9 0.7 0.4 2.3 0.3 0.3 0.4 0.2 0.3 12.6 7.6 2.4 7.3 8.9 7.4 9.2 4.0 7.2 9.3 PDGFRB "CD140b, JTK12, PDGFR, PDGFR1" ENSG00000113721 "Platelet derived growth factor receptor beta" P09619 5 150113837-150155872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Chemotaxis "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 4 "ASC diff: 169.0;ASC TERT1: 58.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.9;non-classical monocyte: 4.1" "Group enriched" "Detected in many" 8 "monocytes: 4.1;T-cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003842, CAB018144, HPA028499" Enhanced Supported "Golgi apparatus,Vesicles" 35000000 Vesicles "Golgi apparatus" "CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018" "unprognostic (4.75e-2)" "unprognostic (2.48e-1)" "unprognostic (5.21e-2)" "unprognostic (3.60e-2)" "unprognostic (3.27e-1)" "unprognostic (5.61e-2)" "unprognostic (1.02e-1)" "unprognostic (3.36e-2)" "unprognostic (2.12e-2)" "unprognostic (2.57e-3)" "unprognostic (6.72e-2)" "unprognostic (1.25e-1)" "prognostic unfavourable (5.87e-8)" "unprognostic (3.13e-3)" "unprognostic (1.25e-2)" "unprognostic (5.47e-2)" "prognostic unfavourable (8.11e-4)" 61.8 10.4 8.3 11.0 9.1 0.5 66.1 4.6 10.4 73.1 15.7 6.7 6.9 5.1 44.3 17.3 21.7 26.1 51.7 24.2 8.2 3.9 17.0 4.6 28.9 21.5 7.9 8.1 46.5 7.5 10.4 7.7 46.4 7.7 24.2 6.3 22.9 11.2 19.3 29.8 20.3 11.2 29.8 5.0 19.6 9.2 21.5 6.7 1.4 21.4 16.0 7.3 23.6 35.1 0.4 0.1 0.0 4.1 0.0 2.9 0.6 0.0 0.0 1.0 0.0 169.0 58.5 0.3 5.9 24.5 4.1 7.0 0.6 0.0 0.0 0.7 16.9 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.3 0.4 24.0 0.0 0.0 26.3 0.0 5.7 0.0 0.0 0.0 0.6 0.6 0.0 0.0 0.0 1.1 0.0 0.4 0.3 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 6.7 2.2 2.8 0.3 0.0 0.0 0.0 4.1 0.0 0.1 0.0 0.0 0.0 2.9 0.6 0.0 0.4 0.1 0.8 0.1 0.1 0.0 1.3 0.0 0.0 4.1 0.0 0.0 0.6 8.3 9.1 4.6 10.4 8.2 3.9 7.9 8.1 7.7 6.7 PDK1 ENSG00000152256 "Pyruvate dehydrogenase kinase 1" Q15118 2 172555373-172608669 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Carbohydrate metabolism, Glucose metabolism" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-266/70: 31.3;U-87 MG: 32.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in all" 5 "B-cells: 5.9;granulocytes: 16.0;T-cells: 15.8" "Low region specificity" "Detected in all" "CAB017554, HPA027376, HPA059083" Approved Approved Nucleoli,Mitochondria 22000 "Nucleoli, Mitochondria" "CAB017554: AB_2161138, HPA027376: AB_1855139, HPA059083: " "unprognostic (2.14e-1)" "prognostic unfavourable (7.30e-5)" "unprognostic (1.21e-1)" "unprognostic (3.94e-2)" "unprognostic (6.47e-2)" "unprognostic (1.58e-1)" "unprognostic (1.02e-2)" "unprognostic (1.45e-1)" "unprognostic (9.69e-3)" "unprognostic (6.44e-2)" "unprognostic (5.44e-3)" "unprognostic (1.55e-1)" "prognostic unfavourable (1.10e-8)" "unprognostic (1.82e-1)" "unprognostic (1.94e-1)" "unprognostic (2.56e-2)" "unprognostic (5.34e-2)" 9.9 16.2 6.8 11.0 10.5 13.4 16.7 7.1 15.6 7.3 15.3 3.3 2.9 15.5 5.4 8.0 11.2 4.4 5.8 27.6 6.9 5.2 6.8 14.2 6.1 21.4 7.2 5.2 19.5 7.2 3.4 7.5 7.9 7.2 6.5 13.1 7.6 14.1 7.6 9.6 24.7 8.4 5.2 10.7 14.2 12.5 11.0 6.7 10.3 5.1 5.0 20.8 18.0 9.8 5.9 2.3 16.0 2.2 1.4 15.8 6.2 14.1 0.6 3.7 9.1 1.5 2.3 5.2 12.5 10.1 6.3 13.4 3.6 3.0 13.5 6.9 3.8 6.2 2.5 7.8 20.1 2.7 5.0 16.4 3.3 4.2 2.7 8.1 6.1 2.9 2.8 4.3 7.3 3.3 3.4 9.3 8.3 1.4 5.1 10.2 8.9 3.9 5.4 6.0 21.7 3.2 4.6 6.9 7.9 3.2 3.8 4.7 2.4 3.4 3.8 10.0 3.2 5.2 3.3 31.3 18.1 11.1 32.0 5.9 2.0 12.2 2.2 16.0 2.5 1.5 3.0 4.7 4.2 2.8 2.3 5.9 15.8 9.6 8.5 1.4 1.9 0.4 8.0 6.2 6.8 10.5 7.1 15.6 6.9 5.2 7.2 5.2 7.2 6.7 PDXK "C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79" ENSG00000160209 "Pyridoxal kinase" O00764 21 43719094-43762307 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 68.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030196, HPA030197, HPA030198, CAB033918" Enhanced Enhanced Nucleoplasm 870000 Nucleoplasm "CAB033918: AB_2162502, HPA030196: AB_10599735, HPA030197: AB_10601792, HPA030198: AB_10603570" "unprognostic (1.01e-1)" "unprognostic (1.99e-1)" "unprognostic (5.88e-2)" "unprognostic (1.87e-1)" "unprognostic (8.29e-2)" "unprognostic (4.31e-3)" "unprognostic (3.64e-3)" "unprognostic (1.32e-1)" "unprognostic (8.66e-2)" "unprognostic (9.34e-2)" "unprognostic (2.10e-1)" "unprognostic (3.54e-1)" "unprognostic (3.70e-2)" "unprognostic (1.31e-3)" "unprognostic (1.10e-1)" "unprognostic (4.78e-2)" "unprognostic (1.51e-3)" 28.1 13.2 37.4 8.7 36.6 13.3 13.3 21.9 38.5 9.7 13.8 11.0 15.7 16.7 9.0 13.2 11.0 12.9 8.8 11.4 26.1 30.4 22.8 17.4 20.4 9.5 24.1 22.7 16.4 17.6 25.7 20.7 12.6 20.3 10.6 11.8 7.8 18.3 13.9 5.8 14.3 22.1 8.8 10.1 7.8 15.2 68.9 10.7 3.9 13.6 7.0 11.0 9.7 8.6 2.7 2.5 1.3 7.7 1.9 3.3 2.4 17.2 21.2 3.4 6.4 8.3 11.8 4.1 6.2 9.8 6.1 5.1 17.2 27.1 5.8 6.7 8.9 13.1 6.5 17.8 4.0 6.5 5.6 5.9 23.2 12.7 16.4 5.5 8.7 16.7 17.0 6.4 7.1 2.8 10.3 13.5 5.7 11.7 0.8 10.1 9.2 8.1 6.6 2.0 16.2 26.3 21.2 3.3 3.9 25.9 24.0 9.2 7.9 7.8 5.1 4.4 8.7 5.9 5.8 8.2 3.8 3.4 18.3 16.1 4.3 1.3 4.8 0.2 1.7 4.4 3.3 1.4 1.7 1.9 2.5 2.7 2.0 1.4 1.3 1.9 7.7 1.2 1.5 2.4 37.4 36.6 21.9 38.5 26.1 30.4 24.1 22.7 20.3 10.7 PGR "NR3C3, PR" ENSG00000082175 "Progesterone receptor" P06401 11 101029624-101130524 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "cervix, uterine: 50.7;endometrium 1: 116.4;smooth muscle: 31.2" "Cell line enriched" "Detected in single" 349 "T-47d: 60.8" "Group enriched" "Detected in some" 13 "breast cancer: 10.1;endometrial cancer: 11.1" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000068, HPA004751, HPA008428, HPA017176, CAB055100" Enhanced "CAB000068: AB_442124, CAB055100: AB_2532076, HPA004751: AB_1079681, HPA008428: AB_1079680, HPA017176: AB_1855728" "unprognostic (2.59e-2)" "unprognostic (9.80e-3)" "unprognostic (5.23e-3)" "prognostic favourable (5.76e-8)" "unprognostic (2.81e-2)" "unprognostic (1.56e-1)" "unprognostic (4.11e-1)" "unprognostic (1.64e-1)" "unprognostic (2.08e-1)" "unprognostic (2.50e-1)" "unprognostic (3.29e-2)" "unprognostic (1.77e-1)" "unprognostic (7.71e-3)" "unprognostic (1.90e-2)" "unprognostic (2.35e-2)" "unprognostic (1.15e-1)" "unprognostic (5.44e-3)" 0.8 0.7 0.2 0.3 0.6 0.0 5.0 0.2 0.7 50.7 1.3 0.2 0.4 0.0 116.4 6.1 0.5 13.2 0.4 2.0 0.5 0.6 0.4 0.1 1.2 0.3 0.4 0.1 10.6 0.8 0.0 2.8 1.8 0.8 3.8 0.1 0.7 3.5 5.5 0.3 0.3 1.2 31.2 0.9 0.5 0.4 1.5 0.3 0.1 0.3 0.8 0.2 1.1 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 60.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.6 0.2 0.7 0.5 0.6 0.4 0.1 0.8 0.3 PIK3CA PI3K ENSG00000121879 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha" P42336 3 179148114-179240093 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Angiogenesis, Phagocytosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009985, CAB017804" Approved Approved Cytosol Cytosol "CAB017804: , HPA009985: AB_1079610" "unprognostic (1.81e-1)" "unprognostic (2.77e-1)" "unprognostic (2.18e-1)" "unprognostic (2.69e-3)" "unprognostic (6.49e-3)" "unprognostic (1.43e-1)" "unprognostic (2.65e-2)" "unprognostic (1.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.37e-1)" "unprognostic (2.57e-3)" "unprognostic (5.21e-2)" "unprognostic (4.50e-2)" "unprognostic (1.16e-2)" "unprognostic (2.48e-1)" "unprognostic (9.74e-2)" "unprognostic (3.82e-2)" 20.1 12.3 13.7 11.5 13.4 25.7 22.4 17.1 24.5 12.9 14.0 5.2 5.7 6.5 15.3 7.9 11.6 11.1 13.2 14.2 18.4 9.7 11.7 10.8 13.2 13.8 9.8 15.7 15.4 9.2 24.7 11.6 16.5 16.3 10.7 8.9 7.2 10.9 10.9 15.2 12.0 10.5 12.8 14.4 16.2 10.6 9.3 9.8 29.6 11.0 7.3 13.9 15.1 15.7 6.2 2.6 7.8 3.8 2.4 5.0 1.1 14.4 4.9 7.9 7.3 18.7 21.8 5.7 9.2 12.5 9.1 14.4 4.2 10.7 13.2 15.8 11.0 5.9 6.4 8.0 13.2 22.0 5.7 18.1 5.3 3.7 8.9 10.1 10.3 13.7 8.5 10.0 11.5 13.0 9.0 14.7 13.0 5.7 7.7 9.1 6.2 6.7 11.8 8.0 15.8 7.2 8.8 4.4 7.6 10.0 8.9 12.0 14.9 8.7 13.8 8.6 5.6 13.5 9.2 7.1 10.1 23.7 7.7 7.6 5.0 2.1 3.8 1.6 5.0 2.9 3.9 5.8 4.2 2.8 2.2 6.2 4.6 3.8 7.8 2.4 3.0 2.6 4.1 1.1 13.7 13.4 17.1 24.5 18.4 9.7 9.8 15.7 16.3 9.8 PIK3CD p110D ENSG00000171608 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta" O00329 1 9651732-9729114 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Adaptive immunity, Chemotaxis, Differentiation, Immunity, Inflammatory response, Innate immunity" "Kinase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 35.0;bone marrow: 32.8;lymphoid tissue: 40.3" "Cell line enhanced" "Detected in many" "HDLM-2: 50.5;NB-4: 21.8;REH: 22.7;THP-1: 22.0;U-937: 26.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015420, HPA044953" Enhanced Approved "Vesicles,Cytokinetic bridge" Vesicles "Cytokinetic bridge" "CAB015420: AB_831654, HPA044953: " "unprognostic (5.73e-3)" "unprognostic (2.75e-3)" "unprognostic (8.93e-2)" "unprognostic (4.05e-2)" "unprognostic (4.71e-2)" "unprognostic (1.40e-2)" "unprognostic (2.13e-1)" "unprognostic (7.42e-2)" "unprognostic (2.78e-2)" "unprognostic (1.54e-2)" "unprognostic (3.46e-2)" "unprognostic (6.75e-2)" "unprognostic (8.65e-3)" "unprognostic (2.09e-1)" "unprognostic (1.34e-1)" "unprognostic (2.04e-1)" "unprognostic (6.78e-2)" 4.5 2.1 3.4 34.8 7.1 32.8 2.9 3.3 4.3 3.2 3.3 5.5 0.7 3.1 3.7 3.4 3.5 4.0 6.5 2.9 4.2 3.1 4.6 3.3 8.2 40.3 7.4 1.8 5.3 2.2 2.3 2.2 3.3 4.6 3.2 2.1 3.1 11.2 1.8 0.9 2.0 11.4 2.9 5.3 35.5 3.3 3.0 5.7 23.5 4.1 2.3 36.0 5.8 3.6 8.4 14.5 35.0 15.0 14.5 13.7 16.6 2.6 1.7 0.1 0.5 0.4 0.4 0.2 4.1 8.4 9.0 7.4 0.1 1.1 7.1 1.7 3.3 0.8 0.7 3.7 5.7 50.5 0.1 0.8 0.4 3.0 1.8 18.4 6.4 1.5 1.5 10.1 3.4 1.3 2.6 0.0 5.1 0.2 1.7 21.8 0.7 0.5 22.7 4.5 0.2 3.8 0.0 0.5 0.5 0.9 1.7 4.0 0.2 22.0 3.3 2.7 2.8 0.0 3.8 1.6 1.6 10.0 5.8 26.3 1.5 9.6 11.8 21.1 12.9 13.1 13.7 7.8 9.8 11.8 12.5 8.4 12.9 13.4 35.0 14.5 15.0 14.5 7.4 16.6 3.4 7.1 3.3 4.3 4.2 3.1 7.4 1.8 4.6 5.7 PLA2G1B "PLA2, PLA2A, PPLA2" ENSG00000170890 "Phospholipase A2 group IB" P04054 12 120322111-120327789 "Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Lipid degradation, Lipid metabolism" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 933 "pancreas: 2360.6" "Cell line enhanced" "Detected in some" "EFO-21: 2.2;Hep G2: 6.3;U-2 OS: 4.6" "Cancer enriched" "Detected in many" 185 "pancreatic cancer: 763.5" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.5" "Group enriched" "Detected in many" 19 "NK-cells: 1.3;T-cells: 2.5" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA047822, HPA060803" Enhanced "Secreted to digestive system" 3900000 "HPA047822: , HPA060803: " "unprognostic (1.28e-4)" "unprognostic (6.02e-2)" "unprognostic (1.84e-2)" "unprognostic (2.86e-2)" "unprognostic (2.74e-2)" "unprognostic (2.41e-1)" "unprognostic (1.05e-1)" "unprognostic (1.13e-1)" "unprognostic (2.63e-2)" "unprognostic (3.61e-2)" "unprognostic (1.27e-1)" "unprognostic (1.03e-1)" "unprognostic (2.80e-4)" "unprognostic (2.15e-1)" "unprognostic (1.97e-1)" "unprognostic (3.60e-1)" "unprognostic (8.61e-4)" 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.1 1.1 0.1 0.1 0.1 1.1 2360.6 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 1.3 2.5 0.9 0.2 0.0 1.2 0.2 0.0 0.0 0.0 0.0 0.0 0.3 1.6 0.0 0.0 0.0 2.2 0.0 0.0 0.3 0.0 0.0 1.4 0.0 0.0 0.0 6.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.7 0.4 0.0 0.0 0.5 0.0 0.3 1.3 0.3 1.6 0.0 0.0 0.2 0.0 0.6 0.0 1.0 0.2 4.6 0.6 0.6 0.0 1.1 0.4 0.0 0.6 0.0 0.0 0.0 0.0 0.9 0.0 1.7 0.0 0.0 0.3 0.0 0.0 2.5 0.9 0.0 1.3 0.0 0.0 0.0 0.9 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 PLA2G2A "PLA2B, PLA2L" ENSG00000188257 "Phospholipase A2 group IIA" P14555 1 19975431-19980416 "Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins" "Lipid degradation, Lipid metabolism" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 377.9" "Group enriched" "Detected in some" 14 "Hep G2: 34.2;RT4: 31.4" "Cancer enhanced" "Detected in all" "prostate cancer: 875.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA015236 Enhanced "Secreted to blood" 1000000 290000 "HPA015236: AB_10601047" "unprognostic (2.33e-2)" "unprognostic (1.28e-1)" "unprognostic (2.79e-2)" "unprognostic (7.85e-3)" "unprognostic (8.71e-2)" "unprognostic (9.27e-2)" "unprognostic (2.02e-1)" "unprognostic (1.80e-1)" "prognostic favourable (1.49e-4)" "unprognostic (1.68e-1)" "unprognostic (1.06e-1)" "unprognostic (1.58e-2)" "unprognostic (3.77e-15)" "unprognostic (2.72e-2)" "unprognostic (9.14e-2)" "unprognostic (1.24e-1)" "unprognostic (1.51e-1)" 25.2 1.0 0.0 13.1 0.0 0.6 14.0 0.0 0.6 1.4 63.9 0.0 0.1 35.0 0.7 22.7 31.5 11.7 2.4 105.4 0.0 0.0 1.6 377.9 3.0 6.5 0.0 0.0 35.6 2.4 0.6 0.5 15.5 0.0 27.1 68.2 6.1 9.5 1.0 30.6 5.0 99.0 39.7 0.0 0.6 4.0 9.8 0.0 0.0 16.0 8.9 19.3 39.0 72.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 34.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 31.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PLA2G4A "cPLA2-alpha, PLA2G4" ENSG00000116711 "Phospholipase A2 group IVA" P47712 1 186828953-186988981 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Lipid degradation, Lipid metabolism" Hydrolase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ductus deferens: 52.6;parathyroid gland: 63.5;seminal vesicle: 56.1" "Cell line enhanced" "Detected in many" "A549: 16.7;HeLa: 24.3;RPMI-8226: 30.2;U-2197: 28.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "classical monocyte: 7.1;eosinophil: 7.7;intermediate monocyte: 8.4;myeloid DC: 7.8;non-classical monocyte: 3.9;plasmacytoid DC: 3.2" "Group enriched" "Detected in many" 7 "dendritic cells: 7.8;granulocytes: 7.7;monocytes: 8.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB010050, HPA050062, HPA054206" Approved Supported Cytosol 78000 Cytosol "CAB010050: AB_631312, HPA050062: , HPA054206: " "prognostic favourable (9.07e-4)" "unprognostic (1.18e-1)" "unprognostic (2.03e-1)" "prognostic favourable (2.85e-4)" "unprognostic (5.55e-2)" "unprognostic (1.51e-3)" "unprognostic (2.67e-2)" "unprognostic (2.43e-1)" "unprognostic (2.63e-1)" "unprognostic (7.14e-3)" "unprognostic (1.50e-1)" "unprognostic (1.68e-1)" "unprognostic (2.96e-2)" "unprognostic (8.07e-2)" "unprognostic (1.58e-1)" "unprognostic (1.90e-2)" "unprognostic (4.26e-2)" 6.0 8.6 3.4 3.5 5.3 2.2 3.8 1.5 4.7 8.5 10.9 2.9 52.6 5.4 7.7 7.4 7.0 12.3 4.2 6.6 3.3 2.5 6.7 1.1 4.9 5.2 6.5 1.4 5.1 3.8 63.5 2.7 2.9 5.6 10.9 4.2 2.9 5.8 56.1 0.6 6.1 10.3 14.6 7.5 4.2 5.1 2.7 5.3 0.4 2.7 5.9 2.3 19.4 9.4 0.0 7.8 7.7 8.4 1.1 0.2 1.5 0.0 16.7 0.0 0.0 10.5 4.2 0.0 0.6 6.4 0.8 1.4 0.1 6.6 0.0 0.0 0.0 1.2 10.4 3.1 0.3 5.1 0.2 3.1 24.3 0.0 6.5 4.5 1.6 2.3 2.2 8.4 1.7 7.0 6.8 2.5 0.0 0.0 0.0 0.0 0.9 2.2 0.0 0.0 30.2 0.0 2.3 0.1 0.0 2.5 0.8 2.9 0.3 6.2 1.4 6.2 0.8 28.5 1.3 1.0 0.0 0.0 2.3 13.6 8.8 0.1 7.1 7.7 0.0 8.4 0.2 0.0 0.0 0.0 7.8 0.0 0.0 0.0 0.6 1.1 3.9 3.2 0.0 1.5 3.4 5.3 1.5 4.7 3.3 2.5 6.5 1.4 5.6 5.3 PLA2G6 "iPLA2, iPLA2beta, NBIA2, PARK14, PNPLA9" ENSG00000184381 "Phospholipase A2 group VI" O60733 22 38111495-38205690 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Chemotaxis, Lipid degradation, Lipid metabolism" "Calmodulin-binding, Hydrolase" "Disease mutation, Dystonia, FDA approved drug targets, Neurodegeneration, Parkinson disease, Parkinsonism" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 31.4;HMC-1: 20.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001171 Approved Approved "Centriolar satellite,Cytosol" "Centriolar satellite, Cytosol" "HPA001171: AB_1079145" "unprognostic (5.26e-2)" "prognostic favourable (7.29e-4)" "unprognostic (8.74e-2)" "unprognostic (6.27e-2)" "unprognostic (3.83e-1)" "unprognostic (3.70e-3)" "unprognostic (8.67e-3)" "unprognostic (9.55e-2)" "unprognostic (3.48e-1)" "unprognostic (1.91e-1)" "unprognostic (2.37e-3)" "unprognostic (4.95e-2)" "unprognostic (1.94e-3)" "unprognostic (1.01e-1)" "unprognostic (3.00e-1)" "unprognostic (1.48e-1)" "prognostic favourable (1.55e-4)" 16.2 17.7 15.6 8.5 20.5 13.1 15.6 15.9 26.3 14.8 7.9 36.9 18.5 9.8 16.3 20.5 8.7 21.6 25.3 6.3 19.7 7.2 18.1 8.6 9.0 12.4 19.3 16.7 21.3 12.8 24.2 12.7 6.8 19.5 17.6 6.3 12.9 20.2 17.4 7.4 18.1 8.7 7.8 14.9 12.1 9.5 30.0 23.2 16.3 45.7 4.1 11.3 12.1 11.2 1.8 5.4 4.1 0.9 8.8 5.7 1.9 0.7 2.8 3.0 7.7 10.0 4.9 8.1 0.9 0.9 0.8 1.1 3.1 1.8 5.8 6.6 2.3 3.6 3.4 1.9 1.0 8.9 13.1 31.4 3.8 3.5 2.8 3.5 20.1 16.1 4.3 2.8 4.4 1.0 5.1 10.6 1.5 4.6 6.5 2.1 2.5 1.8 4.8 1.1 4.5 2.9 6.9 5.7 2.4 1.3 3.1 7.1 3.2 2.5 1.2 2.6 4.4 1.1 0.5 17.4 3.1 3.1 3.7 4.0 1.5 4.1 0.9 0.4 3.8 0.3 1.9 1.8 3.1 5.7 1.5 1.5 1.4 3.9 3.3 8.8 0.6 5.4 3.7 1.9 15.6 20.5 15.9 26.3 19.7 7.2 19.3 16.7 19.5 23.2 PLAT ENSG00000104368 "Plasminogen activator, tissue type" P00750 8 42175233-42207724 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Plasminogen activation" "Hydrolase, Protease, Serine protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 132.2" "Cell line enhanced" "Detected in many" "CAPAN-2: 85.8;HMC-1: 55.1;LHCN-M2: 55.6;U-2197: 58.0;WM-115: 115.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 2.1;T-reg: 2.3" "Group enriched" "Detected in many" 7 "granulocytes: 1.6;T-cells: 2.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003412, CAB009335" Supported Approved "Actin filaments" "Secreted to blood" 9900000 12000 "Actin filaments" "CAB009335: AB_2237146, HPA003412: AB_1858205" "prognostic favourable (7.57e-4)" "unprognostic (2.23e-1)" "unprognostic (4.08e-1)" "unprognostic (3.39e-1)" "unprognostic (4.88e-3)" "unprognostic (9.39e-2)" "unprognostic (4.65e-3)" "unprognostic (5.78e-2)" "unprognostic (1.55e-1)" "unprognostic (1.75e-1)" "unprognostic (2.98e-3)" "unprognostic (2.46e-1)" "prognostic unfavourable (4.95e-4)" "unprognostic (8.72e-3)" "unprognostic (1.37e-2)" "unprognostic (2.63e-2)" "unprognostic (6.09e-2)" 19.3 14.9 5.2 12.9 6.8 0.4 13.3 2.2 6.2 24.5 17.1 9.1 19.0 11.2 35.5 28.1 18.1 19.1 18.5 7.3 6.0 5.9 67.6 2.8 15.9 1.9 8.2 3.6 18.4 5.8 132.2 5.1 15.5 9.4 27.4 12.2 39.4 6.1 12.7 5.8 2.0 31.7 23.0 7.0 1.0 14.6 12.2 3.8 0.6 11.2 14.7 7.4 47.9 13.7 0.3 0.1 1.6 0.0 0.0 2.3 0.3 0.5 0.2 4.2 1.0 7.7 10.5 0.1 18.0 32.0 7.7 6.6 0.2 85.8 0.0 0.6 2.3 1.4 0.0 4.0 15.9 7.8 1.4 0.1 0.1 0.1 37.9 0.0 55.1 10.5 0.0 18.8 0.7 14.4 0.5 0.1 55.6 0.0 0.0 0.0 5.6 7.6 0.0 15.6 0.0 2.5 0.0 0.0 0.9 0.0 0.1 24.5 0.1 0.0 27.5 1.5 5.7 58.0 1.8 0.0 0.1 0.0 1.2 0.0 115.3 1.6 0.0 0.0 0.3 0.0 1.0 0.3 2.1 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 2.3 0.3 5.2 6.8 2.2 6.2 6.0 5.9 8.2 3.6 9.4 3.8 PLCL1 "PLC-L, PLCE, PLCL, PPP1R127, PRIP" ENSG00000115896 "Phospholipase C like 1 (inactive)" Q15111 2 197804702-198572581 "FDA approved drug targets, Predicted intracellular proteins" Transducer "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 34.9" "Cell line enhanced" "Detected in some" "HUVEC TERT2: 8.6;K-562: 14.4;Karpas-707: 10.9;MOLT-4: 10.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 4.1" "Lineage enriched" "Detected in single" 6 "T-cells: 4.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031849 Enhanced "HPA031849: AB_10602192" "unprognostic (7.77e-3)" "unprognostic (2.57e-1)" "unprognostic (2.09e-1)" "unprognostic (5.18e-3)" "unprognostic (4.40e-2)" "unprognostic (7.14e-2)" "unprognostic (2.05e-1)" "unprognostic (4.42e-3)" "unprognostic (1.07e-1)" "unprognostic (1.32e-1)" "unprognostic (3.02e-2)" "unprognostic (7.42e-2)" "prognostic favourable (3.91e-7)" "unprognostic (1.07e-4)" "unprognostic (6.74e-2)" "unprognostic (1.68e-1)" "unprognostic (3.20e-2)" 4.4 5.2 11.1 3.3 26.0 2.2 4.4 3.4 16.3 5.3 4.5 21.2 3.4 1.3 15.4 3.9 4.3 4.1 3.7 32.8 14.9 10.9 32.8 1.3 3.9 4.4 34.9 8.8 8.1 2.2 20.7 3.0 8.4 19.9 11.8 2.1 4.8 2.9 8.2 28.4 1.8 2.5 6.7 23.0 2.5 3.1 2.3 26.9 22.1 4.0 3.2 3.2 5.3 2.9 0.0 0.1 0.6 0.1 0.0 4.1 0.2 0.0 0.0 0.1 0.0 1.7 0.4 0.0 0.4 0.2 0.1 0.1 0.0 0.1 0.0 0.1 2.0 0.0 0.0 0.0 0.0 0.3 0.8 0.0 1.5 0.0 0.2 0.2 1.9 4.2 0.0 0.0 0.0 8.6 14.4 10.9 0.1 0.4 10.0 0.0 0.1 0.0 0.0 0.0 4.4 0.2 0.0 1.7 0.9 1.8 0.0 2.5 0.3 0.0 0.7 0.2 0.0 0.0 0.1 3.9 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.0 2.5 0.0 1.8 0.0 0.1 0.0 1.3 0.4 0.6 0.0 0.1 0.0 4.1 0.2 11.1 26.0 3.4 16.3 14.9 10.9 34.9 8.8 19.9 26.9 PLG ENSG00000122194 Plasminogen P00747 6 160702238-160753315 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Fibrinolysis, Hemostasis, Tissue remodeling" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 11 "liver: 269.9" "Cell line enhanced" "Detected in some" "HL-60: 3.5;RH-30: 3.9;U-698: 2.0;U-937: 1.6" "Cancer enriched" "Detected in some" 84 "liver cancer: 180.7" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000668, CAB016678, HPA021602, HPA048823" Supported "Secreted to blood" 140000000000 41000000000 "CAB000668: , CAB016678: AB_1621208, HPA021602: AB_1855453, HPA048823: " "unprognostic (1.70e-1)" "unprognostic (2.16e-3)" "unprognostic (2.44e-1)" "unprognostic (8.54e-3)" "unprognostic (1.41e-1)" "unprognostic (1.76e-3)" "unprognostic (6.28e-2)" "unprognostic (7.25e-2)" "prognostic favourable (4.22e-4)" "unprognostic (3.97e-3)" "unprognostic (5.21e-2)" "unprognostic (2.33e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.0 269.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.5 0.0 3.5 0.6 0.0 0.0 0.0 0.0 0.0 0.9 0.4 0.0 0.0 0.3 0.2 0.8 0.0 0.4 3.9 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 1.0 0.0 2.0 0.0 1.6 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PNLIP PL ENSG00000175535 "Pancreatic lipase" P16233 10 116545931-116567855 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Lipid degradation, Lipid metabolism" Hydrolase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 1895 "pancreas: 3207.8" "Cell line enhanced" "Detected in some" "EFO-21: 3.0;HDLM-2: 2.7;U-2 OS: 4.5;U-251 MG: 1.0;U-266/84: 1.5" "Cancer enriched" "Detected in some" 4854 "pancreatic cancer: 2731.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Region enhanced" "Detected in single" "cerebral cortex: 0.4" "HPA062430, HPA062494" Enhanced "Secreted to digestive system" 13000000 "HPA062430: AB_2684761, HPA062494: AB_2684782" "unprognostic (2.05e-2)" "unprognostic (4.46e-2)" 0.2 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.1 0.1 0.0 0.1 0.4 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 1.6 3207.8 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.4 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.5 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.1 0.0 0.0 2.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.0 1.0 0.0 1.5 0.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 PNP "NP, PUNP" ENSG00000198805 "Purine nucleoside phosphorylase" P00491 14 20468954-20477094 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Glycosyltransferase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "epididymis: 153.1" "Cell line enhanced" "Detected in many" "HL-60: 81.4;U-937: 92.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001625 Enhanced Supported Cytosol 100000000 Cytosol "HPA001625: AB_1854577" "unprognostic (1.20e-3)" "unprognostic (2.68e-2)" "unprognostic (1.04e-2)" "unprognostic (1.70e-1)" "unprognostic (3.10e-1)" "unprognostic (7.06e-2)" "prognostic unfavourable (4.43e-4)" "unprognostic (4.94e-3)" "unprognostic (3.87e-2)" "unprognostic (7.45e-2)" "unprognostic (1.85e-2)" "unprognostic (2.21e-1)" "prognostic favourable (2.24e-4)" "unprognostic (1.69e-1)" "unprognostic (7.54e-2)" "unprognostic (2.46e-1)" "unprognostic (1.64e-3)" 24.7 7.6 9.5 15.0 14.0 69.4 15.7 13.9 11.8 9.5 19.1 6.2 25.2 29.4 5.9 153.1 34.0 7.8 15.7 12.1 11.5 8.4 49.7 24.2 18.3 13.2 13.5 3.4 3.6 11.0 8.7 8.4 45.3 17.7 6.0 16.1 3.8 9.2 7.9 3.3 10.6 32.0 9.8 16.3 18.0 17.0 4.5 12.5 7.0 7.1 21.7 19.1 7.5 14.7 13.1 20.7 4.1 12.4 15.7 33.7 12.1 13.2 17.9 3.8 8.6 4.3 3.5 11.7 13.6 6.4 11.1 11.0 10.3 12.2 35.4 15.8 7.2 14.3 20.1 25.6 14.8 11.4 17.7 29.6 15.3 17.0 4.0 81.4 15.4 2.3 9.3 33.5 14.8 47.3 14.5 22.1 13.9 12.3 23.9 48.0 10.8 29.9 20.2 5.7 13.7 39.4 12.6 16.6 3.7 26.0 33.2 2.1 12.2 14.5 37.9 7.6 10.1 17.1 23.0 10.2 17.0 40.1 6.5 92.8 0.7 4.0 12.4 4.1 18.1 11.5 33.7 11.2 20.3 20.0 20.7 13.1 12.9 16.3 1.6 15.7 10.6 11.7 6.9 12.1 9.5 14.0 13.9 11.8 11.5 8.4 13.5 3.4 17.7 12.5 POLA1 "NSX, p180, POLA" ENSG00000101868 "DNA polymerase alpha 1, catalytic subunit" P09884 X 24693919-24996986 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "DNA replication, Host-virus interaction" "DNA-binding, DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002947, CAB012274" Supported Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB012274: , HPA002947: AB_1079652" "unprognostic (6.92e-2)" "unprognostic (4.43e-3)" "unprognostic (3.27e-3)" "unprognostic (1.53e-2)" "unprognostic (2.53e-1)" "unprognostic (1.49e-1)" "prognostic unfavourable (4.80e-5)" "unprognostic (1.87e-1)" "unprognostic (9.25e-3)" "unprognostic (2.48e-2)" "unprognostic (8.41e-2)" "unprognostic (7.42e-2)" "unprognostic (2.09e-1)" "unprognostic (1.44e-1)" "unprognostic (3.66e-2)" "unprognostic (3.48e-2)" "unprognostic (3.08e-1)" 10.5 5.5 8.0 15.0 10.2 14.3 10.9 12.0 9.6 10.1 9.7 11.8 5.8 5.7 11.2 7.7 10.2 8.9 5.5 9.3 7.8 6.6 6.1 4.9 7.2 12.7 10.3 4.5 12.9 7.3 8.5 8.5 10.7 8.7 7.3 11.0 7.5 7.9 9.3 22.4 9.3 7.5 9.7 13.1 9.0 7.9 5.7 10.0 30.1 7.0 8.5 14.7 9.9 10.6 4.6 2.5 1.2 4.6 2.7 3.8 1.7 14.0 10.5 13.9 11.2 2.6 3.1 3.1 10.5 5.8 11.3 13.0 8.7 7.4 18.0 3.6 4.5 11.6 26.4 8.5 15.3 9.3 11.2 13.4 20.5 6.5 1.1 17.5 7.2 2.0 1.8 14.1 4.1 5.8 12.3 9.2 7.8 9.8 19.0 5.9 13.5 8.8 17.1 36.5 13.6 4.1 9.3 12.6 7.8 12.4 5.9 5.6 11.6 5.8 4.6 10.0 6.9 19.1 10.0 5.5 7.9 14.5 5.8 8.3 11.1 0.0 2.0 1.2 3.0 4.6 2.9 4.6 3.4 3.8 2.5 3.2 2.4 2.4 0.6 2.7 1.3 1.6 3.6 1.7 8.0 10.2 12.0 9.6 7.8 6.6 10.3 4.5 8.7 10.0 POLB ENSG00000070501 "DNA polymerase beta" P06746 8 42338454-42371808 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication, DNA synthesis" "DNA-binding, DNA-directed DNA polymerase, Lyase, Nucleotidyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 73.6" "Cell line enhanced" "Detected in all" "HMC-1: 79.7" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in all" 4 "cerebellum: 73.6" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011616, HPA049104" Enhanced Uncertain Vesicles Vesicles "CAB011616: AB_731977, HPA049104: " "unprognostic (1.67e-1)" "unprognostic (2.68e-3)" "unprognostic (2.43e-1)" "prognostic unfavourable (1.46e-4)" "unprognostic (8.49e-2)" "unprognostic (2.64e-2)" "unprognostic (4.24e-2)" "unprognostic (1.02e-1)" "unprognostic (2.31e-2)" "unprognostic (1.99e-1)" "unprognostic (4.57e-2)" "unprognostic (4.77e-1)" "prognostic unfavourable (2.15e-5)" "unprognostic (1.06e-2)" "unprognostic (1.40e-1)" "unprognostic (4.22e-2)" "prognostic favourable (5.65e-4)" 5.5 8.6 10.1 9.5 10.7 21.9 13.5 73.6 16.6 7.0 5.5 5.8 6.0 4.9 6.2 11.2 12.4 6.3 11.3 16.3 9.8 9.6 7.2 15.8 9.1 11.8 8.4 10.3 10.3 7.7 10.3 11.6 5.0 10.9 11.4 6.3 6.8 22.1 6.9 36.6 10.8 4.9 6.6 10.0 8.1 6.4 29.5 5.4 9.7 7.7 17.2 10.1 11.5 9.2 4.9 33.8 25.1 9.4 7.9 7.2 4.2 10.8 6.5 11.3 22.5 6.3 6.0 9.5 6.9 8.0 11.5 10.6 9.1 12.7 9.8 8.8 4.4 5.5 9.4 8.1 14.2 6.4 10.2 7.1 5.4 12.3 9.7 5.0 79.7 5.3 9.6 8.5 10.0 8.7 15.5 6.3 11.1 6.4 20.7 14.2 15.2 7.5 11.9 11.4 8.4 21.6 8.8 6.4 11.7 8.2 5.5 20.9 14.7 8.6 4.8 5.5 7.7 13.7 6.7 9.2 15.3 13.9 5.5 10.7 14.3 12.5 5.9 17.3 4.9 7.2 5.5 4.9 5.2 5.3 6.1 4.5 5.8 5.4 25.1 7.9 9.4 33.8 7.2 4.2 10.1 10.7 73.6 16.6 9.8 9.6 8.4 10.3 10.9 5.4 POLE POLE1 ENSG00000177084 "DNA polymerase epsilon, catalytic subunit" Q07864 12 132623753-132687365 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication" "DNA-binding, DNA-directed DNA polymerase, Hydrolase, Nucleotidyltransferase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 34.8" "Cell type enhanced" "Detected in some" "NK-cell: 4.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "HPA058210, HPA067385" Supported "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "HPA058210: , HPA067385: " "unprognostic (1.60e-1)" "unprognostic (1.77e-3)" "unprognostic (2.00e-1)" "unprognostic (9.17e-2)" "unprognostic (1.68e-1)" "unprognostic (2.01e-2)" "unprognostic (3.96e-3)" "unprognostic (2.23e-1)" "prognostic unfavourable (1.44e-4)" "unprognostic (7.12e-2)" "unprognostic (2.21e-1)" "unprognostic (1.67e-1)" "prognostic unfavourable (3.19e-8)" "unprognostic (8.60e-2)" "unprognostic (3.18e-1)" "unprognostic (1.28e-1)" "unprognostic (9.95e-2)" 6.1 3.4 6.7 10.2 4.4 29.3 6.2 34.8 14.4 7.0 6.6 2.0 7.6 7.3 6.1 4.4 7.5 6.2 6.5 4.7 5.6 1.6 3.8 8.6 5.4 8.2 3.3 4.3 8.7 6.8 3.6 3.1 6.5 5.1 6.8 7.7 4.3 8.7 7.4 8.9 17.9 8.5 6.8 3.7 16.7 7.8 25.6 4.4 29.8 5.1 6.0 10.3 6.7 8.7 0.5 1.7 0.8 0.8 4.8 0.7 0.5 11.1 14.9 22.1 10.6 4.7 3.6 19.7 11.4 5.2 13.7 10.0 18.0 6.6 12.8 4.8 6.2 15.5 15.4 7.7 8.4 5.9 19.5 20.2 19.2 8.8 0.9 15.8 11.6 2.8 3.0 14.2 4.7 4.8 22.6 7.2 6.7 18.1 25.9 28.9 17.2 8.9 21.5 12.5 5.8 4.3 18.3 18.5 10.6 13.3 10.9 2.5 16.1 9.8 4.3 12.5 12.8 9.4 11.5 9.6 6.5 20.1 6.8 21.9 8.8 0.0 0.3 0.8 0.5 0.1 0.7 0.5 0.3 0.4 0.7 0.3 0.5 0.3 0.1 4.8 0.8 1.7 0.6 0.5 6.7 4.4 34.8 14.4 5.6 1.6 3.3 4.3 5.1 4.4 POLE2 DPE2 ENSG00000100479 "DNA polymerase epsilon 2, accessory subunit" P56282 14 49643555-49688422 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "DNA replication" DNA-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 17.6;lymphoid tissue: 17.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" HPA027555 Uncertain Supported "Nucleoplasm,Nuclear bodies,Vesicles" "Nucleoplasm, Nuclear bodies" Vesicles "HPA027555: AB_10610282" "unprognostic (1.42e-1)" "unprognostic (6.57e-3)" "unprognostic (3.53e-2)" "unprognostic (7.44e-2)" "unprognostic (2.04e-2)" "unprognostic (4.99e-3)" "unprognostic (7.60e-3)" "unprognostic (2.32e-3)" "unprognostic (1.10e-3)" "unprognostic (2.69e-2)" "unprognostic (1.88e-2)" "unprognostic (1.37e-3)" "unprognostic (5.13e-11)" "unprognostic (9.97e-2)" "unprognostic (1.66e-1)" "unprognostic (1.27e-1)" "unprognostic (1.50e-3)" 3.3 2.2 1.5 11.6 2.8 17.6 3.4 1.7 1.6 4.4 4.2 1.1 1.5 2.6 2.8 3.5 9.0 2.4 2.3 1.6 1.0 1.2 2.5 5.1 2.2 5.3 1.1 0.3 2.7 5.0 1.4 2.5 4.1 1.4 2.1 5.2 2.6 2.6 0.7 1.1 3.7 7.7 2.9 2.7 5.4 3.0 5.3 2.4 17.6 1.6 10.3 8.4 2.1 4.2 1.2 0.9 0.7 0.0 3.2 2.7 0.5 17.1 8.8 16.7 7.7 0.8 4.9 8.5 9.8 5.0 15.6 18.1 8.8 13.5 10.7 5.6 5.5 10.6 16.7 6.0 18.5 12.5 9.2 15.9 9.7 10.9 0.4 18.9 6.9 1.4 0.4 8.5 1.4 9.0 13.9 6.9 15.6 15.0 19.2 12.4 9.8 20.6 16.4 15.4 9.7 5.6 9.7 12.0 6.9 9.9 5.8 3.1 11.7 6.7 3.2 2.5 18.6 10.4 7.7 5.0 10.2 24.7 4.7 14.0 10.0 0.0 0.0 0.7 0.9 0.0 0.7 1.2 0.9 1.7 0.6 1.2 0.1 0.8 0.0 3.2 0.0 0.9 2.7 0.5 1.5 2.8 1.7 1.6 1.0 1.2 1.1 0.3 1.4 2.4 POLE3 "CHARAC17, CHRAC17, p17, Ybl1" ENSG00000148229 "DNA polymerase epsilon 3, accessory subunit" Q9NRF9 9 113407235-113410672 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" DNA-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA047945 Uncertain Approved Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "HPA047945: " "unprognostic (9.55e-2)" "unprognostic (3.39e-3)" "unprognostic (1.56e-1)" "unprognostic (1.67e-1)" "unprognostic (6.52e-2)" "unprognostic (1.86e-2)" "prognostic unfavourable (8.35e-4)" "unprognostic (1.04e-2)" "unprognostic (1.60e-2)" "unprognostic (1.10e-1)" "unprognostic (4.59e-3)" "unprognostic (2.31e-3)" "unprognostic (1.75e-2)" "unprognostic (1.56e-2)" "unprognostic (1.04e-1)" "unprognostic (1.28e-1)" "unprognostic (1.18e-1)" 16.9 23.9 18.2 22.0 18.5 56.3 19.3 36.0 25.0 17.0 17.6 15.8 12.5 15.1 18.2 16.5 27.8 17.6 17.0 17.9 16.1 14.8 14.3 29.5 15.8 29.0 15.1 18.5 15.4 20.8 13.1 8.4 21.2 20.0 15.9 20.3 12.4 17.9 16.3 48.3 24.7 17.3 16.9 16.9 26.8 17.2 29.9 15.9 35.0 16.3 27.3 32.4 18.8 16.7 34.9 33.5 34.3 34.4 28.0 44.0 47.7 15.7 19.7 13.9 20.8 7.9 7.1 12.2 21.1 10.8 23.9 18.9 18.2 14.4 57.4 13.1 12.3 27.1 27.0 23.2 22.1 10.9 16.3 29.8 20.4 18.6 8.5 61.7 18.0 8.1 16.0 20.7 26.8 16.5 41.5 32.1 16.6 40.1 42.3 33.2 17.9 35.7 43.4 57.9 32.2 10.4 15.1 30.1 17.4 30.6 19.4 16.5 29.0 27.8 13.6 17.8 24.1 22.4 36.0 16.8 54.9 77.4 16.2 36.5 21.2 25.4 34.0 34.3 35.5 34.4 44.0 34.9 34.0 33.7 33.2 33.5 36.9 34.3 7.2 28.0 26.6 33.5 39.0 47.7 18.2 18.5 36.0 25.0 16.1 14.8 15.1 18.5 20.0 15.9 POLE4 p12 ENSG00000115350 "DNA polymerase epsilon 4, accessory subunit" Q9NR33 2 74958492-74970128 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" DNA-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NB-4: 35.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054979, HPA071815" Approved Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA054979: , HPA071815: " "unprognostic (2.56e-2)" "unprognostic (4.27e-2)" "unprognostic (1.17e-1)" "unprognostic (4.19e-2)" "unprognostic (4.85e-2)" "unprognostic (1.59e-2)" "prognostic unfavourable (6.49e-4)" "unprognostic (3.09e-1)" "unprognostic (1.99e-1)" "unprognostic (2.95e-1)" "unprognostic (1.39e-2)" "unprognostic (4.44e-2)" "unprognostic (8.64e-3)" "unprognostic (6.61e-2)" "unprognostic (3.73e-1)" "unprognostic (3.47e-2)" "unprognostic (1.95e-1)" 19.2 14.5 23.6 15.2 17.3 27.1 21.4 4.4 15.5 18.4 13.4 8.6 7.0 9.0 10.4 9.0 10.0 9.7 13.1 18.1 15.9 10.6 11.6 18.8 10.7 17.0 13.9 12.6 12.8 12.5 2.8 3.9 9.6 12.2 12.0 8.8 13.9 16.2 11.2 28.1 8.1 12.4 14.1 11.7 12.2 12.5 11.0 10.0 5.5 13.1 15.1 10.4 13.9 31.9 14.7 14.7 8.0 22.2 4.4 9.9 12.3 11.7 11.2 1.0 1.0 3.8 8.6 0.0 8.0 9.9 12.8 10.9 14.9 5.2 11.5 6.7 9.0 5.3 5.3 6.6 15.0 5.2 14.4 8.9 6.5 14.7 13.9 12.6 14.1 8.7 13.0 5.3 11.8 5.5 10.9 6.8 9.7 11.4 3.7 35.6 7.8 21.1 4.5 9.6 9.3 10.6 0.3 3.5 5.3 11.0 4.6 6.3 3.4 4.1 6.2 2.9 3.3 2.0 7.6 2.4 1.6 4.2 10.5 18.9 14.1 2.3 22.2 8.0 6.3 13.2 7.0 14.7 8.9 7.8 12.9 13.7 9.9 6.9 1.6 4.4 12.4 14.7 8.5 12.3 23.6 17.3 4.4 15.5 15.9 10.6 13.9 12.6 12.2 10.0 PPARA "hPPAR, NR1C1, PPAR" ENSG00000186951 "Peroxisome proliferator activated receptor alpha" Q07869 22 46150521-46243756 "FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "eosinophil: 12.1;plasmacytoid DC: 3.8" "Group enriched" "Detected in many" 5 "dendritic cells: 3.8;granulocytes: 12.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058901, HPA067049, CAB075701" Supported Enhanced Nucleoplasm Nucleoplasm "CAB075701: , HPA058901: , HPA067049: " "unprognostic (1.96e-1)" "unprognostic (2.19e-1)" "unprognostic (1.02e-1)" "unprognostic (4.76e-2)" "unprognostic (3.94e-3)" "unprognostic (4.30e-2)" "unprognostic (1.24e-1)" "unprognostic (4.94e-2)" "unprognostic (2.95e-1)" "unprognostic (5.52e-3)" "unprognostic (4.50e-2)" "unprognostic (1.01e-1)" "prognostic favourable (4.39e-9)" "unprognostic (4.84e-2)" "unprognostic (2.76e-1)" "unprognostic (1.23e-1)" "unprognostic (3.18e-2)" 5.7 6.6 5.8 6.0 6.2 4.2 6.9 2.6 4.5 3.8 11.8 5.9 9.9 13.9 4.8 6.6 6.3 3.9 9.1 19.6 5.1 4.1 17.8 30.9 3.8 3.4 6.1 4.9 9.1 13.4 6.6 3.5 3.1 7.8 6.2 7.1 13.5 8.1 8.2 17.1 5.8 19.7 5.0 4.7 3.5 5.7 2.7 7.1 1.3 5.4 10.4 4.8 7.3 12.3 1.5 3.8 12.1 1.4 0.9 1.5 0.3 6.8 1.7 2.1 7.6 12.1 7.8 4.8 5.9 11.9 6.4 6.6 3.3 3.3 2.4 3.0 13.8 3.1 6.4 7.8 5.8 7.0 8.1 7.6 4.3 7.0 7.6 5.1 13.0 6.1 6.3 4.7 10.9 1.3 2.7 5.7 5.9 1.7 5.8 1.9 0.3 1.7 6.9 7.8 3.2 4.4 4.0 2.1 6.4 2.3 2.1 7.5 2.4 4.0 2.3 6.7 7.2 6.0 2.6 5.7 3.3 1.0 10.5 5.8 2.0 1.7 1.0 12.1 1.4 1.4 1.2 1.0 0.7 0.7 0.7 1.5 0.8 0.6 0.8 0.9 0.8 3.8 1.5 0.3 5.8 6.2 2.6 4.5 5.1 4.1 6.1 4.9 7.8 7.1 PPARD "FAAR, NR1C2, NUC1, NUCII" ENSG00000112033 "Peroxisome proliferator activated receptor delta" Q03181 6 35342558-35428191 "FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB017635 Approved "CAB017635: AB_1128605" "unprognostic (3.70e-2)" "unprognostic (8.75e-2)" "unprognostic (1.00e-1)" "unprognostic (1.89e-1)" "unprognostic (1.57e-1)" "unprognostic (8.68e-2)" "prognostic unfavourable (4.57e-4)" "unprognostic (4.59e-3)" "unprognostic (4.34e-1)" "unprognostic (1.45e-1)" "unprognostic (1.05e-1)" "unprognostic (1.51e-3)" "unprognostic (7.27e-3)" "unprognostic (1.43e-1)" "unprognostic (9.42e-2)" "unprognostic (5.95e-2)" "unprognostic (2.00e-2)" 16.4 13.4 20.4 19.4 21.8 8.8 11.3 19.0 29.5 14.0 19.0 20.4 24.5 12.7 15.0 22.7 29.6 13.4 16.7 15.7 23.8 14.5 11.9 19.9 18.1 15.6 22.5 14.6 21.6 11.1 14.2 16.2 30.4 19.8 18.0 13.9 15.4 15.2 20.6 22.5 26.3 16.5 12.8 20.9 20.0 23.4 12.8 20.8 6.2 26.8 9.5 15.8 14.5 19.4 4.4 2.9 6.7 3.5 2.3 5.6 2.5 20.7 3.7 5.9 12.5 8.7 15.4 31.9 17.0 15.3 14.7 12.3 5.0 3.9 3.4 5.0 12.1 7.5 5.5 16.5 10.3 4.8 5.0 3.1 4.9 7.3 15.3 0.7 3.6 26.1 5.5 21.7 11.2 6.8 3.3 3.8 12.3 6.5 2.2 3.3 2.8 10.1 3.2 10.1 3.3 3.6 18.6 3.3 9.2 6.8 11.9 14.5 4.4 11.6 14.7 20.1 7.6 12.0 20.2 3.2 4.4 3.7 6.5 6.7 8.9 1.1 3.5 6.7 3.1 3.3 2.2 3.4 3.3 3.0 2.9 4.4 5.6 5.1 5.4 2.3 1.9 1.8 3.2 2.5 20.4 21.8 19.0 29.5 23.8 14.5 22.5 14.6 19.8 20.8 PPARG "NR1C3, PPARG1, PPARG2, PPARgamma" ENSG00000132170 "Peroxisome proliferator activated receptor gamma" P37231 3 12287368-12434356 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 97.6;breast: 102.1" "Cell line enhanced" "Detected in many" "ASC diff: 47.4;ASC TERT1: 27.0;BEWO: 55.9;CAPAN-2: 25.0;HSkMC: 27.8;PC-3: 24.9;RT4: 34.1" "Cancer enhanced" "Detected in all" "urothelial cancer: 33.5" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "classical monocyte: 1.8;intermediate monocyte: 2.3" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB004282, HPA051239, HPA063663" Approved Enhanced Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB004282: AB_628115, HPA051239: , HPA063663: " "unprognostic (7.35e-3)" "unprognostic (3.27e-2)" "unprognostic (4.05e-2)" "unprognostic (8.37e-2)" "unprognostic (2.41e-2)" "unprognostic (5.27e-3)" "prognostic unfavourable (3.41e-5)" "unprognostic (9.13e-2)" "unprognostic (2.32e-2)" "unprognostic (1.38e-1)" "unprognostic (1.02e-2)" "unprognostic (2.77e-1)" "prognostic favourable (1.59e-8)" "unprognostic (1.51e-2)" "unprognostic (1.46e-1)" "unprognostic (9.68e-3)" "prognostic favourable (5.52e-5)" 97.6 1.6 1.9 17.1 1.2 0.7 102.1 1.5 1.3 3.1 24.9 0.8 2.1 7.5 3.5 2.2 2.8 2.4 8.7 12.5 1.4 0.9 6.7 5.9 24.8 11.4 1.1 0.9 6.7 1.2 2.8 0.3 26.8 0.9 10.4 13.9 1.1 5.8 1.5 5.0 2.7 9.6 7.4 1.2 7.0 11.9 3.5 0.6 0.9 6.2 4.3 2.1 30.2 14.1 0.0 0.4 0.0 2.3 0.0 0.7 0.3 9.6 8.6 0.0 0.0 47.4 27.0 55.9 0.9 10.4 1.3 0.5 1.8 25.0 0.0 0.0 0.9 3.9 3.4 0.1 0.2 23.2 4.8 0.0 1.9 2.3 12.6 0.0 0.0 27.8 2.3 2.3 9.0 0.1 0.0 0.0 2.0 2.4 0.0 0.1 0.1 24.9 0.0 0.0 0.0 7.1 34.1 0.0 0.2 4.0 1.5 0.5 0.0 7.7 7.8 1.8 2.6 1.0 0.0 0.0 0.0 0.0 0.8 0.1 0.2 0.0 1.8 0.0 0.0 2.3 0.0 0.0 0.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.3 1.9 1.2 1.5 1.3 1.4 0.9 1.1 0.9 0.9 0.6 PPP3R2 PPP3RL ENSG00000188386 "Protein phosphatase 3 regulatory subunit B, beta" Q96LZ3 9 101591615-101595021 "FDA approved drug targets, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 90 "testis: 81.9" "Cell line enhanced" "Detected in single" "Karpas-707: 1.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" HPA047157 Uncertain Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA047157: " "unprognostic (8.81e-2)" "unprognostic (2.65e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 81.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.6 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 PRDX5 "ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10" ENSG00000126432 "Peroxiredoxin 5" P30044 11 64318088-64321811 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Antioxidant, Oxidoreductase, Peroxidase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008661, HPA037915, HPA037916" Enhanced Enhanced Mitochondria 19000000 Mitochondria "CAB008661: AB_1620988, HPA037915: AB_2675735, HPA037916: AB_2675736" "unprognostic (2.75e-1)" "unprognostic (4.08e-1)" "unprognostic (1.33e-1)" "unprognostic (1.46e-1)" "unprognostic (9.43e-2)" "unprognostic (6.71e-3)" "unprognostic (1.08e-3)" "unprognostic (3.11e-1)" "unprognostic (9.30e-2)" "unprognostic (1.07e-3)" "unprognostic (1.57e-2)" "unprognostic (2.20e-1)" "prognostic favourable (1.24e-5)" "unprognostic (8.19e-2)" "unprognostic (2.30e-1)" "unprognostic (9.63e-2)" "unprognostic (5.03e-2)" 28.7 69.7 70.3 38.6 60.3 57.0 35.5 69.3 73.9 47.2 79.3 31.9 49.0 49.5 26.6 54.8 69.6 94.9 44.8 102.4 56.7 74.2 57.3 54.2 50.3 25.0 68.6 70.2 42.2 72.0 36.0 53.7 49.1 71.4 30.7 71.2 33.9 77.5 62.6 104.7 27.0 51.2 30.9 44.1 27.3 64.5 35.0 29.3 25.1 82.0 64.8 33.5 34.4 50.4 55.2 69.2 115.0 66.9 48.4 40.5 75.3 26.0 53.2 32.3 53.3 34.8 52.3 37.3 32.7 52.4 24.0 30.0 38.7 53.6 38.3 57.2 52.2 59.7 30.1 69.4 15.3 53.1 23.7 38.6 83.8 44.1 71.4 14.6 32.9 53.0 90.7 40.3 40.9 36.5 21.7 91.0 33.8 66.2 25.5 63.5 48.9 68.2 24.6 33.1 135.2 90.0 51.8 27.4 52.0 27.3 60.7 93.2 44.4 33.3 35.1 34.4 32.0 39.7 14.4 46.6 55.4 45.0 41.6 29.5 26.8 79.8 66.9 85.4 37.7 59.6 32.7 53.8 35.0 30.8 52.4 55.2 34.8 35.0 115.0 48.4 52.5 69.2 40.5 75.3 70.3 60.3 69.3 73.9 56.7 74.2 68.6 70.2 71.4 29.3 PRKAA1 AMPKa1 ENSG00000132356 "Protein kinase AMP-activated catalytic subunit alpha 1" Q13131 5 40759379-40798374 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Autophagy, Biological rhythms, Cholesterol biosynthesis, Cholesterol metabolism, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism, Transcription, Transcription regulation, Wnt signaling pathway" "Chromatin regulator, Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005050, HPA035409, HPA064946" Supported Supported "Nuclear speckles" "Nuclear speckles" "CAB005050: AB_562037, HPA035409: , HPA064946: " "unprognostic (2.07e-1)" "unprognostic (1.41e-2)" "unprognostic (2.51e-2)" "unprognostic (3.57e-2)" "unprognostic (3.97e-1)" "unprognostic (1.05e-1)" "unprognostic (3.51e-2)" "unprognostic (7.53e-2)" "unprognostic (1.66e-2)" "unprognostic (2.88e-1)" "unprognostic (3.34e-3)" "unprognostic (2.63e-1)" "unprognostic (2.82e-2)" "unprognostic (1.35e-1)" "unprognostic (1.60e-1)" "unprognostic (1.27e-2)" "unprognostic (1.10e-2)" 40.6 15.7 9.4 15.9 16.1 29.0 26.2 14.3 17.7 30.2 24.0 19.9 18.9 21.7 23.5 20.9 22.5 20.4 21.3 15.0 10.5 11.7 35.9 40.7 24.8 16.7 12.2 8.5 28.8 20.6 25.3 20.0 16.8 35.7 26.1 22.3 20.0 23.2 17.9 18.5 16.6 32.6 20.7 14.1 25.1 22.1 29.3 11.4 21.4 28.0 20.5 22.9 32.5 17.9 8.4 6.5 15.9 8.9 10.8 12.6 6.5 11.3 11.8 9.5 12.6 23.5 24.5 9.0 19.3 19.8 14.5 13.0 11.1 14.7 6.7 9.0 19.8 9.2 8.7 17.6 27.5 19.6 7.9 13.3 27.3 8.8 19.4 12.6 14.0 22.6 8.6 19.4 20.0 21.4 6.2 19.4 21.6 5.4 11.6 9.9 4.1 14.3 9.8 20.3 9.8 22.3 19.3 8.2 8.3 33.9 22.6 11.5 11.9 10.5 22.9 26.2 14.2 15.1 15.7 7.7 6.0 8.0 16.4 27.4 13.9 14.1 6.6 12.7 10.0 8.1 12.6 8.4 9.4 9.4 6.5 7.7 11.5 10.0 15.9 10.8 8.9 2.0 11.3 6.5 9.4 16.1 14.3 17.7 10.5 11.7 12.2 8.5 35.7 11.4 PRKAB1 ENSG00000111725 "Protein kinase AMP-activated non-catalytic subunit beta 1" Q9Y478 12 119667753-119681630 "FDA approved drug targets, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004247, CAB005058" Enhanced Approved Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB005058: AB_562038, HPA004247: AB_1078149" "unprognostic (1.20e-1)" "unprognostic (3.08e-2)" "unprognostic (7.42e-2)" "prognostic favourable (8.66e-4)" "unprognostic (2.33e-1)" "unprognostic (2.89e-2)" "unprognostic (8.97e-3)" "unprognostic (1.46e-2)" "unprognostic (6.26e-2)" "unprognostic (3.63e-2)" "unprognostic (2.85e-1)" "unprognostic (1.23e-1)" "prognostic favourable (5.40e-9)" "unprognostic (5.60e-2)" "unprognostic (2.28e-1)" "unprognostic (1.92e-1)" "unprognostic (1.32e-2)" 16.3 17.2 8.1 16.6 11.9 23.4 13.8 12.5 20.7 16.8 22.8 14.6 6.7 20.4 13.6 13.2 17.9 11.6 19.3 9.2 8.3 7.2 40.1 12.3 21.4 20.6 8.9 9.8 14.2 21.7 11.7 10.8 19.1 11.1 9.7 22.7 20.6 15.3 10.7 12.0 10.6 23.9 12.5 10.5 20.7 25.0 33.4 8.3 20.0 17.5 9.4 16.6 16.3 10.6 26.4 17.4 38.8 19.9 22.1 20.9 18.3 4.7 12.8 10.1 9.6 8.7 7.5 13.4 7.7 10.0 12.5 9.6 13.4 10.8 15.9 10.2 10.5 6.7 10.2 15.9 11.6 10.1 9.4 24.9 5.6 19.4 15.7 11.5 31.6 11.3 13.5 11.4 15.3 9.3 37.9 6.2 9.7 13.1 26.0 12.9 14.3 14.3 15.1 8.7 9.2 14.3 15.1 8.1 13.8 10.2 3.9 10.5 12.5 15.1 11.0 7.7 8.2 5.9 7.7 20.0 17.5 11.8 7.6 7.8 11.0 24.8 16.4 38.8 17.2 18.4 20.9 26.4 18.3 18.3 17.4 21.7 19.9 18.6 19.1 22.1 19.9 15.4 19.7 18.3 8.1 11.9 12.5 20.7 8.3 7.2 8.9 9.8 11.1 8.3 PRKCA PKCA ENSG00000154229 "Protein kinase C alpha" P17252 17 66302636-66810743 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Angiogenesis, Apoptosis, Cell adhesion" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-87 MG: 53.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 17 "dendritic cells: 1.4;monocytes: 2.7;T-cells: 4.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003844, HPA006563, HPA006564, CAB016290" Enhanced Approved Enhanced "Plasma membrane,Cytosol" 1900000 Cytosol "Plasma membrane" "CAB003844: AB_562331, CAB016290: AB_628141, HPA006563: AB_1079626, HPA006564: AB_1079625" "unprognostic (3.06e-1)" "unprognostic (3.56e-2)" "unprognostic (1.38e-2)" "unprognostic (1.01e-1)" "unprognostic (1.53e-1)" "unprognostic (7.41e-3)" "unprognostic (7.43e-2)" "unprognostic (6.86e-3)" "unprognostic (4.93e-2)" "unprognostic (1.50e-1)" "unprognostic (2.09e-1)" "unprognostic (2.24e-2)" "unprognostic (5.50e-2)" "unprognostic (2.46e-1)" "unprognostic (1.83e-1)" "unprognostic (1.35e-3)" "unprognostic (8.77e-2)" 4.0 19.6 26.5 9.0 22.8 2.5 3.0 10.8 33.9 7.0 13.8 19.0 3.5 14.6 14.8 6.7 4.7 6.1 10.8 5.8 31.6 15.6 16.7 6.5 6.0 8.4 18.7 15.6 20.4 5.5 1.7 6.0 6.5 17.6 17.2 11.2 7.0 3.1 22.3 6.6 3.8 12.7 13.7 15.0 7.9 7.9 3.7 14.4 0.4 4.5 1.3 5.9 9.5 9.5 0.0 1.4 0.1 2.7 0.1 4.0 1.0 2.3 12.3 2.5 2.6 6.2 15.9 0.3 13.3 8.7 9.6 8.2 1.4 1.5 3.1 3.6 21.4 0.3 1.3 1.5 20.9 5.1 3.0 0.0 7.3 6.4 8.5 3.8 20.9 6.9 0.6 12.0 10.3 8.2 8.0 0.0 14.8 0.7 7.7 2.3 1.0 6.6 1.4 18.8 0.0 3.4 2.0 1.5 8.5 4.4 2.5 0.1 0.3 5.4 24.5 16.7 9.7 10.4 8.3 0.0 0.0 0.3 53.0 0.0 8.2 0.1 0.6 0.0 0.5 0.8 1.5 0.0 2.5 1.2 1.1 0.0 4.0 2.3 0.0 0.1 2.7 1.4 0.5 1.0 26.5 22.8 10.8 28.2 31.6 15.6 18.7 15.6 17.6 14.4 PROC ENSG00000115718 "Protein C, inactivator of coagulation factors Va and VIIIa" P04070 2 127418427-127429246 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "liver: 137.5" "Cell line enriched" "Detected in some" 16 "Hep G2: 57.5" "Cancer enriched" "Detected in many" 22 "liver cancer: 118.3" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 9 "plasmacytoid DC: 29.2" "Lineage enriched" "Detected in many" 9 "dendritic cells: 29.2" "Not detected" "Not detected" "Not detected" "Not detected" "HPA005550, CAB016721, CAB016792" Supported "Secreted to blood" 6400000000 "CAB016721: , CAB016792: , HPA005550: AB_1079687" "unprognostic (2.46e-2)" "unprognostic (1.08e-1)" "unprognostic (1.38e-1)" "unprognostic (1.58e-1)" "unprognostic (6.64e-2)" "unprognostic (3.13e-2)" "unprognostic (4.90e-3)" "unprognostic (2.63e-1)" "unprognostic (1.67e-1)" "unprognostic (3.29e-1)" "unprognostic (3.74e-3)" "unprognostic (2.56e-2)" "unprognostic (8.12e-3)" "unprognostic (2.01e-2)" "unprognostic (1.71e-1)" "unprognostic (4.60e-3)" "unprognostic (8.06e-2)" 0.0 0.0 0.4 0.1 0.1 0.2 0.0 0.1 0.2 0.1 0.2 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.6 0.0 0.4 0.2 4.2 137.5 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.4 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.5 0.0 0.1 0.0 0.6 0.0 0.0 0.7 0.0 0.0 0.1 0.1 0.0 0.4 29.2 3.1 0.0 0.0 0.0 0.1 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.5 0.0 0.3 0.0 3.6 0.0 0.1 0.0 0.0 0.0 0.0 2.7 57.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 3.1 0.0 0.0 29.2 0.0 0.1 0.4 0.1 0.1 0.2 0.4 0.2 0.1 0.1 0.4 0.0 PROS1 PROS ENSG00000184500 "Protein S" P07225 3 93873033-93974066 "Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Blood coagulation, Fibrinolysis, Hemostasis" "Disease mutation, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 114.6" "Cell line enhanced" "Detected in many" "ASC diff: 42.5;ASC TERT1: 31.6;HSkMC: 28.6;SK-MEL-30: 45.8" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in many" 6 "pons and medulla: 24.2" "Cell type enhanced" "Detected in single" "neutrophil: 1.9" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA007724, HPA023974" Approved "Secreted to blood" 3400000000 "HPA007724: AB_1079688, HPA023974: AB_1855738" "unprognostic (2.00e-2)" "unprognostic (2.81e-2)" "unprognostic (9.21e-2)" "unprognostic (8.03e-3)" "unprognostic (3.35e-2)" "unprognostic (2.41e-1)" "unprognostic (6.48e-2)" "unprognostic (3.07e-1)" "unprognostic (5.18e-2)" "unprognostic (3.12e-1)" "unprognostic (1.10e-1)" "unprognostic (1.91e-1)" "unprognostic (1.10e-1)" "prognostic unfavourable (8.35e-4)" "unprognostic (4.90e-2)" "unprognostic (1.05e-2)" "prognostic unfavourable (4.42e-5)" 16.0 3.9 2.5 3.8 3.8 0.1 15.5 0.8 2.8 7.4 8.0 4.1 2.8 3.9 7.6 9.5 10.9 8.5 11.3 30.2 4.0 3.1 17.6 114.6 17.3 13.7 4.3 1.8 23.9 2.7 10.1 6.2 10.2 24.2 6.8 8.5 9.3 5.6 4.3 5.6 8.5 6.5 8.3 4.8 8.8 4.9 5.5 2.2 0.1 10.6 6.9 3.3 8.0 9.5 0.0 0.8 1.9 0.8 0.1 0.4 6.8 0.3 2.4 2.5 10.2 42.5 31.6 0.8 1.5 3.5 0.8 3.1 6.0 0.9 0.2 9.3 2.3 0.1 0.8 0.6 1.1 0.1 2.7 16.5 1.1 16.9 3.6 0.6 0.8 28.6 0.6 1.8 0.6 3.5 11.4 0.2 16.5 0.2 0.1 0.0 2.0 2.4 0.3 2.0 0.0 9.0 0.0 3.8 7.0 1.8 0.0 45.8 0.1 8.0 3.0 6.8 1.5 3.7 0.8 0.0 0.1 0.0 21.0 10.5 9.8 0.0 0.8 0.7 0.1 0.6 0.0 0.0 0.0 0.0 0.8 0.0 0.4 0.0 1.9 0.1 0.2 0.0 0.2 6.8 2.5 3.8 0.8 2.8 4.0 3.1 4.3 1.8 24.2 2.2 PRSS1 TRY1 ENSG00000204983 "Serine protease 1" P07477 7 142749468-142753076 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Digestion "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 1708 "pancreas: 3057.4" "Cell line enhanced" "Detected in some" "EFO-21: 3.5;HDLM-2: 1.7;RPMI-8226: 6.9;U-2 OS: 4.1;U-251 MG: 1.5;U-266/84: 2.5" "Cancer enriched" "Detected in many" 224 "pancreatic cancer: 1920.3" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 1.7" "Low lineage specificity" "Detected in many" "CAB025487, CAB025538, HPA062452, HPA063471" Enhanced Approved "Endoplasmic reticulum,Vesicles" "Secreted to digestive system" 26000000000 Vesicles "Endoplasmic reticulum" "CAB025487: , CAB025538: , HPA062452: , HPA063471: " "unprognostic (6.55e-5)" "unprognostic (5.28e-1)" "unprognostic (7.58e-2)" "prognostic unfavourable (6.41e-6)" "unprognostic (8.26e-2)" "prognostic favourable (7.05e-4)" "unprognostic (1.35e-1)" "unprognostic (3.93e-2)" "unprognostic (1.96e-1)" "prognostic favourable (4.91e-4)" "unprognostic (3.12e-1)" 0.4 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.0 0.1 0.4 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 1.6 3057.4 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.4 0.2 0.1 0.0 0.4 0.1 0.1 0.1 0.5 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 1.0 0.0 1.7 0.0 0.0 0.9 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 1.5 0.0 2.5 0.6 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 1.0 0.9 0.0 0.0 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 PSMB1 "HC5, PMSB1" ENSG00000008018 "Proteasome subunit beta 1" P20618 6 170535117-170553341 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Hydrolase, Protease, Threonine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029635, HPA029637, CAB033911" Enhanced Supported Nucleoplasm 14000000 Nucleoplasm "CAB033911: AB_2268890, HPA029635: AB_10599738, HPA029637: AB_10601793" "unprognostic (2.78e-2)" "unprognostic (3.10e-2)" "unprognostic (6.73e-2)" "unprognostic (1.34e-1)" "unprognostic (1.20e-1)" "unprognostic (5.41e-3)" "unprognostic (2.36e-2)" "unprognostic (3.32e-2)" "unprognostic (8.39e-2)" "unprognostic (4.28e-2)" "unprognostic (3.07e-1)" "unprognostic (1.09e-1)" "prognostic unfavourable (3.76e-6)" "unprognostic (3.63e-1)" "unprognostic (7.50e-2)" "unprognostic (1.45e-3)" "unprognostic (9.62e-2)" 60.8 59.3 38.5 40.4 53.7 53.2 55.0 31.4 46.4 40.5 48.6 37.9 49.9 45.1 56.8 90.6 51.7 49.8 43.1 71.9 40.9 40.1 56.4 93.2 46.9 66.7 40.8 41.1 43.7 67.3 35.4 48.4 80.6 48.4 40.6 52.7 43.8 43.6 50.0 109.3 56.1 46.0 59.7 44.9 51.4 46.9 47.1 38.1 47.1 47.9 75.2 60.4 50.1 42.0 71.0 98.1 51.9 81.9 71.6 79.3 104.1 42.5 40.0 57.1 73.6 51.1 40.2 60.8 40.8 60.0 68.0 69.6 87.5 36.8 62.3 53.2 54.5 43.1 63.3 64.8 71.0 63.4 71.2 53.2 40.6 109.7 60.0 62.4 47.5 45.8 39.9 65.6 42.6 58.0 105.0 53.5 62.0 114.6 46.7 87.1 52.1 55.1 45.2 45.3 79.0 70.5 25.6 57.1 46.6 39.2 60.9 31.2 41.7 90.4 44.1 27.7 44.5 67.3 75.3 45.8 60.6 77.4 64.7 70.7 59.4 40.1 81.9 51.9 53.2 75.8 62.1 71.0 62.2 57.7 98.1 53.4 59.2 57.2 47.5 71.6 67.6 55.8 79.3 104.1 38.5 53.7 31.4 46.4 40.9 40.1 40.8 41.1 48.4 38.1 PSMB10 "beta2i, LMP10, MECL1, MGC1665" ENSG00000205220 "Proteasome subunit beta 10" P40306 16 67934502-67937087 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Hydrolase, Protease, Threonine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 117.3" "Cell line enhanced" "Detected in many" "REH: 36.0;U-266/70: 40.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA030224, HPA030225, CAB034384" Enhanced Supported Vesicles,Cytosol 1400000 Cytosol Vesicles "CAB034384: AB_2171876, HPA030224: , HPA030225: AB_10603231" "unprognostic (1.18e-2)" "unprognostic (1.90e-3)" "unprognostic (2.00e-1)" "unprognostic (2.53e-3)" "unprognostic (2.00e-1)" "unprognostic (1.85e-2)" "unprognostic (7.22e-2)" "unprognostic (3.35e-2)" "unprognostic (1.07e-1)" "unprognostic (2.60e-1)" "unprognostic (8.22e-2)" "unprognostic (1.79e-1)" "unprognostic (1.32e-2)" "unprognostic (2.97e-2)" "unprognostic (1.98e-1)" "unprognostic (1.32e-2)" "prognostic favourable (5.44e-4)" 11.5 13.0 9.1 24.9 11.8 23.9 11.4 4.0 7.8 8.0 21.6 5.6 8.5 42.4 9.3 9.5 10.6 12.4 16.6 12.0 6.9 4.9 16.9 17.2 19.5 38.3 9.5 5.6 8.7 61.5 0.9 6.9 11.2 8.5 13.5 6.3 5.8 27.9 11.6 6.9 7.0 35.6 7.7 6.5 49.7 23.8 2.5 7.8 39.2 13.1 10.4 20.5 13.2 8.4 50.8 75.2 100.0 98.1 69.1 68.8 117.3 5.9 5.3 0.4 0.8 0.4 3.5 21.0 2.0 8.5 6.9 9.8 2.7 29.1 21.6 3.7 2.7 8.7 0.1 1.9 0.5 9.6 0.5 7.7 1.8 3.0 12.0 14.3 23.6 5.3 1.2 3.0 0.0 4.0 0.7 8.3 1.9 7.4 28.1 14.7 0.3 2.0 36.0 2.2 29.5 4.7 10.4 0.3 0.4 6.7 11.8 2.6 2.4 31.0 6.7 4.4 1.2 1.9 2.3 40.3 7.2 14.4 10.9 18.7 9.5 57.1 89.4 67.1 68.8 98.1 50.2 50.8 54.0 57.3 74.6 49.1 45.3 50.1 100.0 69.1 71.4 75.2 60.8 117.3 9.1 11.8 4.0 7.8 6.9 4.9 9.5 5.6 8.5 7.8 PSMB2 HC7-I ENSG00000126067 "Proteasome subunit beta 2" P49721 1 35599544-35641844 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Hydrolase, Protease, Threonine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026322, HPA026324" Approved Enhanced Nucleoplasm 15000000 Nucleoplasm "HPA026322: AB_1855821, HPA026324: AB_1855822" "unprognostic (3.54e-2)" "unprognostic (8.53e-2)" "unprognostic (1.63e-3)" "unprognostic (6.93e-2)" "unprognostic (6.41e-2)" "unprognostic (1.37e-1)" "prognostic unfavourable (3.49e-7)" "unprognostic (2.81e-2)" "unprognostic (5.23e-2)" "unprognostic (3.34e-3)" "unprognostic (7.87e-2)" "unprognostic (4.45e-1)" "prognostic unfavourable (2.80e-6)" "unprognostic (1.65e-1)" "unprognostic (2.83e-1)" "unprognostic (3.77e-2)" "unprognostic (2.93e-2)" 26.5 30.5 29.4 28.0 35.1 37.2 25.3 20.1 50.9 23.2 26.1 35.9 15.4 27.5 27.8 25.0 30.4 26.5 20.7 23.8 30.6 33.4 27.9 63.8 24.6 30.4 30.6 24.8 22.7 24.6 22.0 21.8 37.5 32.6 23.1 27.8 22.8 23.0 24.9 54.7 28.2 27.0 28.7 32.5 29.3 22.8 23.5 21.5 42.8 22.7 29.1 34.0 23.9 22.4 24.6 30.2 19.4 35.3 25.1 28.1 25.4 40.6 25.5 27.8 19.0 14.8 17.8 35.2 19.3 22.7 39.8 32.5 30.2 48.9 40.6 45.3 22.7 25.3 35.8 32.0 33.5 33.1 33.2 36.8 27.9 29.5 26.7 38.6 21.7 19.4 20.3 47.5 23.1 31.2 43.9 23.2 25.6 18.7 50.2 28.9 37.2 27.1 31.1 28.4 28.6 27.6 22.0 24.7 18.2 22.1 20.9 29.8 15.4 17.6 21.5 19.9 23.5 18.8 45.5 20.0 32.2 41.1 29.5 40.7 34.5 17.4 27.0 19.4 23.1 33.0 23.4 24.6 23.1 24.2 29.7 19.3 16.7 20.9 9.7 25.1 35.3 30.2 28.1 25.4 29.4 35.1 20.1 50.9 30.6 33.4 30.6 24.8 32.6 21.5 PSMB5 "MB1, X" ENSG00000100804 "Proteasome subunit beta 5" P28074 14 23016543-23035230 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Hydrolase, Protease, Threonine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049518, HPA061796" Approved Supported Nucleoplasm,Centrosome 8200000 "Nucleoplasm, Centrosome" "HPA049518: , HPA061796: " "unprognostic (3.03e-1)" "unprognostic (1.99e-2)" "unprognostic (8.35e-2)" "unprognostic (6.13e-2)" "unprognostic (1.24e-1)" "prognostic unfavourable (2.85e-4)" "prognostic unfavourable (2.90e-5)" "unprognostic (2.55e-2)" "unprognostic (9.95e-2)" "prognostic favourable (1.08e-4)" "unprognostic (2.06e-1)" "unprognostic (1.19e-1)" "unprognostic (5.30e-2)" "unprognostic (1.75e-1)" "unprognostic (1.95e-1)" "unprognostic (4.95e-2)" "prognostic unfavourable (4.73e-4)" 28.1 38.8 33.6 19.3 35.5 9.6 29.0 19.4 42.9 24.7 28.3 26.8 25.4 21.0 24.2 49.2 31.6 31.6 22.0 37.7 32.9 33.3 35.3 45.4 20.6 18.3 37.5 35.4 22.2 36.6 35.4 26.6 32.5 33.9 27.2 32.2 21.1 28.4 28.7 101.2 22.3 17.2 34.9 32.5 16.7 25.1 27.6 27.3 15.7 29.0 47.3 22.7 20.6 25.2 32.3 53.4 24.6 39.9 19.4 46.8 39.5 22.1 47.1 33.7 31.9 45.4 39.2 33.3 31.6 37.6 55.8 47.4 39.6 35.2 27.5 29.5 42.9 30.2 53.8 39.4 53.9 16.8 37.2 17.4 34.4 139.6 35.9 21.1 21.0 43.7 37.0 41.3 34.5 57.6 26.2 15.6 45.6 65.1 12.0 29.0 37.4 76.4 16.2 25.4 18.3 43.3 32.1 43.0 33.5 22.2 45.2 30.3 21.8 27.5 30.9 27.3 27.8 25.2 31.0 13.5 26.8 20.6 21.3 17.1 33.8 24.6 39.9 17.3 29.3 39.0 34.2 32.3 35.1 28.1 42.6 30.1 46.8 35.6 15.5 19.4 27.9 53.4 28.7 39.5 33.6 35.5 19.4 42.9 32.9 33.3 37.5 35.4 33.9 27.3 PSMB8 "beta5i, D6S216E, LMP7, PSMB5i, RING10" ENSG00000204264 "Proteasome subunit beta 8" P28062 6 32840717-32844703 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Differentiation, Host-virus interaction, Immunity" "Hydrolase, Protease, Threonine protease" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 24.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046995, HPA050327" Enhanced Approved "Vesicles,Cytokinetic bridge" 3300000 Vesicles "Cytokinetic bridge" "HPA046995: AB_2679896, HPA050327: AB_2681088" "prognostic favourable (5.08e-4)" "unprognostic (4.22e-2)" "unprognostic (2.39e-2)" "prognostic favourable (7.16e-4)" "unprognostic (1.92e-1)" "unprognostic (1.68e-1)" "unprognostic (7.78e-2)" "unprognostic (1.09e-1)" "unprognostic (5.71e-2)" "unprognostic (1.17e-2)" "unprognostic (2.79e-2)" "unprognostic (1.47e-1)" "unprognostic (4.14e-2)" "unprognostic (1.24e-1)" "unprognostic (4.35e-2)" "unprognostic (1.97e-3)" "unprognostic (7.11e-3)" 17.0 21.9 7.9 34.8 11.7 14.0 14.9 3.6 7.5 10.0 20.8 5.1 8.8 20.1 12.5 15.3 16.6 13.2 23.8 10.6 6.6 5.7 20.9 30.0 29.0 46.3 9.9 5.1 11.3 12.7 3.6 8.2 9.7 8.8 13.5 24.4 9.2 14.6 11.2 5.1 14.7 37.3 11.5 9.0 42.8 19.4 3.9 9.0 32.2 18.7 18.7 29.0 13.9 12.5 28.9 27.4 37.6 33.2 23.3 29.9 52.2 6.3 2.0 0.1 0.0 2.7 7.0 4.4 1.5 10.1 12.4 17.9 0.0 11.2 24.8 4.8 4.1 4.5 1.4 6.0 3.4 10.2 0.0 10.9 1.3 0.4 14.8 0.2 4.1 7.9 2.8 6.9 2.3 8.4 0.3 5.2 3.1 0.0 5.7 6.0 0.0 1.6 15.5 0.8 12.2 10.1 1.8 0.1 0.1 2.2 5.3 3.3 2.4 20.3 2.5 3.7 1.9 3.5 0.2 8.8 8.3 5.5 1.3 14.3 4.6 19.4 29.0 37.4 25.5 33.2 22.1 28.9 21.7 26.4 27.4 26.3 15.1 21.6 37.6 23.3 28.6 23.3 29.9 52.2 7.9 11.7 3.6 7.5 6.6 5.7 9.9 5.1 8.8 9.0 PSMB9 "beta1i, LMP2, PSMB6i, RING12" ENSG00000240065 "Proteasome subunit beta 9" P28065 6 32844136-32859585 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Immunity" "Hydrolase, Protease, Threonine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 69.1;lymphoid tissue: 54.9" "Cell line enhanced" "Detected in many" "Daudi: 29.1;REH: 21.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB015180, HPA042818, HPA053280" Enhanced Supported Cytosol 420000 Cytosol "CAB015180: AB_2172368, HPA042818: , HPA053280: " "unprognostic (1.09e-2)" "unprognostic (1.68e-2)" "unprognostic (1.26e-2)" "unprognostic (2.18e-3)" "unprognostic (7.84e-2)" "unprognostic (1.89e-1)" "unprognostic (5.68e-2)" "unprognostic (6.67e-2)" "unprognostic (1.56e-2)" "unprognostic (6.50e-3)" "unprognostic (1.87e-3)" "unprognostic (1.84e-1)" "prognostic unfavourable (1.33e-4)" "unprognostic (2.65e-1)" "unprognostic (1.09e-1)" "unprognostic (4.96e-3)" "unprognostic (5.99e-2)" 13.3 9.7 5.0 30.0 7.9 10.7 11.6 1.6 5.3 7.6 16.5 6.0 3.4 15.7 8.8 7.1 10.8 7.4 10.8 8.9 5.1 4.7 12.2 12.2 17.7 32.7 7.3 3.7 9.2 5.4 1.2 4.5 5.5 6.3 12.5 5.8 7.7 9.0 3.5 6.2 7.6 36.1 5.7 9.8 54.9 11.2 3.0 6.7 35.4 14.4 9.3 35.2 15.9 8.8 31.8 17.2 69.1 30.5 23.4 31.1 45.7 0.0 1.4 0.0 0.1 1.1 2.9 2.0 0.2 3.2 4.2 9.7 0.0 9.1 29.1 0.4 2.6 5.9 0.4 6.2 0.5 16.4 0.0 17.7 0.5 1.1 15.7 3.1 1.3 1.3 0.2 2.6 0.4 1.5 0.7 5.4 1.4 0.4 13.4 4.1 0.0 0.9 21.5 0.0 6.9 2.8 0.5 0.0 0.0 2.7 1.7 1.9 2.3 6.5 1.5 4.5 0.4 8.5 2.5 10.1 15.3 9.3 4.6 11.8 3.8 21.9 22.4 39.3 28.7 30.5 23.8 31.8 23.3 27.5 17.2 23.4 17.5 22.9 69.1 23.4 29.4 12.7 31.1 45.7 5.0 7.9 1.6 5.3 5.1 4.7 7.3 3.7 6.3 6.7 PTAFR ENSG00000169403 "Platelet activating factor receptor" P25105 1 28147166-28193936 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Chemotaxis "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 98.3" "Group enriched" "Detected in some" 4 "HBEC3-KT: 14.3;HMC-1: 52.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "classical monocyte: 28.2;eosinophil: 98.3;neutrophil: 85.7" "Group enriched" "Detected in many" 5 "granulocytes: 98.3;monocytes: 28.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA027543 Approved Uncertain "Nucleoplasm,Vesicles,Plasma membrane" "Nucleoplasm, Vesicles" "Plasma membrane" "HPA027543: AB_10610287" "unprognostic (2.22e-2)" "unprognostic (2.59e-2)" "unprognostic (6.73e-2)" "unprognostic (1.24e-1)" "unprognostic (2.75e-1)" "unprognostic (3.74e-2)" "unprognostic (1.07e-1)" "unprognostic (1.72e-1)" "unprognostic (3.35e-1)" "unprognostic (1.23e-1)" "unprognostic (2.39e-1)" "unprognostic (1.60e-1)" "unprognostic (2.79e-2)" "unprognostic (3.52e-1)" "unprognostic (2.59e-2)" "unprognostic (5.48e-2)" "unprognostic (1.38e-2)" 5.6 2.3 2.4 16.2 1.9 20.3 2.4 0.6 2.0 6.9 3.4 1.6 3.5 1.8 2.8 1.4 16.8 2.8 7.5 3.5 2.1 2.3 6.4 1.8 9.2 6.1 4.1 1.0 1.5 2.7 0.9 0.7 3.5 1.8 2.6 3.4 0.6 3.4 2.6 1.1 2.8 5.0 3.8 5.1 15.4 2.3 2.2 1.1 2.3 1.4 22.2 21.7 5.9 3.6 1.5 13.2 98.3 28.2 0.0 0.1 10.1 7.5 0.1 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.3 0.1 0.0 2.1 0.5 0.0 0.0 5.2 0.2 14.3 0.3 0.1 0.2 2.8 0.0 0.3 0.0 0.7 52.4 0.0 2.3 0.1 0.1 0.0 0.2 0.2 0.0 0.5 0.0 7.1 0.2 0.1 0.1 0.0 0.0 3.5 0.8 0.1 0.0 0.0 7.1 0.0 0.1 2.0 0.0 0.1 0.3 0.0 0.0 0.5 0.4 2.1 0.0 0.9 0.2 5.9 28.2 98.3 0.0 8.9 0.1 1.5 0.0 0.0 13.2 0.7 0.0 0.0 85.7 0.0 3.5 0.1 0.1 10.1 2.4 1.9 0.6 2.0 2.1 2.3 4.1 1.0 1.8 1.1 PTGER3 EP3 ENSG00000050628 "Prostaglandin E receptor 3" P43115 1 70852353-71047808 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 71.2;endometrium 1: 65.2" "Cell line enhanced" "Detected in some" "ASC diff: 14.9;HAP1: 10.5;HDLM-2: 15.9;HEL: 7.7;T-47d: 36.6" "Group enriched" "Detected in some" 7 "breast cancer: 4.1;renal cancer: 9.4" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 49 "basophil: 22.4" "Lineage enriched" "Detected in single" 49 "granulocytes: 22.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010689 Uncertain "HPA010689: AB_1855883" "unprognostic (1.53e-3)" "unprognostic (3.48e-1)" "unprognostic (1.11e-1)" "unprognostic (3.86e-3)" "unprognostic (1.47e-1)" "unprognostic (3.37e-2)" "unprognostic (4.80e-2)" "unprognostic (2.01e-2)" "unprognostic (1.24e-1)" "unprognostic (4.64e-3)" "unprognostic (1.54e-1)" "unprognostic (1.97e-1)" "prognostic unfavourable (3.50e-4)" "unprognostic (8.83e-3)" "unprognostic (1.86e-1)" "unprognostic (1.92e-2)" "unprognostic (1.41e-4)" 32.5 3.0 3.9 6.8 0.7 0.0 71.2 0.2 1.7 7.8 6.3 0.1 3.0 0.5 65.2 16.6 1.7 4.8 11.3 2.6 0.6 2.0 41.5 0.3 0.6 2.2 0.4 1.4 2.4 10.7 0.0 0.4 0.5 1.6 3.3 1.0 0.1 15.5 3.7 0.5 6.2 1.8 31.9 0.5 0.3 9.1 4.0 0.0 0.0 0.7 3.2 0.7 4.4 5.7 0.0 0.4 22.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 14.9 0.3 0.0 0.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 1.7 0.0 10.5 0.0 0.0 15.9 0.0 7.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.5 0.0 0.1 0.0 36.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 3.5 0.0 22.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.7 0.2 1.7 0.6 2.0 0.4 1.4 1.6 0.0 PTGER4 EP4 ENSG00000171522 "Prostaglandin E receptor 4" P35408 5 40679498-40693735 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pancreas: 57.2" "Cell line enhanced" "Detected in many" "HDLM-2: 18.8;HUVEC TERT2: 13.3;LHCN-M2: 13.0;RT4: 18.9;THP-1: 12.6;TIME: 23.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA011226, HPA012756" Approved "HPA011226: AB_1855885, HPA012756: AB_1855884" "unprognostic (1.79e-2)" "unprognostic (6.53e-3)" "unprognostic (9.43e-3)" "unprognostic (6.77e-3)" "unprognostic (1.44e-1)" "unprognostic (7.16e-2)" "unprognostic (7.28e-3)" "unprognostic (1.86e-2)" "unprognostic (2.19e-1)" "unprognostic (2.83e-1)" "unprognostic (1.02e-1)" "unprognostic (2.76e-1)" "unprognostic (3.61e-2)" "unprognostic (2.17e-1)" "unprognostic (2.48e-2)" "unprognostic (1.44e-1)" "prognostic favourable (2.48e-4)" 10.3 5.1 1.4 12.8 1.2 34.7 6.9 0.4 0.8 8.5 24.8 1.7 1.1 9.4 4.8 2.8 6.0 6.1 14.5 9.0 1.1 1.3 8.4 3.7 16.5 16.6 2.2 0.1 4.3 57.2 0.3 1.6 2.3 2.1 7.0 7.9 4.1 3.6 1.0 7.4 4.0 28.7 6.6 4.5 18.2 8.9 2.1 1.2 23.3 3.3 5.7 9.5 11.6 6.2 1.3 5.4 9.3 15.6 2.5 11.4 4.1 1.6 0.3 0.0 0.0 8.1 9.7 0.0 0.1 0.6 0.5 0.3 0.0 0.5 0.2 0.1 0.0 1.2 0.1 3.0 0.8 18.8 0.3 0.0 0.6 0.0 7.3 6.9 1.4 1.0 0.5 4.8 1.9 13.3 0.0 4.5 13.0 0.0 6.9 3.2 0.0 2.8 4.7 1.3 0.6 1.8 18.9 0.0 0.0 0.3 0.6 0.0 2.9 12.6 23.9 2.5 0.0 0.0 0.6 0.0 0.1 0.9 1.1 5.2 0.6 3.5 4.5 9.3 11.4 12.8 6.6 1.3 6.9 7.1 5.4 1.3 4.2 6.1 8.7 2.5 15.6 0.8 5.5 4.1 1.4 1.2 0.4 0.8 1.1 1.3 2.2 0.1 2.1 1.2 PTGIS "CYP8A1, PGIS" ENSG00000124212 "Prostaglandin I2 synthase" Q16647 20 49503874-49568146 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" Isomerase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 88.2" "Group enriched" "Detected in some" 4 "ASC diff: 17.4;ASC TERT1: 17.5;U-2197: 53.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB009517, HPA014193, HPA052244" Enhanced Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "CAB009517: AB_2173209, HPA014193: AB_1855746, HPA052244: " "unprognostic (7.68e-2)" "unprognostic (1.90e-1)" "unprognostic (5.09e-3)" "unprognostic (1.38e-2)" "unprognostic (1.80e-2)" "unprognostic (1.74e-1)" "unprognostic (1.21e-2)" "unprognostic (1.29e-2)" "unprognostic (1.25e-1)" "unprognostic (4.02e-2)" "unprognostic (2.45e-2)" "unprognostic (5.22e-2)" "prognostic unfavourable (4.74e-8)" "unprognostic (2.29e-2)" "unprognostic (7.61e-2)" "unprognostic (4.89e-3)" "prognostic unfavourable (9.99e-5)" 18.2 2.5 0.6 8.0 1.3 0.1 28.3 0.2 1.6 23.3 14.6 0.5 6.5 1.7 36.5 21.7 13.2 32.0 36.3 23.8 0.3 0.5 3.0 3.8 7.5 1.6 0.5 0.9 51.2 1.3 0.2 0.5 1.0 1.0 27.2 3.7 3.2 3.7 4.6 7.0 3.2 4.4 88.2 1.4 0.3 8.7 16.2 0.3 0.0 6.7 5.6 1.7 64.2 36.1 1.0 0.8 2.7 0.6 0.8 0.5 0.1 0.0 0.0 0.7 0.0 17.4 17.5 0.2 0.3 2.1 0.0 0.0 0.0 0.0 0.0 6.9 5.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 1.2 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.9 53.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.6 0.4 0.4 0.4 0.3 0.4 0.3 0.3 0.1 1.0 0.4 0.5 2.7 0.8 0.3 0.8 0.2 0.1 0.6 1.3 0.2 1.6 0.3 0.5 0.5 0.9 1.0 0.3 PTGS1 "COX1, PGHS-1, PTGHS" ENSG00000095303 "Prostaglandin-endoperoxide synthase 1" P23219 9 122370530-122395703 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" "Dioxygenase, Oxidoreductase, Peroxidase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 211.4;urinary bladder: 163.9" "Cell line enhanced" "Detected in some" "ASC diff: 28.1;ASC TERT1: 22.3;BJ: 27.3;BJ hTERT+: 37.3;HEL: 17.1;HMC-1: 72.7" "Cancer enhanced" "Detected in all" "ovarian cancer: 53.4" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "dendritic cells: 13.0;granulocytes: 14.4;monocytes: 8.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002834, CAB020315" Enhanced Supported "Golgi apparatus,Vesicles" "Intracellular and membrane" 25000000 "Golgi apparatus" Vesicles "CAB020315: , HPA002834: AB_1079711" "unprognostic (4.20e-1)" "unprognostic (6.23e-2)" "unprognostic (1.08e-2)" "unprognostic (2.27e-2)" "unprognostic (5.88e-2)" "unprognostic (2.00e-2)" "unprognostic (1.22e-3)" "unprognostic (3.32e-1)" "unprognostic (2.24e-1)" "unprognostic (3.16e-2)" "unprognostic (1.23e-1)" "unprognostic (1.46e-1)" "prognostic unfavourable (8.68e-4)" "unprognostic (4.03e-2)" "unprognostic (1.78e-2)" "unprognostic (2.08e-1)" "prognostic unfavourable (9.35e-4)" 4.5 1.1 1.8 9.1 3.1 2.6 2.5 0.5 2.7 2.6 35.3 4.6 3.0 3.9 2.5 1.6 25.7 16.7 9.4 4.9 1.9 1.6 3.9 1.8 4.0 1.4 3.5 0.7 3.6 1.0 0.7 2.4 0.8 2.5 60.9 9.3 1.5 1.9 2.3 0.7 55.9 6.5 211.4 4.9 3.6 7.8 1.0 3.1 0.4 1.5 5.3 4.2 163.9 19.5 2.5 13.0 14.4 8.5 1.9 0.1 13.7 0.0 0.1 0.1 0.0 28.1 22.3 0.0 27.3 37.3 0.2 0.2 0.0 0.0 0.9 1.3 4.6 1.7 0.0 2.5 0.2 0.0 0.0 17.1 0.1 0.0 8.1 1.1 72.7 11.4 0.2 1.4 0.0 10.1 0.0 0.0 0.5 0.0 0.0 1.5 0.3 0.1 0.0 0.3 2.0 3.5 0.0 0.1 0.1 0.1 2.3 0.0 0.0 1.9 0.2 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.1 7.4 0.0 12.0 7.6 14.4 0.0 8.5 0.0 1.7 0.0 0.0 13.0 2.5 0.0 0.0 3.5 1.9 6.1 0.9 0.1 13.7 1.8 3.1 0.5 2.7 1.9 1.6 3.5 0.7 2.5 3.1 PTGS2 COX2 ENSG00000073756 "Prostaglandin-endoperoxide synthase 2" P35354 1 186671791-186680427 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" "Dioxygenase, Oxidoreductase, Peroxidase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 11 "ductus deferens: 324.6;seminal vesicle: 377.9" "Cell line enriched" "Detected in some" 4 "BJ hTERT+: 93.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 16 "neutrophil: 12.8" "Lineage enriched" "Detected in single" 16 "granulocytes: 12.8" "Region enhanced" "Detected in many" "hippocampal formation: 16.5" "Low region specificity" "Detected in many" "CAB000113, HPA001335" Approved Supported "Endoplasmic reticulum" "Intracellular and membrane" "Endoplasmic reticulum" "CAB000113: , HPA001335: AB_1079712" "unprognostic (1.36e-3)" "unprognostic (9.97e-3)" "unprognostic (3.97e-2)" "unprognostic (3.31e-2)" "unprognostic (1.55e-1)" "unprognostic (1.11e-1)" "unprognostic (5.96e-2)" "unprognostic (9.50e-2)" "unprognostic (9.03e-3)" "unprognostic (2.81e-1)" "unprognostic (3.24e-2)" "unprognostic (3.07e-2)" "prognostic unfavourable (9.79e-4)" "unprognostic (8.04e-3)" "unprognostic (4.38e-2)" "unprognostic (8.89e-2)" "unprognostic (3.74e-2)" 5.7 2.1 1.2 3.7 1.1 32.6 1.5 0.8 1.9 21.1 11.4 1.1 324.6 0.4 2.3 1.8 1.7 4.0 9.5 9.1 1.1 1.0 3.3 2.7 22.1 2.3 1.3 0.8 1.6 0.4 3.1 2.2 2.5 1.9 9.2 2.7 3.9 0.9 377.9 1.0 1.1 2.4 7.7 4.7 0.9 11.4 1.0 0.9 0.6 1.5 3.4 1.3 17.3 1.9 0.0 0.5 12.8 0.8 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.5 0.5 0.0 21.3 93.1 0.1 0.8 3.3 3.9 0.0 0.0 0.1 2.8 0.0 1.7 0.3 0.0 0.0 0.1 0.5 0.0 3.1 0.0 0.1 0.2 0.6 2.6 6.7 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.3 0.0 0.2 0.0 0.2 0.0 0.1 0.3 4.5 0.1 3.1 0.1 0.0 0.0 0.0 6.5 0.1 0.5 0.0 0.4 0.3 0.0 0.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 12.8 0.0 0.4 0.0 0.0 0.0 1.2 1.1 0.8 1.9 1.1 1.0 1.3 0.8 1.9 0.9 PTK2B "CADTK, CAKB, FAK2, PTK, PYK2, RAFTK" ENSG00000120899 "Protein tyrosine kinase 2 beta" Q14289 8 27311482-27459391 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Angiogenesis, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 46.7;brain: 65.2" "Cell line enhanced" "Detected in many" "Daudi: 37.0;REH: 41.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Group enriched" "Detected in many" 4 "amygdala: 202.9;basal ganglia: 236.9;cerebral cortex: 189.7;hippocampal formation: 443.3;olfactory region: 185.5" "Low region specificity" "Detected in many" "CAB003850, HPA026091, HPA026276" Approved Supported "Plasma membrane,Cytosol" 84000 "Plasma membrane, Cytosol" "CAB003850: AB_562205, HPA026091: AB_10599739, HPA026276: AB_10601234" "unprognostic (2.36e-2)" "prognostic favourable (3.32e-4)" "unprognostic (1.06e-1)" "unprognostic (7.36e-3)" "unprognostic (3.72e-2)" "unprognostic (3.11e-2)" "unprognostic (2.70e-2)" "unprognostic (2.13e-2)" "unprognostic (3.23e-1)" "unprognostic (1.45e-1)" "unprognostic (5.74e-2)" "unprognostic (3.32e-1)" "unprognostic (2.40e-3)" "unprognostic (1.44e-1)" "unprognostic (1.38e-1)" "prognostic favourable (5.11e-4)" "unprognostic (3.33e-3)" 7.2 4.7 20.4 24.3 30.0 46.7 4.9 65.2 48.3 5.4 14.5 7.8 5.0 16.6 4.3 4.7 7.9 6.8 6.4 4.7 30.5 7.0 6.8 5.0 11.5 35.6 4.3 25.4 2.4 5.4 5.2 5.3 4.1 3.9 10.1 11.9 8.3 12.6 6.7 2.2 15.1 18.4 5.5 4.8 32.0 10.8 4.3 3.7 37.8 5.6 2.9 35.4 13.0 6.0 26.9 18.7 24.0 25.8 14.7 19.0 21.5 10.9 3.0 0.8 0.9 23.5 1.7 6.4 0.8 0.5 0.6 0.8 2.9 6.3 37.0 1.2 1.7 10.1 0.3 9.2 0.3 2.5 0.2 7.6 2.9 0.5 4.8 8.2 13.8 12.7 13.8 0.8 5.3 0.3 8.9 25.7 0.6 1.1 14.0 16.5 0.6 0.8 41.0 0.2 25.3 2.6 8.6 5.8 1.0 3.9 2.7 1.4 3.3 21.2 5.2 0.4 0.8 0.7 0.3 20.7 8.9 20.0 1.6 17.8 0.7 22.3 23.7 18.0 19.0 22.4 12.5 25.5 9.6 13.3 18.7 26.9 12.1 14.2 24.0 14.7 25.8 6.2 9.5 21.5 20.4 30.0 65.2 48.3 30.5 7.0 4.3 25.4 3.9 3.7 QPRT QPRTase ENSG00000103485 "Quinolinate phosphoribosyltransferase" Q15274 16 29679008-29698699 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Pyridine nucleotide biosynthesis" "Glycosyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 61.2" "Cell line enhanced" "Detected in many" "EFO-21: 96.7;Hep G2: 40.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 7.7" "Group enriched" "Detected in many" 4 "dendritic cells: 4.6;monocytes: 7.7" HPA011887 Approved "Intracellular and membrane" 230000 "HPA011887: AB_2668555" "prognostic unfavourable (5.10e-5)" "unprognostic (2.00e-1)" "unprognostic (9.48e-2)" "unprognostic (2.88e-1)" "prognostic unfavourable (9.31e-4)" "unprognostic (1.44e-2)" "unprognostic (8.75e-2)" "unprognostic (1.22e-1)" "unprognostic (8.16e-2)" "unprognostic (1.01e-2)" "unprognostic (2.39e-1)" "unprognostic (6.81e-2)" "unprognostic (3.37e-2)" "unprognostic (1.33e-2)" "unprognostic (2.65e-1)" "unprognostic (1.63e-1)" "unprognostic (1.58e-2)" 3.2 36.4 6.1 3.0 5.2 1.1 2.4 1.6 5.8 17.9 10.8 4.4 43.3 20.0 12.7 44.3 1.3 14.9 4.9 11.3 4.9 7.5 40.1 61.2 4.7 2.9 7.9 7.5 15.3 22.9 6.1 2.6 24.3 10.0 4.4 5.2 12.6 15.0 19.4 1.5 1.6 24.1 4.7 6.4 5.3 2.7 3.1 2.6 3.7 2.2 0.3 2.1 5.9 5.1 0.1 4.6 1.2 7.7 0.5 1.4 2.2 0.1 0.2 9.2 10.1 1.5 3.8 22.6 0.9 0.9 1.5 1.8 23.1 16.5 0.4 96.7 1.8 0.1 3.1 0.1 0.8 0.1 2.1 4.7 0.3 40.3 8.8 0.6 1.9 12.0 0.2 0.8 0.0 0.0 11.8 0.5 0.0 22.5 3.0 16.4 28.1 0.0 13.0 2.8 9.1 8.4 0.7 7.4 15.1 0.0 26.3 19.3 19.6 21.1 0.1 0.4 3.8 0.1 0.0 0.3 0.7 3.0 0.7 1.7 1.5 0.0 3.7 0.4 1.3 4.7 1.4 0.1 0.9 1.0 4.6 0.1 0.1 0.7 1.2 0.5 7.7 2.6 0.8 2.2 6.1 5.2 1.6 5.8 4.9 7.5 7.9 7.5 10.0 2.6 RAF1 "c-Raf, CRAF, Raf-1" ENSG00000132155 "Raf-1 proto-oncogene, serine/threonine kinase" P04049 3 12583601-12664226 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 53.9" "Lineage enriched" "Detected in all" 5 "granulocytes: 53.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002640, CAB019291" Approved Approved "Nuclear speckles" "Nuclear speckles" "CAB019291: , HPA002640: AB_1856047" "unprognostic (6.33e-2)" "unprognostic (1.29e-1)" "unprognostic (5.92e-2)" "unprognostic (2.17e-3)" "unprognostic (6.51e-3)" "unprognostic (7.66e-3)" "unprognostic (2.66e-3)" "unprognostic (1.53e-2)" "unprognostic (2.72e-1)" "unprognostic (7.66e-2)" "unprognostic (2.92e-2)" "unprognostic (1.29e-2)" "unprognostic (2.79e-2)" "unprognostic (1.79e-1)" "unprognostic (1.27e-1)" "unprognostic (2.64e-2)" "unprognostic (2.36e-2)" 19.5 15.6 15.1 14.7 17.1 32.2 17.5 35.2 18.9 19.9 20.3 21.1 19.6 18.4 24.9 15.7 24.6 18.6 20.2 39.3 15.3 11.0 21.7 36.2 19.7 15.7 16.0 13.4 24.9 31.3 30.7 16.9 24.8 14.3 18.8 19.2 25.0 18.3 18.4 79.7 23.9 29.6 23.7 13.8 22.1 23.7 16.7 17.8 27.7 26.9 27.9 26.1 20.5 20.4 6.6 9.3 53.9 9.9 8.5 8.6 7.7 15.1 17.4 26.6 20.5 23.1 18.7 53.5 23.1 39.2 30.6 34.8 13.6 12.5 15.9 11.1 35.8 9.7 28.0 20.5 31.9 27.7 21.9 21.4 21.0 12.6 23.4 20.8 20.3 17.2 20.7 31.5 25.6 21.9 15.5 41.8 29.5 25.9 26.7 15.3 27.0 23.7 21.6 23.4 20.0 18.3 22.9 8.3 17.5 18.9 18.3 12.3 30.4 27.5 15.7 21.1 20.1 17.6 25.7 32.6 51.8 34.2 18.2 24.3 22.4 11.3 9.7 18.4 7.4 9.9 7.5 6.6 7.3 7.2 9.3 6.3 7.5 7.6 53.9 8.5 9.6 4.2 8.6 7.7 15.1 17.1 35.2 18.9 15.3 11.0 16.0 13.4 14.3 17.8 RARA "NR1B1, RAR" ENSG00000131759 "Retinoic acid receptor alpha" P10276 17 40309192-40357643 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 63.1;SK-BR-3: 40.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 26.6" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA058282 Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA058282: " "unprognostic (8.05e-3)" "unprognostic (1.89e-1)" "unprognostic (9.48e-3)" "prognostic favourable (2.60e-4)" "unprognostic (8.67e-3)" "unprognostic (4.87e-3)" "unprognostic (2.77e-1)" "unprognostic (5.73e-2)" "unprognostic (1.45e-1)" "unprognostic (3.54e-2)" "unprognostic (1.19e-1)" "unprognostic (1.79e-1)" "unprognostic (2.29e-3)" "unprognostic (1.59e-2)" "unprognostic (5.60e-2)" "unprognostic (1.60e-1)" "unprognostic (1.09e-2)" 27.6 13.5 5.0 18.6 7.6 32.3 23.7 11.5 15.2 30.2 29.6 5.0 16.8 18.0 23.8 23.9 17.3 23.3 30.2 24.3 5.9 6.1 14.6 24.0 32.0 23.4 4.6 7.8 50.0 9.3 7.4 18.1 16.6 6.5 22.9 8.5 26.8 12.1 32.7 43.1 14.3 31.6 18.6 3.7 31.1 14.3 21.8 2.9 9.7 16.3 15.4 20.2 31.5 20.3 1.0 6.1 26.6 9.3 2.5 2.6 1.9 5.0 11.9 3.6 6.0 7.0 10.8 3.6 4.2 6.3 6.2 4.0 8.2 4.4 2.7 6.6 9.4 14.9 4.1 9.9 3.5 20.2 6.1 7.7 6.0 8.0 11.3 2.7 24.4 15.1 2.9 6.5 8.3 9.1 4.8 5.9 6.9 63.1 1.7 9.4 3.1 3.8 3.6 21.1 10.2 3.6 4.0 1.5 12.2 8.9 40.1 12.2 37.8 11.1 10.6 7.7 13.2 13.5 4.5 14.2 4.7 2.3 12.9 5.5 22.8 8.7 4.2 15.7 1.6 6.9 2.6 1.0 1.7 1.7 6.1 0.9 0.8 1.3 26.6 2.5 9.3 1.8 1.4 1.9 5.0 7.6 11.5 15.2 5.9 6.1 4.6 7.8 6.5 2.9 RARB "HAP, NR1B2, RRB2" ENSG00000077092 "Retinoic acid receptor beta" P10826 3 25174332-25597932 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Microphthalmia, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "retina: 39.1" "Cell line enhanced" "Detected in some" "ASC diff: 9.9;HEK 293: 11.2;HUVEC TERT2: 9.3;WM-115: 25.6" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "basal ganglia: 22.6" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Region enriched" "Detected in many" 9 "basal ganglia: 97.9" "Low region specificity" "Detected in all" "CAB002617, HPA004174" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB002617: , HPA004174: AB_1079744" "unprognostic (2.04e-2)" "unprognostic (3.53e-2)" "unprognostic (1.93e-1)" "unprognostic (1.09e-1)" "unprognostic (1.56e-1)" "unprognostic (6.72e-2)" "unprognostic (1.30e-2)" "unprognostic (2.70e-2)" "unprognostic (2.43e-1)" "unprognostic (4.71e-2)" "unprognostic (1.62e-1)" "unprognostic (2.86e-1)" "prognostic favourable (3.43e-5)" "unprognostic (9.24e-3)" "unprognostic (2.28e-1)" "unprognostic (9.99e-2)" "unprognostic (6.56e-3)" 3.9 7.1 2.4 2.3 22.6 0.0 6.8 1.5 9.1 13.4 6.0 2.2 6.8 1.7 14.4 7.5 8.1 6.2 5.3 13.6 2.6 2.2 17.5 6.2 5.6 5.6 2.0 3.7 12.2 1.5 12.8 18.9 13.9 3.2 13.0 2.3 39.1 13.7 11.8 2.5 1.4 2.4 14.7 4.6 7.7 4.8 1.7 4.8 0.0 10.0 2.9 4.6 12.1 10.2 1.0 0.4 0.1 0.6 0.1 0.8 0.0 0.0 1.3 0.8 4.5 9.9 2.6 0.0 1.1 0.5 0.0 0.4 0.2 0.0 0.1 0.1 1.7 0.2 0.0 0.1 0.0 0.0 11.2 0.1 0.1 0.7 0.2 0.1 0.1 5.2 0.0 0.0 0.0 9.3 0.1 3.9 0.1 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.4 5.9 0.0 0.1 0.1 0.0 0.0 0.0 0.8 0.1 1.5 4.8 0.1 0.0 0.0 4.0 0.1 25.6 0.0 0.6 0.0 0.8 0.1 0.3 0.3 0.5 0.5 0.4 1.0 0.6 0.8 0.1 0.1 0.1 0.4 0.0 0.0 2.4 22.6 1.5 9.1 2.6 2.2 2.0 3.7 3.2 4.8 RARG "NR1B3, RARC" ENSG00000172819 "Retinoic acid receptor gamma" P13631 12 53210567-53232980 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 49.4;skin 1: 52.1" "Cell line enhanced" "Detected in many" "CAPAN-2: 33.2;MCF7: 35.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 17.0" "Group enriched" "Detected in all" 4 "dendritic cells: 5.6;T-cells: 17.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA053883 Supported Supported Nucleoplasm Nucleoplasm "HPA053883: AB_2682292" "unprognostic (7.29e-2)" "unprognostic (1.95e-2)" "unprognostic (6.11e-2)" "prognostic unfavourable (3.68e-6)" "unprognostic (2.53e-1)" "unprognostic (5.43e-2)" "unprognostic (2.28e-1)" "unprognostic (1.08e-2)" "unprognostic (3.54e-3)" "unprognostic (7.21e-3)" "unprognostic (3.78e-3)" "unprognostic (4.44e-2)" "prognostic unfavourable (3.08e-6)" "unprognostic (5.41e-3)" "unprognostic (1.98e-2)" "unprognostic (5.94e-3)" "unprognostic (7.41e-2)" 4.8 5.0 2.7 7.0 3.6 1.3 10.8 6.3 3.8 26.8 6.3 1.8 7.3 1.0 14.6 6.0 49.4 10.6 8.6 6.9 3.0 1.4 3.7 1.9 7.4 6.7 2.4 2.3 12.6 2.7 4.2 2.8 4.4 1.6 11.3 3.4 10.3 9.5 10.6 2.6 52.1 3.0 9.7 1.5 4.7 6.0 3.9 1.7 2.3 7.3 30.6 26.8 10.9 19.8 1.8 5.6 1.5 2.5 1.7 17.0 2.9 7.2 8.0 1.8 16.9 18.8 16.2 0.5 7.6 16.6 10.0 7.8 2.7 33.2 0.1 4.1 30.5 24.4 6.1 14.6 2.5 1.9 3.1 1.0 6.1 2.3 7.9 0.0 3.0 11.9 21.4 9.5 2.1 4.2 0.2 3.2 3.9 35.0 0.4 0.3 5.4 14.1 2.3 0.6 5.8 2.9 12.0 1.5 7.6 15.4 16.7 10.1 14.5 0.4 4.5 12.0 5.6 7.9 0.4 1.5 0.8 0.5 14.7 1.2 16.9 1.5 2.5 0.7 6.6 0.8 17.0 1.8 5.7 4.8 5.6 0.6 4.8 4.1 0.0 1.7 0.0 0.4 1.5 2.9 2.7 3.6 6.3 3.8 3.0 1.4 2.4 2.3 1.6 1.7 REN ENSG00000143839 Renin P00797 1 204154819-204190324 "Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Aspartyl protease, Hydrolase, Protease" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "kidney: 63.6" "Cell line enhanced" "Detected in some" "A-431: 2.3;BJ: 4.8;HMC-1: 6.3;RT4: 1.8;SK-BR-3: 4.5" "Cancer enriched" "Detected in many" 8 "renal cancer: 39.4" "Region enriched" "Detected in single" 12 "basal ganglia: 1.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA005131, CAB025903" Approved "Secreted to blood" 692000 "CAB025903: , HPA005131: AB_1079174" "unprognostic (4.45e-2)" "unprognostic (3.35e-1)" "unprognostic (1.62e-1)" "unprognostic (8.58e-2)" "unprognostic (2.89e-1)" "unprognostic (1.23e-2)" "unprognostic (1.24e-1)" "unprognostic (1.13e-1)" "unprognostic (7.20e-3)" "unprognostic (1.37e-1)" "unprognostic (1.57e-1)" "prognostic unfavourable (6.45e-5)" "unprognostic (1.22e-1)" "unprognostic (1.70e-1)" "unprognostic (4.98e-2)" "unprognostic (6.49e-2)" 0.4 0.3 0.0 0.0 1.2 0.0 0.5 0.0 0.0 3.1 0.2 0.0 0.8 0.1 4.4 13.5 0.1 0.3 0.0 0.6 0.0 0.0 63.6 0.4 0.3 0.0 0.0 0.0 11.6 0.0 0.0 0.4 14.4 0.0 0.3 0.1 0.4 0.3 0.5 0.0 0.0 0.1 1.0 0.0 0.0 0.0 2.0 0.0 0.0 1.1 0.0 0.2 4.4 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 2.3 0.0 0.0 0.0 0.3 0.0 0.0 4.8 0.9 0.0 0.0 0.1 0.6 0.0 0.3 0.0 0.4 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.3 0.0 6.3 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.2 0.6 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 1.8 0.2 0.1 0.0 4.5 0.2 0.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 RET "CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51" ENSG00000165731 "Ret proto-oncogene" P07949 10 43077027-43130351 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Hirschsprung disease, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 63.9" "Cell line enhanced" "Detected in some" "MCF7: 17.6;NB-4: 11.6;SH-SY5Y: 89.7;THP-1: 26.8" "Cancer enhanced" "Detected in many" "breast cancer: 11.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "non-classical monocyte: 6.7" "Group enriched" "Detected in many" 13 "dendritic cells: 2.1;monocytes: 6.7" "Low region specificity" "Detected in many" "Region enriched" "Detected in many" 6 "midbrain: 95.5" "CAB002581, HPA008356, HPA008495" Approved Supported Approved "Golgi apparatus,Plasma membrane,Cytosol" 260000 "Golgi apparatus, Cytosol" "Plasma membrane" "CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: " "unprognostic (7.94e-2)" "unprognostic (3.68e-2)" "unprognostic (4.49e-1)" "prognostic unfavourable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (9.13e-4)" "unprognostic (1.27e-2)" "unprognostic (3.62e-2)" "unprognostic (2.86e-1)" "unprognostic (2.01e-1)" "unprognostic (1.54e-3)" "unprognostic (4.43e-1)" "unprognostic (9.35e-5)" "unprognostic (1.64e-3)" "unprognostic (8.28e-2)" "unprognostic (3.67e-3)" "unprognostic (2.02e-2)" 1.8 15.2 1.1 1.8 1.3 0.7 1.2 4.1 9.0 1.9 3.1 0.9 1.1 1.5 0.9 0.6 1.2 0.7 1.0 1.2 1.5 5.8 1.0 11.7 0.7 0.8 17.5 1.2 0.8 1.3 63.9 6.3 0.8 16.8 2.2 1.5 2.8 13.6 2.0 4.5 1.1 2.6 1.1 2.8 0.6 2.1 2.0 0.0 0.1 0.8 5.1 0.6 1.9 1.4 0.2 2.1 0.0 6.7 0.0 0.3 0.4 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 17.6 0.0 11.6 2.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 89.7 0.0 0.0 0.0 1.2 26.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 6.7 2.1 0.3 0.4 1.1 1.3 4.1 9.0 1.5 5.8 17.5 1.2 16.8 0.0 RFK "FLJ11149, RIFK" ENSG00000135002 "Riboflavin kinase" Q969G6 9 76385517-76394517 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023259, CAB033887, HPA057163" Approved Approved "Golgi apparatus" "Golgi apparatus" "CAB033887: AB_2178617, HPA023259: , HPA057163: " "unprognostic (1.79e-1)" "unprognostic (3.98e-2)" "unprognostic (1.83e-1)" "unprognostic (1.03e-1)" "unprognostic (1.34e-1)" "unprognostic (1.76e-3)" "unprognostic (8.61e-3)" "unprognostic (3.11e-1)" "unprognostic (1.39e-1)" "unprognostic (2.88e-1)" "unprognostic (1.02e-1)" "unprognostic (4.61e-2)" "unprognostic (1.22e-3)" "unprognostic (3.22e-2)" "unprognostic (1.83e-1)" "unprognostic (2.70e-1)" "unprognostic (3.88e-2)" 8.1 15.4 24.8 9.8 31.0 15.2 8.7 15.3 27.7 8.9 22.1 5.7 6.2 23.9 9.5 14.3 9.4 10.0 14.5 11.4 33.0 33.5 19.4 23.6 8.8 7.4 22.8 13.2 10.8 11.9 10.3 16.5 26.0 28.3 9.6 16.8 13.3 9.1 7.6 10.3 3.8 39.3 8.5 10.2 8.2 20.3 12.2 8.0 8.1 14.4 5.7 11.6 9.2 7.3 4.9 9.6 3.8 16.3 6.8 6.7 7.8 9.8 10.5 6.5 8.3 9.7 9.6 19.5 11.5 8.4 8.2 6.5 3.7 6.1 16.0 13.6 8.1 10.6 8.7 7.4 16.5 4.8 8.5 5.1 14.7 11.9 17.5 16.7 12.1 6.4 13.5 9.8 10.8 26.5 13.4 13.3 16.4 9.2 21.5 6.1 8.4 11.2 12.0 8.5 4.1 37.7 4.9 16.5 6.1 12.2 17.2 10.0 4.3 9.2 16.6 8.7 15.8 18.8 16.0 14.5 14.4 5.5 14.4 15.0 11.9 3.8 8.1 2.8 4.4 16.0 6.7 4.9 6.5 5.2 9.6 4.0 6.3 6.0 1.2 6.8 16.3 3.6 6.1 7.8 24.8 31.0 15.3 27.7 33.0 33.5 22.8 13.2 28.3 8.0 ROCK1 p160ROCK ENSG00000067900 "Rho associated coiled-coil containing protein kinase 1" Q13464 18 20946906-21111851 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Apoptosis "Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004562, HPA007567, HPA045639" Approved 240000 "CAB004562: AB_628223, HPA007567: AB_1856393, HPA045639: " "unprognostic (7.86e-2)" "unprognostic (2.86e-2)" "unprognostic (1.22e-1)" "unprognostic (6.63e-2)" "unprognostic (9.90e-2)" "unprognostic (1.17e-1)" "unprognostic (6.74e-2)" "unprognostic (1.00e-1)" "unprognostic (1.63e-1)" "unprognostic (8.89e-3)" "prognostic unfavourable (9.93e-4)" "unprognostic (3.85e-2)" "unprognostic (8.93e-3)" "unprognostic (3.04e-2)" "unprognostic (5.47e-2)" "unprognostic (3.19e-1)" "unprognostic (1.28e-1)" 19.3 9.7 9.7 16.3 9.7 40.0 15.1 18.3 11.0 13.9 12.6 7.1 14.4 10.1 16.0 14.9 13.3 14.4 11.7 11.9 10.3 5.6 10.5 9.2 17.0 20.5 10.1 6.0 13.7 9.5 11.2 12.2 11.5 10.3 14.2 9.4 9.5 9.4 9.8 7.9 8.5 11.6 27.7 10.7 17.3 12.0 6.6 12.4 24.8 10.9 9.6 11.2 17.9 21.0 5.4 5.3 17.9 5.0 2.6 5.1 2.0 6.4 4.0 4.0 3.9 7.6 8.2 6.6 9.0 4.4 4.0 4.4 6.7 2.8 8.0 6.5 10.6 5.3 3.6 5.2 8.1 11.3 4.2 6.4 7.4 2.9 3.9 17.5 10.0 5.9 4.8 6.0 4.9 6.1 3.6 8.3 4.7 4.1 8.2 3.8 3.4 6.8 11.7 4.7 3.1 3.9 6.0 4.7 3.7 7.2 4.9 3.6 4.8 6.7 10.1 8.1 6.7 7.3 7.3 11.4 5.1 9.2 6.1 7.5 5.0 2.8 5.0 6.3 5.1 3.1 4.1 3.7 3.8 3.9 4.0 5.4 3.7 3.6 17.9 2.6 3.6 5.3 3.2 2.0 9.7 9.7 18.3 11.0 10.3 5.6 10.1 6.0 10.3 12.4 ROCK2 ENSG00000134318 "Rho associated coiled-coil containing protein kinase 2" O75116 2 11179761-11348330 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007459, CAB008666, HPA044109" Approved Supported Cytosol 3700000 Cytosol "CAB008666: AB_1622617, HPA007459: AB_1079828, HPA044109: AB_2678813" "unprognostic (4.55e-2)" "unprognostic (1.05e-2)" "unprognostic (4.18e-3)" "unprognostic (4.87e-2)" "unprognostic (1.49e-1)" "unprognostic (2.71e-1)" "unprognostic (1.39e-2)" "unprognostic (2.72e-1)" "unprognostic (3.62e-2)" "unprognostic (6.66e-2)" "unprognostic (3.83e-2)" "unprognostic (1.48e-1)" "prognostic unfavourable (1.57e-5)" "unprognostic (1.51e-1)" "unprognostic (1.99e-1)" "unprognostic (2.52e-2)" "unprognostic (3.47e-2)" 26.9 7.8 14.6 9.5 21.9 4.4 21.4 26.1 26.4 16.6 16.5 5.6 8.6 12.3 22.4 11.0 12.4 13.2 11.9 12.3 13.4 7.6 11.4 12.3 16.7 6.8 7.2 16.7 15.1 8.6 12.9 14.8 18.4 10.3 14.4 20.3 5.6 10.3 14.4 28.0 8.7 13.8 42.9 7.1 12.6 10.7 5.8 9.6 5.9 10.5 5.1 6.2 22.1 20.8 2.5 3.0 3.6 2.2 3.5 3.3 0.9 6.5 15.9 13.2 12.9 23.8 16.7 8.4 15.5 14.5 10.1 10.7 15.0 14.3 8.2 9.2 24.5 7.3 9.5 8.9 16.0 11.7 5.7 16.4 27.4 30.0 8.6 9.1 4.7 13.0 5.7 12.4 8.9 16.1 14.2 3.3 15.0 5.5 6.7 4.7 7.3 9.8 8.1 29.0 2.6 5.5 18.5 6.2 6.6 30.4 10.6 10.6 4.3 5.1 21.9 20.9 15.1 8.3 13.6 2.6 3.2 7.3 9.0 10.8 29.1 3.6 1.8 1.7 2.7 2.2 3.3 1.6 2.2 1.8 1.3 2.5 1.9 2.1 3.0 3.5 1.7 3.0 1.8 0.9 14.6 21.9 26.1 26.4 13.4 7.6 7.2 16.7 10.3 9.6 RPL3 L3 ENSG00000100316 "Ribosomal protein L3" P39023 22 39312882-39320389 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Ribonucleoprotein, Ribosomal protein" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003365, HPA055361" Uncertain Supported Nucleoli,Cytosol 120000 "Nucleoli, Cytosol" "HPA003365: AB_1079841, HPA055361: " "unprognostic (9.79e-3)" "unprognostic (2.06e-1)" "unprognostic (2.31e-1)" "unprognostic (1.68e-3)" "unprognostic (5.44e-3)" "unprognostic (1.72e-1)" "unprognostic (3.51e-2)" "unprognostic (1.22e-1)" "unprognostic (3.63e-1)" "unprognostic (5.81e-2)" "unprognostic (5.87e-2)" "unprognostic (7.09e-2)" "unprognostic (2.54e-2)" "unprognostic (1.85e-1)" "unprognostic (6.09e-2)" "unprognostic (2.72e-1)" "unprognostic (4.32e-2)" 71.7 71.8 51.3 72.3 50.3 107.0 134.5 50.8 49.3 102.2 94.4 42.7 78.1 63.1 207.5 79.6 126.9 101.6 96.2 54.5 41.4 38.8 66.6 102.5 74.5 205.9 47.4 57.7 217.8 453.1 50.9 75.0 74.5 58.0 138.7 57.0 74.8 216.3 68.5 48.9 118.1 62.6 115.6 50.7 84.3 74.4 76.4 23.3 105.5 158.5 82.3 109.8 119.9 105.7 198.9 114.8 18.9 56.4 150.3 249.0 326.4 86.4 80.1 91.6 101.3 117.3 254.3 123.5 67.0 127.6 67.1 60.3 100.6 66.1 357.7 92.9 80.7 57.6 97.7 143.3 44.7 60.8 96.3 90.0 95.8 150.5 173.2 127.9 76.0 245.7 194.2 58.0 206.7 130.4 101.3 124.4 96.9 111.3 129.8 186.2 95.8 55.9 104.3 88.9 179.5 123.9 128.2 83.9 99.1 42.0 137.6 219.3 103.7 208.6 129.2 45.1 71.3 47.2 76.3 95.6 72.2 158.4 101.6 113.1 50.9 18.9 56.4 11.9 132.5 51.7 205.6 198.9 192.1 153.7 101.2 175.8 249.0 195.2 8.1 150.3 44.5 114.8 126.1 326.4 51.3 50.3 50.8 49.3 41.4 38.8 47.4 57.7 58.0 23.3 RRM1 ENSG00000167325 "Ribonucleotide reductase catalytic subunit M1" P23921 11 4094707-4138876 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA replication" "Allosteric enzyme, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 78.6" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022093, HPA057265, HPA064297" Enhanced Enhanced Cytosol 13000 Cytosol "CAB022093: , HPA057265: , HPA064297: " "unprognostic (4.47e-2)" "unprognostic (1.73e-2)" "unprognostic (1.99e-3)" "unprognostic (3.65e-1)" "unprognostic (2.83e-1)" "unprognostic (2.19e-1)" "prognostic unfavourable (1.53e-4)" "unprognostic (1.31e-2)" "unprognostic (3.43e-2)" "unprognostic (6.90e-2)" "unprognostic (1.06e-3)" "unprognostic (4.21e-2)" "unprognostic (6.88e-3)" "unprognostic (9.20e-3)" "unprognostic (6.16e-2)" "unprognostic (8.41e-2)" "unprognostic (9.93e-3)" 13.9 25.3 8.0 15.2 12.2 18.5 14.4 18.0 12.6 15.7 15.9 11.1 11.5 11.9 13.0 9.8 25.4 10.7 8.7 11.9 7.9 9.0 9.2 13.1 11.0 20.2 9.0 10.3 13.6 10.7 24.2 11.2 22.7 18.4 14.0 18.9 12.0 15.4 10.7 28.3 26.8 12.5 17.5 10.7 12.4 13.8 10.5 9.1 78.6 9.8 28.0 27.1 17.5 18.5 5.6 4.3 3.3 8.3 5.7 24.3 6.0 45.4 24.7 40.5 23.5 6.2 12.4 15.7 41.9 20.8 47.7 49.2 22.2 34.6 49.2 10.2 20.9 36.6 37.5 30.1 56.5 24.2 39.8 25.0 37.1 17.3 2.5 42.8 18.4 5.8 8.1 26.1 18.8 22.8 32.6 23.3 39.7 20.6 50.3 9.3 25.6 25.1 40.8 31.7 17.6 13.1 12.9 34.7 19.0 36.9 22.3 6.7 22.0 15.0 13.0 44.9 23.5 44.4 30.7 15.2 21.1 53.8 24.9 28.7 27.8 3.3 2.5 2.6 7.7 6.5 13.3 5.6 14.2 10.7 4.3 3.5 11.3 9.2 0.0 5.7 8.3 2.7 24.3 6.0 8.0 12.2 18.0 12.6 7.9 9.0 9.0 10.3 18.4 9.1 RRM2 ENSG00000171848 "Ribonucleotide reductase regulatory subunit M2" P31350 2 10120698-10131419 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "DNA replication" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 120.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "T-reg: 10.4" "Lineage enriched" "Detected in many" 6 "T-cells: 10.4" HPA056994 Enhanced Supported Cytosol Cytosol "HPA056994: " "unprognostic (2.10e-2)" "unprognostic (1.62e-1)" "unprognostic (6.40e-3)" "unprognostic (4.42e-3)" "unprognostic (5.70e-2)" "unprognostic (1.69e-1)" "prognostic unfavourable (1.39e-5)" "unprognostic (1.04e-3)" "unprognostic (6.67e-3)" "unprognostic (4.53e-2)" "prognostic unfavourable (1.62e-4)" "unprognostic (5.11e-3)" "prognostic unfavourable (0.00e+0)" "unprognostic (3.05e-2)" "unprognostic (2.24e-1)" "unprognostic (1.38e-1)" "unprognostic (2.09e-2)" 4.7 2.2 0.4 32.6 0.4 29.0 4.2 0.4 0.9 3.5 9.3 0.4 0.4 5.2 2.1 1.7 21.6 0.7 5.0 3.3 0.4 0.5 2.0 3.9 5.7 16.4 0.6 0.1 0.9 2.9 0.0 0.7 5.4 0.3 1.0 10.6 0.1 2.9 0.0 0.5 2.8 11.3 3.2 0.8 19.8 5.4 8.0 0.0 120.9 0.8 22.3 33.1 3.8 5.2 1.4 0.3 0.6 0.2 1.8 10.4 2.6 29.1 17.7 25.0 17.1 2.2 4.1 24.8 47.7 23.6 34.1 37.1 29.5 14.0 26.8 6.6 14.9 14.3 40.5 24.6 41.8 60.0 15.6 51.6 17.0 26.0 0.1 38.2 24.8 1.4 0.5 41.7 3.5 27.5 21.6 79.5 42.4 22.0 42.2 20.5 20.2 20.7 31.8 54.6 18.4 16.7 22.2 24.8 20.4 39.2 27.9 4.8 15.0 6.9 9.6 26.1 38.0 19.5 66.8 51.6 40.5 54.7 18.5 32.4 37.5 0.3 0.1 0.1 3.7 0.0 0.0 1.4 2.6 2.9 0.2 0.4 0.2 1.2 0.6 1.8 0.2 0.3 10.4 2.6 0.4 0.4 0.4 0.9 0.4 0.5 0.6 0.1 0.3 0.0 RRM2B p53R2 ENSG00000048392 "Ribonucleotide reductase regulatory TP53 inducible subunit M2B" Q7LG56 8 102204502-102239118 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA repair, DNA replication" Oxidoreductase "Disease mutation, FDA approved drug targets, Neuropathy, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB006854, HPA028812" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB006854: , HPA028812: AB_10602246" "unprognostic (7.76e-3)" "unprognostic (4.14e-2)" "unprognostic (9.41e-3)" "unprognostic (3.41e-1)" "unprognostic (1.13e-2)" "unprognostic (1.28e-1)" "unprognostic (5.51e-2)" "unprognostic (1.35e-2)" "unprognostic (1.66e-1)" "unprognostic (9.40e-2)" "unprognostic (1.74e-2)" "unprognostic (1.03e-1)" "unprognostic (1.70e-2)" "unprognostic (4.32e-1)" "unprognostic (1.47e-1)" "unprognostic (2.52e-1)" "unprognostic (7.17e-2)" 11.8 18.6 11.7 11.5 11.4 4.3 9.3 8.5 13.5 9.5 10.1 9.8 9.5 10.2 8.2 10.8 8.0 9.7 8.2 11.3 17.5 12.8 17.5 15.1 15.8 12.6 14.9 10.6 9.7 9.5 34.7 24.8 11.6 23.1 11.2 11.1 7.7 9.7 10.9 34.6 7.4 7.6 8.2 26.1 10.6 7.1 6.6 9.4 6.3 37.1 8.1 13.1 10.7 7.0 7.4 6.2 18.3 8.4 3.0 3.3 2.8 5.6 10.1 12.0 7.1 17.0 16.4 9.6 13.2 16.0 7.1 8.3 3.6 4.6 36.4 12.5 14.6 2.1 5.8 13.4 10.1 5.9 6.3 9.1 4.3 7.6 13.8 2.8 19.5 20.8 25.3 7.8 11.9 19.8 6.7 5.6 22.7 5.6 4.8 5.3 6.7 7.5 3.1 4.9 7.3 16.5 6.5 3.0 6.0 6.9 3.7 7.9 9.9 6.3 15.1 11.0 21.4 7.6 3.6 5.9 5.4 33.1 16.2 4.3 11.6 10.0 5.1 5.3 2.2 4.5 3.3 5.6 2.0 2.8 6.2 7.4 2.3 2.5 18.3 3.0 8.4 1.8 1.4 2.8 11.7 11.4 8.5 13.5 17.5 12.8 14.9 10.6 23.1 9.4 RXRA NR2B1 ENSG00000186350 "Retinoid X receptor alpha" P19793 9 134317098-134440585 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HaCaT: 27.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 14.9;non-classical monocyte: 12.3" "Group enriched" "Detected in many" 8 "granulocytes: 14.9;monocytes: 12.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004565, CAB005352" Supported Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "CAB004565: AB_2184877, CAB005352: AB_2184874" "unprognostic (2.68e-1)" "unprognostic (7.94e-2)" "unprognostic (3.67e-2)" "unprognostic (7.22e-2)" "unprognostic (2.07e-2)" "unprognostic (6.69e-2)" "unprognostic (1.52e-1)" "unprognostic (2.15e-1)" "unprognostic (3.45e-2)" "unprognostic (1.65e-3)" "prognostic favourable (7.02e-4)" "unprognostic (7.72e-2)" "prognostic unfavourable (5.58e-4)" "unprognostic (1.25e-2)" "unprognostic (2.58e-1)" "unprognostic (1.49e-2)" "unprognostic (2.59e-1)" 18.5 10.1 9.9 10.4 6.7 19.6 36.8 4.6 9.8 11.0 9.3 4.9 8.1 14.0 10.1 6.1 24.2 9.3 12.9 14.2 9.0 3.7 11.7 49.3 12.8 10.4 6.0 7.0 11.7 20.6 8.0 10.7 9.6 9.4 9.7 2.0 9.5 9.3 9.7 45.8 19.0 15.2 10.6 9.5 11.5 8.8 5.9 8.1 1.5 13.6 18.3 5.9 16.0 23.7 0.1 1.7 14.9 12.3 1.3 1.1 1.8 5.5 15.6 2.0 5.0 3.5 3.3 24.0 3.0 3.5 4.3 2.5 8.6 8.7 0.0 8.2 4.3 27.0 0.7 10.6 0.2 7.9 2.0 0.0 19.0 13.1 4.5 6.5 2.4 5.3 4.5 5.4 2.5 3.7 10.7 0.5 1.0 14.9 0.5 1.4 3.8 5.4 2.8 7.4 10.8 0.2 24.1 4.4 2.0 9.5 9.1 2.4 12.6 8.9 4.8 5.3 6.4 5.7 2.6 0.7 0.0 0.1 4.0 6.6 3.4 1.1 5.2 2.8 1.1 9.3 0.0 0.1 0.7 0.7 1.7 0.0 0.2 0.9 14.9 1.3 12.3 0.1 0.9 1.8 9.9 6.7 4.6 9.8 9.0 3.7 6.0 7.0 9.4 8.1 RXRB "H-2RIIBP, NR2B2, RCoR-1" ENSG00000204231 "Retinoid X receptor beta" P28702 6 33193588-33200688 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "CACO-2: 7.0;RH-30: 8.7;RT4: 8.2;T-47d: 8.5;U-698: 8.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002003, HPA063653" Supported Supported Nucleoplasm Nucleoplasm "CAB002003: , HPA063653: " "unprognostic (3.51e-1)" "unprognostic (8.46e-2)" "unprognostic (1.94e-1)" "unprognostic (2.22e-2)" "unprognostic (2.00e-2)" "unprognostic (4.71e-3)" "unprognostic (4.18e-2)" "unprognostic (2.21e-2)" "unprognostic (1.86e-1)" "unprognostic (2.03e-1)" "unprognostic (1.67e-3)" "unprognostic (8.13e-3)" "unprognostic (9.53e-3)" "unprognostic (8.30e-2)" "unprognostic (1.55e-1)" "unprognostic (6.38e-2)" "unprognostic (8.53e-3)" 24.9 18.9 13.0 14.0 16.1 9.8 16.0 24.7 23.2 22.8 17.1 17.7 17.3 19.0 17.4 56.6 13.7 18.5 17.1 27.7 13.5 12.3 14.1 17.4 16.5 9.8 16.4 15.6 19.1 16.2 3.6 17.5 19.2 15.5 20.1 8.4 16.0 16.2 22.0 19.7 25.5 14.1 28.4 10.4 19.8 13.9 10.4 18.2 18.5 22.0 10.9 24.5 14.0 14.5 1.9 1.4 5.2 1.2 1.9 2.5 0.7 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 7.0 0.0 5.3 4.0 0.0 3.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 5.8 0.0 0.0 0.0 0.0 0.0 5.2 0.0 5.2 0.0 0.0 0.2 3.1 0.0 0.0 8.7 0.0 5.3 8.2 0.0 4.7 0.0 0.0 0.0 8.5 0.0 0.0 0.0 3.8 0.0 0.0 6.8 5.8 8.4 0.0 0.0 0.0 5.2 0.8 2.9 2.5 0.9 1.8 1.9 2.5 2.4 1.3 0.8 2.4 1.5 1.9 1.9 1.2 1.4 2.5 0.7 13.0 16.1 24.7 23.2 13.5 12.3 16.4 15.6 15.5 18.2 RXRG NR2B3 ENSG00000143171 "Retinoid X receptor gamma" P48443 1 165400917-165445355 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 14.9;pituitary gland: 29.8;retina: 13.5;skeletal muscle: 44.8" "Cell line enriched" "Detected in some" 7 "SK-MEL-30: 28.3" "Group enriched" "Detected in many" 13 "melanoma: 25.7;thyroid cancer: 34.8" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 5 "basal ganglia: 89.8" "Low region specificity" "Detected in all" "CAB002615, HPA012933" Uncertain Approved "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "CAB002615: , HPA012933: " "unprognostic (2.29e-1)" "unprognostic (1.08e-2)" "unprognostic (1.51e-1)" "unprognostic (1.66e-1)" "unprognostic (4.29e-2)" "unprognostic (6.19e-2)" "unprognostic (1.35e-1)" "unprognostic (1.05e-2)" "unprognostic (9.13e-2)" "unprognostic (6.86e-2)" "unprognostic (2.95e-2)" "unprognostic (5.41e-3)" "unprognostic (2.52e-2)" "unprognostic (6.12e-3)" "unprognostic (1.18e-1)" "prognostic favourable (9.40e-5)" "unprognostic (5.03e-2)" 1.9 3.9 5.4 1.0 14.9 0.6 1.0 0.3 5.9 4.0 2.5 5.3 0.6 1.3 1.8 1.3 1.7 3.6 1.2 5.8 7.5 8.9 0.7 0.8 3.4 0.8 4.1 4.3 1.7 2.7 0.8 29.8 1.3 14.1 1.1 2.7 13.5 1.9 2.1 44.8 2.9 2.0 1.8 8.9 1.0 1.1 1.5 5.4 0.0 1.1 2.5 0.6 1.2 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.0 0.0 0.0 1.3 0.0 0.0 0.0 28.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 14.9 0.3 5.9 7.5 8.9 4.1 4.3 14.1 5.4 RYR1 "CCO, MHS, MHS1, PPP1R137, RYR" ENSG00000196218 "Ryanodine receptor 1" P21817 19 38433699-38587564 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Developmental protein, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "skeletal muscle: 231.0" "Cell line enhanced" "Detected in some" "HaCaT: 13.7;RH-30: 11.3;SiHa: 22.3;U-2 OS: 9.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "intermediate monocyte: 3.2;myeloid DC: 5.3;non-classical monocyte: 6.3" "Group enriched" "Detected in many" 7 "dendritic cells: 5.3;monocytes: 6.3" "Low region specificity" "Detected in some" HPA056416 Enhanced Approved "Golgi apparatus,Vesicles,Cytosol" "Golgi apparatus, Vesicles" Cytosol "HPA056416: " "unprognostic (2.22e-3)" "unprognostic (1.91e-3)" "unprognostic (9.59e-2)" "unprognostic (5.34e-4)" "unprognostic (2.50e-1)" "unprognostic (6.00e-2)" "unprognostic (2.11e-1)" "unprognostic (1.06e-1)" "unprognostic (1.18e-1)" "unprognostic (3.20e-3)" "unprognostic (3.52e-1)" "unprognostic (2.35e-1)" "unprognostic (1.07e-5)" "unprognostic (1.13e-2)" "unprognostic (8.10e-2)" "unprognostic (6.62e-3)" "unprognostic (1.34e-1)" 5.3 0.7 3.0 0.6 1.9 0.4 0.6 2.7 1.7 0.6 0.4 2.7 0.0 0.4 0.4 6.7 3.0 0.6 0.5 0.4 1.8 4.0 0.5 0.4 0.7 0.6 1.5 1.3 0.4 0.4 0.3 0.3 0.6 1.9 0.9 0.4 0.4 2.2 0.6 231.0 2.4 0.5 0.4 1.1 0.6 0.5 1.6 1.9 0.0 1.6 55.1 3.2 0.6 0.5 0.7 5.3 0.1 6.3 0.0 0.6 0.6 0.0 5.6 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 2.0 0.3 0.3 4.7 0.0 13.7 0.2 0.0 0.0 0.0 0.2 1.0 0.0 0.0 0.0 0.0 0.4 1.3 5.6 0.0 0.0 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 11.3 1.0 0.6 0.0 0.0 1.1 22.3 0.0 0.0 0.5 4.2 0.0 0.0 9.4 0.2 0.0 0.3 0.9 0.3 0.1 0.0 0.0 0.0 0.6 0.0 0.4 3.2 0.5 0.4 0.3 0.6 5.3 0.7 0.0 0.0 0.1 0.0 6.3 0.0 0.6 0.6 3.0 1.9 2.7 1.7 1.8 4.0 1.5 1.3 1.9 1.9 RYR2 "ARVC2, ARVD2, VTSIP" ENSG00000198626 "Ryanodine receptor 2" Q92736 1 237042205-237833988 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Developmental protein, Ion channel, Ligand-gated ion channel, Receptor" "Cardiomyopathy, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "heart muscle: 106.6" "Cell line enhanced" "Detected in some" "HDLM-2: 7.7;HEK 293: 10.4;K-562: 3.2;NB-4: 2.7;NTERA-2: 3.9;U-937: 4.8" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020028 Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" "Nucleoplasm, Plasma membrane, Cytosol" "HPA020028: AB_1856528" "unprognostic (5.23e-3)" "unprognostic (2.15e-2)" "unprognostic (5.02e-4)" "unprognostic (6.26e-2)" "unprognostic (8.74e-2)" "unprognostic (2.99e-3)" "unprognostic (5.28e-2)" "unprognostic (1.45e-3)" "unprognostic (2.69e-2)" "unprognostic (1.04e-1)" "unprognostic (1.10e-1)" "unprognostic (4.04e-2)" "unprognostic (0.00e+0)" "unprognostic (2.36e-2)" "unprognostic (1.42e-1)" "unprognostic (3.13e-2)" "unprognostic (1.06e-2)" 1.1 0.9 6.2 0.9 18.7 0.5 1.1 14.8 10.5 1.3 1.2 0.0 1.2 0.7 1.1 0.7 1.8 1.0 1.8 106.6 5.7 1.1 0.9 0.9 1.4 0.6 1.0 7.3 2.2 4.2 0.5 2.0 1.1 1.6 2.0 0.8 0.2 0.9 1.4 0.9 1.0 1.0 4.6 1.0 1.0 1.2 1.1 3.0 0.0 2.7 0.0 0.6 1.2 1.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.3 0.0 0.3 0.5 0.0 0.0 7.7 10.4 2.1 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 3.2 0.2 0.0 0.0 0.0 2.7 3.9 0.4 0.0 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 4.8 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 6.2 18.7 14.8 10.5 5.7 1.1 1.0 7.3 1.6 3.0 S1PR5 "Edg-8, EDG8" ENSG00000180739 "Sphingosine-1-phosphate receptor 5" Q9H228 19 10512742-10517931 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 62.0;brain: 37.8;skin 1: 25.4" "Cell line enhanced" "Detected in some" "HaCaT: 21.5;HBEC3-KT: 8.3;RT4: 14.0;T-47d: 8.9;U-2 OS: 8.0" "Group enriched" "Detected in many" 5 "cervical cancer: 11.7;head and neck cancer: 8.0;lung cancer: 3.7;urothelial cancer: 6.2" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "gdT-cell: 62.0;MAIT T-cell: 38.0;memory CD8 T-cell: 29.2;naive CD8 T-cell: 23.2" "Lineage enriched" "Detected in many" 8 "T-cells: 62.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA029683 Enhanced "HPA029683: AB_10603237" "unprognostic (9.07e-3)" "unprognostic (1.27e-1)" "unprognostic (1.28e-2)" "unprognostic (5.55e-4)" "unprognostic (4.21e-1)" "unprognostic (4.85e-2)" "unprognostic (9.30e-2)" "unprognostic (1.55e-1)" "unprognostic (3.48e-2)" "unprognostic (2.29e-1)" "unprognostic (1.81e-1)" "unprognostic (1.27e-1)" "prognostic unfavourable (6.71e-7)" "unprognostic (2.46e-2)" "unprognostic (2.90e-2)" "unprognostic (1.19e-1)" "unprognostic (1.52e-1)" 1.4 1.0 10.0 1.6 17.4 21.0 1.1 1.9 15.1 2.7 1.0 37.8 0.0 0.9 1.1 6.9 6.5 1.0 1.0 0.9 15.7 8.0 1.1 2.7 3.0 1.7 28.8 9.3 0.7 0.8 0.6 0.2 2.8 13.9 2.0 0.8 0.7 1.3 1.4 1.4 25.4 1.0 0.9 26.2 11.6 0.9 0.9 21.0 0.0 0.8 0.2 3.3 3.1 5.0 0.1 0.1 0.8 0.1 8.1 62.0 10.2 1.4 2.2 0.4 0.0 0.0 0.1 0.1 0.5 0.3 0.6 0.4 0.2 0.1 0.0 5.9 0.2 21.5 1.4 8.3 1.6 0.0 1.4 0.2 1.7 0.0 0.0 0.0 0.1 0.0 3.9 2.3 0.4 0.0 0.1 0.0 0.0 2.7 0.8 0.0 3.4 0.4 0.0 1.6 0.0 0.0 14.0 0.0 0.0 3.5 0.0 0.4 8.9 2.5 0.0 1.1 8.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.1 0.2 62.0 0.0 38.0 0.1 7.8 29.2 0.1 0.1 2.4 23.2 0.8 8.1 0.1 0.1 0.1 10.2 10.0 17.4 1.9 15.1 15.7 8.0 28.8 9.3 13.9 21.0 SCN11A "NaN, Nav1.9, SCN12A, SNS-2" ENSG00000168356 "Sodium voltage-gated channel alpha subunit 11" Q9UI33 3 38845769-38950561 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 7.5;placenta: 5.2" "Cell line enhanced" "Detected in some" "AF22: 1.7;HDLM-2: 4.9;SCLC-21H: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 8 "amygdala: 0.9;basal ganglia: 0.4;cerebral cortex: 0.6;hippocampal formation: 0.8" "HPA036746, HPA036747" Uncertain "HPA036746: AB_10696785, HPA036747: " "unprognostic (6.11e-2)" "unprognostic (5.16e-1)" "unprognostic (1.66e-1)" "unprognostic (4.75e-2)" "unprognostic (4.21e-2)" "unprognostic (2.34e-2)" "unprognostic (2.79e-2)" "unprognostic (5.66e-2)" "unprognostic (4.44e-2)" "unprognostic (5.21e-2)" "unprognostic (2.30e-4)" "unprognostic (1.91e-2)" "unprognostic (5.43e-2)" "unprognostic (5.02e-2)" "unprognostic (2.95e-1)" "unprognostic (3.12e-2)" "unprognostic (8.30e-4)" 0.9 0.2 0.8 0.5 0.8 0.0 0.6 0.1 0.3 0.0 1.1 0.4 0.0 1.4 0.0 0.1 0.1 0.0 0.4 0.5 0.4 0.3 0.0 0.2 0.4 0.0 0.1 0.0 0.4 5.2 0.1 1.3 0.0 0.0 0.1 0.8 1.0 0.5 0.6 7.5 0.0 2.6 0.1 0.1 3.4 0.1 0.2 0.4 0.9 0.1 0.1 0.2 0.0 0.0 0.0 1.7 0.0 0.1 0.1 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.3 0.1 0.1 4.9 0.4 0.1 0.0 0.0 0.3 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.6 0.4 0.0 0.1 0.0 0.0 0.0 0.5 1.1 0.6 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.1 0.0 0.0 0.7 0.1 0.3 0.0 0.0 0.1 0.7 0.1 0.0 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.9 0.1 0.1 0.4 0.0 0.0 SCN1A "FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI" ENSG00000144285 "Sodium voltage-gated channel alpha subunit 1" P35498 2 165984641-166149214 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 33.9" "Group enriched" "Detected in some" 4 "ASC TERT1: 11.3;Hep G2: 6.0" "Cancer enriched" "Detected in single" 8 "glioma: 1.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA078664 Supported "Nucleoplasm,Nuclear bodies,Plasma membrane" "Nucleoplasm, Plasma membrane" "Nuclear bodies" "HPA078664: " "unprognostic (9.25e-2)" "unprognostic (3.97e-2)" "unprognostic (6.88e-2)" "unprognostic (7.44e-2)" "unprognostic (1.50e-1)" "unprognostic (2.74e-1)" "unprognostic (4.70e-2)" "unprognostic (2.88e-1)" "unprognostic (1.67e-1)" "unprognostic (9.59e-2)" "unprognostic (1.23e-1)" "unprognostic (5.03e-9)" "unprognostic (6.92e-2)" "unprognostic (3.69e-2)" "unprognostic (5.06e-3)" "unprognostic (6.93e-1)" 1.1 1.3 5.2 1.1 13.6 1.0 1.1 10.3 26.6 1.1 1.1 2.3 0.0 1.0 1.1 1.1 1.0 6.8 1.0 1.1 6.9 8.3 1.1 1.1 5.6 1.0 5.7 9.7 1.0 1.0 1.1 2.9 1.2 33.9 1.1 1.1 0.3 1.0 1.0 1.2 1.1 1.1 1.1 3.6 1.1 1.1 1.4 4.2 0.0 1.1 0.0 1.0 1.1 0.1 0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 11.3 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 6.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 5.2 13.6 10.3 26.6 6.9 8.3 5.7 9.7 33.9 4.2 SCN2A "HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2" ENSG00000136531 "Sodium voltage-gated channel alpha subunit 2" Q99250 2 165194993-165392310 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 68.0" "Cell line enhanced" "Detected in some" "HSkMC: 3.3;SH-SY5Y: 3.1;U-138 MG: 5.7;U-266/84: 11.8;U-87 MG: 3.5" "Cancer enhanced" "Detected in single" "glioma: 1.3" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "naive B-cell: 1.4" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB022567 Enhanced "CAB022567: " "unprognostic (1.16e-1)" "unprognostic (3.56e-4)" "unprognostic (5.28e-2)" "unprognostic (6.12e-3)" "unprognostic (2.97e-1)" "unprognostic (8.62e-3)" "unprognostic (1.18e-1)" "unprognostic (7.25e-3)" "unprognostic (1.40e-1)" "unprognostic (2.78e-1)" "unprognostic (1.32e-2)" "unprognostic (5.21e-2)" "unprognostic (3.44e-2)" "unprognostic (1.76e-1)" "unprognostic (1.05e-1)" "unprognostic (4.88e-2)" "unprognostic (2.14e-1)" 1.3 3.0 19.1 1.3 36.4 1.1 2.2 68.0 50.3 1.5 1.3 1.1 0.0 1.5 1.9 2.6 1.2 1.3 2.3 1.3 30.3 8.2 4.0 1.4 1.5 1.2 3.8 23.5 1.5 1.3 1.1 8.2 1.3 9.9 1.3 1.3 0.0 1.5 1.8 1.1 1.2 1.5 2.0 3.7 1.3 1.5 1.5 4.1 0.0 1.1 0.0 1.2 1.3 0.5 1.4 0.6 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.2 0.7 0.0 0.0 2.7 0.0 2.7 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 0.1 1.0 0.7 0.0 0.4 0.0 0.4 0.0 0.2 3.3 0.1 0.3 0.0 0.0 0.0 0.3 1.5 0.0 0.2 0.0 2.0 0.2 0.0 0.0 0.0 0.1 0.1 2.8 3.1 0.0 0.0 0.0 0.0 0.0 0.0 5.7 0.4 0.3 0.0 0.5 11.8 0.0 3.5 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 1.4 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 19.1 36.4 68.0 43.7 30.3 8.2 3.8 23.5 9.9 4.1 SCN3A Nav1.3 ENSG00000153253 "Sodium voltage-gated channel alpha subunit 3" Q9NY46 2 165087522-165204067 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 13.6;brain: 28.5;pituitary gland: 13.7" "Cell line enhanced" "Detected in some" "Karpas-707: 8.5;MOLT-4: 24.1;RPTEC TERT1: 12.1;SH-SY5Y: 5.4" "Cancer enriched" "Detected in some" 6 "glioma: 3.4" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 31 "memory B-cell: 8.4;naive B-cell: 13.6" "Lineage enriched" "Detected in single" 38 "B-cells: 13.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA035396 Approved "HPA035396: " "unprognostic (1.80e-3)" "unprognostic (1.84e-2)" "unprognostic (1.20e-3)" "unprognostic (1.50e-2)" "unprognostic (6.69e-2)" "unprognostic (1.10e-2)" "unprognostic (4.96e-4)" "unprognostic (2.46e-1)" "unprognostic (1.48e-1)" "unprognostic (1.90e-1)" "unprognostic (1.21e-4)" "unprognostic (4.55e-2)" "unprognostic (5.87e-3)" "unprognostic (2.88e-2)" "unprognostic (6.85e-2)" "unprognostic (2.66e-1)" "unprognostic (4.93e-2)" 2.6 4.0 16.7 1.9 28.5 1.0 2.5 19.6 19.7 2.1 2.1 0.8 0.0 1.2 1.4 0.7 1.5 1.4 1.8 2.1 9.8 11.3 1.8 1.0 1.0 2.7 4.8 9.8 1.8 1.7 2.3 13.7 0.8 9.1 0.9 2.1 0.0 0.7 1.4 0.9 0.5 1.9 1.7 4.0 1.8 2.7 1.8 4.9 2.0 1.3 0.0 3.5 1.7 0.5 13.6 0.3 0.0 0.0 0.1 0.1 0.1 0.0 0.1 2.3 0.0 0.0 0.1 0.0 0.0 0.2 0.5 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 8.5 0.1 0.0 24.1 0.0 0.0 2.0 0.1 1.1 0.0 12.1 0.0 3.1 5.4 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.1 0.7 0.0 1.3 0.4 0.0 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 8.4 0.0 0.0 0.0 13.6 0.1 0.0 0.0 0.1 0.0 0.3 0.0 0.1 16.7 28.5 19.6 17.2 9.8 11.3 4.8 9.8 9.1 4.9 SCN3B HSA243396 ENSG00000166257 "Sodium voltage-gated channel beta subunit 3" Q9NY72 11 123629187-123655244 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Brugada syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 70.3" "Group enriched" "Detected in some" 4 "CACO-2: 2.9;hTCEpi: 9.4;RH-30: 4.2;SCLC-21H: 9.4;SH-SY5Y: 7.0" "Cancer enhanced" "Detected in some" "glioma: 2.2" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA041707 Approved "Intermediate filaments,Cytosol" "Intermediate filaments" Cytosol "HPA041707: " "unprognostic (1.41e-1)" "unprognostic (8.72e-2)" "unprognostic (8.13e-4)" "unprognostic (3.93e-3)" "unprognostic (7.05e-2)" "unprognostic (3.29e-3)" "unprognostic (5.64e-2)" "unprognostic (3.34e-4)" "unprognostic (1.72e-1)" "unprognostic (1.13e-2)" "unprognostic (9.16e-4)" "unprognostic (4.01e-1)" "unprognostic (1.89e-4)" "unprognostic (2.01e-2)" "unprognostic (9.01e-2)" "unprognostic (8.23e-2)" "unprognostic (1.43e-2)" 2.2 8.5 17.7 1.5 23.5 1.3 2.0 2.8 70.3 1.6 1.5 1.2 0.0 1.6 1.5 1.5 1.5 1.8 1.4 1.9 26.2 13.2 1.6 1.0 1.4 1.2 5.2 18.8 1.7 1.9 3.9 12.6 1.1 3.8 1.8 1.6 3.7 1.2 1.4 5.8 1.7 1.5 2.1 1.5 1.3 1.4 2.2 1.2 0.0 3.7 0.0 1.2 1.1 0.4 1.2 1.3 2.7 0.6 1.1 0.8 0.1 0.0 0.2 0.3 0.2 0.1 0.1 0.3 0.2 0.3 0.0 0.0 2.9 0.1 0.3 1.4 0.4 0.2 1.0 0.1 0.1 0.1 0.6 0.0 0.5 0.3 0.1 0.0 0.5 0.4 9.4 0.1 0.1 0.3 0.4 0.5 0.0 0.1 0.1 0.2 0.8 0.1 0.2 4.2 0.0 0.0 0.2 9.4 7.0 0.6 0.1 0.0 0.0 0.0 0.2 0.1 0.4 0.1 0.1 0.1 0.0 0.2 0.2 0.1 0.1 0.6 0.6 0.5 0.6 0.4 0.4 0.7 0.7 0.7 0.3 1.2 0.5 0.8 2.7 1.1 0.5 1.3 0.4 0.1 17.7 23.5 2.8 39.5 26.2 13.2 5.2 18.8 3.8 1.2 SCN4A "HYKPP, HYPP, Nav1.4, SkM1" ENSG00000007314 "Sodium voltage-gated channel alpha subunit 4" P35499 17 63938554-63972918 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "skeletal muscle: 53.7" "Group enriched" "Detected in some" 11 "REH: 9.8;RH-30: 30.9" "Cancer enhanced" "Detected in some" "thyroid cancer: 2.2" "Cell type enhanced" "Detected in single" "naive B-cell: 1.9" "Lineage enhanced" "Detected in single" "B-cells: 1.9" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA053992 Approved "Nucleoplasm,Centriolar satellite" Nucleoplasm "Centriolar satellite" "HPA053992: " "unprognostic (2.47e-1)" "unprognostic (1.74e-1)" "unprognostic (1.57e-2)" "unprognostic (1.78e-3)" "unprognostic (2.80e-2)" "unprognostic (1.63e-2)" "unprognostic (3.87e-4)" "unprognostic (3.84e-3)" "unprognostic (1.61e-1)" "unprognostic (1.36e-1)" "unprognostic (1.59e-3)" "unprognostic (3.15e-2)" "unprognostic (2.70e-2)" "unprognostic (4.38e-3)" "unprognostic (3.46e-1)" "unprognostic (4.15e-1)" "unprognostic (6.45e-2)" 5.9 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.3 0.0 0.1 0.0 0.5 0.0 53.7 0.0 0.0 0.0 0.0 0.1 0.0 0.4 1.6 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.0 0.0 9.8 30.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.9 0.9 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 SCN4B LQT10 ENSG00000177098 "Sodium voltage-gated channel beta subunit 4" Q8IWT1 11 118133377-118152888 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Disease mutation, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 36.4;skeletal muscle: 25.6" "Cell line enhanced" "Detected in some" "AN3-CA: 3.8;HBEC3-KT: 2.9;NTERA-2: 4.3;SH-SY5Y: 1.7;U-2 OS: 3.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 11 "basal ganglia: 731.2" "Region enhanced" "Detected in many" "basal ganglia: 122.8" HPA017293 Approved "HPA017293: AB_2184174" "unprognostic (1.98e-1)" "unprognostic (1.13e-1)" "unprognostic (1.13e-1)" "unprognostic (2.43e-1)" "unprognostic (1.45e-1)" "unprognostic (1.07e-1)" "unprognostic (9.82e-3)" "unprognostic (9.17e-3)" "unprognostic (1.20e-2)" "unprognostic (1.23e-2)" "unprognostic (1.03e-2)" "unprognostic (3.27e-2)" "unprognostic (1.07e-1)" "unprognostic (2.07e-2)" "unprognostic (2.18e-3)" "unprognostic (1.53e-1)" "unprognostic (5.31e-4)" 20.5 5.4 1.9 1.2 36.4 0.1 6.1 11.7 21.7 2.4 2.6 2.0 0.5 2.4 3.7 1.8 5.4 5.5 3.2 11.0 3.1 2.9 1.4 0.6 8.7 2.0 5.3 2.1 0.7 5.0 6.4 2.4 1.9 28.7 2.1 2.2 4.3 2.8 2.6 25.6 3.8 4.6 7.0 5.5 0.5 3.0 0.8 8.7 1.5 10.4 9.5 1.1 3.4 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 3.8 0.0 0.0 0.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.3 2.9 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 1.1 0.4 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.1 0.0 0.0 0.1 1.7 0.4 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.0 0.1 0.0 0.1 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 36.4 11.7 21.7 3.1 2.9 5.3 2.1 28.7 8.7 SCN5A "CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1" ENSG00000183873 "Sodium voltage-gated channel alpha subunit 5" Q14524 3 38548057-38649673 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Calmodulin-binding, Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Brugada syndrome, Cardiomyopathy, Disease mutation, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "heart muscle: 67.3" "Group enriched" "Detected in some" 4 "LHCN-M2: 21.5;RH-30: 17.9" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "amygdala: 3.2;basal ganglia: 10.5;hypothalamus: 7.0" "Low region specificity" "Detected in many" HPA063346 Supported "Nucleoplasm,Nucleoli,Plasma membrane" "Plasma membrane" "Nucleoplasm, Nucleoli" "HPA063346: " "unprognostic (9.29e-4)" "unprognostic (4.05e-2)" "unprognostic (9.95e-2)" "unprognostic (1.74e-1)" "unprognostic (9.21e-2)" "unprognostic (1.24e-2)" "unprognostic (1.15e-1)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (8.48e-2)" "unprognostic (7.12e-3)" "unprognostic (5.28e-2)" "unprognostic (1.16e-4)" "unprognostic (4.85e-3)" "unprognostic (1.09e-1)" "unprognostic (5.35e-2)" "unprognostic (4.95e-3)" 0.3 0.2 1.3 0.2 0.3 0.4 0.6 0.1 2.3 2.0 0.4 0.0 0.4 0.3 0.9 0.8 0.2 0.4 0.3 67.3 0.5 0.7 0.1 0.1 0.2 0.1 0.1 0.3 0.6 0.2 0.1 0.8 0.3 0.0 1.3 0.2 1.2 0.3 1.6 5.5 0.2 0.3 0.4 0.1 0.2 0.2 0.5 0.0 0.0 0.3 0.1 0.1 0.8 1.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.5 0.1 0.0 0.1 0.8 0.3 0.0 0.1 0.3 2.7 0.0 0.0 0.0 0.8 2.7 0.0 0.3 0.0 1.1 0.7 0.0 0.1 0.1 0.0 0.1 0.5 0.0 0.5 0.0 3.5 0.0 0.0 21.5 1.0 0.0 0.0 2.0 0.0 0.0 17.9 0.0 0.0 2.4 0.3 2.3 0.0 0.0 0.0 0.0 0.0 4.3 0.0 4.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.3 0.1 2.3 0.5 0.7 0.1 0.3 0.0 0.0 SCN7A "NaG, Nav2.1, Nav2.2, SCN6A" ENSG00000136546 "Sodium voltage-gated channel alpha subunit 7" Q01118 2 166403573-166494326 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 51.9" "Cell line enhanced" "Detected in some" "MOLT-4: 2.8;SH-SY5Y: 1.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "basophil: 2.1" "Lineage enhanced" "Detected in single" "granulocytes: 2.1" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" HPA072715 Approved "HPA072715: " "unprognostic (1.22e-1)" "unprognostic (6.42e-3)" "unprognostic (9.72e-2)" "unprognostic (7.43e-2)" "unprognostic (2.18e-1)" "unprognostic (1.78e-1)" "unprognostic (1.86e-1)" "unprognostic (4.00e-3)" "unprognostic (5.21e-2)" "unprognostic (6.84e-3)" "unprognostic (6.88e-2)" "unprognostic (1.27e-1)" "unprognostic (5.80e-2)" "unprognostic (3.71e-2)" "unprognostic (1.47e-2)" "unprognostic (1.35e-1)" "unprognostic (1.22e-4)" 4.9 6.0 1.0 10.4 0.7 0.0 2.9 0.3 0.7 16.2 23.3 0.0 13.0 2.0 24.6 8.1 28.1 7.8 6.8 16.0 0.7 3.6 1.8 1.3 51.9 1.6 3.6 0.5 33.3 3.1 0.3 1.1 8.1 2.6 18.4 6.1 14.0 4.9 11.3 3.7 1.5 6.2 10.5 4.3 5.5 6.4 6.9 0.1 0.5 1.3 4.9 0.2 9.7 7.6 0.0 0.8 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.3 0.5 0.1 0.1 0.8 0.0 0.2 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.7 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 1.0 0.7 0.3 0.7 0.7 3.6 3.6 0.5 2.6 0.1 SCN8A "CerIII, CIAT, MED, NaCh6, Nav1.6, PN4" ENSG00000196876 "Sodium voltage-gated channel alpha subunit 8" Q9UQD0 12 51590266-51812864 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 27.6;pituitary gland: 9.7" "Cell line enhanced" "Detected in many" "AF22: 11.8;ASC TERT1: 12.4;BJ hTERT+: 11.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "memory CD8 T-cell: 1.0" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022169, HPA043937, HPA073590" Approved "Vesicles,Plasma membrane,Cell Junctions" "Plasma membrane" "Vesicles, Cell Junctions" "CAB022169: , HPA043937: , HPA073590: " "unprognostic (2.96e-2)" "unprognostic (8.49e-2)" "unprognostic (6.93e-2)" "unprognostic (3.52e-6)" "unprognostic (8.13e-2)" "unprognostic (1.51e-2)" "unprognostic (1.16e-1)" "unprognostic (7.77e-2)" "unprognostic (5.44e-2)" "unprognostic (1.16e-1)" "unprognostic (4.73e-4)" "unprognostic (1.69e-2)" "unprognostic (1.29e-5)" "unprognostic (4.38e-1)" "unprognostic (1.56e-1)" "unprognostic (2.37e-1)" "unprognostic (4.75e-2)" 1.1 3.0 9.1 1.5 18.1 1.9 1.9 16.7 27.6 1.0 2.0 1.6 0.0 1.1 1.5 2.0 0.9 1.1 2.5 0.9 12.6 4.5 1.9 4.3 1.0 1.3 3.2 13.7 1.8 3.2 1.5 9.7 0.9 14.8 1.8 2.5 0.9 1.7 1.2 1.0 1.1 1.2 1.0 2.2 1.7 2.7 3.8 1.6 0.0 1.7 0.0 1.2 1.0 0.6 0.4 0.2 0.0 0.0 0.0 1.0 0.0 1.3 1.0 11.8 0.1 1.6 12.4 0.2 6.7 11.0 7.7 7.2 1.9 1.3 0.3 1.5 8.7 0.0 1.9 0.0 9.1 1.2 0.6 0.1 0.1 0.2 0.1 0.2 0.9 1.7 0.0 5.1 1.1 8.2 0.1 0.1 4.8 0.8 1.9 0.1 4.0 3.8 0.0 0.6 0.0 0.0 0.4 4.7 1.9 3.4 1.7 0.2 0.3 0.1 2.2 7.5 5.0 2.7 4.2 0.1 0.1 0.0 1.5 1.6 10.7 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.7 1.0 0.0 0.4 0.4 0.2 0.0 0.0 0.0 0.2 0.0 0.0 9.1 18.1 16.7 25.0 12.6 4.5 3.2 13.7 14.8 1.6 SCN9A "ETHA, Nav1.7, NE-NA, NENA, PN1" ENSG00000169432 "Sodium voltage-gated channel alpha subunit 9" Q15858 2 166195185-166376001 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 17.3;BJ hTERT+: 12.9;HHSteC: 14.9" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 17 "plasmacytoid DC: 18.6" "Lineage enriched" "Detected in single" 24 "dendritic cells: 18.6" "Region enriched" "Detected in some" 5 "hypothalamus: 10.9" "Low region specificity" "Detected in many" "CAB013679, HPA061843" Uncertain Approved "Plasma membrane,Actin filaments,Focal adhesion sites" "Plasma membrane, Actin filaments, Focal adhesion sites" "CAB013679: , HPA061843: " "unprognostic (2.10e-1)" "unprognostic (2.83e-1)" "unprognostic (1.13e-1)" "unprognostic (8.98e-5)" "unprognostic (1.47e-3)" "unprognostic (9.43e-3)" "unprognostic (2.28e-2)" "unprognostic (2.24e-1)" "unprognostic (2.23e-1)" "unprognostic (3.64e-1)" "unprognostic (1.45e-1)" "unprognostic (2.27e-1)" "prognostic unfavourable (2.30e-5)" "unprognostic (1.69e-3)" "unprognostic (6.74e-2)" "unprognostic (2.46e-2)" "unprognostic (2.46e-1)" 6.6 4.2 3.8 2.8 9.1 4.2 2.7 0.9 4.4 1.8 10.2 0.5 0.1 1.4 0.9 3.8 2.6 1.2 5.8 2.9 2.8 15.9 4.8 8.3 4.5 3.5 4.1 2.3 2.1 4.8 0.6 11.3 9.2 7.3 2.0 7.0 1.7 1.8 1.9 0.9 1.8 4.2 5.2 2.5 12.4 1.7 16.2 0.4 10.3 1.4 1.9 1.2 3.6 1.8 0.0 18.6 0.7 0.1 0.4 0.0 0.0 0.0 1.9 0.1 0.0 7.5 6.5 0.0 17.3 12.9 4.0 1.4 0.5 0.1 0.0 0.0 2.1 0.0 5.0 0.6 6.7 0.0 1.6 1.3 1.5 1.4 14.9 0.0 0.0 0.4 0.2 6.9 1.3 0.8 4.3 5.0 0.6 0.0 2.6 0.0 1.5 0.5 0.7 2.5 6.5 1.8 7.3 0.8 7.3 0.0 0.0 0.3 0.2 0.0 0.0 0.0 1.1 0.1 0.3 0.1 0.0 0.0 2.5 0.0 1.4 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.7 0.4 0.1 18.6 0.0 0.0 3.8 9.1 0.9 4.4 2.8 15.9 4.1 2.3 7.3 0.4 SCNN1A "ENaCalpha, SCNN1" ENSG00000111319 "Sodium channel epithelial 1 alpha subunit" P37088 12 6346843-6377730 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 100.4" "Cell line enhanced" "Detected in some" "CAPAN-2: 70.2;HBEC3-KT: 47.1;hTCEpi: 20.2;RPTEC TERT1: 24.6;RT4: 26.4;SK-BR-3: 22.8" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in some" 8 "pons and medulla: 9.4" "Group enriched" "Detected in some" 4 "naive CD4 T-cell: 1.7;neutrophil: 4.4;plasmacytoid DC: 3.0;T-reg: 1.3" "Group enriched" "Detected in many" 5 "dendritic cells: 3.0;granulocytes: 4.4;T-cells: 1.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA012743 Enhanced "HPA012743: AB_1856627" "unprognostic (1.68e-1)" "unprognostic (4.16e-2)" "unprognostic (1.62e-1)" "unprognostic (2.19e-1)" "unprognostic (5.16e-2)" "unprognostic (6.77e-3)" "unprognostic (3.09e-2)" "unprognostic (2.62e-2)" "unprognostic (5.13e-2)" "prognostic unfavourable (8.86e-4)" "prognostic unfavourable (2.30e-4)" "unprognostic (5.56e-2)" "prognostic favourable (9.21e-8)" "unprognostic (2.38e-1)" "unprognostic (3.93e-2)" "unprognostic (1.16e-1)" "unprognostic (1.01e-2)" 0.9 3.7 0.4 7.5 0.4 0.0 10.1 0.4 0.9 22.0 20.6 2.2 60.9 5.6 8.1 15.7 47.3 19.3 7.0 0.4 1.1 0.1 100.4 2.2 53.6 0.4 0.5 0.4 5.9 14.2 0.0 10.2 1.6 9.4 15.0 21.5 6.2 53.1 55.5 0.6 14.4 11.8 1.0 0.4 0.4 20.3 2.8 0.4 0.9 74.7 21.1 41.3 10.3 13.8 0.0 3.0 4.4 0.5 0.0 1.7 0.3 4.9 0.9 0.0 0.4 0.0 0.1 4.2 0.0 0.0 0.0 0.0 1.4 70.2 0.0 0.1 0.0 3.2 0.0 47.1 0.0 0.0 0.0 0.0 3.9 0.7 5.1 0.0 0.0 1.2 20.2 0.0 14.8 0.0 0.0 0.0 0.1 0.4 0.0 0.0 4.1 0.1 0.0 0.0 0.1 24.6 26.4 0.2 0.0 0.5 22.8 0.0 5.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.3 0.5 0.0 0.0 0.2 0.6 0.5 0.0 1.7 0.3 4.4 0.0 0.1 3.0 1.3 0.3 0.4 0.4 0.4 0.9 1.1 0.1 0.5 0.4 9.4 0.4 SCNN1B ENaCbeta ENSG00000168447 "Sodium channel epithelial 1 beta subunit" P51168 16 23278231-23381299 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 42.4" "Cell line enhanced" "Detected in some" "hTCEpi: 19.0;RT4: 10.1;U-266/70: 31.3;U-266/84: 10.9" "Cancer enhanced" "Detected in many" "urothelial cancer: 26.4" "Region enhanced" "Detected in single" "cerebellum: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA015612 Uncertain "HPA015612: AB_1856629" "unprognostic (7.45e-2)" "unprognostic (1.76e-3)" "unprognostic (1.39e-1)" "unprognostic (6.74e-3)" "unprognostic (1.74e-2)" "unprognostic (5.11e-3)" "unprognostic (7.74e-2)" "unprognostic (5.49e-3)" "unprognostic (2.60e-1)" "unprognostic (2.40e-1)" "unprognostic (3.68e-1)" "unprognostic (2.84e-1)" "prognostic unfavourable (2.09e-6)" "unprognostic (2.32e-1)" "unprognostic (4.66e-2)" "unprognostic (3.93e-3)" "unprognostic (1.25e-2)" 35.1 0.2 0.1 4.0 0.2 0.0 21.2 1.1 0.1 28.3 27.2 0.0 1.3 1.3 2.9 2.5 42.4 1.3 3.3 0.6 0.0 0.0 13.0 0.0 31.1 1.3 0.0 0.0 2.0 0.8 0.3 1.6 25.2 0.3 5.7 19.7 0.5 29.7 2.4 3.9 13.2 1.7 4.2 0.1 1.9 8.9 1.6 0.0 0.6 16.2 17.8 15.5 5.6 19.6 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.0 0.0 0.0 0.0 0.0 1.1 0.0 0.9 0.0 0.0 0.0 3.9 0.0 0.0 4.8 0.0 10.1 0.1 0.0 0.0 0.2 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 31.3 10.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.1 0.2 1.1 0.1 0.0 0.0 0.0 0.0 0.3 0.0 SCNN1D "dNaCh, ENaCdelta" ENSG00000162572 "Sodium channel epithelial 1 delta subunit" P51172 1 1280436-1292029 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-266/70: 11.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" HPA026884 Enhanced Supported "Plasma membrane,Actin filaments" "Plasma membrane, Actin filaments" "HPA026884: AB_10601501" "unprognostic (2.08e-2)" "unprognostic (2.08e-1)" "unprognostic (7.39e-4)" "unprognostic (1.06e-2)" "unprognostic (2.74e-1)" "prognostic favourable (1.60e-4)" "unprognostic (1.44e-2)" "unprognostic (1.81e-1)" "unprognostic (2.08e-2)" "unprognostic (1.14e-1)" "prognostic favourable (1.32e-4)" "unprognostic (5.27e-2)" "prognostic unfavourable (6.67e-5)" "unprognostic (3.13e-1)" "unprognostic (4.18e-2)" "unprognostic (2.13e-1)" "unprognostic (7.06e-2)" 3.2 3.8 4.0 1.9 5.1 3.6 1.2 12.8 6.3 1.7 2.0 7.0 3.2 1.1 1.1 3.9 1.5 1.5 4.1 3.3 1.4 3.2 1.5 2.5 3.1 4.6 3.0 0.8 5.9 1.3 2.3 0.2 8.6 2.4 3.9 4.6 5.1 1.0 3.2 3.8 2.4 10.2 1.3 0.7 0.7 1.8 0.5 0.9 0.0 0.2 0.0 0.8 0.2 0.6 5.0 1.9 5.2 1.4 0.8 0.9 3.3 1.0 1.7 1.9 0.9 2.8 3.5 1.8 1.5 0.8 0.9 0.8 0.3 6.6 3.0 0.4 5.9 1.3 1.4 0.1 3.6 2.3 1.1 2.6 0.0 0.5 2.4 8.4 0.4 1.8 1.4 2.4 1.0 3.7 9.3 0.4 0.8 0.7 0.2 2.7 3.8 1.4 1.5 2.2 6.6 1.8 1.4 3.1 2.6 4.9 1.1 11.3 0.7 2.9 2.8 6.1 3.5 0.0 0.2 0.0 0.8 0.0 0.0 0.0 0.3 0.0 0.0 0.5 0.3 0.1 0.0 0.0 0.0 0.9 0.0 0.2 SCNN1G "ENaCgamma, SCNEG" ENSG00000166828 "Sodium channel epithelial 1 gamma subunit" P51170 16 23182715-23216883 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 42.9;salivary gland: 26.8" "Group enriched" "Detected in some" 7 "hTCEpi: 30.7;RT4: 13.8" "Cancer enhanced" "Detected in many" "urothelial cancer: 15.6" "Region enriched" "Detected in some" 6 "cerebellum: 9.7" "Cell type enhanced" "Detected in single" "neutrophil: 1.8" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.8" "Region enriched" "Detected in single" 13 "cerebellum: 2.8" "Low region specificity" "Detected in all" HPA071194 Supported "Nucleoplasm,Plasma membrane" "Plasma membrane" Nucleoplasm "HPA071194: " "unprognostic (2.90e-1)" "unprognostic (5.21e-3)" "unprognostic (5.79e-2)" "unprognostic (4.31e-2)" "unprognostic (1.92e-3)" "unprognostic (1.71e-3)" "unprognostic (1.97e-1)" "unprognostic (4.85e-2)" "unprognostic (7.84e-3)" "unprognostic (1.90e-1)" "unprognostic (2.57e-2)" "prognostic unfavourable (3.20e-7)" "unprognostic (2.80e-2)" "unprognostic (1.34e-1)" "unprognostic (2.63e-1)" "unprognostic (4.17e-3)" 1.1 0.3 0.6 0.2 0.0 0.4 2.5 9.7 0.4 14.0 5.5 0.0 4.8 0.2 3.2 1.7 10.3 0.5 0.2 0.2 1.5 0.0 42.9 0.2 15.6 0.2 0.0 0.3 0.2 3.8 0.2 6.5 0.7 0.7 10.2 1.1 0.0 26.8 12.8 2.2 6.6 0.2 0.3 0.3 0.2 6.9 0.3 0.0 1.5 25.5 3.3 3.9 1.7 11.3 0.3 0.3 1.8 0.2 0.2 0.3 0.0 0.7 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 30.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.9 0.0 0.0 0.0 0.0 13.8 1.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.2 0.3 0.2 0.1 0.1 0.1 0.1 0.0 0.3 0.2 0.1 1.8 0.2 0.1 0.3 0.1 0.0 0.6 0.0 9.7 0.4 1.5 0.0 0.0 0.3 0.7 0.0 SDHA "FP, SDH2, SDHF" ENSG00000073578 "Succinate dehydrogenase complex flavoprotein subunit A" P31040 5 218241-256700 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Electron transport, Transport, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Cardiomyopathy, Disease mutation, FDA approved drug targets, Leigh syndrome, Primary mitochondrial disease, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 100.1;skeletal muscle: 114.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB034929, HPA041981, HPA064582" Enhanced Supported Nucleoli,Mitochondria 780000 Mitochondria Nucleoli "CAB034929: AB_2183443, HPA041981: AB_2677779, HPA064582: AB_2685293" "prognostic unfavourable (6.00e-4)" "unprognostic (1.93e-1)" "unprognostic (5.97e-2)" "unprognostic (1.36e-1)" "unprognostic (1.89e-1)" "unprognostic (1.62e-1)" "unprognostic (2.80e-1)" "unprognostic (3.14e-2)" "unprognostic (2.88e-1)" "unprognostic (1.67e-2)" "unprognostic (1.97e-1)" "unprognostic (1.24e-1)" "prognostic favourable (9.53e-8)" "unprognostic (1.11e-2)" "unprognostic (2.62e-1)" "unprognostic (3.57e-1)" "unprognostic (1.79e-1)" 17.6 31.4 15.3 11.5 20.3 10.6 12.8 18.8 29.0 10.2 29.4 17.3 10.0 44.3 11.3 12.1 15.3 12.6 14.8 100.1 15.8 14.5 36.5 55.4 10.7 11.7 19.6 19.3 14.5 14.7 23.2 9.5 9.2 29.7 10.7 24.6 14.5 17.3 12.0 114.0 11.5 39.9 16.5 13.2 13.9 21.2 14.6 14.8 15.7 12.5 39.6 12.5 13.2 11.1 28.3 31.9 29.1 29.2 27.1 48.9 32.4 18.4 29.9 12.3 20.1 21.2 15.9 33.4 14.2 18.1 24.5 25.0 32.4 25.1 22.8 45.0 16.2 23.9 21.7 29.0 14.5 48.6 19.9 11.6 82.6 42.0 13.1 14.4 15.1 15.8 18.7 18.3 9.7 26.5 18.6 19.0 11.5 28.2 19.1 39.0 4.2 37.9 24.7 17.9 44.2 52.2 24.5 13.6 7.8 67.0 43.3 17.6 26.3 18.3 19.2 18.2 17.9 10.8 11.7 20.2 8.6 16.8 17.6 20.9 11.5 17.8 24.4 29.1 36.4 29.2 32.1 28.3 34.8 35.1 31.9 24.5 34.5 31.7 5.9 27.1 24.1 20.5 48.9 32.4 15.3 20.3 18.8 29.0 15.8 14.5 19.6 19.3 29.7 14.8 SDHD "cybS, PGL, PGL1" ENSG00000204370 "Succinate dehydrogenase complex subunit D" O14521 11 112086773-112120013 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Electron transport, Transport, Tricarboxylic acid cycle" "Cancer-related genes, Disease mutation, FDA approved drug targets, Primary mitochondrial disease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA045727 Approved "Intracellular and membrane" "HPA045727: AB_10963114" "unprognostic (9.13e-2)" "unprognostic (3.51e-2)" "unprognostic (4.47e-3)" "unprognostic (4.21e-2)" "unprognostic (1.93e-1)" "unprognostic (4.98e-2)" "unprognostic (5.69e-2)" "unprognostic (2.50e-1)" "unprognostic (1.83e-3)" "unprognostic (7.10e-2)" "unprognostic (3.03e-2)" "unprognostic (1.80e-1)" "prognostic favourable (1.99e-10)" "unprognostic (5.14e-2)" "unprognostic (1.58e-2)" "unprognostic (1.56e-2)" "unprognostic (7.51e-2)" 20.9 23.1 17.1 21.7 19.4 10.9 19.6 14.1 18.4 18.1 33.6 14.2 23.9 36.0 22.7 17.5 35.2 17.3 17.9 42.5 15.1 13.7 66.6 75.4 19.1 23.3 17.1 15.1 18.6 23.2 22.5 16.1 20.1 18.0 23.7 33.9 15.7 32.6 21.7 65.4 15.5 61.2 24.0 15.3 22.8 22.2 8.8 14.8 21.7 46.2 33.9 24.6 23.5 20.3 55.5 74.7 62.1 91.7 46.1 53.7 68.9 16.8 17.3 11.8 17.9 44.2 35.5 19.8 20.6 29.3 21.6 27.1 59.9 44.3 30.7 63.7 27.7 42.4 36.8 29.1 26.5 27.2 18.5 29.2 12.9 31.8 34.4 45.9 22.2 39.1 32.3 25.7 41.2 30.4 30.1 42.4 26.7 21.2 27.5 41.5 16.0 43.0 25.5 31.4 57.2 44.2 41.3 17.1 11.3 28.9 39.0 20.5 40.1 33.1 23.7 21.1 27.7 23.4 18.9 12.6 16.1 56.2 12.0 60.2 20.1 46.1 73.0 48.7 41.4 91.7 44.1 55.5 44.5 43.1 74.7 45.6 53.7 49.8 62.1 46.1 70.7 36.8 44.2 68.9 17.1 19.4 14.1 18.4 15.1 13.7 17.1 15.1 18.0 14.8 SERPINC1 "AT3, ATIII, MGC22579" ENSG00000117601 "Serpin family C member 1" P01008 1 173903804-173917378 "Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Heparin-binding, Protease inhibitor, Serine protease inhibitor" "Disease mutation, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 203 "liver: 450.5" "Cell line enriched" "Detected in some" 35 "Hep G2: 41.6" "Cancer enriched" "Detected in some" 871 "liver cancer: 1504.0" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "eosinophil: 2.2" "Lineage enhanced" "Detected in single" "granulocytes: 2.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA001816, CAB016790, HPA024007" Supported "Secreted to blood" 210000000000 "CAB016790: , HPA001816: AB_1079926, HPA024007: AB_1856732" "unprognostic (1.28e-2)" "unprognostic (2.22e-1)" "unprognostic (3.83e-2)" "unprognostic (5.98e-2)" "unprognostic (6.91e-2)" "unprognostic (1.93e-2)" "prognostic favourable (3.40e-5)" "unprognostic (1.75e-2)" "unprognostic (8.67e-2)" "unprognostic (3.48e-2)" "unprognostic (4.74e-2)" "unprognostic (1.91e-1)" "unprognostic (2.36e-2)" "unprognostic (5.28e-3)" "unprognostic (5.80e-2)" "unprognostic (6.35e-2)" "unprognostic (8.21e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 450.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 41.6 0.0 0.8 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.1 0.5 0.0 0.0 0.0 2.2 0.5 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 SERPIND1 "D22S673, HC-II, HC2, HCF2, HLS2" ENSG00000099937 "Serpin family D member 1" P05546 22 20773879-20787720 "Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Chemotaxis, Hemostasis" "Heparin-binding, Protease inhibitor, Serine protease inhibitor" "Disease mutation, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 47 "liver: 170.8" "Cell line enriched" "Detected in some" 10 "Hep G2: 62.7" "Cancer enriched" "Detected in many" 80 "liver cancer: 334.4" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008639, HPA055767" Supported Approved Vesicles "Secreted to blood" 94000000000 Vesicles "CAB008639: AB_1618010, HPA055767: " "unprognostic (1.68e-1)" "unprognostic (8.27e-2)" "unprognostic (4.40e-2)" "prognostic favourable (4.09e-4)" "unprognostic (5.42e-2)" "unprognostic (1.23e-1)" "unprognostic (1.12e-3)" "unprognostic (1.56e-1)" "unprognostic (1.13e-1)" "unprognostic (1.74e-1)" "unprognostic (1.21e-2)" "unprognostic (2.88e-1)" "unprognostic (3.94e-9)" "unprognostic (2.01e-1)" "unprognostic (4.66e-2)" "unprognostic (8.36e-3)" "unprognostic (1.46e-1)" 0.0 0.0 0.0 0.0 2.3 0.0 0.2 0.6 0.9 0.3 0.0 1.4 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 170.8 0.3 0.0 0.0 0.7 0.3 0.0 3.6 0.1 0.2 2.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.4 0.0 0.1 0.1 0.5 0.0 0.1 0.0 0.0 0.0 0.1 1.9 2.7 0.7 0.4 1.3 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 62.7 0.0 0.2 0.1 0.0 0.0 0.5 0.0 6.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 0.2 0.0 0.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 4.3 0.0 0.4 0.0 1.0 0.2 1.7 0.4 0.5 0.6 0.1 1.9 0.9 0.7 0.7 1.3 0.2 2.7 0.7 0.1 0.0 2.3 0.6 0.9 0.0 0.0 0.0 0.7 2.6 0.5 SHMT1 "CSHMT, MGC15229, MGC24556, SHMT" ENSG00000176974 "Serine hydroxymethyltransferase 1" P34896 17 18327860-18363563 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "One-carbon metabolism" Transferase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "kidney: 57.8;liver: 108.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" HPA023314 Enhanced Supported Nucleoplasm,Cytosol 240000 "Nucleoplasm, Cytosol" "HPA023314: AB_1856830" "unprognostic (4.76e-2)" "unprognostic (1.98e-2)" "unprognostic (5.46e-2)" "unprognostic (3.76e-1)" "unprognostic (2.45e-1)" "unprognostic (8.44e-3)" "prognostic favourable (2.52e-4)" "unprognostic (7.55e-3)" "unprognostic (4.50e-1)" "unprognostic (2.42e-1)" "unprognostic (2.14e-1)" "unprognostic (1.70e-1)" "prognostic favourable (8.54e-6)" "unprognostic (1.70e-2)" "unprognostic (2.66e-1)" "unprognostic (2.57e-3)" "unprognostic (4.04e-2)" 10.9 3.2 2.2 4.9 4.1 2.1 10.4 6.5 3.0 4.6 15.2 5.3 7.3 12.3 2.8 7.4 16.3 3.9 4.0 2.0 2.6 1.8 57.8 108.3 4.3 3.8 3.5 1.9 4.1 3.5 30.1 1.6 2.8 3.6 3.4 3.5 7.2 9.8 8.0 5.7 6.2 15.1 2.3 2.9 8.6 3.9 6.3 3.8 11.1 10.9 10.8 8.7 4.3 6.3 8.6 6.7 6.2 10.6 13.0 18.7 7.9 23.7 24.1 7.6 12.0 19.5 12.2 28.3 5.0 6.2 16.9 18.7 23.9 10.6 18.5 15.0 4.3 23.5 16.0 20.2 9.6 11.0 23.3 8.3 18.9 18.0 4.9 5.5 9.0 10.1 8.0 13.1 5.9 11.6 7.0 4.2 6.0 17.5 27.4 7.6 9.6 7.9 22.5 30.3 15.7 26.9 16.2 10.5 5.5 34.2 6.5 8.6 26.6 7.8 2.7 3.3 9.8 29.9 15.8 8.6 8.2 7.4 6.4 13.0 7.8 6.0 8.2 6.2 10.1 10.6 17.1 8.6 12.3 12.8 6.7 6.9 12.3 13.0 0.1 13.0 7.5 3.1 18.7 7.9 2.2 4.1 6.5 3.0 2.6 1.8 3.5 1.9 3.6 3.8 SI ENSG00000090402 Sucrase-isomaltase P14410 3 164978898-165078495 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Glycosidase, Hydrolase, Multifunctional enzyme" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 123 "intestine: 181.4" "Cell line enhanced" "Detected in some" "BEWO: 2.8;CACO-2: 4.0;HeLa: 3.1;NB-4: 3.3;RPMI-8226: 4.8;SH-SY5Y: 2.9" "Cancer enhanced" "Detected in some" "stomach cancer: 6.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA011897 Enhanced "HPA011897: AB_1856840" "unprognostic (2.71e-2)" "unprognostic (1.62e-2)" "unprognostic (2.68e-1)" "unprognostic (2.05e-1)" "unprognostic (4.41e-2)" 0.1 0.1 0.1 1.4 0.1 0.0 0.1 0.1 0.1 0.1 93.3 0.0 0.0 94.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 5.4 0.0 0.1 0.0 0.1 0.1 181.4 0.0 0.1 0.1 0.1 0.7 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.6 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 SIGMAR1 "OPRS1, SR-BP1" ENSG00000147955 "Sigma non-opioid intracellular receptor 1" Q99720 9 34634722-34637809 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Lipid transport, Transport" Receptor "Amyotrophic lateral sclerosis, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 89.1" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013470, HPA018002, HPA024071" Approved "CAB013470: AB_2533521, HPA018002: AB_1854802, HPA024071: AB_1854803" "unprognostic (1.39e-1)" "unprognostic (2.64e-1)" "unprognostic (1.56e-1)" "unprognostic (1.95e-1)" "unprognostic (8.06e-2)" "unprognostic (3.71e-2)" "unprognostic (4.89e-2)" "unprognostic (2.50e-2)" "unprognostic (2.58e-2)" "unprognostic (2.01e-3)" "unprognostic (3.88e-2)" "unprognostic (4.28e-1)" "unprognostic (2.78e-2)" "unprognostic (2.46e-1)" "unprognostic (2.39e-1)" "unprognostic (6.44e-3)" "prognostic unfavourable (3.42e-4)" 15.3 19.7 9.2 9.8 14.5 8.5 13.0 9.4 16.1 17.0 18.2 13.4 13.3 23.0 18.6 13.4 18.6 17.4 17.1 12.1 9.4 12.0 14.2 89.1 9.6 14.5 10.7 10.7 20.1 22.9 15.0 8.3 17.8 14.0 18.9 13.2 15.7 12.0 19.6 7.7 16.8 24.9 15.1 9.2 9.8 14.6 9.4 9.3 9.6 11.8 15.0 15.8 16.4 15.2 14.0 23.8 12.4 19.3 13.1 32.6 20.1 40.7 36.2 12.5 41.0 46.5 32.3 16.2 29.7 20.1 26.2 24.3 22.6 17.8 20.0 17.7 32.2 25.5 16.0 33.7 5.7 34.8 43.3 19.1 53.9 24.7 30.6 32.8 16.6 32.6 36.1 28.9 35.9 19.8 7.1 37.1 28.1 0.2 19.9 47.6 15.8 47.0 23.3 14.0 56.2 23.9 8.1 14.8 16.6 29.5 21.1 15.6 25.0 22.4 16.7 21.8 17.5 22.9 4.4 10.3 16.2 0.5 22.5 28.6 45.0 10.5 19.1 12.4 22.2 18.4 24.2 14.0 32.6 26.7 23.8 10.8 27.8 22.6 5.4 13.1 19.3 17.5 29.9 20.1 9.2 14.5 9.4 16.1 9.4 12.0 10.7 10.7 14.0 9.3 SIRT5 ENSG00000124523 "Sirtuin 5" Q9NXA8 6 13574529-13615158 "FDA approved drug targets, Predicted intracellular proteins" Transferase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA021798, HPA022002, HPA022992" Approved Supported Mitochondria Mitochondria "HPA021798: AB_1856911, HPA022002: AB_1856913, HPA022992: AB_1856915" "unprognostic (8.53e-2)" "unprognostic (7.79e-2)" "unprognostic (4.71e-2)" "unprognostic (5.26e-3)" "unprognostic (6.19e-2)" "unprognostic (1.63e-1)" "unprognostic (8.72e-2)" "unprognostic (1.38e-1)" "unprognostic (8.54e-3)" "unprognostic (2.77e-3)" "unprognostic (1.02e-1)" "unprognostic (1.65e-1)" "prognostic favourable (8.76e-10)" "unprognostic (2.39e-1)" "unprognostic (6.88e-2)" "unprognostic (6.86e-2)" "unprognostic (2.36e-3)" 5.9 6.2 8.8 6.8 10.4 5.9 9.2 11.1 13.5 4.9 7.2 6.4 12.5 8.1 6.8 6.7 5.7 8.0 6.6 22.9 8.5 8.3 9.9 29.9 9.8 6.9 9.5 6.9 8.8 10.5 12.9 7.6 5.3 8.3 6.5 8.3 6.2 8.6 8.7 25.8 8.8 8.5 6.2 6.9 9.5 7.6 6.6 6.1 7.5 8.5 7.0 6.5 6.8 6.0 9.2 4.6 10.9 9.3 7.3 10.0 5.6 6.0 4.7 6.0 7.8 3.8 5.0 4.6 3.1 3.3 3.4 5.1 7.6 7.2 8.7 18.9 2.4 9.8 4.2 6.1 5.2 4.0 7.0 5.5 4.4 12.2 6.3 4.4 4.8 5.4 12.4 3.0 10.8 6.1 7.8 3.3 4.0 7.3 4.8 8.8 5.1 7.5 8.7 3.9 15.8 7.0 6.6 10.0 3.6 3.5 6.1 13.8 7.0 2.9 5.4 5.2 3.0 3.2 3.4 8.1 9.1 5.9 2.9 4.4 5.0 0.5 4.5 10.9 8.1 6.1 8.2 9.2 10.0 7.9 4.6 9.1 9.5 8.5 1.5 7.3 9.3 4.6 7.2 5.6 8.8 10.4 11.1 13.5 8.5 8.3 9.5 6.9 8.3 6.1 SLC12A1 NKCC2 ENSG00000074803 "Solute carrier family 12 member 1" Q13621 15 48178438-48304078 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Symport, Transport" "Bartter syndrome, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 75 "kidney: 143.2" "Cell line enriched" "Detected in single" 26 "RPTEC TERT1: 23.7" "Cancer enhanced" "Detected in single" "renal cancer: 1.0" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 9 "basophil: 1.9;neutrophil: 1.5" "Lineage enriched" "Detected in single" 10 "granulocytes: 1.9" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA014967, HPA018107" Enhanced Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "HPA014967: AB_1854503, HPA018107: AB_1854504" "unprognostic (3.52e-2)" "unprognostic (1.30e-2)" "unprognostic (9.65e-2)" "unprognostic (1.74e-2)" "unprognostic (7.77e-2)" "unprognostic (1.04e-1)" "unprognostic (8.72e-2)" "unprognostic (2.06e-1)" "unprognostic (9.85e-3)" "unprognostic (2.81e-4)" "unprognostic (9.75e-2)" "unprognostic (2.61e-1)" "unprognostic (5.47e-2)" "unprognostic (2.03e-1)" "unprognostic (5.20e-4)" "unprognostic (8.52e-2)" 0.0 0.0 0.3 0.0 1.0 0.0 0.0 1.4 1.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 143.2 0.1 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.1 0.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 1.9 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.7 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 1.5 0.1 0.0 0.1 0.0 0.0 0.3 1.0 1.4 1.5 0.1 0.3 0.3 0.4 1.4 0.1 SLC12A2 "BSC, BSC2, NKCC1, PPP1R141" ENSG00000064651 "Solute carrier family 12 member 2" P55011 5 128083766-128189688 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 50.7;salivary gland: 61.2" "Cell line enhanced" "Detected in all" "A549: 31.1;AF22: 32.1" "Cancer enhanced" "Detected in all" "colorectal cancer: 54.3" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 9.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020130, HPA063697" Approved Approved "Vesicles,Plasma membrane" Vesicles "Plasma membrane" "HPA020130: AB_1854502, HPA063697: " "unprognostic (4.61e-2)" "unprognostic (2.63e-1)" "unprognostic (4.20e-3)" "prognostic favourable (8.60e-4)" "unprognostic (3.99e-1)" "unprognostic (5.65e-3)" "unprognostic (1.44e-3)" "unprognostic (1.81e-1)" "unprognostic (3.30e-1)" "unprognostic (2.95e-2)" "unprognostic (7.22e-2)" "unprognostic (1.39e-1)" "prognostic favourable (7.09e-4)" "unprognostic (1.63e-1)" "unprognostic (2.30e-1)" "unprognostic (3.79e-1)" "unprognostic (3.88e-3)" 5.5 11.0 10.8 9.4 24.1 2.7 26.2 11.4 18.1 5.1 28.5 37.2 0.0 24.6 5.7 1.9 3.8 4.1 50.7 4.1 15.5 9.9 4.5 2.9 6.5 3.5 36.1 13.5 5.6 5.3 11.2 5.5 3.3 30.0 14.8 36.3 8.5 61.2 2.1 8.5 23.0 28.8 6.6 27.7 2.9 36.3 5.5 26.7 2.0 5.6 6.8 18.3 4.2 3.6 3.6 9.8 0.5 1.2 3.6 3.0 0.4 6.2 31.1 32.1 12.4 8.0 5.2 6.6 5.8 4.4 4.2 4.4 12.4 10.0 9.3 7.9 5.0 19.0 6.1 6.7 6.5 9.3 7.6 2.7 5.5 1.8 2.5 3.3 4.7 5.5 2.4 9.3 5.5 6.8 4.3 6.4 6.5 6.6 5.9 2.8 3.7 10.2 3.3 9.0 3.8 4.9 21.4 5.6 3.6 11.7 5.1 4.6 2.8 1.7 11.4 10.5 7.0 7.9 7.4 5.4 4.8 10.4 5.5 2.0 8.4 0.5 0.7 0.2 1.9 1.2 3.0 2.7 1.8 2.3 0.9 3.6 2.0 2.7 0.3 3.6 0.8 9.8 1.6 0.4 10.8 24.1 11.4 18.1 15.5 9.9 36.1 13.5 30.0 26.7 SLC12A3 NCCT ENSG00000070915 "Solute carrier family 12 member 3" P55017 16 56865207-56915850 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "kidney: 88.6" "Group enriched" "Detected in some" 12 "BEWO: 10.1;HAP1: 5.6;HeLa: 11.2" "Cancer enhanced" "Detected in some" "renal cancer: 2.5" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 17 "plasmacytoid DC: 14.6" "Lineage enriched" "Detected in single" 17 "dendritic cells: 14.6" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA028748 Enhanced "HPA028748: AB_10603886" "unprognostic (1.54e-3)" "unprognostic (7.09e-5)" "unprognostic (1.35e-1)" "unprognostic (1.41e-2)" "unprognostic (2.91e-1)" "unprognostic (2.38e-4)" "unprognostic (1.81e-1)" "unprognostic (9.70e-2)" "unprognostic (1.34e-1)" "unprognostic (7.25e-2)" "unprognostic (6.84e-2)" "unprognostic (1.83e-1)" "unprognostic (1.43e-1)" "unprognostic (2.09e-1)" "unprognostic (1.38e-1)" "unprognostic (1.40e-2)" "unprognostic (1.70e-1)" 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 88.6 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 14.6 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 10.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.7 5.6 0.0 0.0 0.0 0.0 0.0 11.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.0 14.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 SLC12A4 KCC1 ENSG00000124067 "Solute carrier family 12 member 4" Q9UP95 16 67943474-67969601 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041138 Approved Approved Endosomes Endosomes "HPA041138: AB_10794544" "unprognostic (5.07e-2)" "unprognostic (6.18e-2)" "unprognostic (1.25e-1)" "unprognostic (2.68e-2)" "unprognostic (9.28e-2)" "unprognostic (1.48e-2)" "unprognostic (4.28e-2)" "unprognostic (3.26e-3)" "unprognostic (9.58e-2)" "unprognostic (1.55e-1)" "unprognostic (2.01e-2)" "unprognostic (1.81e-2)" "prognostic favourable (2.25e-6)" "unprognostic (6.42e-2)" "unprognostic (1.42e-1)" "unprognostic (7.64e-2)" "unprognostic (2.26e-1)" 16.6 18.3 9.2 8.0 8.8 3.1 26.5 7.0 12.7 19.4 16.5 20.1 12.0 5.1 20.7 9.7 11.8 13.8 15.5 24.4 12.2 5.2 10.7 17.1 19.5 6.6 11.4 8.2 14.2 11.9 30.1 8.1 32.6 18.1 17.8 4.3 23.0 10.5 20.7 14.6 16.9 8.6 27.4 10.0 10.2 10.9 17.6 9.8 8.8 21.0 9.1 8.4 16.5 16.6 1.0 2.4 8.3 5.4 2.7 1.6 1.6 5.0 6.8 5.2 9.9 17.4 15.3 28.3 15.4 16.0 13.3 11.6 13.5 8.1 1.7 7.6 21.3 9.2 2.4 19.1 10.1 1.8 2.0 1.3 8.8 14.7 19.8 0.1 6.3 16.9 12.5 17.9 6.5 8.2 4.0 1.5 18.2 0.7 1.9 5.0 3.9 3.6 2.0 9.9 1.6 7.3 4.4 0.0 3.2 29.4 1.8 2.6 14.0 2.0 11.1 19.0 13.5 8.4 6.6 9.2 2.3 3.0 11.1 1.4 16.4 8.3 3.9 2.0 1.5 5.4 1.0 0.4 0.9 0.9 2.4 1.0 0.8 0.7 1.4 2.7 3.8 1.1 1.6 1.6 9.2 8.8 7.0 8.6 12.2 5.2 11.4 8.2 18.1 9.8 SLC12A5 "KCC2, KIAA1176" ENSG00000124140 "Solute carrier family 12 member 5" Q9H2X9 20 46021690-46060152 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Symport, Transport" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 64.6" "Cell line enhanced" "Detected in many" "Hep G2: 13.4;NB-4: 27.6;SK-BR-3: 14.0;U-2 OS: 16.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 5.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA072058 Enhanced "HPA072058: " "unprognostic (2.01e-1)" "unprognostic (3.58e-1)" "unprognostic (7.55e-2)" "unprognostic (9.44e-4)" "prognostic unfavourable (5.60e-4)" "unprognostic (2.48e-1)" "unprognostic (5.16e-3)" "unprognostic (3.61e-1)" "unprognostic (2.49e-1)" "unprognostic (6.63e-2)" "unprognostic (3.72e-3)" "unprognostic (5.61e-4)" "unprognostic (8.78e-4)" "unprognostic (3.25e-2)" "unprognostic (9.22e-2)" "unprognostic (1.99e-1)" "unprognostic (2.34e-2)" 1.4 11.2 21.1 2.0 28.8 1.5 1.7 52.1 64.6 2.3 2.1 2.7 0.0 2.2 1.6 2.2 1.3 1.7 1.9 2.1 20.5 19.2 1.4 2.2 2.7 3.1 9.5 32.1 2.0 3.6 1.5 4.8 3.3 15.3 1.5 2.1 4.9 1.9 1.8 1.5 1.5 2.1 1.6 6.3 2.8 3.1 3.4 5.8 0.0 1.3 0.0 2.6 1.2 0.5 1.3 0.2 0.1 1.5 0.7 5.7 1.3 0.0 8.4 3.7 2.7 0.3 0.0 0.8 0.3 0.0 0.0 0.3 1.1 0.0 3.1 12.8 0.2 0.7 2.4 1.2 0.2 2.0 3.2 2.7 1.6 13.4 1.4 0.0 3.7 0.5 0.0 0.0 0.2 0.7 5.0 0.0 0.0 12.7 1.8 27.6 1.3 4.3 3.1 2.4 0.7 1.3 0.0 4.6 6.6 1.6 14.0 4.0 5.1 7.9 1.3 1.5 16.0 0.1 0.6 0.0 2.1 4.4 3.4 3.2 0.1 0.0 1.5 0.0 2.6 0.8 1.0 1.0 0.3 0.4 0.2 1.3 5.7 3.2 0.1 0.7 0.2 0.0 3.5 1.3 21.1 28.8 52.1 36.4 20.5 19.2 9.5 32.1 15.3 5.8 SLC18A1 "CGAT, VAT1, VMAT1" ENSG00000036565 "Solute carrier family 18 member A1" P54219 8 20144855-20183206 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 25.4;intestine: 10.8" "Cell line enriched" "Detected in some" 8 "SH-SY5Y: 38.3" "Cancer enhanced" "Detected in some" "colorectal cancer: 0.8" "Region enriched" "Detected in single" 4 "midbrain: 2.0" "Group enriched" "Detected in some" 12 "intermediate monocyte: 2.3;non-classical monocyte: 6.0" "Lineage enriched" "Detected in single" 18 "monocytes: 6.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA006877, HPA063797" Enhanced "HPA006877: , HPA063797: AB_2685125" "unprognostic (8.03e-4)" "unprognostic (1.02e-1)" "unprognostic (3.75e-3)" "unprognostic (3.50e-1)" "unprognostic (6.61e-2)" "unprognostic (3.09e-3)" "unprognostic (1.67e-1)" "unprognostic (2.16e-2)" "unprognostic (3.45e-2)" "unprognostic (1.48e-1)" "unprognostic (1.32e-3)" "unprognostic (1.61e-1)" "unprognostic (2.48e-2)" "unprognostic (8.25e-2)" "unprognostic (4.41e-2)" "unprognostic (2.06e-1)" "unprognostic (1.05e-1)" 0.0 25.4 0.2 0.8 0.1 0.0 0.0 0.0 0.2 0.2 8.8 1.3 1.3 1.4 0.4 0.0 0.0 0.0 0.7 0.1 0.1 0.4 0.0 0.0 0.0 0.0 2.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 1.0 2.7 0.0 0.0 2.8 0.0 0.0 10.8 0.0 0.1 0.3 1.1 0.2 0.0 0.2 0.2 0.0 0.1 1.3 0.4 0.0 0.3 0.2 6.0 0.0 0.0 0.3 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 4.5 0.0 0.0 0.0 2.2 38.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 6.0 0.0 0.0 0.3 0.2 0.1 0.0 0.2 0.1 0.4 2.0 0.0 0.4 0.0 SLC18A2 "SVAT, SVMT, VMAT2" ENSG00000165646 "Solute carrier family 18 member A2" Q05940 10 117241073-117279430 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "Disease mutation, Dystonia, FDA approved drug targets, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 26.3;brain: 28.3;cervix, uterine: 31.2" "Cell line enriched" "Detected in some" 20 "HMC-1: 89.0" "Low cancer specificity" "Detected in some" "Group enriched" "Detected in many" 10 "hypothalamus: 9.0;midbrain: 28.3;pons and medulla: 26.5" "Cell type enriched" "Detected in some" 13 "basophil: 26.3" "Lineage enriched" "Detected in many" 13 "granulocytes: 26.3" "Region enhanced" "Detected in many" "midbrain: 75.4" "Group enriched" "Detected in all" 5 "midbrain: 143.8;pons and medulla: 34.7" HPA073224 Enhanced Supported Vesicles,Centrosome Vesicles Centrosome "HPA073224: " "unprognostic (1.49e-1)" "unprognostic (2.48e-1)" "unprognostic (2.33e-3)" "unprognostic (9.00e-2)" "unprognostic (2.85e-1)" "unprognostic (5.33e-3)" "unprognostic (2.23e-1)" "unprognostic (1.71e-2)" "unprognostic (1.40e-1)" "unprognostic (4.55e-2)" "unprognostic (2.00e-1)" "unprognostic (6.06e-3)" "unprognostic (7.94e-5)" "unprognostic (2.95e-2)" "unprognostic (2.31e-1)" "unprognostic (2.43e-1)" "unprognostic (3.57e-2)" 1.7 13.9 1.7 3.1 2.0 2.0 2.0 1.7 1.6 31.2 2.3 0.5 2.2 1.5 11.2 4.9 3.0 1.1 15.9 1.0 1.9 9.0 1.1 3.3 7.6 1.5 28.3 0.2 9.7 3.7 0.5 1.6 2.1 26.5 10.8 3.4 3.1 1.0 4.0 1.1 5.8 2.5 5.4 2.9 0.5 3.5 1.5 0.3 14.1 0.6 3.4 2.9 3.1 5.4 0.0 2.0 26.3 0.0 0.0 0.3 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 4.5 0.0 0.0 0.0 0.2 89.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.2 0.1 0.1 0.0 0.1 0.4 0.0 26.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.2 0.0 0.0 2.0 0.0 1.1 1.7 2.0 1.7 1.6 1.9 9.0 28.3 0.2 26.5 0.3 SLC1A5 "AAAT, ASCT2, M7V1, RDRC" ENSG00000105281 "Solute carrier family 1 member 5" Q15758 19 46774883-46788594 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Host-virus interaction, Symport, Transport" "Host cell receptor for virus entry, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 34.6" "Group enriched" "Detected in many" 4 "dendritic cells: 34.6;monocytes: 22.4" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA035239, HPA035240" Enhanced Enhanced "Plasma membrane" "Plasma membrane" "HPA035239: AB_10670587, HPA035240: AB_10604092" "unprognostic (8.26e-3)" "unprognostic (6.38e-2)" "unprognostic (7.24e-2)" "unprognostic (7.94e-2)" "unprognostic (2.32e-1)" "unprognostic (1.24e-1)" "prognostic unfavourable (1.66e-8)" "unprognostic (2.08e-1)" "unprognostic (1.06e-2)" "unprognostic (9.82e-2)" "unprognostic (9.40e-3)" "unprognostic (9.57e-3)" "prognostic unfavourable (1.18e-7)" "unprognostic (1.28e-2)" "unprognostic (6.30e-2)" "unprognostic (1.06e-2)" "unprognostic (9.83e-2)" 39.3 5.7 3.4 16.0 5.4 16.2 45.0 0.9 3.0 20.7 15.8 5.0 50.4 4.9 14.3 33.7 33.9 18.1 31.2 10.0 4.5 2.2 23.7 4.1 23.4 17.7 8.2 0.9 33.3 24.6 0.2 9.1 25.8 4.9 35.2 13.8 5.2 99.0 55.7 6.9 18.6 12.1 23.1 5.3 19.8 17.9 21.7 6.1 14.9 6.5 28.4 25.9 48.3 44.9 7.0 34.6 0.9 22.4 6.9 5.6 7.4 24.2 44.9 10.8 16.3 28.2 24.0 25.6 34.7 39.7 26.1 37.9 40.7 27.5 26.6 17.0 86.1 39.2 31.5 41.2 19.5 17.6 28.5 44.2 17.2 38.1 73.0 30.7 26.1 39.0 103.2 30.6 77.6 13.8 46.6 70.6 13.9 41.3 14.0 82.7 18.9 19.8 16.0 12.2 37.9 14.6 53.1 16.7 12.2 17.1 46.8 37.2 26.9 40.6 10.3 15.7 25.1 12.2 28.2 43.8 42.3 22.2 29.5 38.4 38.4 0.0 11.5 0.9 5.3 19.9 4.4 7.0 3.1 3.7 17.8 2.5 0.7 2.3 0.3 6.9 22.4 34.6 5.6 7.4 3.4 5.4 0.9 3.0 4.5 2.2 8.2 0.9 4.9 6.1 SLC22A11 OAT4 ENSG00000168065 "Solute carrier family 22 member 11" Q9NSA0 11 64555626-64572875 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 10 "epididymis: 22.2;kidney: 47.6;placenta: 64.7" "Cell line enhanced" "Detected in some" "BEWO: 4.8;CACO-2: 1.1;Hep G2: 3.4" "Group enriched" "Detected in some" 14 "liver cancer: 3.7;renal cancer: 15.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA026076 Enhanced "HPA026076: AB_1854756" "unprognostic (8.21e-5)" "unprognostic (3.29e-2)" "unprognostic (3.57e-1)" "unprognostic (1.57e-1)" "unprognostic (3.20e-2)" "unprognostic (4.57e-3)" "unprognostic (3.48e-1)" "unprognostic (1.93e-1)" "unprognostic (4.86e-2)" "unprognostic (4.51e-2)" "unprognostic (7.56e-2)" "unprognostic (1.13e-1)" "prognostic favourable (3.68e-5)" "unprognostic (4.62e-2)" "unprognostic (6.52e-2)" "unprognostic (3.50e-2)" "unprognostic (8.24e-3)" 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 4.4 0.0 0.1 22.2 0.1 0.1 0.0 0.1 0.1 0.1 47.6 0.4 0.1 0.0 0.2 0.0 0.1 0.3 0.0 0.1 64.7 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.3 0.1 0.4 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.2 4.8 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.0 SLC22A12 "OAT4L, RST, URAT1" ENSG00000197891 "Solute carrier family 22 member 12" Q96S37 11 64590641-64602353 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 349 "kidney: 70.1" "Not detected" "Not detected" "Group enriched" "Detected in some" 207 "liver cancer: 4.0;renal cancer: 16.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Low region specificity" "Detected in some" HPA024575 Enhanced "HPA024575: AB_1858650" "unprognostic (5.88e-2)" "unprognostic (2.33e-1)" "prognostic favourable (2.63e-4)" "unprognostic (6.19e-2)" "unprognostic (3.91e-2)" 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 70.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SLC22A6 "OAT1, PAHT, ROAT1" ENSG00000197901 "Solute carrier family 22 member 6" Q4U2R8 11 62936385-62984983 "FDA approved drug targets, Predicted membrane proteins, Transporters" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "kidney: 94.2" "Not detected" "Not detected" "Cancer enriched" "Detected in single" 102 "renal cancer: 18.8" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA074559, CAB075704" Enhanced "CAB075704: , HPA074559: " "unprognostic (2.42e-2)" "unprognostic (2.25e-3)" "unprognostic (4.43e-1)" 0.2 0.2 0.8 0.2 1.3 0.2 0.2 0.4 1.4 0.2 0.2 0.7 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.8 1.8 94.2 0.2 0.2 0.2 2.4 0.6 0.2 0.2 0.2 0.1 0.2 4.1 0.2 0.2 9.4 0.2 0.2 0.2 0.2 0.2 0.2 2.4 0.2 0.2 0.2 0.5 0.0 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 1.3 0.4 1.4 0.8 1.8 2.4 0.6 4.1 0.5 SLC22A8 OAT3 ENSG00000149452 "Solute carrier family 22 member 8" Q8TCC7 11 62989154-63015839 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Detoxification, Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 341 "brain: 33.7;kidney: 127.3;retina: 93.5" "Cell line enriched" "Detected in single" 13 "EFO-21: 1.2" "Cancer enhanced" "Detected in single" "renal cancer: 0.6" "Region enriched" "Detected in some" 25 "pons and medulla: 33.7" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044174 Enhanced "HPA044174: AB_10963058" "unprognostic (5.35e-4)" "unprognostic (4.66e-1)" "unprognostic (6.88e-3)" "unprognostic (1.72e-1)" "unprognostic (2.20e-1)" 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.4 1.0 0.1 0.1 3.8 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.7 0.1 127.3 0.1 0.1 0.1 0.1 1.3 0.1 0.1 0.1 0.2 0.1 33.7 0.1 0.1 93.5 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.4 1.0 0.7 0.1 0.1 1.3 33.7 0.0 SLC25A4 "ANT1, PEO2, PEO3, T1" ENSG00000151729 "Solute carrier family 25 member 4" P12235 4 185143241-185150382 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Host-virus interaction, Transport" "Cardiomyopathy, Disease mutation, FDA approved drug targets, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 5 "heart muscle: 163.7;skeletal muscle: 92.5;tongue: 62.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "B-cells: 3.5;dendritic cells: 3.0;T-cells: 4.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046835, HPA071684" Approved Supported Mitochondria Mitochondria "HPA046835: , HPA071684: " "unprognostic (4.19e-2)" "unprognostic (1.06e-2)" "unprognostic (3.11e-1)" "unprognostic (8.85e-2)" "unprognostic (1.37e-1)" "unprognostic (2.90e-3)" "unprognostic (8.25e-2)" "unprognostic (1.26e-2)" "unprognostic (7.87e-2)" "unprognostic (1.60e-1)" "prognostic favourable (3.41e-4)" "unprognostic (2.05e-1)" "prognostic favourable (0.00e+0)" "unprognostic (1.98e-1)" "unprognostic (1.05e-1)" "unprognostic (1.73e-1)" "unprognostic (8.28e-3)" 3.0 4.2 6.9 2.0 10.8 1.4 3.1 19.4 14.4 2.6 6.6 3.7 2.9 2.8 3.0 3.4 6.7 3.7 3.5 163.7 7.4 7.3 8.3 4.3 3.0 2.0 6.3 6.1 3.6 3.0 4.6 4.6 2.2 12.8 6.2 3.4 7.9 4.4 8.5 92.5 2.3 4.1 5.5 4.5 2.1 5.3 3.1 2.3 0.0 4.6 62.4 3.4 4.4 2.1 3.5 3.0 0.4 0.0 0.7 4.1 1.5 0.7 3.2 2.7 5.4 2.9 0.3 4.9 2.7 0.9 3.3 3.3 7.0 1.8 2.3 1.9 3.2 2.6 10.3 2.8 2.1 4.0 8.8 1.6 4.9 8.2 6.0 1.4 1.6 2.2 7.0 5.0 1.4 2.4 3.8 1.8 2.0 5.1 1.6 3.1 4.3 7.0 2.6 1.4 3.3 7.4 5.0 8.7 6.6 3.2 1.4 12.4 2.5 1.2 1.8 0.2 1.5 1.6 3.4 7.8 3.5 3.0 2.4 0.3 3.0 0.0 0.0 0.0 4.1 0.0 3.1 3.5 1.4 3.5 0.1 2.2 1.2 3.0 0.4 0.7 0.0 3.0 1.2 1.5 6.9 10.8 19.4 14.1 7.4 7.3 6.3 6.1 12.8 2.3 SLC25A5 "2F1, ANT2, T2, T3" ENSG00000005022 "Solute carrier family 25 member 5" P05141 X 119468400-119471319 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Chromosome partition, Host-virus interaction, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046835, HPA071684" Approved Supported Mitochondria 7800000 Mitochondria "HPA046835: , HPA071684: " "unprognostic (1.25e-2)" "prognostic favourable (7.35e-4)" "prognostic favourable (7.47e-4)" "unprognostic (1.48e-1)" "unprognostic (4.58e-2)" "unprognostic (1.45e-2)" "unprognostic (2.73e-2)" "unprognostic (1.36e-1)" "unprognostic (6.52e-2)" "unprognostic (2.47e-1)" "unprognostic (1.60e-1)" "unprognostic (2.17e-1)" "prognostic favourable (8.06e-6)" "unprognostic (1.41e-1)" "unprognostic (2.65e-1)" "unprognostic (4.36e-2)" "unprognostic (3.03e-1)" 26.0 28.9 26.8 32.2 29.5 36.5 36.6 21.8 39.0 23.0 74.1 16.3 26.0 120.7 22.5 18.3 64.1 17.5 39.5 31.4 22.5 18.8 80.7 71.0 38.3 53.8 27.2 23.8 18.1 128.2 22.5 14.6 30.7 24.2 18.9 84.9 20.1 58.3 21.5 16.6 42.1 157.5 33.6 20.5 34.3 68.2 16.8 17.1 87.0 31.1 59.9 47.0 30.8 33.8 51.6 97.8 18.5 113.2 33.4 48.0 84.9 81.9 78.8 30.9 53.1 19.8 29.2 57.4 30.6 33.4 64.7 58.0 65.5 52.0 104.1 41.3 29.4 57.7 75.7 64.0 59.2 27.5 73.0 35.1 47.6 46.6 25.1 95.2 58.0 31.7 72.0 66.6 42.5 67.1 28.1 43.1 35.3 182.5 84.2 96.7 65.0 127.1 46.3 39.1 80.8 49.3 66.0 37.4 35.4 52.7 80.2 62.1 33.1 48.2 27.9 30.6 44.3 68.2 109.9 50.6 62.9 83.3 33.9 97.4 49.5 10.1 68.1 18.5 20.7 113.2 23.9 51.6 30.1 26.9 97.8 39.7 30.1 28.3 11.3 33.4 84.9 53.9 48.0 84.9 26.8 29.5 21.8 39.0 22.5 18.8 27.2 23.8 24.2 17.1 SLC25A6 "ANT3, ANT3Y, MGC17525" ENSG00000169100 "Solute carrier family 25 member 6" P12236 X 1386152-1392724 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Apoptosis, Host-virus interaction, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 85.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA046835, HPA071684" Approved Supported Mitochondria 7200000 Mitochondria "HPA046835: , HPA071684: " "unprognostic (1.13e-1)" "unprognostic (1.65e-2)" "unprognostic (4.79e-2)" "unprognostic (1.45e-1)" "unprognostic (2.14e-1)" "unprognostic (1.41e-1)" "unprognostic (1.01e-3)" "unprognostic (1.34e-1)" "unprognostic (8.07e-2)" "unprognostic (1.48e-1)" "unprognostic (1.37e-3)" "unprognostic (2.51e-1)" "unprognostic (3.96e-2)" "unprognostic (2.73e-1)" "unprognostic (1.69e-1)" "unprognostic (2.85e-1)" "unprognostic (4.57e-3)" 18.5 19.7 12.1 12.2 14.0 23.7 14.4 8.2 12.2 9.8 16.5 28.9 14.3 4.8 16.4 10.4 7.0 9.4 10.3 8.2 18.4 5.4 11.1 14.4 9.4 25.6 38.7 10.1 14.0 8.6 12.4 8.8 45.0 12.5 6.1 14.9 23.3 7.7 5.8 15.4 19.2 2.4 16.3 9.5 14.2 11.2 62.2 85.7 3.7 69.0 30.1 43.6 71.2 22.0 48.3 34.3 35.0 23.8 46.4 37.1 33.8 32.4 24.9 24.8 63.8 27.0 81.9 27.3 22.2 14.3 23.0 40.3 7.9 20.5 73.1 44.8 33.1 72.8 55.8 32.2 54.7 76.5 74.3 19.5 28.7 37.0 31.2 19.3 24.4 46.9 59.6 61.7 43.5 65.0 30.1 28.4 63.5 30.4 55.4 56.0 88.0 22.8 69.4 96.1 38.5 66.4 42.2 25.5 14.3 49.7 33.6 50.1 8.0 55.3 3.8 31.1 13.8 2.4 58.1 3.7 29.4 69.0 43.6 62.2 40.4 34.8 85.7 47.5 38.1 37.2 3.0 30.1 67.9 41.0 38.7 71.2 SLC52A2 "D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2" ENSG00000185803 "Solute carrier family 52 member 2" Q9HAB3 8 144354135-144361286 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport "Host cell receptor for virus entry, Receptor" "Deafness, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "PC-3: 50.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063036 Approved "HPA063036: " "unprognostic (7.80e-3)" "prognostic unfavourable (7.55e-4)" "unprognostic (2.15e-1)" "unprognostic (2.94e-1)" "unprognostic (3.09e-2)" "unprognostic (3.94e-2)" "prognostic unfavourable (2.04e-6)" "unprognostic (7.74e-3)" "unprognostic (9.20e-2)" "unprognostic (2.24e-2)" "unprognostic (4.85e-2)" "unprognostic (3.99e-2)" "prognostic unfavourable (1.23e-4)" "unprognostic (3.12e-2)" "unprognostic (1.73e-1)" "unprognostic (1.51e-1)" "unprognostic (1.07e-1)" 16.0 12.8 7.3 13.2 8.8 9.9 23.7 19.2 10.5 10.9 18.1 7.5 19.3 19.6 10.7 19.9 14.6 7.4 16.3 8.0 7.7 9.0 14.7 12.4 10.7 10.7 13.0 5.9 10.6 22.4 7.9 10.9 19.5 9.5 10.8 9.3 7.2 21.3 14.1 7.0 12.6 17.8 8.5 7.9 15.2 16.8 17.0 7.4 11.5 12.4 11.6 14.6 8.6 13.1 7.7 9.0 9.2 7.4 5.7 6.3 1.9 12.6 18.2 2.6 6.8 4.9 3.6 13.2 9.8 6.9 8.9 7.1 14.5 15.3 6.0 16.1 7.0 15.1 4.3 7.5 1.9 7.4 10.3 10.4 10.5 13.1 15.8 3.8 9.0 5.0 9.1 8.1 6.7 5.1 14.3 7.7 4.6 36.9 5.9 10.1 5.6 50.4 11.0 3.1 13.6 7.2 9.3 8.1 9.6 12.1 12.5 11.3 9.9 5.0 7.3 7.3 16.6 18.2 14.0 3.9 5.3 4.6 12.1 9.5 8.4 1.2 4.2 9.2 5.9 6.1 3.7 4.2 4.7 6.3 5.2 7.7 4.6 3.1 1.4 5.7 7.4 9.0 5.7 1.9 7.3 8.8 19.2 10.5 7.7 9.0 13.0 5.9 9.5 7.4 SLC5A2 SGLT2 ENSG00000140675 "Solute carrier family 5 member 2" P31639 16 31483002-31490860 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Sugar transport, Symport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 17 "kidney: 33.7" "Cell line enhanced" "Detected in some" "BEWO: 1.2;EFO-21: 1.9;Hep G2: 2.6;NB-4: 1.3;U-2 OS: 1.2;U-266/84: 1.8;U-937: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 1.6" "Group enriched" "Detected in many" 16 "NK-cells: 1.4;T-cells: 1.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA041603 Enhanced "HPA041603: AB_10960540" "unprognostic (1.61e-1)" "unprognostic (2.95e-1)" "unprognostic (2.84e-1)" "unprognostic (3.00e-2)" "unprognostic (8.04e-2)" "unprognostic (8.23e-3)" "unprognostic (1.49e-1)" "unprognostic (2.25e-3)" "unprognostic (2.57e-1)" "unprognostic (1.12e-2)" "unprognostic (6.43e-2)" "unprognostic (2.47e-1)" "unprognostic (1.42e-3)" "unprognostic (5.88e-2)" "unprognostic (2.14e-1)" "unprognostic (4.18e-2)" "unprognostic (3.22e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 1.6 0.6 0.1 0.4 0.0 0.9 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.3 1.2 0.1 0.0 0.0 1.8 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 1.6 0.5 0.0 0.0 0.5 0.1 0.0 1.4 0.0 0.0 1.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SLC6A1 "GABATHG, GABATR, GAT1" ENSG00000157103 "Solute carrier family 6 member 1" P30531 3 10992186-11039249 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "brain: 56.2;liver: 75.6" "Cell line enhanced" "Detected in many" "HeLa: 4.5" "Group enriched" "Detected in some" 16 "glioma: 16.1;liver cancer: 24.4" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013341, CAB022293" Enhanced Uncertain Mitochondria Mitochondria "CAB022293: , HPA013341: AB_1849509" "unprognostic (1.66e-3)" "unprognostic (1.30e-3)" "unprognostic (4.12e-3)" "unprognostic (1.70e-1)" "unprognostic (2.53e-1)" "unprognostic (2.53e-1)" "prognostic favourable (3.20e-4)" "unprognostic (1.05e-1)" "unprognostic (4.27e-2)" "unprognostic (8.26e-2)" "unprognostic (2.90e-1)" "unprognostic (2.69e-1)" "prognostic unfavourable (5.05e-6)" "unprognostic (7.32e-3)" "unprognostic (2.36e-1)" "unprognostic (1.35e-1)" "unprognostic (5.34e-2)" 1.8 2.1 32.2 1.6 31.0 3.0 1.8 15.1 56.2 2.0 1.7 25.4 0.0 1.7 1.9 3.9 4.3 2.4 2.3 3.3 22.2 16.6 2.1 75.6 2.5 1.7 22.7 25.3 2.4 1.4 9.3 1.0 2.0 17.0 2.1 1.8 1.7 1.6 5.0 3.3 1.7 1.7 1.8 13.7 1.9 1.7 4.4 14.3 0.5 1.9 0.0 1.7 1.9 0.9 1.0 0.8 1.2 0.3 0.2 0.8 0.2 0.8 0.6 1.8 1.3 1.5 0.4 1.0 0.7 0.2 0.8 1.1 1.4 1.0 1.6 0.3 0.4 1.3 2.3 0.9 0.7 0.2 1.7 1.3 4.5 2.7 0.7 2.2 2.2 1.1 0.2 0.2 1.2 0.3 1.1 3.6 0.2 1.0 0.7 1.7 0.8 1.4 1.2 0.2 0.1 0.6 1.7 0.8 0.3 1.0 0.6 0.2 1.0 1.0 0.3 0.8 0.5 0.7 0.6 1.1 0.3 1.2 0.9 1.7 0.4 0.3 0.3 1.1 0.5 0.1 0.8 0.9 0.6 0.5 0.3 1.0 0.3 0.5 1.2 0.2 0.3 0.8 0.3 0.2 32.2 31.0 15.1 41.5 22.2 16.6 22.7 25.3 17.0 14.3 SLC6A2 "NAT1, NET, NET1, SLC6A5" ENSG00000103546 "Solute carrier family 6 member 2" P23975 16 55655604-55706192 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 20.4;placenta: 41.8" "Cell line enriched" "Detected in some" 30 "SH-SY5Y: 104.5" "Cancer enhanced" "Detected in some" "liver cancer: 1.9" "Region enriched" "Detected in single" 27 "pons and medulla: 9.7" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 4 "pons and medulla: 8.2" "Region enriched" "Detected in single" 32 "pons and medulla: 23.1" "HPA004057, HPA076311, CAB078195" Enhanced Supported Approved Mitochondria,Cytosol Cytosol Mitochondria "CAB078195: , HPA004057: AB_1080012, HPA076311: " "unprognostic (9.58e-3)" "unprognostic (5.48e-2)" "unprognostic (1.26e-4)" "unprognostic (4.07e-1)" "unprognostic (4.16e-1)" "unprognostic (8.38e-2)" "unprognostic (2.97e-2)" "unprognostic (3.29e-1)" "unprognostic (2.31e-1)" "unprognostic (3.27e-1)" "unprognostic (2.12e-2)" "unprognostic (2.95e-2)" "unprognostic (1.72e-1)" "unprognostic (6.02e-2)" "unprognostic (8.48e-2)" "unprognostic (1.43e-2)" 2.4 20.4 0.3 0.1 0.1 0.0 1.8 0.1 0.3 3.2 0.3 0.3 0.1 0.0 4.5 7.2 0.8 0.4 0.4 0.1 0.1 0.0 0.4 1.0 0.5 0.1 0.1 0.1 0.2 0.1 0.0 0.1 41.8 9.7 0.5 0.1 0.1 1.6 1.7 0.1 11.4 0.4 1.0 0.2 0.1 0.2 8.3 0.2 0.1 0.2 0.9 0.5 0.5 1.7 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.0 0.8 104.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.1 0.3 0.1 0.0 0.1 0.1 9.7 0.2 SLC6A3 "DAT, DAT1" ENSG00000142319 "Solute carrier family 6 member 3" Q01959 5 1392790-1445430 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, Dystonia, FDA approved drug targets, Neurodegeneration, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "brain: 48.4" "Group enriched" "Detected in some" 5 "NTERA-2: 1.2;RPMI-8226: 2.0;SCLC-21H: 3.7" "Cancer enriched" "Detected in some" 18 "renal cancer: 25.7" "Region enriched" "Detected in some" 47 "midbrain: 48.4" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "midbrain: 96.4;thalamus: 31.8" "Region enriched" "Detected in single" 139 "midbrain: 362.2" "HPA012763, HPA013602, CAB016249, CAB078172" Enhanced Supported Approved Vesicles Vesicles "CAB016249: AB_627402, CAB078172: , HPA012763: , HPA013602: AB_1847484" "unprognostic (2.25e-4)" "unprognostic (2.22e-1)" "unprognostic (8.45e-2)" "unprognostic (5.24e-2)" "unprognostic (7.75e-2)" "unprognostic (1.41e-2)" "unprognostic (4.64e-5)" "unprognostic (9.31e-2)" "unprognostic (7.89e-2)" "unprognostic (4.81e-2)" "unprognostic (1.30e-1)" "unprognostic (2.12e-2)" "prognostic unfavourable (3.40e-7)" "unprognostic (6.98e-2)" "unprognostic (1.64e-1)" "unprognostic (2.22e-2)" "unprognostic (4.74e-2)" 0.2 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.3 0.7 0.0 0.0 0.0 0.3 1.1 0.8 0.1 0.8 0.6 0.1 0.0 0.6 0.3 0.0 3.4 0.0 48.4 0.0 1.5 0.0 0.0 0.0 0.1 1.0 0.7 0.0 1.7 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.1 0.0 0.8 0.0 2.4 2.2 0.0 0.3 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.2 0.0 0.0 0.0 2.0 0.0 0.1 3.7 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.3 0.0 0.6 48.4 0.0 1.0 0.0 SLC6A4 "5-HTT, HTT, OCD1, SERT1" ENSG00000108576 "Solute carrier family 6 member 4" P31645 17 30194319-30236002 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 25.0;lung: 50.5" "Cell line enhanced" "Detected in some" "BEWO: 2.8;CACO-2: 5.4;Hep G2: 14.4" "Cancer enhanced" "Detected in some" "breast cancer: 2.3" "Region enriched" "Detected in single" 36 "pons and medulla: 11.2" "Cell type enhanced" "Detected in single" "neutrophil: 1.0" "Low lineage specificity" "Detected in single" "Region enriched" "Detected in some" 5 "midbrain: 69.9" "Low region specificity" "Detected in all" "HPA054723, HPA071354, HPA074728" Supported Supported Supported "Golgi apparatus,Vesicles" "Golgi apparatus, Vesicles" "HPA054723: , HPA071354: , HPA074728: " "unprognostic (7.45e-2)" "unprognostic (7.13e-2)" "unprognostic (2.26e-1)" "unprognostic (3.72e-4)" "unprognostic (2.07e-1)" "unprognostic (8.42e-3)" "unprognostic (2.73e-2)" "unprognostic (3.39e-2)" "unprognostic (3.37e-3)" "unprognostic (1.17e-3)" "unprognostic (2.70e-3)" "unprognostic (1.16e-1)" "unprognostic (8.78e-2)" "unprognostic (4.98e-2)" "unprognostic (1.76e-1)" "unprognostic (4.05e-2)" "unprognostic (7.18e-2)" 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.3 0.2 0.2 0.1 0.1 6.3 0.1 0.3 1.6 0.9 0.1 0.7 0.1 0.1 0.3 0.1 50.5 0.1 0.1 0.1 0.1 0.6 0.0 0.1 11.3 11.2 0.1 0.0 0.2 0.7 0.1 0.1 0.4 25.0 0.4 0.1 0.1 0.5 0.3 0.1 0.1 0.2 0.1 0.3 0.1 0.3 0.0 0.1 1.0 0.2 0.4 0.3 2.3 0.0 0.0 0.0 0.1 0.0 0.0 2.8 0.0 0.0 0.0 0.0 5.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 14.4 1.4 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.4 0.1 0.1 0.0 1.0 0.0 0.8 0.0 0.0 0.1 0.2 0.2 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.3 0.1 0.1 0.3 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.2 0.1 1.0 0.4 0.2 0.1 0.0 2.3 0.1 0.1 0.2 0.3 0.1 0.1 0.1 0.1 11.2 0.1 SLC7A11 xCT ENSG00000151012 "Solute carrier family 7 member 11" Q9UPY5 4 138164097-138242349 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 27.2" "Cell line enhanced" "Detected in many" "hTCEpi: 28.0;TIME: 30.7;WM-115: 45.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 8 "plasmacytoid DC: 3.8" "Lineage enriched" "Detected in single" 8 "dendritic cells: 3.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA064215 Approved Vesicles Vesicles "HPA064215: " "unprognostic (3.55e-3)" "unprognostic (4.64e-3)" "unprognostic (2.43e-2)" "unprognostic (7.18e-3)" "unprognostic (2.59e-1)" "unprognostic (8.80e-3)" "unprognostic (2.07e-8)" "unprognostic (1.98e-2)" "unprognostic (1.09e-2)" "prognostic favourable (1.77e-4)" "unprognostic (1.90e-2)" "unprognostic (4.07e-2)" "unprognostic (2.22e-8)" "unprognostic (3.81e-2)" "unprognostic (3.76e-2)" "unprognostic (2.29e-2)" "unprognostic (1.54e-2)" 1.1 0.9 16.3 4.7 15.8 2.2 1.5 8.2 26.0 2.4 2.0 17.9 0.0 1.5 1.3 13.4 3.3 8.9 3.8 2.5 17.4 6.9 0.9 0.9 2.3 1.5 12.6 16.8 1.7 5.4 1.0 1.2 2.1 17.2 2.0 2.8 0.3 1.6 1.0 0.8 1.9 1.4 1.0 27.2 1.4 9.2 2.2 14.0 0.0 8.9 6.0 2.2 4.0 0.8 0.1 3.8 0.4 0.0 0.1 0.0 0.0 1.6 13.5 6.1 4.7 1.3 1.7 1.6 7.5 5.2 1.7 3.9 1.5 5.7 3.1 9.8 26.0 2.2 3.2 6.4 7.2 5.8 0.6 2.2 12.8 3.4 20.2 5.6 2.1 4.0 28.0 4.8 21.6 21.2 2.9 8.0 8.9 1.2 0.7 0.5 1.2 3.9 0.9 2.0 3.5 1.0 6.4 2.5 0.5 3.2 0.9 11.5 1.4 12.1 30.7 2.2 6.3 3.3 5.9 6.8 3.1 3.1 3.8 3.1 45.1 0.3 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.0 3.8 0.0 0.0 16.3 15.8 8.2 15.9 17.4 6.9 12.6 16.8 17.2 14.0 SLC7A3 "ATRC3, CAT-3, FLJ14541" ENSG00000165349 "Solute carrier family 7 member 3" Q8WY07 X 70925582-70931125 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 45.5" "Cell line enhanced" "Detected in some" "Daudi: 8.8;HAP1: 24.5;MOLT-4: 9.6;NTERA-2: 50.3;REH: 10.5" "Cancer enriched" "Detected in some" 12 "testis cancer: 43.0" "Region enhanced" "Detected in many" "hypothalamus: 6.7" "Cell type enriched" "Detected in single" 16 "naive CD8 T-cell: 1.5" "Lineage enriched" "Detected in single" 16 "T-cells: 1.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA003629 Approved "HPA003629: AB_2190964" "unprognostic (1.42e-4)" "unprognostic (4.30e-4)" "unprognostic (3.59e-3)" "unprognostic (1.81e-2)" "unprognostic (6.45e-2)" "unprognostic (1.45e-2)" "unprognostic (3.66e-1)" "unprognostic (9.18e-3)" "unprognostic (1.89e-1)" "unprognostic (7.99e-5)" "unprognostic (1.31e-2)" "unprognostic (5.42e-4)" "unprognostic (3.57e-2)" 0.1 0.0 1.0 0.1 1.0 1.3 1.4 0.1 2.1 2.0 0.1 1.1 0.8 0.1 9.1 6.2 0.7 2.7 0.1 0.0 1.2 6.7 0.2 0.0 0.1 0.5 0.5 0.5 1.7 0.0 0.0 0.6 0.0 1.2 10.4 0.0 0.5 0.2 9.4 0.0 0.0 0.3 4.6 0.2 0.1 5.6 2.4 0.4 45.5 0.0 0.2 0.5 4.0 1.4 0.0 0.0 0.0 0.0 0.0 1.5 0.3 0.0 0.0 1.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 8.8 0.2 0.0 0.0 24.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.6 0.0 50.3 0.0 10.5 3.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.3 1.0 1.0 0.1 2.1 1.2 6.7 0.5 0.5 1.2 0.4 SLC7A7 "LPI, y+LAT-1" ENSG00000155465 "Solute carrier family 7 member 7" Q9UM01 14 22773222-22829820 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 63.8;intestine: 93.5;kidney: 67.3" "Cell line enhanced" "Detected in some" "BEWO: 48.1;CACO-2: 78.0;EFO-21: 16.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "intermediate monocyte: 59.5;non-classical monocyte: 63.8" "Lineage enriched" "Detected in many" 4 "monocytes: 63.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA036227 Enhanced "HPA036227: AB_10696653" "unprognostic (1.34e-1)" "unprognostic (7.65e-2)" "unprognostic (4.25e-2)" "unprognostic (2.52e-1)" "unprognostic (6.12e-2)" "unprognostic (3.69e-2)" "unprognostic (7.84e-3)" "unprognostic (1.47e-1)" "unprognostic (2.88e-2)" "unprognostic (1.73e-2)" "unprognostic (2.60e-3)" "unprognostic (7.15e-2)" "prognostic unfavourable (6.28e-6)" "unprognostic (2.68e-3)" "unprognostic (1.86e-2)" "unprognostic (2.61e-1)" "unprognostic (1.12e-1)" 10.4 2.8 1.9 8.3 3.1 3.6 3.2 0.7 2.7 2.6 48.0 4.1 0.2 24.1 2.7 2.3 2.1 4.6 7.6 3.0 2.2 1.6 67.3 6.5 15.3 20.5 3.7 1.0 2.6 2.7 26.3 1.0 6.5 3.2 2.7 3.4 2.1 3.3 0.9 1.6 1.8 93.5 3.5 4.5 32.4 3.0 13.4 2.7 2.1 2.8 0.8 5.7 4.1 3.6 3.0 14.6 5.4 63.8 0.0 0.1 17.8 0.0 2.6 0.2 0.1 0.4 0.9 48.1 0.5 3.9 0.1 0.3 78.0 7.9 3.8 16.9 0.3 2.9 0.0 0.0 0.1 0.1 0.0 0.2 0.0 0.8 2.3 0.4 0.4 1.7 0.2 0.2 0.1 6.0 0.0 3.0 0.6 0.1 0.0 0.3 0.8 0.0 0.6 8.4 2.2 0.2 0.2 0.0 0.2 0.1 0.1 0.5 0.1 1.8 0.3 0.2 0.4 0.1 0.1 0.6 0.2 2.0 0.2 0.2 0.0 0.0 41.2 0.1 0.0 59.5 0.0 3.0 0.0 0.0 14.6 2.3 0.1 0.0 5.4 0.0 63.8 0.5 0.1 17.8 1.9 3.1 0.7 2.7 2.2 1.6 3.7 1.0 3.2 2.7 SLC8A1 NCX1 ENSG00000183023 "Solute carrier family 8 member A1" P32418 2 40097270-40611053 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Antiport, Calcium transport, Ion transport, Sodium transport, Transport" Calmodulin-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 67.7" "Cell line enhanced" "Detected in many" "BJ: 15.1;fHDF/TERT166: 36.6;hTERT-HME1: 10.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 4 "neutrophil: 25.2" "Lineage enriched" "Detected in many" 4 "granulocytes: 25.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022694, HPA070007" Uncertain Supported "Nucleoplasm,Plasma membrane" "Intracellular and membrane" "Nucleoplasm, Plasma membrane" "CAB022694: , HPA070007: " "unprognostic (2.46e-1)" "unprognostic (1.33e-2)" "unprognostic (1.42e-2)" "unprognostic (7.57e-6)" "unprognostic (1.56e-1)" "unprognostic (3.94e-1)" "unprognostic (2.28e-2)" "unprognostic (4.60e-2)" "unprognostic (1.31e-1)" "unprognostic (7.71e-2)" "unprognostic (1.21e-2)" "unprognostic (1.07e-1)" "unprognostic (3.66e-2)" "unprognostic (7.04e-3)" "unprognostic (3.93e-2)" "unprognostic (5.46e-2)" "unprognostic (6.77e-2)" 3.9 2.9 7.7 4.4 14.3 1.4 2.0 3.5 15.3 5.5 7.3 1.8 7.1 3.3 12.2 3.9 4.0 3.9 5.3 67.7 7.7 6.6 11.0 2.2 3.7 2.5 5.2 8.2 2.1 1.5 1.1 1.9 6.8 7.6 12.2 3.4 1.0 1.5 17.2 1.5 2.1 3.6 20.5 2.8 4.4 2.5 1.4 2.5 0.1 1.6 0.0 1.3 9.8 2.8 0.0 2.4 25.2 6.0 0.0 0.0 0.5 1.5 1.1 1.1 0.1 1.7 3.5 0.0 15.1 5.8 5.0 3.3 0.0 2.5 0.0 1.2 36.6 0.6 0.2 2.5 5.2 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.2 2.0 0.0 5.7 10.7 0.4 0.0 0.2 6.4 0.0 0.4 0.0 0.7 2.1 4.0 7.9 0.0 1.7 0.2 1.7 0.3 0.0 0.0 0.0 0.0 0.3 5.1 4.8 0.1 0.0 1.6 0.8 0.0 0.0 0.8 0.9 0.7 0.0 4.9 0.0 0.0 5.1 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 25.2 0.0 6.0 0.1 0.0 0.5 7.7 14.3 3.5 15.3 7.7 6.6 5.2 8.2 7.6 2.5 SLCO2B1 "OATP-B, OATP2B1, SLC21A9" ENSG00000137491 "Solute carrier organic anion transporter family member 2B1" O94956 11 75100563-75206549 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 98.1" "Cell line enhanced" "Detected in some" "CACO-2: 42.9;HEL: 7.0;Hep G2: 9.7;HMC-1: 13.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020659 Uncertain "HPA020659: AB_1857219" "unprognostic (8.25e-2)" "unprognostic (5.30e-2)" "unprognostic (2.02e-2)" "unprognostic (3.57e-1)" "unprognostic (3.40e-1)" "unprognostic (1.03e-1)" "unprognostic (1.58e-2)" "unprognostic (1.09e-1)" "unprognostic (2.61e-1)" "unprognostic (2.00e-3)" "unprognostic (1.99e-1)" "unprognostic (2.09e-1)" "unprognostic (9.75e-3)" "unprognostic (2.54e-2)" "unprognostic (4.57e-3)" "unprognostic (1.04e-1)" "unprognostic (3.87e-2)" 21.4 15.2 15.0 13.4 23.1 1.4 7.8 4.8 15.8 8.6 12.9 22.8 0.8 18.0 5.8 7.7 8.8 8.3 12.3 7.1 15.6 11.9 9.6 98.1 24.9 21.4 23.9 7.4 4.9 9.6 3.7 4.0 18.3 17.7 4.9 10.4 9.1 6.3 4.7 2.6 3.0 21.2 10.9 24.1 23.6 6.5 4.4 21.3 4.0 6.8 3.6 11.8 12.5 4.8 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.3 1.3 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 42.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 7.0 0.3 9.7 0.0 0.5 13.0 0.0 0.0 0.2 0.0 0.0 3.7 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 4.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.1 0.0 0.8 0.8 0.0 0.7 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.0 23.1 4.8 15.8 15.6 11.9 23.9 7.4 17.7 21.3 SMO "FZD11, SMOH" ENSG00000128602 "Smoothened, frizzled class receptor" Q99835 7 129188872-129213545 "Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 20.0;AN3-CA: 37.1;NTERA-2: 28.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB011446 Approved "CAB011446: " "unprognostic (2.48e-2)" "unprognostic (2.69e-2)" "unprognostic (7.09e-2)" "unprognostic (1.10e-1)" "unprognostic (8.16e-2)" "unprognostic (2.02e-1)" "unprognostic (3.63e-1)" "unprognostic (5.89e-2)" "unprognostic (5.38e-3)" "unprognostic (1.59e-1)" "unprognostic (1.17e-2)" "unprognostic (8.74e-3)" "unprognostic (1.62e-1)" "unprognostic (5.15e-3)" "unprognostic (2.09e-1)" "unprognostic (2.25e-1)" "unprognostic (2.61e-2)" 4.0 4.1 4.2 3.8 4.8 0.5 7.4 5.3 4.6 18.2 5.8 5.1 9.2 2.5 20.9 18.7 10.3 11.4 10.0 5.2 8.4 3.7 10.6 13.7 2.4 2.0 4.3 4.5 23.0 7.1 14.4 13.5 2.6 9.0 18.4 2.2 17.2 9.4 12.8 3.5 16.6 3.5 9.8 7.0 2.0 4.2 7.9 3.4 5.3 9.2 6.8 4.6 6.3 17.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.6 7.8 20.0 37.1 0.5 0.1 6.3 2.2 2.9 4.4 2.6 6.0 0.1 0.0 6.1 4.4 12.2 12.0 0.6 1.7 0.0 9.8 3.9 0.0 9.6 2.5 0.1 0.0 7.3 4.9 1.4 0.0 2.5 0.6 0.0 1.3 0.0 10.2 0.0 28.4 2.2 14.8 8.5 0.0 2.3 0.0 0.6 13.4 0.0 0.0 5.2 4.9 2.5 0.0 0.3 6.4 7.7 4.2 0.4 0.0 0.0 0.0 0.0 7.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 4.8 5.3 4.6 8.4 3.7 4.3 4.5 9.0 3.4 SMOX "C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO" ENSG00000088826 "Spermine oxidase" Q9NWM0 20 4120980-4187747 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 34.7;Karpas-707: 59.3;RPTEC TERT1: 27.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "myeloid DC: 2.1;neutrophil: 3.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047117, HPA060198" Approved Supported "Nucleoplasm,Nuclear membrane,Vesicles" "Nuclear membrane" "Nucleoplasm, Vesicles" "HPA047117: , HPA060198: " "unprognostic (1.24e-2)" "unprognostic (6.55e-2)" "unprognostic (7.24e-3)" "unprognostic (2.77e-1)" "unprognostic (1.40e-1)" "unprognostic (2.32e-1)" "prognostic unfavourable (3.33e-6)" "prognostic unfavourable (1.36e-4)" "unprognostic (4.92e-2)" "unprognostic (3.37e-1)" "unprognostic (7.18e-2)" "unprognostic (7.58e-2)" "prognostic unfavourable (1.06e-4)" "unprognostic (4.08e-2)" "unprognostic (2.64e-3)" "unprognostic (1.26e-2)" "unprognostic (3.07e-1)" 3.5 3.1 26.0 4.1 22.7 24.2 3.4 10.1 29.0 9.6 6.7 23.5 17.6 9.5 10.2 6.9 6.1 4.7 14.0 2.9 28.8 16.2 3.8 4.4 2.1 4.0 25.1 16.5 9.2 28.9 8.7 6.0 5.7 20.7 8.1 1.4 6.5 10.6 10.2 2.5 7.8 7.1 3.9 25.9 2.9 7.4 3.9 24.1 0.3 3.9 3.4 2.6 5.3 5.2 0.1 2.1 3.5 0.9 0.2 0.2 15.3 3.1 34.7 2.4 1.8 1.7 2.5 4.4 4.5 8.7 3.3 2.2 14.2 8.7 0.0 1.5 4.1 6.3 2.0 2.1 1.4 0.0 1.0 6.1 1.1 14.4 10.7 1.1 2.5 9.6 3.9 6.9 2.9 5.8 1.3 59.3 1.9 0.9 2.3 3.4 3.0 4.7 2.0 3.0 8.2 27.3 2.4 0.4 2.1 8.4 0.9 15.6 0.1 1.5 6.9 3.8 3.6 0.6 3.5 2.7 0.4 0.0 3.2 1.5 2.9 0.0 0.9 0.1 0.0 0.4 0.0 0.1 0.2 0.2 2.1 0.0 0.0 0.0 3.5 0.2 0.1 1.0 0.0 15.3 26.0 22.7 10.1 17.6 28.8 16.2 25.1 16.5 20.7 24.1 SMS "MRSR, SPMSY, SpS, SRS" ENSG00000102172 "Spermine synthase" P52788 X 21940573-21994835 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Polyamine biosynthesis" Transferase "FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029849, HPA029852" Approved Approved "Nuclear bodies,Cytosol" 26000 "Nuclear bodies" Cytosol "HPA029849: AB_10602072, HPA029852: AB_10611521" "unprognostic (2.51e-2)" "unprognostic (2.91e-1)" "unprognostic (1.89e-2)" "unprognostic (1.39e-1)" "unprognostic (1.43e-1)" "prognostic unfavourable (7.49e-4)" "prognostic unfavourable (7.79e-8)" "unprognostic (1.02e-2)" "unprognostic (2.72e-1)" "unprognostic (3.18e-3)" "unprognostic (3.95e-3)" "unprognostic (2.45e-1)" "prognostic unfavourable (7.85e-5)" "unprognostic (2.70e-1)" "unprognostic (1.22e-1)" "unprognostic (1.67e-1)" "unprognostic (8.50e-2)" 21.7 48.1 29.7 18.7 25.0 18.6 28.4 36.6 35.4 20.8 23.1 8.1 26.0 23.5 20.8 31.3 19.2 13.3 20.9 26.3 22.3 25.0 55.1 19.5 17.6 18.5 25.6 28.5 42.4 16.7 13.6 19.2 63.6 24.2 61.3 24.4 15.7 20.7 20.6 18.0 9.7 25.1 36.8 17.4 18.9 18.8 18.4 11.0 19.6 27.6 11.7 20.8 28.2 16.5 13.2 19.4 37.0 25.7 11.7 20.3 12.3 90.6 23.2 39.6 15.0 10.5 17.8 12.3 24.9 14.9 38.3 36.7 28.8 29.7 32.9 8.6 25.4 19.9 38.7 45.4 75.8 15.2 18.1 17.0 28.0 20.4 19.3 32.9 15.0 11.7 13.9 39.3 73.9 36.6 36.2 4.6 52.1 19.3 24.3 33.0 67.1 34.5 24.3 27.2 25.0 51.0 12.9 18.9 15.3 19.9 25.6 65.5 23.1 13.7 32.3 27.8 28.0 57.6 40.4 3.5 7.0 19.6 54.2 14.7 38.5 2.9 21.4 37.0 7.6 22.1 9.4 13.2 12.0 13.2 19.4 8.3 7.9 9.3 21.1 11.7 25.7 4.0 20.3 12.3 29.7 25.0 36.6 35.4 22.3 25.0 25.6 28.5 24.2 11.0 SOAT1 "ACAT, SOAT, STAT" ENSG00000057252 "Sterol O-acyltransferase 1" P35610 1 179293714-179358680 "Enzymes, FDA approved drug targets, Predicted membrane proteins" "Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism" "Acyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 87.4" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009533, HPA047171" Enhanced Enhanced "Endoplasmic reticulum" "Endoplasmic reticulum" "CAB009533: AB_633499, HPA047171: " "unprognostic (3.29e-2)" "unprognostic (7.60e-2)" "unprognostic (1.11e-1)" "unprognostic (3.21e-2)" "unprognostic (2.83e-1)" "unprognostic (1.81e-3)" "unprognostic (7.81e-3)" "unprognostic (3.29e-1)" "unprognostic (9.00e-2)" "unprognostic (9.84e-2)" "unprognostic (1.06e-1)" "unprognostic (5.45e-3)" "unprognostic (7.02e-3)" "unprognostic (4.67e-3)" "unprognostic (9.64e-2)" "unprognostic (4.67e-2)" "unprognostic (1.82e-1)" 23.9 87.4 4.1 8.3 5.7 7.0 9.6 2.9 4.0 6.8 7.2 5.6 7.8 5.5 8.2 6.0 3.4 8.3 9.8 5.7 5.5 4.1 12.1 8.8 18.6 13.0 6.2 2.3 10.8 15.5 8.1 14.6 11.6 4.9 13.1 6.9 9.6 51.1 8.9 4.1 5.8 7.0 7.5 10.5 13.6 8.1 6.8 4.9 4.0 6.2 2.9 7.2 9.4 8.7 6.6 24.3 19.8 26.8 18.5 16.0 14.8 20.2 9.5 7.8 11.6 30.5 16.7 42.0 9.8 17.3 21.7 25.5 9.7 23.2 11.5 15.5 17.8 7.5 24.9 5.8 23.5 13.1 5.1 5.3 8.0 10.1 12.5 9.1 2.1 13.2 3.8 25.4 21.8 9.3 11.4 5.9 33.8 4.3 9.6 2.9 3.8 3.1 12.1 10.1 6.7 19.2 12.7 2.4 6.1 15.1 6.4 5.6 6.7 6.3 8.8 25.9 12.4 28.3 21.5 8.4 30.6 9.8 10.3 4.9 48.0 19.6 26.8 0.7 14.0 17.0 13.5 6.6 13.1 13.1 24.3 5.5 12.7 12.6 19.8 18.5 11.1 4.4 16.0 14.8 4.1 5.7 2.9 4.0 5.5 4.1 6.2 2.3 4.9 4.9 SQLE ENSG00000104549 "Squalene epoxidase" Q14534 8 124998497-125022283 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018038, HPA020762" Enhanced Uncertain Vesicles,Cytosol "Vesicles, Cytosol" "HPA018038: , HPA020762: " "unprognostic (1.37e-2)" "unprognostic (6.26e-3)" "unprognostic (5.12e-2)" "unprognostic (9.51e-3)" "unprognostic (4.63e-1)" "prognostic unfavourable (7.42e-4)" "unprognostic (4.76e-3)" "prognostic unfavourable (4.67e-4)" "unprognostic (3.45e-2)" "unprognostic (7.21e-2)" "prognostic unfavourable (2.73e-4)" "unprognostic (7.51e-2)" "prognostic unfavourable (5.70e-4)" "unprognostic (9.71e-2)" "unprognostic (4.62e-2)" "unprognostic (1.19e-3)" "unprognostic (7.74e-3)" 4.6 15.7 11.1 9.9 13.9 10.4 12.1 8.9 19.9 15.1 11.5 28.8 4.4 15.8 8.9 5.1 40.3 10.0 6.3 4.2 15.4 14.5 7.8 38.1 16.0 8.6 10.8 9.7 17.5 6.3 16.5 9.5 24.7 28.5 13.8 10.1 9.3 10.4 4.7 1.3 23.8 8.7 6.6 36.0 5.6 11.5 29.3 18.7 9.8 5.7 24.2 15.0 5.3 21.6 15.1 12.4 1.2 9.7 9.5 9.0 6.1 25.5 9.9 59.4 17.0 18.5 31.4 6.0 6.7 20.7 9.2 16.9 13.4 37.3 17.6 9.7 8.3 19.5 24.7 37.2 10.7 14.5 52.3 50.2 6.7 34.2 27.2 5.9 14.8 21.4 39.8 27.4 22.6 10.0 28.6 34.3 7.4 42.1 20.3 7.4 24.6 6.8 8.9 10.9 23.9 64.7 29.4 18.6 9.4 13.8 44.4 13.8 11.8 15.4 9.8 3.8 13.4 4.5 6.0 6.2 12.6 24.1 6.4 17.9 6.5 1.2 5.1 0.5 9.0 8.5 4.4 13.6 5.4 8.3 12.4 15.1 7.5 7.8 0.1 9.5 9.7 8.8 5.6 6.1 11.1 13.9 8.9 16.4 15.4 14.5 10.8 9.7 28.5 18.7 SRC "ASV, c-src, SRC1" ENSG00000197122 "SRC proto-oncogene, non-receptor tyrosine kinase" P12931 20 37344685-37406050 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell adhesion, Cell cycle, Host-virus interaction, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 35.5;HBEC3-KT: 33.0;PC-3: 32.1;RT4: 34.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 5.3;non-classical monocyte: 4.4" "Group enriched" "Detected in many" 6 "dendritic cells: 3.0;monocytes: 5.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004023, HPA030875" Approved Supported "Plasma membrane,Cell Junctions,Cytosol" 20000000 "Plasma membrane, Cell Junctions" Cytosol "CAB004023: AB_2106059, HPA030875: " "unprognostic (5.58e-2)" "unprognostic (9.83e-2)" "unprognostic (3.56e-1)" "unprognostic (4.54e-3)" "unprognostic (1.52e-1)" "unprognostic (1.54e-2)" "prognostic unfavourable (4.90e-5)" "unprognostic (3.89e-2)" "unprognostic (7.04e-2)" "unprognostic (8.13e-2)" "unprognostic (1.54e-2)" "prognostic unfavourable (1.63e-4)" "prognostic unfavourable (1.22e-4)" "unprognostic (2.33e-2)" "unprognostic (4.72e-2)" "unprognostic (3.65e-2)" "prognostic favourable (5.22e-5)" 6.9 17.5 12.8 11.1 12.0 5.4 9.9 6.4 16.0 16.0 16.4 3.5 15.1 29.5 20.3 9.7 16.2 14.2 42.1 5.8 11.3 6.6 13.4 2.9 10.4 7.0 3.3 9.9 15.8 19.1 6.6 11.3 6.3 5.1 19.9 13.1 13.1 7.5 22.5 3.4 7.7 28.1 27.2 3.6 12.2 29.8 27.3 4.8 4.0 6.6 10.5 10.4 26.4 20.0 0.3 3.0 0.1 5.3 0.6 0.1 1.6 7.6 35.5 8.1 7.3 3.1 4.9 17.0 7.1 6.1 8.6 5.5 13.3 6.9 0.2 4.4 12.8 14.0 4.9 33.0 3.4 0.0 4.4 1.9 1.2 20.7 7.4 0.1 3.0 5.3 11.2 5.6 7.5 7.8 0.2 0.0 1.4 5.2 1.8 0.2 3.8 32.1 8.3 2.1 0.2 3.6 34.0 7.6 27.5 8.0 11.3 8.8 10.1 2.8 11.5 10.4 7.0 3.8 6.3 0.1 0.2 0.1 7.3 0.0 7.7 0.0 2.6 0.0 0.0 5.3 0.0 0.3 0.0 0.1 1.1 0.3 0.0 0.0 0.1 0.6 4.4 3.0 0.1 1.6 12.8 12.0 6.4 16.0 11.3 6.6 3.3 9.9 5.1 4.8 SRD5A1 ENSG00000145545 "Steroid 5 alpha-reductase 1" P18405 5 6633343-6674386 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins" "Differentiation, Sexual differentiation" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 42.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051402 Approved "HPA051402: " "unprognostic (1.40e-2)" "unprognostic (1.33e-2)" "unprognostic (2.30e-3)" "prognostic unfavourable (8.73e-6)" "unprognostic (9.38e-3)" "unprognostic (8.90e-2)" "unprognostic (3.78e-2)" "unprognostic (5.90e-2)" "unprognostic (3.83e-1)" "unprognostic (1.42e-1)" "unprognostic (7.70e-3)" "unprognostic (1.54e-1)" "unprognostic (1.56e-3)" "unprognostic (3.01e-1)" "unprognostic (2.24e-1)" "unprognostic (1.59e-1)" "unprognostic (5.47e-2)" 2.4 3.3 7.7 2.9 8.2 3.2 14.8 9.2 11.8 5.6 5.2 5.3 0.7 5.7 3.1 4.6 24.2 2.9 4.0 1.9 9.3 7.5 6.4 42.4 3.0 3.5 6.2 5.5 4.1 4.3 3.0 1.9 2.1 13.4 2.6 3.6 2.4 5.0 2.1 2.2 17.5 10.4 2.6 3.1 2.9 3.9 2.7 2.9 3.3 2.4 15.3 12.1 2.6 10.1 1.9 3.7 7.0 3.3 1.3 1.3 1.3 5.5 5.5 7.3 6.2 7.0 6.9 3.4 5.4 4.1 5.3 3.3 5.5 4.9 6.7 8.9 7.8 9.0 5.9 3.6 5.7 4.1 2.5 2.1 13.7 3.3 3.2 3.0 1.8 5.0 10.2 3.8 3.0 2.6 3.6 6.2 6.8 6.5 1.4 3.4 4.6 4.4 4.6 5.6 2.0 7.1 5.2 13.8 6.3 16.4 7.3 5.0 3.0 0.8 5.4 8.1 4.0 13.1 6.7 3.3 4.4 2.4 6.7 3.5 7.4 7.0 3.3 1.4 1.0 2.4 0.7 1.7 1.0 1.3 3.7 1.9 0.9 1.0 2.0 1.3 2.6 1.8 1.1 1.3 7.7 8.2 9.2 11.8 9.3 7.5 6.2 5.5 13.4 2.9 SSTR1 ENSG00000139874 "Somatostatin receptor 1" P30872 14 38207999-38213067 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 15.0;intestine: 14.3;stomach 1: 22.8" "Cell line enhanced" "Detected in some" "BJ: 46.8;BJ hTERT+: 13.0;BJ hTERT+ SV40 Large T+: 8.6;fHDF/TERT166: 27.6;HeLa: 10.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA003207, HPA031506" Approved Supported "Plasma membrane" "Plasma membrane" "HPA003207: , HPA031506: " "unprognostic (1.40e-1)" "unprognostic (1.37e-1)" "unprognostic (3.36e-1)" "unprognostic (2.50e-3)" "unprognostic (4.34e-2)" "unprognostic (9.90e-2)" "unprognostic (3.66e-3)" "unprognostic (1.91e-1)" "unprognostic (6.16e-3)" "unprognostic (3.20e-2)" "unprognostic (1.72e-2)" "unprognostic (9.19e-2)" "prognostic favourable (4.28e-4)" "unprognostic (2.17e-1)" "unprognostic (1.67e-1)" "unprognostic (4.71e-2)" "unprognostic (3.28e-2)" 0.7 0.4 6.8 0.6 6.9 0.0 0.6 0.5 15.0 0.9 3.7 0.6 0.1 14.3 1.0 0.6 0.4 0.7 0.5 0.8 4.3 10.4 2.2 6.7 5.5 0.1 6.8 4.0 0.6 3.8 0.1 1.4 2.8 2.8 1.2 2.5 0.2 0.2 0.5 0.7 0.4 8.2 0.6 1.3 0.7 22.8 0.1 0.7 0.1 0.3 0.1 0.1 1.3 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 46.8 13.0 8.6 0.7 0.4 0.0 0.0 0.0 27.6 0.1 0.0 0.0 6.3 0.0 0.0 0.0 10.6 0.0 2.6 0.0 0.0 0.1 0.0 0.0 0.1 0.6 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.9 0.0 1.3 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.8 6.9 0.5 15.0 4.3 10.4 6.8 4.0 2.8 0.7 SSTR2 ENSG00000180616 "Somatostatin receptor 2" P30874 17 73165012-73176633 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 26.6" "Cell line enriched" "Detected in some" 7 "SCLC-21H: 16.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA007264 Uncertain Supported Cytosol Cytosol "HPA007264: AB_1080053" "unprognostic (2.13e-3)" "unprognostic (2.61e-3)" "unprognostic (7.43e-2)" "unprognostic (9.37e-3)" "unprognostic (6.25e-2)" "unprognostic (1.52e-1)" "unprognostic (2.29e-3)" "unprognostic (7.46e-2)" "unprognostic (2.96e-1)" "unprognostic (6.55e-2)" "prognostic favourable (6.63e-4)" "unprognostic (1.07e-1)" "prognostic unfavourable (9.04e-7)" "unprognostic (1.35e-1)" "unprognostic (1.00e-1)" "unprognostic (3.71e-3)" "unprognostic (2.95e-2)" 4.5 7.4 6.1 2.3 15.8 2.5 4.2 23.1 26.6 1.4 2.2 0.5 0.6 3.3 1.9 4.1 1.5 2.3 1.8 2.2 9.3 5.3 13.6 3.3 1.4 2.7 2.6 13.1 1.5 2.0 1.4 5.7 1.0 4.9 2.8 2.7 1.1 1.8 3.6 1.7 1.9 2.5 2.2 3.3 8.3 7.2 1.4 1.9 0.3 2.3 0.0 2.9 2.0 1.9 1.4 1.0 4.7 0.9 0.9 1.0 0.3 0.3 0.5 0.6 1.1 0.2 0.2 0.7 0.2 0.3 0.5 0.5 0.5 0.5 0.7 0.3 0.1 0.5 0.1 0.1 0.2 0.6 0.9 0.6 1.0 0.5 0.1 0.4 2.2 0.2 0.1 0.2 0.0 0.0 0.7 1.2 0.2 0.6 0.4 1.3 1.5 0.6 0.7 0.8 0.4 0.4 0.6 16.8 1.4 0.3 0.3 0.2 2.1 0.3 0.3 0.4 2.2 0.6 0.3 0.8 0.4 1.6 0.3 1.7 0.4 3.8 0.9 1.2 1.0 0.7 0.8 0.8 0.8 0.8 0.3 1.4 0.8 0.9 4.7 0.9 0.8 1.0 0.5 0.3 6.1 15.8 23.1 22.1 9.3 5.3 2.6 13.1 4.9 1.9 SSTR3 ENSG00000278195 "Somatostatin receptor 3" P32745 22 37204238-37212322 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 11.1;lymphoid tissue: 29.6;testis: 11.3" "Group enriched" "Detected in some" 11 "RPMI-8226: 21.8;SCLC-21H: 8.2" "Cancer enhanced" "Detected in some" "pancreatic cancer: 1.9" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 3.9;naive CD8 T-cell: 3.0" "Lineage enriched" "Detected in single" 10 "T-cells: 3.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB022647 Approved "CAB022647: " "unprognostic (1.63e-2)" "unprognostic (5.58e-3)" "unprognostic (1.32e-2)" "unprognostic (3.18e-2)" "unprognostic (7.03e-2)" "unprognostic (6.26e-5)" "unprognostic (1.11e-1)" "unprognostic (1.72e-2)" "unprognostic (1.90e-2)" "unprognostic (8.95e-2)" "unprognostic (3.88e-3)" "unprognostic (2.93e-1)" "unprognostic (1.51e-7)" "unprognostic (1.55e-1)" "unprognostic (1.24e-2)" "unprognostic (5.61e-3)" "unprognostic (1.06e-2)" 0.1 0.8 2.8 1.9 1.9 0.9 0.1 2.7 11.1 0.0 0.5 0.2 0.0 2.6 1.9 0.2 0.1 0.1 0.1 0.0 5.6 0.1 0.0 0.1 3.5 0.0 7.9 5.8 3.9 0.0 6.4 0.0 7.9 0.2 0.6 0.0 0.6 0.1 0.0 0.0 1.0 2.2 4.3 1.2 0.5 11.3 0.1 29.6 0.0 0.0 2.0 0.3 0.0 0.3 0.1 0.1 0.0 0.0 3.9 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.8 0.0 0.0 8.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.9 0.0 0.0 0.3 3.9 3.0 0.1 0.0 0.0 0.1 0.3 0.8 SSTR4 ENSG00000132671 "Somatostatin receptor 4" P31391 20 23035386-23036812 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in single" 4 "brain: 3.8" "Cell line enhanced" "Detected in single" "SCLC-21H: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA064252 Uncertain "HPA064252: " 0.0 0.0 1.7 0.0 1.1 0.0 0.0 3.0 3.8 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 1.3 0.4 0.0 0.0 0.8 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SSTR5 ENSG00000162009 "Somatostatin receptor 5" P35346 16 1078781-1080142 "FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "gallbladder: 8.2;lymphoid tissue: 5.2;pituitary gland: 9.0" "Group enriched" "Detected in some" 15 "Hep G2: 9.2;PC-3: 34.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "basal ganglia: 4.2;hypothalamus: 2.7" "Low region specificity" "Detected in many" HPA066503 Supported "Plasma membrane" "Plasma membrane" "HPA066503: " "unprognostic (2.16e-2)" "unprognostic (7.31e-2)" "unprognostic (3.69e-2)" "unprognostic (2.39e-2)" "unprognostic (2.14e-1)" "unprognostic (9.89e-3)" "unprognostic (1.72e-2)" "unprognostic (1.72e-2)" "unprognostic (2.06e-1)" "unprognostic (2.05e-1)" "unprognostic (4.09e-2)" 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 1.4 0.4 0.0 0.7 0.6 0.9 0.5 0.0 8.2 2.9 0.0 0.2 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 9.0 0.0 0.0 1.1 0.0 0.0 1.1 0.9 0.1 0.1 0.8 0.0 0.0 0.0 1.7 0.3 0.0 0.0 0.0 0.0 5.2 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 9.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 34.1 0.0 1.3 0.3 0.0 1.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 SV2A "KIAA0736, SV2" ENSG00000159164 "Synaptic vesicle glycoprotein 2A" Q7L0J3 1 149903318-149917882 "FDA approved drug targets, Predicted membrane proteins" "Neurotransmitter transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 75.3;parathyroid gland: 34.0" "Cell line enhanced" "Detected in many" "NTERA-2: 26.0" "Cancer enriched" "Detected in many" 6 "glioma: 27.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002226, HPA007863" Enhanced Approved Cytosol Cytosol "CAB002226: AB_564144, HPA007863: AB_1080135" "unprognostic (8.05e-3)" "unprognostic (3.86e-3)" "unprognostic (2.24e-1)" "unprognostic (5.39e-2)" "unprognostic (2.66e-1)" "unprognostic (2.02e-1)" "unprognostic (6.24e-2)" "unprognostic (2.69e-1)" "unprognostic (1.40e-1)" "unprognostic (2.06e-1)" "unprognostic (9.00e-3)" "unprognostic (1.00e-1)" "prognostic unfavourable (3.22e-4)" "unprognostic (1.44e-2)" "unprognostic (9.86e-2)" "unprognostic (1.95e-2)" "unprognostic (4.81e-3)" 2.0 7.3 20.4 2.8 24.7 4.5 1.5 36.8 75.3 3.2 2.3 4.8 0.9 1.9 5.6 18.0 2.0 3.2 3.2 1.5 22.3 30.5 1.7 1.2 1.8 2.3 21.6 25.1 2.6 1.9 34.0 7.2 1.9 32.9 3.1 2.2 3.1 1.7 3.7 1.1 1.5 2.2 6.6 16.8 2.0 2.0 1.6 6.0 0.3 4.0 0.0 2.0 2.5 1.2 1.2 0.8 2.1 0.7 1.7 2.5 0.6 0.1 0.0 10.2 0.0 1.0 3.0 1.1 4.3 15.1 12.9 18.7 0.3 0.4 0.1 3.9 6.5 0.2 0.1 0.9 11.2 0.0 2.4 13.4 0.7 0.7 9.9 0.1 0.2 6.7 0.1 20.6 1.5 1.1 0.1 14.0 8.5 0.1 12.9 0.6 26.0 0.0 4.5 6.5 0.2 0.1 0.3 21.5 17.3 0.0 0.1 9.8 0.1 8.1 0.0 12.0 12.1 0.5 15.7 0.1 0.1 0.0 21.1 0.1 4.7 1.5 0.7 0.4 1.8 0.3 1.9 0.7 1.9 1.1 0.2 1.2 1.0 2.2 2.1 1.7 0.3 0.8 2.5 0.6 20.4 24.7 36.8 40.0 22.3 30.5 21.6 25.1 32.9 6.0 TAAR1 "TA1, TAR1, TRAR1" ENSG00000146399 "Trace amine associated receptor 1" Q96RJ0 6 132644984-132646003 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 6 "stomach 1: 13.6" "Cell line enhanced" "Detected in some" "EFO-21: 1.7;HBF TERT88: 1.1" "Cancer enhanced" "Detected in single" "cervical cancer: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA055614 Approved "HPA055614: " "unprognostic (2.19e-2)" "unprognostic (1.87e-1)" "unprognostic (1.47e-1)" "unprognostic (2.68e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.2 2.3 0.0 0.0 0.0 0.0 0.3 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 13.6 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 TACR1 "NK1R, NKIR, SPR, TAC1R" ENSG00000115353 "Tachykinin receptor 1" P25103 2 75046463-75199700 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 23.9" "Cell line enhanced" "Detected in some" "BJ: 1.3;EFO-21: 3.1;fHDF/TERT166: 2.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 40 "basophil: 4.4" "Lineage enriched" "Detected in single" 40 "granulocytes: 4.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA074573 Enhanced "HPA074573: " "unprognostic (5.74e-4)" "unprognostic (2.41e-3)" "unprognostic (1.46e-2)" "unprognostic (1.08e-1)" "unprognostic (1.24e-1)" "unprognostic (8.62e-3)" "unprognostic (1.10e-1)" "unprognostic (3.33e-2)" "unprognostic (4.38e-2)" "unprognostic (1.46e-1)" "unprognostic (2.14e-3)" "unprognostic (1.63e-2)" "unprognostic (5.91e-4)" "unprognostic (1.03e-2)" "unprognostic (2.75e-1)" "unprognostic (1.06e-1)" "unprognostic (2.76e-2)" 23.9 1.0 2.0 1.8 8.5 0.3 8.2 0.3 4.8 15.2 1.9 0.1 1.5 0.8 17.7 3.6 4.8 6.9 2.5 0.9 1.5 2.5 1.5 0.4 2.1 2.9 0.9 1.0 4.2 0.7 1.3 1.1 1.6 2.3 6.1 1.4 0.3 2.6 2.5 2.6 8.7 1.4 6.5 0.9 0.4 1.2 2.0 1.5 0.2 1.1 4.3 3.4 4.8 14.3 0.1 0.0 4.4 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 1.3 0.2 0.0 0.0 1.1 0.0 0.5 3.1 2.7 0.1 0.0 0.0 0.0 0.0 0.3 0.3 0.5 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.8 0.3 0.3 0.6 0.3 0.0 0.0 0.2 0.1 0.0 0.1 0.2 0.0 1.0 0.0 0.1 0.1 0.0 0.5 0.0 0.0 0.5 0.1 0.0 0.0 1.2 0.1 0.1 4.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 8.5 0.3 3.6 1.5 2.5 0.9 1.0 2.3 1.5 TBXA2R ENSG00000006638 "Thromboxane A2 receptor" P21731 19 3594506-3606840 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HeLa: 11.7;U-2197: 8.4;U-937: 7.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "naive B-cell: 12.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" HPA077366 Supported "Nuclear speckles,Plasma membrane" "Plasma membrane" "Nuclear speckles" "HPA077366: " "unprognostic (1.59e-1)" "unprognostic (3.86e-2)" "unprognostic (1.21e-2)" "unprognostic (1.74e-1)" "unprognostic (8.97e-2)" "unprognostic (4.19e-2)" "unprognostic (1.52e-2)" "unprognostic (2.17e-3)" "unprognostic (8.41e-2)" "unprognostic (6.25e-2)" "prognostic favourable (7.17e-4)" "unprognostic (3.89e-2)" "prognostic unfavourable (1.45e-4)" "unprognostic (4.32e-2)" "unprognostic (9.63e-2)" "unprognostic (1.76e-1)" "unprognostic (2.02e-1)" 8.7 11.8 1.4 3.9 1.6 2.1 3.9 0.5 1.6 13.5 3.8 1.7 3.9 2.6 7.4 4.8 8.0 4.7 6.0 6.8 2.4 1.5 10.1 18.4 6.7 7.3 1.4 1.9 8.3 2.2 2.5 1.7 10.6 2.7 3.6 1.4 5.0 1.7 4.2 3.1 1.8 4.4 6.5 2.1 14.9 3.7 3.4 1.9 2.2 3.9 3.2 1.8 6.8 9.6 12.6 0.3 3.2 0.4 3.1 9.6 3.9 0.1 0.2 0.2 4.1 0.9 2.2 0.7 2.9 0.7 2.3 1.8 0.1 0.3 0.1 4.3 1.2 0.1 0.8 0.0 0.8 0.2 1.0 2.8 11.7 0.3 1.2 0.0 5.2 1.1 0.0 3.0 0.0 0.9 4.4 0.4 0.4 0.2 0.2 1.5 0.1 2.5 0.1 0.0 0.2 0.0 0.1 0.2 1.7 0.2 0.4 0.1 1.8 5.0 2.5 4.7 1.0 8.4 2.8 0.2 0.3 0.2 3.9 7.2 1.1 2.9 0.4 0.2 2.6 0.2 0.3 1.8 0.8 2.3 0.0 12.6 4.6 9.6 3.2 3.1 0.2 0.3 0.2 3.9 1.4 1.6 0.5 1.6 2.4 1.5 1.4 1.9 2.7 1.9 TBXAS1 "CYP5, CYP5A1, THAS, TS, TXAS, TXS" ENSG00000059377 "Thromboxane A synthase 1" P24557 7 139777051-140020325 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" "Isomerase, Monooxygenase, Oxidoreductase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 67.1;lymphoid tissue: 51.7" "Cell line enhanced" "Detected in some" "NB-4: 34.7;PC-3: 11.1;RPTEC TERT1: 9.9;U-937: 28.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 13 "basophil: 38.1;classical monocyte: 44.5;eosinophil: 45.2;intermediate monocyte: 67.1;myeloid DC: 18.7;neutrophil: 38.8;non-classical monocyte: 56.4" "Group enriched" "Detected in all" 20 "dendritic cells: 18.7;granulocytes: 45.2;monocytes: 67.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA031257, HPA031258, HPA031259" Enhanced 32000000 "HPA031257: , HPA031258: AB_2673813, HPA031259: AB_2673814" "unprognostic (4.46e-2)" "unprognostic (3.07e-1)" "unprognostic (8.80e-2)" "unprognostic (1.12e-1)" "unprognostic (2.72e-1)" "unprognostic (9.41e-2)" "unprognostic (5.10e-2)" "unprognostic (3.12e-1)" "unprognostic (2.38e-1)" "unprognostic (3.07e-2)" "unprognostic (1.11e-1)" "unprognostic (3.03e-2)" "prognostic unfavourable (1.14e-4)" "unprognostic (1.52e-1)" "unprognostic (5.00e-3)" "unprognostic (8.53e-2)" "unprognostic (5.34e-2)" 13.5 7.7 6.6 17.6 8.9 13.8 5.4 1.5 5.6 3.7 6.3 13.9 0.8 6.5 3.2 4.1 3.4 5.0 13.9 3.7 7.6 5.7 6.1 8.1 20.3 43.9 12.6 2.0 2.5 3.1 1.4 3.5 9.0 9.0 5.2 8.6 4.4 8.2 2.6 1.6 1.9 9.3 7.9 19.3 51.7 7.1 2.0 12.7 7.5 2.4 2.2 6.1 9.3 2.5 1.3 18.7 45.2 67.1 1.5 2.2 25.1 0.1 3.0 0.1 0.0 0.6 1.9 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 5.8 0.0 0.0 0.0 0.0 0.0 4.5 0.3 8.2 0.0 0.0 0.8 2.7 7.3 1.0 0.0 0.0 0.4 1.0 0.2 1.0 0.3 0.0 1.0 34.7 0.1 11.1 1.3 0.0 0.5 9.9 0.0 0.1 0.5 0.1 0.0 0.3 0.0 6.6 0.9 0.2 0.1 0.6 0.5 2.3 0.4 0.1 0.2 28.2 0.8 38.1 44.5 45.2 1.1 67.1 1.7 1.3 2.2 0.6 18.7 0.5 0.3 0.2 38.8 1.5 56.4 3.3 2.0 25.1 6.6 8.9 1.5 5.6 7.6 5.7 12.6 2.0 9.0 12.7 TEK "CD202b, TIE-2, TIE2, VMCM, VMCM1" ENSG00000120156 "TEK receptor tyrosine kinase" Q02763 9 27109141-27230175 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Angiogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Glaucoma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 9 "HUVEC TERT2: 35.8;NTERA-2: 17.8;TIME: 38.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "neutrophil: 2.2" "Lineage enhanced" "Detected in single" "granulocytes: 2.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010359, HPA073265" Approved Supported "Plasma membrane,Centriolar satellite" "Secreted to blood" 7750000 8300000 "Plasma membrane" "Centriolar satellite" "CAB010359: AB_2203226, HPA073265: " "unprognostic (2.24e-1)" "unprognostic (1.74e-1)" "unprognostic (5.55e-2)" "unprognostic (1.83e-2)" "unprognostic (1.68e-1)" "unprognostic (1.26e-3)" "prognostic favourable (2.31e-5)" "unprognostic (7.48e-2)" "unprognostic (1.72e-2)" "unprognostic (1.41e-1)" "unprognostic (5.58e-2)" "unprognostic (2.72e-1)" "prognostic favourable (7.81e-4)" "unprognostic (7.50e-3)" "unprognostic (6.87e-3)" "unprognostic (1.83e-1)" "unprognostic (5.24e-3)" 28.6 7.8 8.1 4.6 5.9 0.4 17.9 3.4 5.4 10.8 4.7 4.6 3.4 3.2 14.5 5.3 6.7 5.9 9.1 13.0 7.1 6.1 25.4 8.7 27.8 2.9 6.9 3.4 6.1 4.5 3.5 4.0 36.3 6.9 5.4 4.7 12.4 3.4 5.5 7.8 3.0 5.3 10.6 5.3 23.4 4.0 3.7 3.5 0.3 9.7 8.4 2.4 6.4 12.4 0.0 0.1 2.2 0.6 0.0 0.0 0.0 0.1 0.0 1.4 0.0 0.2 2.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 2.3 1.0 0.0 0.6 0.0 0.0 0.7 0.0 0.8 0.3 35.8 0.0 0.0 0.3 0.0 0.0 0.0 17.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 38.8 0.0 0.2 3.6 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 8.1 5.9 3.4 5.4 7.1 6.1 6.9 3.4 6.9 3.5 TFPI "EPI, LACI, TFI, TFPI1" ENSG00000003436 "Tissue factor pathway inhibitor" P10646 2 187464230-187565760 "Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Protease inhibitor, Serine protease inhibitor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 98.2;placenta: 192.3" "Cell line enhanced" "Detected in many" "HHSteC: 55.2;HUVEC TERT2: 103.8;LHCN-M2: 63.6;TIME: 62.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 5.5;plasmacytoid DC: 5.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in single" "HPA005575, CAB020842" Supported Approved "Intermediate filaments,Cytosol" "Secreted to blood" 95000000 Cytosol "Intermediate filaments" "CAB020842: , HPA005575: AB_1080290" "unprognostic (8.75e-2)" "prognostic unfavourable (2.02e-4)" "unprognostic (7.95e-2)" "unprognostic (4.99e-2)" "unprognostic (2.32e-2)" "unprognostic (1.48e-1)" "unprognostic (3.05e-1)" "unprognostic (5.63e-2)" "unprognostic (3.86e-3)" "unprognostic (9.22e-2)" "unprognostic (2.43e-2)" "unprognostic (2.72e-2)" "unprognostic (7.05e-2)" "unprognostic (3.39e-3)" "unprognostic (4.05e-2)" "unprognostic (4.49e-2)" "unprognostic (5.81e-2)" 52.8 5.0 1.3 5.2 2.2 1.6 18.5 1.9 2.4 22.8 32.1 0.3 7.2 12.8 13.3 14.8 25.9 12.5 15.0 14.0 1.2 1.1 35.6 98.2 89.7 40.2 2.4 1.0 17.3 7.7 0.9 4.9 192.3 2.3 18.2 6.9 3.8 6.0 3.8 15.8 6.6 37.0 13.6 5.4 16.5 7.7 13.7 1.6 3.4 22.6 10.4 4.0 30.0 14.7 1.5 5.1 5.5 0.6 1.0 0.6 4.9 5.0 3.5 4.1 0.1 32.1 38.5 0.0 9.1 21.7 5.9 9.2 3.2 27.0 0.0 3.6 7.1 0.3 1.2 0.4 15.5 0.2 1.0 1.6 10.9 27.4 55.2 0.1 0.0 17.6 0.7 32.1 8.6 103.8 4.0 0.1 63.6 4.7 0.6 0.1 2.5 8.8 0.0 5.7 0.0 10.1 0.2 0.0 0.0 7.4 0.2 0.4 0.1 0.0 62.1 4.3 4.0 8.5 1.7 0.0 0.1 0.0 34.6 0.0 4.9 5.5 0.6 0.5 0.5 0.3 0.2 0.9 0.4 0.2 0.5 1.5 0.5 0.6 2.6 1.0 0.3 5.1 0.2 4.9 1.3 2.2 1.9 2.4 1.2 1.1 2.4 1.0 2.3 1.6 TH DYT5b ENSG00000180176 "Tyrosine hydroxylase" P07101 11 2163929-2171877 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Catecholamine biosynthesis, Neurotransmitter biosynthesis" "Monooxygenase, Oxidoreductase" "Disease mutation, Dystonia, FDA approved drug targets, Parkinson disease, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 31 "adrenal gland: 83.5;brain: 41.4" "Group enriched" "Detected in some" 32 "PC-3: 35.1;SK-BR-3: 12.5" "Cancer enhanced" "Detected in some" "urothelial cancer: 4.0" "Group enriched" "Detected in many" 6 "hypothalamus: 15.5;midbrain: 41.4;pons and medulla: 41.2" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in many" "olfactory region: 220.1" "Region enriched" "Detected in many" 19 "midbrain: 692.0" "CAB002522, HPA013768, HPA014010, HPA061003, CAB072340" Enhanced Supported Approved Cytosol Cytosol "CAB002522: AB_564047, CAB072340: , HPA013768: , HPA014010: , HPA061003: " "unprognostic (1.31e-1)" "unprognostic (1.30e-1)" "unprognostic (9.08e-2)" "unprognostic (1.75e-4)" "unprognostic (8.82e-3)" "unprognostic (5.88e-2)" "unprognostic (1.93e-1)" "unprognostic (1.74e-3)" "unprognostic (3.83e-2)" "unprognostic (4.39e-4)" "unprognostic (4.97e-1)" "unprognostic (3.61e-2)" "unprognostic (1.92e-1)" "unprognostic (1.60e-1)" "unprognostic (2.43e-1)" "unprognostic (2.70e-2)" "unprognostic (2.18e-2)" 1.3 83.5 0.0 0.3 5.4 0.2 0.2 0.0 0.7 1.8 0.2 6.2 0.0 0.2 0.3 0.3 0.2 0.3 0.4 0.2 0.3 15.5 0.2 0.2 0.2 0.2 41.4 0.0 0.3 0.3 0.2 0.2 0.9 41.2 0.6 0.2 0.3 0.2 2.0 0.2 0.5 0.4 0.2 0.0 0.3 0.2 0.3 1.5 0.0 0.2 0.0 0.2 0.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 35.1 0.0 0.0 0.0 0.1 0.0 0.6 0.1 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.7 0.3 15.5 41.4 0.0 41.2 1.5 THRA "AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3" ENSG00000126351 "Thyroid hormone receptor, alpha" P10827 17 40058290-40093867 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 90.7" "Cell line enhanced" "Detected in many" "ASC diff: 37.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009654, CAB023349" Approved Supported Cytosol Cytosol "CAB023349: AB_619577, HPA009654: AB_1854603" "unprognostic (2.75e-2)" "unprognostic (2.20e-1)" "unprognostic (6.64e-2)" "unprognostic (4.22e-2)" "unprognostic (8.78e-2)" "unprognostic (1.64e-1)" "unprognostic (3.41e-3)" "prognostic favourable (1.84e-4)" "unprognostic (1.47e-1)" "unprognostic (5.47e-2)" "unprognostic (7.85e-2)" "unprognostic (2.65e-2)" "prognostic favourable (6.05e-8)" "unprognostic (3.05e-1)" "unprognostic (1.35e-1)" "unprognostic (4.21e-1)" "unprognostic (1.88e-3)" 17.1 20.7 58.6 5.7 90.7 9.9 12.9 37.4 73.1 19.8 12.6 24.1 8.2 15.1 19.3 11.5 9.7 29.3 12.7 30.1 43.8 38.1 12.1 2.7 11.6 4.5 34.3 45.5 46.5 12.3 13.0 10.7 8.5 29.6 12.4 9.6 10.4 13.7 18.8 38.5 10.0 16.7 17.4 29.4 6.1 11.9 7.8 43.6 1.8 12.5 7.9 3.3 10.0 18.6 1.0 1.5 3.7 0.7 5.1 4.7 1.4 2.1 17.2 5.4 13.4 37.1 13.6 1.9 8.8 10.6 9.2 8.6 14.3 12.5 2.5 14.7 17.2 5.2 10.5 5.4 5.0 0.9 9.9 4.6 20.5 6.1 12.5 7.5 5.2 21.6 4.4 8.6 3.3 12.3 9.3 2.4 7.6 3.2 10.0 12.4 4.9 5.4 14.4 10.6 12.4 3.1 1.5 9.1 8.3 6.8 10.9 15.4 12.7 8.9 8.5 9.2 9.2 8.2 2.6 5.6 3.9 1.5 5.7 8.7 4.9 0.3 0.6 3.7 4.7 0.3 2.0 0.6 1.9 2.8 0.8 1.0 3.4 4.1 2.5 5.1 0.7 1.5 2.2 1.4 58.6 90.7 37.4 41.8 43.8 38.1 34.3 45.5 29.6 43.6 THRB "ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2" ENSG00000151090 "Thyroid hormone receptor beta" P10828 3 24117153-24495756 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "K-562: 26.0;RT4: 19.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 7.2;naive B-cell: 4.3" "Group enriched" "Detected in many" 11 "B-cells: 4.3;granulocytes: 7.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002008, CAB002009, HPA061035" Approved Supported "Nuclear bodies" "Nuclear bodies" "CAB002008: , CAB002009: , HPA061035: " "unprognostic (1.82e-1)" "unprognostic (4.22e-1)" "unprognostic (2.83e-1)" "unprognostic (2.20e-6)" "unprognostic (3.37e-1)" "unprognostic (2.66e-2)" "unprognostic (1.93e-2)" "unprognostic (1.73e-1)" "unprognostic (5.78e-3)" "unprognostic (2.95e-2)" "unprognostic (4.43e-1)" "unprognostic (2.01e-2)" "prognostic favourable (9.46e-8)" "unprognostic (1.32e-3)" "unprognostic (6.75e-2)" "unprognostic (2.73e-2)" "unprognostic (3.34e-2)" 10.7 5.5 12.5 3.2 14.8 1.1 12.0 2.6 27.0 3.6 11.2 1.9 5.5 2.7 7.5 2.2 7.0 4.3 2.5 7.9 9.2 5.7 12.9 20.8 5.4 1.6 4.3 20.1 2.9 9.6 6.8 20.3 4.7 3.5 8.2 9.0 3.2 6.1 10.4 21.9 7.1 4.0 11.1 3.0 5.7 8.1 1.0 4.0 0.0 4.9 4.7 1.6 9.8 14.6 4.3 0.5 7.2 0.1 0.0 0.0 3.5 5.9 1.8 0.4 0.0 10.7 5.6 4.0 0.2 1.3 1.0 1.9 3.9 5.9 0.0 1.5 4.2 9.0 6.4 2.5 0.7 0.0 3.9 0.0 1.6 5.1 0.3 0.0 0.0 9.9 4.4 0.1 0.7 0.0 26.0 0.0 0.9 0.3 0.0 0.0 3.9 2.2 0.0 0.0 0.0 6.1 19.3 1.1 0.4 9.8 5.3 0.1 5.8 0.0 0.5 2.4 1.9 0.0 1.1 0.1 0.3 0.0 1.7 0.0 0.2 7.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 4.3 0.0 0.0 1.6 0.0 0.0 0.0 0.0 3.5 12.5 14.8 2.6 27.0 9.2 5.7 4.3 20.1 3.5 4.0 TLR4 "ARMD10, CD284, hToll, TLR-4" ENSG00000136869 "Toll like receptor 4" O00206 9 117704175-117724730 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Immunity, Inflammatory response, Innate immunity" Receptor "Age-related macular degeneration, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 29.1;TIME: 21.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 30.1" "Group enriched" "Detected in many" 30 "dendritic cells: 7.5;granulocytes: 30.1;monocytes: 21.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB004025, HPA049174" Approved Supported "Golgi apparatus,Plasma membrane" "Intracellular and membrane" "Plasma membrane" "Golgi apparatus" "CAB004025: , HPA049174: " "unprognostic (1.60e-1)" "unprognostic (8.34e-2)" "unprognostic (7.22e-2)" "prognostic favourable (6.29e-4)" "unprognostic (3.39e-1)" "unprognostic (7.48e-2)" "unprognostic (8.68e-2)" "unprognostic (1.80e-1)" "unprognostic (3.38e-1)" "unprognostic (5.18e-2)" "unprognostic (8.00e-2)" "unprognostic (9.42e-2)" "unprognostic (4.08e-2)" "unprognostic (8.63e-2)" "prognostic unfavourable (3.79e-4)" "unprognostic (1.09e-2)" "unprognostic (1.96e-2)" 29.2 12.1 15.5 23.5 12.5 17.8 21.9 9.4 10.3 6.9 6.8 10.6 3.0 4.4 5.8 7.7 5.0 6.8 10.6 10.9 19.9 7.5 9.0 16.5 16.0 30.9 12.4 11.4 6.7 3.0 2.9 3.8 22.8 10.5 5.7 7.4 7.2 9.0 3.6 7.4 5.2 6.6 10.4 11.1 41.4 4.5 2.4 13.0 1.1 8.3 5.6 7.5 12.1 16.1 0.6 7.5 30.1 21.4 0.0 0.0 6.9 0.0 0.0 12.5 0.0 5.8 11.8 0.1 5.0 8.7 1.2 0.7 0.0 1.2 1.7 0.2 12.8 0.0 0.0 1.1 1.8 0.0 0.0 2.6 2.6 0.1 4.4 9.0 0.0 7.3 0.0 2.7 0.3 15.2 0.0 29.1 15.2 0.0 0.0 1.8 1.5 0.6 0.0 14.1 9.1 0.5 14.6 0.0 0.0 3.1 0.0 0.5 0.0 4.9 21.1 0.6 9.5 0.0 2.3 0.0 0.0 0.0 0.4 9.5 7.4 17.6 21.4 7.2 0.0 19.6 0.0 0.6 0.0 0.0 7.5 0.2 0.0 0.0 30.1 0.0 20.2 0.3 0.0 6.9 15.5 12.5 9.4 10.3 19.9 7.5 12.4 11.4 10.5 13.0 TLR7 ENSG00000196664 "Toll like receptor 7" Q9NYK1 X 12867083-12890380 "FDA approved drug targets, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 26.5" "Group enriched" "Detected in some" 5 "Daudi: 15.6;U-266/70: 16.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 15.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA059613 Supported "HPA059613: " "unprognostic (1.22e-1)" "unprognostic (1.09e-2)" "unprognostic (2.36e-3)" "unprognostic (9.29e-2)" "unprognostic (2.06e-1)" "unprognostic (1.06e-2)" "unprognostic (8.27e-2)" "unprognostic (6.20e-3)" "unprognostic (3.75e-1)" "unprognostic (6.91e-2)" "unprognostic (3.55e-1)" "unprognostic (8.47e-2)" "unprognostic (2.54e-1)" "unprognostic (4.17e-3)" "unprognostic (1.19e-3)" "unprognostic (1.53e-3)" "unprognostic (1.34e-1)" 2.9 3.1 7.6 7.2 11.3 1.0 7.6 1.7 7.9 2.5 3.3 10.6 0.0 3.2 1.8 2.9 1.8 1.7 5.3 4.1 8.4 5.1 2.2 1.5 7.7 6.9 17.4 2.6 1.6 1.9 1.5 2.2 11.0 12.9 2.2 4.0 1.5 2.7 2.0 1.4 1.4 4.9 3.5 26.5 6.7 3.0 1.5 17.2 7.7 1.7 0.5 9.4 5.2 1.6 6.9 15.7 3.2 8.9 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 15.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 16.1 0.0 3.0 0.0 0.3 0.0 0.2 7.2 3.2 0.0 8.9 0.0 6.9 0.0 0.0 3.7 5.8 0.0 0.0 0.4 0.0 6.8 15.7 0.0 2.2 7.6 11.3 1.7 7.9 8.4 5.1 17.4 2.6 12.9 17.2 TNFSF11 "CD254, ODF, OPGL, RANKL, TRANCE" ENSG00000120659 "TNF superfamily member 11" O14788 13 42562736-42608013 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Differentiation "Cytokine, Developmental protein, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Osteopetrosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 14.3;lymphoid tissue: 19.8" "Cell line enhanced" "Detected in some" "Daudi: 1.7;HSkMC: 5.2;NTERA-2: 7.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 8 "NK-cell: 14.3" "Lineage enriched" "Detected in many" 8 "NK-cells: 14.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB009193, HPA045142" Enhanced "Secreted to blood" 17195 "CAB009193: , HPA045142: " "unprognostic (3.97e-4)" "unprognostic (1.40e-1)" "unprognostic (9.01e-3)" "unprognostic (3.81e-3)" "unprognostic (1.12e-1)" "unprognostic (1.09e-1)" "unprognostic (7.09e-2)" "unprognostic (7.70e-2)" "unprognostic (2.29e-1)" "unprognostic (1.25e-3)" "unprognostic (1.00e-1)" "unprognostic (1.50e-1)" "unprognostic (3.94e-5)" "unprognostic (1.87e-1)" "unprognostic (9.67e-2)" "unprognostic (5.46e-2)" "unprognostic (7.74e-2)" 0.5 0.2 0.2 19.5 0.2 0.0 4.6 0.1 0.2 0.8 0.8 0.1 2.4 0.2 0.2 0.1 3.7 0.2 1.3 0.3 0.1 0.7 0.6 5.3 0.4 19.8 0.1 0.1 0.1 0.6 0.0 0.3 0.3 0.4 0.5 2.2 0.1 1.6 1.0 0.2 0.5 6.0 0.1 0.1 0.8 0.3 3.3 0.1 2.8 0.4 0.1 5.2 2.3 0.7 0.0 0.1 1.8 0.0 14.3 0.1 0.1 0.0 0.3 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.7 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.0 0.1 0.5 0.0 0.6 0.0 0.1 5.2 0.5 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.2 7.4 0.1 0.0 0.2 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.7 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 14.3 0.0 0.0 0.0 0.1 0.2 0.2 0.1 0.2 0.1 0.7 0.1 0.1 0.4 0.1 TNNC1 TNNC ENSG00000114854 "Troponin C1, slow skeletal and cardiac type" P63316 3 52451102-52454070 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Muscle protein" "Cardiomyopathy, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "heart muscle: 431.6;skeletal muscle: 765.7" "Cell line enhanced" "Detected in some" "CACO-2: 23.8;EFO-21: 23.9;HeLa: 15.7;Hep G2: 15.9;HSkMC: 24.8;U-2 OS: 36.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "MAIT T-cell: 4.0" "Lineage enriched" "Detected in single" 7 "T-cells: 4.0" "Region enriched" "Detected in many" 4 "cerebral cortex: 88.3" "Region enriched" "Detected in single" 7 "midbrain: 8.5" "CAB002450, HPA044848, HPA056897" Enhanced Approved "Nucleoplasm,Actin filaments,Mitochondria" 260000 "Nucleoplasm, Actin filaments, Mitochondria" "CAB002450: AB_564152, HPA044848: AB_2679110, HPA056897: AB_2683269" "unprognostic (2.18e-2)" "unprognostic (1.70e-1)" "unprognostic (8.66e-2)" "unprognostic (3.43e-1)" "unprognostic (4.00e-2)" "unprognostic (1.88e-2)" "unprognostic (1.11e-1)" "unprognostic (1.43e-1)" "unprognostic (1.53e-1)" "unprognostic (3.92e-1)" "unprognostic (1.03e-1)" "unprognostic (1.07e-1)" "unprognostic (2.15e-2)" "unprognostic (4.95e-2)" "unprognostic (2.31e-1)" "unprognostic (4.15e-2)" "unprognostic (4.86e-1)" 2.0 0.3 0.1 0.0 0.1 0.0 0.7 0.2 0.1 0.2 0.1 0.0 0.0 0.0 0.1 17.8 12.8 0.1 0.0 431.6 0.1 0.1 0.6 0.1 2.6 0.0 0.1 0.0 0.1 0.2 0.0 0.6 0.2 0.5 5.5 0.1 0.7 10.4 0.0 765.7 0.4 0.1 0.1 0.7 0.1 0.1 0.7 0.0 0.0 3.0 86.9 8.7 0.4 0.2 0.2 0.6 0.0 0.0 0.0 4.0 0.5 0.2 1.8 1.3 0.2 0.0 0.2 2.9 0.1 0.1 0.1 0.1 23.8 11.9 0.2 23.9 3.4 0.1 0.0 0.1 0.0 0.4 0.5 0.1 15.7 15.9 0.1 0.1 0.0 24.8 0.4 0.0 0.2 0.0 0.0 1.8 0.7 0.0 0.0 0.2 0.1 0.2 0.0 1.0 0.8 1.1 4.5 0.0 0.0 0.1 2.4 0.0 9.6 0.2 0.0 0.0 36.7 0.3 0.0 1.0 0.4 0.3 0.1 0.2 0.0 0.0 0.0 0.0 0.7 0.0 4.0 0.2 0.9 0.5 0.0 0.1 1.4 0.5 0.0 0.0 0.0 0.6 2.5 0.5 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.5 0.0 TNNC2 ENSG00000101470 "Troponin C2, fast skeletal type" P02585 20 45823214-45833745 "FDA approved drug targets, Predicted intracellular proteins" "Muscle protein" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "skeletal muscle: 851.6" "Group enriched" "Detected in some" 7 "Hep G2: 9.7;HSkMC: 15.3;SCLC-21H: 11.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "memory B-cell: 6.0" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "HPA043174, HPA058481" Enhanced Approved Nucleoplasm,Vesicles 63000 Nucleoplasm Vesicles "HPA043174: AB_10806380, HPA058481: " "unprognostic (1.13e-1)" "unprognostic (7.25e-2)" "unprognostic (3.43e-1)" "unprognostic (1.27e-1)" "unprognostic (3.21e-5)" "unprognostic (1.80e-2)" "unprognostic (5.72e-3)" "unprognostic (3.12e-3)" "unprognostic (2.19e-1)" "unprognostic (2.06e-1)" "unprognostic (2.38e-1)" "unprognostic (1.05e-1)" "unprognostic (9.03e-3)" "unprognostic (7.15e-3)" "unprognostic (4.79e-1)" "unprognostic (5.23e-2)" "unprognostic (1.13e-1)" 12.0 0.2 0.1 0.1 0.4 0.1 0.3 0.1 0.2 0.1 0.2 0.0 0.0 0.1 0.1 2.7 4.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.0 1.4 0.1 0.0 7.8 0.1 851.6 0.2 0.3 0.1 0.1 0.1 0.1 0.1 0.0 0.0 1.6 169.1 6.6 0.1 0.1 6.0 0.8 2.4 1.1 0.3 4.1 11.9 0.1 0.0 0.2 0.5 1.7 1.2 1.7 0.2 0.4 0.0 0.1 0.2 1.1 0.4 1.2 1.0 0.4 0.0 0.4 0.0 0.0 0.3 0.0 0.9 9.7 0.4 0.3 0.2 15.3 0.2 0.1 0.7 0.0 0.1 0.5 0.2 1.2 0.7 0.1 0.0 0.6 0.2 0.6 0.2 0.3 0.0 11.5 0.5 1.7 0.1 0.4 1.3 0.4 0.5 0.3 0.4 0.9 0.2 1.5 0.4 0.3 1.6 0.1 0.2 0.0 0.7 1.4 0.2 1.1 0.7 6.0 1.5 0.2 0.3 3.8 0.0 0.3 2.4 0.3 0.8 0.8 4.1 11.9 0.1 0.4 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.0 TOP1 ENSG00000198900 "DNA topoisomerase I" P11387 20 41028818-41124487 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009058, HPA019039" Supported Supported "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "CAB009058: AB_2303554, HPA019039: AB_1858187" "unprognostic (1.46e-1)" "unprognostic (8.65e-2)" "unprognostic (1.33e-2)" "unprognostic (1.92e-3)" "unprognostic (5.05e-2)" "unprognostic (1.49e-3)" "prognostic unfavourable (6.42e-4)" "unprognostic (5.86e-2)" "unprognostic (1.51e-1)" "unprognostic (4.60e-2)" "unprognostic (3.74e-3)" "unprognostic (6.51e-2)" "unprognostic (8.65e-2)" "unprognostic (4.70e-2)" "unprognostic (5.14e-1)" "unprognostic (3.64e-1)" "unprognostic (1.29e-1)" 26.6 31.0 24.6 46.3 25.3 55.3 37.4 39.6 31.1 21.3 30.0 11.1 26.7 29.7 22.9 22.5 36.0 20.5 29.2 21.0 23.0 18.3 31.8 32.7 37.9 38.6 21.9 20.9 25.5 22.5 22.2 39.9 43.9 25.2 23.3 27.2 13.6 25.3 34.3 26.2 24.6 48.4 23.1 27.4 36.9 26.7 14.2 24.2 54.2 31.5 25.1 40.6 25.2 41.7 9.0 17.2 18.4 11.1 5.8 8.2 4.6 21.5 15.1 28.3 23.1 11.5 13.7 28.0 19.5 17.2 22.7 20.7 39.6 27.2 61.5 20.9 10.1 21.0 33.9 31.2 33.3 13.3 17.3 78.4 12.1 28.1 29.9 33.8 27.0 15.5 16.7 22.1 36.4 23.7 34.0 21.4 25.6 47.9 47.7 21.4 22.8 28.1 40.8 26.6 32.7 24.2 20.1 23.5 16.3 30.6 19.0 19.8 21.1 30.3 23.2 18.4 15.6 17.0 20.9 13.6 15.2 71.7 24.7 19.0 17.4 9.1 9.2 14.3 6.5 9.2 8.2 9.0 7.2 6.8 8.6 8.7 7.7 6.9 18.4 5.8 11.1 17.2 7.9 4.6 24.6 25.3 39.6 31.1 23.0 18.3 21.9 20.9 25.2 24.2 TOP1MT ENSG00000184428 "DNA topoisomerase I mitochondrial" Q969P6 8 143304384-143359979 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "DNA-binding, Isomerase, Topoisomerase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MOLT-4: 57.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001915, HPA021542" Approved Supported Mitochondria Mitochondria "HPA001915: AB_1080331, HPA021542: AB_1858186" "unprognostic (5.02e-3)" "unprognostic (3.79e-2)" "unprognostic (6.57e-2)" "unprognostic (6.92e-3)" "unprognostic (2.32e-2)" "unprognostic (1.04e-2)" "unprognostic (3.05e-3)" "unprognostic (1.44e-1)" "unprognostic (1.44e-1)" "unprognostic (1.13e-1)" "unprognostic (1.50e-2)" "unprognostic (4.42e-2)" "prognostic unfavourable (1.52e-7)" "unprognostic (3.66e-2)" "unprognostic (3.62e-2)" "unprognostic (8.55e-3)" "unprognostic (5.66e-3)" 11.7 13.5 8.1 13.7 9.8 33.0 22.1 2.2 10.3 14.7 10.7 4.5 3.9 6.0 10.0 7.4 14.9 11.3 11.0 5.9 8.8 5.6 9.6 22.5 8.5 11.4 6.9 8.1 27.0 15.9 5.9 8.6 5.9 7.3 14.7 8.0 5.9 11.0 10.8 5.7 15.4 8.3 8.8 6.8 11.4 9.3 18.1 6.4 25.1 19.2 9.6 11.4 14.0 30.9 16.7 18.8 11.7 5.5 0.2 14.3 4.7 7.5 11.6 4.9 18.2 7.0 7.8 8.7 3.5 4.5 6.4 6.6 14.5 10.9 22.2 13.2 4.9 8.1 10.4 6.5 5.5 8.7 15.9 19.5 6.5 14.6 7.9 13.0 21.2 7.9 6.9 5.3 7.8 7.6 23.3 8.7 5.6 31.5 57.7 25.9 8.5 19.9 7.3 6.4 33.2 4.7 12.2 8.7 10.6 10.0 9.0 18.1 5.9 21.7 5.0 4.4 18.1 5.0 9.0 4.7 4.9 11.3 7.5 19.5 5.3 11.7 5.5 0.2 3.5 3.2 3.6 16.7 6.4 4.8 18.8 8.0 14.3 10.4 0.4 0.2 0.6 16.4 1.7 4.7 8.1 9.8 2.2 10.3 8.8 5.6 6.9 8.1 7.3 6.4 TOP2A TOP2 ENSG00000131747 "DNA topoisomerase II alpha" P11388 17 40388516-40417950 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "lymphoid tissue: 146.3;testis: 36.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "T-reg: 5.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB002448, HPA006458, HPA026773" Enhanced Approved Supported Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "CAB002448: AB_564035, HPA006458: AB_1858189, HPA026773: AB_1858190" "unprognostic (2.09e-1)" "unprognostic (1.24e-1)" "unprognostic (2.28e-3)" "unprognostic (9.42e-3)" "unprognostic (1.80e-1)" "unprognostic (1.52e-1)" "prognostic unfavourable (5.92e-6)" "prognostic unfavourable (4.99e-4)" "unprognostic (6.21e-3)" "unprognostic (2.09e-1)" "prognostic unfavourable (3.83e-5)" "unprognostic (5.03e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (7.46e-2)" "unprognostic (1.07e-1)" "unprognostic (2.18e-1)" "unprognostic (2.29e-1)" 2.7 2.0 0.4 20.0 0.5 14.6 4.1 0.4 0.5 3.0 6.9 0.5 0.5 7.0 2.0 3.4 18.2 0.7 2.4 2.3 0.6 0.5 1.4 1.9 5.5 15.4 0.6 0.4 1.2 1.1 0.0 0.4 10.7 0.6 1.2 8.0 0.6 3.2 0.3 0.6 5.9 9.2 2.6 1.8 7.3 4.5 36.8 0.3 146.3 0.9 11.8 16.7 3.2 5.7 1.3 0.3 0.3 0.3 3.2 5.7 1.1 33.7 44.9 57.2 26.1 2.8 5.8 12.7 46.4 25.0 42.7 37.9 21.0 25.9 54.5 23.6 15.7 53.8 43.9 18.5 57.4 29.1 29.3 36.0 28.7 35.1 0.2 50.4 38.3 1.2 1.5 30.0 30.6 22.4 38.9 37.4 46.1 11.7 58.4 33.9 23.7 17.9 49.6 88.8 22.6 10.3 21.6 33.8 24.3 37.4 46.7 14.7 39.2 23.2 14.7 28.2 39.7 32.5 44.5 21.5 24.3 47.6 15.9 34.8 46.9 0.3 0.0 0.0 0.6 0.0 0.0 1.3 0.9 0.9 0.3 0.4 0.2 0.1 0.3 3.2 0.3 0.0 5.7 1.1 0.4 0.5 0.4 0.5 0.6 0.5 0.6 0.4 0.6 0.3 TOP2B ENSG00000077097 "DNA topoisomerase II beta" Q02880 3 25597905-25664907 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA-binding, Isomerase, Topoisomerase" "Autism spectrum disorder, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "REH: 104.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004601, HPA024120, HPA050441" Supported Enhanced Nucleoplasm Nucleoplasm "CAB004601: AB_628384, HPA024120: AB_1858191, HPA050441: AB_2681127" "unprognostic (2.90e-2)" "unprognostic (5.17e-2)" "unprognostic (7.21e-3)" "unprognostic (2.42e-1)" "unprognostic (1.60e-1)" "unprognostic (1.43e-2)" "prognostic unfavourable (1.86e-7)" "unprognostic (7.86e-2)" "unprognostic (1.89e-1)" "unprognostic (2.84e-1)" "unprognostic (7.14e-2)" "unprognostic (1.08e-1)" "prognostic favourable (2.43e-4)" "unprognostic (1.01e-1)" "unprognostic (1.59e-1)" "unprognostic (1.49e-1)" "unprognostic (7.93e-2)" 19.3 18.8 23.4 23.1 29.7 26.5 21.1 48.4 33.5 24.1 22.4 21.1 18.9 17.1 29.6 25.6 21.1 20.6 20.7 22.7 22.0 19.9 20.3 18.4 17.7 28.2 21.0 28.5 26.8 17.2 43.0 21.6 22.3 26.4 24.7 20.8 17.6 21.3 22.3 31.3 20.9 19.3 24.4 23.4 24.6 20.1 11.3 22.7 60.2 28.3 20.7 27.3 34.8 21.5 5.5 5.6 5.3 4.6 7.8 7.2 2.2 10.5 10.9 24.1 29.5 8.0 10.2 9.6 10.2 13.1 9.5 10.4 5.5 8.4 32.6 7.1 14.7 9.0 20.0 11.3 16.0 15.6 10.7 49.5 13.6 9.3 5.6 38.7 26.5 7.3 5.7 10.6 9.3 15.4 16.6 16.1 12.2 11.7 25.0 9.6 18.3 8.3 104.7 13.6 15.1 8.5 37.2 12.2 21.1 15.2 10.9 9.3 11.3 34.6 14.7 13.2 10.3 10.5 10.9 24.9 14.1 34.7 8.7 29.0 8.8 4.2 2.9 5.3 6.3 3.3 6.9 4.3 6.1 6.4 4.3 5.5 7.2 6.4 2.0 7.8 4.6 5.6 4.4 2.2 23.4 29.7 48.4 33.5 22.0 19.9 21.0 28.5 26.4 22.7 TPH1 "TPH, TPRH" ENSG00000129167 "Tryptophan hydroxylase 1" P17752 11 18017564-18042426 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Serotonin biosynthesis" "Monooxygenase, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 4.2;intestine: 16.2;pituitary gland: 5.4;stomach 1: 13.3" "Cell line enhanced" "Detected in many" "HL-60: 4.5" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 6 "cerebral cortex: 4.2" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "CAB010767, HPA022483" Approved Uncertain Cytosol Cytosol "CAB010767: AB_261587, HPA022483: AB_1858378" "unprognostic (2.14e-4)" "unprognostic (9.97e-2)" "unprognostic (6.92e-2)" "unprognostic (6.78e-2)" "unprognostic (1.55e-1)" "unprognostic (6.26e-5)" "unprognostic (1.73e-1)" "unprognostic (5.33e-2)" "unprognostic (1.60e-1)" "unprognostic (2.12e-2)" "unprognostic (1.19e-4)" "unprognostic (6.72e-2)" "unprognostic (5.40e-8)" "unprognostic (3.76e-2)" "unprognostic (7.42e-2)" "unprognostic (3.10e-1)" "unprognostic (2.46e-5)" 0.7 0.0 0.7 0.7 0.7 0.6 0.9 0.7 4.2 0.7 7.1 0.7 0.7 8.2 0.7 0.7 0.7 1.5 0.7 0.7 0.7 0.3 0.7 0.7 0.7 0.7 0.7 0.7 1.0 0.7 0.0 5.4 0.7 0.7 1.3 16.2 0.7 0.7 0.7 0.7 1.0 9.1 0.7 0.7 1.0 13.3 0.9 0.7 0.7 0.7 0.7 0.7 0.7 0.7 1.4 0.8 1.5 0.5 0.9 1.6 0.2 0.4 0.1 1.7 1.5 0.1 0.0 0.6 0.6 0.5 0.2 1.1 1.8 0.3 1.4 0.3 0.0 0.6 0.4 1.5 0.7 1.3 3.1 2.2 0.8 3.5 0.0 4.5 1.2 0.0 1.8 0.2 0.6 0.7 0.9 0.8 0.1 0.5 1.0 0.7 0.5 0.3 1.7 0.3 0.0 0.0 1.0 1.3 0.9 0.2 0.4 0.9 0.3 2.9 0.2 0.4 1.3 0.5 1.7 0.2 0.3 1.1 0.2 1.0 1.4 1.5 0.4 0.4 1.6 0.2 0.8 0.5 0.5 0.4 0.1 1.4 0.6 0.6 1.5 0.9 0.5 0.8 0.6 0.2 0.7 0.7 0.7 4.2 0.7 0.3 0.7 0.7 0.7 0.7 TPH2 "FLJ37295, NTPH" ENSG00000139287 "Tryptophan hydroxylase 2" Q8IWU9 12 71938846-72186618 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Serotonin biosynthesis" "Monooxygenase, Oxidoreductase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "brain: 46.2" "Group enriched" "Detected in some" 9 "EFO-21: 2.8;NTERA-2: 3.1;SCLC-21H: 1.5" "Not detected" "Not detected" "Region enriched" "Detected in many" 15 "pons and medulla: 46.2" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 32 "midbrain: 127.6;pons and medulla: 36.3" "Group enriched" "Detected in some" 10 "midbrain: 95.6;pons and medulla: 91.5" CAB078198 Enhanced "CAB078198: " "unprognostic (1.19e-1)" "unprognostic (6.01e-1)" "unprognostic (3.46e-2)" "unprognostic (2.31e-1)" "unprognostic (5.91e-2)" "unprognostic (2.02e-1)" "unprognostic (5.01e-2)" "unprognostic (7.32e-2)" "unprognostic (1.34e-1)" 0.1 0.2 0.4 0.3 0.5 0.1 0.1 0.3 4.4 0.1 0.2 0.0 0.0 0.1 0.1 0.1 0.1 0.2 0.2 0.2 3.0 1.5 0.1 0.3 0.1 0.1 0.9 0.0 0.1 1.7 0.1 3.2 0.1 46.2 0.1 0.1 0.0 0.1 0.3 0.1 0.1 0.1 0.2 0.3 0.1 0.1 1.0 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.5 0.3 1.4 3.0 1.5 0.9 0.0 46.2 0.0 TPK1 "HTPK1, PP20" ENSG00000196511 "Thiamin pyrophosphokinase 1" Q9H3S4 7 144451941-144836395 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Kinase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "AN3-CA: 26.6;CACO-2: 6.3;EFO-21: 8.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA021545, HPA021849" Approved Approved Vesicles 78000 Vesicles "HPA021545: AB_1858209, HPA021849: AB_1858210" "unprognostic (4.05e-2)" "unprognostic (3.28e-2)" "unprognostic (2.38e-2)" "unprognostic (3.32e-2)" "unprognostic (2.42e-1)" "unprognostic (1.63e-1)" "unprognostic (7.62e-2)" "unprognostic (6.08e-2)" "unprognostic (2.37e-1)" "unprognostic (1.68e-1)" "unprognostic (3.76e-2)" "unprognostic (6.06e-2)" "unprognostic (1.45e-3)" "unprognostic (3.15e-1)" "unprognostic (2.87e-1)" "unprognostic (1.59e-1)" "unprognostic (9.22e-3)" 12.2 7.4 5.1 9.6 4.7 3.6 7.6 4.0 7.2 4.3 8.4 4.2 2.4 18.2 5.1 5.0 3.3 3.9 5.4 6.4 5.6 6.6 6.0 6.2 8.8 23.3 4.9 3.1 4.4 3.3 3.6 4.6 7.0 4.4 3.7 8.5 8.9 7.1 4.1 3.0 2.9 13.9 5.1 6.0 15.1 4.0 5.9 2.0 5.1 4.9 4.1 14.2 5.5 3.3 5.4 9.6 3.4 7.4 4.0 5.5 3.8 0.2 0.2 0.2 26.6 0.2 0.2 2.2 0.1 0.1 0.0 0.0 6.3 1.0 0.4 8.1 0.4 0.0 0.5 0.3 0.2 1.6 0.4 0.1 0.1 0.1 0.7 2.0 0.6 0.5 0.5 0.3 0.4 5.1 0.5 1.2 0.1 0.8 0.5 3.0 0.6 2.2 0.2 0.6 0.9 4.1 2.3 0.2 0.0 0.4 0.0 0.4 0.3 3.8 6.1 0.3 0.6 0.5 0.3 0.6 1.4 0.6 0.9 5.1 0.2 0.3 7.3 0.2 3.9 5.3 4.0 5.0 4.4 3.5 9.6 5.4 5.2 4.2 3.4 4.0 7.4 2.3 5.5 3.8 5.1 4.7 4.0 7.2 5.6 6.6 4.9 3.1 4.4 2.0 TPMT ENSG00000137364 "Thiopurine S-methyltransferase" P51580 6 18128311-18155074 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Methyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "thyroid gland: 48.2" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019851 Enhanced "HPA019851: AB_1858213" "unprognostic (6.24e-2)" "unprognostic (3.16e-2)" "unprognostic (5.46e-3)" "prognostic unfavourable (8.45e-5)" "unprognostic (4.98e-2)" "unprognostic (2.25e-1)" "unprognostic (8.16e-2)" "unprognostic (4.36e-3)" "unprognostic (9.62e-2)" "prognostic favourable (1.41e-4)" "unprognostic (4.49e-2)" "unprognostic (3.40e-2)" "prognostic favourable (1.10e-4)" "unprognostic (7.56e-2)" "unprognostic (1.31e-1)" "unprognostic (1.07e-1)" "unprognostic (8.39e-3)" 5.3 13.2 11.5 6.6 10.2 4.9 5.6 13.1 14.3 4.6 18.2 4.1 6.2 18.4 6.5 10.1 8.9 4.1 7.6 6.5 9.0 8.0 40.2 36.2 6.5 6.2 9.3 7.5 3.8 9.4 12.9 11.6 3.3 8.5 6.2 19.4 6.9 12.9 7.2 7.0 5.7 29.4 6.2 7.2 9.4 6.6 4.1 7.5 5.4 48.2 6.3 5.3 6.4 5.6 1.6 16.9 3.7 23.8 5.4 8.3 8.3 11.7 3.6 4.0 9.8 6.6 12.9 9.8 13.7 15.2 11.7 18.3 8.3 2.9 1.5 10.2 18.0 5.9 5.6 9.8 19.6 7.7 8.1 9.7 6.1 12.1 7.2 4.4 8.8 7.4 10.6 13.0 8.3 16.2 19.1 2.8 8.5 5.4 4.5 6.1 6.6 10.3 5.7 9.8 6.6 13.6 12.1 6.5 5.0 8.9 15.9 17.5 11.5 4.5 6.9 26.9 5.2 14.0 19.3 4.1 18.2 3.8 9.6 6.1 26.9 3.4 12.0 3.7 6.5 23.8 8.3 1.5 5.3 6.2 16.9 1.6 4.8 6.5 1.2 5.4 19.6 3.7 8.2 8.3 11.5 10.2 13.1 14.3 9.0 8.0 9.3 7.5 8.5 7.5 TPO TPX ENSG00000115705 "Thyroid peroxidase" P07202 2 1374223-1543711 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Hydrogen peroxide, Thyroid hormones biosynthesis" "Oxidoreductase, Peroxidase" "Congenital hypothyroidism, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 58 "thyroid gland: 411.3" "Group enriched" "Detected in some" 5 "Karpas-707: 14.0;RPMI-8226: 5.9" "Cancer enriched" "Detected in some" 364 "thyroid cancer: 188.3" "Not detected" "Not detected" "Group enriched" "Detected in some" 13 "memory CD4 T-cell: 5.1;T-reg: 3.0" "Lineage enriched" "Detected in single" 21 "T-cells: 5.1" "Low region specificity" "Detected in single" "Not detected" "Not detected" "HPA007987, CAB009587" Enhanced "Intracellular and membrane" "CAB009587: , HPA007987: AB_1080270" "unprognostic (1.55e-1)" "unprognostic (1.04e-1)" "unprognostic (2.88e-1)" "unprognostic (1.77e-2)" "unprognostic (3.56e-2)" "unprognostic (9.11e-2)" "unprognostic (2.24e-2)" "unprognostic (1.85e-1)" "unprognostic (1.32e-1)" "unprognostic (1.19e-4)" "unprognostic (2.61e-2)" "unprognostic (3.29e-1)" "unprognostic (5.44e-4)" "unprognostic (1.21e-1)" "unprognostic (3.73e-2)" "unprognostic (4.98e-3)" "unprognostic (7.10e-3)" 1.1 0.0 0.1 0.1 0.1 0.0 0.9 0.1 0.1 0.1 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.4 1.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 1.2 0.1 0.5 0.0 0.2 0.1 0.1 7.1 0.2 0.1 0.1 0.1 411.3 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.0 0.0 5.1 0.9 0.1 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.0 0.0 1.4 0.0 0.0 0.1 0.2 0.0 0.0 5.9 0.0 0.0 0.0 0.1 0.0 2.0 0.0 1.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 5.1 0.3 0.0 0.1 0.0 0.3 0.2 0.0 0.0 0.0 3.0 0.9 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 TRHR ENSG00000174417 "Thyrotropin releasing hormone receptor" P34981 8 109086621-109119584 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 1.0;pituitary gland: 3.3;thyroid gland: 1.6" "Cell line enhanced" "Detected in some" "PC-3: 1.6;SH-SY5Y: 1.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA055162 Approved "HPA055162: " "unprognostic (1.92e-2)" "unprognostic (8.58e-2)" "unprognostic (1.17e-1)" 0.0 0.0 0.1 0.4 0.1 0.0 0.0 0.0 1.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.3 0.2 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.1 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.1 0.0 1.6 0.0 0.4 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.3 0.2 0.3 0.5 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 TRPV3 VRL3 ENSG00000167723 "Transient receptor potential cation channel subfamily V member 3" Q8NET8 17 3510502-3557995 "Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel" "Disease mutation, FDA approved drug targets, Palmoplantar keratoderma" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 15.4;skeletal muscle: 29.1" "Cell line enhanced" "Detected in some" "A-431: 3.5;BEWO: 5.3;CACO-2: 4.2;RH-30: 13.0;T-47d: 5.5;U-266/70: 3.5" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in some" "basal ganglia: 2.4" "Cell type enhanced" "Detected in some" "basophil: 2.9" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in some" "Region enriched" "Detected in many" 6 "cerebellum: 14.0" HPA069550 Approved "Plasma membrane,Centrosome,Cytosol" "Plasma membrane" "Centrosome, Cytosol" "HPA069550: " "unprognostic (1.84e-4)" "unprognostic (2.25e-1)" "unprognostic (5.22e-2)" "unprognostic (3.92e-4)" "unprognostic (4.87e-3)" "unprognostic (2.96e-2)" "unprognostic (6.66e-2)" "unprognostic (4.88e-2)" "unprognostic (7.02e-2)" "unprognostic (2.68e-1)" "unprognostic (4.88e-2)" "unprognostic (3.69e-2)" "unprognostic (0.00e+0)" "unprognostic (1.12e-1)" "unprognostic (1.77e-1)" "unprognostic (8.64e-2)" "unprognostic (2.93e-2)" 0.4 0.2 0.4 3.2 2.4 0.9 4.1 0.3 1.2 0.6 10.6 0.1 0.3 3.2 0.2 0.2 2.3 0.3 0.8 0.3 0.4 0.3 0.2 1.1 0.3 0.5 0.4 0.2 0.3 0.9 0.0 0.7 0.4 0.0 0.2 2.9 0.3 0.5 0.4 29.1 8.4 15.4 0.5 0.5 0.4 1.6 0.8 0.0 0.0 0.2 9.7 3.0 0.7 2.1 0.7 0.6 2.9 0.6 0.6 0.7 0.1 3.5 0.0 0.5 0.1 0.2 0.6 5.3 0.2 0.0 0.0 0.0 4.2 0.9 0.2 1.0 0.1 0.4 0.0 0.1 0.0 0.1 0.1 0.0 0.3 0.6 0.1 0.2 0.8 0.3 0.0 0.7 1.8 0.0 0.1 0.1 0.0 0.7 0.1 0.2 0.1 0.5 0.1 13.0 0.2 0.0 0.2 0.1 0.0 0.2 0.6 0.0 5.5 0.2 0.1 0.1 0.2 0.1 0.1 3.5 2.7 0.0 0.1 0.1 0.0 2.9 0.4 0.4 0.7 0.2 0.5 0.7 0.4 0.7 0.1 0.5 0.4 0.6 1.0 0.6 0.6 0.6 0.2 0.1 0.4 2.4 0.3 1.2 0.4 0.3 0.4 0.2 0.0 0.0 TSPO "BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS" ENSG00000100300 "Translocator protein" "B1AH88, P30536" 22 43151514-43163242 "Cancer-related genes, FDA approved drug targets, Predicted membrane proteins" "Lipid transport, Transport" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 139.5" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB011232, HPA046260" Uncertain Approved Vesicles,Mitochondria,Cytosol "Mitochondria, Cytosol" Vesicles "CAB011232: , HPA046260: " "unprognostic (5.29e-3)" "unprognostic (1.41e-1)" "unprognostic (3.31e-1)" "unprognostic (4.02e-3)" "unprognostic (3.95e-1)" "unprognostic (1.46e-2)" "prognostic unfavourable (1.61e-4)" "unprognostic (2.16e-1)" "unprognostic (1.17e-1)" "unprognostic (3.75e-2)" "unprognostic (1.07e-2)" "unprognostic (1.33e-1)" "unprognostic (1.69e-1)" "unprognostic (1.53e-2)" "unprognostic (3.03e-1)" "unprognostic (1.04e-1)" "unprognostic (2.34e-3)" 33.9 21.2 9.8 17.8 11.0 117.3 48.7 2.7 8.1 24.9 23.9 12.3 10.3 20.5 12.3 13.6 83.2 14.3 36.8 32.1 8.0 5.4 18.0 22.0 39.8 40.0 15.4 5.2 13.3 13.2 4.0 6.7 15.5 9.7 23.1 9.7 16.4 34.6 9.2 13.2 46.6 23.0 12.7 11.4 27.2 39.0 10.5 10.0 9.4 17.9 44.3 50.0 19.1 41.3 22.9 99.9 91.4 139.5 28.5 43.8 104.8 47.1 23.4 1.6 22.2 8.9 29.6 1.7 35.3 17.3 17.8 18.9 4.5 36.1 0.0 24.4 27.3 39.1 4.4 27.3 2.3 7.9 18.4 4.8 25.7 1.6 32.4 10.7 24.2 22.9 45.1 10.5 9.4 42.0 3.9 8.9 18.2 39.4 0.1 29.9 1.9 58.4 10.6 0.0 80.5 22.6 28.5 2.3 10.9 16.7 33.4 41.1 12.5 41.5 43.3 22.0 16.5 22.5 14.8 3.6 0.6 0.4 28.6 34.8 28.2 43.8 139.5 75.3 28.4 86.3 22.2 16.3 39.5 27.8 99.9 22.9 30.4 24.5 91.4 28.5 57.1 17.7 43.8 104.8 9.8 11.0 2.7 8.1 8.0 5.4 15.4 5.2 9.7 10.0 TUBA1A "B-ALPHA-1, FLJ25113, TUBA3" ENSG00000167552 "Tubulin alpha 1a" Q71U36 12 49184796-49189324 "Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, FDA approved drug targets, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 270.7;smooth muscle: 166.4" "Cell line enhanced" "Detected in many" "AF22: 222.1;SCLC-21H: 149.7" "Cancer enriched" "Detected in all" 9 "glioma: 942.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 151.2" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008686, HPA039247, HPA043684, HPA063394" Enhanced Enhanced Microtubules Microtubules "CAB008686: AB_1624202, HPA039247: , HPA043684: , HPA063394: " "unprognostic (3.11e-1)" "unprognostic (1.61e-1)" "unprognostic (3.77e-1)" "unprognostic (1.14e-1)" "unprognostic (4.73e-1)" "unprognostic (1.15e-2)" "unprognostic (2.56e-2)" "unprognostic (2.12e-1)" "unprognostic (3.49e-2)" "unprognostic (3.80e-1)" "unprognostic (1.11e-3)" "unprognostic (9.79e-2)" "prognostic unfavourable (2.90e-4)" "unprognostic (1.07e-2)" "unprognostic (4.27e-2)" "unprognostic (1.12e-2)" "unprognostic (1.27e-3)" 27.8 25.5 82.1 29.4 81.3 24.7 35.4 63.2 163.0 40.6 48.8 210.9 6.9 9.9 71.7 34.8 27.7 65.3 37.9 26.3 99.3 118.3 10.3 4.2 39.8 13.4 131.0 50.2 35.7 9.9 16.0 20.6 23.1 165.2 35.1 26.7 16.7 13.6 53.4 5.9 20.0 14.5 166.4 270.7 11.6 18.3 15.7 50.4 19.4 7.4 7.3 10.6 35.1 14.5 14.8 28.9 151.2 69.2 7.5 15.7 38.4 0.2 10.0 222.1 31.6 20.2 48.9 0.8 18.7 24.0 12.3 28.7 0.6 4.0 7.9 23.3 60.5 0.4 26.3 6.8 9.6 6.6 9.0 2.6 2.0 2.2 3.9 4.7 0.2 27.5 2.6 24.2 2.5 72.9 3.1 9.0 65.9 4.4 20.1 3.8 23.4 7.4 16.2 15.9 1.0 55.0 0.9 149.7 81.9 5.2 0.3 7.1 15.7 6.4 62.0 13.2 8.3 1.5 5.4 3.1 8.7 15.9 7.2 7.7 13.1 38.8 23.0 73.1 15.7 48.9 11.5 14.8 13.9 14.3 28.9 14.6 13.6 12.5 151.2 7.5 69.2 9.3 15.2 38.4 82.1 81.3 63.2 126.2 99.3 118.3 131.0 50.2 165.2 50.4 TUBA4A "FLJ30169, H2-ALPHA, TUBA1" ENSG00000127824 "Tubulin alpha 4a" P68366 2 219249711-219278170 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Amyotrophic lateral sclerosis, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 124.1" "Cell line enhanced" "Detected in many" "HBEC3-KT: 78.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004621, CAB005887, HPA039247, HPA043684, HPA063394" Approved Enhanced Microtubules 500000000 Microtubules "CAB004621: AB_628411, CAB005887: AB_2288001, HPA039247: , HPA043684: , HPA063394: " "unprognostic (8.08e-2)" "unprognostic (2.31e-1)" "unprognostic (4.03e-2)" "unprognostic (2.56e-2)" "unprognostic (5.18e-3)" "unprognostic (3.99e-2)" "prognostic unfavourable (4.54e-6)" "unprognostic (1.52e-3)" "unprognostic (4.47e-1)" "unprognostic (8.85e-2)" "unprognostic (1.49e-2)" "unprognostic (5.27e-2)" "unprognostic (1.94e-1)" "unprognostic (2.70e-1)" "unprognostic (2.36e-1)" "unprognostic (7.38e-3)" "unprognostic (9.32e-2)" 5.0 9.4 22.4 13.4 30.5 37.7 7.5 23.2 63.3 7.4 13.8 4.5 5.2 8.1 3.4 5.2 27.1 6.1 6.1 23.5 24.9 23.6 13.2 10.5 7.2 20.9 20.4 21.9 6.1 8.0 18.1 6.5 2.9 43.1 7.9 12.4 5.7 15.6 10.7 124.1 63.5 9.5 6.2 6.2 15.7 10.1 8.2 3.3 6.2 3.7 34.8 25.0 9.1 13.9 25.8 4.2 66.8 13.0 14.8 32.0 49.2 19.0 15.9 0.0 0.0 1.7 1.3 0.0 2.9 9.2 0.5 0.3 3.5 20.0 25.1 32.7 2.0 48.3 8.9 78.8 0.7 14.6 0.1 31.5 29.7 2.6 1.4 10.5 11.3 1.2 29.2 4.3 9.3 3.2 3.5 17.2 18.9 0.7 0.0 18.9 6.1 19.0 1.1 25.9 15.3 24.3 1.3 16.1 0.2 37.5 3.3 0.1 1.4 8.9 2.2 9.5 5.1 11.0 10.2 7.0 8.5 30.2 34.8 20.0 0.4 22.1 12.5 32.4 22.5 8.6 23.2 25.8 32.0 30.2 4.2 17.7 30.4 29.5 66.8 14.8 13.0 0.7 27.5 49.2 22.4 30.5 23.2 63.3 24.9 23.6 20.4 21.9 43.1 3.3 TUBB "M40, MGC16435, OK/SW-cl.56, Tubb5" ENSG00000196230 "Tubulin beta class I" P07437 6 30720201-30725426 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 198.7" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005417, CAB012406, HPA043640, HPA046280" Enhanced Supported Microtubules 510000000 Microtubules "CAB005417: AB_2241191, CAB012406: AB_2210370, HPA043640: , HPA046280: " "unprognostic (1.01e-1)" "unprognostic (2.33e-1)" "unprognostic (2.17e-3)" "unprognostic (1.92e-2)" "unprognostic (1.56e-1)" "unprognostic (2.16e-2)" "prognostic unfavourable (5.97e-4)" "unprognostic (2.57e-2)" "unprognostic (2.52e-1)" "unprognostic (2.18e-3)" "unprognostic (1.27e-2)" "unprognostic (2.47e-1)" "prognostic unfavourable (2.62e-8)" "unprognostic (8.63e-2)" "unprognostic (1.47e-1)" "unprognostic (2.49e-1)" "unprognostic (2.50e-1)" 51.6 27.7 30.0 31.8 33.2 78.8 30.0 30.9 57.2 43.3 37.0 24.3 18.7 10.8 58.5 39.7 39.9 41.0 29.6 33.1 23.7 48.2 31.4 74.1 32.7 62.1 27.8 24.0 81.5 27.0 15.3 16.3 41.1 39.9 32.2 34.2 30.6 27.9 24.3 29.6 37.6 24.3 37.6 27.4 47.7 29.1 19.7 14.4 198.7 26.9 36.8 91.5 39.7 34.3 15.4 17.5 8.6 15.4 12.3 18.2 19.8 41.9 15.5 60.6 26.3 17.1 29.7 0.5 0.0 0.0 0.0 0.0 29.6 16.1 21.0 26.0 19.4 14.5 48.9 44.0 0.0 11.8 30.9 0.5 0.0 16.9 8.2 57.2 28.2 22.0 10.3 0.0 0.5 21.3 16.5 0.0 26.6 30.3 41.3 0.2 0.0 18.3 0.0 0.6 12.3 35.4 23.9 10.5 35.4 22.8 10.1 0.4 26.4 5.2 13.1 63.8 28.4 0.0 0.2 19.6 37.6 48.6 12.6 56.9 80.6 4.9 7.7 8.6 15.5 12.2 18.2 15.4 12.1 17.6 6.2 10.0 12.3 12.2 4.3 12.3 15.4 17.5 14.2 19.8 30.0 33.2 30.9 57.2 23.7 48.2 27.8 24.0 39.9 14.4 TUBB1 dJ543J19.4 ENSG00000101162 "Tubulin beta 1 class VI" Q9H4B7 20 59019254-59026654 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 58.6;lymphoid tissue: 28.2" "Cell line enriched" "Detected in some" 19 "HEL: 24.4" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 13 "basophil: 8.7;neutrophil: 6.5" "Lineage enriched" "Detected in single" 14 "granulocytes: 8.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB004286, HPA043640, HPA046280" Approved 480000000 "CAB004286: AB_2288090, HPA043640: , HPA046280: " "unprognostic (3.76e-1)" "unprognostic (2.69e-1)" "unprognostic (6.10e-4)" "unprognostic (1.02e-1)" "unprognostic (5.00e-2)" "unprognostic (2.02e-1)" "unprognostic (5.86e-2)" "unprognostic (7.51e-4)" "unprognostic (1.90e-2)" "unprognostic (2.63e-1)" "unprognostic (6.80e-5)" "unprognostic (3.46e-1)" "unprognostic (1.16e-1)" "unprognostic (2.55e-1)" "unprognostic (1.40e-1)" "unprognostic (2.31e-1)" "unprognostic (1.00e-1)" 0.6 0.3 0.2 0.4 0.6 12.2 0.2 0.7 0.7 0.2 0.2 0.1 0.0 0.2 0.2 0.9 0.2 0.5 0.6 10.8 0.2 0.2 0.2 1.0 8.3 0.4 0.2 0.4 0.8 0.4 0.0 0.7 3.2 0.6 0.3 0.0 0.5 0.2 0.6 0.6 0.2 0.5 0.0 0.6 28.2 0.3 1.8 0.0 0.0 0.5 0.3 0.2 0.4 1.8 0.1 0.6 8.7 0.5 0.0 0.1 58.6 0.1 0.2 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.6 0.1 0.3 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.1 24.4 0.6 1.2 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.1 0.3 0.2 0.0 0.3 0.2 0.1 0.2 0.0 0.2 0.3 0.2 0.1 0.5 0.1 0.1 0.1 0.0 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.3 8.7 0.5 0.4 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.0 6.5 0.0 0.0 0.6 0.1 58.6 0.2 0.6 0.7 0.7 0.2 0.2 0.2 0.4 0.6 0.0 TUBB3 "beta-4, CFEOM3, CFEOM3A, FEOM3" ENSG00000258947 "Tubulin beta 3 class III" Q13509 16 89921392-89938761 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 85.1" "Cell line enhanced" "Detected in many" "A549: 65.2;SCLC-21H: 66.4;SH-SY5Y: 67.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 5 "naive B-cell: 5.2" "Lineage enriched" "Detected in single" 7 "B-cells: 5.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043640, HPA046280" Approved 250000000 "HPA043640: , HPA046280: " "unprognostic (7.08e-2)" "unprognostic (3.37e-4)" "unprognostic (1.05e-1)" "unprognostic (1.06e-1)" "unprognostic (8.01e-2)" "unprognostic (3.12e-2)" "unprognostic (4.04e-3)" "unprognostic (1.12e-3)" "unprognostic (1.22e-2)" "unprognostic (6.06e-2)" "unprognostic (1.99e-2)" "unprognostic (1.38e-2)" "unprognostic (7.57e-2)" "unprognostic (1.27e-3)" "unprognostic (3.70e-2)" "unprognostic (3.05e-1)" "unprognostic (1.91e-2)" 5.1 19.4 23.9 8.9 23.3 3.2 1.2 24.1 85.1 2.4 4.1 7.8 0.0 3.6 7.9 1.1 2.2 1.0 7.3 1.8 25.0 66.5 1.1 1.1 1.6 5.7 44.5 15.9 1.1 2.5 1.0 9.9 2.2 60.9 1.6 2.8 5.5 1.9 1.3 1.0 4.1 4.8 9.3 12.9 1.1 2.5 11.2 3.3 0.0 1.0 1.7 4.4 5.3 0.6 5.2 0.7 0.2 0.3 0.0 0.2 0.2 4.5 65.2 24.3 27.6 2.9 28.0 1.0 27.9 4.8 16.9 7.7 8.8 8.4 13.8 14.6 21.1 17.2 23.4 4.1 4.3 3.4 2.3 0.1 5.5 57.7 0.9 0.0 10.8 16.0 1.2 25.8 2.2 13.8 1.4 0.4 19.2 43.4 0.1 4.6 42.6 35.8 0.0 8.5 1.4 20.9 1.3 66.4 67.0 39.2 0.7 19.0 2.1 0.2 17.4 23.1 24.9 30.9 28.2 0.2 2.8 5.2 23.9 1.7 40.8 0.2 0.0 0.0 0.2 0.0 0.0 1.0 0.0 0.2 0.0 5.2 0.0 0.0 0.0 0.0 0.3 0.7 0.0 0.2 23.9 23.3 24.1 51.0 25.0 66.5 44.5 15.9 60.9 3.3 TUBB4B "Beta2, TUBB2C" ENSG00000188229 "Tubulin beta 4B class IVb" P68371 9 137241213-137243707 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Deafness, Disease mutation, FDA approved drug targets, Leber congenital amaurosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 207.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010880, HPA043640, HPA046280" Enhanced Supported Microtubules Microtubules "CAB010880: AB_609915, HPA043640: , HPA046280: " "unprognostic (2.24e-1)" "unprognostic (1.77e-3)" "unprognostic (1.50e-1)" "prognostic favourable (4.91e-4)" "unprognostic (1.29e-2)" "unprognostic (8.93e-2)" "prognostic unfavourable (9.98e-4)" "unprognostic (9.92e-3)" "unprognostic (2.90e-1)" "unprognostic (3.63e-1)" "unprognostic (2.34e-1)" "unprognostic (4.09e-2)" "unprognostic (2.47e-3)" "unprognostic (6.37e-2)" "unprognostic (1.36e-2)" "prognostic favourable (6.36e-6)" "unprognostic (1.69e-1)" 31.1 22.1 33.0 22.1 32.7 87.5 24.4 22.3 67.2 23.0 44.0 35.9 25.2 33.4 22.7 52.7 65.7 122.5 32.1 66.4 35.2 55.5 46.6 49.7 28.4 21.0 33.8 46.6 33.7 33.0 13.4 25.3 31.9 48.4 29.8 27.3 40.9 41.8 31.8 37.1 55.9 38.9 28.4 21.5 21.0 30.5 207.7 12.2 61.1 40.1 56.7 40.1 21.8 25.7 17.2 18.3 37.0 14.6 11.2 21.7 14.4 59.3 89.1 38.1 27.5 19.2 20.3 53.2 55.8 47.0 77.3 53.4 94.1 73.2 36.5 42.8 54.2 113.2 47.1 89.9 29.5 25.9 39.9 26.4 71.0 73.9 12.2 31.1 29.4 13.0 25.5 59.0 16.2 55.1 36.8 21.0 63.6 163.4 28.1 42.3 40.2 155.5 35.9 72.8 33.7 58.0 55.6 26.7 28.7 74.0 42.6 14.8 61.3 33.9 42.8 55.2 61.6 62.5 73.4 8.2 22.5 40.2 45.0 24.3 47.9 37.0 14.1 20.5 21.4 14.6 20.6 17.2 16.7 18.2 17.5 14.1 10.7 14.3 28.6 11.2 14.6 18.3 21.7 14.4 33.0 32.7 22.3 67.2 35.2 55.5 33.8 46.6 48.4 12.2 TUBD1 "FLJ12709, TUBD" ENSG00000108423 "Tubulin delta 1" Q9UJT1 17 59859482-59892945 "FDA approved drug targets, Predicted intracellular proteins" "Cilium biogenesis/degradation" "Developmental protein" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 41.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004609, HPA023980, HPA027090" Approved Enhanced Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB004609: AB_628416, HPA023980: AB_1858456, HPA027090: AB_1858457" "unprognostic (1.92e-1)" "unprognostic (5.95e-2)" "prognostic favourable (2.04e-4)" "unprognostic (1.39e-1)" "unprognostic (1.32e-2)" "unprognostic (5.64e-2)" "prognostic unfavourable (1.00e-5)" "unprognostic (2.86e-2)" "unprognostic (8.87e-3)" "unprognostic (1.02e-1)" "unprognostic (1.77e-3)" "unprognostic (2.59e-1)" "prognostic unfavourable (6.06e-4)" "unprognostic (4.97e-2)" "unprognostic (1.63e-1)" "unprognostic (1.36e-1)" "unprognostic (8.83e-2)" 8.7 8.0 9.3 8.1 13.8 6.8 12.4 19.9 12.2 12.3 11.2 13.5 16.6 6.7 13.6 16.4 18.2 10.0 8.3 8.4 8.9 7.2 8.5 9.3 8.8 10.2 16.1 8.5 16.3 13.2 10.4 18.7 7.2 12.3 12.3 8.2 11.7 11.4 12.2 9.9 11.6 7.5 9.3 13.4 9.3 9.6 9.2 16.4 16.2 15.5 10.3 13.8 14.1 13.0 10.1 8.8 14.1 7.6 8.1 17.6 6.9 5.9 8.1 6.4 6.7 3.6 2.6 5.4 4.6 2.7 6.1 5.1 8.8 3.9 5.4 7.9 1.0 5.0 8.9 2.8 5.9 3.1 10.9 6.3 6.9 10.4 1.9 3.7 3.4 1.4 4.4 5.3 2.0 4.8 13.5 3.8 2.1 41.9 7.6 4.3 5.6 3.6 8.2 9.4 8.4 2.4 2.7 6.0 3.6 3.3 2.6 3.2 6.3 3.6 1.5 4.4 9.8 3.1 5.0 4.4 6.6 8.2 2.1 4.3 3.9 5.6 7.6 14.1 10.9 5.0 12.4 10.1 13.5 11.5 5.2 8.6 17.6 14.2 8.2 8.1 5.3 8.8 14.1 6.9 9.3 13.8 19.9 12.2 8.9 7.2 16.1 8.5 12.3 16.4 TUBE1 "dJ142L7.2, FLJ22589, TUBE" ENSG00000074935 "Tubulin epsilon 1" Q9UJT0 6 112070777-112087529 "FDA approved drug targets, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-2197: 29.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA032073, HPA032074" Approved "HPA032073: AB_10601773, HPA032074: AB_10601216" "unprognostic (4.79e-2)" "unprognostic (1.61e-1)" "unprognostic (3.76e-2)" "unprognostic (1.29e-1)" "unprognostic (2.22e-2)" "unprognostic (7.36e-2)" "unprognostic (1.22e-1)" "unprognostic (8.36e-3)" "unprognostic (2.18e-1)" "unprognostic (1.04e-1)" "unprognostic (4.99e-3)" "unprognostic (1.70e-1)" "unprognostic (5.15e-3)" "unprognostic (1.64e-1)" "unprognostic (7.68e-2)" "unprognostic (2.50e-1)" "unprognostic (1.59e-3)" 10.3 10.7 12.4 7.0 18.5 5.1 11.9 32.4 18.9 15.5 10.3 12.2 11.4 6.7 21.4 11.5 6.6 12.7 11.6 17.4 10.5 12.2 11.4 47.4 8.4 8.8 15.4 14.5 14.9 12.5 11.8 20.4 11.7 14.0 12.1 8.5 9.3 9.9 12.6 7.1 13.8 7.0 14.4 18.2 8.0 10.5 32.7 15.5 5.3 10.6 4.3 7.3 11.5 12.6 3.2 1.7 2.2 1.4 3.6 7.5 2.8 1.2 1.8 4.6 13.9 10.5 5.8 4.0 5.6 8.3 4.2 7.2 2.9 2.5 4.5 3.5 2.2 3.9 5.2 2.6 7.1 2.7 4.8 2.1 1.0 3.5 17.3 9.7 6.3 6.2 15.4 5.4 13.4 5.1 9.2 6.4 3.2 1.1 5.4 11.4 4.3 3.7 5.9 2.8 3.0 5.3 1.3 6.9 6.3 4.3 3.6 14.5 2.7 19.8 2.7 3.2 3.1 29.0 5.4 2.1 0.7 5.3 5.0 10.8 8.1 0.1 0.9 2.2 2.7 1.2 7.5 3.2 5.3 3.5 1.7 2.5 7.4 5.8 0.6 3.6 1.4 1.5 5.1 2.8 12.4 18.5 32.4 18.9 10.5 12.2 15.4 14.5 14.0 15.5 TUBG1 "TUBG, TUBGCP1" ENSG00000131462 "Tubulin gamma 1" P23258 17 42609676-42615234 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Disease mutation, FDA approved drug targets, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 102.4" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" CAB004608 Enhanced "CAB004608: AB_628417" "unprognostic (1.00e-1)" "unprognostic (5.57e-2)" "unprognostic (1.79e-2)" "prognostic favourable (8.99e-4)" "unprognostic (2.86e-2)" "unprognostic (2.01e-1)" "prognostic unfavourable (1.08e-8)" "unprognostic (2.62e-3)" "unprognostic (5.67e-2)" "unprognostic (1.83e-1)" "unprognostic (3.79e-1)" "unprognostic (2.16e-1)" "prognostic unfavourable (6.48e-5)" "unprognostic (2.64e-1)" "unprognostic (3.52e-1)" "unprognostic (2.61e-3)" "unprognostic (1.97e-2)" 11.7 14.1 8.8 10.7 11.2 23.9 13.0 12.4 19.3 7.5 9.8 6.9 7.8 9.6 9.7 7.8 15.4 7.7 10.4 18.3 13.2 12.6 16.2 20.5 8.6 9.2 8.7 12.0 8.8 30.1 13.1 9.5 14.2 12.2 9.6 8.6 8.3 9.2 11.1 24.3 15.9 7.7 14.1 6.8 10.3 12.8 102.4 5.2 14.6 9.7 11.8 10.8 10.8 9.5 9.7 26.2 1.8 15.4 6.8 8.3 6.3 23.2 61.7 23.9 26.1 15.6 10.8 21.6 26.8 18.5 44.0 34.2 37.3 16.3 16.8 19.8 22.0 37.4 25.8 37.6 32.0 44.0 32.9 13.5 41.0 62.0 7.6 14.7 19.2 8.4 11.7 54.0 16.4 27.7 24.6 17.1 32.5 68.6 36.0 15.6 12.4 30.8 17.4 35.5 26.8 19.0 28.9 34.2 16.6 16.8 15.9 13.0 49.4 14.4 17.7 44.0 28.3 36.1 41.6 24.8 30.4 25.0 23.2 14.6 30.6 1.3 8.4 1.8 7.3 15.4 7.6 9.7 6.7 7.5 9.7 8.3 7.1 7.3 0.4 6.8 15.2 26.2 8.3 6.3 8.8 11.2 12.4 19.3 13.2 12.6 8.7 12.0 12.2 5.2 TXNRD1 "GRIM-12, Trxr1, TXNR" ENSG00000198431 "Thioredoxin reductase 1" Q16881 12 104215779-104350305 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Electron transport, Transport" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "fHDF/TERT166: 143.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001395, CAB004607, CAB015834, HPA043871" Approved Supported Nucleoplasm 5900000 Nucleoplasm "CAB004607: AB_628405, CAB015834: , HPA001395: AB_1858377, HPA043871: " "unprognostic (2.52e-2)" "unprognostic (1.16e-1)" "unprognostic (5.48e-2)" "unprognostic (1.01e-1)" "unprognostic (3.15e-1)" "unprognostic (1.94e-2)" "prognostic unfavourable (1.12e-5)" "unprognostic (5.55e-2)" "unprognostic (1.18e-1)" "unprognostic (1.08e-1)" "unprognostic (6.42e-2)" "unprognostic (2.21e-1)" "prognostic unfavourable (1.20e-5)" "unprognostic (2.13e-1)" "unprognostic (1.27e-1)" "unprognostic (1.18e-2)" "unprognostic (8.80e-2)" 19.1 79.2 14.1 15.6 16.9 22.6 18.5 11.1 13.7 13.0 21.8 9.7 19.7 23.5 23.5 14.7 16.7 19.0 23.2 32.4 11.0 11.7 25.3 19.6 29.3 18.1 12.0 10.9 16.4 7.9 10.5 16.2 30.8 16.4 25.3 19.1 18.1 10.6 26.5 30.0 5.7 17.0 99.6 10.9 14.9 24.2 14.8 8.9 15.6 16.5 16.9 13.2 73.2 72.0 8.1 14.2 37.6 16.2 8.3 10.2 8.7 22.0 102.6 11.9 11.2 57.5 32.2 41.6 41.0 26.0 18.5 19.2 10.8 32.9 16.5 19.1 143.4 7.7 23.5 15.7 22.0 8.0 10.2 13.9 80.6 45.6 92.3 21.7 15.2 18.3 16.2 40.9 13.1 63.4 19.1 7.8 27.7 10.6 22.2 9.9 11.5 105.8 22.0 8.3 14.3 21.5 12.1 18.6 11.2 33.1 52.4 32.7 12.4 12.8 84.7 9.1 18.9 20.3 33.5 8.6 16.8 24.8 19.1 12.0 53.9 33.0 10.6 24.7 9.1 14.0 10.2 8.1 8.4 9.0 14.2 5.2 7.6 6.6 37.6 8.3 16.2 9.2 7.1 8.7 14.1 16.9 11.1 11.2 11.0 11.7 12.0 10.9 16.4 8.9 TYMP "ECGF1, MNGIE" ENSG00000025708 "Thymidine phosphorylase" P19971 22 50525752-50530056 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Angiogenesis, Chemotaxis, Differentiation" "Developmental protein, Glycosyltransferase, Growth factor, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 57.8" "Cell line enhanced" "Detected in many" "CAPAN-2: 15.9;HHSteC: 39.3;Karpas-707: 38.0;U-266/70: 18.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 6 "classical monocyte: 23.0;eosinophil: 18.2;intermediate monocyte: 22.4;myeloid DC: 12.2;neutrophil: 6.7;non-classical monocyte: 15.9" "Group enriched" "Detected in many" 18 "dendritic cells: 12.2;granulocytes: 18.2;monocytes: 23.0" "Low region specificity" "Detected in some" "HPA000530, HPA001072, CAB002518" Enhanced Approved "Nuclear bodies,Golgi apparatus" 16000000 "Nuclear bodies" "Golgi apparatus" "CAB002518: AB_563953, HPA000530: , HPA001072: AB_1080274" "unprognostic (7.02e-3)" "unprognostic (1.00e-1)" "unprognostic (3.61e-1)" "prognostic favourable (4.34e-5)" "unprognostic (7.60e-2)" "unprognostic (1.16e-2)" "unprognostic (2.40e-1)" "unprognostic (7.17e-2)" "unprognostic (4.64e-2)" "unprognostic (1.33e-1)" "unprognostic (3.31e-2)" "unprognostic (2.17e-1)" "prognostic unfavourable (3.50e-8)" "unprognostic (1.32e-1)" "unprognostic (4.02e-2)" "unprognostic (1.52e-2)" "unprognostic (4.60e-2)" 25.2 7.9 2.8 41.6 8.4 12.1 19.0 1.5 4.4 10.7 10.7 3.8 2.3 10.4 4.4 15.7 22.0 13.7 9.6 15.0 7.0 2.6 18.6 38.1 28.8 57.8 6.5 0.4 7.5 5.8 1.7 3.9 11.5 9.1 7.9 4.9 5.4 16.5 3.8 10.0 8.8 13.9 7.3 15.2 43.9 12.4 3.0 5.0 13.3 12.5 25.5 28.8 12.4 9.4 0.9 12.2 18.2 23.0 0.8 0.9 2.6 6.5 0.7 0.0 0.1 0.9 1.2 0.6 1.1 0.1 2.4 5.3 0.0 15.9 0.5 0.8 2.7 5.8 0.2 0.2 0.0 2.8 1.4 0.3 1.1 0.4 39.3 0.1 7.6 2.4 2.4 3.2 0.0 0.0 0.2 38.0 0.2 0.1 0.0 1.0 0.0 2.1 0.2 0.0 7.6 0.0 0.0 0.0 1.4 6.1 8.3 0.5 0.6 4.8 1.5 0.0 0.6 0.1 0.2 18.2 3.7 0.4 0.2 0.1 0.2 2.5 23.0 18.2 0.3 22.4 0.2 0.8 0.3 0.2 12.2 0.9 0.2 0.1 6.7 0.8 15.9 1.1 0.9 2.6 2.8 8.4 1.5 4.4 7.0 2.6 6.5 0.4 9.1 5.0 TYMS "HsT422, TMS, TS, Tsase" ENSG00000176890 "Thymidylate synthetase" P04818 18 657604-673578 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Nucleotide biosynthesis" "Methyltransferase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 34.9;lymphoid tissue: 75.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 13.8" "Group enriched" "Detected in many" 6 "NK-cells: 6.8;T-cells: 13.8" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 5 "cerebellum: 6.7;olfactory region: 8.8" CAB002784 Enhanced "CAB002784: " "unprognostic (7.58e-2)" "unprognostic (2.06e-3)" "unprognostic (9.31e-2)" "unprognostic (2.34e-2)" "unprognostic (7.35e-2)" "unprognostic (1.05e-1)" "prognostic unfavourable (5.10e-6)" "unprognostic (1.62e-3)" "unprognostic (1.68e-2)" "unprognostic (9.82e-2)" "unprognostic (1.07e-3)" "unprognostic (3.28e-2)" "unprognostic (1.23e-2)" "unprognostic (6.34e-2)" "unprognostic (1.66e-1)" "unprognostic (5.65e-3)" "unprognostic (2.47e-1)" 3.0 2.6 4.6 15.5 5.8 34.9 2.8 1.2 6.3 3.4 10.1 10.2 1.5 4.8 2.5 3.6 12.3 2.4 4.6 2.0 5.8 2.9 4.8 5.1 4.2 15.4 3.4 4.5 2.0 3.1 1.1 1.3 14.3 3.4 3.0 12.9 1.1 3.4 0.8 0.7 3.6 6.9 5.5 4.6 8.9 4.2 21.5 5.3 75.5 1.7 10.9 19.3 4.8 4.3 1.2 1.8 1.0 0.1 6.8 13.8 2.5 13.7 21.2 44.3 21.4 4.9 8.2 22.5 32.5 19.4 35.1 42.1 17.9 11.0 21.4 12.7 17.5 6.2 30.9 12.2 30.4 20.1 34.3 36.3 19.9 30.7 1.1 74.5 39.8 7.3 2.9 22.1 6.9 29.3 29.1 34.4 44.1 15.8 89.7 41.3 15.9 15.9 59.4 39.9 25.8 13.2 12.2 15.1 24.5 27.4 12.7 8.2 8.7 34.0 11.6 40.6 80.2 37.1 63.3 42.7 52.5 48.9 10.7 32.3 46.4 0.0 0.0 1.0 1.1 0.1 0.0 1.2 2.9 2.2 1.8 0.0 0.0 0.7 0.6 6.8 0.1 0.3 13.8 2.5 4.6 5.8 1.2 6.3 5.8 2.9 3.4 4.5 3.4 5.3 TYR "OCA1, OCA1A, OCAIA" ENSG00000077498 Tyrosinase P14679 11 89177452-89295759 "Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins" "Melanin biosynthesis" "Monooxygenase, Oxidoreductase, Tumor antigen" "Albinism, Deafness, Disease mutation, FDA approved drug targets, Waardenburg syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 70 "retina: 82.0;skin 1: 25.2" "Cell line enriched" "Detected in single" 844 "SK-MEL-30: 84.3" "Cancer enriched" "Detected in single" 1755 "melanoma: 351.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000079, HPA043241, HPA050889, HPA064583" Enhanced Enhanced Vesicles Vesicles "CAB000079: AB_564045, HPA043241: , HPA050889: , HPA064583: " "unprognostic (1.16e-1)" "unprognostic (1.01e-1)" "unprognostic (1.85e-3)" "unprognostic (9.75e-3)" 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 82.0 0.7 0.0 0.0 25.2 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 84.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 UGCG GCS ENSG00000148154 "UDP-glucose ceramide glucosyltransferase" Q16739 9 111896766-111935369 "Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Lipid biosynthesis, Lipid metabolism, Sphingolipid metabolism" "Glycosyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "LHCN-M2: 52.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 19 "plasmacytoid DC: 39.7" "Lineage enriched" "Detected in many" 19 "dendritic cells: 39.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA024124 Approved "HPA024124: AB_1858595" "unprognostic (1.22e-2)" "prognostic favourable (6.62e-4)" "unprognostic (5.39e-2)" "prognostic favourable (4.44e-5)" "unprognostic (1.53e-2)" "unprognostic (9.70e-2)" "unprognostic (3.20e-2)" "unprognostic (2.04e-1)" "unprognostic (3.40e-1)" "unprognostic (1.31e-1)" "unprognostic (1.95e-2)" "unprognostic (3.22e-1)" "unprognostic (9.84e-3)" "unprognostic (2.24e-2)" "unprognostic (4.92e-2)" "unprognostic (1.99e-1)" "unprognostic (3.77e-2)" 33.7 37.7 5.9 21.4 7.8 55.2 20.5 9.5 11.2 14.6 19.6 5.0 3.3 13.3 10.6 8.6 34.0 11.1 24.5 17.5 8.6 9.0 23.8 18.4 28.1 35.4 7.1 5.8 15.9 11.4 3.5 11.9 15.3 6.8 12.4 10.5 11.9 10.8 5.4 14.0 21.7 25.5 12.4 12.9 33.1 26.1 11.7 6.2 17.9 8.5 16.9 27.7 34.2 25.9 2.0 39.7 0.4 0.3 0.5 1.2 0.5 24.1 2.6 4.2 2.8 9.2 11.1 2.2 15.1 16.0 17.8 24.1 5.1 18.6 5.7 12.0 10.0 12.4 4.9 6.5 19.1 2.3 2.8 2.3 3.9 2.5 6.6 2.5 3.7 11.0 5.1 16.9 24.4 5.4 12.6 11.1 52.4 4.1 2.7 2.8 4.8 2.7 3.2 30.2 1.8 40.9 9.2 2.0 3.2 6.7 5.7 16.6 30.5 2.6 25.5 8.2 4.2 22.9 10.8 2.1 7.6 2.6 10.1 1.6 11.1 0.0 0.1 0.0 0.4 0.2 0.7 1.6 0.8 0.6 0.6 2.0 0.7 0.7 0.4 0.5 0.3 39.7 1.2 0.5 5.9 7.8 9.5 11.2 8.6 9.0 7.1 5.8 6.8 6.2 VDR "NR1I1, PPP1R163" ENSG00000111424 "Vitamin D receptor" P11473 12 47841537-47943048 "Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 57.1;parathyroid gland: 45.8" "Cell line enhanced" "Detected in many" "HBEC3-KT: 22.7;HDLM-2: 32.0;U-937: 31.4" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 6 "classical monocyte: 3.7;eosinophil: 2.1;intermediate monocyte: 7.0;myeloid DC: 5.7;neutrophil: 7.5;non-classical monocyte: 6.9" "Group enriched" "Detected in many" 8 "dendritic cells: 5.7;granulocytes: 7.5;monocytes: 7.0" "Region enhanced" "Detected in single" "olfactory region: 2.5" "Low region specificity" "Detected in some" "CAB004617, HPA047740, HPA072102" Supported "Nucleoplasm,Intermediate filaments,Cytosol" Nucleoplasm "Intermediate filaments, Cytosol" "CAB004617: AB_628040, HPA047740: , HPA072102: " "unprognostic (1.11e-2)" "unprognostic (5.49e-2)" "unprognostic (1.01e-1)" "unprognostic (7.59e-3)" "unprognostic (3.33e-3)" "unprognostic (2.74e-2)" "unprognostic (4.78e-2)" "unprognostic (1.69e-1)" "unprognostic (1.40e-1)" "unprognostic (1.62e-1)" "unprognostic (5.53e-3)" "unprognostic (6.72e-2)" "prognostic favourable (4.89e-6)" "unprognostic (1.46e-1)" "unprognostic (8.76e-2)" "unprognostic (3.28e-1)" "unprognostic (3.82e-2)" 3.0 9.2 0.2 10.0 0.3 2.5 7.8 0.3 0.6 3.5 40.9 0.4 4.1 21.2 1.2 7.7 10.2 1.1 10.7 1.5 0.5 0.3 13.0 0.6 8.3 3.8 0.5 0.1 1.3 6.5 45.8 11.7 4.4 0.6 2.1 12.6 0.4 4.9 2.8 5.3 15.2 57.1 1.2 1.5 3.1 2.6 1.5 0.2 2.0 1.9 9.4 8.2 4.0 5.2 0.7 5.7 7.5 7.0 0.2 0.8 1.2 5.4 0.9 0.0 0.0 4.7 6.9 0.1 6.7 3.4 5.7 5.0 4.0 4.6 1.4 7.3 4.6 10.2 0.2 22.7 2.7 32.0 1.6 2.4 1.3 0.3 3.5 4.8 7.7 9.3 10.6 6.3 10.4 0.4 0.7 1.5 2.6 3.7 0.1 2.3 0.0 7.4 0.1 0.0 3.5 5.2 5.5 2.6 0.1 5.7 16.5 2.0 18.6 2.7 0.4 11.0 2.9 3.2 3.8 0.9 0.0 1.2 3.4 31.4 2.7 0.2 3.7 2.1 0.0 7.0 0.1 0.7 0.3 0.0 5.7 0.1 0.1 0.0 7.5 0.2 6.9 0.6 0.8 1.2 0.2 0.3 0.3 0.6 0.5 0.3 0.5 0.1 0.6 0.2 VEGFA "VEGF, VEGF-A, VPF" ENSG00000112715 "Vascular endothelial growth factor A" P15692 6 43770184-43786487 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 49.7;hTERT-HME1: 49.5;U-87 MG: 108.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "classical monocyte: 1.2;eosinophil: 1.9" "Group enriched" "Detected in many" 9 "granulocytes: 1.9;monocytes: 1.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005429, CAB039240, HPA069116, CAB069907" Supported "Secreted to blood" 214485 "CAB005429: AB_2212984, CAB039240: , CAB069907: AB_10001947, HPA069116: " "unprognostic (1.12e-1)" "prognostic unfavourable (4.50e-4)" "unprognostic (2.42e-2)" "prognostic unfavourable (2.10e-4)" "unprognostic (4.35e-2)" "unprognostic (1.49e-1)" "prognostic unfavourable (2.34e-5)" "unprognostic (5.10e-2)" "unprognostic (5.27e-3)" "unprognostic (2.30e-2)" "unprognostic (1.40e-1)" "unprognostic (1.00e-2)" "prognostic unfavourable (1.76e-5)" "unprognostic (2.20e-1)" "unprognostic (1.80e-1)" "unprognostic (1.43e-1)" "prognostic favourable (2.73e-4)" 35.0 17.5 16.6 11.4 20.1 12.8 39.5 6.5 32.3 11.8 25.9 8.7 15.0 16.0 54.1 9.4 19.4 10.4 27.5 57.0 13.4 5.4 25.8 58.6 30.0 2.9 15.8 3.7 16.4 25.1 20.6 7.3 16.7 19.8 40.5 7.2 24.4 15.1 23.8 52.9 11.9 26.3 19.2 35.1 19.0 20.5 4.5 15.4 0.3 87.9 19.6 13.6 47.5 15.7 0.0 0.1 1.9 1.2 0.0 0.0 0.0 12.4 2.2 2.1 12.2 3.6 5.8 14.4 7.6 13.7 5.1 10.1 7.1 1.6 4.1 6.1 4.6 5.1 5.7 15.4 9.0 4.5 1.8 3.1 2.9 4.8 38.7 3.3 6.9 10.1 30.7 49.7 49.5 1.3 5.7 20.7 18.5 5.1 0.3 4.6 1.3 3.5 0.3 2.0 9.8 19.7 10.4 3.8 8.0 11.0 7.5 26.4 2.9 12.5 1.7 21.2 5.7 30.6 12.5 11.8 6.9 8.0 108.8 7.9 7.3 0.0 1.2 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 16.6 20.1 6.5 32.3 13.4 5.4 15.8 3.7 19.8 15.4 VKORC1 VKCFD2 ENSG00000167397 "Vitamin K epoxide reductase complex subunit 1" Q9BQB6 16 31090842-31095980 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Oxidoreductase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 173.3" "Cell line enhanced" "Detected in all" "ASC diff: 98.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042720 Approved Supported "Endoplasmic reticulum" "Intracellular and membrane" "Endoplasmic reticulum" "HPA042720: AB_10961864" "unprognostic (5.99e-2)" "unprognostic (2.98e-1)" "unprognostic (7.11e-3)" "unprognostic (7.68e-3)" "unprognostic (5.49e-2)" "unprognostic (3.23e-3)" "unprognostic (3.02e-2)" "unprognostic (2.32e-2)" "unprognostic (2.42e-1)" "unprognostic (2.66e-1)" "unprognostic (1.04e-1)" "unprognostic (1.19e-1)" "prognostic unfavourable (2.09e-10)" "unprognostic (1.11e-2)" "unprognostic (6.65e-2)" "unprognostic (3.12e-2)" "unprognostic (9.66e-2)" 21.3 23.0 9.3 11.5 11.0 12.9 28.1 9.4 14.5 24.3 19.3 17.1 16.5 12.6 24.0 27.4 18.5 17.8 22.6 20.1 9.8 10.2 29.9 173.3 16.4 17.5 13.7 9.1 25.5 55.5 14.0 25.0 22.5 13.3 22.3 12.6 20.8 34.8 21.4 11.4 15.9 26.8 27.7 12.5 15.4 17.5 18.2 10.6 15.8 25.6 13.8 14.6 28.4 18.7 32.3 49.9 59.6 40.6 24.7 43.7 33.6 10.4 26.9 8.9 25.3 98.2 58.5 9.9 38.9 33.8 19.1 32.6 11.2 12.1 8.2 21.0 48.6 9.7 12.2 15.2 21.8 11.6 29.7 7.5 37.3 53.6 15.5 14.5 11.3 33.8 8.2 26.4 22.7 20.7 9.8 19.6 37.4 37.9 10.6 29.8 16.0 25.9 19.3 23.5 40.9 18.9 9.2 18.1 21.9 17.0 12.4 18.8 20.4 17.7 18.0 25.7 9.2 23.6 14.6 11.9 11.0 7.2 66.9 25.1 13.2 21.5 40.6 59.6 40.3 28.1 39.7 29.9 40.5 40.7 39.6 32.3 36.4 35.4 34.2 24.7 28.3 49.9 43.7 33.6 9.3 11.0 9.4 14.5 9.8 10.2 13.7 9.1 13.3 10.6 VKORC1L1 ENSG00000196715 "Vitamin K epoxide reductase complex subunit 1 like 1" Q8N0U8 7 65873267-65959563 "Enzymes, FDA approved drug targets, Predicted membrane proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA053954 Approved Supported "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA053954: " "unprognostic (3.01e-1)" "unprognostic (1.76e-3)" "unprognostic (4.64e-2)" "unprognostic (4.65e-2)" "unprognostic (3.00e-3)" "unprognostic (7.15e-3)" "unprognostic (1.30e-3)" "unprognostic (8.84e-3)" "unprognostic (5.12e-2)" "unprognostic (5.59e-2)" "unprognostic (9.23e-3)" "unprognostic (1.07e-1)" "unprognostic (1.59e-2)" "unprognostic (1.17e-1)" "unprognostic (7.03e-3)" "unprognostic (4.30e-1)" "unprognostic (5.06e-2)" 38.2 9.2 10.5 8.3 16.7 3.0 23.7 9.0 19.7 10.4 11.1 14.2 9.2 8.6 10.1 8.8 10.0 8.8 8.0 9.3 10.3 11.4 8.2 17.8 14.3 6.2 12.0 12.1 14.4 11.7 28.5 8.0 9.7 14.1 9.9 10.0 8.0 9.0 10.5 14.9 11.4 9.7 9.3 13.2 5.7 9.9 9.4 7.6 9.1 11.1 4.5 6.6 9.7 9.3 2.8 7.5 5.6 4.2 6.5 3.4 1.8 22.1 14.4 11.6 14.5 37.0 14.7 21.1 24.2 15.7 14.5 14.7 13.8 22.0 19.4 19.6 17.3 15.3 16.5 9.8 24.2 12.1 16.3 13.2 13.1 11.8 18.1 18.3 10.2 11.8 12.6 14.7 20.5 14.3 27.7 14.9 17.2 8.7 14.9 21.3 27.8 10.8 16.5 16.9 24.1 13.9 9.0 14.0 19.9 18.7 33.9 10.6 17.1 14.2 16.2 23.5 16.1 14.7 24.5 13.4 21.9 22.3 14.4 20.8 20.4 3.8 2.7 5.6 2.9 2.5 2.4 2.8 3.4 3.2 2.8 2.5 2.3 2.3 3.1 6.5 4.2 7.5 3.1 1.8 10.5 16.7 9.0 19.7 10.3 11.4 12.0 12.1 14.1 7.6 XDH "XO, XOR" ENSG00000158125 "Xanthine dehydrogenase" P47989 2 31334321-31414715 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 78.6;liver: 32.5" "Cell line enhanced" "Detected in some" "BJ: 6.1;HBEC3-KT: 15.0;hTERT-HME1: 23.9;U-251 MG: 6.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA062641, HPA069323" Supported Uncertain Nucleoplasm,Nucleoli "Intracellular and membrane" Nucleoplasm Nucleoli "HPA062641: , HPA069323: " "unprognostic (8.58e-2)" "unprognostic (4.07e-2)" "unprognostic (1.34e-2)" "unprognostic (1.79e-1)" "unprognostic (2.08e-2)" "unprognostic (7.06e-2)" "unprognostic (4.38e-3)" "unprognostic (7.48e-3)" "unprognostic (3.55e-1)" "unprognostic (3.60e-2)" "unprognostic (3.95e-3)" "unprognostic (3.51e-2)" "unprognostic (1.24e-6)" "unprognostic (2.25e-1)" "unprognostic (5.25e-2)" "unprognostic (2.54e-1)" "prognostic favourable (8.73e-6)" 0.2 0.2 0.2 2.4 0.2 0.0 17.8 0.2 0.2 2.6 17.9 0.1 0.0 20.1 0.3 6.3 9.3 0.2 1.8 0.2 0.1 0.2 0.4 32.5 0.2 0.0 0.2 0.0 0.2 0.4 0.0 1.5 3.7 0.1 1.2 4.2 0.1 20.9 0.0 0.7 1.0 78.6 0.1 0.2 0.2 1.3 0.2 0.0 0.2 0.3 2.4 6.1 1.8 1.1 0.7 0.3 1.0 0.6 0.7 0.5 0.0 1.5 0.3 0.0 0.0 0.0 0.1 0.1 6.1 3.5 0.7 1.1 0.2 1.7 0.0 1.2 0.2 3.2 0.0 15.0 0.8 0.7 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 1.3 0.9 23.9 0.0 0.0 0.2 0.2 0.0 0.0 0.1 0.3 0.1 0.0 1.1 3.3 4.4 3.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.9 1.9 0.1 6.5 1.9 0.1 0.0 0.2 0.0 0.0 0.5 0.6 0.2 0.2 0.2 0.4 0.1 0.3 0.3 0.0 0.7 0.2 0.5 1.0 0.7 0.2 0.3 0.2 0.0 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.0 0.1 0.0 XIAP "API3, BIRC4, hILP" ENSG00000101966 "X-linked inhibitor of apoptosis" P98170 X 123859724-123913979 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway, Wnt signaling pathway" "Protease inhibitor, Thiol protease inhibitor, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB009203, HPA042428" Approved Supported "Nucleoplasm,Plasma membrane,Cytosol" "Nucleoplasm, Cytosol" "Plasma membrane" "CAB009203: AB_2257167, HPA042428: " "prognostic unfavourable (9.21e-4)" "unprognostic (8.43e-2)" "unprognostic (1.50e-2)" "unprognostic (2.14e-1)" "unprognostic (1.40e-1)" "unprognostic (9.41e-2)" "unprognostic (1.95e-2)" "unprognostic (8.51e-2)" "unprognostic (9.17e-2)" "unprognostic (3.90e-2)" "unprognostic (7.50e-2)" "unprognostic (4.41e-2)" "unprognostic (3.15e-3)" "unprognostic (8.21e-3)" "unprognostic (2.26e-1)" "unprognostic (4.99e-2)" "unprognostic (4.65e-2)" 17.4 14.4 20.0 18.1 20.2 12.0 15.9 21.3 18.9 17.2 19.4 14.5 22.9 16.1 17.4 17.0 18.9 12.6 14.7 15.7 18.9 22.1 19.8 19.4 16.5 15.5 18.8 14.6 13.9 19.7 36.6 26.1 18.2 15.9 15.6 16.8 16.9 14.6 22.9 21.5 14.2 23.4 17.0 19.0 15.8 16.2 7.0 12.3 13.9 24.3 11.4 14.0 15.4 20.5 5.7 4.3 11.1 3.9 3.3 5.5 1.9 11.5 9.9 7.8 6.7 9.2 11.9 10.2 12.6 9.4 6.9 5.9 4.4 13.6 10.8 18.7 10.7 4.3 11.5 7.9 12.7 11.2 6.3 7.3 8.3 6.7 11.7 13.2 15.2 8.2 12.3 11.4 14.7 9.5 11.5 12.5 13.3 12.0 7.3 6.4 6.4 7.8 7.9 9.1 11.4 10.4 16.8 5.3 7.7 17.2 10.0 10.1 6.1 6.5 11.7 0.3 4.7 20.6 14.0 10.5 10.5 12.0 14.2 9.4 8.7 11.1 2.6 3.5 5.0 2.3 4.7 4.6 3.8 5.5 1.4 5.7 4.4 3.0 8.2 3.3 3.9 4.3 2.5 1.9 20.0 20.2 21.3 18.9 18.9 22.1 18.8 14.6 15.9 12.3 YES1 "c-yes, HsT441, Yes" ENSG00000176105 "YES proto-oncogene 1, Src family tyrosine kinase" P07947 18 721588-812546 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "basophil: 14.7" "Lineage enriched" "Detected in many" 6 "granulocytes: 14.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004370, HPA026480" Approved Supported "Plasma membrane,Cytosol" 4300000 "Plasma membrane, Cytosol" "CAB004370: AB_627370, HPA026480: AB_1858921" "unprognostic (3.28e-1)" "unprognostic (1.62e-2)" "unprognostic (5.87e-2)" "unprognostic (2.47e-2)" "unprognostic (6.24e-2)" "unprognostic (4.24e-2)" "unprognostic (6.01e-2)" "unprognostic (1.03e-2)" "unprognostic (1.95e-2)" "unprognostic (1.85e-3)" "prognostic unfavourable (2.46e-4)" "unprognostic (2.14e-1)" "unprognostic (8.12e-2)" "unprognostic (4.65e-2)" "unprognostic (1.81e-1)" "unprognostic (4.79e-2)" "unprognostic (4.11e-1)" 26.2 13.1 17.0 9.4 15.6 2.6 47.2 6.7 12.8 15.8 23.8 8.9 13.7 18.2 13.1 17.4 22.0 10.7 14.9 17.9 14.8 12.4 22.6 43.2 23.6 13.7 15.8 6.6 13.2 21.4 16.7 10.7 31.3 16.8 12.2 17.3 6.5 23.7 21.0 10.6 12.3 24.8 18.8 16.8 34.5 15.5 13.6 12.0 8.1 16.8 15.6 7.1 21.9 17.5 0.1 0.1 14.7 0.0 1.0 2.5 0.6 14.2 7.1 22.4 17.5 13.5 16.7 26.4 9.5 19.4 11.2 15.4 16.8 10.5 0.0 10.1 16.1 8.3 20.9 16.8 22.0 0.0 7.1 4.2 7.0 11.7 11.0 3.2 7.6 12.7 18.1 16.9 18.9 37.8 18.4 6.3 15.9 9.8 1.9 4.2 14.2 9.1 2.4 17.6 1.2 16.3 16.9 4.6 5.3 19.6 14.9 12.4 10.3 6.8 32.5 27.7 30.7 20.8 25.5 5.5 2.7 0.8 10.5 4.7 16.4 14.7 0.0 0.9 2.5 0.0 1.6 0.1 0.5 1.4 0.0 0.0 1.2 1.9 0.0 1.0 0.0 0.1 0.1 0.6 17.0 15.6 6.7 12.8 14.8 12.4 15.8 6.6 16.8 12.0